PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GJERTSON, DW; TERASAKI, PI; TAKEMOTO, S; MICKEY, MR				GJERTSON, DW; TERASAKI, PI; TAKEMOTO, S; MICKEY, MR			NATIONAL ALLOCATION OF CADAVERIC KIDNEYS BY HLA MATCHING - PROJECTED EFFECT ON OUTCOME AND COSTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL	Background. Although receiving a cadaveric kidney matched at the HLA-A, B, and DR loci enhances graft survival in cyclosporine-treated patients, the value of a national system of kidney allocation based on HLA matching, with the attendant increased likelihood of better matching, is still questioned. Some fear that the costs of a national system are unjustified when only a small fraction of donors would exactly match any of the 16,000 potential recipients anyway. We estimated the effect on graft survival of the use of HLA matching for all allocations of cadaveric kidneys in the United States. Methods. The graft-survival rates in five mutually exclusive groups of transplants with increasing numbers of HLA mismatches were estimated by partitioning the data for 22,190 first-time recipients of cadaveric kidneys. Overall graft survival was projected as a weighted average with use of the percentages of transplants in the hierarchical groups in recipient waiting pools of various sizes. We compared the benefits and costs of HLA matching in a national system with those of introducing cyclosporine, which was projected to enhance graft survival by 7 percentage points at 10 years. Results. Sharing kidneys nationally on the basis of hierarchical HLA matching was estimated to enhance graft survival by an additional 5 percentage points at 10 years. The anticipated five-year cost of national allocation of kidneys by HLA matching for 7000 recipients, including consideration of the costs of graft removal and dialysis after transplant rejection, would be $6.5 million less than the cost of using cyclosporine alone. Conclusions. The use of an HLA allocation system will not add to the cost of renal transplantation, but it will improve the long-term results to the same extent as cyclosporine. We propose the initiation of a national kidney-sharing system based on hierarchical levels of HLA matches.	UNIV CALIF LOS ANGELES,TISSUE TYPING LAB,950 VET AVE,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					PHS HHS [2375] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Cook D J, 1987, Clin Transpl, P277; EVANS RW, 1988, TRANSPL P, V20, P49; GILKS WR, 1987, TRANSPLANTATION, V43, P669, DOI 10.1097/00007890-198705000-00013; Gjertson D W, 1989, Clin Transpl, P353; HELD PJ, 1990, 16TH ANN SCI M AM SO; MANNINEN DL, 1991, TRANSPLANT P, V23, P1312; McClelland J, 1989, Clin Transpl, P471; MICKEY MR, 1989, TRANSPLANTATION, V47, P401; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; Persijn G G, 1988, Clin Transpl, P237; PFAFF WW, 1989, TRANSPL P, V21, P1405; STARZL TE, 1987, JAMA-J AM MED ASSOC, V257, P3073, DOI 10.1001/jama.257.22.3073; Takemoto S, 1989, Clin Transpl, P463; TAKEMOTO S, 1991, TRANSPLANT P, V23, P1318; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033; TERASAKI P, 1989, TRANSPLANT P, V21, P615; 1990, NIH90583 PUBL	17	83	84	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1032	1036		10.1056/NEJM199104113241505	http://dx.doi.org/10.1056/NEJM199104113241505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	2005940	Bronze			2022-12-28	WOS:A1991FF77100005
J	BRADDOCK, M; THORBURN, AM; KINGSMAN, AJ; KINGSMAN, SM				BRADDOCK, M; THORBURN, AM; KINGSMAN, AJ; KINGSMAN, SM			BLOCKING OF TAT-DEPENDENT HIV-1 RNA MODIFICATION BY AN INHIBITOR OF RNA POLYMERASE-II PROCESSIVITY	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATION; UNWINDING ACTIVITY; MAMMALIAN-CELLS; EXPRESSION; ELONGATION; PROTEIN	HUMAN immunodeficiency virus gene expression is regulated transcriptionally and post-transcriptionally 1-4 by the virally encoded tat protein (Tat). Tat functions through an RNA target sequence located in the untranslated region at the 5' end of viral transcripts 5-8. In Xenopus oocytes, translation of RNA containing the target sequence is specifically activated by Tat. This activation only occurs if the RNA is injected into the nucleus, and might be due to a Tat-dependent, nucleus-specific chemical modification of the RNA which somehow facilitates translation 8. Here we demonstrate that Tat activation of its target RNA in the nucleus involves a Tat-dependent covalent modification. The modified RNA is competent for translation after reinjection into either the nucleus or the cytoplasm in the absence of Tat. Furthermore, we find that the nucleoside analogue 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, which inhibits processivity of RNA polymerase II (ref. 9), blocks this Tat-dependent modification.	DEPT BIOCHEM,VIRUS MOLEC BIOL GRP,S PARKS RD,OXFORD OX1 3QU,ENGLAND; BRITISH BIOTECHNOL LTD,OXFORD OX4 5LY,ENGLAND	University of Oxford								BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; ELLIOTT MS, 1984, J BIOL CHEM, V259, P2407; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; KIMMELMAN M, 1989, CELL, V59, P687; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693	23	48	49	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					439	441		10.1038/350439a0	http://dx.doi.org/10.1038/350439a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011194				2022-12-28	WOS:A1991FF04200056
J	[Anonymous]				[Anonymous]			EVEN MISCONDUCT TRIALS SHOULD BE FAIR	NATURE			English	Editorial Material																		1991, NATURE, V350, P100	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					259	260						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008201				2022-12-28	WOS:A1991FD83800001
J	WAECKERLE, JF				WAECKERLE, JF			CURRENT CONCEPTS - DISASTER PLANNING AND RESPONSE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SKYWALK COLLAPSE; MASS CASUALTIES; MEDICAL SYSTEM; EMERGENCY; EXPERIENCE; BELFAST		UNIV MISSOURI,SCH MED,KANSAS CITY,MO 64108	University of Missouri System; University of Missouri Kansas City	WAECKERLE, JF (corresponding author), BAPTIST MED CTR,DEPT EMERGENCY MED,6601 ROCKHILL RD,KANSAS CITY,MO 64131, USA.							Aghababian R V, 1986, Top Emerg Med, V7, P46; Auf der Heide E., 1989, DISASTER RESPONSE PR; BARRIER G, 1989, CRIT CARE MED, V17, P1062, DOI 10.1097/00003246-198910000-00020; BERN AI, 1989, PRINCIPLES EMS SYSTE, P77; BLAKE PA, 1989, PUBLIC HLTH CONSEQUE, P7; BRANDT EN, 1985, PUBLIC HEALTH REP, V100, P455; Cohen E, 1983, JEMS, V8, P30; COLEBERD JC, 1985, FIRE ENG         APR, P61; DOYLE C J, 1990, Emergency Medicine Clinics of North America, V8, P163; DUCLOS PJ, 1989, INT J EPIDEMIOL, V18, P213, DOI 10.1093/ije/18.1.213; Dynes Russell R., 1990, COMMUNITY EMERGENCY; EDWARDS JD, 1989, BRIT J HOSP MED, V42, P99; ESCH VH, 1982, DOT HS806302 DEP TRA, P163; FELDSTEIN BD, 1985, ANN EMERG MED, V14, P36, DOI 10.1016/S0196-0644(85)80733-2; FRYKBERG ER, 1988, ANN SURG, V208, P569, DOI 10.1097/00000658-198811000-00005; Goodwin C, 1986, Top Emerg Med, V7, P20; GREGG MB, 1989, PUBLIC HLTH CONSEQUE, P5; HOOFT PJ, 1989, FORENSIC SCI INT, V40, P3, DOI 10.1016/0379-0738(89)90163-1; Irwin R. L., 1989, DISASTER RESPONSE PR, P133; JACOBS LM, 1979, J TRAUMA, V19, P157, DOI 10.1097/00005373-197903000-00005; LAVALLA R, 1983, BLUEPRINT COMMUNITY; MAHONEY LE, 1987, ANN EMERG MED, V16, P1085, DOI 10.1016/S0196-0644(87)80764-3; MASON JK, 1989, FORENSIC SCI INT, V40, P1, DOI 10.1016/0379-0738(89)90162-X; Melton R J, 1981, Ann Emerg Med, V10, P39, DOI 10.1016/S0196-0644(81)80459-3; MILLER PJ, 1980, INJURY, V12, P130, DOI 10.1016/0020-1383(80)90137-0; Mitchell G W, 1986, Top Emerg Med, V7, P34; Mitchell J., 1990, EMERGENCY SERVICES S; MITCHELL J, 1982, DOT HS806302 DEP TRA, P239; NOJI EK, 1990, ANN EMERG MED, V19, P891, DOI 10.1016/S0196-0644(05)81563-X; NOJI EK, 1987, DISASTERS, V11, P291; ORR SM, 1983, ANN EMERG MED, V12, P601, DOI 10.1016/S0196-0644(83)80203-0; PAGE JR, 1983, MANUAL DISASTER MANA; PESOLA G, 1989, CRIT CARE MED, V17, P582, DOI 10.1097/00003246-198906000-00021; PHILLIPS J, 1987, MANAGEMENT EMERGENCY, P95; PLANTE D M, 1989, Journal of Emergency Medicine, V7, P55, DOI 10.1016/0736-4679(89)90411-3; QUARANTELLI EL, 1985, DELIVERY EMERGENCY M; RAPHAEL B, 1989, ACTA PSYCHIAT SCAN S, V353, P1; RUTHERFORD WH, 1973, INJURY, V4, P189, DOI 10.1016/0020-1383(73)90038-7; Safar P., 1986, PREHOSP DISASTER MED, V2, P34, DOI DOI 10.1017/S1049023X00030314; SANNER PH, 1983, ANN EMERG MED, V12, P426, DOI 10.1016/S0196-0644(83)80338-2; SILVERSTEIN ME, 1984, TRIAGE DECISION TREE; Sklar DP, 1987, J WORLD ASS EMERG DI, V3, P49; Ueberle H K, 1985, Med Law, V4, P275; VAYER JS, 1986, ANN EMERG MED, V15, P927, DOI 10.1016/S0196-0644(86)80677-1; WAECKERLE JF, 1983, ANN EMERG MED, V12, P651, DOI 10.1016/S0196-0644(83)80218-2; Wenger D., 1986, 34 U DEL DIS RES CTR; 1989, 1990 ACCREDITATION M; 1990, DISASTER HIST SIGNIF; 1975, BMJ, V3, P727	49	120	121	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					815	821						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC442	1997854				2022-12-28	WOS:A1991FC44200006
J	MIDDLETON, J; BINYSH, K; CHISHTY, V; POLLOCK, G				MIDDLETON, J; BINYSH, K; CHISHTY, V; POLLOCK, G			WRITE THE ANNUAL-REPORT OF THE DIRECTOR OF PUBLIC-HEALTH	BRITISH MEDICAL JOURNAL			English	Article									DEPT HLTH LONDON,LONDON SW1A 2NS,ENGLAND; BROMSGROVE & REDDITCH HLTH AUTHOR,BROMSGROVE B61 0DJ,ENGLAND; W MIDLANDS REG HLTH AUTHOR,BIRMINGHAM B16 9PA,ENGLAND		MIDDLETON, J (corresponding author), SANDWELL HLTH AUTHOR,W BROMWICH B70 9LD,ENGLAND.							Ashton J, 1985, Health Educ J, V44, P178, DOI 10.1177/001789698504400407; ASHTON J, 1984, HLTH MERSEY REV; BINYSH K, 1985, HLTH COVENTRY; BINYSH K, 1986, COVENTRY HLTH 2000; BINYSH K, 1989, HLTH ED J, V48, P94; BOULTON G, 1985, MID GLAMORGAN DEPRIV; FRYER P, 1988, HLTH PROMOTION, V3, P213, DOI DOI 10.1093/HEAPRO/3.2.213; GARDNER K, 1984, LIVERPOOLS STATE HLT; MIDDLETON JD, 1987, COMMUNITY MED, V9, P343; Secretary of State for Social Services, 1988, PUBLIC HLTH ENGLAND; THUNHURST C, 1984, POVERTY HLTH CITY SH; Townsend P., 1982, INEQUALITIES HLTH BL; 1987, BRIT MED J, V295, P71; 1984, GLASGOW HLTH CITY; 1985, HLTH ALL; 1989, LIFE DEATH SANDWELL; 1982, HLTH INEQUALITIES MA; 1988, HLTH POPULATION RESP; 1988, HLH ALL NOTTINGHAM; 1985, TARGETS SUPPORT EURO; DYING OUR TIME HLTH	21	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					521	524		10.1136/bmj.302.6775.521	http://dx.doi.org/10.1136/bmj.302.6775.521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB055	2012852	Green Published, Bronze			2022-12-28	WOS:A1991FB05500027
J	TACHAKRA, SS; PAWSEY, S; BECKETT, M; POTTS, D; IDOWU, A				TACHAKRA, SS; PAWSEY, S; BECKETT, M; POTTS, D; IDOWU, A			OUTCOME OF PATIENTS WITH CHEST PAIN DISCHARGED FROM AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article									W MIDDLESEX HOSP,DEPT ACCID & EMERGENCY,ISLEWORTH TW7 6AF,ENGLAND	Imperial College London	TACHAKRA, SS (corresponding author), CENT MIDDLESEX HOSP,DEPT ACCID & EMERGENCY,LONDON NW10 7NS,ENGLAND.							COLQUHOUN MC, 1989, BMJ-BRIT MED J, V299, P433, DOI 10.1136/bmj.299.6696.433; Slosberg B, 1977, JACEP, V6, P445; TACHAKRA SS, 1987, BRIT J ACCIDENT EMER, V2, P8; WILCOX RG, 1981, BRIT MED J, V282, P431, DOI 10.1136/bmj.282.6262.431; 1985, LANCET, V2, P578	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					504	505		10.1136/bmj.302.6775.504	http://dx.doi.org/10.1136/bmj.302.6775.504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012846	Bronze, Green Published			2022-12-28	WOS:A1991FB05500019
J	MAKI, DG; KLEIN, BS; MCCORMICK, RD; ALVARADO, CJ; ZILZ, MA; STOLZ, SM; HASSEMER, CA; GOULD, J; LIEGEL, AR				MAKI, DG; KLEIN, BS; MCCORMICK, RD; ALVARADO, CJ; ZILZ, MA; STOLZ, SM; HASSEMER, CA; GOULD, J; LIEGEL, AR			NOSOCOMIAL PSEUDOMONAS-PICKETTII BACTEREMIAS TRACED TO NARCOTIC TAMPERING - A CASE FOR SELECTIVE DRUG SCREENING OF HEALTH-CARE PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAINING-PROGRAMS; INFECTION; OUTBREAK; DEATHS; ABUSE	Three patients in a university hospital developed nosocomial infusion-related Pseudomonas pickettii bacteremia. Investigation identified six additional patients who had received intravenous fluid contaminated by P pickettii but did not become ill. All nine patients had had surgery, and each of these patients but only nine of 19 operated-on control patients had received intravenous fentanyl citrate in the operating room; the mean dose given to the nine case patients was far greater than that given to control patients. Fentanyl in 20 (40%) of 50 predrawn 30-mL syringes was shown to be contaminated by P pickettii. Contamination was caused by theft of fentanyl from predrawn syringes and replacement by distilled water contaminated by P pickettii. Narcotic theft by health care personnel may cause patients to suffer pain needlessly and can also result in dire unanticipated consequences, such as nosocomial bacteremia. Whereas drug testing in the workplace is highly controversial, we believe that testing of health care personnel is indicated when drug abuse or theft is suspected.	UNIV WISCONSIN HOSP & CLIN,HOSP PHARM,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,DEPT MED,INFECT DIS SECT,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	MAKI, DG (corresponding author), UNIV WISCONSIN HOSP & CLIN,DEPT INFECT CONTROL,H4-574,MADISON,WI 53792, USA.							ANDERSON HJ, 1986, MOD HEALTHCARE, V16, P46; AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BUEHLER JW, 1985, NEW ENGL J MED, V313, P211, DOI 10.1056/NEJM198507253130402; DURANT W, 1967, AM J HOSP PHARM, V24, P112; GARDNER S, 1984, PEDIATR INFECT DIS J, V3, P420, DOI 10.1097/00006454-198409000-00006; GILARDI GL, 1985, MANUAL CLIN MICROBIO, P350; Goerth C R, 1985, Occup Health Saf, V54, P55; HALL RJ, 1978, INTRO HIGH PERFORMAN, P1; ISTRE GR, 1985, NEW ENGL J MED, V313, P205, DOI 10.1056/NEJM198507253130401; Japp H., 1981, CLIN MICROBIOL NEWSL, V3, P124; KAHAN A, 1983, J INFECTION, V7, P256, DOI 10.1016/S0163-4453(83)97196-7; KING A, 1979, J GEN MICROBIOL, V114, P137, DOI 10.1099/00221287-114-1-137; LABARBERA M, 1984, J PSYCHOACTIVE DRUGS, V15, P293; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; LEWIS DC, 1986, NEW ENGL J MED, V315, P826, DOI 10.1056/NEJM198609253151309; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V256, P3003, DOI 10.1001/jama.256.21.3003; MAKI DG, 1982, NEW ENGL J MED, V307, P1562, DOI 10.1056/NEJM198212163072507; MAKI DG, 1987, JAMA-J AM MED ASSOC, V258, P2396, DOI 10.1001/jama.258.17.2396; MAKI DG, 1980, 11TH P INT C CHEM 19, P1089; Maki DG, 1982, CURRENT TOPICS CLIN, P309; MAKI DG, 1981, CRC HDB HOSPITAL ACQ, P371; MAKI DG, 1977, MICROBIOLOGIC HAZARD, P13; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MORGAN JP, 1984, J PSYCHOACTIVE DRUGS, V16, P305, DOI 10.1080/02791072.1984.10472301; PHILLIPS I, 1972, LANCET, V1, P1258; PICKETT MJ, 1980, J GEN MICROBIOL, V120, P439; RAKATANSKY H, 1987, NEW ENGL J MED, V316, P694; RILEY PS, 1975, J CLIN MICROBIOL, V1, P61, DOI 10.1128/JCM.1.1.61-64.1975; ROBERTS LA, 1990, MED J AUSTRALIA, V152, P652, DOI 10.5694/j.1326-5377.1990.tb125422.x; ROSENBERG M, 1986, J ORAL MAXIL SURG, V44, P458, DOI 10.1016/S0278-2391(86)80011-8; SPIEGELMAN WG, 1981, ANESTHESIOLOGY, V60, P335; VERSCHRAEGEN G, 1985, J CLIN MICROBIOL, V21, P278, DOI 10.1128/JCM.21.2.278-279.1985; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; ZIPORYN T, 1986, JAMA-J AM MED ASSOC, V256, P3061, DOI 10.1001/jama.256.22.3061; 1987, REGULATORY DIGEST	37	54	54	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					981	986		10.1001/jama.265.8.981	http://dx.doi.org/10.1001/jama.265.8.981			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1992211				2022-12-28	WOS:A1991EY43200025
J	METCALFE, MA; BAUM, JD				METCALFE, MA; BAUM, JD			INCIDENCE OF INSULIN-DEPENDENT DIABETES IN CHILDREN AGED UNDER 15 YEARS IN THE BRITISH-ISLES DURING 1988	BRITISH MEDICAL JOURNAL			English	Article							INCREASING INCIDENCE; MELLITUS; EPIDEMIOLOGY; SCOTLAND	Objective-To ascertain the annual incidence rate of insulin dependent diabetes diagnosed in children under the age of 15 years in the British Isles during 1988, and to compare the results with an earlier study carried out in 1973-4. Design-Active monthly reporting of cases by consultant paediatricians, with additional input from diabetologists and all specialist diabetes nurses and health visitors. Setting-British Isles (England, Wales, Scotland, Northern Ireland, Republic of Ireland) with a total population at risk of 11 819 000 children. Patients-All children diagnosed under the age of 15 years with primary insulin dependent diabetes from 1 January to 31 December 1988 and resident in the British Isles at diagnosis. Main outcome measures-National incidence rate of insulin dependent diabetes; differences in incidence rates between regions and between three age groups: 4 and under, 5-9, and 10-14 year olds. Results-1600 children (837 boys and 763 girls) had a confirmed diagnosis of insulin dependent diabetes, giving a national incidence rate of 13.5/100 000/year (95% confidence interval 12.9 to 14.2/100 000/year). This was considerably higher than the incidence rate of 7.7/100 000/year in children under the age of 16 years reported in the British Diabetic Association's study of 1973-4. The age-sex adjusted rates varied between regions, ranging from 6.8/100 000/year (Republic of Ireland) to 19.8/100 000/year (Scotland). There were considerable differences in the numbers of cases diagnosed each month, with the 10-14 year age group showing the most seasonal variation. A quarter of the children (404/1600) were under 5 years old. Case ascertainment was estimated as 90%. Conclusions-Insulin dependent diabetes in the British Isles does not seem to occur uniformly over time or geographical area. Even allowing for differences in ascertainment between the 1973-4 and 1988 studies, there seems to have been an increase in the incidence rate of insulin dependent diabetes in children under the age of 15 years during the 15 year time period. If diabetes is becoming more common in this age group, possibly by developing earlier in susceptible children, this would be a matter of considerable public health concern.	ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND	Bristol Royal Hospital For Children; University of Bristol								[Anonymous], 1982, GEIGY SCI TABLES; ARMITAGE P, 1987, JSTATISTICAL METHODS; BARCLAY RPC, 1988, SCOT MED J, V33, P237, DOI 10.1177/003693308803300205; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BLOOM A, 1975, BRIT MED J, V3, P580, DOI 10.1136/bmj.3.5983.580; BURDEN AC, 1989, DIABETIC MED, V6, P334; DAHLQUIST G, 1985, DIABETOLOGIA, V28, P802, DOI 10.1007/BF00291068; FREEDMAN LS, 1979, J EPIDEMIOL COMMUNIT, V33, P233; Hall S M, 1988, Arch Dis Child, V63, P344; JONER G, 1989, DIABETOLOGIA, V32, P79, DOI 10.1007/BF00505178; JONES C, 1990, POPULATION TRENDS, V60, P31; LESLIE PJ, 1990, DIABETIC MED S2, V7, pA24; MATSUURA N, 1981, TOHOKU J EXP MED S, V141, P181; NYSTROM L, 1990, INT J EPIDEMIOL, V19, P141, DOI 10.1093/ije/19.1.141; PATTERSON CC, 1988, DIABETIC MED, V5, P160, DOI 10.1111/j.1464-5491.1988.tb00964.x; PATTERSON CC, 1983, DIABETOLOGIA, V24, P238, DOI 10.1007/BF00282706; REUNANEN A, 1982, ACTA PAEDIATR SCAND, V71, P893, DOI 10.1111/j.1651-2227.1982.tb09545.x; REWERS M, 1987, DIABETES, V36, P106, DOI 10.2337/diabetes.36.1.106; SOLTESZ G, 1990, DIABETIC MED, V7, P111, DOI 10.1111/j.1464-5491.1990.tb01343.x; WILLIAMS DRR, 1989, DIABETIC MED, V6, P320, DOI 10.1111/j.1464-5491.1989.tb01172.x; 1989, 1988 POPULATION ESTI; 1986, ISLE MAN INTERIM CEN; 1987, CENSUS 86 SUMMARY PO; 1987, 1986 EC ADV OFF REP; 1990, KEY POPULATION VIT 5; 1989, 3RD BRIT PAED SURV U; 1990, 67TH REG GEN OFF; 1973, CENSUS POPULATION IR, V2; 1987, GUERNSEY CENSUS 1986; 1975, CENSUS POPULATION 19; 1987, BMJ, V295, P479; 1987, DIRECTORY NURSES SPE; 1973, CENSUS 1971 SUMMARY	34	78	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					443	447		10.1136/bmj.302.6774.443	http://dx.doi.org/10.1136/bmj.302.6774.443			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004172	Green Published, Bronze			2022-12-28	WOS:A1991EZ03300021
J	LECHNER, J; CARBON, J				LECHNER, J; CARBON, J			A 240-KD MULTISUBUNIT PROTEIN COMPLEX, CBF3, IS A MAJOR COMPONENT OF THE BUDDING YEAST CENTROMERE	CELL			English	Article							BASE-PAIR MUTATIONS; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; TRANSCRIPTION FACTOR; DNA; PURIFICATION; INVITRO; CHROMOSOMES; DIGESTION; HISTONES	A key protein component (CBF3) of the budding yeast (S. cerevisiae) centromere/kinetochore has been purified and characterized. CBF3 is a 240 kd multisubunit protein complex that binds specifically to the yeast wild-type centromere DNA (CEN), but not to nonfunctional CEN DNA containing a single base substitution in the critical CDEIII consensus sequence. When purified by affinity chromatography, CBF3 contains three protein components: CBF3A (110 kd), CBF3B (64 kd), and CBF3C (58 kd). Highly purified CBF3 requires the presence of a separate assembly factor or chaperone activity to bind to CEN DNA. Treatment with phosphatase inactivates CBF3, indicating that at least one of the CBF3 subunits must be phosphorylated for DNA binding to occur. A 56 bp region including the 26 bp CDEIII consensus is protected from DNAase I cleavage in the CBF3-CEN DNA complex.			LECHNER, J (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106, USA.				NATIONAL CANCER INSTITUTE [R01CA011034] Funding Source: NIH RePORTER; NCI NIH HHS [CA-11034] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RE, 1989, J BIOL CHEM, V264, P10843; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brinkley B.R., 1989, MITOSIS MOL MECHANIS, P77; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARBON J, 1990, New Biologist, V2, P10; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1983, NATURE, V305, P23, DOI 10.1038/305023a0; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOTAREL G, 1989, MOL CELL BIOL, V9, P3342; CUMBERLEDGE S, 1987, GENETICS, V117, P203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; FUTCHER B, 1986, MOL CELL BIOL, V6, P2213, DOI 10.1128/MCB.6.6.2213; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; JIANG WD, 1989, MOL CELL BIOL, V9, P5585, DOI 10.1128/MCB.9.12.5585; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OW RA, 1987, J BIOL CHEM, V262, P3409; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SINGER MF, 1982, INT REV CYTOL, V76, P67, DOI 10.1016/S0074-7696(08)61789-1; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3	44	277	288	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					717	725		10.1016/0092-8674(91)90501-O	http://dx.doi.org/10.1016/0092-8674(91)90501-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997204				2022-12-28	WOS:A1991EZ47800007
J	PECORA, R				PECORA, R			DNA - A MODEL-COMPOUND FOR SOLUTION STUDIES OF MACROMOLECULES	SCIENCE			English	Article							TRANSIENT ELECTRIC BIREFRINGENCE; DYNAMIC LIGHT-SCATTERING; ROTATIONAL DIFFUSION-COEFFICIENTS; SYMMETRIC TOP MACROMOLECULES; ELASTIC HINGE MODEL; RESTRICTION FRAGMENTS; WORMLIKE CHAINS; CIRCULAR-CYLINDERS; AQUEOUS-SOLUTIONS; STIFF CHAINS	Well-defined, monodisperse, homologous series of oligonucleotides and DNA restriction fragments may now be produced and used as models of rigid and semirigid rodlike molecules in solution. Information from optical experiments on these model systems aids in the formulation and testing of theories of macromolecular dynamics in both dilute and concentrated solution.			PECORA, R (corresponding author), STANFORD UNIV,CHEM,STANFORD,CA 94305, USA.							ALLISON SA, 1990, MACROMOLECULES, V23, P1110, DOI 10.1021/ma00206a033; ARAGON SR, 1987, MACROMOLECULES, V20, P370, DOI 10.1021/ma00168a025; ARGON SR, 1985, MACROMOLECULES, V18, P1868; BERNE B. J., 1976, DYNAMIC LIGHT SCATTE; BLOOMFIELD VA, 1985, DYNAMIC LIGHT SCATTE; BOTT SE, 1984, THESIS STANFORD U ST; BRIAN AA, 1981, BIOPOLYMERS, V20, P1305, DOI 10.1002/bip.1981.360200615; DEGIORGIO V, 1990, PHYS REV LETT, V64, P1043, DOI 10.1103/PhysRevLett.64.1043; DELATORRE JG, 1984, BIOPOLYMERS, V23, P611, DOI 10.1002/bip.360230402; DIEKMANN S, 1982, BIOPHYS CHEM, V15, P263, DOI 10.1016/0301-4622(82)80009-4; Doi M., 1988, THEORY POLYM DYNAMIC; EIMER W, 1990, BIOCHEMISTRY-US, V29, P799, DOI 10.1021/bi00455a030; EIMER W, 1987, THESIS BIELEFELD U B; EIMER W, IN PRESS J CHEM PHYS; ELIAS JG, 1981, BIOPOLYMERS, V20, P2369, DOI 10.1002/bip.1981.360201107; ELIAS JG, 1981, MACROMOLECULES, V14, P410, DOI 10.1021/ma50003a034; FRIED MG, 1984, BIOPOLYMERS, V23, P2141, DOI 10.1002/bip.360231104; FULMER AW, 1981, BIOPOLYMERS, V20, P1147, DOI 10.1002/bip.1981.360200606; GOINGA HT, UNPUB; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HAGERMAN PJ, 1983, BIOPOLYMERS, V22, P811, DOI 10.1002/bip.360220303; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1481, DOI 10.1002/bip.1981.360200709; HARD T, 1986, BIOPOLYMERS, V25, P1519, DOI 10.1002/bip.360250810; HERVET H, 1978, J CHEM PHYS, V68, P2725, DOI 10.1063/1.436110; KITANO T, 1977, POLYM J, V2, P153; LEWIS RJ, 1985, MACROMOLECULES, V18, P1530, DOI 10.1021/ma00150a003; LEWIS RJ, 1985, MACROMOLECULES, V18, P944, DOI 10.1021/ma00147a022; LEWIS RJ, 1988, J CHEM PHYS, V89, P2490, DOI 10.1063/1.455043; LEWIS RJ, 1987, MACROMOLECULES, V20, P2579, DOI 10.1021/ma00176a044; LEWIS RJ, 1981, MACROMOLECULES, V19, P134; LEWIS RJ, 1985, THESIS STANFORD U ST; MANDELKERN M, 1981, J MOL BIOL, V152, P153, DOI 10.1016/0022-2836(81)90099-1; NICOLAI T, 1989, MACROMOLECULES, V22, P2348, DOI 10.1021/ma00195a059; NICOLAI T, 1989, MACROMOLECULES, V22, P438, DOI 10.1021/ma00191a080; PECORA R, 1968, J CHEM PHYS, V49, P1032, DOI 10.1063/1.1670188; PECORA R, 1964, J CHEM PHYS, V40, P1604, DOI 10.1063/1.1725368; PECORA R, 1968, J CHEM PHYS, V48, P4126, DOI 10.1063/1.1669748; Pecora R, 1985, BER BUNSEN PHYS CHEM, DOI DOI 10.1002/BBPC.19870910455; POST CB, 1982, BIOPOLYMERS, V21, P2139, DOI 10.1002/bip.360211105; POST CB, 1982, BIOPOLYMERS, V21, P2123, DOI 10.1002/bip.360211104; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Roitman D. B., 1987, ROTATIONAL DYNAMICS, P192; ROITMAN DB, 1984, J CHEM PHYS, V81, P6333, DOI 10.1063/1.447542; ROITMAN DB, 1984, J CHEM PHYS, V81, P6348, DOI 10.1063/1.447543; RONDELEZ F, 1980, LASER SCATTERING FLU; SCALETTAR BA, 1989, MACROMOLECULES, V22, P4550, DOI 10.1021/ma00202a030; Schmitz K. S., 1990, INTRO DYNAMIC LIGHT; SCHULZ SF, 1990, J CHEM PHYS, V92, P7087, DOI 10.1063/1.458249; SCHURR JM, 1986, ANNU REV PHYS CHEM, V37, P271; SEILS J, UNPUB; SORLIE SS, 1990, MACROMOLECULES, V23, P487, DOI 10.1021/ma00204a022; SORLIE SS, 1988, MACROMOLECULES, V21, P1437, DOI 10.1021/ma00183a039; STELLWAGEN NC, 1981, BIOPOLYMERS, V20, P399, DOI 10.1002/bip.1981.360200302; STRZELECKA TE, 1990, BIOPOLYMERS, V30, P57, DOI 10.1002/bip.360300108; STRZELECKA TE, 1987, J AM CHEM SOC, V109, P4513, DOI 10.1021/ja00249a014; SZWARC M, 1956, J AM CHEM SOC, V78, P2656, DOI 10.1021/ja01592a101; TIRADO MM, 1979, J CHEM PHYS, V71, P2581, DOI 10.1063/1.438613; TIRADO MM, 1980, J CHEM PHYS, V73, P1986, DOI 10.1063/1.440288; TIRADO MM, 1984, J CHEM PHYS, V81, P2047, DOI 10.1063/1.447827; VENABLE RM, 1988, BIOPOLYMERS, V27, P1001, DOI 10.1002/bip.360270609; VOORDOUW G, 1978, BIOPHYS CHEM, V8, P71; WANG L, IN PRESS MACROMOLECU; WEBSTER OW, 1991, SCIENCE, V251, P887, DOI 10.1126/science.251.4996.887; WIDOM J, 1983, BIOPOLYMERS, V22, P1595, DOI 10.1002/bip.360220612; WIDOM J, 1983, BIOPOLYMERS, V22, P1621, DOI 10.1002/bip.360220613; WILLIAMSON JR, 1989, BIOCHEMISTRY-US, V28, P2819, DOI 10.1021/bi00433a012; YAMAKAWA H, 1976, J CHEM PHYS, V64, P5222, DOI 10.1063/1.432197; Yamakawa H., 1971, MODERN THEORY POLYM; YOSHIZAKI T, 1984, J CHEM PHYS, V81, P982, DOI 10.1063/1.447699; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462	70	64	66	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					893	898		10.1126/science.2000490	http://dx.doi.org/10.1126/science.2000490			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000490				2022-12-28	WOS:A1991EY62900034
J	SERDULA, M; WILLIAMSON, DF; KENDRICK, JS; ANDA, RF; BYERS, T				SERDULA, M; WILLIAMSON, DF; KENDRICK, JS; ANDA, RF; BYERS, T			TRENDS IN ALCOHOL-CONSUMPTION BY PREGNANT-WOMEN - 1985 THROUGH 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE; PATTERNS; DRINKING; SMOKING	To examine trends in alcohol consumption among pregnant women, we examined data collected from 21 states participating in the Behavioral Risk Factor Surveillance System for 4 consecutive years: 1985 through 1988. Overall, 429 (25%) of 1712 pregnant women and 19 903 (55%) of 36 057 nonpregnant women 18 to 45 years of age reported using alcohol in the previous month. Pregnant women who used any alcohol reported consuming a median of four drinks per month, whereas nonpregnant women who used any alcohol reported nine. The prevalence of alcohol consumption among pregnant women declined steadily, from 32% in 1985 to 20% in 1988, but the median number of drinks per month for pregnant women who drank did not change. No decline was observed among the less educated or those under the age of 25 years. In 1988, the prevalence of alcohol use among pregnant women remained highest among smokers (37%) and the unmarried (28%). Although the overall consumption of alcohol by pregnant women in the United States appears to be declining, special efforts are needed to reduce alcohol use among pregnant women who are smokers, unmarried, less educated, or younger, women who may already be at high risk of a poor pregnancy outcome.	CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,DIV REPROD HLTH,ATLANTA,GA 30333; CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	SERDULA, M (corresponding author), CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR K26,ATLANTA,GA 30333, USA.							Dean A. G., 1990, EPI INFO VERSION 5 W; DIXON WJ, 1988, BMDP STATISTICAL SOF, V1, P133; JOHNSON SF, 1987, AM J EPIDEMIOL, V126, P695, DOI 10.1093/oxfordjournals.aje.a114709; KUZMA JW, 1981, NEUROBEH TOXICOL TER, V3, P211; LITTLE BB, 1989, OBSTET GYNECOL, V74, P547; MARBURY MC, 1983, AM J PUBLIC HEALTH, V73, P1165, DOI 10.2105/AJPH.73.10.1165; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; PRAGER K, 1984, PUBLIC HEALTH REP, V99, P117; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SMITH PF, 1990, AM J PUBLIC HEALTH, V80, P309, DOI 10.2105/AJPH.80.3.309; STREISSGUTH AP, 1983, AM J OBSTET GYNECOL, V145, P716, DOI 10.1016/0002-9378(83)90579-3; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; 1990, HEALTHY PEOPLE 2000; 1987, PHS DHHS ADM871519 S; 1986, SUGI SUPPLEMENTAL LI, P269; 1986, 1990 HLTH OBJECTIVES, P49; 1988, PHS891992 US DEP HLT; 1981, FDA DRUG B, V11, P9	20	90	91	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					876	879		10.1001/jama.265.7.876	http://dx.doi.org/10.1001/jama.265.7.876			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EX587	1992184				2022-12-28	WOS:A1991EX58700038
J	CLEMMER, CR; BEEBE, TP				CLEMMER, CR; BEEBE, TP			GRAPHITE - A MIMIC FOR DNA AND OTHER BIOMOLECULES IN SCANNING TUNNELING MICROSCOPE STUDIES	SCIENCE			English	Article							TUNNELLING MICROSCOPY; NUCLEIC-ACIDS	Highly ordered pyrolytic graphite (HOPG) is the substrate often used in scanning tunneling microscope (STM) studies of biomolecules such as DNA. All of the images presented in this article are of freshly cleaved HOPG surfaces upon which no deposition has occurred. These images illustrate features previously thought to be due to biological molecules, such as periodicity and meandering of "molecules" over steps. These features can no longer be used to distinguish real molecules from features of the native substrate. The feasibility of the continued use of HOPG as a substrate for biological STM studies is discussed.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,CTR BIOPOLYMERS INTERFACES,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCRR NIH HHS [S07RR07092] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007092] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBRECHT TR, 1988, APPL PHYS LETT, V52, P362, DOI 10.1063/1.99465; AMREIN M, 1989, SCIENCE, V243, P1708, DOI 10.1126/science.2928803; ARSCOTT PG, 1989, NATURE, V339, P484, DOI 10.1038/339484a0; BEEBE TP, 1989, SCIENCE, V243, P370, DOI 10.1126/science.2911747; Binnig G., 1984, TRENDS PHYSICS, P38; BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57; CHANG H, UNPUB; CLEMMER CR, UNPUB; CRICENTI A, IN PRESS J VAC SCI A; DEROSE JA, IN PRESS J VAC SCI A; DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0; DUNLAP DD, 1989, NATURE, V342, P204, DOI 10.1038/342204a0; HEBEN MJ, 1989, J MICROSC-OXFORD, V152, P651; KELLER D, 1989, P NATL ACAD SCI USA, V86, P5356, DOI 10.1073/pnas.86.14.5356; KUWABARA M, 1990, APPL PHYS LETT, V56, P2396, DOI 10.1063/1.102906; LEE G, 1989, SCIENCE, V244, P475, DOI 10.1126/science.2470146; LINDSAY SM, 1988, J VAC SCI TECHNOL A, V6, P543; Liu C.-P., UNPUB; LYDING JW, 1988, J MICROSC-OXFORD, V152, P371, DOI 10.1111/j.1365-2818.1988.tb01398.x; MARTI O, 1987, SURF SCI, V181, P230, DOI 10.1016/0039-6028(87)90163-4; MOORE AW, 1981, CHEM PHYS CARBON, V17, P233; SALEMINK HWM, 1987, SURF SCI, V181, P139, DOI 10.1016/0039-6028(87)90150-6; SALMERON M, 1990, J VAC SCI TECHNOL A, V8, P635, DOI 10.1116/1.576361; SOTO MR, 1990, SURF SCI, V225, P190, DOI 10.1016/0039-6028(90)90437-D; Thrower P.A., 1969, CHEM PHYS CARBON, V5, P217; THUNDAT T, IN PRESS J VAC SCI A; WILSON TE, IN PRESS J VAC SCI A; YOUNGQUIST MG, IN PRESS J VAC SCI A; ZEGLINSKI DM, IN PRESS REV SCI INS; IN PRESS J VAC SCI A	30	288	294	1	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					640	642		10.1126/science.1992517	http://dx.doi.org/10.1126/science.1992517			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1992517				2022-12-28	WOS:A1991EW39900036
J	RUVKUN, G; FINNEY, M				RUVKUN, G; FINNEY, M			REGULATION OF TRANSCRIPTION AND CELL IDENTITY BY POU DOMAIN PROTEINS	CELL			English	Review							DNA-SEQUENCE; BINDING; COMPLEX; OCT-1		HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School	RUVKUN, G (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA.							CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TREISMAN J, 1989, CELL, V59, P553; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	29	231	233	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					475	478		10.1016/0092-8674(91)90227-P	http://dx.doi.org/10.1016/0092-8674(91)90227-P			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991317				2022-12-28	WOS:A1991EX36100002
J	LIPOWSKY, R				LIPOWSKY, R			THE CONFORMATION OF MEMBRANES	NATURE			English	Review							AVOIDING TETHERED MEMBRANES; RED BLOOD-CELL; FLUID MEMBRANES; RENORMALIZATION-GROUP; CRUMPLING TRANSITION; PHOSPHOLIPID-VESICLES; POLYMERIZED MEMBRANES; UNILAMELLAR VESICLES; THERMAL FLUCTUATIONS; ELECTRIC-FIELDS	Membranes composed of amphiphilic molecules are highly flexible surfaces that determine the architecture of biological systems and provide a basic structural element for complex fluids such as microemulsions. Physical theories have been developed to describe many aspects of their conformational behaviour, such as the preferred shapes and shape transformations of closed vesicles, and the shape fluctuations, random-surface configurations, and adhesion and unbinding of interacting membranes. Understanding of these phenomena has been much improved through fruitful interactions between theory and experiment.			LIPOWSKY, R (corresponding author), FORSCHUNGSZENTRUM JULICH,INST FESTKORPERFORSCH,W-5170 JULICH,GERMANY.		Zdilla, Michael J/B-4145-2011; Wunder, Stephanie L/B-5066-2012	Lipowsky, Reinhard/0000-0001-8417-8567				ABRAHAM FF, 1990, SCIENCE, V249, P393, DOI 10.1126/science.249.4967.393; ABRAHAM FF, 1989, PHYS REV LETT, V62, P1757, DOI 10.1103/PhysRevLett.62.1757; Alberts B., 1983, MOL BIOL CELL, V4; Anderson D. M., 1987, PHYS AMPHIPHILIC LAY, P130; BADER H, 1985, ADV POLYM SCI, V64, P1; BANGHAM AD, 1964, J MOL BIOL, V8, P660, DOI 10.1016/S0022-2836(64)80115-7; BAUMGARTNER A, 1990, PHYS REV A, V41, P5747, DOI 10.1103/PhysRevA.41.5747; BERNDL K, 1990, EUROPHYS LETT, V13, P659, DOI 10.1209/0295-5075/13/7/015; BROCHARD F, 1975, J PHYS-PARIS, V36, P1035, DOI 10.1051/jphys:0197500360110103500; CANHAM PB, 1970, J THEOR BIOL, V26, P61, DOI 10.1016/S0022-5193(70)80032-7; CATES ME, 1988, EUROPHYS LETT, V5, P733, DOI 10.1209/0295-5075/5/8/012; CATES ME, 1988, EUROPHYS LETT, V7, P94, DOI 10.1209/0295-5075/7/1/017; CEVC G, 1990, SCIENCE, V249, P1161, DOI 10.1126/science.249.4973.1161; Clegg R. M., 1985, PROGR PROTEIN LIPID, P173; CZAJA C, 1988, 1987 BIOS INT WORKSH, P339; DAVID F, 1987, J PHYS-PARIS, V48, P2059, DOI 10.1051/jphys:0198700480120205900; DAVID F, 1990, PHYS REV B, V41, P12926, DOI 10.1103/PhysRevB.41.12926; DAVID F, 1988, EUROPHYS LETT, V5, P709, DOI 10.1209/0295-5075/5/8/008; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1982, J PHYS CHEM-US, V86, P2294, DOI 10.1021/j100210a011; DEULING HJ, 1976, J PHYS-PARIS, V37, P1335, DOI 10.1051/jphys:0197600370110133500; DIMIGLIO JM, 1985, PHYS REV LETT, V54, P1686; do Carmo M.P., 2017, DIFFERENTIAL GEOMETR, V2nd ed.; DUBOISVIOLETTE E, 1990, J PHYS C FRANCE, V7; DUWE HP, 1990, J PHYS-PARIS, V51, P945, DOI 10.1051/jphys:019900051010094500; ELGSAETER A, 1986, SCIENCE, V234, P1217, DOI 10.1126/science.3775380; ENGELHARDT H, 1988, BIOPHYS J, V54, P495, DOI 10.1016/S0006-3495(88)82982-5; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; EVANS EA, 1974, BIOPHYS J, V14, P923, DOI 10.1016/S0006-3495(74)85959-X; Frenkel Y., 1946, KINETIC THEORY LIQUI; FROMHERZ P, 1986, FARADAY DISCUSS, V81, P39, DOI 10.1039/dc9868100039; GABRIEL NE, 1984, BIOCHEMISTRY-US, V23, P4011, DOI 10.1021/bi00313a001; GROTEHANS S, 1990, PHYS REV A, V41, P4574, DOI 10.1103/PhysRevA.41.4574; GUNNING BES, 1965, PROTOPLASMA, V60, P111, DOI 10.1007/BF01248133; HARBICH W, 1978, Z NATURFORSCH A, V33, P1013, DOI 10.1515/zna-1978-0903; HARBICH W, 1979, Z NATURFORSCH A, V34, P1063; HAUSER H, 1983, BIOCHEMISTRY-US, V22, P4775, DOI 10.1021/bi00289a025; HELFRICH W, 1985, J PHYS-PARIS, V46, P1263, DOI 10.1051/jphys:019850046070126300; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; Helfrich W., 1987, PHYSICS AMPHIPHILIC, V21, P58; HO JS, 1989, PHYS REV LETT, V63, P1324, DOI 10.1103/PhysRevLett.63.1324; HUSE DA, 1988, J PHYS-PARIS, V49, P605, DOI 10.1051/jphys:01988004904060500; ISRAELACHVILI JN, 1990, LANGMUIR, V6, P873, DOI 10.1021/la00094a028; Israelachvili JN, 1985, INTERMOLECULAR SURFA; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KANTOR Y, 1987, PHYS REV LETT, V58, P2774, DOI 10.1103/PhysRevLett.58.2774; KANTOR Y, 1987, PHYS REV A, V35, P3056, DOI 10.1103/PhysRevA.35.3056; KARCHER H, 1989, MANUSCRIPTA MATH, V64, P291, DOI 10.1007/BF01165824; KORNBERG RD, 1971, P NATL ACAD SCI USA, V68, P2564, DOI 10.1073/pnas.68.10.2564; Landau L.D., 1970, THEORY ELASTICITY; LARCHE FC, 1986, PHYS REV LETT, V56, P1700, DOI 10.1103/PhysRevLett.56.1700; LASIC DD, 1988, BIOCHEM J, V256, P1; LEIBLER S, 1987, PHYS REV LETT, V59, P1989, DOI 10.1103/PhysRevLett.59.1989; LEIBLER S, 1987, PHYS REV B, V35, P7004, DOI 10.1103/PhysRevB.35.7004; LEIBLER S, 1989, PHYS REV LETT, V63, P406, DOI 10.1103/PhysRevLett.63.406; LIPOWSKY R, 1989, PHYS REV LETT, V62, P1572, DOI 10.1103/PhysRevLett.62.1572; LIPOWSKY R, 1990, PHYS REV LETT, V65, P2893, DOI 10.1103/PhysRevLett.65.2893; LIPOWSKY R, 1989, PHYS REV A, V40, P2078, DOI 10.1103/PhysRevA.40.2078; LIPOWSKY R, 1986, PHYS REV LETT, V56, P2541, DOI 10.1103/PhysRevLett.56.2541; LIPOWSKY R, 1987, PHYS REV LETT, V59, P1983, DOI 10.1103/PhysRevLett.59.1983; LIPOWSKY R, 1988, EUROPHYS LETT, V7, P255, DOI 10.1209/0295-5075/7/3/012; LIPOWSKY R, 1989, PHYS REV LETT, V62, P704, DOI 10.1103/PhysRevLett.62.704; LIPOWSKY R, 1987, PHYS REV B, V36, P2126, DOI 10.1103/PhysRevB.36.2126; LIPOWSKY R, 1989, PHYS SCRIPTA, VT29, P259, DOI 10.1088/0031-8949/1989/T29/050; Lipowsky R., 1990, FUNDAMENTAL PROBLEMS, P139; LIPOWSKY R, 1990, 13TH P INT LIQ CRYST; LIS LJ, 1981, BIOCHEMISTRY-US, V20, P1771, DOI 10.1021/bi00510a010; LONGLEY W, 1983, NATURE, V303, P612, DOI 10.1038/303612a0; LUZZATI V, 1968, NATURE, V220, P485, DOI 10.1038/220485a0; MARRA J, 1985, BIOCHEMISTRY-US, V24, P4608, DOI 10.1021/bi00338a020; MILNER ST, 1987, PHYS REV A, V36, P4371, DOI 10.1103/PhysRevA.36.4371; MUTZ M, 1989, PHYS REV LETT, V62, P2881, DOI 10.1103/PhysRevLett.62.2881; MUTZ M, 1990, J PHYS-PARIS, V51, P991, DOI 10.1051/jphys:019900051010099100; NELSON DR, 1987, J PHYS-PARIS, V48, P1085, DOI 10.1051/jphys:019870048070108500; NELSON DR, 1988, STATISTICAL MECHANIC; PARSEGIAN VA, 1979, P NATL ACAD SCI USA, V76, P2750, DOI 10.1073/pnas.76.6.2750; PELITI L, 1985, PHYS REV LETT, V54, P1690, DOI 10.1103/PhysRevLett.54.1690; PLISCHKE M, 1988, PHYS REV A, V38, P4943, DOI 10.1103/PhysRevA.38.4943; PORTE G, 1989, J PHYS-PARIS, V50, P1335, DOI 10.1051/jphys:0198900500110133500; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; SACKMANN E, 1986, FARADAY DISCUSS, V81, P281, DOI 10.1039/dc9868100281; SACKMANN E, 1985, BER BUNSEN PHYS CHEM, V89, P1198, DOI 10.1002/bbpc.19850891117; SACKMANN E, 1987, PHYSICS AMPHIPHILIC, P25; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SCRIVEN LE, 1976, NATURE, V263, P123, DOI 10.1038/263123a0; SEIFERT U, 1990, PHYS REV A, V42, P4768, DOI 10.1103/PhysRevA.42.4768; SEIFERT U, UNPUB PHYS REV A; SERVUSS RM, 1989, J PHYS-PARIS, V50, P809, DOI 10.1051/jphys:01989005007080900; SEUNG HS, 1988, PHYS REV A, V38, P1005, DOI 10.1103/PhysRevA.38.1005; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SVETINA S, 1989, EUR BIOPHYS J BIOPHY, V17, P101, DOI 10.1007/BF00257107; TALMON Y, 1983, SCIENCE, V221, P1047, DOI 10.1126/science.221.4615.1047; WAUGH R, 1979, BIOPHYS J, V26, P115, DOI 10.1016/S0006-3495(79)85239-X; WILSON KG, 1971, PHYS REV B, V4, P3184, DOI 10.1103/PhysRevB.4.3184; ZILKER A, 1987, J PHYS-PARIS, V48, P2139, DOI 10.1051/jphys:0198700480120213900; ZIMMERBERG J, 1987, BIOSCIENCE REP, V7, P251, DOI 10.1007/BF01121447	99	814	823	2	184	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					475	481		10.1038/349475a0	http://dx.doi.org/10.1038/349475a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992351				2022-12-28	WOS:A1991EW57100053
J	HOFMEYR, GJ; WILKINS, T; REDMAN, CWG				HOFMEYR, GJ; WILKINS, T; REDMAN, CWG			C4 AND PLASMA-PROTEIN IN HYPERTENSION DURING PREGNANCY WITH AND WITHOUT PROTEINURIA	BRITISH MEDICAL JOURNAL			English	Article							PRE-ECLAMPSIA		JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV WITWATERSRAND,PARKTOWN 2193,SOUTH AFRICA	University of Oxford; University of Witwatersrand								BERGE LN, 1988, ACTA OBSTET GYN SCAN, V67, P499, DOI 10.3109/00016348809029860; BUYON JP, 1986, AM J MED, V81, P194, DOI 10.1016/0002-9343(86)90251-2; MASSOBRIO M, 1985, AM J OBSTET GYNECOL, V152, P578, DOI 10.1016/0002-9378(85)90631-3; REDMAN CWG, 1986, CLIN OBSTET GYNAECOL, V13, P469; ROSIC B, 1988, Clinical and Experimental Obstetrics and Gynecology, V15, P157	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					218	218		10.1136/bmj.302.6770.218	http://dx.doi.org/10.1136/bmj.302.6770.218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998764	Green Published, Bronze			2022-12-28	WOS:A1991EV22800028
J	LEE, J				LEE, J			EVERYDAY AIDS AND APPLIANCES - BREAST PROSTHESES	BRITISH MEDICAL JOURNAL			English	Editorial Material											LEE, J (corresponding author), BREASTCARE & MASTECTOMY ASSOC,LONDON WC1 8JG,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					43	44		10.1136/bmj.302.6767.43	http://dx.doi.org/10.1136/bmj.302.6767.43			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991190	Green Published, Bronze			2022-12-28	WOS:A1991ER37200027
J	HSIAO, K; MEINER, Z; KAHANA, E; CASS, C; KAHANA, I; AVRAHAMI, D; SCARLATO, G; ABRAMSKY, O; PRUSINER, SB; GABIZON, R				HSIAO, K; MEINER, Z; KAHANA, E; CASS, C; KAHANA, I; AVRAHAMI, D; SCARLATO, G; ABRAMSKY, O; PRUSINER, SB; GABIZON, R			MUTATION OF THE PRION PROTEIN IN LIBYAN JEWS WITH CREUTZFELDT-JAKOB DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; SCRAPIE INCUBATION-TIME; HUNTINGTONS-DISEASE; GENE; POLYMORPHISM; LINKAGE; ANTICIPATION; ISRAEL	Background. Creutzfeldt-Jakob disease is a transmissible neurodegenerative disorder that occurs more than 100 times more frequently among Libyan Jews than in the worldwide population. We examined 11 patients with the disease - 10 Libyan Jews from Israel and 1 Libyan Jews from Italy - to determine whether abnormalities of the prion protein could be detected in them. Abnormal forms of this host-encoded protein are the predominant if not sole components of the transmissible agent that causes the disease. Methods. The prion-protein open-reading frame in peripheral-leukocyte DNA from the Italian patient was amplified with the polymerase chain reaction and sequenced. Allele-specific oligonucleotide hybridization was used to assess a prion-protein codon 200 lysine mutation in the 10 Israeli patients and 37 control subjects. Results. The prion-protein sequence in DNA from the Italian patient revealed a single nucleotide change (G --> A) at the first position of codon 200 that resulted in a substitution of lysine for glutamate. This substitution was detected in all 10 Israeli patients, 8 of whom had a positive family history of Creutzfeldt-Jakob disease. One patient was homozygous for the lysine mutation, and her clinical course did not differ from that of the patients heterozygous for the mutation. The lysine mutation was not found in one Moroccan Jew from Israel with Creutzfeldt-Jakob disease. Conclusions. The codon 200 lysine mutation of the prion-protein gene is consistently present among Libyan Jews with Creutzfeldt-Jakob disease, strongly supporting a genetic pathogenesis of their illness. The similarity of the clinical courses of the patient homozygous for this mutation and the patients heterozygous for it argues that familial Creutzfeldt-Jakob disease is a true dominant disorder.	HADASSAH UNIV HOSP,DEPT NEUROL,EIN KAREM,IL-91120 JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,ASHQELON,ISRAEL; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; BARZILAI GOVT HOSP,ASHQELON,ISRAEL; UNIV MILAN,OSPED MAGGIORE POLICLIN,IST CLIN NEUROL,I-20122 MILAN,ITALY	Hebrew University of Jerusalem; Ben Gurion University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ben Gurion University; Barzilai Medical Center; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Cass, Carol E/F-5861-2010	Kahana, Esther/0000-0002-3863-3271	NIA NIH HHS [AG-02132, AG-08967] Funding Source: Medline; NINDS NIH HHS [NS-14069] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS014069, P01NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008967, P01AG002132] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALPERS M, 1970, AM J TROP MED HYG, V19, P133, DOI 10.4269/ajtmh.1970.19.133; ALTER M, 1974, SCIENCE, V186, P848; ALTER M, 1976, SCIENCE, V192, P428, DOI 10.1126/science.192.4238.428-b; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BOCKMAN JM, 1985, NEW ENGL J MED, V312, P73, DOI 10.1056/NEJM198501103120202; BOCKMAN JM, 1987, ANN NEUROL, V21, P589, DOI 10.1002/ana.410210611; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DICKINSON AG, 1969, GENET RES, V13, P213, DOI 10.1017/S0016672300002895; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; Gajdusek D C, 1972, J Clin Pathol Suppl (R Coll Pathol), V6, P78, DOI 10.1136/jcp.25.Suppl_6.78; GOLDBERG H, 1979, SLOW TRANSMISSIBLE D, V1, P195; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; HERZBERG L, 1974, SCIENCE, V186, P848, DOI 10.1126/science.186.4166.848; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; HSIAO K, 1989, ANN NEUROL, V26, P137; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HSIAO KK, IN PRESS NEUROLOGY; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; KAHANA E, 1974, SCIENCE, V183, P90, DOI 10.1126/science.183.4120.90; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1979, SLOW TRANSMISSIBLE D, V1, P143; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; OWEN F, 1989, LANCET, V1, P51; PARRY HB, 1983, SCRAPIE DIS SHEEP, P31; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; RADHAKRISHNAN K, 1988, NEUROEPIDEMIOLOGY, V7, P42, DOI 10.1159/000110134; RIDLEY RM, 1988, J MED GENET, V25, P589, DOI 10.1136/jmg.25.9.589; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WILESMITH JW, 1988, VET REC, V123, P638	40	237	239	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1091	1097		10.1056/NEJM199104183241604	http://dx.doi.org/10.1056/NEJM199104183241604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008182	Bronze			2022-12-28	WOS:A1991FG91200004
J	GELBER, RD; GOLDHIRSCH, A; CAVALLI, F				GELBER, RD; GOLDHIRSCH, A; CAVALLI, F			QUALITY-OF-LIFE-ADJUSTED EVALUATION OF ADJUVANT THERAPIES FOR OPERABLE BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article							ENDPOINT; WOMEN	Objective: To evaluate a single cycle of adjuvant chemotherapy compared with longer duration chemotherapy for premenopausal women or chemoendocrine therapy for postmenopausal women with operable breast cancer using a quality-of-life-oriented end point, Q-TWiST (quality-adjusted analysis of TWiST: Time Without Symptoms and Toxicity). Design: Multicenter randomized clinical trial-International Breast Cancer Study Group (IBCSG: formerly Ludwig Group) Trial V. Setting: IBCSG participating centers in Sweden, Switzerland, Australia, Yugoslavia, Spain, New Zealand, Italy, Germany, and South Africa. Patients: Data were available for 1229 eligible patients with node-positive breast cancer who were randomized to receive one of three adjuvant treatments after at least a total mastectomy and axillary clearance. Interventions: Patients received either a single cycle of perioperative chemotherapy consisting of cyclophosphamide, methotrexate, fluorouracil, and leucovorin; or six cycles (6 months) of a conventionally timed chemotherapy consisting of cyclophosphamide, methotrexate, fluorouracil, and prednisone for premenopausal women or this combination plus tamoxifen for postmenopausal women; or both perioperative and conventionally timed chemotherapy for a 7-month course of adjuvant therapy. Results: At 5 years of median follow-up, patients who received the longer duration therapies had an improved 5-year disease-free survival percentage (53% compared with 36%; P < 0.001) and 5-year overall survival percentage (73% compared with 63%; P = 0.001) compared with those who received the single perioperative cycle alone. By 3.5 years, the greater burden of toxic effects associated with the longer duration treatments was balanced by their superior control of disease. Within 5 years of follow-up, even after subtracting time with adjuvant treatment toxicity, patients gained an average of 2.2 months of Q-TWiST if treated with the longer duration therapies compared with the single cycle (P = 0.03). The gain for premenopausal patients was 2.8 months (P = 0.05), whereas the gain for postmenopausal women was 1.5 months (P > 0.2). Conclusions: Six or seven months of adjuvant chemotherapy or chemoendocrine therapy improve both the quantity and quality of life for patients with node-positive breast cancer compared with a single short course of perioperative combination chemotherapy.	INT BREAST CANC STUDY GRP, OPERAT OFF, BERN, SWITZERLAND	International Breast Cancer Study Group	GELBER, RD (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV BIOSTAT & EPIDEMIOL, 44 BINNEY ST, BOSTON, MA 02115 USA.							[Anonymous], 1988, NEW ENGL J MED, V319, P1681; BONADONNA G, 1985, BREAST CANCER RES TR, V5, P95, DOI 10.1007/BF01805984; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; FISHER B, 1986, J CLIN ONCOL, V4, P929, DOI 10.1200/JCO.1986.4.6.929; GELBER RD, 1986, J CLIN ONCOL, V4, P1772, DOI 10.1200/JCO.1986.4.12.1772; GELBER RD, 1989, BIOMETRICS, V45, P781, DOI 10.2307/2531683; GLASZIOU PP, 1990, STAT MED, V9, P1259, DOI 10.1002/sim.4780091106; GOLDHIRSCH A, 1988, J CLIN ONCOL, V6, P89, DOI 10.1200/JCO.1988.6.1.89; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; GOLDHIRSCH A, 1988, NEW ENGL J MED, V319, P677; PRITCHARD KI, 1989, ANN INTERN MED, V111, P1, DOI 10.7326/0003-4819-111-1-1; RIVKIN S, 1990, AM SOC CLIN ONCOLOGY, V9, P24; STEWART HJ, 1987, LANCET, V2, P171; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Weinstein MC, 1980, CLIN DECISION ANAL; 1990, APR C STAT ADJ THER	17	141	141	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					621	628		10.7326/0003-4819-114-8-621	http://dx.doi.org/10.7326/0003-4819-114-8-621			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003707				2022-12-28	WOS:A1991FG03100002
J	SUBBIAH, S				SUBBIAH, S			LOW-RESOLUTION REAL-SPACE ENVELOPES - AN APPROACH TO THE ABINITIO MACROMOLECULAR PHASE PROBLEM	SCIENCE			English	Article							INFORMATION-THEORY; MAXIMUM-ENTROPY; CRYSTALLOGRAPHY; REFINEMENT; CRYSTAL; IMAGES	An ab initio approach to the phase problem in macromolecular x-ray crystallography is described. A random gas of hard-sphere point scatterers is allowed to condense under the constraint of the solvent fraction and the restraint of the observed Fourier amplitude data. Two applications to real macromolecular examples are discussed. This method produces an approximate outline of the bulk solvent regions and thus yields a low-resolution picture of the unit cell that can be extended to higher resolutions in special cases, such as through the use of molecular replacement or of noncrystallographic symmetry-based phase extension.			SUBBIAH, S (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM-41455] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041455, R37GM041455] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1986, P NATL ACAD SCI USA, V83, P5489, DOI 10.1073/pnas.83.15.5489; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRICOGNE G, 1984, ACTA CRYSTALLOGR A, V40, P410, DOI 10.1107/S0108767384000866; BRICOGNE G, 1982, COMPUTATIONAL CRYSTA, P258; BRITTEN PL, 1982, ACTA CRYSTALLOGR A, V38, P12; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLLINS DM, 1982, NATURE, V298, P49, DOI 10.1038/298049a0; COXETER HSM, 1961, INTRO GEOMETRY, P404; FLAHERTY KM, UNPUB; HAUPTMAN HA, 1972, CRYSTAL STRUCTURE DE; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARLE J, 1986, SCIENCE, V232, P837, DOI 10.1126/science.232.4752.837; KARLE J, 1950, ACTA CRYSTALLOGR, V3, P181, DOI 10.1107/S0365110X50000446; KARLE J, 1989, ACTA CRYSTALLOGR A, V45, P765, DOI 10.1107/S0108767389007403; KARLE J, 1980, INT J QUANTUM CHEM, V7, P357; KEEN DA, 1990, NATURE, V344, P423, DOI 10.1038/344423a0; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KLUG A, 1958, ACTA CRYSTALLOGR, V11, P515, DOI 10.1107/S0365110X58001456; KLUG A, 1958, ACTA CRYSTALLOGR A, V40, P11; LIPSCOMB WN, 1949, ACTA CRYSTALLOGR, V2, P193, DOI 10.1107/S0365110X49000515; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MONDRAGON A, 1989, J MOL BIOL, V205, P189, DOI 10.1016/0022-2836(89)90375-6; NARAYAN R, 1982, ACTA CRYSTALLOGR A, V38, P122, DOI 10.1107/S0567739482000229; NAVAZA J, 1985, ACTA CRYSTALLOGR A, V41, P222; Patterson AL, 1934, PHYS REV, V46, P0372, DOI 10.1103/PhysRev.46.372; PIRO OE, 1983, ACTA CRYSTALLOGR A, V39, P61, DOI 10.1107/S0108767383000094; PODJARNY AD, 1987, ANNU REV BIOPHYS BIO, V16, P351; POST B, 1979, ACTA CRYSTALLOGR A, V35, P17, DOI 10.1107/S0567739479000048; PRINCE E, 1988, ACTA CRYSTALLOGR A, V44, P218; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SEMENOVSKAYA SV, 1985, ACTA CRYSTALLOGR A, V41, P268, DOI 10.1107/S0108767385000563; SHEN W, 1987, NATURE, V329, P232, DOI 10.1038/329232a0; SUBBIAH S, UNPUB; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; THAYER M, IN PRESS J MOL BIOL; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; WILKINS SW, 1983, ACTA CRYSTALLOGR A, V39, P47, DOI 10.1107/S0108767383000082; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813	39	35	38	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					128	133		10.1126/science.2011749	http://dx.doi.org/10.1126/science.2011749			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011749				2022-12-28	WOS:A1991FE95200051
J	ANDERSON, C				ANDERSON, C			POLAR PSYCHOLOGY - COPING WITH IT ALL	NATURE			English	Editorial Material																			0	3	3	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					290	290		10.1038/350290a0	http://dx.doi.org/10.1038/350290a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD838	2008210				2022-12-28	WOS:A1991FD83800048
J	CHAPMAN, KR; VERBEEK, PR; WHITE, JG; REBUCK, AS				CHAPMAN, KR; VERBEEK, PR; WHITE, JG; REBUCK, AS			EFFECT OF A SHORT COURSE OF PREDNISONE IN THE PREVENTION OF EARLY RELAPSE AFTER THE EMERGENCY ROOM TREATMENT OF ACUTE ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE BRONCHIAL-ASTHMA; CORTICOSTEROID-THERAPY; CONTROLLED TRIAL; METHYLPREDNISOLONE	Background. Relapse after the treatment of acute asthma in the emergency room is common (occurring in 25 to 30 percent of cases) and is not accurately predicted by any available measurements. We studied the usefulness of prednisone in reducing this high rate of relapse. Methods. One hundred twenty-two patients treated in the emergency room for acute exacerbations of asthma were assigned in a randomized, double-blind fashion to receive at discharge either prednisone for eighty days (the dose being tapered from 40 to 0 mg per day) or matching placebo. Ninety-three were subsequently discharged from the emergency room and participated in the trial. On days 1, 7, and 14 after discharge, the patients were assessed during home visits with spirometry and diary-card review; they were contacted by telephone on day 21. Relapse was defined as an unscheduled medical visit occasioned by the patient's perceived need for further asthma treatment. Results. The overall risk of relapse was significantly lower in the prednisone group (P < 0.05), with a significantly reduced rate of relapse during the first 10 days of follow-up (3 of 48, as compared with 11 of 45 in the placebo group; P < 0.05). Thereafter (days 11 through 21), there was no further significant difference in relapse rates between treatment groups (five in the prednisone group and six in the placebo group). During the first week after discharge, patients receiving prednisone reported significantly lower mean (+/- SD) daily symptom scores for shortness of breath (1.4 +/- 0.4 vs. 2.5 +/- 0.4, P < 0.01) and less frequent use of an inhaled bronchodilator (5.2 +/- 0.5 vs. 6.9 +/- 0.2 puffs per day, P < 0.05) than patients receiving placebo. Subsequently, symptom scores and bronchodilator use were similar in the two groups. Conclusions. A short course of prednisone reduced early relapse rates after the treatment of acute asthma in the emergency room, an effect limited to the period of steroid administration.			CHAPMAN, KR (corresponding author), TORONTO HOSP,CTR ASTHMA,399 BATHURST ST,4TH FL,EDITH CAVELL WING,TORONTO M5T 2S8,ONTARIO,CANADA.							BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; CHAPMAN KR, 1989, THEOPHYLLINE SYMPTOM, P75; DEANGELIS C, 1985, AM J DIS CHILD, V139, P341, DOI 10.1001/archpedi.1985.02140060023018; ELLULMIC.R, 1974, CLIN SCI MOL MED, V47, P105, DOI 10.1042/cs0470105; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; FISCHL MA, 1981, NEW ENGL J MED, V305, P783, DOI 10.1056/NEJM198110013051402; FISCHL MA, 1985, BRONCHIAL ASTHMA MEC, P802; FITZGERALD JM, 1989, CHEST, V95, P888, DOI 10.1378/chest.95.4.888; GARDNER RM, 1979, AM REV RESPIR DIS, V119, P831; HOFFMAN IB, 1988, CHEST, V93, P11, DOI 10.1378/chest.93.1.11; KELSEN SG, 1978, AM J MED, V64, P622, DOI 10.1016/0002-9343(78)90582-X; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; MARTIN TG, 1982, ANN EMERG MED, V11, P466, DOI 10.1016/S0196-0644(82)80063-2; Matthews D.E., 2016, ACTA HAEMATOL-BASEL, V135, P194; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; REA HH, 1991, ANN ALLERGY, V66, P48; REBUCK AS, 1987, CAN MED ASSOC J, V136, P483; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906; SHAPIRO GG, 1983, PEDIATRICS, V71, P510; SYBERT A, 1985, BRONCHIAL ASTHMA MEC, P808; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V83, P528, DOI 10.1016/0091-6749(89)90034-1; 1962, AM REV RESPIR DIS, V85, P762	24	136	137	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					788	794		10.1056/NEJM199103213241202	http://dx.doi.org/10.1056/NEJM199103213241202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997850				2022-12-28	WOS:A1991FC44200002
J	ALBRIGHT, AL; CERVI, A; SINGLETARY, J				ALBRIGHT, AL; CERVI, A; SINGLETARY, J			INTRATHECAL BACLOFEN FOR SPASTICITY IN CEREBRAL-PALSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Seventeen patients with congenital spastic cerebral palsy and six patients with other forms of spasticity were injected intrathecally with doses of placebo or baclofen, 25-mu-g, 50-mu-g, or 100-mu-g, in a randomized, double-blind manner. Muscle tone in the upper and lower extremities was assessed by Ashworth scores both before the injections and every 2 hours afterward for 8 hours. Function of the upper extremities was evaluated before the injections and 4 hours afterward. Muscle tone in the lower extremities was significantly decreased within 2 hours after baclofen injection and remained lower than baseline 8 hours afterward. Upper extremity tone and function were not significantly affected by these single doses. Confusion and drowsiness occurred in two of the youngest children in the study after the 50-mu-g dose, but cleared within 2 hours. Our findings indicate that intrathecal baclofen reduces spasticity in children with cerebral palsy, as it does in adults with spasticity of spinal origin.	UNIV PITTSBURGH,SCH MED,DEPT NEUROSURG,PITTSBURGH,PA 15261; CHILDRENS HOSP PITTSBURGH,DEPT PHYS THERAPY,PITTSBURGH,PA 15213; CHILDRENS HOSP PITTSBURGH,DEPT OCCUPAT THERAPY,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ALBRIGHT, AL (corresponding author), CHILDRENS HOSP PITTSBURGH,DEPT NEUROSURG,1 CHILDRENS PL,PITTSBURGH,PA 15213, USA.				NCRR NIH HHS [5M01 RR00084] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASHWORTH B, 1964, PRACTITIONER, V192, P540; BLAXTER TJ, 1985, BRAIN RES, V341, P195, DOI 10.1016/0006-8993(85)91489-1; BOWERY NG, 1980, NATURE, V283, P92, DOI 10.1038/283092a0; DELWAIDE PJ, 1981, SPASTICITY, V304, P96; DELWAIDE PJ, 1981, SPASTICITY, V304, P28; DESILVA T, 1987, J APPL PHYSIOL, V62, P2264; Feldman RG, 1980, SPASTICITY DISORDERE, P41; Feldmann RG, 1980, SPASTICITY DISORDERE, P485; KERR DIB, 1987, BRAIN RES, V405, P150, DOI 10.1016/0006-8993(87)90999-1; KNUTSSON E, 1974, J NEUROL SCI, V23, P473, DOI 10.1016/0022-510X(74)90163-4; LZAOTHES Y, 1990, J NEUROSURG, V72, P393; M?ller H., 1988, LOCAL SPINAL THERAPY, P223; Molnar G E, 1987, Int Disabil Stud, V9, P170; MULLERSCHWEFE G, 1989, J NEUROSURG, V71, P273, DOI 10.3171/jns.1989.71.2.0273; PALMER FB, 1988, NEW ENGL J MED, V318, P803, DOI 10.1056/NEJM198803313181302; PARKE B, 1989, ARCH PHYS MED REHAB, V70, P30; PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302; PENN RD, 1985, LANCET, V2, P125; PENN RD, 1987, J NEUROSURG, V66, P181, DOI 10.3171/jns.1987.66.2.0181; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; PRICE GW, 1984, NATURE, V307, P71, DOI 10.1038/307071a0; RICE GPA, 1987, CAN J NEUROL SCI, V14, P510, DOI 10.1017/S0317167100038014; Saltuari L., 1990, NEW ENGL J MED, V322, P1535; Siegfried J, 1987, Acta Neurochir Suppl (Wien), V39, P121; ZEIGLGANSBERGER W, 1988, LOCAL SPINAL THERAPY, P37	25	216	220	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1418	1422		10.1001/jama.265.11.1418	http://dx.doi.org/10.1001/jama.265.11.1418			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999883				2022-12-28	WOS:A1991FB55000023
J	SHULKIN, DJ				SHULKIN, DJ			PREVENTION AND MANAGEMENT OF HIV-CONTAMINATED NEEDLESTICKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SHULKIN, DJ (corresponding author), UNIV PENN,SCH MED,ROBERT WOOD JOHNSON FDN,PHILADELPHIA,PA 19104, USA.							HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; SACKS HS, 1990, J GEN INTERN MED, V5, P132, DOI 10.1007/BF02600514; 1990, MMWR, V39, P19; 1990, MMWR, V39, P1	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1262	1262		10.1001/jama.265.10.1262	http://dx.doi.org/10.1001/jama.265.10.1262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995972				2022-12-28	WOS:A1991FA51100019
J	FLORAS, JS; LEGAULT, L; MORALI, GA; HARA, K; BLENDIS, LM				FLORAS, JS; LEGAULT, L; MORALI, GA; HARA, K; BLENDIS, LM			INCREASED SYMPATHETIC OUTFLOW IN CIRRHOSIS AND ASCITES - DIRECT EVIDENCE FROM INTRANEURAL RECORDINGS	ANNALS OF INTERNAL MEDICINE			English	Article						ASCITES; LIVER CIRRHOSIS; SYMPATHETIC NERVOUS SYSTEM; NOREPINEPHRINE; EPINEPHRINE	NERVOUS-SYSTEM ACTIVITY; OUTPUT CARDIAC-FAILURE; BODY NEGATIVE-PRESSURE; PLASMA NOREPINEPHRINE; WATER-RETENTION; DECOMPENSATED CIRRHOSIS; ESSENTIAL-HYPERTENSION; HEPATORENAL-SYNDROME; NEPHROTIC SYNDROME; VOLUME EXPANSION	Objective: To determine if central sympathetic outflow is increased in patients with cirrhosis and ascites. Patients: Eleven patients with cirrhosis and ascites, 8 patients with cirrhosis but without ascites, and 7 age-matched and 8 young healthy volunteers. Methods: With subjects supine, direct microneurographic recordings of efferent post-ganglionic muscle sympathetic nerve activity were obtained from the peroneal nerve, and sympathetic burst frequency was compared with subjects' blood pressure, heart rate, sodium excretion, catecholamines, and plasma renin activity. All patients with cirrhosis were studied at least 5 days after withdrawal from all medications and after 7 days of a 20 mmol/d sodium, 1-L fluid-restricted diet. Age-matched volunteers were studied after 7 days of 20 mmol/d sodium intake and young healthy volunteers after 7 days of 150 mmol/d sodium intake. Results: Sympathetic nerve activity in ascitic patients (65 +/- 15 bursts/min; mean +/- SD) was markedly increased, whether compared with patients with cirrhosis but without ascites (34 +/- 16 bursts/min; p < 0.001), age-matched healthy volunteers on similar sodium intake (27 +/- 22 bursts/min; P < 0.001), or young healthy subjects (21 +/- 10 bursts/min; P < 0.001). The frequency of muscle sympathetic nerve discharge was directly related to plasma norepinephrine and epinephrine concentrations, plasma renin activity, and heart rate, all of which were increased in those patients with cirrhosis and ascites, and inversely related to 24-hour urinary sodium excretion, the fractional excretion of sodium, and subjects' pulse pressures. Sympathetic nerve activity fell from 78 to 6 bursts/min in one patient after liver transplantation. Conclusions: This study provides the first direct evidence that elevated plasma norepinephrine concentrations in patients with cirrhosis and ascites are due to increased central sympathetic outflow. Sympathetic nerve activity is not increased in patients with cirrhosis but without ascites. Because there were direct positive correlations of sympathetic nerve activity with plasma norepinephrine concentrations, plasma epinephrine concentrations, plasma renin activity, and heart rate, the increase in central sympathetic outflow in patients with cirrhosis and ascites appears generalized and not restricted to muscle nerves. The anti-natriuretic effects of parallel increases in renal and muscle sympathetic nerve activity could account for the inverse correlation between muscle sympathetic nerve activity and sodium excretion.			FLORAS, JS (corresponding author), UNIV TORONTO, TORONTO GEN HOSP, DIV CARDIOL, 12 EN-234, 200 ELIZABETH ST, TORONTO M5G 2C4, ONTARIO, CANADA.		Floras, John S./D-4042-2015					ANDERSON EA, 1989, HYPERTENSION, V14, P177, DOI 10.1161/01.HYP.14.2.177; ANDERSON EA, 1987, HYPERTENSION, V9, P114, DOI 10.1161/01.HYP.9.6_Pt_2.III114; ANGELLJAMES JE, 1971, J PHYSIOL-LONDON, V214, P65; BERNARDI M, 1983, HEPATOLOGY, V3, P56; BETTER OS, 1983, KIDNEY INT, V23, P303, DOI 10.1038/ki.1983.20; BICHET DG, 1982, NEW ENGL J MED, V307, P1552, DOI 10.1056/NEJM198212163072504; BLENDIS LM, 1987, HEPATOLOGY, V7, P143, DOI 10.1002/hep.1840070128; DIBONA GF, 1988, AM J PHYSIOL, V254, pR1017, DOI 10.1152/ajpregu.1988.254.6.R1017; DIBONA GF, 1989, MINER ELECTROL METAB, V15, P44; DIBONA GF, 1984, KIDNEY INT, V25, P841, DOI 10.1038/ki.1984.99; ERIKSSON BM, 1982, J CHROMATOGR, V228, P143, DOI 10.1016/S0378-4347(00)80427-2; ESLER M, 1988, HYPERTENSION, V11, P3, DOI 10.1161/01.HYP.11.1.3; FLORAS JS, 1988, J CLIN INVEST, V81, P1265, DOI 10.1172/JCI113444; FLORAS JS, 1990, CIRCULATION, V81, P1860, DOI 10.1161/01.CIR.81.6.1860; HENRIKSEN JH, 1984, GUT, V25, P1034, DOI 10.1136/gut.25.10.1034; KOEPKE JP, 1987, AM J PHYSIOL, V252, pR1019, DOI 10.1152/ajpregu.1987.252.5.R1019; KOSTREVA DR, 1980, AM J PHYSIOL, V238, pR390, DOI 10.1152/ajpregu.1980.238.5.R390; KOWALSKI HJ, 1953, J CLIN INVEST, V32, P1025, DOI 10.1172/JCI102813; LAWTON W, 1986, FASEB J, V45, P522; LEIMBACH WN, 1986, CIRCULATION, V73, P913, DOI 10.1161/01.CIR.73.5.913; MAJEWSKI H, 1983, J AUTON PHARMACOL, V3, P47, DOI 10.1111/j.1474-8673.1983.tb00496.x; MORLIN C, 1983, ACTA PHYSIOL SCAND, V119, P117, DOI 10.1111/j.1748-1716.1983.tb07315.x; NEZU M, 1985, HYPERTENSION, V7, P187, DOI 10.1161/01.HYP.7.2.187; NICHOLLS KM, 1985, CIRC RES, V56, P457, DOI 10.1161/01.RES.56.3.457; OSBORN JL, 1983, CIRC RES, V53, P298, DOI 10.1161/01.RES.53.3.298; PERSSON PB, 1989, AM J PHYSIOL, V256, pF485, DOI 10.1152/ajprenal.1989.256.3.F485; RINGLARSEN H, 1982, HEPATOLOGY, V2, P304; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1127, DOI 10.1056/NEJM198810273191705; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1065, DOI 10.1056/NEJM198810203191606; SKORECKI KL, 1988, AM J MED, V85, P375, DOI 10.1016/0002-9343(88)90590-6; SOLISHERRUZO JA, 1987, J HEPATOL, V5, P167, DOI 10.1016/S0168-8278(87)80569-X; SUNDLOF G, 1978, J PHYSIOL-LONDON, V278, P525, DOI 10.1113/jphysiol.1978.sp012322; SUNDLOF G, 1977, J PHYSIOL-LONDON, V272, P383, DOI 10.1113/jphysiol.1977.sp012050; SUNDLOF G, 1978, J PHYSIOL-LONDON, V274, P621, DOI 10.1113/jphysiol.1978.sp012170; TAGEJENSEN U, 1988, J HEPATOL, V6, P350, DOI 10.1016/S0168-8278(88)80053-9; THULUVATH PJ, 1989, Q J MED, V72, P737; UNIKOWSKY B, 1983, J CLIN INVEST, V72, P1594, DOI 10.1172/JCI111118; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; VICTOR RG, 1987, J APPL PHYSIOL, V63, P2558, DOI 10.1152/jappl.1987.63.6.2558; WEBB DJ, 1988, J HYPERTENS, V6, pS542, DOI 10.1097/00004872-198812040-00170; WEICKER H, 1984, CLIN CHIM ACTA, V141, P17, DOI 10.1016/0009-8981(84)90162-1; WESTFALL TC, 1985, ANNU REV PHARMACOL, V25, P621, DOI 10.1146/annurev.pharmtox.25.1.621; WILLETT I, 1985, J HEPATOL, V1, P639, DOI 10.1016/S0168-8278(85)80007-6; YAMADA Y, 1989, HYPERTENSION, V13, P870, DOI 10.1161/01.HYP.13.6.870; ZIMMERMAN BG, 1978, FED PROC, V37, P199	47	117	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					373	380		10.7326/0003-4819-114-5-373	http://dx.doi.org/10.7326/0003-4819-114-5-373			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992879				2022-12-28	WOS:A1991EZ17400005
J	GREENSON, JK; BELITSOS, PC; YARDLEY, JH; BARTLETT, JG				GREENSON, JK; BELITSOS, PC; YARDLEY, JH; BARTLETT, JG			AIDS ENTEROPATHY - OCCULT ENTERIC INFECTIONS AND DUODENAL MUCOSAL ALTERATIONS IN CHRONIC DIARRHEA	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA, CHRONIC; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM-AVIUM-INTRACELLULARE INFECTION; MICROSPORIDIA INFECTION	ACQUIRED IMMUNODEFICIENCY SYNDROME; INTESTINAL INFECTIONS; VIRUS HIV; T-CELLS; DISEASE	Objective: To investigate occult enteric infections and morphologic changes in the small intestine in patients with advanced human immunodeficiency virus (HIV) infection and chronic diarrhea of undefined cause. Design: Case-control study. Setting: Referral-based clinic and hospital in tertiary care center. Patients: Twenty-two patients with advanced HIV infection (19 with the acquired immunodeficiency syndrome [AIDS], 3 with AIDS-related complex) with chronic diarrhea, selected because of previously negative stool evaluations for bacterial or parasitic pathogens, were compared with 13 patients with advanced HIV infection (9 with AIDS, 4 with AIDS-related complex) without diarrhea by analysis of endoscopic biopsies using light and electron microscopy, viral culture, and morphometric studies. Both groups were convenience samples and had at least 7 months follow-up. Measurements and main Result: Eleven of twenty-two patients with HIV infection and chronic diarrhea but only 1 of 13 patients without diarrhea showed occult enteric pathogens (that is, undetected by routine studies) after extensive evaluation of duodenal and colorectal biopsies. Mycobacterium avium-intracellulare and microsporidia were the most common occult agents in study patients with diarrhea (5 each). Patients with diarrhea and occult enteric infections had greater weight loss (mean, 14.3 kg compared with 6.2 kg; P < 0.05) and shorter survival (1 of 11 compared with 8 of 11 still alive; P < 0.004) than those with diarrhea but no identified pathogens (defined as "AIDS enteropathy"). Duodenal morphometry showed decreased villus-to-crypt ratios because of villus atrophy and crypt elongation in HIV -infected patients both with and without diarrhea compared with normal controls (P < 0.001 for each). All three groups showed comparable frequencies of epithelial mitoses. Conclusions: Further endoscopic biopsy evaluation of patients with AIDS who had unexplained chronic diarrhea showed an occult infectious cause in half of the cases. However, altered villus and crypt architecture in advanced HIV infection was independent of the presence of diarrhea or enteric infection and therefore did not correlate with AIDS enteropathy. Subnormal epithelial proliferation in response to injury could be a factor, but the underlying cause of the architectural changes remains obscure. We suggest that T-cell dysfunction may play a role.	JOHNS HOPKINS UNIV HOSP, DIV INFECT DIS, BLALOCK 11, 600 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040618] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 RO1DK4061802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONY MA, 1988, DIGEST DIS SCI, V33, P1141, DOI 10.1007/BF01535791; BARTELSMAN JFWM, 1989, SCAND J GASTROENTERO, V24, P112, DOI 10.3109/00365528909091381; BATMAN PA, 1989, J CLIN PATHOL, V42, P275, DOI 10.1136/jcp.42.3.275; COLEBUNDERS R, 1988, GUT, V29, P1687, DOI 10.1136/gut.29.12.1687; CONNOLLY GM, 1989, GUT, V30, P195, DOI 10.1136/gut.30.2.195; CUMMINS AG, 1990, GUT, V31, P317, DOI 10.1136/gut.31.3.317; DESPORTES I, 1985, J PROTOZOOL, V32, P250; ELLAKANY S, 1987, AM J CLIN PATHOL, V87, P356, DOI 10.1093/ajcp/87.3.356; FERREIRA RD, 1990, GASTROENTEROLOGY, V98, P1255, DOI 10.1016/0016-5085(90)90342-X; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; JARRY A, 1990, HISTOPATHOLOGY, V16, P133; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; KOTLER DP, 1984, ANN INTERN MED, V101, P421, DOI 10.7326/0003-4819-101-4-421; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; MACDONALD TT, 1977, CELL TISSUE KINET, V10, P301, DOI 10.1111/j.1365-2184.1977.tb00298.x; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MATHIJS JM, 1988, LANCET, V1, P1111; NELSON JA, 1988, LANCET, V1, P259; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; RENE E, 1989, DIGEST DIS SCI, V34, P773, DOI 10.1007/BF01540353; RODGERS VD, 1986, GASTROENTEROLOGY, V90, P552, DOI 10.1016/0016-5085(86)91108-X; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; ULLRICH R, 1989, ANN INTERN MED, V111, P15, DOI 10.7326/0003-4819-111-1-15; 1989, LANCET, V2, P777; 1985, MMWR, V34, P373	26	158	158	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					366	372		10.7326/0003-4819-114-5-366	http://dx.doi.org/10.7326/0003-4819-114-5-366			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992878				2022-12-28	WOS:A1991EZ17400004
J	STILLMAN, P; SWANSON, D; REGAN, MB; PHILBIN, MM; NELSON, V; EBERT, T; LEY, B; PARRINO, T; SHOREY, J; STILLMAN, A; ALPERT, E; CASLOWITZ, J; CLIVE, D; FLOREK, J; HAMOLSKY, M; HATEM, C; KIZIRIAN, J; KOPELMAN, R; LEVENSON, D; LEVINSON, G; MCCUE, J; POHL, H; SCHIFFMAN, F; SCHWARTZ, J; THANE, M; WOLF, M				STILLMAN, P; SWANSON, D; REGAN, MB; PHILBIN, MM; NELSON, V; EBERT, T; LEY, B; PARRINO, T; SHOREY, J; STILLMAN, A; ALPERT, E; CASLOWITZ, J; CLIVE, D; FLOREK, J; HAMOLSKY, M; HATEM, C; KIZIRIAN, J; KOPELMAN, R; LEVENSON, D; LEVINSON, G; MCCUE, J; POHL, H; SCHIFFMAN, F; SCHWARTZ, J; THANE, M; WOLF, M			ASSESSMENT OF CLINICAL SKILLS OF RESIDENTS UTILIZING STANDARDIZED PATIENTS - A FOLLOW-UP-STUDY AND RECOMMENDATIONS FOR APPLICATION	ANNALS OF INTERNAL MEDICINE			English	Article						CLINICAL COMPETENCE; INTERNSHIP AND RESIDENCY; STANDARDIZED PATIENTS; MEDICAL HISTORY TAKING; PHYSICAL EXAMINATION	SIMULATED PATIENTS	Objective: To determine the reliability and validity of "standardized patients" to assess clinical performance of internal medicine residents. Design: Each resident spent 2 half-days interacting with 19 standardized patients (nonphysicians taught to portray patients in a reproducible fashion). Each resident was asked to obtained focused histories, perform relevant physical examinations, and provide patient education or counseling. At the end of each 10- to 15-minute encounter, the resident was asked to identify positive findings on physical examination and to prioritize a differential diagnosis. Other, more traditional indicators of clinical skills were also obtained. Participants: Three hundred ten residents from nineteen internal medicine training programs in the New England region of the United States. Results: Reproducible estimates of data gathering and interviewing skills were achieved with 1 day of testing. Validity analyses were difficult to interpret because of the lack of an external "gold standard." However, faculty judgments of performance from reviewing videotapes corresponded with standardized-patient-based scores. Differences in group performance were also demonstrated across years of training and between U.S. or Canadian and foreign medical graduates. Conclusions: Systematic and effective procedures for developing standardized-patient-based test materials and for training standardized patients have been developed. This technique is best used for measuring data gathering and interviewing skills. Correlations with commonly used evaluation methods were generally low; this may be because standardized patients measure different skills. Local use of this technique by residency programs and the development of regional consortia sharing resources, costs, and expertise are advocated.	NATL BOARD MED EXAMINERS, PHILADELPHIA, PA 19104 USA; NEW ENGLAND CONSORTIUM INTERNAL MED RESIDENCY TRAI, WORCESTER, MA USA; AMER BOARD INTERNAL MED, PHILADELPHIA, PA USA	American Board of Internal Medicine	STILLMAN, P (corresponding author), UNIV MASSACHUSETTS, MED CTR, CURRICULUM DEANS OFF, 55 LAKE AVE N, WORCESTER, MA 01655 USA.		Levenson, DAvid/AFR-2700-2022					BRENNAN R, 1983, ELEMENTS GENERALIZAB, P9; BURRI A, 1976, 15TH P ANN C RES MED, P295; HERBERS JE, 1989, J GEN INTERN MED, V4, P202, DOI 10.1007/BF02599524; LIVINGSTON SA, 1982, PASSING SCORES; LLOYD JS, 1983, ORAL EXAMINATIONS ME; NORMAN G, 1983, 22ND P ANN C RES MED, P240; NORMAN GR, 1982, J MED EDUC, V57, P708; NORMAN GR, 1985, J MED EDUC, V60, P925; Norman GR, 1985, J INSTRUCTIONAL DEV, V8, P11; OWEN A, 1974, MED J AUSTRALIA, V2, P393, DOI 10.5694/j.1326-5377.1974.tb70862.x; SANSONFISHER RW, 1980, MED EDUC, V14, P249, DOI 10.1111/j.1365-2923.1980.tb02269.x; SEARLE S, 1971, LINEAR MODELS, P487; STILLMAN PL, 1977, EDUC PSYCHOL MEAS, V37, P1031, DOI 10.1177/001316447703700427; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; STILLMAN PL, 1983, J MED EDUC, V58, P941; STILLMAN PL, 1989, NOV USE STANDARDIZED; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WEBSTER G, 1985, RESIDENCY DIRECTORS, P123	18	132	133	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					393	401		10.7326/0003-4819-114-5-393	http://dx.doi.org/10.7326/0003-4819-114-5-393			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992883				2022-12-28	WOS:A1991EZ17400009
J	FRADKIN, JE; SCHONBERGER, LB; MILLS, JL; GUNN, WJ; PIPER, JM; WYSOWSKI, DK; THOMSON, R; DURAKO, S; BROWN, P				FRADKIN, JE; SCHONBERGER, LB; MILLS, JL; GUNN, WJ; PIPER, JM; WYSOWSKI, DK; THOMSON, R; DURAKO, S; BROWN, P			CREUTZFELDT-JAKOB DISEASE IN PITUITARY GROWTH-HORMONE RECIPIENTS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPY; FRANCE	To assess the magnitude of Creutzfeldt-Jakob disease (CJD) occurrence among recipients of pituitary-derived human growth hormone (HGH), we conducted an epidemiologic follow-up of 6284 recipients of HGH distributed through the National Hormone and Pituitary Program. Seven neuropathologically confirmed cases of CJD have occurred in this population to date: six patients with clinical CJD presented with ataxia and imbalance, rather than with altered mentation, which is the most common initial manifestation in sporadic CJD, and one patient died in the preclinical incubation state of the disease. All seven cases occurred among the nearly 700 HGH recipients who started therapy before 1970. Since only 10% of the cohort has been followed up for the 15-year average incubation interval from midpoint of HGH treatment to onset of symptoms, the great majority of potentially exposed patients have not yet attained the requisite incubation period for expression of CJD. The median duration of HGH therapy of 100 months in the CJD cases was significantly longer than 41 months for all patients starting treatment before 1970; thus, the duration of pituitary HGH therapy is a major risk factor for CJD.	CTR DIS CONTROL,ATLANTA,GA 30333; NICHHD,BETHESDA,MD 20892; US FDA,ROCKVILLE,MD 20857; WESTAT CORP,ROCKVILLE,MD; NINCDS,BETHESDA,MD 20892	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); US Food & Drug Administration (FDA); Westat; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	FRADKIN, JE (corresponding author), NIDDKD,ENDOCRINOL & METAB DIS PROGRAMS BRANCH,WESTWOOD BLDG,ROOM 603,BETHESDA,MD 20892, USA.			Mills, James/0000-0003-4496-332X				BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1985, LANCET, V2, P729; BROWN P, 1988, PEDIATRICS, V81, P85; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; BROWN P, 1988, NOVEL INFECTIOUS AGE, P3; COCHIUS JI, 1990, AUST NZ J MED, V20, P592, DOI 10.1111/j.1445-5994.1990.tb01322.x; CROXSON M, 1988, NEUROLOGY, V38, P1128, DOI 10.1212/WNL.38.7.1128; GIBBS CJ, 1969, SCIENCE, V165, P1023, DOI 10.1126/science.165.3897.1023; GIBBS CJ, 1985, NEW ENGL J MED, V313, P734, DOI 10.1056/NEJM198509193131207; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDFARB LG, IN PRESS LANCET; GOUJARD J, 1988, INT J EPIDEMIOL, V17, P423, DOI 10.1093/ije/17.2.423; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; KOCH TK, 1985, NEW ENGL J MED, V313, P731, DOI 10.1056/NEJM198509193131206; MARZEWSKI DJ, 1988, NEUROLOGY, V38, P1131, DOI 10.1212/WNL.38.7.1131; MILLS JL, 1990, HORM RES, V33, P116, DOI 10.1159/000181494; NEW MI, 1988, NEUROLOGY, V38, P1133, DOI 10.1212/WNL.38.7.1133; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; POCCHIARI M, IN PRESS HORM RES; POWELLJACKSON J, 1985, LANCET, V2, P244; RABEN MS, 1959, RECENT PROG HORM RES, V15, P71; SAXENA BB, 1966, BIOCHEM J, V100, P711, DOI 10.1042/bj1000711; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TAYLOR DM, 1985, LANCET, V2, P260; TINTNER R, 1986, NEUROLOGY, V36, P932, DOI 10.1212/WNL.36.7.932; WILHELMI AE, 1961, CAN J BIOCHEM PHYS, V39, P1659, DOI 10.1139/o61-183	28	127	133	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					880	884		10.1001/jama.265.7.880	http://dx.doi.org/10.1001/jama.265.7.880			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992185				2022-12-28	WOS:A1991EX58700039
J	FU, LN; YE, RQ; BROWDER, LW; JOHNSTON, RN				FU, LN; YE, RQ; BROWDER, LW; JOHNSTON, RN			TRANSLATIONAL POTENTIATION OF MESSENGER-RNA WITH SECONDARY STRUCTURE IN XENOPUS	SCIENCE			English	Article							5' NONCODING REGION; C-MYC; UNWINDING ACTIVITY; MAMMALIAN-CELLS; OOCYTE MATURATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; POLIOVIRUS RNA; ANTISENSE RNA; POLY(A) RNAS	Differential translation of messenger RNA (mRNA) with stable secondary structure in the 5' untranslated leader may contribute to the dramatic changes in protein synthetic patterns that occur during oogenesis and early development. Plasmids that contained the bacterial gene chloramphenicol acetyltransferase and which encoded mRNA with (hpCAT) or without (CAT) a stable hairpin secondary structure in the 5' noncoding region were transcribed in vitro, and the resulting mRNAs were injected into Xenopus oocytes, eggs, and early embryos. During early oogenesis, hpCAT mRNA was translated at less than 3 percent of the efficiency of CAT mRNA. The relative translational potential of hpCAT reached 100 percent in the newly fertilized egg and returned to approximately 3 percent after the midblastula transition.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary			Johnston, Randal/B-9247-2009					ADAMSON ED, 1977, DEV BIOL, V57, P136, DOI 10.1016/0012-1606(77)90360-8; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; CAPASSO O, 1987, EMBO J, V6, P1825, DOI 10.1002/j.1460-2075.1987.tb02437.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ETKIN LD, 1985, DEV BIOL, V108, P173, DOI 10.1016/0012-1606(85)90019-3; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FLYNN JM, 1980, DEV BIOL, V75, P222, DOI 10.1016/0012-1606(80)90157-8; GALILI G, 1988, J BIOL CHEM, V263, P5764; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARSAKING ML, 1979, EUCARYOTIC GENE REGU, P239; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; KOZAK M, 1983, MICROBIOL REV, V47, P1; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LAZARUS P, 1988, ONCOGENE, V3, P517; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MCGREW LL, 1989, DEV BIOL, V134, P267, DOI 10.1016/0012-1606(89)90097-3; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PARKIN NT, 1989, ONCOGENE, V4, P815; PATRICK TD, 1989, DEVELOPMENT, V106, P1; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1984, J MOL BIOL, V173, P227, DOI 10.1016/0022-2836(84)90191-8; ROLLER RJ, 1989, DEVELOPMENT, V106, P251; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WAGNER RW, 1990, P NATL ACAD SCI USA, V10, P5586; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	52	46	46	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					807	810		10.1126/science.1990443	http://dx.doi.org/10.1126/science.1990443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990443				2022-12-28	WOS:A1991EX57500049
J	STRACHAN, DP				STRACHAN, DP			VENTILATORY FUNCTION AS A PREDICTOR OF FATAL STROKE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; RISK-FACTORS; CHRONIC-BRONCHITIS; VITAL CAPACITY; LUNG-FUNCTION; MEN; MORTALITY; FRAMINGHAM; DEATH; BREATHLESSNESS	Objective - To investigate the relation between ventilatory function and subsequent mortality due to cerebrovascular disease. Design - Prospective longitudinal study. Subjects - A total of 18403 male civil servants aged 40-64 years at entry examination for the Whitehall study. Main outcome measures - Mortality from cerebrovascular disease (ICD8 430-438) after 18 years of follow up. Results - In all, 262 men with sinus rhythm at entry died due to stroke during the 18 years of follow up. Compared with men with a forced expiratory volume in one second of greater-than-or-equal-to 3.5 litres those with a value of < 3.0 litres were almost twice as likely to die of cerebrovascular disease (rate ratio adjusted for age and systolic blood pressure = 1.88, 95% confidence interval 1.32 to 2.69). This increased risk occurred within each tertile of systolic blood pressure. Nested case-control analyses were used to control precisely for confounding effects of age, height, and smoking (by matching) and employment grade and physiological risk factors (by modelling). The effect of forced expiratory volume in one second was independent of age, height, smoking habits, employment grade, blood pressure, weight, cholesterol concentration, glucose tolerance, electrocardiographic abnormalities, history of chest pain, and history of intermittent claudication. Conclusions - Measurements of ventilatory function may assist clinical decisions about whether to treat mild hypertension. Impaired ventilatory function and stroke may share common causes.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine								ABBOTT RD, 1987, JAMA-J AM MED ASSOC, V257, P949, DOI 10.1001/jama.257.7.949; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARRETTCONNOR E, 1988, AM J EPIDEMIOL, V128, P116, DOI 10.1093/oxfordjournals.aje.a114934; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P204; BROWN WS, 1989, HYPERTENSION S, V1, P51; COOK DG, 1988, EUR HEART J, V9, P1215, DOI 10.1093/oxfordjournals.eurheartj.a062432; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; DENNIS MS, 1987, BRIT J HOSP MED, V37, P194; DYKEN ML, 1984, STROKE, V15, P1105; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FRIEDMAN GD, 1976, NEW ENGL J MED, V294, P1071, DOI 10.1056/NEJM197605132942001; FUGLMEYER AR, 1983, SCAND J REHABIL MED, P118; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; HILLBOM ME, 1987, ACTA MED SCAND, P93; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KALES A, 1984, LANCET, V2, P1005; KANNEL WB, 1983, AM HEART J, V105, P311, DOI 10.1016/0002-8703(83)90532-X; KANNEL WB, 1974, CIRCULATION, V49, P1160, DOI 10.1161/01.CIR.49.6.1160; KANNEL WB, 1983, VASCULAR DISEASE CEN, P1; KELLYHAYES M, 1988, ARCH PHYS MED REHAB, V69, P415; KRYZANOWSKI M, 1986, INT J EPIDEMIOL, V15, P56; LANGE P, 1988, AM REV RESPIR DIS, V137, P1119, DOI 10.1164/ajrccm/137.5.1119; MARCUS EB, 1988, AM REV RESPIR DIS, V138, P1398, DOI 10.1164/ajrccm/138.6.1398; PERSSON C, 1986, AM J EPIDEMIOL, V124, P942, DOI 10.1093/oxfordjournals.aje.a114483; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; REID DD, 1974, LANCET, V1, P469; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; ROSE G, 1978, BRIT HEART J, V40, P636; SCHWARTZ J, 1989, American Review of Respiratory Disease, V139, pA28; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILLIAMS DRR, 1985, RECENT ADV COMMUNITY, V3, P117; ZHANG ZF, 1988, AM J PUBLIC HEALTH, V78, P975, DOI 10.2105/AJPH.78.8.975; 1988, EGRET EPIDEMIOLOGICA; 1985, SAS USERS GUIDE BASI	36	51	51	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	1991	302	6768					84	87		10.1136/bmj.302.6768.84	http://dx.doi.org/10.1136/bmj.302.6768.84			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995121	Bronze, Green Published			2022-12-28	WOS:A1991ER95100018
J	KORENMAN, J; BAKER, B; WAGGONER, J; EVERHART, JE; DIBISCEGLIE, AM; HOOFNAGLE, JH				KORENMAN, J; BAKER, B; WAGGONER, J; EVERHART, JE; DIBISCEGLIE, AM; HOOFNAGLE, JH			LONG-TERM REMISSION OF CHRONIC HEPATITIS-B AFTER ALPHA-INTERFERON THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article							VIRUS-INFECTION; CONTROLLED TRIAL; E-ANTIGEN; HOMOSEXUAL MEN; HBSAG; ANTIBODY; FOLLOW	Objective: To evaluate whether remissions of chronic hepatitis B induced by alpha-interferon therapy are of long duration. Design: Cohort study. Setting: Clinical Center of the National Institutes of Health, a tertiary referral center. Patients: Sixty-four patients with chronic hepatitis B were treated with alpha-interferon between 1984 and 1986. Main Outcome Measures: Patients were followed with frequent examinations and determinations of serum liver biochemical tests and hepatitis B virus (HBV) markers including hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA using blot hybridization and polymerase chain reaction. Results: Among 64 patients with chronic hepatitis B who were treated with alpha-interferon, 23 (36%) responded to treatment with loss of HBeAg and improvement in serum aminotransferases. All 23 have been followed for 3 to 7 years (mean, 4.3 years). During follow-up, 3 of 23 patients relapsed, with reappearance of HBeAg and abnormal serum aminotransferases, all within 1 year of therapy. The remaining 20 patients continued to have no detectable HBeAg or HBV DNA (using blot hybridization) in serum and to be asymptomatic for liver disease, although 3 had minimal elevations in serum aminotransferases. Thirteen patients (65%) became negative for HBsAg between 0.2 and 6 years (mean, 3 years) after loss of HBeAg. Although no patient had HBV DNA that was detectable by blot hybridization, the 7 patients who remained HBsAg positive all had HBV DNA in serum detected by polymerase chain reaction, but only 2 of 13 HBsAg-negative patients had viral genome using this method. Testing sequential samples indicated that HBV DNA detected by polymerase chain reaction usually disappeared at or around the time that test results for HBsAg became negative. Conclusions: Remissions in chronic hepatitis B induced by alpha-interferon are of long duration and are followed, in most patients, by the loss of HBsAg and all evidence of residual virus replication.	NIDDKD, DIV DIGEST DIS & NUTR,BLDG 31,ROOM 9A23, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALEXANDER GJM, 1987, LANCET, V2, P66; BROOK MG, 1989, GUT, V30, P1116, DOI 10.1136/gut.30.8.1116; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CARMAN WF, 1989, LANCET, V2, P588; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; DOOLEY JS, 1986, GASTROENTEROLOGY, V90, P150, DOI 10.1016/0016-5085(86)90087-9; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; Hoofnagle J. H., 1984, VIRAL HEPATITIS LIVE, P97; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989; KASSIANIDES C, 1988, VIRAL HEPATITIS LIVE, P840; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; LOK ASF, 1987, GASTROENTEROLOGY, V92, P1839, DOI 10.1016/0016-5085(87)90613-5; MOESTRUP T, 1986, BRIT MED J, V292, P854, DOI 10.1136/bmj.292.6524.854; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; SAMPLINER RE, 1979, AM J MED SCI, V277, P17, DOI 10.1097/00000441-197901000-00002; SARACCO G, 1989, HEPATOLOGY, V10, P336, DOI 10.1002/hep.1840100315; Ticehurst JR, 1989, DIAGNOSTIC PROCEDURE, P957	22	359	360	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					629	634		10.7326/0003-4819-114-8-629	http://dx.doi.org/10.7326/0003-4819-114-8-629			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003708				2022-12-28	WOS:A1991FG03100003
J	MORRIS, AJ; ALI, MR; NICHOLSON, GI; PEREZPEREZ, GI; BLASER, MJ				MORRIS, AJ; ALI, MR; NICHOLSON, GI; PEREZPEREZ, GI; BLASER, MJ			LONG-TERM FOLLOW-UP OF VOLUNTARY INGESTION OF HELICOBACTER-PYLORI	ANNALS OF INTERNAL MEDICINE			English	Note							CAMPYLOBACTER-PYLORI; GASTRITIS; INFECTION	After ingestion of Helicobacter pylori, a volunteer developed chronic infection, persistent gastritis, and seroconversion to H. pylori antigens. Single-agent therapies suppressed, but did not eradicate, infection, inflammation, and serologic response. Immunoglobulin M seroconversion followed both primary and recurrent infection. With triple-agent therapy, begun on day 966, H. pylori infection was resolved, gastritis was eliminated, and serologic values were normalized. Follow-up for 2 further years has not shown the recurrence of infection. This case illustrates the natural history, pathology, serology, and response to therapy of H. pylori infection.	MIDDLEMORE HOSP, AUCKLAND 6, NEW ZEALAND; UNIV AUCKLAND, AUCKLAND, NEW ZEALAND; VANDERBILT UNIV, MED CTR, NASHVILLE, TN 37240 USA	University of Auckland; Vanderbilt University	MORRIS, AJ (corresponding author), DUKE UNIV, MED CTR, MICROBIOL LAB, BOX 3879, DURHAM, NC 27710 USA.		Perez, Guillermo Perez/AAJ-3761-2020	Perez Perez, Guillermo/0000-0002-0131-5798				DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; GEORGE LL, 1990, MED J AUSTRALIA, V153, P145, DOI 10.5694/j.1326-5377.1990.tb136833.x; GOODWIN CS, 1989, INT J SYST BACTERIOL, V39, P397, DOI 10.1099/00207713-39-4-397; LANGENBERG W, 1986, J CLIN MICROBIOL, V24, P414, DOI 10.1128/JCM.24.3.414-417.1986; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MORRIS A, 1989, J CLIN PATHOL, V42, P727, DOI 10.1136/jcp.42.7.727; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PEREZPEREZ GI, 1987, INFECT IMMUN, V55, P1256, DOI 10.1128/IAI.55.5.1256-1263.1987; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3	10	142	145	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					662	663		10.7326/0003-4819-114-8-662	http://dx.doi.org/10.7326/0003-4819-114-8-662			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003713				2022-12-28	WOS:A1991FG03100008
J	FINE, KD; ANA, CAS; FORDTRAN, JS				FINE, KD; ANA, CAS; FORDTRAN, JS			DIAGNOSIS OF MAGNESIUM-INDUCED DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. There is no specific method of diagnosing magnesium-induced diarrhea. Therefore, the frequency and clinical importance of diarrhea caused by magnesium are unknown. The purposes of this study were to establish a method for diagnosing magnesium-induced diarrhea and to apply it to patients with chronic diarrhea. Methods. We measured fecal output of soluble magnesium and fecal magnesium concentration in 19 normal subjects with formed stools (15 collection periods), with non-magnesium-induced diarrhea (36 collection periods), and with diarrhea induced by magnesium hydroxide alone (11 collection periods) or in combination with phenolphthalein (3 collection periods), and in 359 patients with chronic diarrhea. Results. The upper limits of fecal output of soluble magnesium and fecal magnesium concentration in normal subjects were 14.6 mmol per day and 45.2 mmol per liter, respectively. When normal subjects had diarrhea due to the ingestion of magnesium hydroxide alone or in combination with phenolphthalein, fecal magnesium output was always abnormally high. For each millimole increase in fecal magnesium output, fecal weight increased by approximately 7.3 g. The fecal magnesium concentration was very high when magnesium was the only cause of diarrhea but only moderately elevated when diarrhea was induced by magnesium hydroxide plus phenolphthalein. Biochemical and clinical evidence indicated that excessive ingestion of magnesium was an important cause of chronic diarrhea in 15 of 359 patients with chronic diarrhea (4.2 percent), if not the only cause. Conclusions. Quantitative fecal analysis for soluble magnesium is an accurate method of diagnosing magnesium-induced diarrhea. Some patients with chronic diarrhea ingest excessive amounts of magnesium (in antacids or food supplements), and physicians may fail to discover this before embarking on an expensive and invasive diagnostic evaluation.	BAYLOR UNIV,MED CTR,DEPT INTERNAL MED,3500 GASTON AVE,DALLAS,TX 75246	Baylor University; Baylor University Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-R01-DK37172-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BINDER HJ, 1975, GASTROENTEROLOGY, V69, P1001; BJORK JT, 1976, GASTROENTEROLOGY, V70, P864; FRENCH JM, 1956, LANCET, P551; GAGINELLA TS, 1978, LIFE SCI, V23, P1001, DOI 10.1016/0024-3205(78)90659-8; HAMMER HF, 1989, J CLIN INVEST, V84, P1056, DOI 10.1172/JCI114267; Krejs GJ, 1980, SECRETORY DIARRHEA, P141; MORRIS AI, 1979, GASTROENTEROLOGY, V77, P780; SAUNDERS DR, 1983, WESTERN J MED, V139, P655; WRONG O, 1965, CLIN SCI, V28, P357	9	62	64	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1012	1017		10.1056/NEJM199104113241502	http://dx.doi.org/10.1056/NEJM199104113241502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	2005938				2022-12-28	WOS:A1991FF77100002
J	SANDERSON, SL; IVERIUS, PH; WILSON, DE				SANDERSON, SL; IVERIUS, PH; WILSON, DE			SUCCESSFUL HYPERLIPEMIC PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							LIPOPROTEIN-LIPASE ACTIVITY; PANCREATITIS; METABOLISM; WOMEN	Women with hypertriglyceridemia are prone to gestational pancreatitis, a condition carrying substantial maternal and fetal risk. We describe a 33-year-old woman with familial hypertriglyceridemia who had recurrent hyperlipidemic abdominal crises during previous pregnancies despite dietary fat restrictions. A fifth pregnancy was carried to term without complications after aggressive dietary therapy and intermittent intravenous feeding, administered whenever her triglyceride levels exceeded an arbitrarily selected threshold concentration of 28 mmol/L. The efficacy of this approach may be explained by the published observation that low-fat (high-carbohydrate) isocaloric diets elevate serum triglyceride levels by the oral, but not the intravenous, route in normal individuals. Reduction of this patient's serum triglyceride concentrations by interrupting oral intake and administering intravenous glucose appeared to prevent late-pregnancy pancreatitis and culminated in uncomplicated full-term delivery.	UNIV UTAH,HLTH SCI CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	SANDERSON, SL (corresponding author), VET AFFAIRS MED CTR,ENDOCRINOL SECT,500 FOOTHILL BLVD,SALT LAKE CITY,UT 84148, USA.				NCRR NIH HHS [RR-00064] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHRENS EH, 1961, T ASSOC AM PHYSICIAN, V74, P134; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BRUNZELL JD, 1982, MED CLIN N AM, V66, P455, DOI 10.1016/S0025-7125(16)31430-4; DENBESTEN L, 1973, J CLIN INVEST, V52, P1384, DOI 10.1172/JCI107311; DESOYE G, 1987, J CLIN ENDOCR METAB, V64, P704, DOI 10.1210/jcem-64-4-704; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; HERRERA E, 1988, AM J OBSTET GYNECOL, V158, P1575, DOI 10.1016/0002-9378(88)90193-7; IVERIUS PH, 1988, J CLIN INVEST, V82, P1106, DOI 10.1172/JCI113667; KEKKI M, 1971, METABOLISM, V21, P878; KIM HJ, 1975, J CLIN INVEST, V56, P888, DOI 10.1172/JCI108168; KINNUNEN PKJ, 1980, EUR J CLIN INVEST, V10, P469, DOI 10.1111/j.1365-2362.1980.tb02087.x; KNOPP RH, 1982, AM J OBSTET GYNECOL, V143, P626, DOI 10.1016/0002-9378(82)90107-7; KNOPP RH, 1978, CARBOHYDRATE LIPID M, P35; MILLER A, 1979, ANN SURG, V190, P401, DOI 10.1097/00000658-197909000-00016; MONTGOMERY WH, 1970, OBSTET GYNECOL, V35, P658; PETERS JP, 1951, J CLIN INVEST, V30, P388, DOI 10.1172/JCI102455; WEINBERG RB, 1982, GASTROENTEROLOGY, V83, P1300; WILLIAMS C, 1978, BRIT J OBSTET GYNAEC, V85, P43, DOI 10.1111/j.1471-0528.1978.tb15824.x; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; YAMAUCHI H, 1986, TOHOKU J EXP MED, V148, P197, DOI 10.1620/tjem.148.197; ZINDER O, 1974, AM J PHYSIOL, V226, P744, DOI 10.1152/ajplegacy.1974.226.3.744	21	43	48	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1858	1860		10.1001/jama.265.14.1858	http://dx.doi.org/10.1001/jama.265.14.1858			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005735				2022-12-28	WOS:A1991FE86200028
J	SHARP, KA; NICHOLLS, A; FINE, RF; HONIG, B				SHARP, KA; NICHOLLS, A; FINE, RF; HONIG, B			RECONCILING THE MAGNITUDE OF THE MICROSCOPIC AND MACROSCOPIC HYDROPHOBIC EFFECTS	SCIENCE			English	Article							FREE-ENERGY; SURFACE; DEPENDENCE; AREA	The magnitude of the hydrophobic effect, as measured from the surface area dependence of the solubilities of hydrocarbons in water, is generally thought to be about 25 calories per mole per square angstrom (cal mol-1 angstrom-2). However, the surface tension at a hydrocarbon-water interface, which is a "macroscopic" measure of the hydrophobic effect, is almost-equal-to 72 cal mol-1 angstrom-2. In an attempt to reconcile these values, alkane solubility data have been reevaluated to account for solute-solvent size differences, leading to a revised "microscopic" hydrophobic effect of 47 cal mol-1 angstrom-2. This value, when used in a simple geometric model for the curvature dependence of the hydrophobic effect, predicts a macroscopic alkane-water surface tension that is close to the macroscopic value.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168 ST, NEW YORK, NY 10032 USA; BIOSYM TECHNOL INC, SAN DIEGO, CA 92121 USA	Columbia University					NIGMS NIH HHS [GM41371, GM30518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030518, R01GM030518, R01GM041371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON AW, 1907, PHYSICAL CHEM SURFAC; AVEYARD R, 1965, J COLLOID INTERF SCI, V20, P2255; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BENNAIM A, 1978, J PHYS CHEM-US, V82, P792, DOI 10.1021/j100496a008; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; BUFF FP, 1965, PHYS REV LETT, V15, P621, DOI 10.1103/PhysRevLett.15.621; CHOI DS, 1970, J CHEM PHYS, V53, P2608, DOI 10.1063/1.1674378; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; DEYOUNG LR, 1990, J PHYS CHEM-US, V94, P801, DOI 10.1021/j100365a054; DILL KA, 1990, SCIENCE, V250, P297, DOI 10.1126/science.2218535; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINE R, UNPUB; Flory PJ, 1941, J CHEM PHYS, V9, P660, DOI 10.1063/1.1750971; Harkins WD, 1921, J AM CHEM SOC, V43, P35, DOI 10.1021/ja01434a006; HERMANN RB, 1977, P NATL ACAD SCI USA, V74, P4144, DOI 10.1073/pnas.74.10.4144; HILDEBRAND JH, 1947, J CHEM PHYS, V15, P225, DOI 10.1063/1.1746484; Huggins ML, 1941, J CHEM PHYS, V9, P440, DOI 10.1063/1.1750930; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226; MANSOORI GA, 1971, J CHEM PHYS, V54, P1523, DOI 10.1063/1.1675048; MCAULIFFE C, 1966, J PHYS CHEM-US, V70, P1267, DOI 10.1021/j100876a049; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; NICHOLLS A, UNPUB; PIEROTTI RA, 1965, J PHYS CHEM-US, V69, P281, DOI 10.1021/j100885a043; POSTMA JPM, 1982, FARADAY SYMP CHEM S, P55, DOI 10.1039/fs9821700055; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; REYNOLDS JA, 1974, P NATL ACAD SCI USA, V71, P2925, DOI 10.1073/pnas.71.8.2925; TANFORD C, 1979, P NATL ACAD SCI USA, V76, P4175, DOI 10.1073/pnas.76.9.4175; TANFORD C, 1980, HYDROPHOBIC EFFECT; TOLMAN RC, 1949, J CHEM PHYS, V17, P333, DOI 10.1063/1.1747247	31	483	489	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1991	252	5002					106	109		10.1126/science.2011744	http://dx.doi.org/10.1126/science.2011744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011744				2022-12-28	WOS:A1991FE95200043
J	MEYERS, A; SIEGEL, B; VINCI, R				MEYERS, A; SIEGEL, B; VINCI, R			ECONOMIC BARRIERS TO THE USE OF ORAL REHYDRATION THERAPY - A CASE-REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DIARRHEAL	Diarrheal dehydration is a highly prevalent condition among young children and is readily prevented and treated with oral rehydration therapy. We report a death due to hypernatremic dehydration caused by rotavirus diarrhea of a 9-month-old infant whose mother attempted to purchase oral glucose-electrolyte solution in a pharmacy but was unable to afford it. While efforts such as the National ORT Project should help to promote the proper at-home treatment of this condition, we conclude that oral rehydration therapy will not be used optimally by the parents of children living in poverty until the economic barriers to its use are removed.	BOSTON UNIV,SCH MED,BOSTON,MA 02118	Boston University	MEYERS, A (corresponding author), BOSTON CITY HOSP,DEPT PEDIAT,818 HARRISON AVE,BOSTON,MA 02118, USA.		Meyers, MD, MBA, Arlen/ABE-8184-2021	Siegel, Benjamin/0000-0003-3572-2575; Vinci, Robert/0000-0002-2616-1879				AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; Bloom B, 1990, Adv Data, P1; FINBERG L, 1990, CONT PEDIATR, V7, P45; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; LAUDICINA SS, 1988, MEDICAID POOR CHILDR, P53; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; SNYDER JD, 1991, PEDIATRICS, V87, P28; WALDMAN R, 1990, LINKS HLTH DEV REP, V7, P9; WIECHA JL, 1989, AM J PUBLIC HEALTH, V79, P591, DOI 10.2105/AJPH.79.5.591; 1990, 5 MILLION CHILDREN S; 1990, STATE WORLDS CHILDRE, P22; 1990, AJDC, V144, P627	13	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1724	1725		10.1001/jama.265.13.1724	http://dx.doi.org/10.1001/jama.265.13.1724			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002575				2022-12-28	WOS:A1991FD65900030
J	FALK, RH; LEAVITT, JI				FALK, RH; LEAVITT, JI			DIGOXIN FOR ATRIAL-FIBRILLATION - A DRUG WHOSE TIME HAS GONE	ANNALS OF INTERNAL MEDICINE			English	Article							SINUS RHYTHM; HEART-RATE; DIGITALIS; EXERCISE; VERAPAMIL; FLUTTER; DILTIAZEM; EFFICACY; SAFETY; TRIAL	For over 200 years digitalis compounds have been used to treat atrial fibrillation. The rapid ventricular response to atrial fibrillation is frequently treated with digoxin to produce a controlled heart rate. Digoxin has also been proposed as a treatment for terminating recent-onset atrial fibrillation, for maintaining sinus rhythm after an episode of atrial fibrillation, and as prophylactic therapy in patients with paroxysmal atrial fibrillation to prevent excessive tachycardia during a paroxysm. Perhaps because it has been used for so long, few of these indications have been studied scientifically until recently. Studies now suggest that in patients with atrial fibrillation, digoxin is a poor drug for controlling heart rate during exertion, has little or no effect in terminating the arrhythmia, and may occasionally aggravate paroxysmal atrial fibrillation. Despite adequate digitalization, the heart rate at the onset of a paroxysm of fibrillation in patients receiving the drug does not differ from the heart rate in patients not receiving it. This article discusses the current role of digoxin in the management of patients with chronic, recent-onset, or paroxysmal atrial fibrillation.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Boston University	FALK, RH (corresponding author), BOSTON CITY HOSP, CARDIOL SECT, TALBOT 227W, 818 HARRISON AVE, BOSTON, MA 02118 USA.							ATWOOD JE, 1987, J AM COLL CARDIOL, V10, P314; BEASLEY R, 1985, BRIT MED J, V290, P9, DOI 10.1136/bmj.290.6461.9; COUMEL P, 1989, CARDIOS MON, P213; DIBIANCO R, 1984, AM HEART J, V108, P1121, DOI 10.1016/0002-8703(84)90592-1; ENGEL TR, 1978, AM J CARDIOL, V42, P570, DOI 10.1016/0002-9149(78)90625-2; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; GARRATT C, 1989, LANCET, V1, P367; GILLIS RA, 1979, PHARMACOL REV, V31, P19; GOODMAN DJ, 1975, CIRCULATION, V51, P251, DOI 10.1161/01.CIR.51.2.251; GRANDE P, 1986, CIRCULATION, V74, P101; GUYATT GH, 1988, AM J CARDIOL, V61, P371, DOI 10.1016/0002-9149(88)90947-2; KLEIN HO, 1986, DRUGS, V31, P185, DOI 10.2165/00003495-198631030-00001; KOWEY PR, 1979, CIRCULATION, V60, P253; LAUER MS, 1989, PROG CARDIOVASC DIS, V31, P367, DOI 10.1016/0033-0620(89)90031-5; MEIJLER FL, 1985, J AM COLL CARDIOL, V5, pA60, DOI 10.1016/S0735-1097(85)80464-2; PLATIA EV, 1989, AM J CARDIOL, V63, P925, DOI 10.1016/0002-9149(89)90141-0; RAWLES JM, 1990, BRIT HEART J, V63, P225; ROSEN MR, 1975, AM HEART J, V89, P391, DOI 10.1016/0002-8703(75)90090-3; ROTH A, 1986, CIRCULATION, V73, P316, DOI 10.1161/01.CIR.73.2.316; SALERNO DM, 1989, AM J CARDIOL, V63, P1046, DOI 10.1016/0002-9149(89)90076-3; SELLERS TD, 1977, CIRCULATION, V56, P260, DOI 10.1161/01.CIR.56.2.260; WELLENS LHJ, 1990, CARDIOL CLIN, V8, P503	22	102	103	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					573	575		10.7326/0003-4819-114-7-573	http://dx.doi.org/10.7326/0003-4819-114-7-573			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001090				2022-12-28	WOS:A1991FD66100010
J	TAKEICHI, M				TAKEICHI, M			CADHERIN CELL-ADHESION RECEPTORS AS A MORPHOGENETIC REGULATOR	SCIENCE			English	Article							N-CADHERIN; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; GENE FAMILY; EXPRESSION; CDNA; CAM; IDENTIFICATION; SURFACES; TISSUES	Cadherins are a family of cell adhesion receptors that are crucial for the mutual association of vertebrate cells. Through their homophilic binding interactions, cadherins play a role in cell-sorting mechanisms, conferring adhesion specificities on cells. The regulated expression of cadherins also controls cell polarity and tissue morphology. Cadherins are thus considered to be important regulators of morphogenesis. Moreover, pathological examinations suggest that the down-regulation of cadherin expression is associated with the invasiveness of tumor cells.			TAKEICHI, M (corresponding author), KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				ARMSTRONG PB, 1989, CRIT REV BIOCHEM MOL, V24, P119, DOI 10.3109/10409238909086396; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DUBAND JL, 1987, J CELL BIOL, V104, P1361, DOI 10.1083/jcb.104.5.1361; DUBAND JL, 1988, DEVELOPMENT, V103, P325; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; HAMAGUCHI M, UNPUB; HASHIMOTO M, 1989, JPN J CANCER RES, V80, P459, DOI 10.1111/j.1349-7006.1989.tb02336.x; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HEIMARK RL, 1990, J CELL BIOL, V110, P1745, DOI 10.1083/jcb.110.5.1745; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KANNO Y, 1984, EXP CELL RES, V152, P270, DOI 10.1016/0014-4827(84)90253-2; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; MAHONEY PA, UNPUB; MASOURI A, 1988, DIFFERENTIATION, V38, P67; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; MATSUNAGA M, 1988, NEURON, V1, P289, DOI 10.1016/0896-6273(88)90077-3; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; RANSCHT B, 1989, Society for Neuroscience Abstracts, V15, P959; REICHARDT LF, IN PRESS COLD SPRING; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIMOYAMA Y, UNPUB; SHIOZAKI H, UNPUB; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEINBERG MS, 1963, SCIENCE, V141, P401, DOI 10.1126/science.141.3579.401; SUZUKI S, IN PRESS CELL REGUL; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1981, DEV BIOL, V87, P340, DOI 10.1016/0012-1606(81)90157-3; TAKEICHI M, 1985, MOL DETERMINANTS ANI, P223; TAKEICHI M, IN PRESS COLD SPRING; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; TSUKITA S, UNPUB; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305	62	3102	3210	2	158	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1451	1455		10.1126/science.2006419	http://dx.doi.org/10.1126/science.2006419			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006419				2022-12-28	WOS:A1991FC85300039
J	DANIEL, WG; MUGGE, A; MARTIN, RP; LINDERT, O; HAUSMANN, D; NONNASTDANIEL, B; LAAS, J; LICHTLEN, PR				DANIEL, WG; MUGGE, A; MARTIN, RP; LINDERT, O; HAUSMANN, D; NONNASTDANIEL, B; LAAS, J; LICHTLEN, PR			IMPROVEMENT IN THE DIAGNOSIS OF ABSCESSES ASSOCIATED WITH ENDOCARDITIS BY TRANSESOPHAGEAL ECHOCARDIOGRAPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALVE RING ABSCESS; ACTIVE INFECTIVE ENDOCARDITIS; TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; NECROPSY PATIENTS; BACTERIAL-ENDOCARDITIS; IDENTIFICATION; ANEURYSM; SURGERY	Background. Echocardiography is recognized as the method of choice for the noninvasive detection of valvular vegetations in patients with infective endocarditis, with transesophageal echocardiography being more accurate than transthoracic echocardiography. The diagnosis of associated abscesses by transthoracic echocardiography is difficult or even impossible in many cases, however, and it is not known whether transesophageal echocardiography is any better. Methods. To determine the value of transesophageal echocardiography in the detection of abscesses associated with endocarditis, we studied prospectively by two-dimensional transthoracic and transesophageal echocardiography 118 consecutive patients with infective endocarditis of 137 native or prosthetic valves that was documented during surgery or at autopsy. Results. During surgery or at autopsy, 44 patients (37.3 percent) had a total of 46 definite regions of abscess. Abscesses were more frequent in aortic-valve endocarditis than in infections of other valves, and the infecting organism was more often staphylococcus (52.3 percent of cases) in patients with abscesses than in those without abscesses (16.2 percent). The hospital mortality rate was 22.7 percent in patients with abscesses, as compared with 13.5 percent in patients without abscesses. Whereas transthoracic echocardiography identified only 13 of the 46 areas of abscess, the transesophageal approach allowed the detection of 40 regions (P < 0.001). Sensitivity and specificity for the detection of abscesses associated with endocarditis were 28.3 and 98.6 percent, respectively, for transthoracic echocardiography and 87.0 and 94.6 percent for transesophageal echocardiography; positive and negative predictive values were 92.9 and 68.9 percent, respectively, for the transthoracic approach and 90.9 and 92.1 percent for the transesophageal approach. Variation between observers was 3.4 percent for transthoracic and 4.2 percent for transesophageal echocardiography. Conclusions. The data indicate that transesophageal echocardiography leads to a significant improvement in the diagnosis of abscesses associated with endocarditis. The technique facilitates the identification of patients with endocarditis who have an increased risk of death and permits earlier treatment.	HANOVER MED SCH,DEPT THORAC & CARDIOVASC SURG,HANNOVER,GERMANY; EMORY UNIV,SCH MED,DIV CARDIOL,ATLANTA,GA 30322	Hannover Medical School; Emory University	DANIEL, WG (corresponding author), HANOVER MED SCH,DEPT INTERNAL MED,DIV CARDIOL,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER 61,GERMANY.							AGATSTON AS, 1985, AM HEART J, V109, P171, DOI 10.1016/0002-8703(85)90435-1; ARNETT EN, 1976, AM J CARDIOL, V38, P281, DOI 10.1016/0002-9149(76)90169-7; ARNETT EN, 1976, CIRCULATION, V54, P140, DOI 10.1161/01.CIR.54.1.140; BROWN OR, 1975, AM J CARDIOL, V36, P17, DOI 10.1016/0002-9149(75)90861-9; BUCHBINDER NA, 1972, AM J MED, V53, P20, DOI 10.1016/0002-9343(72)90112-X; BYRD BF, 1990, AM J CARDIOL, V66, P102, DOI 10.1016/0002-9149(90)90745-M; CRIPPS T, 1986, EUR HEART J, V7, P632, DOI 10.1093/oxfordjournals.eurheartj.a062115; CROFT CH, 1983, AM J CARDIOL, V51, P1650, DOI 10.1016/0002-9149(83)90203-5; DANIEL WG, 1987, EUR HEART J, V8, P287, DOI 10.1093/eurheartj/8.suppl_J.287; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; DANIEL WG, 1988, CIRCULATION S2, V78, P297; DREXLER M, 1987, EUR HEART J, V8, P303, DOI 10.1093/eurheartj/8.suppl_J.303; EFFRON MK, 1983, J AM COLL CARDIOL, V2, P597, DOI 10.1016/S0735-1097(83)80298-8; ELLIS SG, 1985, J AM COLL CARDIOL, V5, P647, DOI 10.1016/S0735-1097(85)80390-9; FISHBEIN MC, 1975, AM J CARDIOL, V35, P918, DOI 10.1016/0002-9149(75)90129-0; FISHER EA, 1987, J AM COLL CARDIOL, V10, P222, DOI 10.1016/S0735-1097(87)80184-5; GEIBEL A, 1987, CIRCULATION, V76, P38; GRIFFITHS BE, 1982, BRIT HEART J, V47, P392; HUDSON RE, 1965, CARDIOVASCULAR PATHO, V2, P1202; JAFFE WM, 1990, J AM COLL CARDIOL, V15, P1227, DOI 10.1016/S0735-1097(10)80005-1; KWITTKEN J, 1965, ARCH INTERN MED, V115, P684, DOI 10.1001/archinte.1960.03860180056010; MARDELLI TJ, 1978, CHEST, V74, P576, DOI 10.1378/chest.74.5.576; MARTIN RP, 1980, AM J CARDIOL, V46, P379, DOI 10.1016/0002-9149(80)90004-1; Mitchell M M, 1988, J Am Soc Echocardiogr, V1, P362; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; NAKAMURA K, 1982, CIRCULATION, V65, P816, DOI 10.1161/01.CIR.65.4.816; NEIMANN JL, 1984, EUR HEART J, V5, P59, DOI 10.1093/eurheartj/5.suppl_C.59; OBRIEN JT, 1984, AM HEART J, V108, P386, DOI 10.1016/0002-8703(84)90630-6; POLLAK SJ, 1986, J AM COLL CARDIOL, V7, P1167, DOI 10.1016/S0735-1097(86)80240-6; Roberts WC, 1978, INFECTIVE ENDOCARDIT, P55; SANER HE, 1987, J AM COLL CARDIOL, V10, P859, DOI 10.1016/S0735-1097(87)80281-4; SCANLAN JG, 1982, AM J CARDIOL, V49, P1794, DOI 10.1016/0002-9149(82)90261-2; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; WANN LS, 1976, NEW ENGL J MED, V295, P135, DOI 10.1056/NEJM197607152950304; ZEINEDDIN M, 1988, AM J MED, V85, P97, DOI 10.1016/0002-9343(88)90510-4	36	502	514	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					795	800		10.1056/NEJM199103213241203	http://dx.doi.org/10.1056/NEJM199103213241203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997851				2022-12-28	WOS:A1991FC44200003
J	COHEN, J				COHEN, J			AIDS VACCINE TRIALS - BUMPY ROAD AHEAD	SCIENCE			English	Editorial Material																			0	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1312	1313		10.1126/science.2003218	http://dx.doi.org/10.1126/science.2003218			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003218				2022-12-28	WOS:A1991FB73300030
J	SLOANE, PD; MATHEW, LJ; SCARBOROUGH, M; DESAI, JR; KOCH, GG; TANGEN, C				SLOANE, PD; MATHEW, LJ; SCARBOROUGH, M; DESAI, JR; KOCH, GG; TANGEN, C			PHYSICAL AND PHARMACOLOGICAL RESTRAINT OF NURSING-HOME PATIENTS WITH DEMENTIA - IMPACT OF SPECIALIZED UNITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERMEDIATE-CARE FACILITY; ALZHEIMERS-DISEASE; MECHANICAL RESTRAINTS; DRUG-USE; RESIDENTS; AGITATION	This case-control study of 31 specialized dementia units and 32 traditional units in five states investigated use of physical and pharmacologic restraints among 625 patients with the diagnosis of dementia. Physical restraints were observed in use on 18.1% of dementia unit patients and on 51.6% of comparison unit patients who were out of bed during the day (adjusted odds ratio, 0.283; 95% confidence interval, 0.129 to 0.619). Pharmacologic restraints were routinely given to 45.3% of dementia unit patients and 43.4% of comparison unit patients (adjusted odds ratio, 0.950; 95% confidence interval, 0.611 to 1.477). We used multivariate logistic regression to identify residence in a nonspecialized nursing home unit, nonambulatory status, transfer dependency, mental status impairment, hip fracture history, and a high nursing staff-to-patient ratio, which we found to be independent predictors of physical restraint use. Physically abusive behavior, severe mental status impairment, and frequent family visitation were found to be significant predictors of pharmacologic restraint use, while advanced patient age, large nursing home size, and patient nonambulatory status were protective against such use. These results support the conclusion that physical and pharmacologic restraints constitute separate treatment modalities with different risk factors for use, and indicate that specialized dementia units are successful in reducing the use of physical but not pharmacologic restraints.	UNIV N CAROLINA, SCH PUBL HLTH, DEPT EPIDEMIOL, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, SCH PUBL HLTH, DEPT BIOSTAT, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	SLOANE, PD (corresponding author), UNIV N CAROLINA, SCH MED, DEPT FAMILY MED, CAMPUS BOX 7595, CHAPEL HILL, NC 27599 USA.				NIA NIH HHS [1K08AG00341-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000341] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackermann J O, 1985, J Long Term Care Adm, V13, P90; APPELBAUM PS, 1984, AM J PSYCHIAT, V141, P202; BASEN MM, 1977, PUBLIC HEALTH REP, V92, P43; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; Calkins M P, 1989, Provider, V15, P7; COHENMANSFIELD J, 1986, J AM GERIATR SOC, V34, P722, DOI 10.1111/j.1532-5415.1986.tb04303.x; COVERT AB, 1977, J AM GERIATR SOC, V25, P85, DOI 10.1111/j.1532-5415.1977.tb00236.x; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; FOLMAR S, 1989, GERONTOLOGIST, V29, P650, DOI 10.1093/geront/29.5.650; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; Goldman L S, 1988, Clin Geriatr Med, V4, P589; Gwyther L P, 1986, Provider, V12, P20; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; KASHGARIAN M, 1980, AM J PUBLIC HEALTH, V70, P1217, DOI 10.2105/AJPH.70.11.1217-b; Kolcaba K, 1989, J Gerontol Nurs, V15, P29; LOFGREN RP, 1989, AM J PUBLIC HEALTH, V79, P735, DOI 10.2105/AJPH.79.6.735; MAAS M, 1988, NURS CLIN N AM, V23, P57; *MACE NL, 1990, DEMENTIA CARE PATIEN; MION LC, 1989, J AM GERIATR SOC, V37, P949, DOI 10.1111/j.1532-5415.1989.tb07280.x; OHTA RJ, 1988, GERONTOLOGIST, V28, P803, DOI 10.1093/geront/28.6.803; PRUCHNO RA, 1988, J GERONTOL, V43, pP164, DOI 10.1093/geronj/43.6.P164; RABINS PV, 1986, HOSP COMMUNITY PSYCH, V37, P120; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; ROBBINS LJ, 1987, J AM GERIATR SOC, V35, P290, DOI 10.1111/j.1532-5415.1987.tb04633.x; Rubenstein H S, 1983, Law Med Health Care, V11, P271; SHAH BV, 1984, SURVEY DATA ANAL SOF; SOBEL KG, 1983, DRUG INTEL CLIN PHAR, V17, P539; TERI L, 1989, J AM GERIATR SOC, V37, P109; Wagner L, 1987, Mod Healthc, V17, P40; Weiner A S, 1989, J Long Term Care Adm, V17, P14; WERNER P, 1989, J AM GERIATR SOC, V37, P1122, DOI 10.1111/j.1532-5415.1989.tb06675.x; WILLIAMS CC, 1989, GERONTOLOGIST, V29, P585, DOI 10.1093/geront/29.5.585; ZIMMER JG, 1984, AM J PUBLIC HEALTH, V74, P1118, DOI 10.2105/AJPH.74.10.1118; 1986, SUGI SUPPLEMENTAL LI; 1990, RESTRAINTS PACKET B; 1987, TABA323 C OFF TECHN; 1984, USE RESTRAINTS FEDER	40	82	82	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1278	1282		10.1001/jama.265.10.1278	http://dx.doi.org/10.1001/jama.265.10.1278			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995975				2022-12-28	WOS:A1991FA51100022
J	BOYD, OF; GROUNDS, RM				BOYD, OF; GROUNDS, RM			LIFE THREATENING LARYNGEAL EDEMA AFTER PROLONGED INTUBATION FOR CHICKENPOX PNEUMONIA	BRITISH MEDICAL JOURNAL			English	Article							ENDOTRACHEAL INTUBATION; COMPLICATIONS; TRACHEOTOMY				BOYD, OF (corresponding author), ST GEORGE HOSP,GEN INTENS CARE UNIT,LONDON SW17 0QT,ENGLAND.							DAVIDSON RN, 1988, THORAX, V43, P627, DOI 10.1136/thx.43.8.627; ELLIS ME, 1987, BRIT MED J, V294, P1002, DOI 10.1136/bmj.294.6578.1002; ELNAGGAR M, 1976, ANESTH ANALG, V55, P195; HEFFNER JE, 1989, CHEST, V96, P186, DOI 10.1378/chest.96.1.186; LAMBERT HP, 1982, INFECT DIS, P4; RASHKIN MC, 1986, CHEST, V89, P165, DOI 10.1378/chest.89.2.165; SCHLOSSBERG D, 1988, ARCH INTERN MED, V148, P1630, DOI 10.1001/archinte.148.7.1630; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; WEBBER DM, 1965, JAMA-J AM MED ASSOC, V192, P572	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					516	517		10.1136/bmj.302.6775.516	http://dx.doi.org/10.1136/bmj.302.6775.516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012850	Green Published, Bronze			2022-12-28	WOS:A1991FB05500025
J	BREO, DL				BREO, DL			TIRED OF TAKING THE BLAME, AIDS DRUG REGULATOR COOPER,ELLEN QUITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					1027	1028		10.1001/jama.265.8.1027	http://dx.doi.org/10.1001/jama.265.8.1027			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992198				2022-12-28	WOS:A1991EY43200035
J	HAEFNER, HK				HAEFNER, HK			A DREAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					856	856						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992178				2022-12-28	WOS:A1991EX58700015
J	ENNALS, S				ENNALS, S			MATERNITY BENEFITS	BRITISH MEDICAL JOURNAL			English	Article											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					342	343		10.1136/bmj.302.6772.342	http://dx.doi.org/10.1136/bmj.302.6772.342			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001513	Green Published, Bronze			2022-12-28	WOS:A1991EX56900030
J	LUMSDEN, A				LUMSDEN, A			MOTORIZING THE SPINAL-CORD	CELL			English	Review							NEURAL-TUBE; PLATE				LUMSDEN, A (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV ANAT & CELL BIOL,LONDON SE1 9RT,ENGLAND.		Lumsden, Andrew/C-5146-2009					BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; CLARKE JDW, 1991, IN PRESS DEVELOPMENT; GRAHAM A, 1991, IN PRESS DEVELOPMENT; HATTA K, 1991, IN PRESS NATURE; Holtfreter J, 1934, ARCH EXP ZELLFORSCH, V15, P281; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V87, P163; KITCHIN IC, 1949, J EXP ZOOL, V112, P393, DOI 10.1002/jez.1401120303; LEBER SM, 1990, J NEUROSCI, V10, P2451; NOORNES HO, 1990, DEVELOPMENT, V109, P797; PLACHOV D, 1990, DEVELOPMENT, V110, P643; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; Spemann H., 1938, EMBRYONIC DEV INDUCT; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1985, ACTA MORPHOL NEER SC, V23, P91; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; VANSTRAATEN HWM, 1987, MESENCHYMAL EPITHELI, P153; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WATTERSON RL, 1965, ORGANOGENESIS, P129; YAMADA T, 1991, CELL, V64	21	25	25	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					471	473		10.1016/0092-8674(91)90226-O	http://dx.doi.org/10.1016/0092-8674(91)90226-O			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991316				2022-12-28	WOS:A1991EX36100001
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - THE SOCIAL FUND	BRITISH MEDICAL JOURNAL			English	Editorial Material											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.							1990, 1989 90 SOC FUND COM; 1990, 1989 90 SECR STAT SO	2	0	0	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					95	96		10.1136/bmj.302.6768.95	http://dx.doi.org/10.1136/bmj.302.6768.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995125	Bronze, Green Published			2022-12-28	WOS:A1991ER95100024
J	ANNAS, GJ				ANNAS, GJ			THE HEALTH-CARE PROXY AND THE LIVING WILL	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02118	Boston University	ANNAS, GJ (corresponding author), BOSTON UNIV,SCH MED,BOSTON,MA 02118, USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; ANNAS GJ, 1989, RIGHTS PATIENTS BASI, P196; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; KUTNER L, 1969, INDIANA LAW J, V44, P539; MARGOLICK D, 1991, NY TIMES        0204, pB1; RELMAN AS, 1979, NEW ENGL J MED, V300, P1270, DOI 10.1056/NEJM197905313002210; Rosenthal Elisabeth, 1991, N Y Times Web, pB9; SABATINO CP, 1990, HLTH CARE POWERS ATT; VEATCH RM, 1976, DEATH DYING BIOL REV, P184; 1983, AM J PUBLIC HEALTH, V73, P918; 1987, LIFE SUSTAINING TREA; 1986, ORGAN TRANSPLANTATIO, P38	14	85	85	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1210	1213		10.1056/NEJM199104253241711	http://dx.doi.org/10.1056/NEJM199104253241711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH572	2011167	Green Published			2022-12-28	WOS:A1991FH57200011
J	CAPLAN, RA; POSNER, KL; CHENEY, FW				CAPLAN, RA; POSNER, KL; CHENEY, FW			EFFECT OF OUTCOME ON PHYSICIAN JUDGMENTS OF APPROPRIATENESS OF CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY	Is a permanent injury more likely to elicit a rating of inappropriate care than a temporary injury? To explore this question, we asked 112 practicing anesthesiologists to judge the appropriateness of care in 21 cases involving adverse anesthetic outcomes. The original outcome in each case was classified as either temporary or permanent. The authors then generated a matching alternate case identical to the original in every respect except that a plausible outcome of opposite severity was substituted. The original and alternate cases were randomly divided into two sets and assigned to reviewers who were blind to the intent of the study. The reviewers were asked to rate independently the care in each case as appropriate, less than appropriate, or impossible to judge, based on their personal (implicit) judgment of reasonable and prudent practice. A significant inverse relationship between severity of outcome and judgments of appropriateness of care was observed in 15 (71%) of the 21 matched pairs of cases. Overall, the proportion of ratings for appropriate care decreased by 31 percentage points when the outcome was changed from temporary to permanent and increased by 28 percentage points when the outcome was changed from permanent to temporary. We conclude that knowledge of the severity of outcome can influence a reviewer's judgment of the appropriateness of care.	UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	CAPLAN, RA (corresponding author), VIRGINIA MASON MED CTR,DEPT ANESTHESIOL,POB 900,SEATTLE,WA 98111, USA.							BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; BROOK RH, 1977, NEW ENGL J MED, V296, P170, DOI 10.1056/NEJM197701202960311; BROOK RH, 1973, NEW ENGL J MED, V288, P1323, DOI 10.1056/NEJM197306212882504; BRUNNER EA, 1984, INT ANESTHESIOL CLIN, V22, P17, DOI 10.1097/00004311-198408000-00004; CAPLAN R A, 1988, Anesthesiology (Hagerstown), V69, pA722, DOI 10.1097/00000542-198809010-00722; CAPLAN RA, 1990, ANESTHESIOLOGY, V72, P828, DOI 10.1097/00000542-199005000-00010; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; COHEN J, 1987, STATISTICAL POWER AN, P215; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; EDGINGTON ES, 1987, RANDOMIZATION TESTS, P34; FESSEL WJ, 1972, NEW ENGL J MED, V286, P134, DOI 10.1056/NEJM197201202860305; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; KROLL DA, 1990, ANESTHESIOLOGY, V73, P202, DOI 10.1097/00000542-199008000-00002; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; LOHR KN, 1990, NEW ENGL J MED, V322, P707, DOI 10.1056/NEJM199003083221031; NOBREGA FT, 1977, NEW ENGL J MED, V296, P145, DOI 10.1056/NEJM197701202960305; POSNER KL, 1990, STAT MED, V9, P1103, DOI 10.1002/sim.4780090917; SCHNEIDER AJL, 1983, SURG CLIN N AM, V63, P1113; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201	21	282	283	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1957	1960		10.1001/jama.265.15.1957	http://dx.doi.org/10.1001/jama.265.15.1957			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008024				2022-12-28	WOS:A1991FF76800020
J	GIBBS, JB				GIBBS, JB			RAS C-TERMINAL PROCESSING ENZYMES - MINIREVIEW NEW DRUG TARGETS	CELL			English	Review											GIBBS, JB (corresponding author), MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486, USA.							BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; DECLUE JE, 1991, CANCER RES, V51, P712; EPSTEIN WW, 1990, P NATL ACAD SCI USA, V87, P7352, DOI 10.1073/pnas.87.19.7352; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MARR RS, 1990, J BIOL CHEM, V265, P20057; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINE J, 1990, New Biologist, V2, P219; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	28	372	404	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					1	4		10.1016/0092-8674(91)90352-Y	http://dx.doi.org/10.1016/0092-8674(91)90352-Y			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013090				2022-12-28	WOS:A1991FF77300001
J	OSHEROFF, JA; FORSYTHE, DE; BUCHANAN, BG; BANKOWITZ, RA; BLUMENFELD, BH; MILLER, RA				OSHEROFF, JA; FORSYTHE, DE; BUCHANAN, BG; BANKOWITZ, RA; BLUMENFELD, BH; MILLER, RA			PHYSICIANS INFORMATION NEEDS - ANALYSIS OF QUESTIONS POSED DURING CLINICAL TEACHING	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL-STUDENTS; MANAGEMENT; SERVICE; RECORD; CARE	Objective: To describe information requests expressed during clinical teaching. Setting: Residents' work rounds, attending rounds, morning report, and interns' clinic in a university-based general medicine service. Subjects: Attending physicians, medical house staff, and medical students in a general medicine training program. Methods: An anthropologist observed communication among study subjects and recorded in field notes expressions of a need for information. We developed a coding scheme for describing information requests and applied the coding scheme to the data recorded. Based on assigned codes, we created a subset of strictly clinical requests. Measurements: Five hundred nineteen information requests recorded during 17 hours of observed clinical activity were selected for detailed analysis. These requests related to the care of approximately 90 patients by 24 physicians and medical students. Sixty-five requests were excluded because they were not strictly clinical, leaving a subset of 454 clinical questions for analysis. Main Results: On average, five clinical questions were raised for each patient discussed. Three hundred thirty-seven requests (74%) concerned patient care. Of these 337 questions, 175 (52%) requested a fact that could have been found in a medical record. Seventy-seven (23%) of these questions, motivated by the needs of patient care, were potentially answerable by a library, a textbook, a journal, or MEDLINE. Eighty-eight (26%) of the questions asked for patient care required synthesis of patient information and medical knowledge. Conclusions: Clinicians in the study settings requested information frequently. Many of these information needs required the synthesis of patient information and medical knowledge and thus were potentially difficult to satisfy. A typology is proposed that characterizes information needs as consciously recognized, unrecognized, and currently satisfied.			OSHEROFF, JA (corresponding author), UNIV PITTSBURGH, DEPT MED, MED INFORMAT SECT, B50A LOTHROP HALL, 190 LOTHROP ST, PITTSBURGH, PA 15261 USA.				NLM NIH HHS [N01-LM-8-3514, T 15 LM 07059, K04-LM-00084] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [N01LM083514, K04LM000084, T15LM007059] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Abate MA, 1989, DRUG INF J, V23, P309; BANKOWITZ RA, 1989, ANN INTERN MED, V110, P824, DOI 10.7326/0003-4819-110-10-824; BERNER ES, 1988, 12TH P S COMP APPL M, P232; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; DAROSA DA, 1983, J MED EDUC, V58, P45; FORSYTHE DE, 1990, CSA907 U PITTS COMP; FRIES JF, 1974, MED CARE, V12, P871, DOI 10.1097/00005650-197410000-00006; GLENN JK, 1984, J FAM PRACTICE, V18, P297; GREENES RA, 1990, JAMA-J AM MED ASSOC, V263, P1114; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HUMPHREYS BL, 1989, 13TH P S COMP APPL M, P475; JELOVSEK FR, 1989, OBSTET GYNECOL, V73, P395; MATHESON NW, 1988, B MED LIBR ASSOC, V76, P222; MCDONALD CJ, 1988, JAMA-J AM MED ASSOC, V259, P3433, DOI 10.1001/jama.259.23.3433; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MILLER N, 1985, J MED EDUC, V60, P367; MURPHY JW, 1990, ANN INTERN MED, V112, P961, DOI 10.7326/0003-4819-112-12-961; NORTHUP DE, 1983, J MED EDUC, V58, P873; RENNELS GD, 1987, COMPUT METH PROG BIO, V24, P139, DOI 10.1016/0169-2607(87)90025-3; SCHOOLMAN HM, 1982, WESTERN J MED, V137, P460; SCURA G, 1981, JAMA-J AM MED ASSOC, V245, P50, DOI 10.1001/jama.245.1.50; SHORTLIFFE EH, 1987, JAMA-J AM MED ASSOC, V258, P61, DOI 10.1001/jama.258.1.61; STINSON ER, 1980, JAMA-J AM MED ASSOC, V243, P140, DOI 10.1001/jama.243.2.140; STRASSER TC, 1978, B MED LIBR ASSOC, V66, P200; SZOLOVITS P, 1988, ANN INTERN MED, V108, P80, DOI 10.7326/0003-4819-108-1-80; TAYLOR AT, 1983, J MED EDUC, V58, P824; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIMPKA T, 1989, Scandinavian Journal of Primary Health Care, V7, P105, DOI 10.3109/02813438909088656; TIMPKA T, 1990, METHOD INFORM MED, V29, P23; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405; WILLIAMSON JW, 1989, ANN INTERN MED, V110, P151, DOI 10.7326/0003-4819-110-2-151; WILSON SR, 1989, CRITICAL INCIDENT TE; WOOD GC, 1972, NEW ENGL J MED, V286, P603, DOI 10.1056/NEJM197203162861111; WOOLF SH, 1989, B MED LIBR ASSOC, V77, P372	34	224	227	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					576	581		10.7326/0003-4819-114-7-576	http://dx.doi.org/10.7326/0003-4819-114-7-576			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001091				2022-12-28	WOS:A1991FD66100011
J	BERAL, V; BULL, D; JAFFE, H; EVANS, B; GILL, N; TILLETT, H; SWERDLOW, AJ				BERAL, V; BULL, D; JAFFE, H; EVANS, B; GILL, N; TILLETT, H; SWERDLOW, AJ			IS RISK OF KAPOSIS-SARCOMA IN AIDS PATIENTS IN BRITAIN INCREASED IF SEXUAL PARTNERS CAME FROM UNITED-STATES OR AFRICA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the risk of Kaposi's sarcoma in patients with AIDS is increased by sexual contact with groups from abroad with a high incidence of Kaposi's sarcoma. Design-Analysis of data on patients with AIDS and Kaposi's sarcoma. Setting-United Kingdom. Patients-2830 patients with AIDS reported to the Communicable Disease Surveillance Centre and the Communicable Disease (Scotland) Unit up to March 1990, of whom 566 had Kaposi's sarcoma. Main outcome measures-Number of patients with Kaposi's sarcoma and possible source of HIV infection. Results-537 of 2291 men (23%) who acquired AIDS through sexual contact had Kaposi's sarcoma; the risk associated with heterosexual contact was 10% (14/135). None of the patients with Kaposi's sarcoma for whom information on source of infection was available had contracted AIDS through non-sexual means. Kaposi's sarcoma was more common among homosexual men whose likely source of infection included the United States (171/551, 31%) or Africa (9/134, 26%) than among those infected in the United Kingdom (119/625, 19%; p < 0.05). Conclusion-The data suggest that Kaposi's sarcoma is caused by a transmissible agent and that an important route of transmission is sexual contact.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; PUBL HLTH LAB SERV,CTR AIDS,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine	BERAL, V (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Swerdlow, Anthony/0000-0001-5550-4159				BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; 1989, J INFECTION, V18, P77	4	43	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					624	625		10.1136/bmj.302.6777.624	http://dx.doi.org/10.1136/bmj.302.6777.624			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC071	2012875	Bronze, Green Published			2022-12-28	WOS:A1991FC07100020
J	BOHMFALK, GL				BOHMFALK, GL			NO LAUGHING MATTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1245	1245		10.1001/jama.265.10.1245	http://dx.doi.org/10.1001/jama.265.10.1245			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995964				2022-12-28	WOS:A1991FA51100007
J	HOFMANN, JFX; GASSER, SM				HOFMANN, JFX; GASSER, SM			IDENTIFICATION AND PURIFICATION OF A PROTEIN THAT BINDS THE YEAST ARS CONSENSUS SEQUENCE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; SILENCER; ORIGIN; REQUIREMENTS; SEGREGATION; POLYMERASE; ELEMENTS; PLASMIDS; CLEAVAGE	We have identified a yeast protein that binds specifically to the ARS consensus sequence. By two-step chromatography we have purified the factor to apparent homogeneity as a single polypeptide of 67 kd. The purified ARS consensus-binding protein (ACBP) recognizes the ARS consensus of the four genomic ARS elements tested, binding preferentially to the T-rich single strand. Point mutations in the consensus significantly reduce the affinity of the single-strand binding. At the histone H4 ARS, ACBP recognizes both the perfect ARS consensus and a 9/11 match 3' of it. These two binding sites correlate with the boundaries of the minimal functional H4 ARS element. A similar configuration of binding sites is found at ARS1. We propose a model implicating this factor in an early step of the initiation of DNA replication.			HOFMANN, JFX (corresponding author), SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND.			Gasser, Susan/0000-0003-3610-9123				ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ALLIGER P, 1988, BIOCHIM BIOPHYS ACTA, V951, P396, DOI 10.1016/0167-4781(88)90112-1; AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KEARSEY S, 1984, CELL, V37, P299, DOI 10.1016/0092-8674(84)90326-X; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KIPLING D, 1990, MOL CELL BIOL, V10, P265, DOI 10.1128/MCB.10.1.265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; Maniatis T., 1982, MOL CLONING; NAWOTKA KA, 1988, MOL CELL BIOL, V8, P1408, DOI 10.1128/MCB.8.4.1408; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SMITH MM, 1983, J MOL BIOL, V169, P641, DOI 10.1016/S0022-2836(83)80163-6; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; VAUGHN JP, 1990, NUCLEIC ACIDS RES, V18, P1965, DOI 10.1093/nar/18.8.1965; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801	36	77	79	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					951	960		10.1016/0092-8674(91)90319-T	http://dx.doi.org/10.1016/0092-8674(91)90319-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001590				2022-12-28	WOS:A1991FA94000012
J	ROSA, FW				ROSA, FW			SPINA-BIFIDA IN INFANTS OF WOMEN TREATED WITH CARBAMAZEPINE DURING PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ANTIEPILEPTIC DRUGS; ANTICONVULSANT DRUGS; TERATOGENICITY; MALFORMATIONS; EPILEPSY; RISK		US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)								BARRY JE, 1974, LANCET, V2, P48; BERTOLLINI R, 1987, EUR J EPIDEMIOL, V3, P164; CHATAYAT D, 1987, TERATOLOGY, V35, pA69; DEGIAMBATTISTA M, 1990, 3RD INT C TER INF SE; FEDRICK J, 1973, BMJ-BRIT MED J, V2, P442, DOI 10.1136/bmj.2.5864.442; GLADSTONE DJ, 1990, 3RD INT C TER INF SE; HIILESMAA VK, 1981, LANCET, V2, P165; HOLMES L B, 1990, Teratology, V41, P565; JOHNSON KC, 1989, J CLIN RES DRUG DEV, V3, P215; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; JONES KL, 1989, NEW ENGL J MED, V321, P1481; KALLEN B, 1986, ACTA NEUROL SCAND, V73, P253; KANEKO S, 1988, EPILEPSIA, V29, P459, DOI 10.1111/j.1528-1157.1988.tb03746.x; KELLY TE, 1984, AM J MED GENET, V19, P423; KNUDSEN L, 1985, 1985 INT CLEAR BIRTH, P17; KUHNZ W, 1983, PEDIATR PHARMACOL, V3, P199; LINDHOUT D, 1984, LANCET, V2, P396; LINDHOUT D, 1989, JUN TER SOC M RICHM; MEYER JG, 1973, EUR NEUROL, V10, P179, DOI 10.1159/000114274; MILLAR JHD, 1973, LANCET, V1, P328; NAKANE Y, 1980, EPILEPSIA, V21, P663, DOI 10.1111/j.1528-1157.1980.tb04320.x; PORTER RJ, 1984, ADV EPILEPTOL, P299; ROBERT E, 1982, LANCET, V2, P937, DOI 10.1016/s0140-6736(82)90908-4; ROBERT E, 1986, EUR NEUROL, V25, P436, DOI 10.1159/000116048; ROSA F, 1983, 1983ADR11 FDA DOC; STARREVE.AA, 1973, LANCET, V2, P48	26	349	352	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					674	677		10.1056/NEJM199103073241006	http://dx.doi.org/10.1056/NEJM199103073241006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA144	1994251				2022-12-28	WOS:A1991FA14400006
J	IWASAKI, Y; OISO, Y; KONDO, K; TAKAGI, S; TAKATSUKI, K; HASEGAWA, H; ISHIKAWA, K; FUJIMURA, Y; KAZETO, S; TOMITA, A				IWASAKI, Y; OISO, Y; KONDO, K; TAKAGI, S; TAKATSUKI, K; HASEGAWA, H; ISHIKAWA, K; FUJIMURA, Y; KAZETO, S; TOMITA, A			AGGRAVATION OF SUBCLINICAL DIABETES-INSIPIDUS DURING PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSIENT; VASOPRESSIN; SECRETION; POLYURIA; THIRST; LIVER	Background. Transient polyuria and polydipsia during pregnancy are rare, and their cause is not entirely clear. Possible explanations include the exacerbation of preexisting abnormalities in the secretion or action of vasopressin and abnormally large increases in plasma vasopressinase activity. Methods. We studied two women in whom overt polyuria and polydipsia developed during the third trimester of pregnancy and disappeared after delivery. The secretion and action of vasopressin were studied both when the women had polyuria and polydipsia and later, when their water intake and urine volume were normal. Results. One patient had partial nephrogenic diabetes insipidus. She had little increase in urine osmolality in response to water deprivation, hypertonic-saline infusion, and vasopressin injection and no response to desmopressin acetate (1-deamino-8-D-arginine vasopressin) during the immediate postpartum period. Her basal and stimulated plasma vasopressin concentrations were high (16.5 to 203.4 pmol per liter) before and during hypertonic-saline infusion 30 months post partum. The other patient had partial neurogenic diabetes insipidus. She had subnormal basal plasma vasopressin concentrations, a subnormal increase in the plasma vasopressin level and a subnormal decrease in urine flow in response to the administration of vasopressin, and a normal response to desmopressin. After pregnancy, when her urine volume was normal, she had no increase in plasma vasopressin in response to hypertonic-saline infusion, but she had a normal rise in the plasma vasopressin level and a normal renal response to vasopressin administration. Conclusions. Pregnancy may unmask subclinical forms of both nephrogenic and neurogenic diabetes insipidus. This exacerbation may result from both increased vasopressinase activity and diminished renal responsiveness to vasopressin.	NAGOYA FIRST HOSP, JAPANESE RED CROSS, DEPT OBSTET & GYNECOL, NAGOYA, JAPAN; AICHI MED UNIV, CENT LAB CLIN INVEST, NAGAKUTE, AICHI 48011, JAPAN; NAGOYA FIRST HOSP, JAPANESE RED CROSS, DEPT INTERNAL MED, NAGOYA, JAPAN	Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; Aichi Medical University; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital	IWASAKI, Y (corresponding author), NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, 65 TSURUMAI CHO, SHOWA KU, NAGOYA, AICHI 466, JAPAN.							AMICO JA, 1985, FRONT HORM RES, V13, P266; BARBIERI RL, 1985, FERTIL STERIL, V44, P529; BARRON WM, 1984, NEW ENGL J MED, V310, P442, DOI 10.1056/NEJM198402163100707; BAYLIS PH, 1986, CLIN ENDOCRINOL, V24, P459, DOI 10.1111/j.1365-2265.1986.tb01651.x; BERNHEIM J, 1986, EUR J CLIN INVEST, V16, P113, DOI 10.1111/j.1365-2362.1986.tb01317.x; Blotner H, 1942, NEW ENGL J MED, V227, P287, DOI 10.1056/NEJM194208202270803; BREYER MD, 1990, KIDNEY INT, V38, P618, DOI 10.1038/ki.1990.251; CAMMU H, 1987, BRIT J OBSTET GYNAEC, V94, P173, DOI 10.1111/j.1471-0528.1987.tb02346.x; CARFAGNO SC, 1953, ARCH INTERN MED, V92, P542, DOI 10.1001/archinte.1953.00240220090013; CARTER AC, 1947, J CLIN ENDOCRINOL, V7, P753, DOI 10.1210/jcem-7-11-753; DAVISON JM, 1989, J CLIN INVEST, V83, P1313, DOI 10.1172/JCI114017; DAVISON JM, 1984, AM J PHYSIOL, V246, pF105, DOI 10.1152/ajprenal.1984.246.1.F105; DAVISON JM, 1980, KIDNEY INT, V18, P152, DOI 10.1038/ki.1980.124; DURR JA, 1987, AM J KIDNEY DIS, V9, P276; DURR JA, 1987, NEW ENGL J MED, V316, P1070, DOI 10.1056/NEJM198704233161707; EDWARDS CRW, 1973, BRIT MED J, V3, P375, DOI 10.1136/bmj.3.5876.375; EGLIN JM, 1959, J CLIN ENDOCR METAB, V19, P369, DOI 10.1210/jcem-19-3-369; Ferrara J M, 1980, Diagn Gynecol Obstet, V2, P227; FORD SM, 1986, OBSTET GYNECOL, V68, P726; FORSSMAN H, 1945, ACTA MED SCANDINAV S, V159, P1; GOODMAN H, 1984, AM J OBSTET GYNECOL, V149, P910, DOI 10.1016/0002-9378(84)90619-7; HARPER M, 1987, J REPROD MED, V32, P862; HASHIMOTO T, 1961, J Jpn Obstet Gynecol Soc, V8, P87; Hirota T, 1965, Mie Med J, V14, P205; HUGHES JM, 1989, OBSTET GYNECOL, V73, P462; IWASAKI Y, 1989, J CLIN ENDOCR METAB, V68, P560, DOI 10.1210/jcem-68-3-560; JOUPPILA P, 1971, ANN CHIR GYNAECOL FE, V60, P57; KATZ VL, 1987, SOUTHERN MED J, V80, P524, DOI 10.1097/00007611-198704000-00030; KORBET SM, 1985, AM J NEPHROL, V5, P442, DOI 10.1159/000166981; Krege J, 1989, Obstet Gynecol Surv, V44, P789; MCLAREN HC, 1942, J OBSTET GYN BR COMM, V49, P51; MILLAR DG, 1970, REPRODUCTIVE ENDOCRI, P152; MILLER M, 1970, ANN INTERN MED, V73, P721, DOI 10.7326/0003-4819-73-5-721; MIZUNO O, 1987, ENDOCRINOL JAPON, V34, P449; OISO Y, 1986, Folia Endocrinologica Japonica, V62, P608; PAGE EW, 1946, AM J OBSTET GYNECOL, V52, P1014, DOI 10.1016/0002-9378(46)90419-X; ROBERTSON GL, 1985, VASOPRESSIN, P203; ROTH K, 1962, AM J OBSTET GYNECOL, V83, P1325, DOI 10.1016/S0002-9378(16)36044-6; Sakurai H, 1985, Nihon Naibunpi Gakkai Zasshi, V61, P724; SHAH SV, 1988, ANN INTERN MED, V109, P435, DOI 10.7326/0003-4819-109-5-435_2; TUPPY H, 1968, HANDBOOK EXPERIMENTA, V23, P67; VANDERWEIDEN RMF, 1987, EUR J OBSTET GYN R B, V25, P331, DOI 10.1016/0028-2243(87)90144-4; ZERBE RL, 1981, NEW ENGL J MED, V305, P1539, DOI 10.1056/NEJM198112243052601	43	77	79	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					522	526		10.1056/NEJM199102213240803	http://dx.doi.org/10.1056/NEJM199102213240803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1992305				2022-12-28	WOS:A1991EX91800003
J	WEBB, SJ; DOWELL, AC; HEYWOOD, P				WEBB, SJ; DOWELL, AC; HEYWOOD, P			SURVEY OF GENERAL-PRACTICE AUDIT IN LEEDS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine general practitioners' attitudes to medical audit and to establish what initiatives are already being undertaken; to define future ideas for audit and perceived difficulties in implementing audit in primary care. Design-Analysis of responses to a self administered postal questionnaire. Setting-Urban conurbation with a population of about 750 000. Participants-386 general practitioners on the general medical list of Leeds Family Practitioner Committee. Main outcome measures-Extent of recording of practice activity data and outcome measures and clinical data, use of data, and audit performed; ideas for audit and perceived difficulties. Results-317 doctors responded to the questionnaire (individual response rate 82%) from 121 practices (practice response rate 88%). In all, 206 doctors thought that audit could improve the quality of care; 292 collected practice activity data, though 143 of them did not use it. A total of 111 doctors recorded some outcome measures, though half of them did not use them. Varying proportions of doctors had registers for various diseases (136 had at least one register), disease management policies (60 doctors), and prescribing policies. In all, 184 doctors met monthly with other members of the primary health care team. Conclusions-Much poorly focused data collection is taking place. Some doctors have experience in setting up basic information systems and practice policies, and some audit is being performed. The family health services authorities need to take seriously the perceived difficulties of time, organisation, and resources concerned with audit.			WEBB, SJ (corresponding author), UNIV LEEDS,ST JAMES HOSP,DEPT GEN PRACTICE,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							BAKER R, 1988, 39 ROYAL COLL GEN PR; BAKER R, 1990, PRACTICE AUDIT PLAN; Crombie D, 1988, 41 ROYAL COLL GEN PR; DIFFORD F, 1990, BRIT MED J, V300, P92, DOI 10.1136/bmj.300.6717.92; HUGHES J, 1990, MED AUDIT GENERAL PR; IRVINE DH, 1990, BRIT J GEN PRACT, V40, P75; MARINKER M, 1990, MED AUDIT GENERAL PR; METCALFE DHH, 1989, BRIT MED J, V299, P1293, DOI 10.1136/bmj.299.6711.1293; PATTERSON HR, 1986, J ROY COLL GEN PRACT, V36, P196; SHAW CD, 1989, BRIT MED J, V299, P498, DOI 10.1136/bmj.299.6697.498; Sheldon MG, 1982, 20 ROYAL COLL GEN PR; SMITH T, 1990, BRIT MED J, V300, P65, DOI 10.1136/bmj.300.6717.65; 1983, J R COLL GEN PRACT, V33, P523; 1989, MED AUDIT ED IMPLICA; 1985, QUALITY GENERAL PRAC; 1989, CMND555	16	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					390	392		10.1136/bmj.302.6773.390	http://dx.doi.org/10.1136/bmj.302.6773.390			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	2004145	Green Published, Bronze			2022-12-28	WOS:A1991EX85800029
J	YAMADA, T; PLACZEK, M; TANAKA, H; DODD, J; JESSELL, TM				YAMADA, T; PLACZEK, M; TANAKA, H; DODD, J; JESSELL, TM			CONTROL OF CELL PATTERN IN THE DEVELOPING NERVOUS-SYSTEM - POLARIZING ACTIVITY OF THE FLOOR PLATE AND NOTOCHORD	CELL			English	Article							CHICK LIMB BUD; NEURAL-TUBE; HOMEOBOX GENES; RETINOIC ACID; SPINAL-CORD; EMBRYO; MORPHOGENESIS; NEUROBLASTS; GUIDANCE	Individual classes of neural cells differentiate at distinct locations in the developing vertebrate nervous system. We provide evidence that the pattern of cell differentiation along the dorsoventral axis of the chick neural tube is regulated by signals derived from two ventral midline cell groups, the notochord and floor plate. Grafting an additional notochord or floor plate to ectopic positions, or deleting both cell groups, resulted in changes in the fate and position of neural cell types, defined by expression of specific antigens. These results suggest that the differentiation of neural cells is controlled, in part, by their position with respect to the notochord and floor plate.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; GUNMA UNIV, SCH MED, DEPT PHARMACOL, MAEBASHI, GUNMA 371, JAPAN	Columbia University; Columbia University; Gunma University	YAMADA, T (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Placzek, Marysia/E-6172-2010	Placzek, Marysia/0000-0002-4106-9229				Ahlborn Friedrich, 1883, Z WISS ZOOL, V39, P191; ALTABA AR, 1989, NATURE, V341, P33; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; BOVOLENTA P, 1988, Society for Neuroscience Abstracts, V14, P271; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; DODD J, 1986, J EXP BIOL, V124, P225; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FONTAINEPERUS JC, 1989, DEVELOPMENT, V107, P413; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, IN PRESS COMMUNICATI; HATTA K, 1991, IN PRESS NATURE; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOMMA S, 1990, Society for Neuroscience Abstracts, V16, P836; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; HORSTADIUS S, 1944, ACTA ZOOLOGICA, V25, P257; Hutchinson C, 1936, J COMP NEUROL, V63, P465, DOI 10.1002/cne.900630305; JACOBSON CO, 1964, ZOOL BIDR UPPS, V36, P73; JESSELL TM, 1989, CIBA F SYMP, V144, P255; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KITCHIN IC, 1949, J EXP ZOOL, V112, P393, DOI 10.1002/jez.1401120303; KUWADA JY, 1990, J NEUROSCI, V10, P1299; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; MADEN M, 1989, DEV BIOL, V135, P124, DOI 10.1016/0012-1606(89)90163-2; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MELTON DA, 1989, CIBA F SYMP, V144, P16; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; ROACH FC, 1945, J EXP ZOOL, V99, P53, DOI 10.1002/jez.1400990203; ROSENQUIST GLENN C., 1966, CARNEGIE INST WASH PUBL, V38, P71; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEDING G, 1962, ACTA ANAT, V49, P199; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; VANSTRAATEN HWM, 1987, NATO ASI, V5, P153; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WALLACE JA, 1985, J COMP NEUROL, V236, P443, DOI 10.1002/cne.902360403; WATTERSON RL, 1955, ANAT REC, V122, P539, DOI 10.1002/ar.1091220405; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WATTERSON RL, 1965, ORGANOGENESIS, P129; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAGINUMA H, 1990, DEVELOPMENT, V108, P705	54	647	659	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					635	647		10.1016/0092-8674(91)90247-V	http://dx.doi.org/10.1016/0092-8674(91)90247-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991324	hybrid			2022-12-28	WOS:A1991EX36100019
J	RODERICK, P; VICTOR, C; CONNELLY, J				RODERICK, P; VICTOR, C; CONNELLY, J			IS HOUSING A PUBLIC-HEALTH ISSUE - A SURVEY OF DIRECTORS OF PUBLIC-HEALTH	BRITISH MEDICAL JOURNAL			English	Article							GROUNDS	Objective-To determine the views of directors of public health on the importance of housing for public health and their departments' and health authorities' participation in housing issues. Design-Postal self administered questionnaire survey. Setting-All district health authorities in England and health boards in Wales, Scotland, and Northern Ireland. Subjects-All 221 district directors of public health in England and chief administrative medical officers in Wales, Scotland, and Northern Ireland. Main outcome measure-Response to questionnaire consisting of fixed and open ended questions on housing issues. Results-The response rate was 89% (196/221). Housing was perceived as a major health problem by 33% (65/196) of directors. Positive responses were most likely from inner city districts. In 47% (93/196) of departments there was a formal time commitment to housing issues with a median time of one session/ week (range one per month to 10 per week). The main function was allocation of medical priority for public sector rehousing. Overall, 73% (144/196) reported some participation in this process. Reported participation in joint care planning and links with non-statutory housing organisations were uncommon. 53% (104/196) of directors had included housing issues in their annual health report. In 16% (32/196) of districts specific services for the homeless had been set up. Conclusions-Although concern about the impact of current housing policy on public health was shown by a substantial number of directors, the main activity was still allocation of medical priority despite a background of increasing housing need and homelessness. The underlying need is for greater advocacy to produce a healthy housing policy for all, and the annual public health report could be used to promote this objective.	ST MARYS HOSP,DEPT PUBL HLTH,PUBL HLTH RES UNIT,LONDON W2 1NY,ENGLAND	Imperial College London	RODERICK, P (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,MRC,EPIDEMIOL & MED CARE UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND.			Victor, Christina/0000-0002-4213-3974				CLARK DM, 1990, AFFORDABLE RURAL HOU; COLE O, 1986, PUBLIC HEALTH, V100, P229, DOI 10.1016/S0033-3506(86)80072-5; ELTON PJ, 1986, J CHRON DIS, V39, P221, DOI 10.1016/0021-9681(86)90027-5; FISK MJ, 1982, HLTH B, V42, P92; Gardner P. A., 1981, HOUSING, V17, P20; GRAY JAM, 1978, BMJ, V277, P100; HOWELLS EL, 1984, BRIT MED J, V288, P201, DOI 10.1136/bmj.288.6412.201; KOHLI HS, 1986, BRIT MED J, V293, P370, DOI 10.1136/bmj.293.6543.370; LOWRY S, 1990, BRIT MED J, V300, P321, DOI 10.1136/bmj.300.6720.321; MACLENNAN WJ, 1982, HLTH B, V41, P181; MCKEOWN T, 1976, ROLE MED; MORRIS J, 1990, OUR RIGHTS OUR HOMES; MORRIS JN, 1990, LANCET, V336, P491, DOI 10.1016/0140-6736(90)92026-E; NINER P, 1989, HOUSING NEEDS 1990S; ORMANDY D, 1987, J ROY SOC HEALTH, V107, P39, DOI 10.1177/146642408710700201; PARSONS L, 1987, PUBLIC HEALTH, V101, P435, DOI 10.1016/S0033-3506(87)80005-7; PRESCOTTCLARKE P, 1988, QUEUING HOUSING STUD; THOMAS HF, 1978, BRIT MED J, V2, P358, DOI 10.1136/bmj.2.6133.358-d; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725; 1989, HOUSIGN CONSTRUCTION; 1987, PUBLIC HLTH ENGLAND; 1988, PRESCRIPTION POOR HL; 1988, HOMELESS FAMILIES TH; 1988, HOMELESSNESS STATIST; 1985, TARGETS HLTH ALL YEA; 1989, HLTH PRINCIPLES HOUS; 1989, CARING PEOPLE COMMUN; 1988, ENGLISH HOUSE CONDIT; 1988, HC8864 DEP HLTH; 1990, HOUSING HOMELESSNESS	30	10	10	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					157	160		10.1136/bmj.302.6769.157	http://dx.doi.org/10.1136/bmj.302.6769.157			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995137	Green Published, Bronze			2022-12-28	WOS:A1991EU02000025
J	ROBERTS, J				ROBERTS, J			THE NHS OBSERVED - GENERAL-PRACTICE - FEELING FINE, GETTING BETTER	BRITISH MEDICAL JOURNAL			English	Editorial Material																		Boyle C., 1970, BMJ-BRIT MED J, V1, P286; Cartwright F.F., 1977, SOCIAL HIST MED; Illich I., 1976, MED NEMESIS; Mechanic D, 1972, Med Care, V10, P402, DOI 10.1097/00005650-197209000-00004; PAYER L, 1988, MED CULTURE; 1988, HLTH US 1988; 1989, WORKING PATIENTS; 1989, COMPENDIUM HLTH STAT	8	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					97	100		10.1136/bmj.302.6768.97	http://dx.doi.org/10.1136/bmj.302.6768.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995126	Green Published, Bronze			2022-12-28	WOS:A1991ER95100026
J	JOHNSON, RD; HOROWITZ, M; MADDOX, AF; WISHART, JM; SHEARMAN, DJC				JOHNSON, RD; HOROWITZ, M; MADDOX, AF; WISHART, JM; SHEARMAN, DJC			CIGARETTE-SMOKING AND RATE OF GASTRIC-EMPTYING - EFFECT ON ALCOHOL ABSORPTION	BRITISH MEDICAL JOURNAL			English	Article							1ST-PASS METABOLISM; BLOOD ETHANOL; SMOKERS; HUMANS	Objective - To examine the effects of cigarette smoking on alcohol absorption and gastric emptying. Design - Randomised crossover study. Setting - Research project in departments of medicine and nuclear medicine. Subjects - Eight healthy volunteers aged 19-43 who regularly smoked 20-35 cigarettes a day and drank small amounts of alcohol on social occasions. Interventions - Subjects drank 400 ml of a radiolabelled nutrient test meal containing alcohol labelled nutrient test meal containing alcohol (0.5 g/kg), then had their rates of gastric emptying measured. Test were carried out (a) with the subjects smoking four cigarettes an hour and (b) with the subjects not smoking, having abstained for seven days or more. The order of the tests was randomised and the tests were conducted two weeks apart. Main outcome measures - Peak blood alcohol concentrations, absorption of alcohol at 30 minutes, amount of test meal emptied from the stomach at 30 minutes, and times taken for 50% of the meal to leave the proximal stomach and total stomach. Results - Smoking was associated with reductions in (a) peak blood alcohol concentrations (median values in non-smoking versus smoking periods 13.5 (range 8.7-22.6) mmol/l v 11.1 (4.3-13.5) mmol/l), (b) are under the bolld alcohol concentration-time curve at 30 minutes (264 X 10(3) (0.509 X 10(3)) mmol/l/min v 140 X 10(3) (0-217 X 10(3)) mmol/l/min(, and (c) amount of test meal emptied from the stomach at 30 minutes (39% (5-86%) v 23% (0-35%). In addition, smoking slowed both the 50% gastric emptying time (37 (9-83) minutes v 56 (40-280) minutes) and the intragastric distribution of the meal. There was a close correlation between the amount of test meal emptied from the stomach at 30 minutes and the area under the blood alcohol concentration-time curve at 30 minutes (r = 0.91; p < 0.0001). Conclusion - Cigarette smoking slows gastric emptying and as a consequence delays alcohol absorption.	ROYAL ADELAIDE HOSP,DEPT NUCL MED,ADELAIDE,SA 5000,AUSTRALIA	Royal Adelaide Hospital	JOHNSON, RD (corresponding author), ROYAL ADELAIDE HOSP,DEPT MED,N TERRACE,ADELAIDE,SA 5000,AUSTRALIA.							AZPIROZ F, 1985, AM J PHYSIOL, V249, pG501, DOI 10.1152/ajpgi.1985.249.4.G501; CABALLERIA J, 1989, GASTROENTEROLOGY, V97, P1205, DOI 10.1016/0016-5085(89)91691-0; CABALLERIA J, 1989, GASTROENTEROLOGY, V96, P388, DOI 10.1016/0016-5085(89)91562-X; CARLSON GM, 1970, J PHARMACOL EXP THER, V172, P377; CHAUDHURI TK, 1988, CHEST, V94, P1122, DOI 10.1378/chest.94.5.1122a; COLLINS PJ, 1983, GUT, V24, P117; COOPER JDH, 1971, CLIN CHIM ACTA, V33, P483, DOI 10.1016/0009-8981(71)90516-X; COTTON PB, 1973, POSTGRAD MED J, V49, P27, DOI 10.1136/pgmj.49.567.27; DIPADOVA C, 1987, GASTROENTEROLOGY, V92, P1169, DOI 10.1016/S0016-5085(87)91073-0; FINCH JE, 1974, BR J CLIN PHARM, V1, P223; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GRIMES D, 1978, BRIT MED J, V2, P460, DOI 10.1136/bmj.2.6135.460; GRITZ E R, 1988, Alimentary Pharmacology and Therapeutics, V2, P173; GRUNBERG NE, 1986, PSYCHOPHARMACOL BULL, V22, P875; HEDDLE R, 1988, GUT, V29, P1349, DOI 10.1136/gut.29.10.1349; HEDDLE R, 1989, AM J PHYSIOL, V255, pG491; HOLT S, 1981, CAN MED ASSOC J, V124, P267; HOROWITZ M, 1985, ARCH INTERN MED, V145, P1467, DOI 10.1001/archinte.145.8.1467; HOROWITZ M, 1989, AM J PHYSIOL, V257, pG291, DOI 10.1152/ajpgi.1989.257.2.G291; HOUGHTON LA, 1988, GASTROENTEROLOGY, V94, P1285, DOI 10.1016/0016-5085(88)90665-8; LEWIS KO, 1987, BRIT MED J, V295, P800, DOI 10.1136/bmj.295.6602.800; MCCALLUM RW, 1981, GASTROENTEROLOGY, V80, P1226; MCDONNELL W M, 1989, Gastroenterology, V96, pA332; MCFARLANE A, 1986, GUT, V27, P15, DOI 10.1136/gut.27.1.15; MILLER G, 1989, GUT, V30, P50, DOI 10.1136/gut.30.1.50; MULLERLISSNER SA, 1986, GASTROENTEROLOGY, V90, P1205; NOWAK A, 1987, SCAND J GASTROENTERO, V22, P54, DOI 10.3109/00365528708991856; PETRING OU, 1985, BRIT J ANAESTH, V57, P1104, DOI 10.1093/bja/57.11.1104; VALENZUELA JE, 1976, GASTROENTEROLOGY, V70, P481	29	63	63	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					20	23		10.1136/bmj.302.6767.20	http://dx.doi.org/10.1136/bmj.302.6767.20			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991182	Green Published, Bronze			2022-12-28	WOS:A1991ER37200019
J	JONES, PK; RATNOFF, OD				JONES, PK; RATNOFF, OD			THE CHANGING PROGNOSIS OF CLASSIC HEMOPHILIA (FACTOR-VIII DEFICIENCY)	ANNALS OF INTERNAL MEDICINE			English	Article							SWEDISH HEMOPHILIACS; UNITED-STATES; LIFE EXPECTANCY; KINGDOM; DEATH; AIDS	Objective: To estimate relative risk of mortality and median life expectancy for patients with classic hemophilia by a life-table analysis, taking into account deaths that may have occurred in infancy or childhood before the onset of symptoms. Design: Retrospective chart review of clinical series. Setting: Referral-based university medical center. Patients: Seven hundred one patients with classic hemophilia (hemophilia A; factor VIII "deficiency") were studied for the years from 1900 to 1990; patients were identified in 289 families. Measurements and Main Results: Relative risk for mortality and median life expectancy among hemophiliacs were compared with those among normal U.S. males. Overall, mortality (relative to that of contemporaneous U.S. males) was increased about sixfold among severely affected patients, more than twofold among moderately affected patients, and was equivalent to that of U.S. males among mildly affected patients. Median life expectancy at 1 year of age had reached almost 68 years in the decade 1971 to 1980, but declined to only 49 years in the decade 1981 to 1990. Conclusions: After improvement in survival from 1971-1980 (corresponding to widespread treatment with lyophilized concentrates of antihemophilic factor [factor VIII]), relative mortality is now increasing, especially among severely affected patients, in large measure because of the acquired immunodeficiency syndrome (AIDS).	UNIV HOSP CLEVELAND, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA	University Hospitals of Cleveland; Case Western Reserve University					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00080-25] Funding Source: Medline; NHLBI NIH HHS [HL01661] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGLE DP, 1964, ARCH INTERN MED, V114, P76, DOI 10.1001/archinte.1964.03860070122015; AGLE DP, 1968, TREATMENT HEMORRHAGI; ARONSON DL, 1988, AM J HEMATOL, V27, P7, DOI 10.1002/ajh.2830270103; BAHNER RL, 1966, NEW ENGL J MED, V275, P524; BIGGS R, 1977, BRIT J HAEMATOL, V35, P487, DOI 10.1111/j.1365-2141.1977.tb00615.x; BULLOCH W, 1912, THEORY HUMAN INHERIT, V1; Cochran W.G., 1978, SAMPLING TECHNIQUES; Colton T., 1974, STAT MED, V1; Cox D. R., 1984, ANAL SURVIVAL DATA; EYSTER ME, 1980, AM J HEMATOL, V9, P277, DOI 10.1002/ajh.2830090306; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOODNOUGH LT, 1983, MEDICINE, V62, P248, DOI 10.1097/00005792-198307000-00004; Gross AJ, 1975, SURVIVAL DISTRIBUTIO; IKKALA E, 1982, BRIT J HAEMATOL, V52, P7, DOI 10.1111/j.1365-2141.1982.tb03856.x; KERR C B, 1963, Med Hist, V7, P359; LARSSON SA, 1983, ACTA MED SCAND, V214, P199; LARSSON SA, 1982, ACTA MED SCAND, V212, P195; LARSSON SA, 1985, BRIT J HAEMATOL, V59, P593, DOI 10.1111/j.1365-2141.1985.tb07353.x; LITTLE R, 1987, STATISTICAL ANAL MIS; Maxwell A.E., 1961, ANAL QUALITATIVE DAT; MCGRADY GA, 1987, AM J EPIDEMIOL, V126, P25, DOI 10.1093/oxfordjournals.aje.a114657; NILSSON IM, 1976, ACTA PAEDIATR SCAND, V65, P129, DOI 10.1111/j.1651-2227.1976.tb16525.x; NOURELDIN F, 1961, BRIT MED J, V1, P824, DOI 10.1136/bmj.1.5228.824; NOURELDIN F, 1967, BLOOD COAGULATION SI, P87; RAMGREN O, 1962, ACTA MED SCAND, V171, P237; RAMGREN O, 1962, ACTA MED SCAND, V171, P37; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; STAFFORD RS, 1980, CLIN RES, V28, pA103; STEHRGREEN JK, 1988, AM J PUBLIC HEALTH, V78, P439, DOI 10.2105/AJPH.78.4.439; 1989, STAT ABSTR; [No title captured]; 1954, VITAL STATISTICS US, V1; 1975, HIST STATISTICS US 1; 1987, MMWR S6, V36, P1	35	66	67	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					641	648		10.7326/0003-4819-114-8-641	http://dx.doi.org/10.7326/0003-4819-114-8-641			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003710				2022-12-28	WOS:A1991FG03100005
J	MULLIN, GE				MULLIN, GE			FOOD ALLERGY AND IRRITABLE-BOWEL-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HYPERSENSITIVITY		NIAID,MUCOSAL IMMUN SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	MULLIN, GE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.		Mullin, Gerry/H-5294-2019	Mullin, Gerry/0000-0001-5317-6788				BENTLEY SJ, 1983, LANCET, V2, P295; JOHANSSON SGO, 1984, ANN ALLERGY, V53, P665; JONES AV, 1982, LANCET, V2, P115; PETITPIERRE M, 1985, ANN ALLERGY, V54, P538; ZWETCHKENBAUM JF, 1988, ANN ALLERGY, V60, P1	5	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1736	1736						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002578				2022-12-28	WOS:A1991FD65900033
J	DRAKE, JM; KLAFTER, J; LEVITZ, P				DRAKE, JM; KLAFTER, J; LEVITZ, P			CHEMICAL AND BIOLOGICAL MICROSTRUCTURES AS PROBED BY DYNAMIC PROCESSES	SCIENCE			English	Article							DIRECT ENERGY-TRANSFER; EXCITATION TRANSFER; RESTRICTED GEOMETRIES; SURFACE; FLUORESCENCE; RELAXATION; MORPHOLOGY; SYSTEMS	The dynamic process of electronic energy transfer is shown to be an important tool for probing the microstructure of molecular systems, particularly those in which donors and acceptors occupy specifically labeled sites of spatially confining host matrices. Special attention is given to analyzing the temporal behavior of the direct energy transfer reaction for systems in which the dipolar coupling is between a donor and randomly distributed acceptors. This dynamic process is dependent on two competing lengths when the donor and acceptor distribution is determined by the microstructure of the confining system: R(p), the dominant length characterizing the size of the confinement, and R0, which scales the strength of the dipolar coupling. When energy transfer processes are viewed in the context of these two competing lengths, a picture emerges of the microstructure of the confinement that is consistent with and corroborated by other structural probes.	CNRS, CRSOCI, F-45071 ORLEANS 2, FRANCE; TEL AVIV UNIV, SCH CHEM, IL-69978 TEL AVIV, ISRAEL	Centre National de la Recherche Scientifique (CNRS); Tel Aviv University	DRAKE, JM (corresponding author), EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA.							BAUMANN J, 1986, J CHEM PHYS, V85, P4087, DOI 10.1063/1.450880; BENNETT RG, 1964, J CHEM PHYS, V41, P3037, DOI 10.1063/1.1725670; BLUMEN A, 1981, NUOVO CIMENTO B, V63, P50, DOI 10.1007/BF02721411; BLUMEN A, 1986, J CHEM PHYS, V84, P1397, DOI 10.1063/1.450481; Blumen A., 1986, OPTICAL SPECTROSCOPY, P199; BUCHER H, 1967, MOL CRYST, V2, P199, DOI 10.1080/15421406708083417; Cantor, 1980, BIOPHYS CHEM; CANTOR CR, 1971, P NATL ACAD SCI USA, V68, P2099, DOI 10.1073/pnas.68.9.2099; Drake J. M., 1986, MATER RES STAND, V73, P305; DRAKE JM, 1990, PHYS TODAY, V43, P46, DOI 10.1063/1.881244; EVEN U, 1984, PHYS REV LETT, V52, P2164, DOI 10.1103/PhysRevLett.52.2164; FERNANDEZ SM, 1976, NATURE, V264, P411, DOI 10.1038/264411a0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FORSTER T, 1949, Z NATURFORSCH A, V4, P321; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; INOKUTI M, 1965, J CHEM PHYS, V43, P1978, DOI 10.1063/1.1697063; KASATANI K, 1985, J PHYS CHEM-US, V89, P542, DOI 10.1021/j100249a035; KAUFFMANN HF, 1990, DYNAMICAL PROCESSES IN CONDENSED MOLECULAR SYSTEMS, P90; KLAFTER J, 1985, J LUMIN, V34, P77, DOI 10.1016/0022-2313(85)90096-1; KLAFTER J, 1984, J CHEM PHYS, V80, P875, DOI 10.1063/1.446743; KLAFTER J, 1986, P NATL ACAD SCI USA, V83, P848, DOI 10.1073/pnas.83.4.848; Klafter J, 1989, MOL DYNAMICS RESTRIC; KOPELMAN R, 1988, SCIENCE, V241, P1620, DOI 10.1126/science.241.4873.1620; LEVITZ P, 1987, PHYS REV LETT, V58, P686, DOI 10.1103/PhysRevLett.58.686; LEVITZ P, 1988, J CHEM PHYS, V89, P5224, DOI 10.1063/1.455613; LEVITZ P, 1988, CHEM PHYS LETT, V148, P557, DOI 10.1016/0009-2614(88)80330-0; LEVITZ P, UNPUB; Mandelbrot B, 1983, FRACTAL GEOMETRY NAT; MATAGA N, 1969, J PHYS CHEM-US, V73, P370, DOI 10.1021/j100722a016; OHMINE I, 1977, MACROMOLECULES, V10, P862, DOI 10.1021/ma60058a028; PEKCAN O, 1990, CHEM PHYS, V146, P283, DOI 10.1016/0301-0104(90)80049-4; PEKCAN O, 1988, PHYS REV LETT, V61, P641, DOI 10.1103/PhysRevLett.61.641; REHM D, 1971, CHEM PHYS LETT, V9, P387, DOI 10.1016/0009-2614(71)80249-X; Steinberg I. Z., 1983, TIME RESOLVED FLUORE, P411; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAMAI N, 1988, CHEM PHYS LETT, V147, P25, DOI 10.1016/0009-2614(88)80217-3; TAMAI N, 1987, J PHYS CHEM-US, V91, P3503, DOI 10.1021/j100297a010; ULLMAN EF, 1976, J BIOL CHEM, V251, P4172; YANG CL, 1985, J PHYS CHEM-US, V89, P3442, DOI 10.1021/j100262a003; YANG CL, 1989, MOL DYNAMICS RESTRIC, P371; Yen W. M., 1981, LASER SPECTROSCOPY S	42	106	109	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1574	1579		10.1126/science.2011737	http://dx.doi.org/10.1126/science.2011737			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011737				2022-12-28	WOS:A1991FD89000027
J	GREENBERGER, PA				GREENBERGER, PA			ALLERGY TO SULFA DRUGS WITH POSTCOITAL URTICARIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498				GREEN RL, 1985, JAMA-J AM MED ASSOC, V254, P531, DOI 10.1001/jama.254.4.531; SELL MB, 1985, AM J PSYCHIAT, V142, P271	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1458	1458						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999889				2022-12-28	WOS:A1991FB55000031
J	KHONG, TY; HEALY, DL; MCCLOUD, PI				KHONG, TY; HEALY, DL; MCCLOUD, PI			PREGNANCIES COMPLICATED BY ABNORMALLY ADHERENT PLACENTA AND SEX-RATIO AT BIRTH	BRITISH MEDICAL JOURNAL			English	Article									MONASH UNIV,MONASH MED CTR,DEPT OBSTET & GYNAECOL,CLAYTON,VIC 3168,AUSTRALIA; MONASH UNIV,DEPT MATH,CLAYTON,VIC 3168,AUSTRALIA	Monash University; Monash University								Fox H, 1972, OBSTET GYNECOL SURV, V27, P475; JAMES WH, 1987, HUM BIOL, V59, P721; KHONG TY, IN PRESS IMMUNOLOGIC; METTLER L, 1984, GYNECOL OBSTET INVES, V18, P281, DOI 10.1159/000299094; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					625	626		10.1136/bmj.302.6777.625	http://dx.doi.org/10.1136/bmj.302.6777.625			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012876	Green Published, Bronze			2022-12-28	WOS:A1991FC07100021
J	BLOT, WJ; DEVESA, SS; KNELLER, RW; FRAUMENI, JF				BLOT, WJ; DEVESA, SS; KNELLER, RW; FRAUMENI, JF			RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							UNITED-STATES; BARRETTS ESOPHAGUS; CANCER	Analyses of cancer incidence data from nine areas of the United States revealed steadily rising rates from 1976 to 1987 of adenocarcinomas of the esophagus and gastric cardia. The increases among men in this period ranged from 4% to 10% per year, and thus exceeded those of any other type of cancer. In contrast, there were relatively stable trends for squamous cell carcinoma of the esophagus and slight declines for adenocarcinoma of more distal portions of the stomach. Adenocarcinomas of the esophagus and gastric cardia disproportionately affected white men and rarely occurred among women. By the mid-1980s, among white men, adenocarcinomas accounted for about one third of all esophageal cancers, while cardia cancers accounted for about one half of all stomach cancers with specified subsites. The rising incidence rates and similar demographic patterns point to the need for investigation into the causes of these poorly understood cancers.			BLOT, WJ (corresponding author), NCI,BIOSTAT BRANCH,EPIDEMIOL & BIOSTAT PROGRAM,EPN,SUITE 431,BETHESDA,MD 20892, USA.							[Anonymous], 1976, INT CLASSIFICATION D; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; DYA NE, 1982, CANCER EPIDEMIOLOGY, P596; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LEVI F, 1990, INT J CANCER, V45, P852, DOI 10.1002/ijc.2910450511; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; MACDONALD WC, 1987, CANCER, V60, P1094, DOI 10.1002/1097-0142(19870901)60:5<1094::AID-CNCR2820600529>3.0.CO;2-4; MOELLER H, 1988, 6TH ANN ECP S INT S; POWELL J, 1990, BRIT J CANCER, V59, P440; RIES LAG, 1990, NIH902789 US DEP HLT; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; WANG HH, 1986, HUM PATHOL, V17, P482, DOI 10.1016/S0046-8177(86)80038-7; YANG PC, 1988, INT J EPIDEMIOL, V17, P293, DOI 10.1093/ije/17.2.293; YANG PC, 1988, CANCER, V61, P612, DOI 10.1002/1097-0142(19880201)61:3<612::AID-CNCR2820610332>3.0.CO;2-Q; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P1	16	1981	2037	1	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1287	1289		10.1001/jama.265.10.1287	http://dx.doi.org/10.1001/jama.265.10.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995976				2022-12-28	WOS:A1991FA51100024
J	WANEK, N; GARDINER, DM; MUNEOKA, K; BRYANT, SV				WANEK, N; GARDINER, DM; MUNEOKA, K; BRYANT, SV			CONVERSION BY RETINOIC ACID OF ANTERIOR CELLS INTO ZPA CELLS IN THE CHICK WING BUD	NATURE			English	Article							POLARIZING REGION; PATTERN-FORMATION; LIMB BUD; DIGITS	IN recent years there has been considerable interest in the role of retinoic acid (RA) in vertebrate-limb pattern formation. When RA is applied to the anterior of the chick wing bud, a mirror-image duplication of the limb pattern develops that is identical to the pattern resulting from grafts of posterior tissue (zone of polarizing activity, or ZPA) 1. It has been proposed that position along the anterior-posterior axis in the chick limb is specified by a gradient of a diffusible factor produced by the ZPA 2. The ZPA-mimicking action of RA has led to the hypothesis that exogenously applied RA acts by providing graded spatial information across the anterior-posterior limb axis 3,4. An alternative interpretation is that RA changes anterior cells into ZPA cells, which in turn provide the actual pattern-duplicating stimulus 3-5; there is already some preliminary evidence that this occurs 5. A hybrid interpretation has also been suggested whereby ZPA cells are formed in response to RA exposure and then begin to release retinoids that act as graded spatial cues 3. We have used a functional assay 6 to test anterior chick wing-bud cells for ZPA activity after exposure to RA. The results of our studies indicate that the action of RA is to change anterior cells into ZPA cells. Further, our results indicate that it is unlikely that RA-treated anterior cells then begin producing RA in such a way as to provide a graded positional signal.	UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA	University of California System; University of California Irvine				Muneoka, Ken/0000-0002-7520-6869				BRYANT SV, 1986, TRENDS GENET, V2, P153, DOI 10.1016/0168-9525(86)90210-6; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HONIG LS, 1981, NATURE, V291, P72, DOI 10.1038/291072a0; Javois L.C., 1984, PATTERN FORMATION PR, P557; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1982, NATURE, V295, P672, DOI 10.1038/295672a0; MEINHARDT H, 1989, DEVELOPMENT, V107, P169; SMITH JC, 1979, J EMBRYOL EXP MORPH, V52, P105; SMITH SM, 1989, DEVELOPMENT, V107, P121; STOCUM DL, 1984, J EXP ZOOL, V232, P207, DOI 10.1002/jez.1402320208; Summerbell D, 1983, Prog Clin Biol Res, V110 Pt A, P109; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0	19	219	228	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					81	83		10.1038/350081a0	http://dx.doi.org/10.1038/350081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002849				2022-12-28	WOS:A1991FA69300071
J	PARADIS, NA; MARTIN, GB; ROSENBERG, J; RIVERS, EP; GOETTING, MG; APPLETON, TJ; FEINGOLD, M; CRYER, PE; WORTSMAN, J; NOWAK, RM				PARADIS, NA; MARTIN, GB; ROSENBERG, J; RIVERS, EP; GOETTING, MG; APPLETON, TJ; FEINGOLD, M; CRYER, PE; WORTSMAN, J; NOWAK, RM			THE EFFECT OF STANDARD-DOSE AND HIGH-DOSE EPINEPHRINE ON CORONARY PERFUSION-PRESSURE DURING PROLONGED CARDIOPULMONARY-RESUSCITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLOSED-CHEST RESUSCITATION; AORTIC DIASTOLIC PRESSURE; RIGHT ATRIAL PRESSURES; CARDIAC-ARREST; BLOOD-FLOW; VENTRICULAR-FIBRILLATION; PLASMA-CATECHOLAMINES; MYOCARDIAL PERFUSION; HUMAN-BEINGS; DOGS	We studied the effect of standard and high doses of epinephrine on coronary perfusion pressure during cardiopulmonary resuscitation in 32 patients whose cardiac arrest was refractory to advanced cardiac life support. Simultaneous aortic and right atrial pressures were measured and plasma epinephrine levels were sampled. Patients remaining in cardiac arrest after multiple 1-mg doses of epinephrine received a high dose of 0.2 mg/kg. The increase in the coronary perfusion pressures was 3.7 +/- 5.0 mm Hg following a standard dose, not a statistically significant change. The increase after a high dose was 11.3 +/- 10.0 mm Hg; this was both statistically different than before administration and larger than after a standard dose. High-dose epinephrine was more likely to raise the coronary perfusion pressure above the previously demonstrated critical value of 15 mm Hg. The highest arterial plasma epinephrine level after a standard dose was 152 +/- 162 ng/mL, and after a high dose, 393 +/- 289 ng/mL. Because coronary perfusion pressure is a good predictor of outcome in cardiac arrest, the increase after high-dose epinephrine may improve rates of return of spontaneous circulation.	HENRY FORD HOSP,DEPT EMERGENCY MED,2799 W GRAND BLVD,DETROIT,MI 48202; HENRY FORD HOSP,DEPT PEDIAT,DETROIT,MI 48202; HENRY FORD HOSP,DIV BIOSTAT & RES EPIDEMIOL,DETROIT,MI 48202; WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63130; SO ILLINOIS UNIV,SCH MED,DEPT MED,SPRINGFIELD,IL 62708	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Washington University (WUSTL); Southern Illinois University System; Southern Illinois University								ABRAMSON NS, 1985, CRIT CARE MED, V13, P930, DOI 10.1097/00003246-198511000-00020; ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1987, CRIT CARE MED, V15, P682, DOI 10.1097/00003246-198707000-00011; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; CALLAHAM ML, 1990, ANN EMERG MED, V19, P479; CRILE GW, 1902, CLEVELAND MED J, V2, P35; CRILE GW, 1904, T S SURG GYNECOL ASS, V16, P362; DITCHEY RV, 1982, CIRCULATION, V66, P297, DOI 10.1161/01.CIR.66.2.297; EITEL DR, 1988, ANN EMERG MED, V17, P808, DOI 10.1016/S0196-0644(88)80560-2; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HAFT JI, 1974, PROG CARDIOVASC DIS, V17, P73, DOI 10.1016/0033-0620(74)90039-5; HOLMES HR, 1980, CRIT CARE MED, V8, P137, DOI 10.1097/00003246-198003000-00009; KERN KB, 1989, CRIT CARE MED, V17, P786, DOI 10.1097/00003246-198908000-00013; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; LEVINE RD, 1981, NEW YORK STATE J MED, V81, P1669; LITTLE RA, 1985, Q J MED, V54, P133; MARTIN GB, 1986, ANN EMERG MED, V15, P125, DOI 10.1016/S0196-0644(86)80005-1; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; NIEMANN JT, 1984, ANN EMERG MED, V13, P849, DOI 10.1016/S0196-0644(84)80458-8; OTTO CW, 1985, AM J EMERG MED, V3, P285, DOI 10.1016/0735-6757(85)90048-8; OTTO CW, 1981, CRIT CARE MED, V9, P321, DOI 10.1097/00003246-198104000-00008; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1989, CIRCULATION, V80, P361, DOI 10.1161/01.CIR.80.2.361; PARADIS NA, 1990, ANN EMERG MED, V19, P457; PEARSON JW, 1963, ANESTH ANALG, V42, P599; PEARSON JW, 1967, ANESTH ANALG, V46, P746; PIONKOWSKI RS, 1983, ANN EMERG MED, V12, P733, DOI 10.1016/S0196-0644(83)80245-5; QUINTON DN, 1987, LANCET, V1, P828; RALSTON SH, 1985, ANN EMERG MED, V14, P1044, DOI 10.1016/S0196-0644(85)80916-1; RALSTON SH, 1984, ANN EMERG MED, V13, P79, DOI 10.1016/S0196-0644(84)80566-1; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; REDDING JS, 1968, J AMER MED ASSOC, V203, P255; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; SHAH SD, 1985, J LAB CLIN MED, V106, P624; SWENSON RD, 1988, CIRCULATION, V78, P630, DOI 10.1161/01.CIR.78.3.630; WATERS LL, 1950, SCIENCE, V111, P634, DOI 10.1126/science.111.2893.634; WORTSMAN J, 1984, AM J MED, V77, P779, DOI 10.1016/0002-9343(84)90512-6; YAKAITIS RW, 1979, CRIT CARE MED, V7, P293, DOI 10.1097/00003246-197907000-00001; 1986, JAMA-J AM MED ASSOC, V255, P2841	44	115	121	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1139	1144		10.1001/jama.265.9.1139	http://dx.doi.org/10.1001/jama.265.9.1139			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996000				2022-12-28	WOS:A1991EZ47400031
J	PALEVSKY, HI; FISHMAN, AP				PALEVSKY, HI; FISHMAN, AP			THE MANAGEMENT OF PRIMARY PULMONARY-HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-LUNG TRANSPLANTATION; VASODILATOR THERAPY; HEMODYNAMIC-RESPONSE; DIFFUSING-CAPACITY; NATURAL-HISTORY; PROSTACYCLIN; DISEASE; THROMBOSIS; EXERCISE; FUTURE	Primary pulmonary hypertension is a clinical syndrome characterized by pulmonary hypertension in the absence of sufficient underlying cardiac, parenchymal pulmonary, or systemic disease to account for it. The population of patients with primary pulmonary hypertension is a heterogeneous one, both clinically and histologically. As the etiologic mechanisms are unknown, therapy is directed toward the consequences of the pulmonary vascular process. Oxygen supplementation, the use of digoxin and diuretics for symptomatic heart failure, and anticoagulation all may have a role in treating primary pulmonary hypertension, although vasodilator therapy has been the main area of investigation. Screening for vasodilator responsiveness, defining a favorable vasodilator effect, predicting long-term effectiveness, and deciding who to treat have all been controversial. New approaches, such as use of high-dose calcium channel-blocking agents and continuous intravenous infusion of prostacyclin (an investigational agent), have recently been proposed. When medical therapies are exhausted, heart-lung or lung transplantation has increasingly become an option for selected patients.			PALEVSKY, HI (corresponding author), UNIV PENN,MED CTR,SCH MED,DEPT MED,PULM & CRIT CARE SECT,975 MALONEY BLDG,3600 SPRUCE ST,PHILADELPHIA,PA 19104, USA.							[Anonymous], [No title captured]; ARCHER SL, 1989, PULMONARY VASCULAR P, P241; BARST RJ, 1986, CHEST, V89, P497, DOI 10.1378/chest.89.4.497; BARST RJ, 1986, CARDIOLOGY, P952; BJORNSSON J, 1985, MAYO CLIN PROC, V60, P16, DOI 10.1016/S0025-6196(12)65277-X; COATES AL, 1982, CHEST, V82, P543, DOI 10.1378/chest.82.5.543; COHEN M, 1990, PULMONARY CIRCULATIO, P501; DANTZKER DR, 1989, CHEST, V95, P1185, DOI 10.1378/chest.95.6.1185; DAWKINS KD, 1986, CHEST, V89, P383, DOI 10.1378/chest.89.3.383; DAWKINS KD, 1985, CIRCULATION, V71, P919, DOI 10.1161/01.CIR.71.5.919; DOUGLAS JG, 1981, BMJ-BRIT MED J, V283, P881, DOI 10.1136/bmj.283.6296.881; EDWARDS BS, 1987, J AM COLL CARDIOL, V10, P1233, DOI 10.1016/S0735-1097(87)80123-7; EDWARDS WD, 1977, CIRCULATION, V56, P884, DOI 10.1161/01.CIR.56.5.884; ELKAYAM U, 1982, CARDIAC PROBLEMS PRE, P153; EVANS T W, 1990, American Review of Respiratory Disease, V141, pA665; FAHEY PJ, 1984, AM J MED, V76, P263, DOI 10.1016/0002-9343(84)90783-6; FAHLEN M, 1973, BRIT HEART J, V35, P824; FENLEY DC, 1985, CHEST, V87, P99; FISHMAN AP, 1976, AM REV RESPIR DIS, V114, P775; FISHMAN AP, 1974, CIRC RES, V35, P657, DOI 10.1161/01.RES.35.5.657; FISHMAN AP, 1980, ANNU REV MED, V31, P421, DOI 10.1146/annurev.me.31.020180.002225; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GASSNER A, 1990, CHEST, V98, P829, DOI 10.1378/chest.98.4.829; GOMEZSANCHEZ MA, 1989, CHEST, V95, P325, DOI 10.1378/chest.95.2.325; Griffith B P, 1990, Cardiovasc Clin, V20, P249; GRIFFITH BP, 1987, ANN THORAC SURG, V43, P6, DOI 10.1016/S0003-4975(10)60157-9; GROVES BM, 1985, AM HEART J, V110, P1200, DOI 10.1016/0002-8703(85)90013-4; Gurtner HP, 1990, PULMONARY CIRCULATIO, P397; HANEDA T, 1983, CHEST, V83, P520, DOI 10.1378/chest.83.3.520; HUGHES JD, 1986, MEDICINE, V65, P56, DOI 10.1097/00005792-198601000-00004; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; HUTTER JA, 1988, AM J MED, V85, P4, DOI 10.1016/0002-9343(88)90496-2; HYMAN AL, 1968, CIRC RES, V23, P401, DOI 10.1161/01.RES.23.3.401; JONES DK, 1987, BRIT HEART J, V57, P270; KANEMOTO N, 1987, AM HEART J, V114, P407, DOI 10.1016/0002-8703(87)90510-2; KANEMOTO N, 1979, JPN HEART J, V20, P395; KAY JM, 1969, CROTALARIA SPECTABIL; KELLEY MA, 1986, AM J MED, V80, P807, DOI 10.1016/0002-9343(86)90620-0; KLEIGER RE, 1976, CHEST, V69, P143, DOI 10.1378/chest.69.2.143; KRIEGER J, 1986, B EUR PHYSIOPATH RES, V22, P147; LONG W, 1986, J CRIT CARE, V1, P127; LONG WA, 1987, AM REV RESPIR DIS, V136, P773, DOI 10.1164/ajrccm/136.3.773; LOPEZSENDON J, 1990, PULMONARY CIRCULATIO, P385; LOYD JE, 1988, AM REV RESPIR DIS, V138, P952, DOI 10.1164/ajrccm/138.4.952; MARSHALL RJ, 1959, CIRCULATION, V20, P391, DOI 10.1161/01.CIR.20.3.391; MATHUR PN, 1981, ANN INTERN MED, V95, P283, DOI 10.7326/0003-4819-95-3-283; MCCARTHY PM, 1990, J THORAC CARDIOV SUR, V99, P54; MCCORMACK DG, 1989, AM J PHYSIOL, V256, pH41, DOI 10.1152/ajpheart.1989.256.1.H41; MCCRATH RC, 1978, CIRC RES, V43, P793; MCDONNELL PJ, 1983, AM REV RESPIR DIS, V127, P437, DOI 10.1164/arrd.1983.127.4.437; MCGOON MD, 1987, INT J CARDIOL, V14, P303, DOI 10.1016/0167-5273(87)90200-2; MCGOON MD, 1984, MAYO CLIN PROC, V59, P672, DOI 10.1016/S0025-6196(12)62055-2; MCGREGOR M, 1985, AM J CARDIOL, V55, P217, DOI 10.1016/0002-9149(85)90332-7; MCLEOD AA, 1986, DRUGS, V31, P177, DOI 10.2165/00003495-198631020-00006; MICZOCH J, 1984, PULMONARY HYPERTENSI, P341; MONTEFUSCO CM, 1986, SURG CLIN N AM, V66, P503; NATANO S, 1975, PRIMARY PULMONARY HY; NEWMAN JH, 1989, J AM COLL CARDIOL, V14, P551, DOI 10.1016/0735-1097(89)90091-0; Newman JH, 1990, PULMONARY CIRCULATIO, P301; OAKLEY C, 1968, LANCET, V1, P890; OGRADY J, 1980, PROSTAGLANDINS, V19, P319, DOI 10.1016/0090-6980(80)90030-1; OWENS GR, 1984, NEW ENGL J MED, V310, P1218, DOI 10.1056/NEJM198405103101903; PACKER M, 1989, CHEST, V95, P1173, DOI 10.1378/chest.95.6.1173; PACKER M, 1985, ANN INTERN MED, V103, P258, DOI 10.7326/0003-4819-103-2-258; Palevsky H I, 1989, Cardiovasc Clin, V19, P267; PALEVSKY HI, 1985, ANNU REV MED, V36, P563; PALEVSKY HI, 1990, JAMA-J AM MED ASSOC, V263, P2347, DOI 10.1001/jama.263.17.2347; PALEVSKY HI, 1990, AM REV RESPIR DIS, V142, P426, DOI 10.1164/ajrccm/142.2.426; PALEVSKY HI, 1990, CIRCULATION, V82, P2018, DOI 10.1161/01.CIR.82.6.2018; PALEVSKY HI, 1989, CIRCULATION, V80, P1207, DOI 10.1161/01.CIR.80.5.1207; PALEVSKY HI, 1986, CARDIOPULMONARY EXER, P89; PETER RH, 1984, ADV INTERNAL MED, V29, P494; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; Pietra GG, 1990, PULMONARY CIRCULATIO, P459; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; REID LM, 1989, PULMONARY VASCULAR P, P541; REITZ BA, 1982, NEW ENGL J MED, V306, P557, DOI 10.1056/NEJM198203113061001; RICH S, 1988, PROG CARDIOVASC DIS, V31, P205, DOI 10.1016/0033-0620(88)90016-3; RICH S, 1986, J AM COLL CARDIOL, V8, P1307, DOI 10.1016/S0735-1097(86)80301-1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1984, AM J MED, V76, P573, DOI 10.1016/0002-9343(84)90279-1; RICH S, 1985, CIRCULATION, V71, P1191, DOI 10.1161/01.CIR.71.6.1191; RICH S, 1989, J AM COLL CARDIOL, V14, P545, DOI 10.1016/0735-1097(89)90090-9; RICH S, 1987, CIRCULATION, V76, P134; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; RUBIN LJ, 1982, CIRCULATION, V66, P334, DOI 10.1161/01.CIR.66.2.334; RUBIN LJ, 1984, PULMONARY HEART DISE, P325; SAMET P, 1960, AM HEART J, V60, P433, DOI 10.1016/0002-8703(60)90202-7; SAMET P, 1963, AM HEART J, V66, P197, DOI 10.1016/0002-8703(63)90034-6; SCOTT J, 1988, AM REV RESPIR DIS, V137, pA188; SENIOR RM, 1968, CIRCULATION, V37, P88, DOI 10.1161/01.CIR.37.1.88; SNIDERMAN AD, 1988, INT J CARDIOL, V20, P173, DOI 10.1016/0167-5273(88)90261-6; STUPI AM, 1986, ARTHRITIS RHEUM, V29, P515, DOI 10.1002/art.1780290409; THEODORE J, 1990, NEW ENGL J MED, V322, P772, DOI 10.1056/NEJM199003153221110; TIMMS RM, 1985, ANN INTERN MED, V102, P29, DOI 10.7326/0003-4819-102-1-29; VOELKEL NF, 1989, PULMONARY VASCULAR P, P513; Voelkel NF, 1979, PULMONARY VASCULAR D, P573; Wagenvoort CA, 1979, PULMONARY VASCULAR D, P1; Wagenvoort CA, 1977, PATHOLOGY PULMONARY; WAGENVOORT CA, 1984, PULMONARY HYPERTENSI, P393; WEIR E K, 1988, European Heart Journal, V9, P33; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; Weir EK, 1984, PULMONARY HYPERTENSI, P115; WEIR EK, 1990, PULMONARY CIRCULATIO, P485; WOOD P, 1958, BRIT HEART J, V20, P557; XUAN ATD, 1990, AM REV RESPIR DIS, V141, pA889	106	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					1014	1020		10.1001/jama.265.8.1014	http://dx.doi.org/10.1001/jama.265.8.1014			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992195				2022-12-28	WOS:A1991EY43200032
J	KIRMAIER, C; GAUL, D; DEBEY, R; HOLTEN, D; SCHENCK, CC				KIRMAIER, C; GAUL, D; DEBEY, R; HOLTEN, D; SCHENCK, CC			CHARGE SEPARATION IN A REACTION CENTER INCORPORATING BACTERIOCHLOROPHYLL FOR PHOTOACTIVE BACTERIOPHEOPHYTIN	SCIENCE			English	Article							PHOTOSYNTHETIC REACTION CENTERS; BACTERIAL REACTION CENTERS; INITIAL ELECTRON-TRANSFER; NANOSECOND RECOMBINATION LUMINESCENCE; RHODOPSEUDOMONAS-SPHAEROIDES R-26; RHODOBACTER-SPHAEROIDES; RHODOSPIRILLUM-RUBRUM; FEMTOSECOND SPECTROSCOPY; PURPLE BACTERIA; PRIMARY DONOR	Site-directed mutagenic replacement of M subunit Leu214 by His in the photosynthetic reaction center (RC) from Rhodobacter sphaeroides results in incorporation of a bacteriochlorophyll molecule (BChl) in place of the native bacteriopheophytin (BPh) electron acceptor. Evidence supporting this conclusion includes the ground-state absorption spectrum of the (M)L214H mutant, pigment and metal analyses, and time-resolved optical experiments. The genetically modified RC supports transmembrane charge separation from the photoexcited BChl dimer to the primary quinone through the new BChl molecule, but with a reduced quantum yield of 60 percent (compared to 100 percent in wild-type RCs). These results have important implications for the mechanism of charge separation in the RC, and rationalize the choice (bacterio)pheophytins as electron acceptors in a variety of photosynthetic systems.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523	Colorado State University	KIRMAIER, C (corresponding author), WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130, USA.				NIGMS NIH HHS [GM38214, GM00536, GM18650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000536, R29GM038214, F32GM018650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1986, P NATL ACAD SCI USA, V83, P8589, DOI 10.1073/pnas.83.22.8589; BIXON M, 1989, BIOCHIM BIOPHYS ACTA, V977, P273, DOI 10.1016/S0005-2728(89)80081-7; BIXON M, IN PRESS BIOCH BIOPH; BORISOV AY, 1980, FEBS LETT, V119, P121, DOI 10.1016/0014-5793(80)81012-X; BRESLOW E, 1967, J BIOL CHEM, V242, P4149; BRETON J, 1988, BIOCHEMISTRY-US, V27, P8276, DOI 10.1021/bi00421a043; BUDIL DE, 1987, ANNU REV PHYS CHEM, V38, P561, DOI 10.1146/annurev.pc.38.100187.003021; BYLINA EJ, 1988, P NATL ACAD SCI USA, V85, P7226, DOI 10.1073/pnas.85.19.7226; CALLAHAN PM, 1987, J AM CHEM SOC, V109, P7001, DOI 10.1021/ja00257a016; CHANG CH, 1986, FEBS LETT, V205, P82, DOI 10.1016/0014-5793(86)80870-5; CHIRINO A, UNPUB; COTTON TM, 1979, J AM CHEM SOC, V101, P7605, DOI 10.1021/ja00519a023; DEBEY R, UNPUB; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; FAJER J, 1975, P NATL ACAD SCI USA, V72, P4956, DOI 10.1073/pnas.72.12.4956; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; FRANZEN S, 1990, J PHYS CHEM-US, V94, P5135, DOI 10.1021/j100375a068; FRIESNER RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P99, DOI 10.1016/S0005-2728(89)80062-3; GOLDSTEIN RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P78, DOI 10.1016/S0005-2728(89)80011-8; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOLZAPFEL W, 1990, P NATL ACAD SCI USA, V87, P5168, DOI 10.1073/pnas.87.13.5168; HOLZAPFEL W, 1989, CHEM PHYS LETT, V160, P1, DOI 10.1016/0009-2614(89)87543-8; HU YM, 1989, CHEM PHYS LETT, V160, P410, DOI 10.1016/0009-2614(89)87619-5; KIRMAIER C, 1988, FEBS LETT, V239, P211, DOI 10.1016/0014-5793(88)80919-0; KIRMAIER C, 1989, CHEM PHYS LETT, V159, P251, DOI 10.1016/0009-2614(89)87419-6; KIRMAIER C, 1987, PHOTOSYNTH RES, V13, P225, DOI 10.1007/BF00029401; KIRMAIER C, 1990, P NATL ACAD SCI USA, V87, P3552, DOI 10.1073/pnas.87.9.3552; KIRMAIER C, 1988, P NATL ACAD SCI USA, V85, P7562, DOI 10.1073/pnas.85.20.7562; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KOTOVA EA, 1981, FEBS LETT, V131, P51, DOI 10.1016/0014-5793(81)80885-X; LOCKHART DJ, 1990, J PHYS CHEM-US, V94, P6987, DOI 10.1021/j100381a015; LOCKHART DJ, 1988, J CHEM PHYS, V89, P1408, DOI 10.1063/1.455140; MARCUS RA, 1988, CHEM PHYS LETT, V146, P13, DOI 10.1016/0009-2614(88)85041-3; MARTIN JL, 1986, P NATL ACAD SCI USA, V83, P957, DOI 10.1073/pnas.83.4.957; MCDOWELL LM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P239, DOI 10.1016/0005-2728(90)90153-U; MCDOWELL LM, IN PRESS J PHYS CHEM; MCDOWELL LM, UNPUB; NAGARAJAN V, 1990, P NATL ACAD SCI USA, V87, P7888, DOI 10.1073/pnas.87.20.7888; PARSON WW, 1975, BIOCHIM BIOPHYS ACTA, V387, P265, DOI 10.1016/0005-2728(75)90109-7; SARAI A, 1980, BIOCHIM BIOPHYS ACTA, V589, P71, DOI 10.1016/0005-2728(80)90133-4; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P44, DOI 10.1016/0005-2728(82)90315-2; SCHERER POJ, 1989, CHEM PHYS, V131, P115, DOI 10.1016/0301-0104(89)87084-3; SEBRING ED, 1970, J BIOL CHEM, V245, P5395; SHUVALOV VA, 1981, P NATL ACAD SCI-BIOL, V78, P957, DOI 10.1073/pnas.78.2.957; SISTROM WR, 1977, J BACTERIOL, V131, P526, DOI 10.1128/JB.131.2.526-532.1977; STRALEY SC, 1973, BIOCHIM BIOPHYS ACTA, V305, P597, DOI 10.1016/0005-2728(73)90079-0; VANDERREST M, 1974, J BIOL CHEM, V249, P6446; WARSHEL A, 1988, J PHYS CHEM-US, V92, P2696, DOI 10.1021/j100320a057; WARSHEL A, 1989, SCIENCE, V246, P112, DOI 10.1126/science.2675313; WARSHEL A, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251; WASIELEWSKI MR, 1986, FEBS LETT, V204, P386; WENDT RH, 1965, ANAL CHEM, V37, P920, DOI 10.1021/ac60226a003; WOODBURY N, IN PRESS P FELDAFING; WOODBURY NW, 1985, BIOCHEMISTRY-US, V24, P7516, DOI 10.1021/bi00347a002; WOODBURY NWT, 1984, BIOCHIM BIOPHYS ACTA, V767, P345, DOI 10.1016/0005-2728(84)90205-6; YEATES TO, 1988, P NATL ACAD SCI USA, V85, P7993, DOI 10.1073/pnas.85.21.7993	56	164	168	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					922	927		10.1126/science.2000491	http://dx.doi.org/10.1126/science.2000491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000491				2022-12-28	WOS:A1991EY62900039
J	JAMIESON, DJ; RAHE, B; PRINGLE, J; BEGGS, JD				JAMIESON, DJ; RAHE, B; PRINGLE, J; BEGGS, JD			A SUPPRESSOR OF A YEAST SPLICING MUTATION (PRP8-1) ENCODES A PUTATIVE ATP-DEPENDENT RNA HELICASE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; GENE REGION; PROTEIN; TRANSFORMATION	FIVE small nuclear RNAs (snRNAs) are required for nuclear pre-messenger RNA splicing: U1, U2, U4, U5 and U6 1,2. The yeast U1 and U2 snRNAs base-pair to the 5' splice site and branch-point sequences of introns respectively 1. The role of the U5 and U4/U6 small nuclear ribonucleoprotein particles (snRNPs) is splicing is not clear, through a catalytic role for the U6 snRNA has be proposed 3. Less is known about yeast splicing factors, but the availability of genetic techniques in Saccharomyces cerevisiae has led to the identification of mutants deficient in nuclear pre-mRNA splicing (prp2-prp27)4,5. Several PRP genes have now been cloned and their protein products characterized. The PRP8 protein is a component of the U5 snRNP and associates with the U4/U6 snRNAs/snRNP to form a multi-snRNP particle believed to be important for spliceosome assembly 6. We have isolated extragenic suppressors of the prp8-1 mutation of S. cerevisiae and present here the preliminary characterization of one of these suppressors, spp81. The predicted amino-acid sequence of the SPP81 protein shows extensive similarity to a recently identified family of proteins thought to possess ATP-dependent RNA helicase activity. The possible role of this putative helicase in nuclear pre-mRNA splicing is discussed.	UNIV MICHIGAN,PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48103; UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48103	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	JAMIESON, DJ (corresponding author), UNIV EDINBURGH,INST CELL & MOLEC BIOL,KINGS BLDG,MAYFIELD RD,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.		, jbeggs/N-9551-2019; Beggs, Jean/H-4861-2011	Beggs, Jean/0000-0002-8179-6519				BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HIRLING H, 1989, NATURE, V339, P56; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; JAMIESON DJ, IN PRESS MOL MICROBI; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; PEARSON NJ, 1982, MOL CELL BIOL, V2, P571, DOI 10.1128/MCB.2.5.571; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; Sherman F., 1982, METHODS YEAST GENETI; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; STRUHL K, 1980, J MOL BIOL, V136, P309, DOI 10.1016/0022-2836(80)90376-9; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206	30	100	101	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					715	717		10.1038/349715a0	http://dx.doi.org/10.1038/349715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996139	Green Published			2022-12-28	WOS:A1991EY62700054
J	MOORE, FD; PRIEBE, C				MOORE, FD; PRIEBE, C			BOARD-CERTIFIED PHYSICIANS IN THE UNITED-STATES, 1971-1986	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. This is our third report covering the census of U. S. physicians over a 15-year period. The present report updates the information for 1980 to 1986. Methods. Most of our data are based on published information from the Association of American Medical Colleges, the Educational Council for Foreign Medical Graduates, the American Board of Medical Specialities, and the National Resident Matching Program. Data on board-certified physicians were obtained from the Division of Survey and Data Resources of the American Medical Association and are not published elsewhere. Results. After a steep rise in the 1970s, the annual number of physicians receiving licenses increased at a slower rate. The numbers of new board diplomas in medicine and primary care continued to grow. In other non-surgical clinical specialities there was less growth, and in certain fields of surgery the numbers declined. The board-certified percentage of all practitioners increased slightly (74 to 79 percent). About 14 to 16 percent of all active physicians are still in their residency and fellowship years. The percentage of all practitioners under the age of 35 who are women has increased from 8.4 percent in 1967 to 25.2 percent in 1986. The enrollment of some residency programs is currently more than 50 percent women. Conclusions. The work force of physicians did not grow as rapidly in the 1980s as in the 1970s. This nonlinearity of growth and massive changes in the epidemiology and treatment of disease render predictions about the need for or the numbers of physicians a decade hence unreliable.	HARVARD UNIV,SCH MED,DEPT SURG,HLTH MANPOWER UNIT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								BIDESE CM, 1988, US MED LINCENSURE ST; MOORE FD, 1981, NEW ENGL J MED, V304, P1078, DOI 10.1056/NEJM198104303041805; Peebles R J, 1989, Bull Am Coll Surg, V74, P18; Swanson A G, 1989, Acad Med, V64, P630, DOI 10.1097/00001888-198910000-00016; 1989, 1989 AM BOARD MED SP; 1989, 1989 NAT RES MATCH P; 1986, 1986 AM BOARD MED SP; 1975, SURGERY US SUMMARY R; [No title captured]; 1987, NRMP DIRECTORY INCLU	10	19	20	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					536	543		10.1056/NEJM199102213240806	http://dx.doi.org/10.1056/NEJM199102213240806			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1992307				2022-12-28	WOS:A1991EX91800006
J	[Anonymous]				[Anonymous]			ETHICAL WATCHDOGS JUST DESSERTS	NATURE			English	Editorial Material																		ANDERSON C, 1991, NATURE, V349, P357, DOI 10.1038/349357b0; 1991, NATURE, V349, P95	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					355	355						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992331				2022-12-28	WOS:A1991EV51400001
J	LERMAN, C; TROCK, B; RIMER, BK; BOYCE, A; JEPSON, C; ENGSTROM, PF				LERMAN, C; TROCK, B; RIMER, BK; BOYCE, A; JEPSON, C; ENGSTROM, PF			PSYCHOLOGICAL AND BEHAVIORAL-IMPLICATIONS OF ABNORMAL MAMMOGRAMS	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; HIGH-RISK; WOMEN; NOTIFICATION; DISEASE; WORKERS	Objective: To evaluate women's psychological responses to abnormal mammograms and the effect on mammography adherence. To identify psychological responses and other factors that predict mammography adherence in women with normal or abnormal mammograms. Design: Survey study with prospective analysis of factors associated with mammography adherence. Setting: Health Maintenance Organization of Pennsylvania and New Jersey (HMO PA/NJ). Patients: Study patients, members of HMO PA/NJ who were 50 years of age or older, and who had had mammography done 3 months earlier, included women with normal mammograms (n = 121), women with low-suspicion mammograms (n = 119), and women with high-suspicion mammograms (n = 68), but not women with breast cancer. Measurements: Psychological responses 3 months after mammography and adherence to subsequent annual mammography were assessed. Main Results: Women with high-suspicion mammograms had substantial mammography-related anxiety (47%) and worries about breast cancer (41%). Such worries affected the moods (26%) and daily functioning (17%) of these women, despite diagnostic evaluation excluding malignancy. For each variable, a consistent trend (P > 0.05) was seen with degree of mammogram abnormality. Sixty-eight percent of women with normal results, 78% of women with low-suspicion results, and 74% of women with high-suspicion results obtained their subsequent annual mammograms (P > 0.05). The number of previous mammograms (odds ratio, 3.2; 95% CI, 1.6 to 6.2) and the effect of the previous results on concerns about breast cancer (odds ratio, 0.5; CI, 0.2 to 1.0) were independent predictors of adherence in logistic regression analyses (P < 0.05). Conclusions: A substantial proportion of women with suspicious mammograms have psychological difficulties, even after learning that they do not have cancer. Such sequelae do not appear to interfere with subsequent adherence.			LERMAN, C (corresponding author), FOX CHASE CANC INST, 510 TOWNSHIP LINE RD, PHILADELPHIA, PA 19111 USA.		Lerman, Caryn/AHC-5180-2022		NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005895] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALAGNA SW, 1987, WOMEN HEALTH, V12, P29, DOI 10.1300/J013v12n02_03; BAKER LH, 1982, BREAST CANCER DETECT; CALNAN M, 1984, SOC SCI MED, V19, P823, DOI 10.1016/0277-9536(84)90399-X; DAWSON DA, 1990, DHHS PHS901500 US DE; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; GREENWALD HP, 1978, MILBANK FUND Q, V56, P212, DOI 10.2307/3349519; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; KEGELES SS, 1965, PUBLIC HEALTH REP, V80, P815, DOI 10.2307/4592543; KING ES, 1990, AM J PUBLIC HEALTH, V80, P1386, DOI 10.2105/AJPH.80.11.1386; KIRSCHT JP, 1983, HEALTH PSYCHOL, V2, P227; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; LERMAN C, 1989, CANCER RES, V49, P4955; LERMAN C, 1991, IN PRESS HLTH PSYCHO; MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5; MEYEROWITZ BE, 1989, AM J IND MED, V15, P463, DOI 10.1002/ajim.4700150410; MOSKOWITZ M, 1987, RADIOL CLIN N AM, V25, P1031; REELICK NF, 1984, SOC SCI MED, V18, P1089, DOI 10.1016/0277-9536(84)90169-2; RIMER BK, 1989, RADIOLOGY, V172, P243, DOI 10.1148/radiology.172.1.2740510; Rosenstock I.M., 1990, HLTH BEHAV HLTH ED T, P39; SCHULTE PA, 1984, AM J PUBLIC HEALTH, V74, P485, DOI 10.2105/AJPH.74.5.485; WINCHESTER DP, 1988, CA-CANCER J CLIN, V38, P291, DOI 10.3322/canjclin.38.5.291; 1990, JAMA-J AM MED ASSOC, V264, P54	24	392	395	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					657	661		10.7326/0003-4819-114-8-657	http://dx.doi.org/10.7326/0003-4819-114-8-657			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003712				2022-12-28	WOS:A1991FG03100007
J	CURRAN, WJ				CURRAN, WJ			SCIENTIFIC AND COMMERCIAL DEVELOPMENT OF HUMAN CELL-LINES - ISSUES OF PROPERTY, ETHICS, AND CONFLICT-OF-INTEREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		MOORE F, 1964, GIVE TAKE DEV TISSUE; Owens James Franklin, 1987, Med Trial Tech Q, V33, P335; PARKER PM, 1989, J LEGAL MED, V10, P357, DOI 10.1080/01947648909513576; WAGNER AB, 1987, COMPUT HIGH TECHNOL, V3, P231; 1987, NEW DEV BIOTECHNOLOG, V1	5	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					998	1000		10.1056/NEJM199104043241419	http://dx.doi.org/10.1056/NEJM199104043241419			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	FE376	2002828				2022-12-28	WOS:A1991FE37600031
J	COOPER, E; COUTURIER, S; BALLIVET, M				COOPER, E; COUTURIER, S; BALLIVET, M			PENTAMERIC STRUCTURE AND SUBUNIT STOICHIOMETRY OF A NEURONAL NICOTINIC ACETYLCHOLINE-RECEPTOR	NATURE			English	Article							AFFINITY BINDING-SITE; FUNCTIONAL EXPRESSION; NONCOMPETITIVE BLOCKERS; H-3 CHLORPROMAZINE; XENOPUS OOCYTES; ALPHA-SUBUNIT; ION CHANNEL; CDNA; BRAIN; SEQUENCE	NEURONAL nicotinic acetylcholine receptors are members of a gene family of ligand-gated transmitter receptors that includes muscle nicotinic receptors, GABA(A) receptors and glycine receptors 1-4. Several lines of evidence indicate that neuronal nicotinic receptors can be made up of only two subunits, an alpha (alpha) subunit which binds ligand, and a non-alpha (n-alpha) or beta (beta) subunit 5-13. The stoichiometry of each subunit in the functional receptor has been difficult to assess, however. Estimates of the molecular weight of neuronal nicotinic receptor macromolecules suggest that these receptors contain at least four subunits but probably not more than five 5,12. We have examined the subunit stoichiometry of the chick neuronal alpha-4/n-alpha-1 receptor 7,9 by first using site-directed mutagenesis to create subunits that confer different single channel properties on the receptor. Co-injection with wild-type and mutant subunits led to the appearance of receptors with wild-type, mutant and hybrid conductances. From the number of hybrid conductances, we could deduce the number of each subunit in the functional receptor.	UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	COOPER, E (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1YG,QUEBEC,CANADA.							BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BERTRAND D, 1990, P NATL ACAD SCI USA, V87, P1993, DOI 10.1073/pnas.87.5.1993; BERTRAND D, IN PRESS ELECTROPHYS; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GREENINGLOH G, 1987, NATURE, V328, P215; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KUNDEL TA, 1985, P NATL ACAD SCI USA, V82, P488; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; PRESS WH, 1986, NUMERICAL RECIPES AR; RAFFERTY MA, 1980, SCIENCE, V208, P1454; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WHITING PJ, 1986, BIOCHEMISTRY-US, V25, P2082, DOI 10.1021/bi00356a037; WHITING PJ, 1987, J NEUROSCI, V7, P4005; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	24	416	425	1	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					235	238		10.1038/350235a0	http://dx.doi.org/10.1038/350235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005979	Green Published			2022-12-28	WOS:A1991FC77900059
J	PASSA, P; LEBLANC, H; CHEVREL, A; MENARD, J				PASSA, P; LEBLANC, H; CHEVREL, A; MENARD, J			DISCONTINUING ACE INHIBITION IN PATIENTS WITH DIABETIC NEPHROPATHY	BRITISH MEDICAL JOURNAL			English	Letter									HOP BROUSSAIS,DEPT CARDIOVASC PREVENT MED,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	PASSA, P (corresponding author), HOP ST LOUIS,DEPT DIABETOL,F-75475 PARIS 10,FRANCE.							1991, BMJ, V302, P210	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					658	658		10.1136/bmj.302.6777.658	http://dx.doi.org/10.1136/bmj.302.6777.658			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012888	Green Published			2022-12-28	WOS:A1991FC07100046
J	TATARA, K; SHINSHO, F; SUZUKI, M; TAKATORIGE, T; NAKANISHI, N; KURODA, K				TATARA, K; SHINSHO, F; SUZUKI, M; TAKATORIGE, T; NAKANISHI, N; KURODA, K			RELATION BETWEEN USE OF HEALTH CHECK UPS STARTING IN MIDDLE-AGE AND DEMAND FOR INPATIENT CARE BY ELDERLY PEOPLE IN JAPAN	BRITISH MEDICAL JOURNAL			English	Article								Objective-To find out whether there is any correlation between the use of general health check ups (provided for by the Health Services for the Elderly Act 1982) by insured Japanese residents aged 40 or older and demand by the elderly for inpatient care. Design-A questionnaire was posted in 1988 to municipal offices of Japanese cities. All questionnaires were returned with data for 1983 and 1986. Setting-All 509 Japanese cities with a population of 30 000-199 999. Subjects-All people aged 40 or older who hold a resident card and are not offered health examinations at work are eligible for general health check ups. The questionnaire also inquired about use of inpatient care by elderly residents (aged 70 or older) who were covered by national health insurance. Main outcome measures-Correlation coefficients between the rates of use of general health check ups and mean annual bed days for the elderly. Comparison of relative changes by analysis of correlation between improvement indices in mean bed days and mean inpatient fee. Results-In cities with relatively high rates of use of health check ups both the mean annual bed days and the mean inpatient fee for the elderly tended to be low. Correlation coefficients between the logarithmic rates of use of check ups and mean bed days by sizes of cities and number of beds were all negative values. There tended to be more correlation between improvement indices for rate of use of check ups and both mean bed days and mean inpatient fee with higher rates of use in 1983, and the correlation was significant for rates of 60% or more. Conclusions-Strong health service programmes that start in middle age decrease the demand for inpatient care of the elderly. It was estimated that in a single year from 1985 to 1986, when there was an increase in the rate of use of check ups from 25.5% to 27.6%, the reduction in the number of bed days for the total of 8.5 million elderly insured people was 2.21 million bed days.			TATARA, K (corresponding author), OSAKA UNIV,SCH MED,DEPT PUBL HLTH,OSAKA 530,JAPAN.							BRESLOW L, 1978, PREV MED, V7, P449, DOI 10.1016/0091-7435(78)90255-4; MARMOT MG, 1989, BRIT MED J, V299, P1547, DOI 10.1136/bmj.299.6715.1547; ROWORTH MA, 1989, PUBLIC HEALTH, V103, P377, DOI 10.1016/S0033-3506(89)80008-3; TATARA K, 1984, SHI CHO SON NO HOKEN; 1990, ROJIN HOKEN JIGYO NO; 1987, PROMOTING BETTER HLT; 1990, KOKUMIN EISEI NO DOK	7	28	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					615	618		10.1136/bmj.302.6777.615	http://dx.doi.org/10.1136/bmj.302.6777.615			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC071	2012872	Bronze, Green Published			2022-12-28	WOS:A1991FC07100017
J	DENNING, DW; FOLLANSBEE, SE; SCOLARO, M; NORRIS, S; EDELSTEIN, H; STEVENS, DA				DENNING, DW; FOLLANSBEE, SE; SCOLARO, M; NORRIS, S; EDELSTEIN, H; STEVENS, DA			PULMONARY ASPERGILLOSIS IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY SYNDROME; CHRONIC GRANULOMATOUS-DISEASE; INVASIVE ASPERGILLOSIS; SYNDROME AIDS; OPPORTUNISTIC INFECTIONS; BRONCHIAL ASPERGILLOSIS; PRIMARY CYTOMEGALOVIRUS; PATIENT; THERAPY; CRYPTOCOCCOSIS	Background and Methods. Symptomatic pulmonary aspergillosis has rarely been reported in patients with the acquired immunodeficiency syndrome (AIDS). We describe the predisposing factors, the clinical and radiologic features, and the therapeutic outcomes in 13 patients with pulmonary aspergillosis, all of whom had human immunodeficiency virus (HIV) infection and 12 of whom had AIDS. Results. Pulmonary aspergillosis was detected a median of 25 months after the diagnosis of AIDS, usually following corticosteroid use, neutropenia, pneumonia due to other pathogens, marijuana smoking, or the use of broad-spectrum antibiotics. Two major patterns of disease were observed: invasive aspergillosis (in 10 patients) and obstructing bronchial aspergillosis (in 3). Cough and fever, the most common symptoms, tended to be insidious in onset in patients with invasive disease (median duration, 1.3 months before diagnosis). Breathlessness, cough, and chest pain predominated in the three patients with obstructing bronchial aspergillosis, who coughed up fungal casts. Radiologic patterns included upper-lobe cavitary disease (sometimes mistaken for tuberculosis), nodules, pleural-based lesions, and diffuse infiltrates, usually of the lower lobe. Transbronchial biopsies were usually negative, but positive cultures were obtained from bronchoalveolar-lavage fluid or percutaneous aspirates. Dissemination to other organs occurred in at least two patients, and direct invasion of extrapulmonary sites was seen in two others. The results of treatment with amphotericin B, itraconazole, or both were variable. Ten of the patients died a median of 3 months after the diagnosis (range, 0 to 12 months). Conclusions. Pulmonary aspergillosis is a possible late complication of AIDS; if diagnosed early, it may be treated successfully.	SANTA CLARA VALLEY MED CTR,DEPT MED,DIV INFECT DIS,751 S BASCOM AVE,SAN JOSE,CA 95128; ST VINCENTS MED CTR,LOS ANGELES,CA 90057; COMMUNITY HOSP,INDIANAPOLIS,IN; NIAID,MYCOSES STUDY GRP,BETHESDA,MD 20892; VET AFFAIRS HOSP,MARTINEZ,CA; SANTA CLARA VALLEY MED CTR,DEPT MED,DIV CLIN MICROBIOL,SAN JOSE,CA 95128; SANTA CLARA VALLEY MED CTR,DEPT PATHOL,SAN JOSE,CA 95128; CALIF INST MED RES,SAN JOSE,CA; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV INFECT DIS,STANFORD,CA 94305; INFECT DIS ASSOCIATES MED GRP,SAN FRANCISCO,CA	Santa Clara Valley Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Santa Clara Valley Medical Center; Santa Clara Valley Medical Center; Stanford University			Denning, David/AAC-6931-2019	Denning, David/0000-0001-5626-2251				ASNIS DS, 1988, NEW YORK STATE J MED, V88, P653; BRASS C, 1982, ANTIMICROB AGENTS CH, V21, P151, DOI 10.1128/AAC.21.1.151; CHATTERJEE SN, 1978, JAMA-J AM MED ASSOC, V240, P2446, DOI 10.1001/jama.240.22.2446; CHUSID MJ, 1975, ANN INTERN MED, V82, P682, DOI 10.7326/0003-4819-82-5-682; COHEN MS, 1981, AM J MED, V71, P59, DOI 10.1016/0002-9343(81)90259-X; DENNING DW, 1990, J AM ACAD DERMATOL, V23, P602, DOI 10.1016/0190-9622(90)70262-G; DENNING DW, 1989, AM J MED, V86, P791, DOI 10.1016/0002-9343(89)90475-0; DENNING DW, 1990, REV INFECT DIS, V12, P1147; DENNING DW, 1989, ARCH INTERN MED, V149, P2301; FOURNIER JP, 1989, TOPICS MYCOLOGY MYCO; GRAY F, 1988, NEUROPATH APPL NEURO, V14, P365, DOI 10.1111/j.1365-2990.1988.tb01139.x; GROSSE G, 1989, 5TH P INT C AIDS MON; HAMADEH R, 1988, CHEST, V94, P432, DOI 10.1378/chest.94.2.432; HENOCHOWICZ S, 1985, AM J CARDIOL, V55, P1239, DOI 10.1016/0002-9149(85)90679-4; HUI AN, 1984, HUM PATHOL, V15, P670; JAFFE HW, 1984, J INFECT DIS, V149, P829, DOI 10.1093/infdis/149.5.829; JONES PG, 1983, SEX TRANSM DIS, V10, P202, DOI 10.1097/00007435-198311000-00010; KARAM GH, 1986, REV INFECT DIS, V8, P357; KATZENSTEIN AA, 1988, PULMONARY DISEASES D, P1707; LAZZARIN A, 1986, CLIN EXP IMMUNOL, V65, P105; LEGROS V, 1988, ANN MED INTERNE, V139, P285; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P1497, DOI 10.1001/jama.263.11.1497; LOMBARDO GT, 1987, NEW YORK STATE J MED, V87, P306; MARCHEVSKY A, 1985, HUM PATHOL, V16, P659, DOI 10.1016/S0046-8177(85)80148-9; MIZUSAWA H, 1988, ACTA NEUROPATHOL, V76, P451, DOI 10.1007/BF00686383; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; PERVEZ NK, 1985, AM REV RESPIR DIS, V131, P961; PETITO CK, 1986, J NEUROPATH EXP NEUR, V45, P635, DOI 10.1097/00005072-198611000-00003; RAND KH, 1978, NEW ENGL J MED, V298, P951, DOI 10.1056/NEJM197804272981705; RICKETTI AJ, 1983, ARCH INTERN MED, V143, P1553, DOI 10.1001/archinte.143.8.1553; SALOMON N, 1989, 5TH P INT C AIDS MON; SCHAFFNER A, 1984, J INFECT DIS, V149, P828, DOI 10.1093/infdis/149.5.828-a; SCHWARTZ RS, 1984, CANCER, V53, P411, DOI 10.1002/1097-0142(19840201)53:3&lt;411::AID-CNCR2820530308&gt;3.0.CO;2-E; STAIB F, 1989, MYCOSES, V32, P516, DOI 10.1111/j.1439-0507.1989.tb02174.x; STEVENS DA, IN PRESS ANTIINFECTI; Tucker R M, 1988, Ann N Y Acad Sci, V544, P451, DOI 10.1111/j.1749-6632.1988.tb40443.x; TUCKER RM, 1989, 33RD ANN M COCC STUD; Urschel H C Jr, 1966, Ann Thorac Surg, V2, P1; WILKES MS, 1988, LANCET, V2, P85	39	391	402	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					654	662		10.1056/NEJM199103073241003	http://dx.doi.org/10.1056/NEJM199103073241003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA144	1994248				2022-12-28	WOS:A1991FA14400003
J	SHULKIN, DJ				SHULKIN, DJ			RISKY BUSINESS - NEEDLESTICKS IN RESIDENCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SHULKIN, DJ (corresponding author), UNIV PENN, SCH MED, ROBERT WOOD JOHNSON FDN, PHILADELPHIA, PA 19104 USA.							AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; PORTEOUS MJL, 1990, BRIT MED J, V301, P167, DOI 10.1136/bmj.301.6744.167	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1181	1181		10.1001/jama.265.9.1181	http://dx.doi.org/10.1001/jama.265.9.1181			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996007				2022-12-28	WOS:A1991EZ47400040
J	PIZARRO, D; POSADA, G; SANDI, L; MORAN, JR				PIZARRO, D; POSADA, G; SANDI, L; MORAN, JR			RICE-BASED ORAL ELECTROLYTE-SOLUTIONS FOR THE MANAGEMENT OF INFANTILE DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REHYDRATION SOLUTIONS; CONTROLLED TRIAL; UNITED-STATES; THERAPY; CHILDREN; EFFICACY; POWDER	Background. In infants the treatment of acute diarrhea with glucose-based solutions results in rehydration but does not reduce the severity of diarrhea. Oral rehydration with solutions based on rice powder may reduce stool output as well as restore fluid volume. Methods. We designed a prospective, randomized, double-blind study to evaluate the efficacy of two rice-based rehydration solutions and a conventional glucose-based solution. Solution A contained only rice-syrup solids, solution B contained rice-syrup solids and casein hydrolysate, and solution C, the glucose-based solution, served as control. The study subjects were 86 mildly to moderately dehydrated infant boys, 3 to 18 months old, who were admitted to a children's hospital with acute diarrhea. We measured fluid intake, fecal and urine output, and absorption and retention of fluid, sodium, and potassium at intervals for 48 hours in all 86 infants. Results. The mean (+/- SE) fecal output was significantly lower in the infants given solution A (group A infants) than in the infants given solution C (group C) (29 +/- 4 vs. 46 +/- 7 ml per kilogram of body weight, P < 0.05) during the first six hours of therapy. The infants in group A also had greater fluid absorption (221 +/- 16 vs. 167 +/- 9 ml per kilogram, P < 0.05) over the entire 48 hours of therapy and greater potassium absorption (1.6 +/- 0.2 vs. 0.6 +/- 0.1 mmol per kilogram, P < 0.05) during the first six hours than the infants in group C. Solution B offered no advantages over solution A. Conclusions. Solutions containing rice-syrup solids were effective in the rehydration of infants with acute diarrhea. They decreased stool output and promoted greater absorption and retention of fluid and electrolytes than did a glucose-based solution.	MEAD JOHNSON RES CTR, EVANSVILLE, IN USA		PIZARRO, D (corresponding author), HOSP NACL NINOS DR CARLOS SAENZ HERRERA, DEPT EMERGENCY MED, SAN JOSE, COSTA RICA.							AZAD MAK, 1990, PEDIATR RES, V27, pA100; BHAN MK, 1987, J PEDIATR GASTR NUTR, V6, P392, DOI 10.1097/00005176-198705000-00016; CARPENTER CCJ, 1988, NEW ENGL J MED, V319, P1346, DOI 10.1056/NEJM198811173192009; DEVIZIA B, 1975, J PEDIATR-US, V86, P50, DOI 10.1016/S0022-3476(75)80703-7; FIELD M, 1989, NEW ENGL J MED, V321, P879; GARCIA LS, 1983, J CLIN MICROBIOL, V18, P185, DOI 10.1128/JCM.18.1.185-190.1983; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; HUNT J B, 1988, Clinical Science (London), V74, p2P; KLISH WJ, 1985, PEDIATR REV, V7, P27; LEBENTHAL E, 1980, J PEDIATR-US, V97, P389, DOI 10.1016/S0022-3476(80)80187-9; MATA LJ, 1970, J INFECT DIS, V122, P170, DOI 10.1093/infdis/122.3.170; MOHAN M, 1986, J PEDIATR GASTR NUTR, V5, P423, DOI 10.1097/00005176-198605000-00015; MOLLA AM, 1982, LANCET, V1, P1317; MORRIS GK, 1985, MANUAL CLIN MICROBIO, V302, P8; PATRA FC, 1982, ARCH DIS CHILD, V57, P910, DOI 10.1136/adc.57.12.910; PATRA FC, 1984, ACTA PAEDIATR SCAND, V73, P18, DOI 10.1111/j.1651-2227.1984.tb09891.x; PIZARRO D, 1987, PEDIATRICS, V79, P190; RAHMAN ASMM, 1985, LANCET, V2, P539; SACK DA, 1980, J PEDIATR-US, V96, P20, DOI 10.1016/S0022-3476(80)80317-9; SANTOSHAM M, 1986, J PEDIATR-US, V109, P795, DOI 10.1016/S0022-3476(86)80696-5; SANTOSHAM M, 1982, NEW ENGL J MED, V306, P1070, DOI 10.1056/NEJM198205063061802; SATHANAKRISHNAN B R, 1985, Indian Journal of Pediatrics, V52, P479, DOI 10.1007/BF02751022; TAMER AM, 1985, J PEDIATR-US, V107, P14, DOI 10.1016/S0022-3476(85)80606-5; TAMER AM, 1986, J PEDIATR-US, V108, P160, DOI 10.1016/S0022-3476(86)80801-0; VESIKARI T, 1986, ARCH DIS CHILD, V61, P372, DOI 10.1136/adc.61.4.372; WILSON R, 1990, CEREAL BASED ORAL RE, P13; YOLKEN RH, 1977, LANCET, V2, P263; 1985, SAS USERS GUDIE STAT	28	48	50	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					517	521		10.1056/NEJM199102213240802	http://dx.doi.org/10.1056/NEJM199102213240802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1992304				2022-12-28	WOS:A1991EX91800002
J	HOBBS, FDR				HOBBS, FDR			VIOLENCE IN GENERAL-PRACTICE - A SURVEY OF GENERAL-PRACTITIONERS VIEWS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To survey the extent of abuse and violence directed towards general practitioners during the course of their professional duties and to categorise the characteristics of such aggression. Design-Retrospective survey of the views of a large sample of general practitioners by using a piloted postal questionnaire. Setting-All medical practices in the west midlands. Subjects-A total of 1093 general practitioners (40.6% of the total sample) who responded to the questionnaire. Main outcome measure-Number of incidents of aggression experienced by the general practitioners during a period of 12 months and the incidence of various precipitating factors. Results-Although the response was low at 40.6%, this study is the largest published database on aggression towards family doctors. In all, 687 (62.9%) of the responders had experienced abuse or violence during the previous 12 months, and 191 (17.5%) had experienced some sort of abuse at least once a month and 11 (1%) had experienced verbal abuse every day. Even assuming that all of the non-responders did not experience any violence, then aggression in patients affects 25.5% of general practitioners in the west midlands. For those practitioners who had experienced aggression in patients the annual incidence of an event per general practitioner was 2.42. In all, 96 (14%) of these general practitioners thought that aggression was increasing. A total of 1520 (91.3%) of all incidents comprised verbal abuse or threats with no direct physical act. The surgery was the commonest location for aggression, with 942 (56.6%) incidents; however, 90 (62.5%) of the incidents involving assault or injury occurred during domiciliary visits and 22 (66%) of the injuries were received during night calls. Relatives were the aggressors in 668 (37.6%) cases, anxiety was a precipitant in 435 (25.7%) cases, and a long wait in 183 (10.8%). Conclusions-Violence towards general practitioners is common and may be increasing. Some of the precipitants of aggression are potentially avoidable and practices should make strenuous attempts to identify such factors and remedy them. Staff training in interpersonal skills and recognising anxious or intoxicated patients is essential and should be supplemented by consideration of surgery layout and repair. Doctors should avoid delays for patients by rearranging booking policies or surgery times and lengths. Victims of aggression must be followed up. A prospective study or centralised recording of incidents should be funded.			HOBBS, FDR (corresponding author), UNIV BIRMINGHAM,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			hobbs, richard/0000-0001-7976-7172				Brown R., 1986, SOCIAL WORKERS RISK; CAMBROWICZ S, 1987, BRIT MED J, V294, P616; DURSO P, 1989, BRIT MED J, V298, P97, DOI 10.1136/bmj.298.6666.97; FRICKER J, 1987, J ROY COLL GEN PRACT, V37, P426; HARRIS A, 1989, BRIT MED J, V298, P63, DOI 10.1136/bmj.298.6666.63; NEVILLE RG, 1986, PRACTITIONER, V230, P1105; RAGHU K, 1979, BRIT MED J, V2, P1147, DOI 10.1136/bmj.2.6198.1147-b; RASHEDUDDIN K, 1981, VIOLENCE ITS CAUSES, P167; ROSE JS, 1976, STUDY VIOLENCE LONDO; SAVAGE R, 1984, BRIT MED J, V289, P1618; SHORT PW, 1981, BRIT MED J, V282, P281, DOI 10.1136/bmj.282.6260.281; SIRIWARDENE SK, 1987, PHYSICIAN, V6, P333; WALLS F, 1983, BRIT MED J, V286, P113; WOOLF PG, 1982, PRACTITIONER, V226, P503; 1987, CRIMINAL STATISTICS; 1987, FAMILY PRACTITIONER, V14, P278; 1978, BRIT MED J, V1, P1229; 1986, PUPIL VIOLENCE SERIO; 1986, ASSAULTS BUS STAFF M; 1988, PULSE, V48, P12; 1989, HLTH PERSONAL SOCIAL; 1988, VIOLENCE STAFF REPOR; 1988, PREVENTING VIOLENCE; 1987, VIOLENCE STAFF HLTH; [No title captured]; 1987, COMPENDIUM HLTH STAT; 1986, VIOLENCE STAFF POLIC	27	86	87	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					329	332		10.1136/bmj.302.6772.329	http://dx.doi.org/10.1136/bmj.302.6772.329			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001509	Bronze, Green Published			2022-12-28	WOS:A1991EX56900025
J	MITCHELL, SCM				MITCHELL, SCM			EVERYDAY AIDS AND APPLIANCES - DRESSING AIDS	BRITISH MEDICAL JOURNAL			English	Article											MITCHELL, SCM (corresponding author), ST LUKES HOSP,DEPT MED ELDERLY,BRADFORD,ENGLAND.							CHAMBERLAIN MA, 1980, RHEUMATOL REHABIL, V19, P246, DOI 10.1093/rheumatology/19.4.246; Clarke M, 1984, Health Trends, V16, P3; Clarke M, 1979, HLTH TRENDS, V11, P17; DAWKINS ME, 1986, REPORT ASSESSMENT LO; HOWELL C, 1986, ASSESSMETN USE LOWER; White E, 1989, CLIN REHABIL, V3, P23	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					167	169		10.1136/bmj.302.6769.167	http://dx.doi.org/10.1136/bmj.302.6769.167			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995140	Green Published, Bronze			2022-12-28	WOS:A1991EU02000029
J	EZZAT, S; STROM, C; MELMED, S				EZZAT, S; STROM, C; MELMED, S			COLON POLYPS IN ACROMEGALY	ANNALS OF INTERNAL MEDICINE			English	Note							GROWTH		UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,DIV ENDOCRINOL & METAB,B-131, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041906, R01DK034824] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41906, DK 34824] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNNER JE, 1990, CLIN ENDOCRINOL, V32, P65, DOI 10.1111/j.1365-2265.1990.tb03751.x; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; EZZAT S, 1991, J CLIN ENDOCR METAB, V72, P245, DOI 10.1210/jcem-72-2-245; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; KLEIN I, 1982, ANN INTERN MED, V97, P27, DOI 10.7326/0003-4819-97-1-27; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; MOON HD, 1950, CANCER RES, V10, P297; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1806, DOI 10.1210/endo-120-5-1806; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541	10	80	81	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					754	755		10.7326/0003-4819-114-9-754	http://dx.doi.org/10.7326/0003-4819-114-9-754			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012357				2022-12-28	WOS:A1991FJ11700008
J	BURKHART, J				BURKHART, J			AMA-RPS INSTRUMENTAL IN ACHIEVING NEW MATERNITY LEAVE POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1756	1756						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002585				2022-12-28	WOS:A1991FD65900036
J	KERNAN, WN; HORWITZ, RI; BRASS, LM; VISCOLI, CM; TAYLOR, KJW				KERNAN, WN; HORWITZ, RI; BRASS, LM; VISCOLI, CM; TAYLOR, KJW			A PROGNOSTIC SYSTEM FOR TRANSIENT ISCHEMIA OR MINOR STROKE	ANNALS OF INTERNAL MEDICINE			English	Article							CEREBRAL INFARCTION; SURVIVAL; RECURRENCE; SCORE	Objective: To build a prognostic system for patients with carotid transient ischemic attack or minor stroke. Design: Inception cohort study with 2-year follow-up. Setting: Urban community teaching hospital. Patients: Eligible patients (n = 142), identified on a carotid ultrasound roster, had been hospitalized between 1984 and 1987 within 30 days of a first carotid transient ischemic attack or minor stroke. Measurements: Stroke or death within 2 years. Main Results: Three factors were associated with stroke or death: age of more than 65 years, diabetes, and hypertension. Based on regression coefficients, age of more than 65 years was assigned 3 points; diabetes, 3 points; and hypertension, 2 points. An initial prognostic system comprised risk groups 1 (0 points), 2 (1 to 5 points), and 3 (6 to 8 points). Outcome rates in the three groups were 2%, 31%, and 54% (P < 0.0001), respectively. In an independent test sample, the corresponding outcome rates for the initial system were 12%, 21%, and 31% (P = 0.04). A final prognostic system, including two additional predictors (coronary heart disease [1 point] and the distinction between stroke and transient ischemic attack for the baseline event [2 points]), comprised risk groups 1 (0 to 2 points), 2 (3 to 6 points), and 3 (7 to 11 points). Corresponding outcome rates were 3%, 27%, and 48% (P < 0.001) in the original cohort and 10%, 21%, and 59% (P < 0.001) in the test cohort. Conclusion: For selected patients with carotid transient ischemia or minor stroke, five clinical features can be combined to stratify effectively the risk for a subsequent stroke or death.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA	Yale University								ABUZEID HAH, 1978, ARCH NEUROL-CHICAGO, V35, P121, DOI 10.1001/archneur.1978.00500270003001; ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; BRITTON M, 1980, ACTA MED SCAND, V207, P37; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CHAMBERS BR, 1987, NEUROLOGY, V37, P221, DOI 10.1212/WNL.37.2.221; DAVID N J, 1960, J Chronic Dis, V11, P394, DOI 10.1016/0021-9681(60)90045-X; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FULLERTON KJ, 1988, Q J MED, V66, P147; GENT M, 1979, THROMB HAEMOSTASIS, V41, P123; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; HOWARD G, 1989, J CLIN EPIDEMIOL, V42, P45, DOI 10.1016/0895-4356(89)90024-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLYHAYES M, 1988, ARCH PHYS MED REHAB, V69, P415; MARQUARDSEN J, 1969, NATURAL HIST ACUTE C; MARSHALL J, 1959, BMJ-BRIT MED J, V1, P1614, DOI 10.1136/bmj.1.5138.1614; Matsumoto N, 1973, STROKE, V4, P20, DOI 10.1161/01.STR.4.1.20; MIAH K, 1983, J CHRON DIS, V36, P279, DOI 10.1016/0021-9681(83)90063-2; MOORE DJ, 1985, J VASC SURG, V2, P654, DOI 10.1067/mva.1985.avs0020654; OLSSON T, 1990, DIABETOLOGIA, V33, P244, DOI 10.1007/BF00404803; RABKIN SW, 1978, ANN INTERN MED, V89, P15, DOI 10.7326/0003-4819-89-1-15; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACCO RL, 1989, STROKE, V20, P983, DOI 10.1161/01.STR.20.8.983; SILVER FL, 1984, STROKE, V15, P492, DOI 10.1161/01.STR.15.3.492; TAYLOR KJ, 1988, CLIN APPLICATIONS DO, V6, P120; WADE DT, 1985, Q J MED, V56, P601; WADE DT, 1984, AGE AGEING, V13, P76, DOI 10.1093/ageing/13.2.76; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 1984, BMDP USERS GUIDE CON; 1988, SAS LANGUAGE GUIDE P	30	57	62	2	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					552	557		10.7326/0003-4819-114-7-552	http://dx.doi.org/10.7326/0003-4819-114-7-552			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001088				2022-12-28	WOS:A1991FD66100005
J	TALPAZ, M; KANTARJIAN, H; KURZROCK, R; TRUJILLO, JM; GUTTERMAN, JU				TALPAZ, M; KANTARJIAN, H; KURZROCK, R; TRUJILLO, JM; GUTTERMAN, JU			INTERFERON-ALPHA PRODUCES SUSTAINED CYTOGENETIC RESPONSES IN CHRONIC MYELOGENOUS LEUKEMIA - PHILADELPHIA CHROMOSOME-POSITIVE PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; LEUKOCYTE INTERFERON; GRANULOCYTIC-LEUKEMIA; CULTURE REVEALS; REMISSION; THERAPY; CANCER	Objectives: To evaluate the frequency and the course of complete cytogenetic responses in interferon-alpha (IFN-alpha)-treated patients with chronic myelogenous leukemia. Design: Two prospective trials in consecutive patients. Setting: A major tertiary cancer center. Patients: Ninety-six consecutive patients with chronic myelogenous leukemia with disease duration of less than 1 year. Intervention: Patients received partially pure IFN-alpha intramuscularly, from 3 to 9 million U/d (51 patients) or recombinant IFN-alpha-2a (Roferon, Hoffmann-LaRoche, Inc., Nutley, New Jersey), 5 million U/m2 body surface area daily (45 patients). Measurements: Hematologic and cytogenetic tests were administered. Main Results: Seventy of the patients (73%) achieved hematologic remission (95% CI, 63% to 81%), and 18 (19%) had complete suppression of the Philadelphia chromosome on at least one cytogenetic test. A complete cytogenetic response was induced in 7 of 51 or 14% (CI, 6% to 26%) of the patients treated with the partially pure IFN-alpha and in 11 of 45 or 24% (CI, 13% to 40%) of the patients treated with recombinant IFN-alpha-2a. The difference in complete cytogenetic response between the two groups was 10.7% (CI, -5% to 26%; P > 0.2). Eleven patients had durable, ongoing, complete cytogenetic responses from 6 to more than 45 months (median, more than 30 months). Conclusion: This study was the first to show sustained, complete cytogenetic responses in a subset of patients with chronic myelogenous leukemia treated with single-agent therapy. The nature of this remission, that is, whether it depends on continuous therapy, requires further study.			TALPAZ, M (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT CLIN IMMUNOL & BIOL THERAPY, BOX 41, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.			Talpaz, Moshe/0000-0003-3361-3981				ARTHUR CK, 1988, BLOOD, V71, P1179; CHAMPLIN RE, 1985, BLOOD, V65, P1039; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; CUNNINGHAM I, 1979, BLOOD, V53, P375; DUBE ID, 1984, BLOOD, V63, P1172; ERNSTOFF MS, 1984, AM J MED, V76, P593, DOI 10.1016/0002-9343(84)90282-1; GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399; KANTARJIAN HM, 1985, J CLIN ONCOL, V3, P192, DOI 10.1200/JCO.1985.3.2.192; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1269, DOI 10.1056/NEJM198105213042105; KURZROCK R, 1987, BLOOD, V70, P943; LEE MS, 1988, BLOOD, V72, P893; MAEDA S, 1980, P NATL ACAD SCI-BIOL, V77, P7010, DOI 10.1073/pnas.77.12.7010; MCGLAVE PB, 1984, BLOOD, V63, P219; MORRA E, 1987, ASCO P, V6, P145; NIEDERLE N, 1987, SEMIN ONCOL, V14, P29; QUESADA JR, 1983, CANCER RES, V43, P940; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; SINGER JW, 1980, BLOOD, V56, P356; SOKAL JE, 1988, BLOOD, V72, P294; SPECK B, 1984, LANCET, V1, P665; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TALPAZ M, 1983, BLOOD, V62, P689; TRUJILLO JM, 1979, BLOOD, V53, P695; WILLIAMS CKO, 1981, ONCOLOGY, V38, P356, DOI 10.1159/000225587	26	425	428	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					532	538		10.7326/0003-4819-114-7-532	http://dx.doi.org/10.7326/0003-4819-114-7-532			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001086				2022-12-28	WOS:A1991FD66100002
J	GATIGNOL, A; BUCKLERWHITE, A; BERKHOUT, B; JEANG, KT				GATIGNOL, A; BUCKLERWHITE, A; BERKHOUT, B; JEANG, KT			CHARACTERIZATION OF A HUMAN TAR RNA-BINDING PROTEIN THAT ACTIVATES THE HIV-1 LTR	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATION; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; REGULATORY SEQUENCES; RESPONSIVE REGION; MOLECULAR-CLONING; GENE-PRODUCT; EXPRESSION	Human immunodeficiency virus type 1 (HIV-1) gene expression is activated by Tat, a virally encoded protein. Tat trans-activation requires viral (trans-activation-responsive; TAR) RNA sequences located in the R region of the long terminal repeat (LTR). Existing evidence suggests that Tat probably cooperates with cellular factors that bind to TAR RNA in the overall trans-activation process. A HeLa complementary DNA was isolated and characterized that encodes a TAR RNA-binding protein (TRBP). TRBP activated the HIV-1 LTR and was synergistic with Tat function.	NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Jeang, Kuan-Teh/A-2424-2008; Gatignol, Anne/AAA-6501-2020	Gatignol, Anne/0000-0002-4553-0836				BARDWELL JCA, 1989, EMBO J, V8, P3401, DOI 10.1002/j.1460-2075.1989.tb08504.x; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GATIGNOL A, UNPUB; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GREEN MR, 1989, NATURE, V338, P200, DOI 10.1038/338200a0; GUBZDA DH, 1989, MOL CELL BIOL, V9, P2728; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HART CE, 1989, SCIENCE, V246, P488, DOI 10.1126/science.2683071; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JEANG KT, 1987, J VIROL, V61, P1559, DOI 10.1128/JVI.61.5.1559-1570.1987; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KOZAK CM, UNPUB; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NASHIMOTO H, 1985, MOL GEN GENET, V201, P25, DOI 10.1007/BF00397981; NEWSTEIN M, 1990, J VIROL, V64, P4565, DOI 10.1128/JVI.64.9.4565-4567.1990; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SEIGEL LJ, 1986, VIROLOGY, V148, P226, DOI 10.1016/0042-6822(86)90419-8; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801	50	358	370	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1597	1600		10.1126/science.2011739	http://dx.doi.org/10.1126/science.2011739			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011739	Green Submitted			2022-12-28	WOS:A1991FD89000033
J	SMITH, J				SMITH, J			THE NEW NHS - WEST-SUFFOLK - A VOLCANO UNDER THE WHEAT FIELDS	BRITISH MEDICAL JOURNAL			English	Editorial Material																		CHATFIELD P, 1990, WINDMILL LESSONS MAR	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					641	645		10.1136/bmj.302.6777.641	http://dx.doi.org/10.1136/bmj.302.6777.641			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012882	Green Published, Bronze			2022-12-28	WOS:A1991FC07100028
J	SAAD, MF; LILLIOJA, S; NYOMBA, BL; CASTILLO, C; FERRARO, R; DEGREGORIO, M; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; HOWARD, BV; BOGARDUS, C				SAAD, MF; LILLIOJA, S; NYOMBA, BL; CASTILLO, C; FERRARO, R; DEGREGORIO, M; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; HOWARD, BV; BOGARDUS, C			RACIAL-DIFFERENCES IN THE RELATION BETWEEN BLOOD-PRESSURE AND INSULIN RESISTANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESSENTIAL-HYPERTENSION; LIPID-METABOLISM; PIMA-INDIANS; GLUCOSE; HYPERINSULINEMIA; CHILDREN; SODIUM; MASS	Background. Insulin resistance and the concomitant compensatory hyperinsulinemia have been implicated in the pathogenesis of hypertension. However, reports on the relation between insulin and blood pressure are inconsistent. This study was designed to investigate the possibility of racial differences in this relation. Methods. We studied 116 Pima Indians, 53 whites, and 42 blacks who were normotensive and did not have diabetes; the groups were comparable with respect to mean age (29, 30, and 31 years, respectively) and blood pressure (113/70, 111/68, and 113/68 mm Hg, respectively). Insulin resistance was determined by the euglycemic-hyperinsulinemic clamp technique during low-dose (40 mU per square meter of body-surface area per minute) and high-dose (400 mU per square meter per minute) insulin infusions. Results. The Pima Indians had higher fasting plasma insulin concentrations than the whites or blacks (176, 138, and 122 pmol per liter, respectively; P = 0.002) and lower rates of whole-body glucose disposal during both the low-dose (12.7, 17.1, and 19.5 mmol per minute; P < 0.001) and the high-dose (38.0, 43.1, and 45.7 mmol per minute; P < 0.001) insulin infusions. After adjustment for age, sex, body weight, and percentage of body fat, mean blood pressure (calculated as 1/3 systolic pressure + 2/3 diastolic pressure) was significantly correlated with the fasting plasma insulin concentration (r = 0.42) and the rate of glucose disposal during the low-dose (r = -0.41) and high-dose (r = -0.49) insulin infusions (P < 0.01 for each) in whites, but not in Pima Indians (r = -0.06, -0.02, and -0.04, respectively) or blacks (r = -0.10, -0.04, and 0.02, respectively. Conclusions. The relations between insulinemia, insulin resistance, and blood pressure differ among racial groups and may be mediated by mechanisms active in whites, but not in Pima Indians or blacks.	NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ; MEDLANTIC RES FDN,WASHINGTON,DC	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Lillioja, Stephen/A-8185-2012; Ravussin, Eric/N-1985-2017; Castillo, Carlos Fenandez-del/AAO-2602-2020; Steib, Lori/B-6628-2014	Ravussin, Eric/0000-0003-2129-547X; Steib, Lori/0000-0001-8274-318X; Lillioja, Stephen/0000-0001-5333-5240; Nyomba, B. L. Gregoire/0000-0001-9472-607X				ALBERTI KGM, 1989, DIABETES S2, V38, pA92; ANNEST JL, 1979, AM J EPIDEMIOL, V110, P492, DOI 10.1093/oxfordjournals.aje.a112830; [Anonymous], 1985, WHO TECH REP SER, V727, P1; AVIV A, 1989, HYPERTENSION, V14, P584, DOI 10.1161/01.HYP.14.6.584; BERNTORP K, 1985, Diabetes Research and Clinical Practice, V1, P307, DOI 10.1016/S0168-8227(86)80042-0; BONORA E, 1987, DIABETOLOGIA, V30, P719, DOI 10.1007/BF00296995; CAMBIEN F, 1987, ARTERIOSCLEROSIS, V7, P197, DOI 10.1161/01.ATV.7.2.197; CHANNICK BJ, 1969, ARCH INTERN MED, V123, P131, DOI 10.1001/archinte.123.2.131; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DONAHUE RP, 1987, AM J EPIDEMIOL, V125, P650, DOI 10.1093/oxfordjournals.aje.a114578; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Ferrannini E, 1989, J NEPHROL, V1, P3; FERRARI P, 1990, J HYPERTENS, V8, P491, DOI 10.1097/00004872-199006000-00001; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; HAFFNER SM, 1988, METABOLISM, V37, P338, DOI 10.1016/0026-0495(88)90133-3; LILLIOJA S, 1985, J CLIN INVEST, V75, P1106, DOI 10.1172/JCI111804; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; LUCAS CP, 1985, HYPERTENSION, V7, P702, DOI 10.1161/01.HYP.7.5.702; MANICARDI V, 1986, J CLIN ENDOCR METAB, V62, P1302, DOI 10.1210/jcem-62-6-1302; MANOLIO TA, 1990, ARTERIOSCLEROSIS, V10, P430, DOI 10.1161/01.ATV.10.3.430; MARIGLIANO A, 1990, AM J HYPERTENS, V3, P521, DOI 10.1093/ajh/3.7.521; MBANYA JCN, 1988, LANCET, V1, P733; MOORE RD, 1983, BIOCHIM BIOPHYS ACTA, V737, P1, DOI 10.1016/0304-4157(83)90013-8; NAGULESPARAN M, 1982, DIABETES, V31, P952, DOI 10.2337/diacare.31.11.952; NOSADINI R, 1990, DIABETES S1, V39, pA87; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; PRATT JH, 1989, NEW ENGL J MED, V321, P1152, DOI 10.1056/NEJM198910263211703; REAVEN GM, 1987, LANCET, V2, P435; RESNICK LM, 1990, AM J HYPERTENS, V3, P373, DOI 10.1093/ajh/3.5.373; ROSE HG, 1987, HYPERTENSION, V9, P421; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SAAD MF, 1990, DIABETES, V39, P1430, DOI 10.2337/diabetes.39.11.1430; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; SINGER P, 1985, HYPERTENSION, V7, P182, DOI 10.1161/01.HYP.7.2.182; STOUT RW, 1975, CIRC RES, V36, P319, DOI 10.1161/01.RES.36.2.319; SWISLOCKI ALM, 1989, AM J HYPERTENS, V2, P419, DOI 10.1093/ajh/2.6.419; UUSITUPA M, 1987, DIABETES RES CLIN EX, V4, P19; VOORS AW, 1981, AM J EPIDEMIOL, V113, P347, DOI 10.1093/oxfordjournals.aje.a113103; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; WELBORN TA, 1966, LANCET, V1, P1336; 1978, WHO TECH REP SER, V628, P7; 1985, SAS USERS GUIDE STAT	43	416	428	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					733	739		10.1056/NEJM199103143241105	http://dx.doi.org/10.1056/NEJM199103143241105			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB556	1997839	Green Published			2022-12-28	WOS:A1991FB55600005
J	DIKMEN, SS; TEMKIN, NR; MILLER, B; MACHAMER, J; WINN, HR				DIKMEN, SS; TEMKIN, NR; MILLER, B; MACHAMER, J; WINN, HR			NEUROBEHAVIORAL EFFECTS OF PHENYTOIN PROPHYLAXIS OF POSTTRAUMATIC SEIZURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC SEIZURES; HEAD TRAUMA; EPILEPSY; DIPHENYLHYDANTOIN; MINNESOTA; FAILURE	In order to determine potential negative neurobehavioral effects of phenytoin given to prevent the development of posttraumatic seizures, 244 subjects were randomized to phenytoin or placebo. They received neurobehavioral assessments at 1 and 12 months postinjury while receiving their assigned drug and at 24 months while receiving no drugs. In the severely injured, phenytoin significantly impaired performance at 1 month. No significant differences were found as a function of phenytoin in the moderately injured patients at 1 month or in either severity group at 1 year. Patients who stopped receiving phenytoin according to protocol between 1 and 2 years improved more than corresponding placebo cases on several measures. We conclude that phenytoin has negative cognitive effects. This, combined with lack of evidence for its effectiveness in preventing posttraumatic seizures beyond the first week, raises questions regarding its use for long-term prophylaxis. Our findings do not negate phenytoin's proven efficacy in controlling established seizures nor do they indicate that its cognitive effects are worse than other anticonvulsant drugs.	UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	DIKMEN, SS (corresponding author), UNIV WASHINGTON,DEPT REHABIL MED,RJ-30,SEATTLE,WA 98195, USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019643] Funding Source: NIH RePORTER; AHRQ HHS [R01-HS05304] Funding Source: Medline; NINDS NIH HHS [R01-NS19643] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Copper PR, 1987, HEAD INJURY, P1; DODRILL CB, 1989, EPILEPSIA, V30, P453, DOI 10.1111/j.1528-1157.1989.tb05325.x; DODRILL CB, 1975, EPILEPSIA, V16, P593, DOI 10.1111/j.1528-1157.1975.tb04741.x; DODRILL CB, 1977, NEUROLOGY, V27, P1023, DOI 10.1212/WNL.27.11.1023; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; IDESTROM CM, 1972, PSYCHOL MED, V2, P111, DOI 10.1017/S0033291700040599; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Reitan RM, 1985, HALSTEAD REITAN NEUR; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P82; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; THOMPSON P, 1981, BRIT J CLIN PSYCHOL, V20, P155, DOI 10.1111/j.2044-8260.1981.tb00513.x; TRIMBLE MR, 1983, EPILEPSIA, V24, pS55, DOI 10.1111/j.1528-1157.1983.tb04644.x; TRIMBLE MR, 1987, EPILEPSIA S3, V28, P537; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x	27	150	152	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1271	1277		10.1001/jama.265.10.1271	http://dx.doi.org/10.1001/jama.265.10.1271			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995974				2022-12-28	WOS:A1991FA51100021
J	MOSS, AH; SIEGLER, M				MOSS, AH; SIEGLER, M			SHOULD ALCOHOLICS COMPETE EQUALLY FOR LIVER-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE TECHNOLOGY; ORGAN-TRANSPLANTATION; RESOURCE-ALLOCATION; RATIONING DECISIONS; MEDICAL-CARE; INEVITABILITY; CIRRHOSIS; NO	The circumstances of liver transplantation are unique among organ transplantation because of the dire, absolute scarcity of donor livers and the predominance of one disease-alcohol-related end-stage liver disease-as the principal cause of liver failure. We propose that patients who develop end-stage liver disease through no fault of their own should have higher priority for receiving a liver transplant than those whose end-stage liver disease results from failure to obtain treatment for alcoholism. We base our proposal on considerations of fairness and on whether public support for liver transplantation can be maintained if, as a result of a first-come, first-served approach, patients with alcohol-related end-stage liver disease receive more than half the available donor livers. We conclude that since not all can live, priorities must be established for the use of scarce health care resources.	UNIV CHICAGO, PRITZKER SCH MED, CTR CLIN MED ETH, CHICAGO, IL 60637 USA	University of Chicago	MOSS, AH (corresponding author), W VIRGINIA UNIV, HLTH SCI CTR N, CTR HLTH ETH & LAW, MORGANTOWN, WV 26506 USA.		Embrett, Mark G./H-4466-2014	Embrett, Mark G./0000-0002-3969-0219				ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P187, DOI 10.2105/AJPH.75.2.187; ARONSON MD, 1987, ALCOHOLISM GUIDE PRI, P9; ATTERBURY CE, 1986, J CLIN GASTROENTEROL, V8, P1, DOI 10.1097/00004836-198602000-00001; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P256; BERESFORD TP, 1990, PSYCHOSOMATICS, V31, P241, DOI 10.1016/S0033-3182(90)72160-3; BIGBY JA, 1987, ALCOHOLISM GUIDE PRI, P66; BLANK RH, 1988, RATIONING MED, P1; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; CALLAHAN D, 1988, HASTINGS CENT REP, V18, P14, DOI 10.2307/3562403; CAPER P, 1988, NEW ENGL J MED, V318, P1535, DOI 10.1056/NEJM198806093182310; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; ENGELHARDT HT, 1984, NEW ENGL J MED, V311, P66, DOI 10.1056/NEJM198407053110135; EVANS R W, 1983, Journal of the American Medical Association, V249, P2047, DOI 10.1001/jama.249.15.2047; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; FISHMAN R, 1986, ALCOHOL ALCOHOLISM, P27; FLAVIN DK, 1988, JAMA-J AM MED ASSOC, V259, P1546, DOI 10.1001/jama.259.10.1546; FOX RC, 1978, COURAGE FAIL, P226; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GALANTER M, 1990, AM J PSYCHIAT, V147, P64; GRANT BF, 1988, SEMIN LIVER DIS, V8, P12, DOI 10.1055/s-2008-1040525; JOHNSON B, 1989, J GEN INTERN MED, V4, P445, DOI 10.1007/BF02599698; KLERMAN GL, 1989, NEW ENGL J MED, V320, P394, DOI 10.1056/NEJM198902093200611; KNOWLES JH, 1977, SCIENCE, V198, P1103, DOI 10.1126/science.198.4322.1103; KUMAR S, 1990, HEPATOLOGY, V11, P159, DOI 10.1002/hep.1840110202; MENDELSON JH, 1985, DIAGNOSIS TREATMENT, P1; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; OLBRISCH ME, 1989, JAMA-J AM MED ASSOC, V261, P2958, DOI 10.1001/jama.1989.03420200048032; Outka Gene, 1974, J Relig Ethics, V2, P11; RAMSEY P, 1970, PATIENT PERSON, P242; SAXE L, 1983, EFFECTIVENESS COSTS, P3; SCHARSCHMIDT BF, 1984, HEPATOLOGY, V4, pS95, DOI 10.1002/hep.1840040723; SCHROEDER JS, 1987, JAMA-J AM MED ASSOC, V258, P3142, DOI 10.1001/jama.258.21.3142; STARZL TE, 1988, JAMA-J AM MED ASSOC, V260, P2542, DOI 10.1001/jama.260.17.2542; SURMAN OS, 1989, AM J PSYCHIAT, V146, P972; THORESON RW, 1987, TREATMENT PREVENTION, P157; THUROW LC, 1984, NEW ENGL J MED, V311, P1569, DOI 10.1056/NEJM198412133112410; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310; WINSLOW GR, 1982, TRIAGE JUSTICE, P39; 1990, ASSESSMENT LIVER TRA, V3, P25; 1987, MAKING DIFFICULT HLT, P73; 1990, 901656 US DEP HLTH H; 1986, ORGAN TRANSPLANTATIO, P9; 1990, FED REGISTER, V55, P3545	43	157	158	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1295	1298		10.1001/jama.265.10.1295	http://dx.doi.org/10.1001/jama.265.10.1295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995977				2022-12-28	WOS:A1991FA51100026
J	RAUB, W				RAUB, W			NEW DRUG AMELIORATES EFFECTS OF ASTHMA AND ALLERGIC RHINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, NEW ENGL J MED, V323, P1745; 1990, NEW ENGL J MED, V323, P1740	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-28	WOS:A1991EZ47400007
J	HENRYAMAR, M; FRIEDMAN, S; HAYAT, M; SOMERS, R; MEERWALDT, JH; CARDE, P; BURGERS, JMV; THOMAS, J; MONCONDUIT, M; NOORDIJK, EM; BRON, D; REGNIER, R; DEPAUW, BE; TANGUY, A; COSSET, JM; DUPOUY, N; TUBIANA, M				HENRYAMAR, M; FRIEDMAN, S; HAYAT, M; SOMERS, R; MEERWALDT, JH; CARDE, P; BURGERS, JMV; THOMAS, J; MONCONDUIT, M; NOORDIJK, EM; BRON, D; REGNIER, R; DEPAUW, BE; TANGUY, A; COSSET, JM; DUPOUY, N; TUBIANA, M			ERYTHROCYTE SEDIMENTATION-RATE PREDICTS EARLY RELAPSE AND SURVIVAL IN EARLY-STAGE HODGKIN DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						ERYTHROCYTE SEDIMENTATION RATE; BLOOD SEDIMENTATION; HODGKINS DISEASE; PREDICTIVE VALUE OF TESTS; NEOPLASM RECURRENCE, LOCAL	PROGNOSTIC FACTORS	Objective: To assess the value of an elevated (> 30 mm/h) Westergren erythrocyte sedimentation rate (ESR) for predicting early relapse and survival after therapy in patients with clinical stage I or II hodgkin disease. Interventions: We studied 772 patients with early-stage Hodgkin disease who had participated in two separate multicenter clinical trials. Both trials used modern field radiotherapy and, in some patients, multi-agent chemotherapy. Main Results: The ESR patterns were based on pretherapy and post-therapy assessments: pattern 1, always normal (n = 261); pattern 2, elevated before therapy but normal immediately after therapy (n = 121); pattern 3, elevated before therapy but normal within 3 months after therapy ( n = 89); pattern 4, always elevated (n = 48); pattern 5, normal before therapy but oscillating between normal and elevated after therapy n = 150); pattern 6, elevated before therapy but oscillating between normal and elevated after therapy (n = 130). By multivariate analysis, independent of whether or not patients received chemotherapy in the initial therapy protocol, ESR patterns 4, 5, and 6 were shown to be the best predictors for early relapse and survival when patients were stratified according to the type of chemotherapy received and the number of involved nodal areas. Patients with ESR pattern 4 had a relative risk for death seven times that of patients with patterns 1, 2, or 3. Early relapse was the second most important factor predicting death, irrespective of ESR; patients with early relapse and ESR patterns 1, 2, or 3 had a relative risk for death of 4.5, and those with early relapse and ESR patterns 4, 5, or 6 had a relative risk for death of 15. Whether or not chemotherapy was given initially did not change the relative risk, which shows that ESR, not initial therapy, was the predictor for early relapse and death due to Hodgkin disease. Conclusion: An unexplained elevated ESR after therapy, especially after modern radiotherapy, independent of other factors, strongly suggests the presence of aggressive and resistant Hodgkin disease. An elevated ESR is predictive of early relapse and poor prognosis; its presence justifies early aggressive therapy.	ANTONI VAN LEEUWENHOEK HOSP,AMSTERDAM,NETHERLANDS; ROTTERDAM RADIOTHERAPEUT INST,ROTTERDAM,NETHERLANDS; ST RAFAEL HOSP,LOUVAIN,BELGIUM; ACAD ZIEKENHUIS,NIJMEGEN,NETHERLANDS; CTR FRANCOIS BACLESSE,CAEN,FRANCE; CTR HENRI BECQUEREL,F-76038 ROUEN,FRANCE; STATE UNIV LEIDEN HOSP,2333 AA LEIDEN,NETHERLANDS; INST JULES BORDET,B-1000 BRUSSELS,BELGIUM	UNICANCER; Centre Francois Baclesse; UNICANCER; Centre Henri Becquerel; Leiden University; Leiden University Medical Center (LUMC); Institut Jules Bordet	HENRYAMAR, M (corresponding author), INST GUSTAVE ROUSSY,RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.		Henry-Amar, Michel/S-9358-2019	Henry-Amar, Michel/0000-0002-9357-6476				BRESCIANIPAHOR N, 1979, INORG CHIM ACTA, V32, P181, DOI 10.1016/S0020-1693(00)91658-X; CARDE P, 1988, J CLIN ONCOL, V6, P239, DOI 10.1200/JCO.1988.6.2.239; CHANG IM, 1982, J CHRON DIS, V35, P669, DOI 10.1016/0021-9681(82)90019-4; COX DR, 1972, J R STAT SOC B, V34, P187; DIXON WJ, 1985, BMDP STATISTICAL SOF; FRIEDMAN S, 1988, J CLIN ONCOL, V6, P596, DOI 10.1200/JCO.1988.6.4.596; FRIEDMAN S, 1991, IN PRESS AM J HEMATO; TUBIANA M, 1985, INT J RADIAT ONCOL, V11, P23, DOI 10.1016/0360-3016(85)90358-X; TUBIANA M, 1984, INT J RADIAT ONCOL, V10, P197, DOI 10.1016/0360-3016(84)90004-X; TUBIANA M, 1981, EUR J CANCER, V17, P355, DOI 10.1016/0014-2964(81)90128-6; TUBIANA M, 1984, J CLIN ONCOL, V2, P194, DOI 10.1200/JCO.1984.2.3.194; WARTELLE M, 1983, 2ND P INT WORKSH STA, P124	12	68	69	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					361	365		10.7326/0003-4819-114-5-361	http://dx.doi.org/10.7326/0003-4819-114-5-361			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992877				2022-12-28	WOS:A1991EZ17400003
J	ANDERSEN, IB; SORENSEN, TIA; PRENER, A				ANDERSEN, IB; SORENSEN, TIA; PRENER, A			INCREASE IN INCIDENCE OF DISEASE DUE TO DIAGNOSTIC DRIFT - PRIMARY LIVER-CANCER IN DENMARK, 1943-85	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the extent to which changes in diagnostic methods and classification are responsible for the striking increase in incidence of primary liver cancer in Denmark since 1943. Design-Analysis of the time trends in sex specific, age standardised incidence of primary liver cancer and unspecified liver cancer (either secondary without known primary cancer or not specified as primary cancer) in the entire population from 1943 to 1985. By review of the 727 notifications from three periods of 5 years (1948-52, 1963-7, and 1978-82) the changes in histological diagnosis and classification were assessed. Setting-Denmark. Subjects-Notifications of liver cancer to the Danish cancer registry. Results-Concomitant with the increase in primary liver cancer, the incidence of the unspecified liver cancer declined. The proportion of histologically diagnosed primary liver cancer rose from 85% to 98%, whereas the proportion for unspecified liver cancer rose from 12% to 51%. When the proportion of primary versus unspecified liver cancer obtained by histological diagnosis was extrapolated to all cases, the annual incidence of primary liver cancer was 4.4 rather than 1.6 per 100 000 population in 1948-52 and 6.0 rather than 5.5 per 100 000 in 1978-82. Conclusion-The increase in the incidence of primary liver cancer may be much smaller than the numbers of registered cases indicate. This example emphasises the need to consider diagnostic drift in time trend studies of disease incidence.	HVIDOVRE UNIV HOSP,DEPT MED,DIV HEPATOL,DK-2650 COPENHAGEN,DENMARK; DANISH CANC SOC,DANISH CANC REGISTRY,COPENHAGEN,DENMARK	University of Copenhagen; Danish Cancer Society								[Anonymous], 1976, INT CLASSIFICATION D; BASSENDINE MF, 1987, BAILLIERE CLIN GASTR, V1, P1, DOI 10.1016/0950-3528(87)90031-5; FABER M, 1979, ENVIRON RES, V18, P37, DOI 10.1016/0013-9351(79)90135-X; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HARDELL L, 1984, BRIT J CANCER, V50, P389, DOI 10.1038/bjc.1984.188; JENSEN OM, 1980, CANCER MORBIDITY CAU; KEW MC, 1987, LANCET, V2, P1183; OLSEN JH, 1988, BRIT J CANCER, V58, P392, DOI 10.1038/bjc.1988.226; PRYTZ H, 1981, SCAND J GASTROENTERO, V16, P833; SARACCI R, 1980, J NATL CANCER I, V65, P241; Storm H H, 1986, Ugeskr Laeger, V148, P1110; STORM HH, 1989, CANCER INCIDENCE DEN; TUYNS AJ, 1975, J NATL CANCER I, V54, P61, DOI 10.1093/jnci/54.1.61; WATERHOUSE J, 1982, INT AGENCY RES CANCE, V42; 1957, MANUAL INT STATISTIC; 1986, STATISTICAL YB 1986, P171; 1983, LANCET, V1, P463	17	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					437	440		10.1136/bmj.302.6774.437	http://dx.doi.org/10.1136/bmj.302.6774.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004170	Green Published, Bronze			2022-12-28	WOS:A1991EZ03300019
J	BROEK, D; BARTLETT, R; CRAWFORD, K; NURSE, P				BROEK, D; BARTLETT, R; CRAWFORD, K; NURSE, P			INVOLVEMENT OF P34CDC2 IN ESTABLISHING THE DEPENDENCY OF S-PHASE ON MITOSIS	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; CELL-DIVISION CYCLE; FISSION YEAST; PROTEIN-KINASE; DNA-REPLICATION; TYROSINE PHOSPHORYLATION; CHROMOSOME CONDENSATION; COLORIMETRIC METHOD; MOLECULAR-CLONING; MITOTIC CONTROL	Mutants of cdc2+ can disrupt the dependency of S phase on completion of the previous mitosis. By changing the state of p34cdc2 it is possible to reprogramme a cell from entering mitosis to undergoing S phase. This leads to the proposal that the cell cycle can be considered a p34cdc2 cycle, and has implications for the evolution of life cycles.	UNIV OXFORD,IMPERIAL CANC RES FUND,DEPT BIOCHEM,MICROBIOL UNIT,OXFORD OX1 3QU,ENGLAND	University of Oxford								BARTLETT R, 1990, BIOESSAYS, V10, P457; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; BEERMANN W, 1972, DEV STUDIES GIANT CH, P1; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BOSTOCK CJ, 1970, EXP CELL RES, V60, P16, DOI 10.1016/0014-4827(70)90484-2; BREWER EN, 1968, EXP CELL RES, V49, P79, DOI 10.1016/0014-4827(68)90521-1; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Crandall M, 1977, Adv Microb Physiol, V15, P307, DOI 10.1016/S0065-2911(08)60319-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; EGEL R, 1973, MOL GEN GENET, V122, P339, DOI 10.1007/BF00269434; Egel R., 1989, MOL BIOL FISSION YEA, P31; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GENDIMENICO GJ, 1988, ANAL BIOCHEM, V173, P45, DOI 10.1016/0003-2697(88)90156-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAGAN I, 1988, J CELL SCI, V91, P587; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KAI R, 1986, MOL CELL BIOL, V6, P2027, DOI 10.1128/MCB.6.6.2027; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KOHLI J, 1977, GENETICS, V87, P471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Mitchison J.M., 1971, BIOLOGY CELL CYCLE, P201; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORENO S, 1990, METHOD ENZYMOL, V194, P793; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBERTS J, 1988, CELL, V452, P397; ROMAN H, 1955, GENETICS, V40, P546; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAZER S, 1990, J CELL SCI, V97, P509; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SLUDER G, 1986, J EXP ZOOL, V238, P325, DOI 10.1002/jez.1402380307; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	59	325	330	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					388	393		10.1038/349388a0	http://dx.doi.org/10.1038/349388a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992340				2022-12-28	WOS:A1991EV51400040
J	ADAMS, S				ADAMS, S			PRESCRIBING OF PSYCHOTROPIC-DRUGS TO CHILDREN AND ADOLESCENTS	BRITISH MEDICAL JOURNAL			English	Article									SOUTHAMPTON ROTAT TRAINING SCHEME,ADOLESCENT UNIT,SOUTHAMPTON,ENGLAND									Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; RAPOPORT JL, 1983, DEV NEUROPSYCHIATRY, P385; SHAFFER D, 1968, ARCH DIS CHILD, V43, P665, DOI 10.1136/adc.43.232.665; STEINBERG D, 1985, CHILD ADOLESCENT PSY, P567; VARANKA TM, 1988, AM J PSYCHIAT, V145, P1557	5	26	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					217	217		10.1136/bmj.302.6770.217	http://dx.doi.org/10.1136/bmj.302.6770.217			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV228	1998763	Green Published, Bronze			2022-12-28	WOS:A1991EV22800027
J	SPEAKMAN, JR; RACEY, PA				SPEAKMAN, JR; RACEY, PA			NO COST OF ECHOLOCATION FOR BATS IN FLIGHT	NATURE			English	Article							PTEROPUS-GOULDII; GAS-EXCHANGE; METABOLISM; PHYSIOLOGY	ECHOLOCATION has evolved in relatively few animal species 1. One constraint may be the high cost of producing pulses, the echoes of which can be detected over useful distances 2. The energy cost of echolocation in a small (6 g) insectivorous bat, when hanging at rest, was recently measured at 0.067 Joules per pulse 3, implying a mean cost for echolocation in flight of 9.5 x basal metabolic rate (range 7 to 12x). Because flight is very costly 4, whether the costs of echolocation and flying are additive is an important question. We measured the energy costs of flight in two species of small echolocating Microchiroptera using a novel combination of respirometry and doubly-labelled water 5. Flight energy expenditure (adjusted for body mass) was not significantly different between echolocating bats and non-echolocating bats and birds. The low cost of echolocation for flying vertebrates may have been a significant factor favouring its evolution in these groups.			SPEAKMAN, JR (corresponding author), UNIV ABERDEEN,DEPT ZOOL,ABERDEEN AB9 2TN,SCOTLAND.		Speakman, John R./A-9494-2008	Speakman, John R./0000-0002-2457-1823				BERNSTEIN MH, 1973, J EXP BIOL, V58, P401; BUTLER PJ, 1977, J EXP BIOL, V77, P7; CARPENTER RE, 1985, J EXP BIOL, V114, P619; CARPENTER RE, 1986, J EXP BIOL, V120, P79; COLLINS BG, 1978, PHYSL ZOOL, V52, P165; DAWKINS R, 1908, BIND WATCHMAKER; FLINT EN, 1984, AUK, V101, P288, DOI 10.1093/auk/101.2.288; GESSAMAN JA, 1980, COMP BIOCHEM PHYS A, V65, P273, DOI 10.1016/0300-9629(80)90030-4; GESSAMAN JA, 1988, CONDOR, V90, P662, DOI 10.2307/1368356; GESSAMAN JA, 1988, PHYSIOL ZOOL, V61, P507, DOI 10.1086/physzool.61.6.30156159; GOULD E, 1964, J EXP ZOOL, V156, P19, DOI 10.1002/jez.1401560103; HEALY S, 1990, EVOLUTION, V44, P339, DOI 10.1111/j.1558-5646.1990.tb05203.x; HUDSON DM, 1973, J EXP BIOL, V103, P121; LE FEBVRE EUGENE A., 1964, AUK, V81, P403; LIFSON N, 1966, J THEOR BIOL, V12, P46, DOI 10.1016/0022-5193(66)90185-8; MASMAN D, 1984, THESIS U GRONINGEN; NACTIGALL PE, 1988, ANIMAL SONAR PROCESS; PETTIGREW JD, 1986, SCIENCE, V231, P1304, DOI 10.1126/science.3945827; Racey PA, 1987, S ZOOL SOC LOND, V57, P107; ROTHE HJ, 1987, J COMP PHYSIOL B, V157, P99, DOI 10.1007/BF00702734; SPEAKMAN JR, 1988, PHYSIOL ZOOL, V61, P514, DOI 10.1086/physzool.61.6.30156160; SPEAKMAN JR, 1989, J COMP PHYSIOL A, V165, P679, DOI 10.1007/BF00610999; THOMAS SP, 1981, J EXP BIOL, V94, P231; THOMAS SP, 1975, J EXP BIOL, V63, P273; TORREBUENO JR, 1978, J EXP BIOL, V75, P223; TUCKER VA, 1972, AM J PHYSIOL, V222, P237, DOI 10.1152/ajplegacy.1972.222.2.237; TUCKER VA, 1968, J EXP BIOL, V48, P67; [No title captured]	28	175	178	3	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					421	423		10.1038/350421a0	http://dx.doi.org/10.1038/350421a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011191				2022-12-28	WOS:A1991FF04200049
J	MORROW, JD; MARGOLIES, GR; ROWLAND, J; ROBERTS, LJ				MORROW, JD; MARGOLIES, GR; ROWLAND, J; ROBERTS, LJ			EVIDENCE THAT HISTAMINE IS THE CAUSATIVE TOXIN OF SCOMBROID-FISH POISONING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN MAST-CELLS; PROSTAGLANDIN-D2; RELEASE; SYMPTOMS; INVIVO; ACID; RAT	Background. The highest morbidity world-wide from fish poisoning results from the ingestion of spoiled scombroid fish, such as tuna and mackerel, and its cause is not clear. Histamine could be responsible, because spoiled scombroid fish contain large quantities of histamine. Whether histamine is the causative toxin, however, has remained in question. To address this issue, we investigated whether histamine homeostasis is altered in poisoned people. Methods. The urinary excretion of histamine and its metabolite, N-methylhistamine, was measured in three persons who had scombroid-fish poisoning (scombrotoxism) after the ingestion of marlin. We measured 9-alpha, 11-beta-dihydroxy-15-oxo-2,3,18,19-tetranorprost-5-ene-1,20-dioic acid (PGD-M), the principal metabolite of prostaglandin D2, a mast-cell secretory product, to assess whether mast cells had been activated to release histamine. Results. The fish contained high levels of histamine (842 to 2503-mu-mol per 100 g of tissue). Symptoms of scombrotoxism - flushing and headache - began 10 to 30 minutes after the ingestion of fish. In urine samples collected one to four hours after fish ingestion, the levels of histamine and N-methylhistamine were 9 to 20 times and 15 to 20 times the normal mean, respectively. During the subsequent 24 hours, the levels fell to 4 to 15 times and 4 to 11 times the normal values. Levels of both were normal 14 days later. PGD-M excretion was not increased at any time. Two persons treated with diphenhydramine had prompt amelioration of symptoms. Conclusions. Scombroid-fish poisoning is associated with urinary excretion of histamine in quantities far exceeding those required to produce toxicity. The histamine is most likely derived from the spoiled fish. These results identify histamine as the toxin responsible for scombroid-fish poisoning.	VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; NASHVILLE DAVIDSON CTY METROPOLITAN BOARD HLTH, DIV FOOD INSPECT, NASHVILLE, TN USA; VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NHLBI NIH HHS [HL-02499] Funding Source: Medline; NIGMS NIH HHS [GM-33040, GM-15431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033040, P50GM015431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARZUBIAGA C, IN PRESS J ALLERGY C; BAGNIS R, 1970, B WORLD HEALTH ORGAN, V42, P69; Bean N H, 1990, MMWR CDC Surveill Summ, V39, P15; BLAKESLEY ML, 1983, ANN EMERG MED, V12, P104, DOI 10.1016/S0196-0644(83)80386-2; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHURCH MK, 1989, INT ARCH ALLER A IMM, V88, P70, DOI 10.1159/000234752; DICKINSON G, 1982, ANN EMERG MED, V11, P487, DOI 10.1016/S0196-0644(82)80069-3; GRANERUS G, 1968, SCAND J CLIN LAB INV, VS 22, P49; HUGHES JM, 1976, NEW ENGL J MED, V295, P1117, DOI 10.1056/NEJM197611112952006; HUI JY, 1985, TOXICOL APPL PHARM, V81, P241, DOI 10.1016/0041-008X(85)90160-7; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; LERKE PA, 1978, WESTERN J MED, V129, P381; LEVISCHAFFER F, 1989, INT ARCH ALLER A IMM, V90, P352, DOI 10.1159/000235052; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LUKTON A., 1958, FOOD RES, V23, P611, DOI 10.1111/j.1365-2621.1958.tb17612.x; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MORROW JD, 1989, PROSTAGLANDINS, V38, P263, DOI 10.1016/0090-6980(89)90088-9; MORROW JD, IN PRESS ANAL BIOCH; MURPHY RC, 1982, METHOD ENZYMOL, V86, P547; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OTIL KJ, 1979, TOXICOL LETT, V3, P219; PRAKASH C, 1988, J CHEM SOC PERK T 1, P2821, DOI 10.1039/p19880002821; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; ROBERTS LJ, 1984, ANAL BIOCHEM, V136, P258, DOI 10.1016/0003-2697(84)90333-6; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; TAYLOR SL, 1986, CRC CR REV TOXICOL, V17, P91, DOI 10.3109/10408448609023767; TAYLOR SL, 1989, J TOXICOL-CLIN TOXIC, V27, P225, DOI 10.3109/15563658908994420; Weiss S, 1932, ARCH INTERN MED, V49, P360, DOI 10.1001/archinte.1932.00150100017002; WILLIAMS S, 1984, OFFICIAL METHODS ANA, P341; 1989, MMWR, V38, P140; 1982, FED REGISTER, V47, P40487	33	211	220	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					716	720		10.1056/NEJM199103143241102	http://dx.doi.org/10.1056/NEJM199103143241102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997836				2022-12-28	WOS:A1991FB55600002
J	BARGMANN, CI; HORVITZ, HR				BARGMANN, CI; HORVITZ, HR			CONTROL OF LARVAL DEVELOPMENT BY CHEMOSENSORY NEURONS IN CAENORHABDITIS-ELEGANS	SCIENCE			English	Article							DAUER-INDUCING PHEROMONE; NERVOUS-SYSTEM; C-ELEGANS; CELL; MUTANTS; TEMPERATURE; GENETICS; FOOD	Larval development of the nematode Caenorhabditis elegans is controlled by the activities of four classes of chemosensory neurons. The choice between normal development and development into a specialized larval form called a dauer larva is regulated by competing environmental stimuli: food and a dauer pheromone. When the neuron classes ADF, ASG, ASI, and ASJ are killed, animals develop as dauer larvae regardless of environmental conditions. These neurons might sense food or dauer pheromone, or both, to initiate the specialized differentiation of many cell types that occurs during dauer formation. Entry into and exit from the dauer stage are primarily controlled by different chemosensory neurons. The analysis of mutants defective in dauer formation indicates that the chemosensory neurons are active in the absence of sensory inputs and that dauer pheromone inhibits the ability of these neurons to generate a signal necessary for normal development.			BARGMANN, CI (corresponding author), MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.			Bargmann, Cornelia/0000-0002-8484-0618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024663, R37GM024663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARGMANN CI, UNPUB; BRENNER S, 1974, GENETICS, V77, P71; BROCKES JP, 1984, SCIENCE, V225, P1280, DOI 10.1126/science.6474177; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; Chappell L.H., 1982, P116; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Crisp D.J., 1974, pUnpaginated; GOLDEN JW, 1985, MOL GEN GENET, V198, P534, DOI 10.1007/BF00332953; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GOLDEN JW, 1984, J CHEM ECOL, V10, P1265, DOI 10.1007/BF00988553; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUBBELL WL, 1979, ANNU REV NEUROSCI, V2, P17, DOI 10.1146/annurev.ne.02.030179.000313; KIMURA K, 1990, J NEUROSCI, V10, P403; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; Maggenti A. R., 1981, GENERAL NEMATOLOGY; MELLON D, 1978, NATURE, V272, P246, DOI 10.1038/272246a0; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; TRUMAN JW, 1983, J COMP NEUROL, V216, P445, DOI 10.1002/cne.902160410; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Whitfield P.J., 1982, P34; ZALEWSKI AA, 1969, EXP NEUROL, V24, P285, DOI 10.1016/0014-4886(69)90022-3	38	326	349	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1243	1246		10.1126/science.2006412	http://dx.doi.org/10.1126/science.2006412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006412				2022-12-28	WOS:A1991FA69100045
J	UNGER, RH				UNGER, RH			DIABETIC HYPERGLYCEMIA - LINK TO IMPAIRED GLUCOSE-TRANSPORT IN PANCREATIC BETA-CELLS	SCIENCE			English	Article							INSULIN RESISTANCE; PATHO-PHYSIOLOGY; SKELETAL-MUSCLE; PIMA-INDIANS; ISLET CELLS; MELLITUS; GLUCAGON; EXPRESSION; GENE; RAT	Glucose uptake into pancreatic beta-cells by means of the glucose transporter GLUT-2, which has a high Michaelis constant, is essential for the normal insulin secretory response to hyperglycemia. In both autoimmune and nonautoimmune diabetes, this glucose transport is reduced as a consequence of down-regulation of the normal beta-cell transporter. In autoimmune diabetes, circulating immunoglobulins can further impair this glucose transport by inhibiting functionally intact transporters. Insights into mechanisms of the unresponsiveness of beta-cells to hyperglycemia may improve the management and prevention of diabetes.	VET AFFAIRS MED CTR,DALLAS,TX 75235	US Department of Veterans Affairs; Veterans Health Administration (VHA)	UNGER, RH (corresponding author), UNIV TEXAS,SW MED CTR,CTR DIABET RES,DEPT INTERNAL MED,GIFFORD LABS,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042582, R37DK002700] Funding Source: NIH RePORTER; NIDDK NIH HHS [1-PO1-DK42582-01, 5-R37-DK02700-31] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONOFF SL, 1977, J CLIN ENDOCR METAB, V44, P968, DOI 10.1210/jcem-44-5-968; ARONOFF SL, 1976, J CLIN ENDOCR METAB, V43, P279, DOI 10.1210/jcem-43-2-279; ARONOFF SL, 1976, DIABETES, V25, P404, DOI 10.2337/diabetes.25.5.404; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAISCH JM, 1990, NEW ENGL J MED, V322, P1836, DOI 10.1056/NEJM199006283222602; BELLGI, 1990, DIABETES CARE, V13, P198; Bennett P H, 1976, Recent Prog Horm Res, V32, P333; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BOTTAZZO GF, 1978, BRIT MED J, V2, P1253, DOI 10.1136/bmj.2.6147.1253; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CLARK JB, 1983, P SOC EXP BIOL MED, V173, P68; CLISSOLD SP, 1988, DRUGS, V35, P214, DOI 10.2165/00003495-198835030-00003; DEFRONZO RA, 1982, MEDICINE, V61, P125, DOI 10.1097/00005792-198205000-00001; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EISENBARTH GS, 1987, DIABETES METAB REV, V3, P873, DOI 10.1002/dmr.5610030404; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GABBAY RA, 1984, J BIOL CHEM, V259, P6052; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GENUTH SM, 1976, DIABETES, V25, P1110, DOI 10.2337/diabetes.25.12.1110; GORUS FK, 1984, J BIOL CHEM, V259, P1196; IRVINE WJ, 1980, IMMUNOLOGY DIABETES, P117; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; JONES DB, 1990, LANCET, V336, P583, DOI 10.1016/0140-6736(90)93390-B; KANATSUNA T, 1983, DIABETES, V32, P520, DOI 10.2337/diabetes.32.6.520; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KOMIYA I, 1990, METABOLISM, V39, P614, DOI 10.1016/0026-0495(90)90028-B; LERNMARK A, 1978, NEW ENGL J MED, V299, P375, DOI 10.1056/NEJM197808242990802; LILJENQUIST JE, 1977, J CLIN INVEST, V59, P369, DOI 10.1172/JCI108649; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; MACLAREN NK, 1975, LANCET, V1, P997; MACLEAN N, 1959, DIABETES, V8, P83, DOI 10.2337/diab.8.2.83; MARUYAMA H, 1984, J CLIN INVEST, V74, P2296, DOI 10.1172/JCI111658; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; Opie EL, 1901, J EXP MED, V5, P527, DOI 10.1084/jem.5.5.527; ORCI L, 1990, J CLIN INVEST, V86, P1615, DOI 10.1172/JCI114883; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; PALMER JP, 1976, J CLIN INVEST, V58, P565, DOI 10.1172/JCI108502; PFEIFFER MA, 1980, AM J MED, V70, P579; RAHIER J, 1983, DIABETOLOGIA, V24, P366; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RHOADS DB, 1988, P NATL ACAD SCI USA, V85, P9042, DOI 10.1073/pnas.85.23.9042; SENER A, 1984, EXPERIENTIA, V40, P1026, DOI 10.1007/BF01971448; SRIKANTA S, 1986, DIABETES, V35, P139, DOI 10.2337/diabetes.35.2.139; SRIKANTA S, 1983, NEW ENGL J MED, V308, P322, DOI 10.1056/NEJM198302103080607; STEFAN Y, 1982, DIABETES, V31, P694, DOI 10.2337/diabetes.31.8.694; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1990, DIABETES, V39, P719; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TOMINAGA M, 1986, P NATL ACAD SCI USA, V83, P9749, DOI 10.1073/pnas.83.24.9749; UNGER R H, 1985, P1018; UNGER RH, 1981, NEW ENGL J MED, V304, P1575, DOI 10.1056/NEJM198106253042604; UNGER RH, 1981, NEW ENGL J MED, V304, P1518, DOI 10.1056/NEJM198106183042504; WEIR GC, 1982, AM J MED, V73, P461, DOI 10.1016/0002-9343(82)90321-7; Zimmet P, 1979, Diabetes Care, V2, P144, DOI 10.2337/diacare.2.2.144; ZIMMET P, 1977, DIABETOLOGIA, V13, P111, DOI 10.1007/BF00745137; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	69	297	304	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1200	1205		10.1126/science.2006409	http://dx.doi.org/10.1126/science.2006409			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006409				2022-12-28	WOS:A1991FA69100033
J	ENGLISH, TL				ENGLISH, TL			SKEPTICAL OF SKEPTICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					964	964		10.1001/jama.265.8.964	http://dx.doi.org/10.1001/jama.265.8.964			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992204				2022-12-28	WOS:A1991EY43200007
J	VARNEY, VA; GAGA, M; FREW, AJ; ABER, VR; KAY, AB; DURHAM, SR				VARNEY, VA; GAGA, M; FREW, AJ; ABER, VR; KAY, AB; DURHAM, SR			USEFULNESS OF IMMUNOTHERAPY IN PATIENTS WITH SEVERE SUMMER HAY-FEVER UNCONTROLLED BY ANTIALLERGIC DRUGS	BRITISH MEDICAL JOURNAL			English	Article							PARTIALLY PURIFIED EXTRACT; TIMOTHY GRASS-POLLEN; RHINITIS	Objective-To evaluate the efficacy and safety of immunotherapy (hyposensitisation) in patients with severe summer hay fever. Design-A randomised, double blind, placebo controlled study of a biologically standardised depot grass pollen extract. Setting-Allergy clinic, Royal Brompton and National Heart Hospital, London. Patients-40 adults (mean age 35 years) with a history of severe grass pollen allergy uncontrolled by standard antiallergic drugs. Patients with perennial asthma were specifically excluded. Intervention-Patients were randomised to receive either an active preparation (Alutard SQ, a grass pollen (Phleum pratense) extract) or placebo at a rate of two subcutaneous injections a week in increasing doses until a maintenance dose was reached. This maintenance dose was given once a month. Main outcome measures-Clinical efficacy was evaluated by symptom and drug diary cards, visual analogue scores during the grass pollen season, and a postseasonal assessment by the patients and a doctor. Conjunctival and skin sensitivity to local allergen provocation was measured before and after eight months of treatment. Results-There was a highly significant decrease (median Alutard SQ-upsilon-median placebo (95% confidence interval for difference between medians)) in total symptom scores (p = 0.001) in the Alutard SQ treated group (360-upsilon-928 (238 to 825)). Significant differences were also found in total drug use (p = 0.002, 129-upsilon-627 (178 to 574)). Visual analogue symptom scores were also reduced in the active group (p = 0.02, 2.2-upsilon-5.5 (-4.8 to -0.5)). The postseasonal assessment, by either the doctor or the patients, showed a large improvement (p < 0.001) in favour of Alutard SQ. Provocation tests showed a greater than 10-fold reduction for the active group in immediate conjunctival allergen sensitivity (p = 0.001), a 40% decrease in early phase response (p = 0.02), and a 57% decrease in the late phase (p = 0.001) cutaneous response after intradermal allergen. A total of 523 active injections were given. There was one systemic reaction at 10 minutes after injection, which was rapidly reversed with intramuscular adrenaline. There was one mild delayed urticarial reaction at 2 1/2 hours. Conclusion-Immunotherapy is effective in patients with severe summer hay fever, but immediate anaphylactic reactions limit its use to specialised centres. Patient selection is extremely important, and chronic perennial asthma should be specifically excluded. As serious reactions occur within minutes a two hour wait for all patients after each injection seems unnecessary.	ROYAL BROMPTON & NATL HEART & LUNG HOSP,NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6LY,ENGLAND; ROYAL BROMPTON & NATL HEART & LUNG HOSP,NATL HEART & LUNG INST,DEPT CLIN EPIDEMIOL,LONDON SW3 6LY,ENGLAND	Imperial College London; Imperial College London			Kelly, Frank J/C-6125-2009; Gaga, Mina/AAP-8348-2020	Kelly, Frank J/0000-0003-2558-8392; Gaga, Mina/0000-0002-9949-6012				[Anonymous], 1986, BMJ-BRIT MED J, V293, P948; ARMITAGE P, 1987, STATISTICAL METHODS, P408; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FRANKLAND AW, 1954, LANCET, V1, P1055; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; HOWARTH PH, 1989, RESP MED, V83, P179, DOI 10.1016/S0954-6111(89)80029-0; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KERR JAMES W., 1963, SCOT MED JOUR, V8, P485; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Malling H, 1988, ALLERGY S6, V43, P9; MILLER ACML, 1974, CLIN ALLERGY, V4, P49, DOI 10.1111/j.1365-2222.1974.tb01362.x; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; RAWLINS MD, 1988, REGULATORY CONTROL S, P147; 1989, LANCET, V1, P259	17	315	328	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					265	269		10.1136/bmj.302.6771.265	http://dx.doi.org/10.1136/bmj.302.6771.265			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998791	Bronze, Green Published			2022-12-28	WOS:A1991EX91900019
J	OLEARY, DS				OLEARY, DS			BEYOND GENERIC OCCURRENCE SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											OLEARY, DS (corresponding author), JOINT COMMISS ACCREDITAT HEALTHCARE ORG,1 RENAISSANCE BLVD,OAK BROOK,IL 60181, USA.							SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977	1	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1993	1994		10.1001/jama.265.15.1993	http://dx.doi.org/10.1001/jama.265.15.1993			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008030				2022-12-28	WOS:A1991FF76800028
J	PADAWER, J				PADAWER, J			EMPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1944	1944						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008019				2022-12-28	WOS:A1991FF76800007
J	FREEMAN, DL				FREEMAN, DL			HEAL THYSELF	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								In this personal narrative, an internist asks whether any knowledge that would be of value in his clinical practice can be derived from his own clinical depression. He describes the emotional and situational effects of his wife's severe illness, the symptoms of his own sickness, and the process of his recovery. He concludes that the experience has enhanced his ability to communicate with and to understand his patients.											0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					694	694		10.7326/0003-4819-114-8-694	http://dx.doi.org/10.7326/0003-4819-114-8-694			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003716				2022-12-28	WOS:A1991FG03100012
J	WALSH, TJ; HATHORN, JW; SOBEL, JD; MERZ, WG; SANCHEZ, V; MARET, SM; BUCKLEY, HR; PFALLER, MA; SCHAUFELE, R; SLIVA, C; NAVARRO, E; LECCIONES, J; CHANDRASEKAR, P; LEE, J; PIZZO, PA				WALSH, TJ; HATHORN, JW; SOBEL, JD; MERZ, WG; SANCHEZ, V; MARET, SM; BUCKLEY, HR; PFALLER, MA; SCHAUFELE, R; SLIVA, C; NAVARRO, E; LECCIONES, J; CHANDRASEKAR, P; LEE, J; PIZZO, PA			DETECTION OF CIRCULATING CANDIDA ENOLASE BY IMMUNOASSAY IN PATIENTS WITH CANCER AND INVASIVE CANDIDIASIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYSIS-CENTRIFUGATION; BLOOD CULTURE; SYSTEMIC CANDIDIASIS; CLINICAL-EVALUATION; ALBICANS; FUNGEMIA; SERA; INFECTIONS; ARABINITOL; ANTIGENS	Background. Invasive candidiasis is a major nosocomial infection that is difficult to diagnose. Few biochemically defined markers of invasive candidiasis are known. Initial findings suggested that the presence of candida enolase in the blood may be a novel marker for invasive candidiasis. Methods. We tested 170 patients at high risk for invasive candidiasis for candida enolase antigenemia. All the patients had cancer and neutropenia. We detected antigen using a double-sandwich liposomal immunoassay for candida enolase in serially collected serum samples. Invasive candidiasis was proved by finding candida species in deep nonmucosal tissue, blood cultures, or both. Antigen testing was performed with the investigator blinded to tissue or culture diagnosis. Results. Among 24 patients with proved invasive candidiasis, 149 serum samples were tested for enolase antigenemia; 80 were positive and 69 negative (sensitivity per sample, 54 percent). Multiple sampling improved the detection of antigenemia, which was found in 11 of 13 proved cases of deep tissue infection (85 percent) and in 7 of 11 proved cases of fungemia (64 percent). Specificity was 96 percent as measured against control groups including patients with mucosal colonization, bacteremia, and other deep mycoses. Antigenemia was detected in the absence of fungemia in 5 cases of deep tissue candidiasis, but was not detected in 6 cases of fungemia alone. Conclusions. Candida enolase antigenemia is a novel marker for invasive candidiasis. It may be a useful indicator of deep infection in patients with cancer and neutropenia and may complement the diagnostic usefulness of blood cultures.	NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT LAB MED,BETHESDA,MD 20892; DUKE UNIV,MED CTR,DURHAM,NC 27710; WAYNE STATE UNIV,HARPER HOSP,MED CTR,DETROIT,MI 48202; JOHNS HOPKINS MED INST,BALTIMORE,MD 21205; BECTON DICKINSON & CO,ADV DIAGNOST,BALTIMORE,MD; TEMPLE UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19122; UNIV IOWA HOSP & CLIN,IOWA CITY,IA 52242	National Institutes of Health (NIH) - USA; Duke University; Detroit Medical Center; Wayne State University; Johns Hopkins University; Johns Hopkins Medicine; Becton Dickinson; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Iowa	WALSH, TJ (corresponding author), NCI,PEDIAT BRANCH,INFECT DIS SECT,BLDG 10,RM 13N-240,BETHESDA,MD 20892, USA.							ARMSTRONG D, 1989, REV INFECT DIS    S7, V11, pS1591; BILLE J, 1984, J CLIN MICROBIOL, V19, P126, DOI 10.1128/JCM.19.2.126-128.1984; BOUGNOUX ME, 1990, J CLIN MICROBIOL, V28, P905, DOI 10.1128/JCM.28.5.905-909.1990; BRANNON P, 1985, J CLIN MICROBIOL, V22, P951, DOI 10.1128/JCM.22.6.951-954.1985; BROWN WB, 1977, STATISTICS BIOMEDICA, P174; DEREPENTIGNY L, 1984, REV INFECT DIS, V6, P301; ENG RHK, 1984, SABOURAUDIA, V22, P403; FERREIRA RP, 1990, J CLIN MICROBIOL, V28, P1075, DOI 10.1128/JCM.28.5.1075-1078.1990; FRANKLYN KM, 1990, IMMUNOL CELL BIOL, V68, P173, DOI 10.1038/icb.1990.24; GOLD JWM, 1983, J INFECT DIS, V147, P504, DOI 10.1093/infdis/147.3.504; HENRY NK, 1983, J CLIN MICROBIOL, V17, P864, DOI 10.1128/JCM.17.5.864-869.1983; HORN R, 1985, REV INFECT DIS, V7, P646; JONES JM, 1980, J LAB CLIN MED, V96, P845; LEMIEUX C, 1990, J CLIN MICROBIOL, V28, P249, DOI 10.1128/JCM.28.2.249-253.1990; MASON A B, 1989, Yeast, V5, pS231; MATTHEWS R, 1988, J CLIN MICROBIOL, V26, P459, DOI 10.1128/JCM.26.3.459-463.1988; MATTHEWS RC, 1987, J CLIN MICROBIOL, V25, P230, DOI 10.1128/JCM.25.2.230-237.1987; MEUNIERCARPENTIER F, 1981, AM J MED, V71, P363, DOI 10.1016/0002-9343(81)90162-5; STROCKBINE NA, 1984, INFECT IMMUN, V43, P1012, DOI 10.1128/IAI.43.3.1012-1018.1984; STROCKBINE NA, 1984, INFECT IMMUN, V43, P715, DOI 10.1128/IAI.43.2.715-721.1984; WALSH TJ, 1988, ANNU REV MICROBIOL, V42, P517, DOI 10.1146/annurev.mi.42.100188.002505; WALSH TJ, 1988, 10 C INT SOC HUM AN; WONG B, 1988, J CLIN MICROBIOL, V26, P1670, DOI 10.1128/JCM.26.9.1670-1674.1988	23	201	214	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1026	1031		10.1056/NEJM199104113241504	http://dx.doi.org/10.1056/NEJM199104113241504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	2005939				2022-12-28	WOS:A1991FF77100004
J	NOVELLO, AC				NOVELLO, AC			WOMEN AND HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1805	1805						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005724				2022-12-28	WOS:A1991FE86200005
J	LANZARONE, LM				LANZARONE, LM			HEALING ARTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1663	1663						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002562				2022-12-28	WOS:A1991FD65900008
J	ORENTLICHER, D				ORENTLICHER, D			DENYING TREATMENT TO THE NONCOMPLIANT PATIENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DIALYSIS; LIFE				ORENTLICHER, D (corresponding author), AMER MED ASSOC,ETH & HLTH POLICY COUNSEL,CHICAGO,IL 60610, USA.							ABRAM HS, 1971, AM J PSYCHIAT, V127, P1199, DOI 10.1176/ajp.127.9.1199; APPELBAUM PS, 1983, JAMA-J AM MED ASSOC, V50, P1296; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CONRAD P, 1987, HASTINGS CENT REP, V17, P15, DOI 10.2307/3563177; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; JONSEN AR, 1979, COMPLIANCE HLTH CARE, P113; KAPLAN HI, 1989, COMPREHENSIVE TXB PS, P1318; MEICHENBAUM D, 1987, FACILITATING TREATME, P11; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PETRIE K, 1989, BRIT J MED PSYCHOL, V62, P91, DOI 10.1111/j.2044-8341.1989.tb02814.x; PRYOR DB, 1983, ANN INTERN MED, V99, P528, DOI 10.7326/0003-4819-99-4-528; STEWART RS, 1983, HOSP COMMUNITY PSYCH, V34, P623; 1989, CURRENT OPINIONS, pR9; 1989, CURRENT OPINIONS, P39	17	23	23	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1579	1582		10.1001/jama.265.12.1579	http://dx.doi.org/10.1001/jama.265.12.1579			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC604	1999908				2022-12-28	WOS:A1991FC60400036
J	KLIBANSKI, A; ZERVAS, NT				KLIBANSKI, A; ZERVAS, NT			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - DIAGNOSIS AND MANAGEMENT OF HORMONE-SECRETING PITUITARY-ADENOMAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SOMATOSTATIN ANALOG SMS-201-995; LONG-TERM TREATMENT; GONADOTROPIN-RELEASING HORMONE; DEXAMETHASONE SUPPRESSION TEST; TRANS-SPHENOIDAL MICROSURGERY; GROWTH-HORMONE; ALPHA-SUBUNIT; CUSHINGS-DISEASE; SMS 201-995; ACROMEGALIC PATIENTS		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	KLIBANSKI, A (corresponding author), MASSACHUSETTS GEN HOSP, CTR NEUROENDOCRINE CLIN, NEUROENDOCRINE UNIT, FRUIT ST, BOSTON, MA 02114 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040947] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01066] Funding Source: Medline; NIDDK NIH HHS [DK-40947] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER JM, 1990, J CLIN INVEST, V86, P336, DOI 10.1172/JCI114705; ASA SL, 1984, J CLIN ENDOCR METAB, V58, P796, DOI 10.1210/jcem-58-5-796; BARKAN A, 1988, SANDOSTATIN TREATMEN, P103; BARKAN AL, 1988, J CLIN ENDOCR METAB, V67, P69, DOI 10.1210/jcem-67-1-69; BARKAN AL, 1988, J CLIN ENDOCR METAB, V67, P1040, DOI 10.1210/jcem-67-5-1040; BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X; BECKPECCOZ P, 1986, J CLIN ENDOCR METAB, V62, P704, DOI 10.1210/jcem-62-4-704; BELL PM, 1986, ARCH INTERN MED, V146, P1145, DOI 10.1001/archinte.146.6.1145; BOGGAN JE, 1983, J NEUROSURG, V59, P195, DOI 10.3171/jns.1983.59.2.0195; CARPENTER PC, 1986, MAYO CLIN PROC, V61, P49, DOI 10.1016/S0025-6196(12)61398-6; CHIODINI PG, 1987, J CLIN ENDOCR METAB, V64, P447, DOI 10.1210/jcem-64-3-447; CHRISTENSEN SE, 1987, CLIN ENDOCRINOL, V27, P297, DOI 10.1111/j.1365-2265.1987.tb01156.x; CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; CHROUSOS GP, 1985, ANN INTERN MED, V102, P344, DOI 10.7326/0003-4819-102-3-344; CLEMMONS DR, 1979, NEW ENGL J MED, V301, P1138, DOI 10.1056/NEJM197911223012102; COMI RJ, 1987, NEW ENGL J MED, V317, P12, DOI 10.1056/NEJM198707023170103; DANESHDOOST L, 1990, 72ND ANN M END SOC B; DAVIS PC, 1987, AM J NEURORADIOL, V8, P817; DOPPMAN JL, 1984, RADIOLOGY, V150, P99, DOI 10.1148/radiology.150.1.6316418; DOPPMAN JL, 1988, J COMPUT ASSIST TOMO, V12, P728, DOI 10.1097/00004728-198809010-00002; DWYER AJ, 1987, RADIOLOGY, V163, P421, DOI 10.1148/radiology.163.2.3562821; EASTMAN RC, 1979, J CLIN ENDOCR METAB, V48, P931, DOI 10.1210/jcem-48-6-931; EBERSOLD MJ, 1986, J NEUROSURG, V64, P713, DOI 10.3171/jns.1986.64.5.0713; FRIEDMAN RB, 1989, J NEUROSURG, V71, P520, DOI 10.3171/jns.1989.71.4.0520; GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003-4819-110-7-526; GRISOLI F, 1985, SURG NEUROL, V23, P513, DOI 10.1016/0090-3019(85)90248-4; GROSSMAN AB, 1988, CLIN ENDOCRINOL, V29, P167, DOI 10.1111/j.1365-2265.1988.tb00258.x; HALSE J, 1990, J CLIN ENDOCR METAB, V70, P1254, DOI 10.1210/jcem-70-5-1254; HARRIS AG, 1988, SANDOSTATIN TREATMEN, P117; HARRIS RI, 1983, J CLIN ENDOCR METAB, V56, P1288, DOI 10.1210/jcem-56-6-1288; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; IKUYAMA S, 1985, J CLIN ENDOCR METAB, V61, P666, DOI 10.1210/jcem-61-4-666; ISHIBASHI M, 1987, J CLIN ENDOCR METAB, V64, P1187, DOI 10.1210/jcem-64-6-1187; JACOBS HS, 1976, CLIN ENDOCRINOL, V5, P439, DOI 10.1111/j.1365-2265.1976.tb01974.x; JAMESON JL, 1987, J CLIN INVEST, V80, P1472, DOI 10.1172/JCI113228; JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801; KAYE TB, 1990, ANN INTERN MED, V112, P434, DOI 10.7326/0003-4819-76-3-112-6-434; KJELLBERG RN, 1984, SECRETORY TUMORS PIT, P295; KLIBANSKI A, 1987, J CLIN ENDOCR METAB, V64, P536, DOI 10.1210/jcem-64-3-536; KLIBANSKI A, 1988, J CLIN ENDOCR METAB, V66, P96, DOI 10.1210/jcem-66-1-96; KLIBANSKI A, 1988, J CLIN ENDOCR METAB, V67, P124, DOI 10.1210/jcem-67-1-124; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; KLIBANSKI A, 1989, J CLIN ENDOCR METAB, V68, P81, DOI 10.1210/jcem-68-1-81; KLIBANSKI A, 1987, ENDOCRIN METAB CLIN, V16, P793, DOI 10.1016/S0889-8529(18)30474-2; KLIMAN B, 1987, ACROMEGALY CENTURY S, P221; KOPPELMAN MCS, 1984, ANN INTERN MED, V100, P115, DOI 10.7326/0003-4819-100-1-115; KOURIDES IA, 1976, J CLIN ENDOCR METAB, V43, P97, DOI 10.1210/jcem-43-1-97; KOVACS K, 1987, ENDOCRIN METAB CLIN, V16, P529, DOI 10.1016/S0889-8529(18)30463-8; LAMBERTS SWJ, 1988, ENDOCR REV, V9, P417, DOI 10.1210/edrv-9-4-417; LAMBERTS SWJ, 1985, NEW ENGL J MED, V313, P1576, DOI 10.1056/NEJM198512193132504; LAMBERTS SWJ, 1987, J CLIN ENDOCR METAB, V64, P524, DOI 10.1210/jcem-64-3-524; LAMBERTS SWJ, 1986, J CLIN ENDOCR METAB, V63, P16, DOI 10.1210/jcem-63-1-16; LEYENDECKER G, 1980, ARCH GYNECOL, V229, P177, DOI 10.1007/BF02108310; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LINDHOLM J, 1981, NEW ENGL J MED, V304, P1450, DOI 10.1056/NEJM198106113042402; LIUZZI A, 1974, J CLIN ENDOCR METAB, V38, P910, DOI 10.1210/jcem-38-5-910; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MARCH CM, 1981, AM J OBSTET GYNECOL, V139, P835, DOI 10.1016/0002-9378(81)90553-6; MASON A M S, 1972, Clinical Endocrinology, V1, P3, DOI 10.1111/j.1365-2265.1972.tb00374.x; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; NELSON AT, 1984, J NEUROSURG, V61, P577, DOI 10.3171/jns.1984.61.3.0577; NEWTON DR, 1989, AM J NEURORADIOL, V10, P949; NIEMAN LK, 1986, ANN INTERN MED, V105, P862, DOI 10.7326/0003-4819-105-6-862; OLDFIELD EH, 1985, NEW ENGL J MED, V312, P1457; OPPENHEIM DS, 1990, J CLIN ENDOCR METAB, V70, P859, DOI 10.1210/jcem-70-4-859; OPPENHEIM DS, 1989, ENDOCRIN METAB CLIN, V18, P339, DOI 10.1016/S0889-8529(18)30374-8; OSAMURA RY, 1987, VIRCHOWS ARCH A, V411, P323, DOI 10.1007/BF00713376; PECK WW, 1989, AM J ROENTGENOL, V152, P145, DOI 10.2214/ajr.152.1.145; QUABBE HJ, 1989, J CLIN ENDOCR METAB, V68, P873, DOI 10.1210/jcem-68-5-873; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; REUBI JC, 1989, J CLIN ENDOCR METAB, V68, P844, DOI 10.1210/jcem-68-4-844; RIDGWAY EC, 1983, ENDOCRINOLOGY, V112, P1937, DOI 10.1210/endo-112-6-1937; RIDGWAY EC, 1981, NEW ENGL J MED, V304, P1254, DOI 10.1056/NEJM198105213042102; ROELFSEMA F, 1985, CLIN ENDOCRINOL, V23, P555, DOI 10.1111/j.1365-2265.1985.tb01116.x; ROMAN SH, 1984, J CLIN ENDOCR METAB, V58, P313, DOI 10.1210/jcem-58-2-313; ROSS DA, 1988, J NEUROSURG, V68, P854, DOI 10.3171/jns.1988.68.6.0854; SALASSA RM, 1978, MAYO CLIN PROC, V53, P24; SARIS SC, 1987, RADIOLOGY, V162, P775, DOI 10.1148/radiology.162.3.3809493; SASSOLAS G, 1988, HORM RES, V29, P124, DOI 10.1159/000180987; SCHLECHTE J, 1989, J CLIN ENDOCR METAB, V68, P412, DOI 10.1210/jcem-68-2-412; SERRI O, 1985, J CLIN ENDOCR METAB, V61, P1185, DOI 10.1210/jcem-61-6-1185; SISAM DA, 1987, FERTIL STERIL, V48, P67; SMALLRIDGE RC, 1983, ARCH INTERN MED, V143, P503, DOI 10.1001/archinte.143.3.503; SMALLRIDGE RC, 1987, ENDOCRIN METAB CLIN, V16, P765, DOI 10.1016/S0889-8529(18)30473-0; SNYDER PJ, 1980, J CLIN ENDOCR METAB, V51, P579, DOI 10.1210/jcem-51-3-579; SNYDER PJ, 1984, J CLIN ENDOCR METAB, V59, P1169, DOI 10.1210/jcem-59-6-1169; SNYDER PJ, 1985, ENDOCR REV, V6, P552, DOI 10.1210/edrv-6-4-552; SNYDER PJ, 1986, AM J MED, V81, P457, DOI 10.1016/0002-9343(86)90299-8; SONINO N, 1985, J CLIN ENDOCR METAB, V61, P718, DOI 10.1210/jcem-61-4-718; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; THORNER MO, 1984, J CLIN ENDOCR METAB, V59, P846, DOI 10.1210/jcem-59-5-846; TYRRELL JB, 1978, NEW ENGL J MED, V298, P753, DOI 10.1056/NEJM197804062981401; TYRRELL JB, 1986, ANN INTERN MED, V104, P180, DOI 10.7326/0003-4819-104-2-180; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VANCE ML, 1985, J CLIN ENDOCR METAB, V61, P580, DOI 10.1210/jcem-61-3-580; VANLIESSUM PA, 1989, J CLIN ENDOCR METAB, V69, P557, DOI 10.1210/jcem-69-3-557; WANG C, 1989, J CLIN ENDOCR METAB, V69, P670, DOI 10.1210/jcem-69-3-670; WASS JAH, 1977, BRIT MED J, V1, P875, DOI 10.1136/bmj.1.6065.875; WEMEAU JL, 1988, J CLIN ENDOCR METAB, V66, P636, DOI 10.1210/jcem-66-3-636; ZARATE A, 1986, ACTA ENDOCRINOL-COP, V113, P29, DOI 10.1530/acta.0.1130029	100	127	129	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					822	831						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997855				2022-12-28	WOS:A1991FC44200007
J	LAWLOR, DA; DICKEL, CD; HAUSWIRTH, WW; PARHAM, P				LAWLOR, DA; DICKEL, CD; HAUSWIRTH, WW; PARHAM, P			ANCIENT HLA GENES FROM 7,500-YEAR-OLD ARCHAEOLOGICAL REMAINS	NATURE			English	Article							MOLECULAR ANALYSIS; CHAIN-REACTION; DNA-SEQUENCES; MUMMY DNA; ALLELES; CLONING; NUMBER; EVOLUTION; FAMILY; BRAIN	IN the past decade there has been increasing interest in cloning DNA from ancient and preserved tissues 1-6. Most studies, however, have focused on mitochondrial or chloroplast genes, present at hundreds to thousands of copies per cell compared with one or two for each nuclear gene 7-9. With a probe containing Alu repeat sequences, Paabo isolated a 3.4-kilobase DNA fragment from a 2,400-year-old Egyptian mummy 10 which was subsequently shown to contain an intron of the nuclear gene HLA-DQA (ref. 11). Here we report a more targeted approach to the characterization of nuclear genes from archaeological specimens. The Windover pond of central Florida has provided skeletal and soft tissue remains from 165 humans, radiocarbon-dated to be 6,990-8,130 years old 12-14. Using DNA obtained from one individual we have characterized segments from six nuclear genes: that for beta-2-microglobulin and five members of the class I HLA heavy chain gene family. Distinctive patterns of nucleotide substitution in the cloned heavy chain gene segments permit tentative assignment of the HLA-A,B type of the ancient individual.	STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; UNIV FLORIDA,COLL MED,DEPT IMMUNOL & MED MICROBIOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT OPHTHALMOL,GAINESVILLE,FL 32610	Stanford University; Stanford University; State University System of Florida; University of Florida; State University System of Florida; University of Florida								BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CHIEWSILP P, 1986, HLA ASIA OCEANIA 198, P40; DELPOZZO G, 1989, NATURE, V339, P431; Doran G.H., 1988, WET SITE ARCHAEOLOGY, P263, DOI 10.1201/9781351077750-17; Doran G.H., 1988, FLORIDA ANTHR, V41, P365; DORAN GH, 1986, NATURE, V323, P803, DOI 10.1038/323803a0; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; GOLENBERG EM, 1990, NATURE, V344, P656, DOI 10.1038/344656a0; HAGELBERG E, 1989, NATURE, V342, P485, DOI 10.1038/342485a0; HANSEN T, IN PRESS TISSUE ANTI; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; KATO K, 1989, J IMMUNOL, V143, P3371; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LAMPPA GK, 1980, PLANTA, V148, P437, DOI [10.1007/BF00552656, 10.1007/BF02395311]; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; MICHAELS GS, 1982, DEV BIOL, V94, P246, DOI 10.1016/0012-1606(82)90088-4; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PAABO S, 1985, NATURE, V314, P644, DOI 10.1038/314644a0; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAABO S, 1988, NUCLEIC ACIDS RES, V16, P9775, DOI 10.1093/nar/16.20.9775; PARHAM P, 1989, J IMMUNOL, V142, P3937; POHLA H, 1989, IMMUNOGENETICS, V29, P297, DOI 10.1007/BF00352839; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; THOMAS WK, 1990, J MOL EVOL, V31, P101, DOI 10.1007/BF02109479; ZEMMOUR J, 1990, J IMMUNOL, V144, P3619	30	94	98	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					785	788		10.1038/349785a0	http://dx.doi.org/10.1038/349785a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000147				2022-12-28	WOS:A1991EZ66600054
J	ROVNER, BW; GERMAN, PS; BRANT, LJ; CLARK, R; BURTON, L; FOLSTEIN, MF				ROVNER, BW; GERMAN, PS; BRANT, LJ; CLARK, R; BURTON, L; FOLSTEIN, MF			DEPRESSION AND MORTALITY IN NURSING-HOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; DISORDERS; COMMUNITY; CARE	To determine the prevalence rates of major depressive disorder and of depressive symptoms and their relationship to mortality in nursing homes, research psychiatrists examined 454 consecutive new admissions and followed them up longitudinally for 1 year. Major depressive disorder occurred in 12.6% and 18.1% had depressive symptoms; the majority of cases were unrecognized by nursing home physicians and were untreated. Major depressive disorder, but not depressive symptoms, was a risk factor for mortality over 1 year independent of selected physical health measures and increased the likelihood of death by 59%. Because depression is a prevalent and treatable condition associated with increased mortality, recognition and treatment in nursing homes is imperative.	FRANCIS SCOTT KEY MED CTR,GERONTOL RES CTR,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University								ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; BALLINGER BR, 1988, INT J GERIATR PSYCH, V3, P125, DOI 10.1002/gps.930030209; BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; BLAZER D, 1980, HDB GERIATRIC PSYCHI; BORSON S, 1986, J AM GERIATR SOC, V34, P341, DOI 10.1111/j.1532-5415.1986.tb04316.x; BORSON S, 1987, AM J PSYCHIAT, V144, P1412; BRUCE ML, 1989, AM J PUBLIC HEALTH, V79, P727, DOI 10.2105/AJPH.79.6.727; BURNS BJ, 1988, INT J GERIATR PSYCH, V3, P27, DOI 10.1002/gps.930030105; COX DR, 1972, J R STAT SOC B, V34, P187; DIXON WJ, 1988, BMDP STATISTICAL SOF, P719; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GERMAN PS, 1987, JAMA-J AM MED ASSOC, V257, P489, DOI 10.1001/jama.257.4.489; GURLAND BJ, 1988, INT J GERIATR PSYCH, V3, P163, DOI 10.1002/gps.930030304; HING E, 1987, PHS871250 US DEP HLT; Institute of Medicine report, 1986, IMPROVING QUALITY CA; Katz I R, 1989, Int Psychogeriatr, V1, P5, DOI 10.1017/S1041610289000025; KRAMER M, 1983, AM J SOCIAL PSYCHIAT, V3, P13; LIPSEY JR, 1990, 143RD AM PSYCH ASS A; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRISS RK, 1990, AM J PSYCHIAT, V147, P299; OUSLANDER JG, 1989, JAMA-J AM MED ASSOC, V262, P2582, DOI 10.1001/jama.262.18.2582; OUSLANDER JG, 1982, J AM GERIATR SOC, V30, P593, DOI 10.1111/j.1532-5415.1982.tb05670.x; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; RODIN G, 1986, AM J PSYCHIAT, V143, P696; ROVNER BW, 1989, AM J PSYCHIAT, V146, P350; ROVNER BW, 1990, INT PSYCHOGERIATR, V147, P299; SADAVOY J, 1990, INT J GERIATR PSYCH, V5, P187, DOI 10.1002/gps.930050307; SCHLEIFER SJ, 1989, ARCH GEN PSYCHIAT, V46, P81; SNOWDON J, 1990, INT J GERIATR PSYCH, V5, P141, DOI 10.1002/gps.930050302; STRAHAN G, 1987, PHS871250 US DEP HLT; WEISSMAN MM, 1978, ARCH GEN PSYCHIAT, V35, P1304; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILKINSON IM, 1980, BRIT J PSYCHIAT, V137, P558, DOI 10.1192/bjp.137.6.558; ZWEIG RM, 1988, ANN NEUROL, V24, P233, DOI 10.1002/ana.410240210; 1987, DIAGNOSTIC STATISTIC	36	389	394	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					993	996		10.1001/jama.265.8.993	http://dx.doi.org/10.1001/jama.265.8.993			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1992213				2022-12-28	WOS:A1991EY43200027
J	THEWISSEN, JGM; BABCOCK, SK				THEWISSEN, JGM; BABCOCK, SK			DISTINCTIVE CRANIAL AND CERVICAL INNERVATION OF WING MUSCLES - NEW EVIDENCE FOR BAT MONOPHYLY	SCIENCE			English	Article							PRIMATES; MEGABATS	The traditional view that Old World fruit bats (Megachiroptera) and insect bats (Microchiroptera) are closely related has been challenged by claims that Megachiroptera are the sister group to flying lemurs (Dermoptera) or Primates. We found that the specialized muscles of the rostral part of the wing in Microchiroptera and Megachiroptera receive double innervation by both the facial nerve and cervical spinal nerves, suggesting that bats are monophyletic. Innervation by the facial nerve also occurs in Dermoptera and suggests that bats and Dermoptera share a common ancestor that had wings.			THEWISSEN, JGM (corresponding author), DUKE UNIV, MED CTR, DEPT BIOL ANTHROPOL & ANAT, DURHAM, NC 27710 USA.			Thewissen, J. G. M./0000-0002-0973-4137				ALLAM MW, 1952, ANAT REC, V114, P173, DOI 10.1002/ar.1091140205; FISHER HI, 1955, BIOL MONOGR, V24, P1; FITZGERALD MJT, 1982, J ANAT, V134, P471; Hill J., 1984, BATS NATURAL HIST; JOHNSONMURRAY JL, 1977, J MAMMAL, V58, P374, DOI 10.2307/1379336; Leche W, 1886, KUNGL SVENSKA VETENS, V21, P1; MACALISTER A, 1873, PHIL T R SOC LONDON, V162, P125; MCKENZIE J, 1955, J ANAT, V89, P526; Mori M., 1960, Okajimas Folia Anatomica Japonica, V38, P253; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; NOVACEK M J, 1986, Cladistics, V2, P257, DOI 10.1111/j.1096-0031.1986.tb00463.x; NOVACEK MJ, 1988, SYSTEMATICS ASS SP B, V35, P31; PETTIGREW JD, 1989, PHILOS T ROY SOC B, V325, P489, DOI 10.1098/rstb.1989.0102; PETTIGREW JD, 1986, SCIENCE, V231, P1304, DOI 10.1126/science.3945827; Raikow R.J., 1985, P57; Schumacher S., 1931, Zeitschrift fuer Anatomie Entw Mech, V94, P642; Strickler T.L., 1978, CONTRIB VERT EVOL, V4, P1; VAUGHAN TA, 1970, BIOL BATS, V1, P139; Williams PL, 1989, GRAYS ANATOMY; [No title captured]; [No title captured]	22	48	54	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 22	1991	251	4996					934	936		10.1126/science.2000493	http://dx.doi.org/10.1126/science.2000493			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000493				2022-12-28	WOS:A1991EY62900043
J	JOHNSON, R				JOHNSON, R			REQUIREMENTS OF BRITISH UNIVERSITIES FOR HIGHER MEDICAL DEGREES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the requirements and opportunities for obtaining a doctor of medicine or master of surgery degree from a university in the United Kingdom other than the graduate's own, particularly in the case of foreign graduates. Design-Review of regulations governing the award of doctor of medicine and master of surgery degrees in British universities. Setting-All 19 universities in the United Kingdom offering clinical courses. Main outcome measure-Availability of degrees to graduates of other universities. Results-Opportunities for obtaining a degree differed widely among the medical schools, one university (Edinburgh) not admitting graduates of other universities in any circumstance. Of the remaining universities, none would consider a graduate who had not worked in the area where the medical school was located. Conclusion-The wide differences in opportunity among the medical schools may put some foreign graduates at a disadvantage compared with other graduates. This problem may become more severe as the number of graduates from the European Community who settle in Britain increases.			JOHNSON, R (corresponding author), JOHN RADCLIFFE HOSP,MED SCH OFF,OXFORD OX3 9DU,ENGLAND.							1989, COUNCIL NATIONAL ACA	1	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					397	399		10.1136/bmj.302.6773.397	http://dx.doi.org/10.1136/bmj.302.6773.397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	2004147	Green Published, Bronze			2022-12-28	WOS:A1991EX85800031
J	MOSIER, DE; GULIZIA, RJ; BAIRD, SM; WILSON, DB; SPECTOR, DH; SPECTOR, SA				MOSIER, DE; GULIZIA, RJ; BAIRD, SM; WILSON, DB; SPECTOR, DH; SPECTOR, SA			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION OF HUMAN-PBL-SCID MICE	SCIENCE			English	Article							HUMAN CYTOMEGALO-VIRUS; HU MOUSE; SEQUENCES; CLONES; PROBES	Severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood leukocytes (hu-PBL-SCID mice) have inducible human immune function and may be useful as a small animal model for acquired immunodeficiency syndrome (AIDS) research. Hu-PBL-SCID mice infected with human immunodeficiency virus-1 (HIV-1) contained virus that was recoverable by culture from the peritoneal cavity, spleen, peripheral blood, and lymph nodes for up to 16 weeks after infection; viral sequences were also detected by in situ hybridization and by amplification with the polymerase chain reaction (PCR). Mice could be infected with multiple strains of HIV-1, including LAV-1/Bru, IIIB, MN, SF2, and SF13. HIV-1 infection affected the concentration of human immunoglobulin and the number of CD4+ T cells in the mice. These results support the use of the hu-PBL-SCID mouse for studies of the pathogenesis and treatment of AIDS.	VET ADM MED CTR, LA JOLLA, CA 92161 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, LA JOLLA, CA 92093 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	MOSIER, DE (corresponding author), MED BIOL INST, DIV IMMUNOL, LA JOLLA, CA 92037 USA.			Spector, Deborah/0000-0002-7605-6348	NIAID NIH HHS [AI-29182, AI-27703] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027703, R21AI029182, R01AI029182] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, UNPUB; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SPECTOR SA, 1989, CLIN CHEM, V35, P1581; SPECTOR SA, 1985, CLIN CHEM, V31, P1514	15	252	264	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 15	1991	251	4995					791	794		10.1126/science.1990441	http://dx.doi.org/10.1126/science.1990441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990441				2022-12-28	WOS:A1991EX57500043
J	DALY, LE				DALY, LE			CONFIDENCE-INTERVALS AND SAMPLE SIZES - DONT THROW OUT ALL YOUR OLD SAMPLE-SIZE TABLES	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIAL				DALY, LE (corresponding author), NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT COMMUNITY MED & EPIDEMIOL,DUBLIN 2,IRELAND.							ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ALTMAN DG, 1982, STATISTICS PRACTICE; BEAL SL, 1989, BIOMETRICS, V45, P969, DOI 10.2307/2531696; BRISTOL DR, 1989, STAT MED, V8, P803, DOI 10.1002/sim.4780080705; DALY L, 1989, IRISH MED J, V82, P49; DAY SJ, 1988, LANCET, V2, P1427; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; GARDNER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1355, DOI 10.1001/jama.263.10.1355; GARDNER MJ, 1989, STATISTICS CONFIDENC; GORDON I, 1987, AM J EPIDEMIOL, V125, P158, DOI 10.1093/oxfordjournals.aje.a114499; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P231, DOI 10.1093/oxfordjournals.aje.a114945; GRIEVE AP, 1989, LANCET, V1, P337; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LAMESHOW S, 1988, STAT MED, V7, P759; LANGMAN MJS, 1986, BRIT MED J, V292, P716, DOI 10.1136/bmj.292.6522.716; MCHUGH RB, 1984, CONTROL CLIN TRIALS, V5, P157, DOI 10.1016/0197-2456(84)90121-1; ONEILL RT, 1984, AM J EPIDEMIOL, V120, P145, DOI 10.1093/oxfordjournals.aje.a113863; SPIEGELHALTER DJ, 1986, STAT MED, V5, P1, DOI 10.1002/sim.4780050103; 1987, LANCET, V2, P488	19	30	30	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					333	336		10.1136/bmj.302.6772.333	http://dx.doi.org/10.1136/bmj.302.6772.333			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001510	Green Published, Bronze			2022-12-28	WOS:A1991EX56900026
J	RYAN, M				RYAN, M			USSR LETTER - HEALTH-CARE INSURANCE IN THE SOVIET-UNION	BRITISH MEDICAL JOURNAL			English	Article											RYAN, M (corresponding author), UNIV COLL SWANSEA,CTR RUSSIAN & E EUROPEAN STUDIES,SWANSEA SA2 8PP,W GLAM,WALES.							BORICH I, 1990, MEDITSINSKAYA G 1028, P1; RYAN M, 1989, DOCTORS STATE SOVIET, P98; 1990, MED GAZETA      1026, P1; 1989, 1988 VSES SED VRACH, P22	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					170	171		10.1136/bmj.302.6769.170	http://dx.doi.org/10.1136/bmj.302.6769.170			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995141	Bronze, Green Published			2022-12-28	WOS:A1991EU02000030
J	HOLT, KS				HOLT, KS			EVERYDAY AIDS AND APPLIANCES - MOBILITY AIDS AND APPLIANCES FOR DISABLED-CHILDREN	BRITISH MEDICAL JOURNAL			English	Editorial Material											HOLT, KS (corresponding author), INST CHILD HLTH,WOLFSON CTR,LONDON WC1N 2AP,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					105	107		10.1136/bmj.302.6768.105	http://dx.doi.org/10.1136/bmj.302.6768.105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995105	Bronze, Green Published			2022-12-28	WOS:A1991ER95100029
J	SMITH, JR; MURDOCH, J; CARRINGTON, D; FREW, CE; DOUGALL, AJ; MACKINNON, H; BAILLIE, D; BYFORD, DM; FORREST, CA; DAVIS, JA				SMITH, JR; MURDOCH, J; CARRINGTON, D; FREW, CE; DOUGALL, AJ; MACKINNON, H; BAILLIE, D; BYFORD, DM; FORREST, CA; DAVIS, JA			PREVALENCE OF CHLAMYDIA-TRACHOMATIS INFECTION IN WOMEN HAVING CERVICAL SMEAR TESTS	BRITISH MEDICAL JOURNAL			English	Article							THERAPEUTIC-ABORTION; SEROLOGY	Objective - To determine the prevalence of sexually transmitted diseases in patients with normal and abnormal cervical smears. Design - A prospective study of asymptomatic women with normal cervical smears attending their general practitioner and newly referred patients with abnormal smears attending a colposcopy clinic. Setting - A hospital based colposcopy clinic and an urban general practice (list size 5500) in north west Glasgow. Subjects - 197 asymptomatic women attending their general practitioner for cervical smear tests and 101 randomly selected patients attending the colposcopy clinic for investigation of abnormal smears. Main outcome measures - Presence of various sexually transmitted infections as determined by culture and serological tests. Results - Of the 101 women with cytological abnormalities, six had current chlamydial infection proved by culture and none had gonococcal infection; of the 197 women with normal smears, 24 (12%) had a chlamydial infection and two had gonorrhoea. Serological studies for Chlamydia trachomatis specific antibody also indicated that a large proportion of patients had been exposed to this agent in both groups. There was no significant difference between the groups in the prevalence of any sexually transmitted disease studied. Conclusion - A high prevalence of chlamydial infection is present in women in north west Glasgow irrespective of their cervical cytological state.	STOBHILL GEN HOSP,DEPT GYNAECOL,GLASGOW G21 3UW,SCOTLAND; MARYHILL HLTH CTR,GLASGOW,SCOTLAND; GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,SCOTLAND	University of Glasgow								ALBERICO S, 1988, European Journal of Gynaecological Oncology, V9, P252; ARAL SO, 1984, SEXUALLY TRANSMITTED, P126; BOWIE WR, 1977, J CLIN INVEST, V59, P735, DOI 10.1172/JCI108694; FISH ANJ, 1989, EUR J OBSTET GYN R B, V31, P67, DOI 10.1016/0028-2243(89)90027-0; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HARE MJ, 1986, BRIT MED J, V293, P1225, DOI 10.1136/bmj.293.6556.1225; KROGH C, 1987, J FAM PRACTICE, V24, P597; LONGHURST HJ, 1987, J ROY COLL GEN PRACT, V37, P255; MILLS A, 1983, BRIT MED J, V286, P1649, DOI 10.1136/bmj.286.6378.1649-a; RIDGWAY GL, 1983, BRIT MED J, V286, P1478, DOI 10.1136/bmj.286.6376.1478-a; SCHACHTER J, 1979, J CLIN MICROBIOL, V10, P647, DOI 10.1128/JCM.10.5.647-649.1979; SOUTHGATE L, 1989, BRIT MED J, V299, P1136, DOI 10.1136/bmj.299.6708.1136; WANG SP, 1974, J INFECT DIS, V130, P388, DOI 10.1093/infdis/130.4.388; WOOD PL, 1984, BRIT J OBSTET GYNAEC, V91, P1171, DOI 10.1111/j.1471-0528.1984.tb04732.x	14	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					82	84		10.1136/bmj.302.6768.82	http://dx.doi.org/10.1136/bmj.302.6768.82			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995120	Green Published, Bronze			2022-12-28	WOS:A1991ER95100017
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - MEANS TESTED BENEFITS	BRITISH MEDICAL JOURNAL			English	Editorial Material											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,WELF LAW,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					37	39		10.1136/bmj.302.6767.37	http://dx.doi.org/10.1136/bmj.302.6767.37			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991187	Green Published, Bronze			2022-12-28	WOS:A1991ER37200026
J	BURCHFIELD, DJ; LUCAS, VW; ABRAMS, RM; MILLER, RL; DEVANE, CL				BURCHFIELD, DJ; LUCAS, VW; ABRAMS, RM; MILLER, RL; DEVANE, CL			DISPOSITION AND PHARMACODYNAMICS OF METHAMPHETAMINE IN PREGNANT SHEEP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-FLOW; AMPHETAMINE; HEMORRHAGE; COCAINE; HYPERTENSION; PERFORMANCE; ABUSE	To determine the placental transfer of methamphetamine, its subsequent fetal disposition, and its hemodynamic effects, we administered methamphetamine intravenously to 15 pregnant ewes 3 days after placement of maternal and fetal vascular catheters. Methamphetamine crossed the placenta within 30 seconds of its administration. Although the ewes had higher peak concentrations, the fetuses' longer elimination half-life ultimately led to higher fetal than maternal methamphetamine concentrations. The ratio of fetal tissue to plasma drug concentration 2 hours after administration was highest in the lung, followed by the placenta, kidney, intestine, liver, brain, and heart. Methamphetamine caused a 54% to 63% rise in maternal blood pressure, a 20% to 37% increase in fetal blood pressure, and a drop in fetal oxyhemoglobin saturation and arterial pH. We conclude that methamphetamine, in doses at or below what is commonly abused, has effects that could be detrimental to the health of the mother and her fetus.	UNIV FLORIDA, DEPT OBSTET & GYNECOL, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, DEPT PHARM PRACTICE, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, DEPT PSYCHIAT, GAINESVILLE, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	BURCHFIELD, DJ (corresponding author), UNIV FLORIDA, J HILLIS MILLER HLTH CTR, DEPT PEDIAT, DIV NEONATOL, BOX J-296, GAINESVILLE, FL 32610 USA.		DeVane, Lindsay/B-6645-2012		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005170] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 05170] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abrams R M, 1985, Alcohol Drug Res, V6, P361; ANGGARD E, 1970, EUR J CLIN PHARMACOL, V3, P3, DOI 10.1007/BF00560284; BECKETT AH, 1965, J PHARM PHARMACOL, VS 17, pS109, DOI 10.1111/j.2042-7158.1965.tb07757.x; BOST RO, 1989, J ANAL TOXICOL, V13, P300, DOI 10.1093/jat/13.5.300; BRINKMAN CR, 1984, MATERNAL FETAL MED P, P679; BROWNE JCM, 1953, J OBSTET GYN BRIT EM, V60, P141; BURCHFIELD DJ, 1987, PEDIATR RES, V21, pA256, DOI 10.1203/00006450-198704010-00532; CHASNOFF IJ, 1985, NEW ENGL J MED, V313, P666, DOI 10.1056/NEJM198509123131105; CHYNN KY, 1975, JAMA-J AM MED ASSOC, V233, P55; FARRELL BM, 1983, J CHROMATOGR, V272, P111, DOI 10.1016/S0378-4347(00)86108-3; GARRIOTT J C, 1973, Journal of Forensic Sciences, V18, P434; GOODMAN SJ, 1970, J AMER MED ASSOC, V212, P480, DOI 10.1001/jama.1970.03170160068021; HALL JN, 1988, TRENDS PATTERNS METH; KANE FJ, 1969, J AMER MED ASSOC, V210, P556, DOI 10.1001/jama.1969.03160290108032; Lees M M, 1967, J Obstet Gynaecol Br Commonw, V74, P319; LITTLE BB, 1988, OBSTET GYNECOL, V72, P541; MAYER SE, 1980, PHARMACOL BASIS THER, P56; METCALFE J, 1974, Progress in Cardiovascular Diseases, V16, P363, DOI 10.1016/0033-0620(74)90028-0; NAEYE RL, 1979, AM J OBSTET GYNECOL, V133, P8, DOI 10.1016/0002-9378(79)90402-2; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; PASTERNAK JF, 1983, NEUROLOGY, V33, P559; PIPKIN FB, 1985, PHYSL DEV FETUS NEWB, P699; REYNOLDS ML, 1979, EARLY HUM DEV, V3, P163, DOI 10.1016/0378-3782(79)90005-7; RUBLER S, 1977, AM J CARDIOL, V40, P534, DOI 10.1016/0002-9149(77)90068-6; SZETO HH, 1982, ANNU REV PHARMACOL, V22, P221, DOI 10.1146/annurev.pa.22.040182.001253; TALLEDO OD, 1968, AM J OBSTET GYNECOL, V100, P218, DOI 10.1016/S0002-9378(15)33724-8; WEINER N, 1980, PHARMACOL BASIS THER, P138; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957; ZUSPAN FP, 1964, AM J OBSTET GYNECOL, V90, P88; 1990, NIDA CAPSULES, P1	30	61	63	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1968	1973		10.1001/jama.265.15.1968	http://dx.doi.org/10.1001/jama.265.15.1968			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008026				2022-12-28	WOS:A1991FF76800022
J	HATTA, K; KIMMEL, CB; HO, RK; WALKER, C				HATTA, K; KIMMEL, CB; HO, RK; WALKER, C			THE CYCLOPS MUTATION BLOCKS SPECIFICATION OF THE FLOOR PLATE OF THE ZEBRAFISH CENTRAL-NERVOUS-SYSTEM	NATURE			English	Article							EMBRYO; CELLS	THE floor plate is a set of epithelial cells present in the ventral midline of the neural tube in vertebrates 1 that seems to have an important role in the developmental patterning 2 of central nervous system fibre pathways 3,4, and arrangements of specific neurons 5. The floor plate arises from dorsal ectodermal cells closely associated with the mesoderm that forms notochord 6, and it may depend on interactions from the notochord for its specification. To learn the nature of these interactions we have analysed mutations in zebrafish (Brachydanio rerio). We report here that in wild-type embryos the floor plate develops as a simply organized single cell row, but that its development fails in embryos bearing the newly discovered zygotic lethal 'cyclops' mutation, cyc-1(b16). Mosaic analysis establishes that cyc-1 blocks floor plate development autonomously and reveals the presence of homeogenetic induction between floor plate cells.			HATTA, K (corresponding author), UNIV OREGON, INST NEUROSCI, EUGENE, OR 97403 USA.							Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; Adelmann HB, 1936, Q REV BIOL, V11, P161, DOI 10.1086/394504; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HATTA K, 1990, Society for Neuroscience Abstracts, V16, P310; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; Holtfreter J, 1934, ARCH EXP ZELLFORSCH, V15, P281; JACOBSON AG, 1981, MORPHOGENESIS PATTER, P233; JESSELL TM, 1989, CIBA F SYMP, V144, P255; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1988, TRENDS GENET, V4, P68, DOI 10.1016/0168-9525(88)90043-1; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KUWADA J Y, 1990, Society for Neuroscience Abstracts, V16, P309; KUWADA JY, 1990, J NEUROSCI, V10, P1299; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; METCALFE WK, 1990, DEVELOPMENT, V110, P491; Oppenheimer JM, 1936, J EXP ZOOL, V72, P409, DOI 10.1002/jez.1400720304; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; STREISINGER G, 1986, GENETICS, V112, P311; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; WALKER C, 1983, GENETICS, V103, P125; WARGA RM, 1990, DEVELOPMENT, V108, P569; YAMADA T, IN PRESS CELL	27	389	401	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1991	350	6316					339	341		10.1038/350339a0	http://dx.doi.org/10.1038/350339a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008211				2022-12-28	WOS:A1991FD83800092
J	BOYES, J; BIRD, A				BOYES, J; BIRD, A			DNA METHYLATION INHIBITS TRANSCRIPTION INDIRECTLY VIA A METHYL-CPG BINDING-PROTEIN	CELL			English	Article							EMBRYONAL CARCINOMA-CELLS; GLOBIN GENE-EXPRESSION; INVITRO METHYLATION; ADENOVIRUS TYPE-2; MAMMALIAN NUCLEI; KINASE GENE; 5' REGION; PROMOTER; SEQUENCE; DEMETHYLATION	We have studied the mechanism by which DNA methylation inhibits transcription both in cell-free nuclear extracts and in the living cell. Repression of transcription in vitro for four different promoters was shown to be an indirect effect. The mediator of repression had properties indistinguishable from those of a methyl-CpG binding protein (MeCP-1) that has been previously identified. Use of differentially methylated promoters and methylated competitors in transient transfection assays suggested that indirect repression via MeCP-1 also occurs in the living cell. This was supported by the fact that MeCP-1-deficient cells showed much reduced repression of methylated genes.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Boyes, Joan/0000-0002-8705-9827; Bird, Adrian/0000-0002-8600-0372				ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; BUSSLINGER M, 1983, GLOBIN GENE EXPRESSI, P193; COTTEN M, 1989, MOL CELL BIOL, V9, P4479, DOI 10.1128/MCB.9.10.4479; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1988, J VIROL, V62, P3941, DOI 10.1128/JVI.62.11.3941-3946.1988; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIMURA FK, 1981, CELL, V23, P809, DOI 10.1016/0092-8674(81)90445-1; GILMAN M, 1987, CURRENT PROTOCOLS MO; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HILBERG F, 1987, P NATL ACAD SCI USA, V84, P5232, DOI 10.1073/pnas.84.15.5232; HOELLER M, 1988, Genes and Development, V2, P1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LANGNER KD, 1984, P NATL ACAD SCI-BIOL, V81, P2950, DOI 10.1073/pnas.81.10.2950; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; SOLAGE A, 1978, BIOCHEMISTRY-US, V17, P2934, DOI 10.1021/bi00607a036; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VARDIMON L, 1982, P NATL ACAD SCI-BIOL, V79, P1073, DOI 10.1073/pnas.79.4.1073; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEISSHAAR B, 1988, J MOL BIOL, V202, P255, DOI 10.1016/0022-2836(88)90456-1; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638	40	617	632	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1123	1134		10.1016/0092-8674(91)90267-3	http://dx.doi.org/10.1016/0092-8674(91)90267-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004419				2022-12-28	WOS:A1991FD55800010
J	HAMILTON, DP				HAMILTON, DP			ZAGURY INVESTIGATED	SCIENCE			English	Editorial Material																		1991, SCIENCE, V251, P1306	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1415	1415						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006415				2022-12-28	WOS:A1991FC85300016
J	TSAO, J; CHAPMAN, MS; AGBANDJE, M; KELLER, W; SMITH, K; WU, H; LUO, M; SMITH, TJ; ROSSMANN, MG; COMPANS, RW; PARRISH, CR				TSAO, J; CHAPMAN, MS; AGBANDJE, M; KELLER, W; SMITH, K; WU, H; LUO, M; SMITH, TJ; ROSSMANN, MG; COMPANS, RW; PARRISH, CR			THE 3-DIMENSIONAL STRUCTURE OF CANINE PARVOVIRUS AND ITS FUNCTIONAL IMPLICATIONS	SCIENCE			English	Article							RECEPTOR ATTACHMENT SITE; TOBACCO NECROSIS VIRUS; BEAN MOSAIC-VIRUS; GENOME ORGANIZATION; NUCLEOTIDE-SEQUENCE; 2.9-A RESOLUTION; 3.0-A RESOLUTION; PROTEIN GENE; MINUTE VIRUS; RNA	The three-dimensional atomic structure of a single-stranded DNA virus has been determined. Infectious virions of canine parvovirus contain 60 protein subunits that are predominantly VP-2. The central structural motif of VP-2 has the same topology (an eight-stranded anti-parallel beta-barrel) as has been found in many other icosahedral viruses but represents only about one-third of the capsid protein. There is a 22 angstrom (angstrom) long protrusion on the threefold axes, a 15 angstrom deep canyon circulating about each of the five cylindrical structures at the fivefold axes, and a 15 angstrom deep depression at the twofold axes. By analogy with rhinoviruses, the canyon may be the site of receptor attachment. Residues related to the antigenic properties of the virus are found on the threefold protrusions. Some of the amino termini of VP-2 run to the exterior in full but not empty virions, which is consistent with the observation that some VP-2 polypeptides in full particles can be cleaved by trypsin. Eleven nucleotides are seen in each of 60 symmetry-related pockets on the interior surface of the capsid and together account for 13 percent of the genome.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; CORNELL UNIV,NEW YORK STATE COLL VET MED,JAMES A BAKER INST ANIM HLTH,ITHACA,NY 14853; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Cornell University; University of Alabama System; University of Alabama Birmingham			Compans, Richard W/I-4087-2013; Keller, Walter/AAW-1501-2021; Smith, Thomas J/K-9086-2013	Compans, Richard W/0000-0003-2360-335X; Keller, Walter/0000-0002-2261-958X; Smith, Thomas J/0000-0003-3528-6793; Chapman, Michael/0000-0001-8525-8585				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ANDERSON LJ, 1989, NEW ENGL J MED, V321, P536, DOI 10.1056/NEJM198908243210809; ARNOTT S, 1973, J MOL BIOL, V81, P107, DOI 10.1016/0022-2836(73)90183-6; BASAK S, 1989, J VIROL, V63, P3164, DOI 10.1128/JVI.63.7.3164-3167.1989; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P224; CARTER BJ, 1987, ANIMAL VIRUS STRUCTU, P325; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHAPMAN M, UNPUB; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CLINTON GM, 1976, VIROLOGY, V74, P57, DOI 10.1016/0042-6822(76)90127-6; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; COTMORE SF, 1989, J VIROL, V63, P3902, DOI 10.1128/JVI.63.9.3902-3911.1989; ERICKSON JW, 1985, SCIENCE, V229, P625, DOI 10.1126/science.4023701; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1984, J MOL BIOL, V177, P735, DOI 10.1016/0022-2836(84)90047-0; JONGENEEL CV, 1986, J VIROL, V59, P564, DOI 10.1128/JVI.59.3.564-573.1986; KELLY DC, 1977, J VIROL, V21, P408, DOI 10.1128/JVI.21.1.408-410.1977; KIM S, 1989, J APPL CRYSTALLOGR, V22, P53, DOI 10.1107/S0021889888010878; Koch G., 1985, MOL BIOL POLIOVIRUS; KURTZMAN G, 1989, NEW ENGL J MED, V321, P519, DOI 10.1056/NEJM198908243210807; LILJAS L, 1982, J MOL BIOL, V159, P93, DOI 10.1016/0022-2836(82)90033-X; LUO M, 1988, J MOL BIOL, V200, P209, DOI 10.1016/0022-2836(88)90346-4; MATTHEWS BW, 1985, METHOD ENZYMOL, V115, P397; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; PARRISH CR, 1988, VIROLOGY, V163, P230, DOI 10.1016/0042-6822(88)90255-3; PARRISH CR, 1988, J GEN VIROL, V69, P1111, DOI 10.1099/0022-1317-69-5-1111; PARRISH CR, 1985, SCIENCE, V230, P1046, DOI 10.1126/science.4059921; PARRISH CR, 1988, VIROLOGY, V166, P293, DOI 10.1016/0042-6822(88)90500-4; RANZ AI, 1989, J GEN VIROL, V70, P2541, DOI 10.1099/0022-1317-70-10-2541; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REED AP, 1988, J VIROL, V62, P266, DOI 10.1128/JVI.62.1.266-276.1988; RHODE SL, 1985, J VIROL, V54, P630, DOI 10.1128/JVI.54.2.630-633.1985; ROBERTS MM, 1986, SCIENCE, V232, P1148, DOI 10.1126/science.3704642; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P570, DOI 10.1107/S0021889879013273; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; ROSSMANN MG, 1987, BIOESSAYS, V7, P99, DOI 10.1002/bies.950070302; ROSSMANN MG, 1988, VIROLOGY, V164, P373, DOI 10.1016/0042-6822(88)90550-8; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; Stauffacher C.V., 1987, CRYSTALLOGRAPHY MOL, P293; STUDDERT MJ, 1990, HDB PARVOVIRUSES, V2, P27; TATTERSALL P, 1988, P5; TATTERSALL P, 1977, J MOL BIOL, V111, P375, DOI 10.1016/S0022-2836(77)80060-0; TATTERSALL P, 1990, HDB PARVOVIRUSES, P123; TATTERSALL P, 1990, HDB PARVOVIRUSES, V1, P111; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WOBBE CR, 1984, BIOCHEMISTRY-US, V23, P6565, DOI 10.1021/bi00321a044; 1985, EUR J BIOCHEM, V150, P1	59	428	458	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1456	1464		10.1126/science.2006420	http://dx.doi.org/10.1126/science.2006420			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006420				2022-12-28	WOS:A1991FC85300040
J	HYMAN, C; HOFER, M; BARDE, YA; JUHASZ, M; YANCOPOULOS, GD; SQUINTO, SP; LINDSAY, RM				HYMAN, C; HOFER, M; BARDE, YA; JUHASZ, M; YANCOPOULOS, GD; SQUINTO, SP; LINDSAY, RM			BDNF IS A NEUROTROPHIC FACTOR FOR DOPAMINERGIC-NEURONS OF THE SUBSTANTIA-NIGRA	NATURE			English	Article							INVITRO MATURATION; MESENCEPHALIC NEURONS; GROWTH-FACTOR; CELLS; SURVIVAL; BRAIN; CULTURES; DENSITY; MPTP	Brain-derived neurotrophic factor (BDNF), present in minute amounts in the adult central nervous system 1, is a member of the nerve growth factor (NGF) (ref. 2) family, which includes neurotrophin-3 (NT-3) (refs 3-5). NGF, BDNF and NT-3 all support survival of subpopulations of neural crest-derived sensory neurons 3-5; most sympathetic neurons are responsive to NGF (ref. 2), but not to BDNF 1,6,7; NT-3 and BDNF, but not NGF (ref. 6), promote survival of sensory neurons of the nodose ganglion 3-8. BDNF, but not NGF, supports the survival of cultured retinal ganglion cells 9 but both NGF and BDNF promote the survival of septal cholinergic neurons in vitro 10,11. However, knowledge of their precise physiological role in development and maintenance of the nervous system neurons is still limited. The BDNF gene is expressed in many regions of the adult CNS 12-14, including the striatum 12. A protein partially purified from bovine striatum, a target of nigral dopaminergic neurons, with characteristics apparently similar to those of BDNF, can enhance the survival of dopaminergic neurons in mesencephalic cultures 15. BDNF seems to be a trophic factor for mesencephalic dopaminergic neurons, increasing their survival, including that of neuronal cells which degenerate in Parkinson's disease. Here we report the effects of BDNF on the survival of dopaminergic neurons of the developing substantia nigra.	MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, W-8033 PLANEGG, GERMANY	Max Planck Society	HYMAN, C (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Barde, Yves/F-6019-2011; Lindsay, Ronald/GQP-8001-2022	Barde, Yves/0000-0002-7627-461X				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; DALTOSO R, 1988, J NEUROSCI, V8, P733; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DENISDONINI S, 1983, J NEUROSCI, V3, P2292; DIPORZIO U, 1980, NATURE, V288, P370, DOI 10.1038/288370a0; FERRARI G, 1989, DEV BIOL, V133, P140, DOI 10.1016/0012-1606(89)90305-9; HARTIKKA J, 1988, J NEUROSCI, V8, P2967; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KNUSEL B, 1990, J NEUROSCI, V10, P558; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, BRAIN RES, V292, P390; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MICHEL PP, 1990, J NEUROCHEM, V54, P1102, DOI 10.1111/j.1471-4159.1990.tb01935.x; OTTO D, 1990, J NEUROSCI, V10, P1912; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; PROCHIANTZ A, 1979, P NATL ACAD SCI USA, V76, P5387, DOI 10.1073/pnas.76.10.5387; PROCHIANTZ A, 1981, NATURE, V293, P570, DOI 10.1038/293570a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SANCHEZRAMOS J, 1986, NEUROSCI LETT, V72, P215, DOI 10.1016/0304-3940(86)90083-2; SANCHEZRAMOS JR, 1988, J NEUROCHEM, V50, P1934, DOI 10.1111/j.1471-4159.1988.tb02500.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANCOPOULOS GD, IN PRESS COLD SPRING; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1	34	1330	1377	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1991	350	6315					230	232		10.1038/350230a0	http://dx.doi.org/10.1038/350230a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005978				2022-12-28	WOS:A1991FC77900057
J	JABLON, S; HRUBEC, Z; BOICE, JD				JABLON, S; HRUBEC, Z; BOICE, JD			CANCER IN POPULATIONS LIVING NEAR NUCLEAR-FACILITIES - A SURVEY OF MORTALITY NATIONWIDE AND INCIDENCE IN 2 STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD LEUKEMIA; POWER PLANT; INSTALLATIONS; PATTERNS; VICINITY; SITES	Reports from the United Kingdom have described increases in leukemia and lymphoma among young persons living near certain nuclear installations. Because of concerns raised by these reports, a mortality survey was conducted in populations living near nuclear facilities in the United States. All facilities began service before 1982. Over 900 000 cancer deaths occurred from 1950 through 1984 in 107 counties with or near nuclear installations. Each study county was matched for comparison to three "control counties" in the same region. There were 1.8 million cancer deaths in the 292 control counties during the 35 years studied. Deaths due to leukemia or other cancers were not more frequent in the study counties than in the control counties. For childhood leukemia mortality, the relative risk comparing the study counties with their controls before plant start-up was 1.08, while after start-up it was 1.03. For leukemia mortality at all ages, the relative risks were 1.02 before start-up and 0.98 after. For counties in two states, cancer incidence data were also available. For one facility, the standardized registration ratio for childhood leukemia was increased significantly after start-up. However, the increase also antedated the operation of this facility. The study is limited by the correlational approach and the large size of the geographic areas (counties) used. It does not prove the absence of any effect. If, however, any excess cancer risk was present in US counties with nuclear facilities, it was too small to be detected with the methods employed.			JABLON, S (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892, USA.							[Anonymous], 1990, HLTH EFFECTS EXPOSUR; ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BLOT WJ, 1978, NEW ENGL J MED, V299, P620, DOI 10.1056/NEJM197809212991202; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CLAPP RW, 1987, LANCET, V2, P1324; CLARKE EA, 1989, CHILDHOOD LEUKAEMIA; COOKMOZAFFARI P, 1989, LANCET, V2, P1145; COOKMOZAFFARI PJ, 1989, BRIT J CANCER, V59, P476, DOI 10.1038/bjc.1989.99; COOKMOZAFFARI PJ, 1987, CANCER INCIDENCE MOR; CRUMP KS, 1987, AM J EPIDEMIOL, V126, P127, DOI 10.1093/oxfordjournals.aje.a114644; DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; DOUSSET M, 1989, HEALTH PHYS, V56, P875, DOI 10.1097/00004032-198906000-00005; ENSTROM JE, 1983, AM J PUBLIC HEALTH, V73, P83, DOI 10.2105/AJPH.73.1.83; EWINGS PD, 1989, BRIT MED J, V299, P289, DOI 10.1136/bmj.299.6694.289; FORMAN D, 1987, NATURE, V329, P499, DOI 10.1038/329499a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HEASMAN MA, 1986, LANCET, V1, P266; HILL C, 1990, NATURE, V347, P755, DOI 10.1038/347755a0; JABLON S, 1990, NIH90874 PHS DEP HLT; Kemeny J, 1979, REPORT PRESIDENTS CO; KINLEN L, 1988, LANCET, V2, P1323; RIGGAN WB, 1983, US CANCER MORTALITY; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; VIEL JF, 1990, BRIT MED J, V300, P580, DOI 10.1136/bmj.300.6724.580; 1989, 3RD REPORT INCIDENCE; 1988, 2ND REPORT INVESTIGA; 1984, INVESTIGATION POSSIB; 1986, 1ST REPORT IMPLICATI; 1987, NCRP92 NAT COUNC RAD; 1990, PNL7410 HEDR DOC	30	79	80	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1403	1408						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB550	1999880				2022-12-28	WOS:A1991FB55000020
J	TALBOT, JD; MARRETT, S; EVANS, AC; MEYER, E; BUSHNELL, MC; DUNCAN, GH				TALBOT, JD; MARRETT, S; EVANS, AC; MEYER, E; BUSHNELL, MC; DUNCAN, GH			MULTIPLE REPRESENTATIONS OF PAIN IN HUMAN CEREBRAL-CORTEX	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; SOMATIC SUBMODALITY DISTRIBUTION; HUMAN SOMATOSENSORY CORTEX; RESPONSE CHARACTERISTICS; EPILEPTIC SEIZURES; CINGULATE CORTEX; M FASCICULARIS; PET IMAGES; NEURONS; MONKEY	The representation of pain in the cerebral cortex is less well understood than that of any other sensory system. However, with the use of magnetic resonance imaging and positron emission tomography in humans, it has now been demonstrated that painful heat causes significant activation of the contralateral anterior cingulate, secondary somatosensory, and primary somatosensory cortices. This contrasts with the predominant activation of primary somatosensory cortex caused by vibrotactile stimuli in similar experiments. Furthermore, the unilateral cingulate activation indicates that this forebrain area, thought to regulate emotions, contains an unexpectedly specific representation of pain.	UNIV MONTREAL, FAC MED DENT, NEUROPHYSIOL COMPORTEMENTALE LAB, MONTREAL H3C 3J7, QUEBEC, CANADA; MONTREAL NEUROL HOSP & INST, MCCONNELL BRAIN IMAGING CTR, POSITRON IMAGING LABS, MONTREAL H3A 2B4, QUEBEC, CANADA	Universite de Montreal; McGill University				Marrett, Sean/0000-0001-8179-6511				ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P108; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DEANE GE, 1961, J EXP PSYCHOL, V61, P489, DOI 10.1037/h0049220; DONG WK, 1989, BRAIN RES, V484, P314, DOI 10.1016/0006-8993(89)90375-2; DOSTROVSKY JR, 1990, APR S NEUR NOC KAW; DUCLAUX R, 1980, J NEUROPHYSIOL, V43, P1; Evans A.C., 1989, PROC SPIE, V1092, P264, DOI [10.1117/12.953267, DOI 10.1117/12.953267]; EVANS AC, 1988, J CEREBR BLOOD F MET, V8, P513, DOI 10.1038/jcbfm.1988.92; EVANS AC, IN PRESS IEEE T MED; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1987, J NEUROSURG, V67, P34, DOI 10.3171/jns.1987.67.1.0034; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; HENSEL H, 1971, PFLUG ARCH EUR J PHY, V329, P1, DOI 10.1007/BF00586896; Hurt R W, 1974, Clin Neurosurg, V21, P334; KENSHALO DR, 1988, BRAIN RES, V454, P378, DOI 10.1016/0006-8993(88)90841-4; LARSON MA, 1987, J NEUROSCI, V7, P547; LASSEN NA, 1978, SCI AM, V239, P62, DOI 10.1038/scientificamerican1078-62; MACLEAN PD, 1949, PSYCHOSOM MED, V11, P338, DOI 10.1097/00006842-194911000-00003; MAIXNER W, 1989, J NEUROPHYSIOL, V62, P437, DOI 10.1152/jn.1989.62.2.437; MANTZ J, 1988, NEUROSCIENCE, V27, P517, DOI 10.1016/0306-4522(88)90285-0; MELZACK R, 1968, P423; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; MUSIL SY, 1988, J COMP NEUROL, V272, P203, DOI 10.1002/cne.902720205; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Penfield W, 1954, EPILEPSY FUNCTIONAL, P77; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; RAINVILLE P, 1989, AM PAIN SOC ABSTR, V8, P64; REIMAN EM, 1989, SCIENCE, V243, P1071, DOI 10.1126/science.2784226; ROBINSON CJ, 1980, J COMP NEUROL, V192, P93, DOI 10.1002/cne.901920106; SANTO JL, 1990, PAIN, V41, P55, DOI 10.1016/0304-3959(90)91109-V; SUMINO R, 1981, BRAIN RES REV, V3, P105, DOI 10.1016/0165-0173(81)90001-1; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1987, PAIN, V30, P221, DOI 10.1016/0304-3959(87)91078-5; TSUBOKAWA T, 1981, BRAIN RES, V217, P179, DOI 10.1016/0006-8993(81)90197-9; VOGT BA, 1979, SCIENCE, V204, P205, DOI 10.1126/science.107587; White JC., 1969, PAIN NEUROSURGEON, P6; WILLER JC, 1984, BRAIN, V107, P1095, DOI 10.1093/brain/107.4.1095; WILSON DH, 1974, CONFIN NEUROL, V36, P61; YASUI Y, 1988, J COMP NEUROL, V274, P91, DOI 10.1002/cne.902740109; YOUNG GB, 1986, ANN NEUROL, V19, P412, DOI 10.1002/ana.410190423; YOUNG GB, 1983, BRAIN, V106, P537, DOI 10.1093/brain/106.3.537	49	761	774	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1991	251	4999					1355	1358		10.1126/science.2003220	http://dx.doi.org/10.1126/science.2003220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003220				2022-12-28	WOS:A1991FB73300043
J	KROOK, JE; MOERTEL, CG; GUNDERSON, LL; WIEAND, HS; COLLINS, RT; BEART, RW; KUBISTA, TP; POON, MA; MEYERS, WC; MAILLIARD, JA; TWITO, DI; MORTON, RF; VEEDER, MH; WITZIG, TE; CHA, S; VIDYARTHI, SC				KROOK, JE; MOERTEL, CG; GUNDERSON, LL; WIEAND, HS; COLLINS, RT; BEART, RW; KUBISTA, TP; POON, MA; MEYERS, WC; MAILLIARD, JA; TWITO, DI; MORTON, RF; VEEDER, MH; WITZIG, TE; CHA, S; VIDYARTHI, SC			EFFECTIVE SURGICAL ADJUVANT THERAPY FOR HIGH-RISK RECTAL-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREOPERATIVE IRRADIATION; CANCER; SURVIVAL; RADIATION; 5-FLUOROURACIL; RADIOTHERAPY; FLUOROURACIL; COMBINATION; TRIAL; CELLS	Background. Radiation therapy as an adjunct to surgery for rectal cancer has been shown to reduce local recurrence but has not improved survival. In a previous study, combined radiation and chemotherapy improved survival significantly as compared with surgery alone, but not as compared with adjuvant radiation, which many regard as standard therapy. We designed a combination regimen to optimize the contribution of chemotherapy, decrease recurrence, and improve survival as compared with adjuvant radiation alone. Methods. Two hundred four patients with rectal carcinoma that was either deeply invasive or metastatic to regional lymph nodes were randomly assigned to postoperative radiation alone (4500 to 5040 cGy) or to radiation plus fluorouracil, which was both preceded and followed by a cycle of systemic therapy with fluorouracil plus semustine (methyl-CCNU). Results. After a median follow-up of more than seven years, the combined therapy had reduced the recurrence of rectal cancer by 34 percent (P = 0.0016; 95 percent confidence interval, 12 to 50 percent). Initial local recurrence was reduced by 46 percent (P = 0.036; 95 percent confidence interval, 2 to 70 percent), and distant metastasis by 37 percent (P = 0.011; 95 percent confidence interval, 9 to 57 percent). In addition, combined therapy reduced the rate of cancer-related deaths by 36 percent (P = 0.0071; 95 percent confidence interval, 14 to 53 percent) and the overall death rate by 29 percent (P = 0.025; 95 percent confidence interval, 7 to 45 percent). Its acute toxic effects included nausea, vomiting, diarrhea, leukopenia, and thrombocytopenia. These effects were seldom severs. Severe, delayed treatment-related reactions, usually small-bowel obstruction requiring surgery, occurred in 6.7 percent of all patients receiving radiation, and the frequencies of these complications were comparable in both treatment groups. Conclusions. The combination of postoperative local therapy with radiation plus fluorouracil and systemic therapy with a fluorouracil-based regimen significantly and substantively improves the results of therapy for rectal carcinoma with a poor prognosis, as compared with postoperative radiation alone.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; DULUTH COMMUNITY CLIN ONCOL PROGRAM, DULUTH, MN USA; MAYO CLIN, SCOTTSDALE, AZ USA; BILLINGS CLIN, BILLINGS, MT USA; IOWA ONCOL RES ASSOC, COMMUNITY CLIN ONCOL PROGRAM, DES MOINES, IA USA; ILLINOIS ONCOL RES ASSOC, COMMUNITY CLIN ONCOL PROGRAM, PEORIA, IL USA; CREIGHTON UNIV, NEBRASKA ONCOL GRP, OMAHA, NE 68178 USA; SASKATCHEWAN CANC FDN, REGINA, SASKATCHEWAN, CANADA; UNIV NEBRASKA, MED CTR, OMAHA, NE 68105 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Creighton University; University of Nebraska System; University of Nebraska Medical Center; Duke University					NATIONAL CANCER INSTITUTE [U10CA037404, P01CA031224, U10CA025224] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31224, CA-25224, CA-37404] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, NEW ENGL J MED, V312, P1465; BALSLEV IB, 1986, CANCER-AM CANCER SOC, V58, P22, DOI 10.1002/1097-0142(19860701)58:1<22::AID-CNCR2820580106>3.0.CO;2-Q; BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BYFIELD JE, 1982, INT J RADIAT ONCOL, V8, P1923, DOI 10.1016/0360-3016(82)90451-5; COX DR, 1972, J R STAT SOC B, V34, P187; DOUGLASS HO, 1986, NEW ENGL J MED, V315, P1294; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; GERARD A, 1988, ANN SURG, V208, P606, DOI 10.1097/00000658-198811000-00011; GONCHOROFF NJ, 1990, CYTOMETRY, V11, P642, DOI 10.1002/cyto.990110513; GUNDERSON LL, 1985, INT RAD ONCOL BIOL P, V11, P379; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HEIDELBERGER C, 1958, CANCER RES, V18, P305; HIGGINS GA, 1986, CANCER, V58, P352, DOI 10.1002/1097-0142(19860715)58:2<352::AID-CNCR2820580226>3.0.CO;2-D; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MANTEL N, 1959, J NATL CANCER I, V22, P719; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1969, LANCET, V2, P865; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; RIDER WD, 1977, CAN J SURG, V20, P335; ROSWIT B, 1975, CANCER, V35, P1597, DOI 10.1002/1097-0142(197506)35:6<1597::AID-CNCR2820350618>3.0.CO;2-S; SMITH AN, 1984, BRIT J SURG, V71, P21; VIETTI T, 1971, JNCI-J NATL CANCER I, V47, P865; WASSIF SB, 1979, ADJUVANT THERAPY CAN, V2, P613; WEAVER D, 1990, P AN M AM SOC CLIN, V9, P106; 1986, SUGI SUPPLEMENTAL LI, P662	28	1529	1565	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					709	715		10.1056/NEJM199103143241101	http://dx.doi.org/10.1056/NEJM199103143241101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997835	Bronze			2022-12-28	WOS:A1991FB55600001
J	NOLAN, GP; GHOSH, S; LIOU, HC; TEMPST, P; BALTIMORE, D				NOLAN, GP; GHOSH, S; LIOU, HC; TEMPST, P; BALTIMORE, D			DNA-BINDING AND I-KAPPA-B INHIBITION OF THE CLONED P65 SUBUNIT OF NF-KAPPA-B, A REL-RELATED POLYPEPTIDE	CELL			English	Article							TRANSCRIPTION FACTOR; PROTO-ONCOGENE; V-REL; C-REL; RETICULOENDOTHELIOSIS VIRUS; REGULATORY SEQUENCE; ENHANCER SEQUENCES; CELLULAR PROTEINS; GENE-EXPRESSION; NUCLEAR FACTOR	The sequence and biochemical properties of the product of the cloned cDNA for the p65 subunit of nuclear factor kappa-B (NF-kappa-B) have been determined. The cDNA has an open reading frame of 549 amino acids capable of encoding a 60 kd protein. NF-kappa-B p65 contains an amino-terminal region of 320 amino acids with extensive similarity to the oncogene c-rel and lesser similarity to NF-kappa-B p50. In vitro translated p65 forms a DNA-binding complex with NF-kappa-B p50, and the binding of this complex can be specifically inhibited by purified I-kappa-B. Progressive carboxy-terminal deletions of p65 show that, contrary to previous assumptions, p65 does include a DNA-binding domain that in vivo might become activated only through hetero-oligomerization with p50. DNA binding by truncated p65 is inhibited by I-kappa-B, thus mapping the I-kappa-B interaction domain to the rel-homologous region and suggesting that I-kappa-B exerts its inhibitory effect upon NF-kappa-B primarily through interaction with p65.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; ROCKEFELLER UNIV,NEW YORK,NY 10021	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Rockefeller University	NOLAN, GP (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; Maniatis T., 1982, MOL CLONING; MORRISON LE, 1989, ONCOGENE, V4, P677; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	46	592	606	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					961	969		10.1016/0092-8674(91)90320-X	http://dx.doi.org/10.1016/0092-8674(91)90320-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001591				2022-12-28	WOS:A1991FA94000013
J	HUNT, AJ; DAVIES, PM; WEATHERBURN, P; COXON, APM; MCMANUS, TJ				HUNT, AJ; DAVIES, PM; WEATHERBURN, P; COXON, APM; MCMANUS, TJ			CHANGES IN SEXUAL-BEHAVIOR IN A LARGE COHORT OF HOMOSEXUAL MEN IN ENGLAND AND WALES, 1988-9	BRITISH MEDICAL JOURNAL			English	Article									UNIV ESSEX,COLCHESTER CO4 3SQ,ESSEX,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	University of Essex; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	HUNT, AJ (corresponding author), S BANK POLYTECH,DEPT SOCIAL SCI,PROJECT SIGMA,LONDON SE1 0AA,ENGLAND.		Weatherburn, Peter/AAC-2701-2019	Weatherburn, Peter/0000-0002-4950-6163				GELLAN MCA, 1986, LANCET, V2, P920; HUNT AJ, 1990, GENITOURIN MED, V66, P423; MCMANUS TJ, 1987, BRIT J SEX MED, V20, P110; WEATHERBURN P, 1990, AIDS Care, V2, P319, DOI 10.1080/09540129008257747; 1988, SHORT TERM PREDICTIO	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					505	506		10.1136/bmj.302.6775.505	http://dx.doi.org/10.1136/bmj.302.6775.505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB055	2012847	Green Published, Bronze			2022-12-28	WOS:A1991FB05500020
J	NORTH, CS; ALPERS, DH; HELZER, JE; SPITZNAGEL, EL; CLOUSE, RE				NORTH, CS; ALPERS, DH; HELZER, JE; SPITZNAGEL, EL; CLOUSE, RE			DO LIFE EVENTS OR DEPRESSION EXACERBATE INFLAMMATORY BOWEL-DISEASE - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						INFLAMMATORY BOWEL DISEASE; PSYCHIATRIC STATUS RATING SCALES; DEPRESSION; COLITIS, ULCERATIVE; CROHN DISEASE	CROHNS-DISEASE; PSYCHIATRIC-ILLNESS; ULCERATIVE-COLITIS; ASSOCIATION; DISORDERS	Objective: To determine whether depressed mood or life events are associated with an exacerbation of inflammatory bowel disease. Design: A prospective study of a consecutive sample of patients with relapsing inflammatory bowel disease, followed by monthly questionnaires and periodic office visits. Setting: A referral-based gastroenterology clinic at a medical school. Patients: A consecutive sample of 32 patients with inflammatory bowel disease who had had at least one relapse in a 2-year period after entry into the study. Measurements and Main Results: The Social Readjustment Rating Scale (measuring life events), the Beck Depression Inventory (a visual analog scale for depressed mood) and an inventory of intestinal symptoms were completed monthly by each subject with a 78% rate of compliance. A mean of 2.2 exacerbations was seen per subject during the study period. Life events were not temporally associated with changes in intestinal symptoms. Significant associations were found between intestinal symptoms and the two mood scales (P < 0.05 for each), but no directionality in symptom occurrence could be detected in a time-lagged analysis. The results were similar when the months preceding exacerbations of inflammatory bowel disease were analyzed separately. Conclusions: Although these findings suggest that mood changed concurrently with exacerbation of inflammatory bowel disease, no evidence indicated that stressful life events or depressed mood precipitated exacerbations in this study group.	WASHINGTON UNIV, SCH MED, DEPT BIOSTAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MATH, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	NORTH, CS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, 4940 AUDUBON AVE, ST LOUIS, MO 63110 USA.							ANDREWS H, 1987, GUT, V28, P1600, DOI 10.1136/gut.28.12.1600; ARAPAKIS G, 1986, PSYCHOTHER PSYCHOSOM, V46, P171, DOI 10.1159/000287981; BACHMAN JG, 1984, PUBLIC OPIN QUART, V48, P491, DOI 10.1086/268845; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; CAMPBELL D, 1986, GASTROENTEROLOGY, V90, P1364; CREED F, 1988, GUT, V29, P235, DOI 10.1136/gut.29.2.235; DROSSMAN DA, 1986, STRESS MEDICINE, V2, P119, DOI 10.1002/smi.2460020209; DRUSS RG, 1969, ARCH GEN PSYCHIAT, V20, P419; FAVA GA, 1977, PSYCHOTHER PSYCHOSOM, V27, P100; FINLAYJONES R, 1981, AUST NZ J PSYCHIAT, V15, P229, DOI 10.3109/00048678109159440; FREEMAN H, 1986, STRESS MEDICINE, V2, P291, DOI 10.1002/smi.2460020404; GAZZARD BG, 1978, BRIT MED J, V2, P1117, DOI 10.1136/bmj.2.6145.1117; GERBERT B, 1980, Journal of Behavioral Medicine, V3, P41, DOI 10.1007/BF00844913; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; GOLDBERG D, 1970, GUT, V11, P459, DOI 10.1136/gut.11.6.459; HELZER JE, 1982, DIGEST DIS SCI, V27, P513, DOI 10.1007/BF01296730; HELZER JE, 1984, GASTROENTEROLOGY, V86, P324; HELZER JE, 1985, COLON RECTAL ANAL SU, P329; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; LATIMER PR, 1978, PSYCHOL MED, V8, P649, DOI 10.1017/S0033291700018857; Lourens P J, 1973, Ala J Med Sci, V10, P285; MURRAY JB, 1984, J GEN PSYCHOL, V110, P201, DOI 10.1080/00221309.1984.9709964; NORTH CS, 1990, AM J PSYCHIAT, V147, P974; PAYKEL ES, 1976, BRIT J MED PSYCHOL, V49, P237, DOI 10.1111/j.2044-8341.1976.tb02370.x; ROSE JDR, 1986, GUT, V27, P1025, DOI 10.1136/gut.27.9.1025; SCHWARTZ RA, 1982, INT J PSYCHIAT MED, V12, P67, DOI 10.2190/FL8Y-1WU6-1N5L-1FQV; SUDMAN S, 1974, RESPONSE EFFECTS SUR, P93; TARTER RE, 1987, INT J PSYCHIAT MED, V17, P173; WELLS KB, 1988, AM J PSYCHIAT, V145, P976; WHYBROW PC, 1968, PSYCHOSOM MED, V30, P209, DOI 10.1097/00006842-196803000-00006; WHYBROW PC, 1973, EMOTIONAL FACTORS GA, P82; WRIGHT JP, 1987, DIGEST DIS SCI, V32, P164, DOI 10.1007/BF01297104; YOUNG SJ, 1976, GASTROENTEROLOGY, V70, P162	33	135	136	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					381	386		10.7326/0003-4819-114-5-381	http://dx.doi.org/10.7326/0003-4819-114-5-381			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992880				2022-12-28	WOS:A1991EZ17400006
J	BARNARD, SM; WALT, DR				BARNARD, SM; WALT, DR			CHEMICAL SENSORS BASED ON CONTROLLED-RELEASE POLYMER SYSTEMS	SCIENCE			English	Article							FIBER	A novel chemical sensor has been developed in which the polymer ethylene-vinyl acetate is used as a controlled-release system to deliver reagents to the sensing region of an optical fiber for a homogeneous competitive immunoassay based on fluorescence energy transfer. A competition reaction is used to enable continuous measurements of the solution antigen concentration. More generally, the technique allows irreversible indicating chemistries to be used in the construction of chemical sensors that can measure continuously for long periods. Although the sensor configuration has not been optimized in all respects, data are presented for a model system in which a fluorescein-labeled antibody and Texas Red-labeled immunoglobulin G (IgG) are used.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155	Tufts University								ANDERSON FP, 1988, CLIN CHEM, V34, P1417; Bawa R., 1985, J CONTR RELEASE, V1, P259, DOI [10.1016/0168-3659(85)90002-1, DOI 10.1016/0168-3659(85)90002-1]; BRIGHT FV, 1990, ANAL CHEM, V62, P1065, DOI 10.1021/ac00209a019; CHRISTIAN LM, 1988, TALANTA, V35, P119, DOI 10.1016/0039-9140(88)80049-3; Forster T., 1959, DISCUSS FARADAY SOC, V27, P7, DOI DOI 10.1039/DF9592700007; HELLER J, 1980, BIOMATERIALS, V1, P51, DOI 10.1016/0142-9612(80)90060-5; INMAN SM, 1989, ANAL CHIM ACTA, V217, P249, DOI 10.1016/S0003-2670(00)80407-9; JANATA J, 1990, ANAL CHEM, V62, pR33, DOI 10.1021/ac00211a017; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LUO SF, 1989, ANAL CHEM, V61, P174, DOI 10.1021/ac00177a019; NISONOFF A, 1985, INTRO MOL IMMUNOLOGY, P29; ODONNELL CM, 1979, ANAL CHEM, V51, pA33, DOI 10.1021/ac50037a003; SCHULMAN SG, 1985, MOL LUMINESCENCE S 1, V77, P1; SEITZ WR, 1988, CRC CR REV ANAL CHEM, V19, P135, DOI 10.1080/10408348808542810; SOINI E, 1979, CLIN CHEM, V25, P353; TROMBERG BJ, 1987, ANAL CHEM, V59, P1226, DOI 10.1021/ac00135a033	16	52	55	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					927	929		10.1126/science.2000492	http://dx.doi.org/10.1126/science.2000492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000492				2022-12-28	WOS:A1991EY62900040
J	YELLEN, G; JURMAN, ME; ABRAMSON, T; MACKINNON, R				YELLEN, G; JURMAN, ME; ABRAMSON, T; MACKINNON, R			MUTATIONS AFFECTING INTERNAL TEA BLOCKADE IDENTIFY THE PROBABLE PORE-FORMING REGION OF A K+ CHANNEL	SCIENCE			English	Article							POTASSIUM CHANNELS; GIANT-AXONS; FLUX RATIO; IONS; CHARYBDOTOXIN; DROSOPHILA	The active site of voltage-activated potassium channels is a transmembrane aqueous pore that permits ions to permeate the cell membrane in a rapid yet highly selective manner. A useful probe for the pore of potassium-selective channels is the organic ion tetraethylammonium (TEA), which binds with millimolar affinity to the intracellular opening of the pore and blocks potassium current. In the potassium channel encoded by the Drosophila Shaker gene, an amino acid residue that specifically affects the affinity for intracellular TEA has now been identified by site-directed mutagenesis. This residue is in the middle of a conserved stretch of 18 amino acids that separates two locations that are both near the external opening of the pore. These findings suggest that this conserved region is intimately involved in the formation of the ion conduction pore of voltage-activated potassium channels. Further, a stretch of only eight amino acid residues must traverse 80 percent of the transmembrane electric potential difference.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS CHEM,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School	YELLEN, G (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.			Yellen, Gary/0000-0003-4228-7866	NIGMS NIH HHS [GM4399] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; BEGENISICH T, 1980, J GEN PHYSIOL, V76, P83, DOI 10.1085/jgp.76.1.83; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; FRENCH RJ, 1981, BIOPHYS J, V34, P271, DOI 10.1016/S0006-3495(81)84849-7; GUY HR, 1989, MONOVALENT CATIONS B; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; HOROWICZ P, 1968, J GEN PHYSIOL, V51, pS193; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KOPPENHOFER E, 1969, PFLUG ARCH EUR J PHY, V313, P361, DOI 10.1007/BF00593959; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MACKINNON R, IN PRESS NATURE; MACKINNON RN, UNPUB; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SPALDING BC, 1981, AM J PHYSIOL, V241, pC68, DOI 10.1152/ajpcell.1981.241.1.C68; STANFIELD PR, 1983, REV PHYSIOL BIOCH P, V97, P1, DOI 10.1007/BFb0035345; Stryer L., 1988, BIOCHEMISTRY-US; TASAKI I, 1957, J GEN PHYSIOL, V40, P859, DOI 10.1085/jgp.40.6.859; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; VILLARROEL A, 1988, PFLUG ARCH EUR J PHY, V413, P118, DOI 10.1007/BF00582521; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YELLEN G, 1987, ANNU REV BIOPHYS BIO, V16, P227	32	562	569	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					939	942		10.1126/science.2000494	http://dx.doi.org/10.1126/science.2000494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000494				2022-12-28	WOS:A1991EY62900045
J	SANTAMARINAFOJO, S; BREWER, HB				SANTAMARINAFOJO, S; BREWER, HB			THE FAMILIAL HYPERCHYLOMICRONEMIA SYNDROME - NEW INSIGHTS INTO UNDERLYING GENETIC-DEFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-C-II; LIPOPROTEIN-LIPASE DEFICIENCY; AMYLASE ACTIVITY; MUTATION; PATIENT; HYPERTRIGLYCERIDEMIA; ABETALIPOPROTEINEMIA; PANCREATITIS; HYPERLIPEMIA				SANTAMARINAFOJO, S (corresponding author), NHLBI,MOLEC DIS BRANCH,9000 ROCKVILLE PIKE,BLDG 10,ROOM 7N117,BETHESDA,MD 20892, USA.							AMEIS D, 1990, ARTERIOSCLEROSIS, V10, pA765; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BAGGIO G, 1986, J CLIN INVEST, V77, P520, DOI 10.1172/JCI112332; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BRUIN T, 1990, 55TH M EUR ATH SOC B; BRUNZELL JD, 1983, J LIPID RES, V24, P12; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CONNELLY PW, 1987, P NATL ACAD SCI USA, V84, P270, DOI 10.1073/pnas.84.1.270; CONNELLY PW, 1987, J CLIN INVEST, V80, P1597, DOI 10.1172/JCI113246; COX DW, 1988, J MED GENET, V25, P649, DOI 10.1136/jmg.25.10.649; CRECCHIO C, 1990, BIOCHEM BIOPH RES CO, V168, P1118, DOI 10.1016/0006-291X(90)91145-I; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DICHEK HL, 1991, J BIOL CHEM, V266, P473; EMI M, 1990, J BIOL CHEM, V265, P5910; EMI M, 1990, AM J HUM GENET, V47, P107; FALLAT RW, 1973, JAMA-J AM MED ASSOC, V225, P1331, DOI 10.1001/jama.225.11.1331; FOJO SS, 1989, J CLIN INVEST, V84, P1215, DOI 10.1172/JCI114287; FOJO SS, 1988, J CLIN INVEST, V82, P1489, DOI 10.1172/JCI113756; FOJO SS, 1989, J BIOL CHEM, V264, P20839; FOJO SS, 1988, J BIOL CHEM, V263, P17913; FOJO SS, IN PRESS HYPERTRIGLY; FUNKE H, 1990, ARTERIOSCLEROSIS, V10, pA830; HATA A, 1990, AM J HUM GENET, V47, P721; HATA A, 1990, NUCLEIC ACIDS RES, V18, P407; ILLINGWORTH DR, 1980, ARCH NEUROL-CHICAGO, V37, P659, DOI 10.1001/archneur.1980.00500590083015; KARMALLY W, 1989, CIRCULATION, V80, P332; KIHARA S, 1989, NEW ENGL J MED, V320, P1255, DOI 10.1056/NEJM198905113201906; LANGLOIS S, 1989, P NATL ACAD SCI USA, V86, P948, DOI 10.1073/pnas.86.3.948; LESSER PB, 1975, ANN INTERN MED, V82, P795, DOI 10.7326/0003-4819-82-6-795; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; PARKER F, 1970, J CLIN INVEST, V49, P2172, DOI 10.1172/JCI106436; PARTIN JS, 1974, GASTROENTEROLOGY, V67, P107; SPRECHER DL, 1988, J LIPID RES, V29, P273; WARSHAW AL, 1975, ANN SURG, V182, P72, DOI 10.1097/00000658-197507000-00014	34	52	53	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					904	908		10.1001/jama.265.7.904	http://dx.doi.org/10.1001/jama.265.7.904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992190				2022-12-28	WOS:A1991EX58700045
J	DENTON, M; MORGAN, MS; WHITE, RR				DENTON, M; MORGAN, MS; WHITE, RR			QUALITY OF PRESCRIBING OF INTRAVENOUS ANTIBIOTICS IN A DISTRICT GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									WALTON HOSP,DEPT MICROBIOL,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND	University of Liverpool; Walton Centre				morgan, marina/0000-0002-9336-481X				BAIN PG, 1990, BRIT MED J, V300, P1463; BAKKERWOUDENBERG IAJM, 1988, J ANTIMICROB CHEMOTH, V21, P145, DOI 10.1093/jac/21.2.145; BROWN B, 1989, ANN INTERN MED, V110, P247, DOI 10.7326/0003-4819-110-3-247; ZALIN AM, 1989, BRIT MED J, V299, P1279, DOI 10.1136/bmj.299.6710.1279	4	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					327	328		10.1136/bmj.302.6772.327-a	http://dx.doi.org/10.1136/bmj.302.6772.327-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001508	Bronze, Green Published			2022-12-28	WOS:A1991EX56900024
J	LAWSON, DM; ARTYMIUK, PJ; YEWDALL, SJ; SMITH, JMA; LIVINGSTONE, JC; TREFFRY, A; LUZZAGO, A; LEVI, S; AROSIO, P; CESARENI, G; THOMAS, CD; SHAW, WV; HARRISON, PM				LAWSON, DM; ARTYMIUK, PJ; YEWDALL, SJ; SMITH, JMA; LIVINGSTONE, JC; TREFFRY, A; LUZZAGO, A; LEVI, S; AROSIO, P; CESARENI, G; THOMAS, CD; SHAW, WV; HARRISON, PM			SOLVING THE STRUCTURE OF HUMAN H-FERRITIN BY GENETICALLY ENGINEERING INTERMOLECULAR CRYSTAL CONTACTS	NATURE			English	Article							HORSE SPLEEN APOFERRITIN; SUBUNIT GENE; ESCHERICHIA-COLI; CHAIN FERRITINS; IRON; EXPRESSION; RESOLUTION; IDENTIFICATION; CONSERVATION; PSEUDOGENE	FERRITIN is important in iron homeostasis. Its twenty-four chains of two types, H and L, assemble as a hollow shell providing an iron-storage cavity 1-3. Ferritin molecules in cells containing high levels of iron tend to be rich in L chains, and may have a long-term storage function, whereas H-rich ferritins are more active in iron metabolism 3-7. The molecular basis for the greater activity of H-rich ferritins has until now been obscure, largely because the structure of H-chain ferritin has remained unknown owing to the difficulties in obtaining crystals ordered enough for X-ray crystallographic analysis. Here we report the three-dimensional structure of a human ferritin H-chain homopolymer. By genetically engineering a change in the sequence of the intermolecular contact region, we obtained crystals isomorphous with the homologous rat L ferritin 8,9 and of high enough quality for X-ray diffraction analysis. The X-ray structure of human H ferritin shows a novel metal site embedded within each of its four-helix bundles and we suggest that ferroxidase activity associated with this site accounts for its rapid uptake of iron 10.	UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY; UNIV MILANO,OSPED SAN RAFFAELE,DIPARTIMENTO SCI & TECNOL BIOMED,I-20132 MILAN,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO BIOL,I-00173 ROME,ITALY; UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7HR,ENGLAND	University of Sheffield; European Molecular Biology Laboratory (EMBL); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Rome Tor Vergata; University of Leicester			Cesareni, Gianni/AAW-1382-2020; arosio, paolo/S-3272-2019; arosio, paolo/E-6817-2010; levi, sonia/A-3161-2015; Thomas, Christopher D./E-1236-2015; Lawson, David M/D-1810-2009	arosio, paolo/0000-0002-5343-8992; levi, sonia/0000-0002-5092-0847; Thomas, Christopher D./0000-0003-0316-6391; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AROSIO P, 1978, J BIOL CHEM, V253, P4451; AROSIO P, 1983, BIOCHIM BIOPHYS ACTA, V774, P230; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BAUMINGER ER, 1989, BIOCHEMISTRY-US, V28, P5486, DOI 10.1021/bi00439a025; BOYD D, 1985, J BIOL CHEM, V260, P1755; CHASTEEN ND, 1982, J BIOL CHEM, V257, P7672; CONNOLLY MJ, 1983, J APPL CRYSTALLOGR, V16, P23; DANIELSMCQUEEN S, 1988, NUCLEIC ACIDS RES, V16, P7741, DOI 10.1093/nar/16.15.7741; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FRASER RDB, 1978, J APPL CRYSTALLOGR, V11, P693, DOI 10.1107/S0021889878014296; HARRISON PM, 1989, BIOMINERALIZATION CH, P257; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1990, THESIS SHEFFIELD U; LEIBOLD EA, 1987, J BIOL CHEM, V262, P7335; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; MURRAY MT, 1987, P NATL ACAD SCI USA, V84, P7438, DOI 10.1073/pnas.84.21.7438; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THOMAS CD, 1988, BIOCHEM SOC T, V16, P838, DOI 10.1042/bst0160838; TREFFRY A, 1984, J INORG BIOCHEM, V21, P9, DOI 10.1016/0162-0134(84)85035-7; TREFFRY A, 1989, FEBS LETT, V247, P268, DOI 10.1016/0014-5793(89)81350-X	30	668	690	2	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					541	544		10.1038/349541a0	http://dx.doi.org/10.1038/349541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992356				2022-12-28	WOS:A1991EW57100073
J	CUMMING, BG; JOHNSTON, EB; PARKER, AJ				CUMMING, BG; JOHNSTON, EB; PARKER, AJ			VERTICAL DISPARITIES AND PERCEPTION OF 3-DIMENSIONAL SHAPE	NATURE			English	Article							DEPTH; DISTANCE	THE information about depth and three-dimensional shape available from the horizontal component of the stereo disparity field requires interpretation in conjunction with information about ego-centric viewing distance (D). A novel computational approach for estimating D was proposed by Mayhew and Longuet-Higgins 1,2, who demonstrated that the horizontal gradient of vertical disparities uniquely specifies the viewing distance. We have now used random dot stereograms in a shape judgement task to show that changes in vertical disparities have no effect on perceived three-dimensional shape. Changes in ocular convergence do alter perceived shape, suggesting substantial changes in the subjects' scaling of horizontal disparities. We conclude that vertical disparities are not used to scale disparities for viewing distance, and that extraretinal signals must be considered when analysing human three-dimensional shape perception.			CUMMING, BG (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Parker, Andrew J/I-7867-2013	Parker, Andrew J/0000-0001-5800-0407	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BISHOP PO, 1989, PROC R SOC SER B-BIO, V237, P445, DOI 10.1098/rspb.1989.0059; FOLEY JM, 1980, PSYCHOL REV, V87, P411, DOI 10.1037/0033-295X.87.5.411; FRISBY J, 1985, NATURE, V307, P592; JOHNSTON E B, 1988, Investigative Ophthalmology and Visual Science, V29, P399; JOHNSTON EB, IN PRESS VISION RES; KOENDERINK J, 1976, BIOL CYBERNT, V21, P755; MAYHEW J, 1982, PERCEPTION, V11, P387, DOI 10.1068/p110387; MAYHEW JEW, 1982, NATURE, V297, P376, DOI 10.1038/297376a0; OGLE KN, 1950, BINOCULAR VISION; ROGERS B, 1989, NATURE, V339, P135, DOI 10.1038/339135a0; WESTHEIMER G, 1984, NATURE, V307, P632, DOI 10.1038/307632a0	11	83	84	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					411	413		10.1038/349411a0	http://dx.doi.org/10.1038/349411a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EV514	1992341				2022-12-28	WOS:A1991EV51400049
J	SINGH, S				SINGH, S			COLIN STORY	BRITISH MEDICAL JOURNAL			English	Editorial Material											SINGH, S (corresponding author), LONDON LIGHTHOUSE,LONDON,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					242	243						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998784				2022-12-28	WOS:A1991EV22800063
J	BLUM, RA; DANDREA, DT; FLORENTINO, BM; WILTON, JH; HILLIGOSS, DM; GARDNER, MJ; HENRY, EB; GOLDSTEIN, H; SCHENTAG, JJ				BLUM, RA; DANDREA, DT; FLORENTINO, BM; WILTON, JH; HILLIGOSS, DM; GARDNER, MJ; HENRY, EB; GOLDSTEIN, H; SCHENTAG, JJ			INCREASED GASTRIC PH AND THE BIOAVAILABILITY OF FLUCONAZOLE AND KETOCONAZOLE	ANNALS OF INTERNAL MEDICINE			English	Note							ACIDITY		SUNY BUFFALO, BUFFALO, NY 14260 USA; PFIZER INC, GROTON, CT 06340 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Pfizer	BLUM, RA (corresponding author), MILLARD FILLMORE HOSP, CLIN PHARMACOKINET LAB, 3 GATES CIRCLE, BUFFALO, NY 14209 USA.							CARLSON JA, 1983, AM J HOSP PHARM, V40, P1334, DOI 10.1093/ajhp/40.8.1334; DANESHMEND TK, 1988, CLIN PHARMACOKINET, V14, P13, DOI 10.2165/00003088-198814010-00002; DREW RH, 1988, CLIN PHARMACY, V7, P622; LELAWONGS P, 1988, CLIN PHARMACY, V7, P228; VANDERMEER JWM, 1980, J ANTIMICROB CHEMOTH, V6, P552, DOI 10.1093/jac/6.4.552	5	130	131	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					755	757		10.7326/0003-4819-114-9-755	http://dx.doi.org/10.7326/0003-4819-114-9-755			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012358				2022-12-28	WOS:A1991FJ11700009
J	MCCOMBS, PR				MCCOMBS, PR			OCTOBER DAYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1820	1820						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005727				2022-12-28	WOS:A1991FE86200008
J	COHEN, DJ; LECKMAN, JF				COHEN, DJ; LECKMAN, JF			TOURETTES-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											COHEN, DJ (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.		Leckman, James/O-2426-2015					COHEN DJ, 1988, TOURETTES SYNDROME C; SHAPIRO A, 1988, G DELATOURETTE SYNDR	2	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1738	1738		10.1001/jama.265.13.1738	http://dx.doi.org/10.1001/jama.265.13.1738			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002580				2022-12-28	WOS:A1991FD65900035
J	CHAN, BMC; MATSUURA, N; TAKADA, Y; ZETTER, BR; HEMLER, ME				CHAN, BMC; MATSUURA, N; TAKADA, Y; ZETTER, BR; HEMLER, ME			INVITRO AND INVIVO CONSEQUENCES OF VLA-2 EXPRESSION ON RHABDOMYOSARCOMA CELLS	SCIENCE			English	Article							INHIBITS EXPERIMENTAL METASTASIS; MELANOMA-CELLS; MONOCLONAL-ANTIBODY; INTEGRIN RECEPTORS; DEPENDENT ADHESION; SURFACE RECEPTORS; COLLAGEN RECEPTOR; LAMININ RECEPTOR; T-CELLS; FIBRONECTIN	Cloned integrin alpha-2 subunit complementary DNA was expressed on human rhabdomyosarcoma (RD) cells to give a functional VLA-2 (alpha-2-beta-1) adhesion receptor. The VLA-2-positive RDA2 cells not only showed increased adhesion to collagen and laminin in vitro, but also formed substantially more metastatic tumor colonies in nude mice after either intravenous or subcutaneous injection. These results show that a specific adhesion receptor (VLA-2) can markedly enhance both experimental and spontaneous metastasis. In contrast to the metastasis results, there was no difference in either the in vitro growth rate or apparent in vivo tumorigenicity of RD and RDA2 cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School				takada, yoshikazu/0000-0001-5481-9589	NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37393] Funding Source: Medline; NIGMS NIH HHS [GM 38903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1990, CANCER RES, V50, P1601; ANICHINI A, 1990, INT J CANCER, V46, P508, DOI 10.1002/ijc.2910460330; BAND H, 1989, J IMMUNOL, V142, P3267; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; NATALI P, 1990, CANCER RES, V50, P1271; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OTOOLE TE, 1989, BLOOD, V74, P14; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIGNATELLI M, 1990, BRIT J CANCER, V61, P636, DOI 10.1038/bjc.1990.141; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAGA S, 1988, CANCER RES, V48, P5510; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; TERRANOVA VP, 1982, CANCER RES, V42, P2265; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILSON JM, 1990, SCIENCE, V248, P1413, DOI 10.1126/science.1972597; YAMADA KM, 1990, CANCER RES, V50, P4485; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; ZYLSTRA S, 1986, CANCER RES, V46, P6446	49	314	323	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1600	1602		10.1126/science.2011740	http://dx.doi.org/10.1126/science.2011740			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011740				2022-12-28	WOS:A1991FD89000034
J	KENDIG, JW; NOTTER, RH; COX, C; REUBENS, LJ; DAVIS, JM; MANISCALCO, WM; SINKIN, RA; BARTOLETTI, A; DWECK, HS; HORGAN, MJ; RISEMBERG, H; PHELPS, DL; SHAPIRO, DL				KENDIG, JW; NOTTER, RH; COX, C; REUBENS, LJ; DAVIS, JM; MANISCALCO, WM; SINKIN, RA; BARTOLETTI, A; DWECK, HS; HORGAN, MJ; RISEMBERG, H; PHELPS, DL; SHAPIRO, DL			A COMPARISON OF SURFACTANT AS IMMEDIATE PROPHYLAXIS AND AS RESCUE THERAPY IN NEWBORNS OF LESS THAN 30 WEEKS GESTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; HYALINE-MEMBRANE DISEASE; BIRTH-WEIGHT INFANTS; CLINICAL-TRIAL; PREMATURE-INFANTS; DOUBLE-BLIND; REPLACEMENT THERAPY; PREVENTION; HEMORRHAGE; EXTRACT	Background. Exogenous pulmonary surfactants are administered into the trachea either to prevent respiratory distress syndrome in premature infants or to treat it. In a randomized, multicenter trial, we compared the results of surfactant therapy initiated as prophylaxis with the results of rescue therapy with surfactant. Methods. Before birth, 479 infants with an estimated gestational age of less than 30 weeks were randomly assigned to receive surfactant as prophylaxis (n = 235) or rescue therapy (n = 244). The infants in the prophylaxis group received a 90-mg intratracheal dose of an exogenous calf-lung surfactant extract at the time of delivery, whereas the infants in the rescue-therapy group received 90 mg of the surfactant several hours after delivery if the fractional inspiratory oxygen concentration was at least 0.40 or if the mean airway pressure was at least 0.686 kPa (7 cm of water), or both. Infants in both groups received additional doses of surfactant at intervals of 12 to 24 hours if these criteria were met. Results. The proportion of infants surviving until discharge to their homes was significantly higher in the prophylaxis group than in the rescue-therapy group (88 vs. 80 percent, P = 0.028). This difference was due primarily to the longer survival of very premature infants (less-than-or-equal-to 26 weeks' gestation) in the prophylaxis group than in the rescue-therapy group (75 vs. 54 percent, P = 0.006). According to proportional-hazards regression analysis, the distribution of survival times was better for all infants in the prophylaxis group (P = 0.007) and for the subgroup of infants in the prophylaxis group who were delivered at 26 weeks' gestation or earlier (P = 0.0048). Infants in the prophylaxis group who were delivered at 26 weeks' gestation or earlier had a lower incidence of pneumothorax than similar infants in the rescue-therapy group (7 vs. 18 percent, P = 0.03). Conclusions. We found a significant advantage to the administration of the initial dose of surfactant as prophylaxis rather than as rescue therapy in very premature infants.	UNION UNIV,DEPT PEDIAT,NEWBORN SERV,ALBANY,NY 12208; NEW YORK MED COLL,WESTCHESTER MED CTR,DEPT PEDIAT,DIV NEONATOL PERINATAL MED,VALHALLA,NY 10595; UNIV ROCHESTER,SCH MED,DEPT PEDIAT NEONATOL,ROCHESTER,NY 14627; UNIV ROCHESTER,SCH MED,DIV BIOSTAT,ROCHESTER,NY 14627; UNIV ROCHESTER,SCH MED,SPECIALIZED CTR RES PULM DIS NEWBORNS,ROCHESTER,NY 14627	Union College; New York Medical College; Westchester Medical Center; University of Rochester; University of Rochester; University of Rochester				horgan, michael/0000-0003-0991-6464	NCRR NIH HHS [RR000-44] Funding Source: Medline; NHLBI NIH HHS [HL-36453] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AVERY ME, 1987, PEDIATRICS, V79, P26; BROWNLEE KA, 1965, STATISTICAL THEORY M; CONSTANTINE NA, 1987, J PEDIATR-US, V110, P921, DOI 10.1016/S0022-3476(87)80416-X; Cox D. R., 1984, ANAL SURVIVAL DATA; ENHORNING G, 1985, PEDIATRICS, V76, P145; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P690; GAIL MH, 1985, CANCER TREAT REP, V10, P1107; GITLIN JD, 1987, PEDIATRICS, V79, P31; HALLMAN M, 1983, PEDIATRICS, V71, P473; HALLMAN M, 1985, J PEDIATR-US, V106, P963, DOI 10.1016/S0022-3476(85)80253-5; HOBAR JD, 1989, NEW ENGL J MED, V320, P959; KENDIG JW, 1988, PEDIATRICS, V82, P756; KINDIG JW, 1987, PEDIATR RES S, V21, pA365; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KWONG MS, 1985, PEDIATRICS, V76, P585; MAETA H, 1988, PEDIATRICS, V81, P277; MCCORD FB, 1988, ARCH DIS CHILD, V63, P10, DOI 10.1136/adc.63.1.10; MERRITT TA, 1986, NEW ENGL J MED, V315, P785, DOI 10.1056/NEJM198609253151301; NOTTER RH, 1987, CLIN PERINATOL, V14, P433, DOI 10.1016/S0095-5108(18)30746-2; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; RAJU TNK, 1987, LANCET, V1, P651; ROBERTSON B, 1980, LUNG, V158, P57, DOI 10.1007/BF02713705; Robertson B., 1984, PULMONARY SURFACTANT, P383; SHAPIRO DL, 1985, PEDIATRICS, V76, P593; SOLL RF, 1990, PEDIATRICS, V85, P1092; 1987, BMJ, V294, P991; 1988, PEDIATRICS, V82, P683	27	192	196	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					865	871		10.1056/NEJM199103283241301	http://dx.doi.org/10.1056/NEJM199103283241301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD111	2000109				2022-12-28	WOS:A1991FD11100001
J	LOWNDES, NF; JOHNSON, AL; JOHNSTON, LH				LOWNDES, NF; JOHNSON, AL; JOHNSTON, LH			COORDINATION OF EXPRESSION OF DNA-SYNTHESIS GENES IN BUDDING YEAST BY A CELL-CYCLE REGULATED TRANS FACTOR	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HO GENE; PERIODIC TRANSCRIPTION; GEL-ELECTROPHORESIS; LIGASE GENES; CDC9; IDENTIFICATION; ACTIVATION; SEQUENCES; BINDING	ALL of the DNA synthesis genes of budding yeast examined so far are periodically expressed and hence under cell-cycle control (Table 1). Expression occurs near the G1/S phase boundary and the genes seem to be coordinately regulated (reviewed in ref. 4). The upstream promoter sequences of these genes have only a hexamer element, ACGCGT (an MluI restriction site), in common. Here we show that this hexamer is able to impart periodic expression to a heterologous gene and, significantly, this expression occurs coincidentally with that of CDC9, one of the DNA synthesis genes (Table 1). We have also identified a protein that binds specifically to these sequences in a similar periodic manner. These ACGCGT sequences and the transcription factor that binds to them therefore seem to be the elements controlling both the periodic expression and coordinate regulation of the DNA synthesis genes.	NATL INST MED RES,CELL PROPAGAT LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research			Lowndes, Noel F/B-9084-2008	Lowndes, Noel F/0000-0002-3216-4427				ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARTISHEVSKY A, 1987, NATURE, V328, P822; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BARKER DG, 1985, MOL GEN GENET, V200, P458, DOI 10.1007/BF00425731; BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JOHNSON AL, 1986, CURR GENET, V11, P107, DOI 10.1007/BF00378201; Johnston LH, 1990, CURR OPIN CELL BIOL, V2, P274, DOI 10.1016/0955-0674(90)90019-B; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; JOHNSTON LH, 1990, MOL GEN GENET, V221, P44, DOI 10.1007/BF00280366; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Osley M. A., 1987, MOL CELL BIOL, V7, P4202; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STORMS RK, 1984, MOL CELL BIOL, V4, P2858, DOI 10.1128/MCB.4.12.2858; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WHITE JHM, 1988, THESIS COUNCIL NATIO	27	185	185	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					247	250		10.1038/350247a0	http://dx.doi.org/10.1038/350247a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005980				2022-12-28	WOS:A1991FC77900063
J	KELLIE, SE; KELLY, JT				KELLIE, SE; KELLY, JT			MEDICARE PEER-REVIEW ORGANIZATION PREPROCEDURE REVIEW CRITERIA - AN ANALYSIS OF CRITERIA FOR 3 PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDARTERECTOMY; POPULATION	The Medicare Peer Review Organization (PRO) program includes preprocedure review using explicit criteria to assess the appropriateness of specific procedures. This study evaluates the variability in the PRO preprocedure criteria for the three procedures most frequently reviewed by PROs: carotid endarterectomy, cataract removal, and cardiac pacemaker implants. In August 1989, the PRO review criteria were received from the Health Care Financing Administration. To provide a reference point for reviewing the PRO criteria, national practice guidelines for these three procedures were identified. Wide variability was demonstrated in the PRO procedure-specific carotid endarterectomy and cataract removal review criteria among PROs, and the criteria differed significantly from the identified practice guidelines. The criteria for cardiac pacemaker implants were somewhat less variable, and were based, to varying degrees, on practice guidelines developed by the American College of Cardiology (ACC). Greater attention is needed to improve the development of review criteria, including the use of relevant practice guidelines, to ensure that review criteria are optimal.			KELLIE, SE (corresponding author), AMER MED ASSOC,DEPT TECHNOL ASSESSMENT,OFF QUAL ASSURANCE,515 N STATE ST,CHICAGO,IL 60610, USA.							[Anonymous], 1990, CLIN PRACTICE GUIDEL; DONABEDIAN A, 1981, AM J PUBLIC HEALTH, V71, P409, DOI 10.2105/AJPH.71.4.409; FALK RH, 1990, J AM COLL CARDIOL, V15, P1087, DOI 10.1016/0735-1097(90)90245-K; FRYE R L, 1984, Journal of the American College of Cardiology, V4, P434; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KELLY JT, 1990, ARCH PATHOL LAB MED, V114, P1119; KELLY JT, 1990, DIRECTORY PRACTICE P; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LEVIT KR, 1990, HEALTH AFFAIR, V9, P171, DOI 10.1377/hlthaff.9.2.171; LOHR KN, 1989, MED CARE, V27, pS1, DOI 10.1097/00005650-198903001-00001; Mariano L A, 1989, Health Care Financ Rev, V10, P123; MERRICK NJ, 1986, R32046CWFHFPMTRWJ RA; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; PARK RE, 1989, R3280CWFHFPMTRWJ RAN; POKRAS R, 1988, STROKE, V19, P1289, DOI 10.1161/01.STR.19.10.1289; SCHAFFARZICK RW, 1988, QUALITY CARE TECHNOL; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; 1988, CATARACT SURGERY; 1989, MEDICARE IMPROVEMENT; 1989, MED REV SYSTEM; 1988, PB88954099; 1989, EFFECTIVENESS RES PR; 1990, MEDICARE STRATEGY QU; 1984, HCFA PRO MANUAL, V2, P37; 1989, CONTROLLING COSTS CH; 1989, CATARACT OTHERWISE H; 1989, ANN INTERN MED, V111, P675; 1989, MEDICARE COVERAGE IS; 1987, STUDY PREADMISSION R, P1; 1974, JAMA-J AM MED ASSOC, V229, P166; 1987, MINIMUM CRITERIA CAT	32	28	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1265	1270		10.1001/jama.265.10.1265	http://dx.doi.org/10.1001/jama.265.10.1265			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995973				2022-12-28	WOS:A1991FA51100020
J	PETERS, TG				PETERS, TG			LIFE OR DEATH - THE ISSUE OF PAYMENT IN CADAVERIC ORGAN DONATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRANSPLANTATION; DONORS; RECIPIENTS				PETERS, TG (corresponding author), JACKSONVILLE TRANSPLANT CTR, 580 W 8TH ST, JACKSONVILLE, FL 32209 USA.							BATTEN HL, 1987, HEALTH AFFAIR, V6, P35, DOI 10.1377/hlthaff.6.2.35; Callender C O, 1982, J Natl Med Assoc, V74, P807; CAPLAN AL, 1984, NEW ENGL J MED, V311, P981, DOI 10.1056/NEJM198410113111510; CAPLAN AL, 1988, HASTINGS CTR REP APR, P34; CAPLAN AL, 1989, HASTINGS CENT REP, P45; CHATTERJEE SN, 1975, JAMA-J AM MED ASSOC, V232, P822, DOI 10.1001/jama.232.8.822; DIETHELM AG, 1990, ANN SURG, V211, P505, DOI 10.1097/00000658-199005000-00001; ENGLEHARDT HT, 1984, NEW ENGL J MED, V311, P66; EVANS R W, 1986, Journal of the American Medical Association, V255, P1892, DOI 10.1001/jama.255.14.1892; EVANS RW, 1990, DIALYSIS TRANSPLANT, V19, P234; FERNANDEZBUENO C, 1988, TRANSPLANT P, V20, P398; HAGLE ME, 1989, TRANSPLANTATION, V48, P421, DOI 10.1097/00007890-198909000-00013; HANTO DW, 1990, CHIMERA, V1, P12; JOHNSON LW, 1988, TRANSPLANT P, V20, P822; KRAMER NC, 1990, TRANSPLANTATION, V49, P343, DOI 10.1097/00007890-199002000-00023; MANNINEN DL, 1985, JAMA-J AM MED ASSOC, V253, P3111, DOI 10.1001/jama.253.21.3111; MILES MS, 1988, DIALYSIS TRANSPLANT, V17, P74; OVERCAST TD, 1984, JAMA-J AM MED ASSOC, V251, P1559, DOI 10.1001/jama.251.12.1559; PETERS TG, 1990, SOUTHERN MED J, V83, P889, DOI 10.1097/00007611-199008000-00010; RETTORI R, 1989, J MAL VASCUL, V14, P191, DOI 10.1215/03616878-14-1-191; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SELLS RA, 1990, DIALYSIS TRANSPLANT, V19, P10; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STRAWN J, 1990, UNOS MONTHLY ACTIVIT; Sutton E C, 1989, Med Staff Couns, V3, P43; 1986, TRANSPLANTATION, V41, P1	26	101	101	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1302	1305		10.1001/jama.265.10.1302	http://dx.doi.org/10.1001/jama.265.10.1302			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995979				2022-12-28	WOS:A1991FA51100028
J	LIP, GYH; MCCOLL, KEL; GOLDBERG, A; MOORE, MR				LIP, GYH; MCCOLL, KEL; GOLDBERG, A; MOORE, MR			SMOKING AND RECURRENT ATTACKS OF ACUTE INTERMITTENT PORPHYRIA	BRITISH MEDICAL JOURNAL			English	Article							ESTRADIOL		UNIV GLASGOW,WESTERN INFIRM,GARDINER INST,DEPT MED,GLASGOW G11 6NT,SCOTLAND	University of Glasgow			Moore, Michael R/C-4163-2012	Moore, Michael R/0000-0002-7012-9534				APPEL BR, 1990, AM J PUBLIC HEALTH, V80, P560, DOI 10.2105/AJPH.80.5.560; KANARKOWSKI R, 1988, CLIN PHARMACOL THER, V43, P23, DOI 10.1038/clpt.1988.7; KLAIBER EL, 1988, FERTIL STERIL, V50, P630; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; Moore M. R., 1987, DISORDERS PORPHYRIN	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					507	507		10.1136/bmj.302.6775.507	http://dx.doi.org/10.1136/bmj.302.6775.507			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB055	2012848	Green Published, Bronze			2022-12-28	WOS:A1991FB05500022
J	DESHAIES, RJ; SANDERS, SL; FELDHEIM, DA; SCHEKMAN, R				DESHAIES, RJ; SANDERS, SL; FELDHEIM, DA; SCHEKMAN, R			ASSEMBLY OF YEAST SEC PROTEINS INVOLVED IN TRANSLOCATION INTO THE ENDOPLASMIC-RETICULUM INTO A MEMBRANE-BOUND MULTISUBUNIT COMPLEX	NATURE			English	Article							LAMBDA-DNA-REPLICATION; HEAT-SHOCK PROTEIN; NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; INITIATION; GENE; SEQUENCE; ENCODES; MUTANT; ORIGIN	SECRETORY-protein translocation into the endoplasmic reticulum (ER) is thought to be catalysed by integral membrane proteins. Genetic selections uncovered three Saccharomyces cerevisiae genes (SEC61, SEC62 and SEC63), mutations in which block import of precursor proteins into the ER lumen in vivo 1-3 and in vitro 2-4. The DNA sequences of SEC62 (ref. 4) and SEC63 (ref. 5) predict multispanning membrane proteins, and biochemical characterization of the SEC62 protein (Sec62) confirms that it is an integral ER membrane protein6. Here we show that Sec61, Sec62 and Sec63 are assembled with two additional proteins into a multisubunit membrane-associated complex. These results confirm previous predictions, based upon genetic interactions between the SEC genes, that Sec61, Sec62 and Sec63 act together to facilitate protein translocation into the ER.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DODSON M, 1989, J BIOL CHEM, V264, P10719; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; RAPOPORT TA, 1990, NATO ADV SCI I H-CEL, V40, P231; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	22	276	281	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					806	808		10.1038/349806a0	http://dx.doi.org/10.1038/349806a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000150				2022-12-28	WOS:A1991EZ66600061
J	KEMPLE, TJ; HAYTER, SR				KEMPLE, TJ; HAYTER, SR			AUDIT OF DIABETES IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To complete a first audit cycle of diabetes care in a general practice and to develop a simple method for continuing the audit cycle. Design-Retrospective examination of the medical records of all diabetic patients in a general practice in 1990. Setting-A group general practice in a Bristol health centre with roughly 13 200 patients, which since 1983 has had a protocol for care of its diabetic patients. Patients-223 known diabetic patients in the practice. Main audited measures-Comparison against previously agreed standards of process and outcome of diabetes care in the practice, including number of patients whose care had been reviewed in accordance with the practice protocol, serum fructosamine and blood glucose concentrations in patients aged under 70, and number of newly diagnosed patients given explicit education and referred for diatetic advice. Results-Defined standards were not met for several criteria-for example, percentages of patients aged below 70 (n = 149) with serum fructosamine concentrations < 3.5 mmol/l (62% v 90% defined value) and < 2.8 mmol/l (35% v 70%) and last recorded blood glucose concentrations < 10 mmol/l in insulin dependent patients (n = 48) (23% v 90%) and < 8 mmol/l in non-insulin dependent patients (n = 101) (17% v 90%). Of newly identified diabetic patients (n = 32), 59% and 28% respectively were referred to dieticians and given educational material compared with the 100% standard. Conclusions-The practice has a high prevalence of diabetes (1.7%) but has the resources for their care. The format and implementation of the agreed systematic process of care for diabetic patients needs improvement. Implications-A simple audit suitable for most general practices might record two measures of the process of care-a disease register of all diabetic patients in a practice and an attendance register to determine whether they have regular check ups-and one measure of the outcome of care, such as serum fructosamine concentration (or local equivalent). A practice could establish its own standards for these measures and monitor its performance against them.			KEMPLE, TJ (corresponding author), HORFIELD HLTH CTR,LOCKLEAZE RD,BRISTOL BS7 9RR,ENGLAND.			Kemple, Terence/0000-0002-9217-4598				FLEMING PC, 1985, PRACTICAL DIABETES, V2, P26; FOSTER W, 1989, PRACTITIONER, V233, P1023; GROL R, 1990, BRIT J GEN PRACT, V40, P361; HILL RD, 1986, PRACTICAL DIABETES, V3, P67; HILL RD, 1990, PRACTICAL DIABETES, V7, P149; IRVING JMR, 1988, PRACTICAL DIABETES, V3, P125; MALINS JM, 1971, BRIT MED J, V4, P161, DOI 10.1136/bmj.4.5780.161; SMITH T, 1990, BRIT MED J, V300, P65, DOI 10.1136/bmj.300.6717.65; THORN PA, 1973, BRIT MED J, V2, P534, DOI 10.1136/bmj.2.5865.534; WAINE C, 1990, PRACTICAL DIABETES, V7, P152; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; Wood J, 1990, Health Trends, V22, P39; 1988, DIABETES; 1989, MED AUDIT 1ST REPORT; 1989, 6 SECRE STAT HLTH WO	15	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					451	453		10.1136/bmj.302.6774.451	http://dx.doi.org/10.1136/bmj.302.6774.451			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004174	Green Published, Bronze			2022-12-28	WOS:A1991EZ03300024
J	DECHIARA, TM; ROBERTSON, EJ; EFSTRATIADIS, A				DECHIARA, TM; ROBERTSON, EJ; EFSTRATIADIS, A			PARENTAL IMPRINTING OF THE MOUSE INSULIN-LIKE GROWTH FACTOR-II GENE	CELL			English	Article							RIBONUCLEIC-ACID; PATERNAL GENOMES; 2 PROMOTERS; EXPRESSION; EMBRYOGENESIS; METHYLATION; RECEPTOR; LOCALIZATION; CHICKEN; FETUS	We are studying mice that carry a targeted disruption of the gene encoding insulin-like growth factor II (IGF-II). Transmission of this mutation through the male germline results in heterozygous progeny that are growth deficient. In contrast, when the disrupted gene is transmitted maternally, the heterozygous offspring are phenotypically normal. Therefore, the difference in growth phenotypes depends on the type of gamete contributing the mutated allele. Homozygous mutants are indistinguishable in appearance from growth-deficient heterozygous siblings. Nuclease protection and in situ hybridization analyses of the transcripts from the wild-type and mutated alleles indicate that only the paternal allele is expressed in embryos, while the maternal allele is silent. An exception is the choroid plexus and leptomeninges, where both alleles are transcriptionally active. These results demonstrate that IGF-II is indispensable for normal embryonic growth and that the IGF-II gene is subject to tissue-specific parental imprinting.			DECHIARA, TM (corresponding author), COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							Adams R. L. P., 1985, MOL BIOL DNA METHYLA; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BELL GI, 1985, P NATL ACAD SCI USA, V82, P6450, DOI 10.1073/pnas.82.19.6450; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; BRILLIANT MH, 1987, J NEUROGENET, V4, P259, DOI 10.3109/01677068709102346; BRISSENDEN JE, 1984, NATURE, V310, P781, DOI 10.1038/310781a0; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CATTANACH BM, 1986, J EMBRYOL EXP MORPH, V97, P137; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CHARD T, 1989, J ENDOCRINOL, V123, P3, DOI 10.1677/joe.0.1230003; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEPAGTERHOLTHUIZEN P, 1985, HUM GENET, V69, P170, DOI 10.1007/BF00293291; DERCOLE AJ, 1980, DEV BIOL, V75, P315, DOI 10.1016/0012-1606(80)90166-9; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FRUNZIO R, 1986, J BIOL CHEM, V261, P7138; GAMMELTOFT S, 1989, PEPTIDE HORMONES PRO, P176; GIRARD J, 1989, INTRAUTERINE GROWTH, P23; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IKEJIRI K, 1990, BIOCHIM BIOPHYS ACTA, V1049, P350, DOI 10.1016/0167-4781(90)90110-N; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1974, GENET RES, V24, P207, DOI 10.1017/S0016672300015226; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LALLEY PA, 1984, CYTOGENET CELL GENET, V37, P515; LEE JE, 1990, DEVELOPMENT, V110, P151; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MCGRATH J, 1984, NATURE, V308, P550, DOI 10.1038/308550a0; MILNER RDG, 1987, EUR J PEDIATR, V146, P113, DOI 10.1007/BF02343214; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1988, GENE DEV, V2, P921, DOI 10.1101/gad.2.8.921; MOSES AC, 1980, P NATL ACAD SCI-BIOL, V77, P3649, DOI 10.1073/pnas.77.6.3649; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RAPPOLEE DA, 1990, UCLA SYM BI, V117, P11; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; Sambrook J, 1989, MOL CLONING LABORATO; SAPIENZA C, 1989, PROG NUCLEIC ACID RE, V36, P145; SAPIENZA C, 1989, ANN NY ACAD SCI, V564, P24, DOI 10.1111/j.1749-6632.1989.tb25885.x; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SEARLE AG, 1989, ANN HUM GENET, V53, P89, DOI 10.1111/j.1469-1809.1989.tb01777.x; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SEARLE AG, 1985, ANEUPLOIDY ETIOLOGY, P363; SLACK J, 1991, NATURE, V349, P17, DOI 10.1038/349017a0; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SMITH JC, 1989, DEVELOPMENT, V107, P149; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SOLTER D, 1988, ANNU REV GENET, V22, P127; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; STYLIANOPOULOU F, 1988, DEVELOPMENT, V103, P497; SURANI MA, 1990, PHILOS T ROY SOC B, V326, P313, DOI 10.1098/rstb.1990.0014; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MA, 1986, EXPT APPROACHES MAMM, P431; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SURANI MAH, 1986, J EMBRYOL EXP MORPH, V97, P123; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; SZULMAN AE, 1984, HUMAN TROPHOBLAST NE, P135; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TRICOLI JV, 1984, NATURE, V310, P784, DOI 10.1038/310784a0; UENO T, 1989, BIOCHIM BIOPHYS ACTA, V1009, P27, DOI 10.1016/0167-4781(89)90074-2; UENO T, 1987, BIOCHEM BIOPH RES CO, V148, P344, DOI 10.1016/0006-291X(87)91116-8; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLPERT L, 1989, DEVELOPMENT, V107, P3; WYLIE C, 1990, NATURE, V347, P337, DOI 10.1038/347337a0	80	1477	1531	3	88	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					849	859		10.1016/0092-8674(91)90513-X	http://dx.doi.org/10.1016/0092-8674(91)90513-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997210				2022-12-28	WOS:A1991EZ47800019
J	STGEORGE, IM; WILLIAMS, S; STANTON, WR; SILVA, PA				STGEORGE, IM; WILLIAMS, S; STANTON, WR; SILVA, PA			SMOKING AND BLOOD-PRESSURE IN 15 YEAR OLDS IN DUNEDIN, NEW-ZEALAND	BRITISH MEDICAL JOURNAL			English	Article									UNIV OTAGO,DEPT PREVENT & SOCIAL MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,DUNEDIN MULTIDISCIPLINARY HLTH & DEV RES UNIT,DUNEDIN,NEW ZEALAND	University of Otago; University of Otago	STGEORGE, IM (corresponding author), UNIV OTAGO,DEPT GEN PRACTICE,POB 913,DUNEDIN,NEW ZEALAND.							Silva P A, 1990, Paediatr Perinat Epidemiol, V4, P76, DOI 10.1111/j.1365-3016.1990.tb00621.x; SIMPSON FO, 1979, PROPHYLACTIC APPROAC, P31; STANTON WR, 1989, ORIGINS DEV ADDICTIV; STGEORGE IM, 1990, NZ MED J, V886, P1415	4	12	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					89	90		10.1136/bmj.302.6768.89	http://dx.doi.org/10.1136/bmj.302.6768.89			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995122	Green Published, Bronze			2022-12-28	WOS:A1991ER95100020
J	THANABALASINGHAM, T; BECKETT, MW; MURRAY, V				THANABALASINGHAM, T; BECKETT, MW; MURRAY, V			LESSON OF THE WEEK - HOSPITAL RESPONSE TO A CHEMICAL INCIDENT - REPORT ON CASUALTIES OF AN ETHYLDICHLOROSILANE SPILL	BRITISH MEDICAL JOURNAL			English	Editorial Material									GUYS & ST THOMAS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND; W MIDDLESEX UNIV HOSP,DEPT ACCID & EMERGENCY,ISLEWORTH,MIDDX,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Imperial College London								BAXTER PJ, 1989, BRIT MED J, V298, P1437, DOI 10.1136/bmj.298.6685.1437; CANADINE IC, 1990, INT C S SERIES, V155, P33; DALLOS V, 1990, INT C S SERIES, V155, P73; JERROM DA, 1990, INT C S SERIES, V155, P51; ROWE VK, 1948, J IND HYG TOXICOL, V30, P332; SACH M, 1988, BRIT J ACCIDENT EMER, V3, P9; TAYLOR D, 1990, INT C S SERIES, V155, P203; TONG TG, 1990, INT C S SERIES, V155, P141; 1985, TRADE UNION REPORT B; 1988, MMWR, V37, P733	10	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					101	102		10.1136/bmj.302.6768.101	http://dx.doi.org/10.1136/bmj.302.6768.101			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995104	Green Published, Bronze			2022-12-28	WOS:A1991ER95100027
J	GWINN, M; PAPPAIOANOU, M; GEORGE, JR; HANNON, WH; WASSER, SC; REDUS, MA; HOFF, R; GRADY, GF; WILLOUGHBY, A; NOVELLO, AC; PETERSEN, LR; DONDERO, TJ; CURRAN, JW				GWINN, M; PAPPAIOANOU, M; GEORGE, JR; HANNON, WH; WASSER, SC; REDUS, MA; HOFF, R; GRADY, GF; WILLOUGHBY, A; NOVELLO, AC; PETERSEN, LR; DONDERO, TJ; CURRAN, JW			PREVALENCE OF HIV-INFECTION IN CHILDBEARING WOMEN IN THE UNITED-STATES - SURVEILLANCE USING NEWBORN BLOOD-SAMPLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; AIDS; SEROPREVALENCE; INFANTS	A national, population-based survey was initiated in 1988 to measure the prevalence of human immunodeficiency virus (HIV) infection in women giving birth to infants in the United States. Following standardized procedures, residual dried-blood specimens collected on filter paper for newborn metabolic screening were tested anonymously in state public health laboratories for maternal antibody to HIV. As of September 1990, annual survey data were available from 38 states and the District of Columbia. The highest HIV seroprevalence rates were observed in New York (5.8 per 1000), the District of Columbia (5.5 per 1000), New Jersey (4.9 per 1000), and Florida (4.5 per 1000). Nationwide, an estimated 1.5 per 1000 women giving birth to infants in 1989 were infected with HIV. Assuming a perinatal transmission rate of 30%, we estimate that approximately 1800 newborns acquired HIV infection during one 12-month period. Preventing transmission of HIV infection to women and infants is an urgent public health priority.	CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30333; MASSACHUSETTS DEPT HLTH,BOSTON,MA; NICHHD,WASHINGTON,DC	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	GWINN, M (corresponding author), CTR DIS CONTROL,DIV HIV AIDS,MAILSTOP E-49,ATLANTA,GA 30333, USA.							ANDIMAN WA, 1989, SEMIN PERINATOL, V13, P16; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; GRANT CM, 1990, 6TH INT C AIDS SAN F; GWINN M, 1990, 6TH INT C AIDS SAN F; HARDY LM, 1991, HIV SCREENING PREGNA; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; Hummel R. F., 1990, AIDS and Public Policy Journal, V5, P68; LEE FK, 1989, AIDS RES HUM RETROV, V5, P517, DOI 10.1089/aid.1989.5.517; MITCHELL JL, 1989, J NATL MED ASSOC, V81, P841; MOFENSON LM, 1989, 5TH INT AIDS C MONTR; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P113; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; PIZZO PA, 1990, PEDIATR INFECT DIS J, V9, P690, DOI 10.1097/00006454-199010000-00002; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SELIK RM, 1989, AIDS GYNECOLOGY CLIN, V1, P33; STRICOF RL, 1989, 5TH ANN NAT PED AIDS; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; 1989, CURRENT POPULATI P25, V1018; 1988, MMWR, V37, P341; 1988, ACOG TECHNICAL B, V123; 1990, MONTHLY VITAL STAT R, V38, P1; 1989, MMWR SS7, V38, P1; 1990, HIV AIDS SURVEILLANC, P1; 1988, MMWR, V37, P351; 1987, MMWR, V36, P509; 1988, MMWR, V37, P1	31	247	250	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1704	1708		10.1001/jama.265.13.1704	http://dx.doi.org/10.1001/jama.265.13.1704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002571				2022-12-28	WOS:A1991FD65900026
J	MCNEIL, JG; BRUNDAGE, JF; GARDNER, LI; WANN, ZF; RENZULLO, PO; REDFIELD, RR; BURKE, DS; MILLER, RN				MCNEIL, JG; BRUNDAGE, JF; GARDNER, LI; WANN, ZF; RENZULLO, PO; REDFIELD, RR; BURKE, DS; MILLER, RN			TRENDS OF HIV SEROCONVERSION AMONG YOUNG-ADULTS IN THE UNITED-STATES-ARMY, 1985 TO 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HTLV-III; INFECTION; AIDS; MEN; ANTIBODIES; TESTS	Because soldiers in the US Army are recurrently tested for the presence of antibody to the human immunodeficiency virus (HIV), HIV seroconversion rates can be directly measured. From November 1985 through October 1989, 429 HIV seroconversions were detected among 718 780 soldiers who contributed 1 088 447 person-years of follow-up time (HIV seroconversion rate, 0.39 per 1000 person-years). Period-specific seroconversion rates declined significantly, from 0.49 per 1000 person-years (November 1985 through October 1987) to 0.33 per 1000 person-years (November 1987 through October 1988) to 0.29 per 1000 person-years (November 1988 through October 1989). The HIV seroconversion risk among active-duty soldiers was significantly associated with race/ethnic group, age, gender, and marital status. Based on these trends, we estimate that approximately 220 soldiers (95% confidence interval, 160 to 297 soldiers) were infected with HIV during 1989 and 1990, with potentially fewer in future years.	SRA TECHNOL, ALEXANDRIA, VA USA; WALTER REED ARMY MED CTR, DIV RETROVIROL, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	MCNEIL, JG (corresponding author), WALTER REED ARMY MED CTR, DEPT EPIDEMIOL, DIV PREVENT MED, WASHINGTON, DC 20307 USA.		Brundage, John/Q-9244-2019	/0000-0002-5704-8094				Breslow N.E., 1987, STATISTICAL METHODS, V2, P133; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; BURKE DS, 1986, JAMA-J AM MED ASSOC, V256, P347, DOI 10.1001/jama.256.3.347; BURKE DS, 1989, CLIN LAB MED, V9, P369, DOI 10.1016/S0272-2712(18)30609-7; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; DETELS R, 1989, J ACQ IMMUN DEF SYND, V2, P77; DODD RY, 1988, 4TH INT C AIDS STOCK, V2, P347; GAIL MH, 1988, J NATL CANCER I, V80, P900, DOI 10.1093/jnci/80.12.900; GARLAND FC, 1989, JAMA-J AM MED ASSOC, V262, P3161, DOI 10.1001/jama.262.22.3161; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HERBOLD JR, 1986, MIL MED, V151, P623; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KELLEY PW, 1987, AIDS ACQUIRED IMMUNE, P67; MCNEIL JG, 1989, NEW ENGL J MED, V320, P1581, DOI 10.1056/NEJM198906153202403; MCNEIL JG, 1989, 5TH INT C AIDS OTT, V1, P158; MCNEIL JG, 1990, 6TH INT C AIDS SAN F, V1, P265; PETRICCIANI JC, 1985, ANN INTERN MED, V103, P726, DOI 10.7326/0003-4819-103-5-726; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; 1990, MMWR, V39, P81; 1990, EGRET VERSION 25; 1990, MMWR, V39, P110; 1983, HIV AIDS SURVEILLANC	29	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1709	1714		10.1001/jama.265.13.1709	http://dx.doi.org/10.1001/jama.265.13.1709			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002572				2022-12-28	WOS:A1991FD65900027
J	EMANUEL, LL; BARRY, MJ; STOECKLE, JD; ETTELSON, LM; EMANUEL, EJ				EMANUEL, LL; BARRY, MJ; STOECKLE, JD; ETTELSON, LM; EMANUEL, EJ			ADVANCE DIRECTIVES FOR MEDICAL-CARE - A CASE FOR GREATER USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; CARDIOPULMONARY RESUSCITATION; ELDERLY OUTPATIENTS; PHYSICIANS; DECISIONS; PREFERENCES; ATTITUDES; CHOICES; END	Background. Advance directives for medical care and the designation of proxy decision makers to guide medical care after a patient has become incompetent have been widely advocated but little studied. We investigated the attitudes of patients toward planning, perceived barriers to such planning, treatment preferences in four hypothetical scenarios, and the feasibility of using a particular document (the Medical Directive) in the outpatient setting to specify advance directives. Methods. We surveyed 405 outpatients of 30 primary care physicians at Massachusetts General Hospital and 102 members of the general public in Boston and asked them as part of the survey to complete the Medical Directive. Results. Advance directives were desired by 93 percent of the outpatients and 89 percent of the members of the general public (P > 0.2). Both the young and the healthy subgroups expressed at least as much interest in planning as those older than 65 and those in fair-to-poor health. Of the perceived barriers to issuing advance directives, the lack of physician initiative was among the most frequently mentioned, and the disturbing nature of the topic was among the least. The outpatients refused life-sustaining treatments in 71 percent of their responses to options in the four scenarios (coma with chance of recovery, 57 percent; persistent vegetative state, 85 percent; dementia, 79 percent; and dementia with a terminal illness, 87 percent), with small differences between widely differing types of treatments. Specific treatment preferences could not be usefully predicted according to age, self-rated state of health, or other demographic features. Completing the Medical Directive took a median of 14 minutes. Conclusions. When people are asked to imagine themselves incompetent with a poor prognosis, they decide against life-sustaining treatments about 70 percent of the time. Health, age, or other demographic features cannot be used, however, to predict specific preferences. Advance directives as part of a comprehensive approach such as that provided by the Medical Directive are desired by most people, require physician initiative, and can be achieved during a regular office visit.	BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,PROGRAM ETH & PROFESS,CAMBRIDGE,MA 02138	Harvard University; Beth Israel Deaconess Medical Center; Harvard University	EMANUEL, LL (corresponding author), MASSACHUSETTS GEN HOSP,GEN INTERNAL MED UNIT,BOSTON,MA 02114, USA.				AHRQ HHS [R01 HS06120] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; BUCHANAN A, 1988, PHILOS PUBLIC AFF, V17, P277; COLTON T, 1974, STAT MED, P120; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1989, AM J MED, V86, P87, DOI 10.1016/0002-9343(89)90234-9; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; Lubitz J, 1984, Health Care Financ Rev, V5, P117; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; READLEAF DL, 1979, STANFORD LAW REV, V31, P913; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; Shapiro R S, 1986, Wis Med J, V85, P17; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; STEIBER SR, 1987, HOSPITALS, V61, P72; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615; 1989, RESOLUTION LEGISLATI; 1989, CURRENT OPINIONS COU; 1987, HDB LIVING WILL LAWS	26	595	598	0	31	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					889	895		10.1056/NEJM199103283241305	http://dx.doi.org/10.1056/NEJM199103283241305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000111				2022-12-28	WOS:A1991FD11100005
J	BLANCK, RR; BELL, WH				BLANCK, RR; BELL, WH			MEDICAL SUPPORT FOR AMERICAN TROOPS IN THE PERSIAN GULF	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BLANCK, RR (corresponding author), USA,FALLS CHURCH,VA 22041, USA.								0	14	14	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					857	859		10.1056/NEJM199103213241228	http://dx.doi.org/10.1056/NEJM199103213241228			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997865				2022-12-28	WOS:A1991FC44200035
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - ORGANIZATION OF ANTENATAL CARE	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					647	650		10.1136/bmj.302.6777.647	http://dx.doi.org/10.1136/bmj.302.6777.647			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012884	Green Published, Bronze			2022-12-28	WOS:A1991FC07100030
J	MARSDEN, PD				MARSDEN, PD			LETTER FROM BRASILIA - SEMIOLOGIA	BRITISH MEDICAL JOURNAL			English	Editorial Material											MARSDEN, PD (corresponding author), UNIV BRASILIA,CP 153121,BR-70010 BRASILIA,DF,BRAZIL.								0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					645	646		10.1136/bmj.302.6777.645	http://dx.doi.org/10.1136/bmj.302.6777.645			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012883	Bronze, Green Published			2022-12-28	WOS:A1991FC07100029
J	SANTOS, WC				SANTOS, WC			THE COMPETITIVE EDGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Software Review											SANTOS, WC (corresponding author), UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616, USA.							Iserson KV, 1990, GETTING RESIDENCY GU, VSecond; RAFF MJ, 1974, NEW ENGL J MED, V291, P601, DOI 10.1056/NEJM197409192911204; 1990, AMA FREIDA; 1990, DIRECTORY GRADUATE M	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1191	1191		10.1001/jama.265.9.1191	http://dx.doi.org/10.1001/jama.265.9.1191			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996009				2022-12-28	WOS:A1991EZ47400042
J	WONG, KF; HUI, PK; CHAN, JKC; CHAN, YW; HA, SY				WONG, KF; HUI, PK; CHAN, JKC; CHAN, YW; HA, SY			THE ACUTE LUPUS HEMOPHAGOCYTIC SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						LUPUS ERYTHEMATOSUS, SYSTEMIC; PANCYTOPENIA; LUPUS HEMOPHAGOCYTIC SYNDROME; HISTIOCYTOSIS, NON-LANGERHANS-CELL; STEROIDS	MALIGNANT HISTIOCYTOSIS; ERYTHEMATOSUS	Objective: To characterize an unusual mode of presentation of systemic lupus erythematosus: acute and severe pancytopenia related to reactive hemophagocytosis. Design: Retrospective case series. Setting: Two general community hospitals in Hong Kong. Patients: Six patients presenting with a reactive hemophagocytic syndrome, identified over a 3.5 year period, diagnosed with systemic lupus erythematosus according to the criteria of the American Rheumatism Association. Results: In addition to severe pancytopenia and marrow hemophagocytosis, other characteristic features were fever, hypocomplementemia, high antinuclear antibody titer, and cutaneous and visceral vasculitis. There was no evidence of an underlying infection. The pancytopenia responded dramatically to treatment with steroids. Conclusion: Recognition of the acute lupus hemophagocytic syndrome and distinction from an infection-associated hemophagocytic syndrome is important because it responds well to steroid therapy. The evaluation of patients presenting with a hemophagocytic syndrome should include serologic tests for systemic lupus erythematosus.	KWONG WAH HOSP, CLIN PATHOL UNIT, KOWLOON, HONG KONG; KWONG WAH HOSP, MED UNIT A, KOWLOON, HONG KONG	Kwong Wah Hospital; Kwong Wah Hospital	WONG, KF (corresponding author), QUEEN ELIZABETH HOSP, INST PATHOL, KOWLOON, HONG KONG.			HA, Shau Yin/0000-0002-9191-8743				BUDMAN DR, 1977, ANN INTERN MED, V86, P220, DOI 10.7326/0003-4819-86-2-220; CHAN JKC, 1987, PATHOLOGY, V19, P43, DOI 10.3109/00313028709065134; CHAN JKC, 1987, LANCET, V1, P507; GOLD SC, 1953, Q J MED, V22, P457; HUANG LM, 1990, LANCET, V336, P60, DOI 10.1016/0140-6736(90)91580-4; JAFFE ES, 1983, AM J MED, V75, P741, DOI 10.1016/0002-9343(83)90402-3; KOFFLER D, 1982, ARTHRITIS RHEUM, V25, P858, DOI 10.1002/art.1780250729; Meyerhoff J, 1983, Md State Med J, V32, P935; MICHAEL SR, 1951, BLOOD, V6, P1059, DOI 10.1182/blood.V6.11.1059.1059; REINER AP, 1988, MEDICINE, V67, P369, DOI 10.1097/00005792-198811000-00002; Richert-Boe K E, 1987, Hematol Oncol Clin North Am, V1, P301; RISDALL RJ, 1979, CANCER, V44, P993, DOI 10.1002/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5; RISDALL RJ, 1984, CANCER, V54, P2968, DOI 10.1002/1097-0142(19841215)54:12<2968::AID-CNCR2820541226>3.0.CO;2-4; ROSENTHAL NS, 1989, AM J CLIN PATHOL, V92, P650, DOI 10.1093/ajcp/92.5.650; SAKURAI T, 1984, Henry Ford Hospital Medical Journal, V32, P142; SERDULA MK, 1979, ARTHRITIS RHEUM-US, V22, P328, DOI 10.1002/art.1780220403; SIMRELL CR, 1982, B T CELL TUMORS, P247; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WOO J, 1987, ASIAN J CLIN SCI, V7, P77	19	173	178	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					387	390		10.7326/0003-4819-114-5-387	http://dx.doi.org/10.7326/0003-4819-114-5-387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992881				2022-12-28	WOS:A1991EZ17400007
J	GREENBERG, DP; VADHEIM, CM; BORDENAVE, N; ZIONTZ, L; CHRISTENSON, P; WATERMAN, SH; WARD, JI				GREENBERG, DP; VADHEIM, CM; BORDENAVE, N; ZIONTZ, L; CHRISTENSON, P; WATERMAN, SH; WARD, JI			PROTECTIVE EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE AND CONJUGATE VACCINES IN CHILDREN 18 MONTHS OF AGE AND OLDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE	To evaluate the protective efficacy of polyribosylribitol phosphate (PRP) and polyribosylribitol phosphate-diphtheria toxoid (PRP-D) vaccines in children 18 to 59 months of age, we conducted a case-control study in Los Angeles (Calif) County between July 1, 1988, and July 31, 1989. Seventy-nine children with invasive Haemophilus influenzae type b disease 18 to 59 months of age were identified, and 212 controls were selected by random-digit telephone dialing methods. Cases and controls were stratified by age and month of disease onset of the case. Seventeen PRP vaccine failures and two PRP-D vaccine failures occurred more than 2 weeks after vaccination. The PRP vaccine was shown not to be effective (point estimate -47%; 95% confidence interval, -307% to 47%), but the PRP-D vaccine was 88% protective (95% confidence interval, 42% to 97%). Adjustment of the efficacy estimates for potential confounding variables did not change the results significantly. The PRP-D vaccine provided significantly better protection than the PRP vaccine against invasive H influenzae type b disease in this population.	LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA		GREENBERG, DP (corresponding author), UNIV CALIF LOS ANGELES,HARBOR MED CTR,SCH MED,CTR VACCINE RES,1124 W CARSON ST,BLDG E-6,TORRANCE,CA 90502, USA.							BERKOWITZ CD, 1987, J PEDIATR-US, V110, P509, DOI 10.1016/S0022-3476(87)80540-1; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; Breslow N, 1980, STAT METHODS CANC RE, P248; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; ESKOLA J, 1989, 29TH INT C ANT AG CH; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; HARRISON LH, 1989, PEDIATRICS, V84, P255; KAYHTY H, 1984, PEDIATRICS, V74, P857; MURPHY TV, 1990, CLIN RES, V38, pA183; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; VADHEIM CM, 1990, PEDIATR INFECT DIS J, V9, P555, DOI 10.1097/00006454-199008000-00006; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WENGER JD, 1990, 30TH INT C ANT AG CH; 1985, MMWR, V34, P201; 1990, MMWR, V39, P925; 1988, MMWR, V37, P13; 1990, MMWR, V39, P698; 1988, HAEMOPHILUS INFLUENZ, V81, P908	25	40	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					987	992		10.1001/jama.265.8.987	http://dx.doi.org/10.1001/jama.265.8.987			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992212				2022-12-28	WOS:A1991EY43200026
J	MARSDEN, PD				MARSDEN, PD			AIDS - IT CAME FOR THE CARNIVAL	BRITISH MEDICAL JOURNAL			English	Editorial Material											MARSDEN, PD (corresponding author), UNIV BRASILIA,CP153121,BR-70010 BRASILIA,DF,BRAZIL.								0	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					337	337		10.1136/bmj.302.6772.337	http://dx.doi.org/10.1136/bmj.302.6772.337			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001511	Bronze, Green Published			2022-12-28	WOS:A1991EX56900028
J	KENNY, C				KENNY, C			ORGANIZE A REUNION OF YOUR UNDERGRADUATE CLASSMATES	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					282	283		10.1136/bmj.302.6771.282	http://dx.doi.org/10.1136/bmj.302.6771.282			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998798	Bronze, Green Published			2022-12-28	WOS:A1991EX91900026
J	MESSINEZY, M; AUBRY, S; OCONNELL, G; TREACHER, DF; PEARSON, TC				MESSINEZY, M; AUBRY, S; OCONNELL, G; TREACHER, DF; PEARSON, TC			OXYGEN DESATURATION IN APPARENT AND RELATIVE POLYCYTHEMIA	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,SLEEP LAB,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT MED,LUNG FUNCT LAB,LONDON SE1 7EH,ENGLAND	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	MESSINEZY, M (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DIV HAEMATOL,ST THOMASS CAMPUS,LONDON SE1 7EH,ENGLAND.							BERLIN NI, 1975, SEMIN HEMATOL, V12, P339; ECKSTEIN JW, 1960, J LAB CLIN MED, V56, P847; MESSINEZY M, 1990, CLIN LAB HAEMATOL, V12, P121, DOI 10.1111/ijlh.1990.12.2.121; MOOREGILLON JC, 1986, BRIT MED J, V293, P588, DOI 10.1136/bmj.293.6547.588; PEARSON TC, 1984, CLIN LAB HAEMATOL, V6, P207	5	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					216	217		10.1136/bmj.302.6770.216	http://dx.doi.org/10.1136/bmj.302.6770.216			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998762	Bronze, Green Published			2022-12-28	WOS:A1991EV22800026
J	ROBERTS, J				ROBERTS, J			THE NHS OBSERVED - JUNIOR DOCTORS YEARS - TRAINING, NOT EDUCATION	BRITISH MEDICAL JOURNAL			English	Article																		Allen, 1988, DOCTORS THEIR CAREER; HARRISON S, 1990, DYNAMICS BRIT HLTH P; MIHILL C, 1990, GUARDIAN        0918, P18; MIHILL C, 1990, GUARDIAN        0921, P13; 1989, WORKING PATIENTS; 1987, HOSPITAL MED STAFFIN; 1989, HLTH TRENDS, V21, P99; 1990, HOSPITAL DOCTOR 0906, P8	8	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					225	228		10.1136/bmj.302.6770.225	http://dx.doi.org/10.1136/bmj.302.6770.225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998767	Green Published, Bronze			2022-12-28	WOS:A1991EV22800032
J	BACHORIK, PS; CLOEY, TA; FINNEY, CA; LOWRY, DR; BECKER, DM				BACHORIK, PS; CLOEY, TA; FINNEY, CA; LOWRY, DR; BECKER, DM			LIPOPROTEIN-CHOLESTEROL ANALYSIS DURING SCREENING - ACCURACY AND RELIABILITY	ANNALS OF INTERNAL MEDICINE			English	Article							PROGRAM; PRECISION; PLASMA	Objective: To evaluate the accuracy and reliability of lipoprotein-cholesterol measurements obtained during screening. Design: Cross-sectional study. Participants: From November 1989 to January 1990, 154 adults were screened. Measurements: Split venous samples from fasting participants were analyzed for total cholesterol, triglyceride, and high-density-lipoprotein (HDL) cholesterol with screening and standardized laboratory methods. Low-density-lipoprotein (LDL)-cholesterol levels were calculated using the Friedewald equation. Split venous samples from nonfasting participants were analyzed for total cholesterol. Capillary blood samples were analyzed for total cholesterol with the screening method. Main Results: Total cholesterol measurements in screening venous blood samples were 5.4% and 3.8% lower than the laboratory values in samples from fasting and nonfasting participants, respectively. Triglyceride and HDL-cholesterol values in venous samples obtained from fasting participants were, on average, 9.8% and 11.2% lower than the respective laboratory measurements. Screening HDL-cholesterol values varied, differing from the laboratory values by as much as 40% in 95% of participants. In fasting participants, total cholesterol in capillary samples averaged 5.5% higher than in venous samples; in nonfasting participants the capillary samples were 3.1% higher. Screening for either total cholesterol or LDL cholesterol identified 93% of the persons with LDL-cholesterol values of 3.36 mmol/L (130 mg/dL) or higher. Conclusions: Total cholesterol can be reliably measured in samples from fasting or nonfasting persons. The values in capillary blood samples were slightly higher than those in venous samples. Screening HDL-cholesterol values were too variable to establish the HDL-cholesterol level reliably. Participants with high LDL-cholesterol levels were identified as accurately by measuring total cholesterol only when compared with calculating the LDL-cholesterol level from total cholesterol, triglyceride, and HDL-cholesterol concentrations.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University								[Anonymous], 1977, CLIN CHEM, V23, P60; BACHORIK PS, 1989, CLIN CHEM, V35, P1734; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CLOEY T, 1990, JAMA-J AM MED ASSOC, V263, P2788, DOI 10.1001/jama.263.20.2788; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GREENLAND P, 1987, AM J PUBLIC HEALTH, V77, P73, DOI 10.2105/AJPH.77.1.73; HAVAS S, 1989, AM J PREV MED, V5, P337, DOI 10.1016/S0749-3797(18)31054-7; KOCH TR, 1987, CLIN CHEM, V33, P2262; KWITEROVICH PO, 1986, CIRCULATION, V73, P30; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; SNEDECOR GW, 1968, STATISTICAL METHODS, P56; WARNICK GR, 1978, J LIPID RES, V19, P65; WONES RG, 1989, PUBLIC HEALTH REP, V104, P425; 1984, JAMA-J AM MED ASSOC, V251, P1196; 1989, NIH893045 US DEP HLT	17	26	26	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					741	747		10.7326/0003-4819-114-9-741	http://dx.doi.org/10.7326/0003-4819-114-9-741			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012356				2022-12-28	WOS:A1991FJ11700006
J	HUNT, RC; BRYAN, DM; BRINKLEY, VS; WHITLEY, TW; BENSON, NH				HUNT, RC; BRYAN, DM; BRINKLEY, VS; WHITLEY, TW; BENSON, NH			INABILITY TO ASSESS BREATH SOUNDS DURING AIR MEDICAL TRANSPORT BY HELICOPTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								This study assessed the capabilities of a traditional and an amplified stethoscope used by flight nurses to assess breath sounds during air medical transport in an MBB BO-105 helicopter. We developed a normal breath sound model using a prerecorded tape of breath sounds interspersed with segments without breath sounds; the recorder had been placed in the chest wall of a resuscitation training manikin. Flight nurses completed control listening sessions in a quiet environment and experimental sessions during flight using a traditional stethoscope for half of the sessions and an amplified stethoscope for the remaining half. In the quiet environment, flight nurses accurately reported the presence or absence of breath sounds in 110 (92%) of 120 trials. During helicopter flight, none of the flight nurses heard breath sounds during any of the recorded segments with either the traditional stethoscope or the amplified stethoscope. We conclude that flight nurses are unable to hear normal breath sounds using a traditional or amplified stethoscope during flight in a medically configured MBB BO-105 helicopter. Improved stethoscopes, innovative methods of listening, and reduction of aircraft noise are potential solutions to the problems of breath sound assessment during air medical transport.	PITT CTY MEM HOSP,EASTCARE EMERGENCY AIR MED SERV,GREENVILLE,NC		HUNT, RC (corresponding author), E CAROLINA UNIV,SCH MED,DEPT EMERGENCY MED,MOYE BLVD,GREENVILLE,NC 27858, USA.							BISHOP LC, 1990, JAMA-J AM MED ASSOC, V263, P233, DOI 10.1001/jama.1990.03440020067017; COLLETT HM, 1990, J AIR MED TRANSP JUL, P20; DICK T, 1986, JEMS, V11, P77; GASAWAY DC, 1986, AVIAT SPACE ENVIR MD, V57, P103; HARMS T, 1990, J AIR MED TRANSP OCT, P76; HUNT RC, 1990, 1990 ROCK MOUNT C EM; PASIC TB, 1985, ARCH OTOLARYNGOL, V111, P507; WILKINS RL, 1988, LUNG SOUNDS PRACTICA; 1990, J AIR MED TRANSP MAR, P6	9	46	47	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1982	1984		10.1001/jama.265.15.1982	http://dx.doi.org/10.1001/jama.265.15.1982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008028				2022-12-28	WOS:A1991FF76800025
J	LEVINE, SJ; WALSH, TJ; MARTINEZ, A; EICHACKER, PQ; LOPEZBERESTEIN, G; NATANSON, C				LEVINE, SJ; WALSH, TJ; MARTINEZ, A; EICHACKER, PQ; LOPEZBERESTEIN, G; NATANSON, C			CARDIOPULMONARY TOXICITY AFTER LIPOSOMAL AMPHOTERICIN-B INFUSION	ANNALS OF INTERNAL MEDICINE			English	Note							SYSTEMIC FUNGAL-INFECTIONS	Liposomal and lipid complex drug delivery systems are being developed to enhance the therapeutic activity, decrease toxicity, and provide site-specific delivery of high doses of amphotericin B. Toxic reactions associated with liposomal amphotericin B therapy in humans have been limited to fever, chills, nausea, and electrolyte disturbances. This report supplements the known toxicities by describing transient, but reproducible, hypoxemia, pulmonary hypertension, and depression of cardiac output in a 22-year-old woman with lymphoblastic lymphoma who required liposomal amphotericin B for therapy of hepatosplenic candidiasis. Although liposomal drug delivery is a promising new approach to various disorders, its potential cardiopulmonary complications must enter into the decision regarding the dose, duration of infusion, and liposomal preparation to be used in individual patients.	UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center								JANOFF AS, 1988, P NATL ACAD SCI USA, V85, P6122, DOI 10.1073/pnas.85.16.6122; LOPEZBERESTEIN G, 1987, J CLIN ONCOL, V5, P310, DOI 10.1200/JCO.1987.5.2.310; LOPEZBERESTEIN G, 1989, ARCH INTERN MED, V149, P2533, DOI 10.1001/archinte.149.11.2533; LOPEZBERESTEIN G, 1985, J INFECT DIS, V151, P704, DOI 10.1093/infdis/151.4.704; LOPEZBERESTEIN G, 1986, ANN INTERN MED, V105, P130, DOI 10.7326/0003-4819-105-1-130; MIYAMOTO K, 1988, J APPL PHYSIOL, V64, P1143, DOI 10.1152/jappl.1988.64.3.1143; SAROSI GA, 1989, ARCH INTERN MED, V149, P2402, DOI 10.1001/archinte.149.11.2402; WIEBE VJ, 1988, REV INFECT DIS, V10, P1097	8	79	81	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					664	666		10.7326/0003-4819-114-8-664	http://dx.doi.org/10.7326/0003-4819-114-8-664			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003714				2022-12-28	WOS:A1991FG03100009
J	GURWITZ, JH; GOLDBERG, RJ; GORE, JM				GURWITZ, JH; GOLDBERG, RJ; GORE, JM			CORONARY THROMBOLYSIS FOR THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE PLASMINOGEN-ACTIVATOR; INTRAVENOUS STREPTOKINASE; ARTERY SURGERY; PHASE-I; MORTALITY; AGE; TRIAL; ANGIOPLASTY; PROGNOSIS		HEBREW REHABIL CTR AGED, BOSTON, MA USA; HARVARD UNIV, SCH MED, CTR GERIATR RES & TRAINING, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	GURWITZ, JH (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, PROGRAM ANAL CLIN STRATEGIES, 333 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-35434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; CHAITMAN BR, 1989, J AM COLL CARDIOL, V14, P1159, DOI 10.1016/0735-1097(89)90410-5; CHAMBERLAIN DA, 1988, LANCET, V1, P545; FISHER LD, 1989, INT J CARDIOL, V24, P317, DOI 10.1016/0167-5273(89)90011-9; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GUERCI AD, 1987, NEW ENGL J MED, V317, P1613, DOI 10.1056/NEJM198712243172601; HACKETT TP, 1969, AM J CARDIOL, V24, P651, DOI 10.1016/0002-9149(69)90452-4; HOLLAND KJ, 1989, AM J CARDIOL, V63, P399, DOI 10.1016/0002-9149(89)90307-X; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KAPANTAIS G, 1989, CHARACTERISTICS PERS; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEE TC, 1990, AM J CARDIOL, V66, P663, DOI 10.1016/0002-9149(90)91126-Q; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; MAGGIONI AP, 1990, CHEST, V97, pS146; MATHEY DG, 1985, J AM COLL CARDIOL, V6, P518, DOI 10.1016/S0735-1097(85)80107-8; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MOSS AJ, 1969, AM J CARDIOL, V24, P659, DOI 10.1016/0002-9149(69)90453-6; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; NAYLOR CD, 1990, JAMA-J AM MED ASSOC, V264, P697, DOI 10.1001/jama.264.6.697; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; PETO R, 1990, AM J CARDIOL, V66, P771, DOI 10.1016/0002-9149(90)91149-Z; PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628; POWELLGRINER E, 1990, CHARACTERISTIC PERSO; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROWE JW, 1985, NEW ENGL J MED, V312, P827, DOI 10.1056/NEJM198503283121305; RUTHERFORD JD, 1990, CHEST, V97, pS136; SLEIGHT P, 1990, CIRCULATION, V81, P1706; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; SOLDO BJ, 1988, GERIATRIC MED, P12; TIEFENBRUNN AJ, 1989, JAMA-J AM MED ASSOC, V261, P2107; WARNES CA, 1984, AM HEART J, V108, P431, DOI 10.1016/0002-8703(84)90404-6; WILCOX RG, 1988, LANCET, V2, P525; YANG XS, 1987, ACTA CARDIOL, V42, P59; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905	45	91	91	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1720	1723		10.1001/jama.265.13.1720	http://dx.doi.org/10.1001/jama.265.13.1720			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002574				2022-12-28	WOS:A1991FD65900029
J	NOVELLO, AC; WISE, PH; KLEINMAN, DV; ORENSTEIN, WA; SEPE, SI				NOVELLO, AC; WISE, PH; KLEINMAN, DV; ORENSTEIN, WA; SEPE, SI			HEALTHY-CHILDREN READY TO LEARN - THE CHALLENGE TO THE MEDICAL COMMUNITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									CTR DIS CONTROL,CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	NOVELLO, AC (corresponding author), OFF SURGEON GEN,WASHINGTON,DC, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1364	1364						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999874				2022-12-28	WOS:A1991FB55000005
J	HAYES, JJ; STEWART, RB; GREENE, HL; BARDY, GH				HAYES, JJ; STEWART, RB; GREENE, HL; BARDY, GH			NARROW QRS VENTRICULAR-TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							BUNDLE-BRANCH-BLOCK; DIFFERENTIAL-DIAGNOSIS; FASCICULAR TACHYCARDIA; COMPLEX TACHYCARDIA; THERAPY; REENTRY	Objective: To determine the frequency and clinical characteristics of narrow Design: Consecutive survey of patients with ventricular tachycardia. Setting: Tertiary, referral-based arrhythmia service at a university medical center. Patients: Sequential sample of patients with inducible ventricular tachycardia who had a 12-lead electrocardiogram of the tachycardia available for review. Measurements and Main Results: Of 106 patients with ventricular tachycardia, 5 (4.7%; 95% CI, 2.1% to 10.6%) had ventricular tachycardia with a QRS duration less-than-or-equal-to 0.11 seconds. Three of the five patients were previously incorrectly diagnosed as having supraventricular tachycardia. All five patients had at least two electrocardiographic findings other than QRS duration to suggest ventricular tachycardia. Conclusions: Narrow QRS ventricular tachycardia should be considered in the differential diagnosis of narrow QRS tachycardias. Electrocardiographic findings other than QRS duration are usually present to suggest the diagnosis.			HAYES, JJ (corresponding author), UNIV WASHINGTON, MED CTR, MAIL STOP RG-22, 1959 NE PACIFIC, SEATTLE, WA 98195 USA.				PHS HHS [31472, 36170] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAR FW, 1984, AM J CARDIOL, V54, P555, DOI 10.1016/0002-9149(84)90247-9; BROHET C, 1988, ACTA CLIN BELG, V43, P236; CACERES J, 1989, CIRCULATION, V79, P256, DOI 10.1161/01.CIR.79.2.256; COHEN HC, 1972, CIRCULATION, V45, P1035, DOI 10.1161/01.CIR.45.5.1035; FORSSELL G, 1976, ACTA MED SCAND, V199, P143; GOOLSBY JP, 1974, AM HEART J, V88, P351, DOI 10.1016/0002-8703(74)90471-2; JOSEPHSON ME, 1978, CIRCULATION, V57, P431, DOI 10.1161/01.CIR.57.3.431; JOSEPHSON ME, 1979, CIRCULATION, V59, P459, DOI 10.1161/01.CIR.59.3.459; KINDWALL KE, 1988, AM J CARDIOL, V61, P1279, DOI 10.1016/0002-9149(88)91169-1; KREMERS MS, 1988, AM J CARDIOL, V62, P1208, DOI 10.1016/0002-9149(88)90261-5; KUCHAR DL, 1988, PACE, V11, P61, DOI 10.1111/j.1540-8159.1988.tb03930.x; MASON JW, 1978, CIRCULATION, V58, P971, DOI 10.1161/01.CIR.58.6.971; MASSUMI RA, 1973, CIRCULATION, V47, P543, DOI 10.1161/01.CIR.47.3.543; PRITCHETT EL, 1978, PRAC CARDIOL, V4, P84; REDDY CP, 1980, CIRCULATION, V61, P641, DOI 10.1161/01.CIR.61.3.641; ROELANDT J, 1969, DIS CHEST, V56, P166, DOI 10.1378/chest.56.2.166; RUFFY R, 1985, J AM COLL CARDIOL, V5, P1008, DOI 10.1016/S0735-1097(85)80451-4; SHIMIZU A, 1988, PACE, V11, P384, DOI 10.1111/j.1540-8159.1988.tb05997.x; STEWART RB, 1986, ANN INTERN MED, V104, P766, DOI 10.7326/0003-4819-104-6-766; VANDEPOL CJ, 1980, AM J CARDIOL, V45, P725, DOI 10.1016/0002-9149(80)90114-9; WEISS J, 1986, AM HEART J, V112, P843, DOI 10.1016/0002-8703(86)90485-0; WELLENS HJJ, 1978, AM J MED, V64, P27, DOI 10.1016/0002-9343(78)90176-6; WELLENS HJJ, 1979, AM J CARDIOL, V43, P400	23	19	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					460	463		10.7326/0003-4819-114-6-460	http://dx.doi.org/10.7326/0003-4819-114-6-460			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994792				2022-12-28	WOS:A1991FB64000005
J	WILLIAMSON, DF; MADANS, J; ANDA, RF; KLEINMAN, JC; GIOVINO, GA; BYERS, T				WILLIAMSON, DF; MADANS, J; ANDA, RF; KLEINMAN, JC; GIOVINO, GA; BYERS, T			SMOKING CESSATION AND SEVERITY OF WEIGHT-GAIN IN A NATIONAL COHORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-WEIGHT; CIGARETTE-SMOKING; ENERGY-EXPENDITURE; PHYSICAL-ACTIVITY; NICOTINE; OBESITY; CONSUMPTION; WOMEN	Background. Many believe that the prospect of weight gain discourages smokers from quitting. Accurate estimates of the weight gain related to the cessation of smoking in the general population are not available, however. Methods. We related changes in body weight to changes in smoking status in adults 25 to 74 years of age who were weighed in the First National Health and Nutrition Examination Survey (NHANES I, 1971 to 1975) and then weighed a second time in the NHANES I Epidemiologic Follow-up Study (1982 to 1984). The cohort included continuing smokers (748 men and 1137 women) and those who had quit smoking for a year or more (409 men and 359 women). Results. The mean weight gain attributable to the cessation of smoking, as adjusted for age, race, level of education, alcohol use, illnesses related to change in weight, base-line weight, and physical activity, was 2.8 kg in men and 3.8 kg in women. Major weight gain (> 13 kg) occurred in 9.8 percent of the men and 13.4 percent of the women who quit smoking. The relative risk of major weight gain in those who quit smoking (as compared with those who continued to smoke) was 8.1 (95 percent confidence interval, 4.4 to 14.9) in men and 5.8 (95 percent confidence interval, 3.7 to 9.1) in women, and it remained high regardless of the duration of cessation. For both sexes, blacks, people under the age of 55, and people who smoked 15 cigarettes or more per day were at higher risk of major weight gain after quitting smoking. Although at base line the smokers weighed less than those who had never smoked, they weighed nearly the same at follow-up. Conclusions. Major weight gain is strongly related to smoking cessation, but it occurs in only a minority of those who stop smoking. Weight gain is not likely to negate the health benefits of smoking cessation, but its cosmetic effects may interfere with attempts to quit. Effective methods of weight control are therefore needed for smokers trying to quit.	CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333; NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								ABRAHAM S, 1983, VITAL HLTH STATIS 11, V230; BENNETT W, 1987, ANN NY ACAD SCI, V499, P250, DOI 10.1111/j.1749-6632.1987.tb36216.x; BLITZER PH, 1977, J CHRON DIS, V30, P415, DOI 10.1016/0021-9681(77)90035-2; BOSSE R, 1980, INT J ADDICT, V15, P969, DOI 10.3109/10826088009040072; CARNEY RM, 1984, NEW ENGL J MED, V310, P614, DOI 10.1056/NEJM198403083101002; COHEN BB, 1987, VITAL HLTH STATIST 1, V22; FRIEDMAN GD, 1980, CIRCULATION, V61, P716, DOI 10.1161/01.CIR.61.4.716; GRITZ E R, 1989, Annals of Behavioral Medicine, V11, P144, DOI 10.1207/s15324796abm1104_4; GRUNBERG N E, 1989, Annals of Behavioral Medicine, V11, P154, DOI 10.1207/s15324796abm1104_5; GRUNBERG NE, 1987, PSYCHOPHARMACOLOGY, V91, P221; GRUNBERG NE, 1988, LIFE SCI, V42, P161, DOI 10.1016/0024-3205(88)90679-0; GRUNBERG NE, 1988, PSYCHOPHARMACOLOGY, V94, P536, DOI 10.1007/BF00212851; GRUNBERG NE, 1985, PHARMACOL BIOCHEM BE, V23, P851, DOI 10.1016/0091-3057(85)90081-4; GRUNBERG NE, 1985, PSYCHOPHARMACOLOGY, V87, P198, DOI 10.1007/BF00431807; Grunberg NE, 1986, ADV BEHAVIORAL MED, V2, P97; GRUNBERG NE, 1990, RES ADV ALCOHOL DRUG, P273; HATZIANDREU EJ, 1989, AM J PUBLIC HEALTH, V79, P1020, DOI 10.2105/AJPH.79.8.1020; HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KLESGES RC, 1989, ANN BEHAV MED, V11, P123; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; NOPPA H, 1980, PREV MED, V9, P534, DOI 10.1016/0091-7435(80)90048-1; PERKINS KA, 1989, NEW ENGL J MED, V320, P898, DOI 10.1056/NEJM198904063201404; RIGOTTI NA, 1989, NEW ENGL J MED, V320, P931, DOI 10.1056/NEJM198904063201409; RISSANEN A, 1988, INT J OBESITY, V12, P391; SCHWARTZ JL, 1987, NIH872940 DEP HLTH H; WACK JT, 1982, AM J CLIN NUTR, V35, P366, DOI 10.1093/ajcn/35.2.366; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; 1985, DHHS8550207 DEP HLTH; [No title captured]; 1990, DHHS CDC908416 PUBL; 1988, DHHS CDC888406 PUBL; 1989, DHHS CDC8988411 PUBL; 1985, SAS USERS GUIDE STAT, P655; 1990, OM902004 DEP HLTH HU	36	633	638	1	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					739	745		10.1056/NEJM199103143241106	http://dx.doi.org/10.1056/NEJM199103143241106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB556	1997840				2022-12-28	WOS:A1991FB55600006
J	LUTHY, DA; WARDINSKY, T; SHURTLEFF, DB; HOLLENBACH, KA; HICKOK, DE; NYBERG, DA; BENEDETTI, TJ				LUTHY, DA; WARDINSKY, T; SHURTLEFF, DB; HOLLENBACH, KA; HICKOK, DE; NYBERG, DA; BENEDETTI, TJ			CESAREAN-SECTION BEFORE THE ONSET OF LABOR AND SUBSEQUENT MOTOR FUNCTION IN INFANTS WITH MENINGOMYELOCELE DIAGNOSED ANTENATALLY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL HYDROCEPHALUS; PRENATAL-DIAGNOSIS; MANAGEMENT; MYELODYSPLASIA; PROGNOSIS; ANOMALIES; FETUS	Background. Meningomyelocele can now be detected before birth. Few data are available on its natural history, however, and optimal management at the time of delivery is controversial, although it has been suggested that labor and vaginal delivery may cause pressure on exposed nerve roots, resulting in additional loss of neural function. Methods. To assess the effect of labor and the type of delivery on the level of motor function in fetuses with uncomplicated meningomyelocele, we identified 200 cases of this disorder, accounting for 95 percent of the cases that occurred in the state of Washington during our 10-year study period. We compared the outcomes of 47 infants delivered by cesarean section before labor began, 35 delivered by cesarean section after a period of labor, and 78 who were delivered vaginally (another 40 were ineligible for the study). In cases of meningomyelocele detected prenatally, cesarean section was performed before the onset of labor if isolated meningomyelocele without severe hydrocephalus was present. The infants delivered in this manner were compared with those who were delivered either vaginally or by cesarean section after labor began. Results. At two years of age, the infants who had been exposed to labor were 2.2 times more likely to have severe paralysis than those delivered by cesarean section without labor (95 percent confidence interval, 1.7 to 2.8). Infants delivered by cesarean section before the beginning of labor had a mean (+/- SD) level of paralysis 3.3 +/- 3.0 segments below the anatomical level of the spinal lesion at two years of age, as compared with 1.1 +/- 2.3 for infants delivered vaginally and 0.9 +/- 4.1 for infants delivered by cesarean section after the beginning of labor (P < 0.001 for both comparisons). Exposure to labor did not affect the frequency of neonatal complications or later intellectual performance. Conclusions. For the fetus with uncomplicated meningomyelocele, delivery by cesarean section before the onset of labor may result in better subsequent motor function than vaginal delivery or delivery by cesarean section after a period of labor.	SWEDISH MED CTR,DIV ULTRASOUND,SEATTLE,WA 98104; UNIV WASHINGTON HOSP,MED CTR,DIV PERINATAL MED,SEATTLE,WA 98105; UNIV WASHINGTON HOSP,MED CTR,DEPT PEDIAT,SEATTLE,WA 98105	Swedish Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LUTHY, DA (corresponding author), SWEDISH MED CTR,DEPT OBSTET & GYNECOL,747 SUMMIT AVE,SEATTLE,WA 98104, USA.							Bayley N., 1969, BAYLEY SCALES INFANT; BENSEN JT, 1988, OBSTET GYNECOL, V71, P532; CHERVENAK FA, 1984, OBSTET GYNECOL, V63, P376; CHERVENAK FA, 1984, AM J OBSTET GYNECOL, V63, P512; DONN SM, 1982, J REPROD MED, V27, P589; GLICK PL, 1984, J PEDIATR-US, V105, P97, DOI 10.1016/S0022-3476(84)80371-6; HARRISON MR, 1981, JAMA-J AM MED ASSOC, V246, P774, DOI 10.1001/jama.246.7.774; HOBBINS JC, 1979, AM J OBSTET GYNECOL, V134, P331, DOI 10.1016/S0002-9378(16)33043-5; MAIN DM, 1986, OBSTET GYNECOL, V67, P1; MCLAUGHLIN JF, 1985, NEW ENGL J MED, V312, P1589, DOI 10.1056/NEJM198506203122501; NYBERG DA, 1987, RADIOLOGY, V163, P187, DOI 10.1148/radiology.163.1.3547493; NYBERG DA, 1988, J ULTRAS MED, V7, P265, DOI 10.7863/jum.1988.7.5.265; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SHARRARD W J, 1964, Ann R Coll Surg Engl, V35, P106; SHURTLEF.DB, 1973, AM J DIS CHILD, V125, P688, DOI 10.1001/archpedi.1973.04160050042008; Shurtleff D, 1986, MYELODYSPLASIAS EXST, P39; Shurtleff D B, 1987, Z Kinderchir, V42 Suppl 1, P50; SHURTLEFF DB, 1974, NEW ENGL J MED, V291, P1005, DOI 10.1056/NEJM197411072911905; STARK G, 1970, DEV MED CHILD NEUR S, V12, P157; WILLIAMSON RA, 1984, AM J MED GENET, V17, P497, DOI 10.1002/ajmg.1320170212	20	152	158	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					662	666		10.1056/NEJM199103073241004	http://dx.doi.org/10.1056/NEJM199103073241004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA144	1994249	Bronze			2022-12-28	WOS:A1991FA14400004
J	HONG, R; MATSUYAMA, E; NUR, K				HONG, R; MATSUYAMA, E; NUR, K			CARDIOMYOPATHY ASSOCIATED WITH THE SMOKING OF CRYSTAL METHAMPHETAMINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMPHETAMINE	The smoking of crystal methamphetamine, or "ice," is a growing drug abuse problem in the United States. The toxic effects of methamphetamine smoking have not been well described. We describe two patients with cardiovascular toxic effects associated with the smoking of crystal methamphetamine. In our first patient, the use of smokable methamphetamine was associated with the subsequent development of pulmonary edema and a dilated cardiomyopathy. In our second patient, the smoking of crystal methamphetamine likely produced diffuse vasospasm that resulted in acute myocardial infarction, cardiogenic shock, and death. The recognition of potentially lethal cardiac complications associated with the smoking of crystal methamphetamine is of extreme significance and should be emphasized to potential abusers of this drug.	UNIV HAWAII,JOHN A BURNS SCH MED,DEPT MED,HONOLULU,HI 96822; QUEENS HEART INST,HONOLULU,HI	University of Hawaii System			Hong, Robert/U-8600-2019	Hong, Robert/0000-0003-4861-9358				CALL TD, 1982, ANN INTERN MED, V97, P559, DOI 10.7326/0003-4819-97-4-559; COHEN S, 1975, JAMA-J AM MED ASSOC, V231, P414, DOI 10.1001/jama.231.4.414; ELLENHORN MJ, 1988, MED TOXICOLOGY DIAGN, P626; JACKSON JG, 1989, NEW ENGL J MED, V321, P907; KENDRICK WC, 1977, ANN INTERN MED, V86, P381, DOI 10.7326/0003-4819-86-4-381; Nestor T A, 1989, Hawaii Med J, V48, P457; SIMPSON DL, 1981, ARCH INTERN MED, V141, P1507, DOI 10.1001/archinte.141.11.1507; SMITH HJ, 1976, AM HEART J, V91, P792, DOI 10.1016/S0002-8703(76)80545-5; ZALIS EG, 1963, ARCH INTERN MED, V112, P822, DOI 10.1001/archinte.1963.03860060060004; 1989, EPIDEMIOLOGIC TRENDS	10	118	120	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1152	1154		10.1001/jama.265.9.1152	http://dx.doi.org/10.1001/jama.265.9.1152			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996001				2022-12-28	WOS:A1991EZ47400033
J	VYSE, T				VYSE, T			RHEUMATIC-FEVER - CHANGES IN ITS INCIDENCE AND PRESENTATION	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; RESURGENCE; AREA				VYSE, T (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0HS,ENGLAND.		Vyse, Tim J/G-3887-2011					ARNOLD MH, 1989, ANN RHEUM DIS, V48, P686, DOI 10.1136/ard.48.8.686; Ayoub EM, 1989, MOSS HEART DISEASE I, P692; CONGENI B, 1987, J PEDIATR-US, V111, P176, DOI 10.1016/S0022-3476(87)80063-X; GORDIS L, 1985, CIRCULATION, V72, P1155, DOI 10.1161/01.CIR.72.6.1155; HOSIER DM, 1987, AM J DIS CHILD, V141, P730, DOI 10.1001/archpedi.1987.04460070032015; KEFALIDES NA, 1986, J EXP MED, V163, P588, DOI 10.1084/jem.163.3.588; KHANNA AK, 1989, J CLIN INVEST, V83, P1710, DOI 10.1172/JCI114071; KRAUS W, 1988, P NATL ACAD SCI USA, V85, P4516, DOI 10.1073/pnas.85.12.4516; ROBINSON RW, 1945, AM HEART J, V29, P378, DOI 10.1016/0002-8703(45)90339-5; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WALD ER, 1987, PEDIATRICS, V80, P371; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; ZABRISKIE JB, 1982, CLIN ASPECTS IMMUNOL, P1428; 1984, CIRCULATION, V69, P204	14	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					518	520		10.1136/bmj.302.6775.518	http://dx.doi.org/10.1136/bmj.302.6775.518			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012851	Green Published, Bronze			2022-12-28	WOS:A1991FB05500026
J	NISSENSON, AR; NIMER, SD; WOLCOTT, DL				NISSENSON, AR; NIMER, SD; WOLCOTT, DL			RECOMBINANT-HUMAN-ERYTHROPOIETIN AND RENAL ANEMIA - MOLECULAR-BIOLOGY, CLINICAL EFFICACY, AND NERVOUS-SYSTEM EFFECTS	ANNALS OF INTERNAL MEDICINE			English	Discussion						ERYTHROPOIETIN, HUMAN, RECOMBINANT; ANEMIA; KIDNEY FAILURE, CHRONIC; RECOMBINANT PROTEINS; DIALYSIS, CHRONIC	COLONY-STIMULATING FACTOR; PLACEBO-CONTROLLED TRIAL; HEMATOPOIETIC STEM-CELLS; INFECTED ERYTHROID-CELLS; SERUM IMMUNOREACTIVE ERYTHROPOIETIN; AMBULATORY PERITONEAL-DIALYSIS; CHRONIC-HEMODIALYSIS PATIENTS; CONGENITAL HEART-DISEASE; FRIEND-VIRUS; HUMAN MARROW	Anemia (hematocrit < 25%) predictably accompanies chronic renal failure and is present in over 90% of patients on chronic dialysis. Relative erythropoietin deficiency is the proximate cause. Recombinant human erythropoietin recently became available for research and clinical use. Erythropoietin production is regulated by a single copy gene located on chromosome 7; its expression has been shown in the kidney, liver, and macrophages. It is a glycosylated protein of 166 amino acids with a molecular weight of 34 000 D. When given to patients with the anemia of renal failure, erythropoietin causes a dose-dependent rise in hematocrit to the normal range within 8 to 14 weeks. Complications of this response are minimal except for a significant incidence of hypertension. When the anemia is corrected, the patient's quality of life, cognitive function, and brain electrophysiology improve dramatically. Recombinant human erythropoietin represents a major breakthrough in the treatment of patients with chronic renal failure. Current reimbursement constraints limit its full application.			NISSENSON, AR (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV NEPHROL, LOS ANGELES, CA 90024 USA.							ABELS R, 1990, SEMIN NEPHROL, V10, P20; ABRAHAM PA, 1990, AM J NEPHROL, V10, P128, DOI 10.1159/000168067; ALFREY AC, 1986, KIDNEY INT       S18, V29, pS53; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BESARAB A, 1989, SEMINARS DIALYSIS, V2, P87; BIRGEGARD G, 1987, BRIT J HAEMATOL, V65, P479, DOI 10.1111/j.1365-2141.1987.tb04154.x; BLAGG CR, 1989, AM J KIDNEY DIS, V14, P347, DOI 10.1016/S0272-6386(89)80166-0; Bocker A, 1988, Contrib Nephrol, V66, P165; BOMMER J, 1988, LANCET, V2, P406; BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; BONDURANT MC, 1986, MOL CELL BIOL, V6, P2731, DOI 10.1128/MCB.6.7.2731; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; Carnot P, 1906, CR HEBD ACAD SCI, V143, P432; CARO J, 1979, J LAB CLIN MED, V93, P449; COTES PM, 1986, NEW ENGL J MED, V315, P283, DOI 10.1056/NEJM198607313150503; COTES PM, 1961, NATURE, V191, P1065, DOI 10.1038/1911065a0; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DELANO BG, 1989, AM J KIDNEY DIS, V14, P14; DENOUR AK, 1982, J PSYCHOSOM RES, V26, P11, DOI 10.1016/0022-3999(82)90058-7; DESSYPRIS EN, 1988, BLOOD, V72, P2060; DESSYPRIS EN, 1987, BRIT J HAEMATOL, V65, P265, DOI 10.1111/j.1365-2141.1987.tb06852.x; EAVES CJ, 1978, BLOOD, V52, P1196; EAVES CJ, 1985, HEMATOPOIETIC STEM C, P19; ERSLEV A, 1953, BLOOD, V8, P349, DOI 10.1182/blood.V8.4.349.349; ERSLEV AJ, 1987, J LAB CLIN MED, V109, P429; ESCHBACH JW, 1984, J CLIN INVEST, V74, P434, DOI 10.1172/JCI111439; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1988, AM J KIDNEY DIS, V11, P203, DOI 10.1016/S0272-6386(88)80150-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, AM J KIDNEY DIS, V14, P2; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; FRASER JK, 1989, EXP HEMATOL, V17, P10; FRIED W, 1972, BLOOD-J HEMATOL, V40, P671, DOI 10.1182/blood.V40.5.671.671; GARCIA DL, 1988, P NATL ACAD SCI USA, V85, P6142, DOI 10.1073/pnas.85.16.6142; GARCIA JF, 1982, J LAB CLIN MED, V99, P624; GARCIA JF, 1979, BLOOD CELLS, V5, P405; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GIBILARO SD, 1989, KIDNEY INT, V35, P247; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDWASSER E, 1974, J BIOL CHEM, V249, P4202; GOLDWASSER E, 1971, P NATL ACAD SCI USA, V68, P697, DOI 10.1073/pnas.68.4.697; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GREGORY CJ, 1978, BLOOD, V51, P527; GREGORY CJ, 1977, BLOOD, V49, P855; GREGORY CJ, 1976, J CELL PHYSIOL, V89, P289, DOI 10.1002/jcp.1040890212; GROTTA JC, 1986, STROKE, V17, P811, DOI 10.1161/01.STR.17.5.811; HAGA P, 1987, BLOOD, V70, P822; HANKINS WD, 1980, CELL, V22, P693; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; IKEBUCHI K, 1988, P NATL ACAD SCI USA, V85, P3445, DOI 10.1073/pnas.85.10.3445; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; ISCOVE NN, 1977, CELL TISSUE KINET, V10, P323, DOI 10.1111/j.1365-2184.1977.tb00300.x; ISCOVE NN, 1978, HEMATOPOIETIC CELL D, P37; JACKSON CW, 1974, J LAB CLIN MED, V84, P357; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; KANNOURAKIS G, 1988, BLOOD, V71, P758; KLEINMAN KS, 1989, AM J KIDNEY DIS, V14, P486, DOI 10.1016/S0272-6386(89)80149-0; KOEFFLER HP, 1981, ANN INTERN MED, V94, P44, DOI 10.7326/0003-4819-94-1-44; KOENE AP, 1990, NEPHROLOGIA, P131; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1982, P NATL ACAD SCI-BIOL, V79, P635, DOI 10.1073/pnas.79.2.635; KOURY MJ, 1986, J CELL PHYSIOL, V126, P259, DOI 10.1002/jcp.1041260216; KOURY ST, 1988, BLOOD, V71, P524; KRANTZ SB, 1963, J BIOL CHEM, V238, P4085; LACOMBE C, 1988, J CLIN INVEST, V81, P620, DOI 10.1172/JCI113363; LAW ML, 1986, P NATL ACAD SCI USA, V83, P6920, DOI 10.1073/pnas.83.18.6920; LEARY AG, 1988, BLOOD, V71, P1759; LIM VS, 1989, ANN INTERN MED, V110, P108, DOI 10.7326/0003-4819-110-2-108; LIM VS, 1990, KIDNEY INT, V37, P131, DOI 10.1038/ki.1990.18; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LOW I, 1989, CLIN NEPHROL, V31, P26; LOWY PH, 1960, NATURE, V185, P102, DOI 10.1038/185102a0; LUNDIN AP, 1989, SEMIN NEPHROL, V9, P22; MARSH JT, 1986, KIDNEY INT, V30, P957, DOI 10.1038/ki.1986.279; MASSRY SG, 1987, KIDNEY INT       S18, V28, pS5; MAXWELL AP, 1990, BRIT J HAEMATOL, V74, P535, DOI 10.1111/j.1365-2141.1990.tb06347.x; MAYER G, 1988, KIDNEY INT, V34, P525, DOI 10.1038/ki.1988.213; MCDONALD TP, 1987, EXP HEMATOL, V15, P719; MCSWEENY AJ, 1985, J CLIN EXP NEUROPSYC, V7, P281, DOI 10.1080/01688638508401260; MEANS RT, 1989, ARTHRITIS RHEUM-US, V32, P638, DOI 10.1002/anr.1780320519; MILES S, 1989, 5TH INT C AIDS MONTR, P550; MILLEDGE JS, 1985, J APPL PHYSIOL, V59, P360, DOI 10.1152/jappl.1985.59.2.360; MILLER CB, 1990, NEW ENGL J MED, V322, P1689, DOI 10.1056/NEJM199006143222401; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; MORELL AG, 1968, J BIOL CHEM, V243, P155; NEFF MS, 1971, CIRCULATION, V43, P876, DOI 10.1161/01.CIR.43.6.876; NEFF MS, 1981, NEW ENGL J MED, V304, P871, DOI 10.1056/NEJM198104093041504; NISSENSON AR, 1989, KIDNEY INT, V35, P257; NISSENSON AR, 1989, SEMIN NEPHROL, V9, P25; OGAWA M, 1983, BLOOD, V61, P823; OSBERG JW, 1982, J CHRON DIS, V35, P445, DOI 10.1016/0021-9681(82)90059-5; PESCHLE C, 1979, EXP HEMATOL, V7, P87; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; POWELL JS, 1986, P NATL ACAD SCI USA, V83, P6465, DOI 10.1073/pnas.83.17.6465; QUESENBERRY P, 1979, NEW ENGL J MED, V301, P755, DOI 10.1056/NEJM197910043011404; RADTKE HW, 1979, BLOOD, V54, P877; RATNER DP, 1983, J BEHAV MED, V6, P291, DOI 10.1007/BF01315115; RECNY MA, 1987, J BIOL CHEM, V262, P17156; REGE AB, 1982, J LAB CLIN MED, V100, P829; REISSMANN KR, 1950, BLOOD, V5, P372, DOI 10.1182/blood.V5.4.372.372; RICH IN, 1982, BLOOD, V60, P1007; Samtleben W, 1988, Contrib Nephrol, V66, P114; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SAWADA K, 1987, J CLIN INVEST, V80, P357, DOI 10.1172/JCI113080; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; SAWYER ST, 1987, P NATL ACAD SCI USA, V84, P3690, DOI 10.1073/pnas.84.11.3690; SAWYER ST, 1988, BLOOD, V72, pA133; SCHUSTER SJ, 1987, BLOOD, V70, P316; SHERWOOD JB, 1986, BLOOD, V67, P46; SHERWOOD JB, 1979, BLOOD, V54, P885; SHINABERGER JH, 1989, KIDNEY INT, V35, P264; SHINABERGER JH, 1989, REPLACEMENT RENAL FU, P360; SIEFF CA, 1985, SCIENCE, V230, P1171, DOI 10.1126/science.3877981; SIMMONS RG, 1984, AM J KIDNEY DIS, V4, P253, DOI 10.1016/S0272-6386(84)80101-8; SONODA Y, 1988, BLOOD, V72, P1381; SONODA Y, 1988, P NATL ACAD SCI USA, V85, P4360, DOI 10.1073/pnas.85.12.4360; SOUHEAVER GT, 1982, J CLIN PSYCHOL, V38, P490, DOI 10.1002/1097-4679(198207)38:3<490::AID-JCLP2270380305>3.0.CO;2-K; STEPHENSON JR, 1971, P NATL ACAD SCI USA, V68, P1542, DOI 10.1073/pnas.68.7.1542; STOHLMAN F, 1954, BLOOD, V9, P721, DOI 10.1182/blood.V9.7.721.721; STONE WJ, 1988, AM J MED SCI, V296, P171, DOI 10.1097/00000441-198809000-00005; TERADA M, 1972, P NATL ACAD SCI USA, V69, P3575, DOI 10.1073/pnas.69.12.3575; TESCHAN PE, 1979, KIDNEY INT, V15, P676, DOI 10.1038/ki.1979.88; TYNDALL MR, 1987, J PEDIATR-US, V110, P538, DOI 10.1016/S0022-3476(87)80544-9; VANDENNOORT S, 1968, J CLIN INVEST, V47, P2133, DOI 10.1172/JCI105899; VANWYCK DB, 1989, AM J KIDNEY DIS, V14, P9; VANZANT G, 1984, GROWTH MATURATION FA, V2, P1; WANG FF, 1985, ENDOCRINOLOGY, V116, P2286, DOI 10.1210/endo-116-6-2286; WARE JE, 1984, CANCER, V53, P2316; WATKINS PC, 1986, CYTOGENET CELL GENET, V42, P214, DOI 10.1159/000132281; WEISS TL, 1981, BIOCHEM J, V198, P17, DOI 10.1042/bj1980017; WESTBROOK CA, 1984, J BIOL CHEM, V259, P9992; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6; WOLCOTT DL, 1989, AM J KIDNEY DIS, V14, P478, DOI 10.1016/S0272-6386(89)80148-9; WOLCOTT DL, 1988, AM J KIDNEY DIS, V11, P402, DOI 10.1016/S0272-6386(88)80053-2; WOLCOTT DL, 1988, AM J KIDNEY DIS, V12, P275, DOI 10.1016/S0272-6386(88)80220-8; WOLCOTT DL, 1990, CLIN DIALYSIS, P735; ZANJANI ED, 1974, BLOOD, V44, P285, DOI 10.1182/blood.V44.2.285.285; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640; ZEHNDER C, 1989, CLIN NEPHROL, V31, P55; 1989, KIDNEY INT, V35, P915	147	61	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					402	416		10.7326/0003-4819-114-5-402	http://dx.doi.org/10.7326/0003-4819-114-5-402			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992884				2022-12-28	WOS:A1991EZ17400010
J	COBB, MM; TEITELBAUM, HS; BRESLOW, JL				COBB, MM; TEITELBAUM, HS; BRESLOW, JL			LOVASTATIN EFFICACY IN REDUCING LOW-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS ON HIGH-FAT VS LOW-FAT DIETS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The effectiveness of lovastatin was compared with both a high-fat vs low-fat diet. Hypercholesterolemic subjects were studied under metabolic ward conditions for diet periods of 3 weeks while receiving lovastatin (40 mg/d) or placebo. Multiple lipoprotein levels were measured during the final week of each diet period. Nineteen subjects completed the study on the high-fat (43% of kilojoules) diet and 16 on the low-fat (25% of kilojoules) diet. Lovastatin reduced total cholesterol by 23% and low-density lipoprotein cholesterol by 30%, compared with placebo on both diets, with no significant diet-drug interaction. High-density lipoprotein cholesterol was raised by 7% to 8% on the diet regimens. Addition of lovastatin to the low-fat diet permitted 80% of subjects on this diet, but less than 50% of those on the high-fat diet, to achieve current guidelines. Although lovastatin produces a comparable percentage reduction in lipoprotein profiles on either diet, the accompanying low-fat diet remains advisable for additional reduction of low-density lipoprotein cholesterol levels to specified goals.	ROCKEFELLER UNIV, BIOCHEM GENET & METAB LAB, NEW YORK, NY 10021 USA; MICHIGAN STATE UNIV, DEPT COMMUNITY HLTH SCI, E LANSING, MI 48824 USA	Rockefeller University; Michigan State University			Breslow, Jan L/B-7544-2008		NATIONAL CANCER INSTITUTE [P01CA029502, P30CA029502] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036461, R01HL032435] Funding Source: NIH RePORTER; NCI NIH HHS [CA29502] Funding Source: Medline; NHLBI NIH HHS [HL32435, HL36461] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; DENKE MA, 1988, J LIPID RES, V29, P963; EHNHOLM C, 1984, ARTERIOSCLEROSIS, V4, P265, DOI 10.1161/01.ATV.4.3.265; FISHER EA, 1983, J LIPID RES, V24, P1039; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; GRUNDY SM, 1984, P NATL ACAD SCI-BIOL, V81, P2538, DOI 10.1073/pnas.81.8.2538; GRUNDY SM, 1984, ARTERIOSCLEROSIS, V4, pA445; HARRIS JA, 1919, CARNEGIE I WASHINGTO, P279; HERBERT PN, 1985, J CLIN INVEST, V76, P403, DOI 10.1172/JCI111986; HORWITZ W, 1987, OFFICIAL METHODS ANA; KAY RM, 1985, ATHEROSCLEROSIS, V55, P15, DOI 10.1016/0021-9150(85)90162-5; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; KEYS A, 1984, AM J CLIN NUTR, V40, P351, DOI 10.1093/ajcn/40.2.351; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; LAROSA J, 1990, AM J CARDIOL, V65, P7; MABUCHI H, 1977, ATHEROSCLEROSIS, V28, P61, DOI 10.1016/0021-9150(77)90199-X; MAHLEY RW, 1981, J CLIN INVEST, V68, P1197, DOI 10.1172/JCI110365; MARTENS LL, 1990, AM J CARDIOL, V65, pF27; MORGAN T, 1988, J HYPERTENS, V6, pS652, DOI 10.1097/00004872-198812040-00205; NETTER J, 1985, APPLIED LINEAR STATI; PENCE BC, 1987, TOXICOL LETT, V37, P177, DOI 10.1016/0378-4274(87)90155-X; RIFKIND BM, 1980, NIH801527 PUBL, P70; ROANE DS, 1990, PHARMACOL BIOCHEM BE, V35, P225, DOI 10.1016/0091-3057(90)90230-F; SCHAEFER EJ, 1981, AM J CLIN NUTR, V34, P1758, DOI 10.1093/ajcn/34.9.1758; SCHEFLER WC, 1984, STATISTICS HLTH PROF, P222; SNEDECOR GW, 1982, STATISTICAL METHODS, P255; TIKKANEN MJ, 1988, AM J CARDIOL, V62, pJ35, DOI 10.1016/0002-9149(88)90005-7; TINT GS, 1990, J LIPID RES, V31, P1301; TOBERT JA, 1990, AM J CARDIOL, V65, pF23; TOBERT JA, 1986, JAMA-J AM MED ASSOC, V256, P2829; WALKER JF, 1990, AM J CARDIOL, V65, pF19; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEINBERGER MH, 1988, J CARDIOVASC PHARM, V12, pS72, DOI 10.1097/00005344-198806124-00014; WITZTUM JL, 1989, CIRCULATION, V79, P16, DOI 10.1161/01.CIR.79.1.16; 1981, VITAL HLTH STAT 11, V231, P46; 1975, USDA AGR HDB, V8	37	49	49	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					997	1001		10.1001/jama.265.8.997	http://dx.doi.org/10.1001/jama.265.8.997			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992214				2022-12-28	WOS:A1991EY43200028
J	CECH, TR				CECH, TR			RNA EDITING - WORLDS SMALLEST INTRONS	CELL			English	Review							TRYPANOSOMA-BRUCEI; MITOCHONDRIA; TRANSCRIPTS; NUCLEOTIDES; MODEL				CECH, TR (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; STUART K, 1991, IN PRESS TRENDS BIOC; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1990, EMBO J, V9, P257, DOI 10.1002/j.1460-2075.1990.tb08103.x; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	19	130	132	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					667	669		10.1016/0092-8674(91)90494-J	http://dx.doi.org/10.1016/0092-8674(91)90494-J			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997201				2022-12-28	WOS:A1991EZ47800001
J	MIRANKER, A; RADFORD, SE; KARPLUS, M; DOBSON, CM				MIRANKER, A; RADFORD, SE; KARPLUS, M; DOBSON, CM			DEMONSTRATION BY NMR OF FOLDING DOMAINS IN LYSOZYME	NATURE			English	Article							EGG-WHITE LYSOZYME; MOLTEN GLOBULE STATE; ALPHA-LACTALBUMIN; RIBONUCLEASE-A; PROTEIN; INTERMEDIATE; EXCHANGE; KINETICS	ALTHOUGH there has been much speculation on the pathways of protein folding, only recently have experimental data on the topic been available. The study of proteins under conditions where species intermediate between the fully folded and unfolded states are stable has provided important information, for example about the disulphide intermediates in BPTI 1,2, cis/trans proline isomers of RNase A3 and the molten globule state of alpha-lactalbumin 4. An alternative approach to investigating folding pathways has involved detection and characterization of transient conformers in refolding studies using stopped-flow methods coupled with NMR measurements of hydrogen exchange 5,6. The formation of intermediate structures has been detected in the early stages of folding of cytochrome c (ref. 7), RNaseA 8 and barnase 9. For alpha-lactalbumin, hydrogen exchange kinetics monitored by NMR proved to be crucial for identifying native-like molten globule state 10. An analogous partially folded protein stable under equilibrium conditions has not been observed for the structurally homologous protein hen egg-white lysozyme, although there is evidence that a similar but transient state is formed during refolding. Here we describe NMR experiments based on competition between hydrogen exchange and the refolding process which not only support the existence of such a transient species for lysozyme, but enable its structural characteristics to be defined. The results indicate that the two structural domains of lysozyme are distinct folding domains, in that they differ significantly in the extent to which compact, probably native-like, structure is present in the early stages of folding.	UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 3QR,ENGLAND; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3QR,ENGLAND	University of Oxford; Harvard University; University of Oxford	MIRANKER, A (corresponding author), HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,7 DIVIN ST,CAMBRIDGE,MA 02138, USA.			Radford, Sheena/0000-0002-3079-8039				BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P365, DOI 10.1098/rspb.1967.0034; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; Imoto T., 1972, ENZYMES, V7, P665; JANIN J, 1983, PROG BIOPHYS MOL BIO, V42, P21, DOI 10.1016/0079-6107(83)90003-2; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KATO S, 1981, BIOCHEMISTRY-US, V20, P1080, DOI 10.1021/bi00508a006; Kim P S, 1986, Methods Enzymol, V131, P136; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0; PEDERSEN TG, 1987, J MOL BIOL, V197, P111; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; REDFIELD C, 1988, BIOCHEMISTRY-US, V27, P122, DOI 10.1021/bi00401a020; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHMID FX, 1983, BIOCHEMISTRY-US, V22, P4690, DOI 10.1021/bi00289a013; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; TANFORD C, 1973, J MOL BIOL, V73, P185, DOI 10.1016/0022-2836(73)90322-7; TOPPING KD, 1988, THESIS U OXFORD; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0	29	240	240	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					633	636		10.1038/349633a0	http://dx.doi.org/10.1038/349633a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000138				2022-12-28	WOS:A1991EX57000067
J	RAVN, P; LUNDGREN, JD; KJAELDGAARD, P; HOLTENANDERSON, W; HOJLYNG, N; NIELSEN, JO; GAUB, J				RAVN, P; LUNDGREN, JD; KJAELDGAARD, P; HOLTENANDERSON, W; HOJLYNG, N; NIELSEN, JO; GAUB, J			NOSOCOMIAL OUTBREAK OF CRYPTOSPORIDIOSIS IN AIDS PATIENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIARRHEA	Objective-To describe a nosocomial outbreak of cryptosporidiosis during four months after June 1989. Setting-A department of infectious diseases in Copenhagen, seeing about half the patients with AIDS in Denmark. Subjects-73 HIV antibody negative subjects and 60 antibody positive subjects admitted as inpatients during the transmission period of the outbreak (20 June-14 August), of whom 18 (17 with AIDS, one with AIDS related complex), developed cryptosporidiosis. Two further HIV negative subjects (one departmental secretary, one visiting relative) developed cryptosporidiosis. Main outcome measures-Cryptosporidia in stool samples, clinical symptoms, CD4 cell count, HIV antigen concentration, chemotherapeutic treatment. Results-The source of the outbreak was identified as ice from an ice machine in the ward, contaminated by an incontinent, psychotic patient with cryptosporidiosis picking out ice for cold drinks. The mean incubation time was at least 13 days-that is, twice that in HIV-negative patients. Of the 18 patients with AIDS who developed cryptosporidiosis, five recovered, two were symptomless carriers, three died of unrelated causes, and eight died after prolonged diarrhoea. Among the 57 exposed HIV antibody positive inpatients (excluding two patients and the index case with cryptosporidiosis diagnosed elsewhere), significantly more of those who developed symptomatic cryptosporidiosis received oral sulphonamides than those who did not (91%, 10/11-upsilon-48%, 21/44, p < 0.05). Conclusions-The clinical and epidemiological findings indicate that infection was the consequence of very small inocula. Increased sensitivity to cryptosporidiosis may be an unrecognised side effect of oral sulphonamide treatment in patients with AIDS.	HVIDOVRE UNIV HOSP, DEPT INFECT DIS, 144, DK-2650 HVIDOVRE, DENMARK; HVIDOVRE UNIV HOSP, DEPT CLIN MICROBIOL, DK-2650 HVIDOVRE, DENMARK; STATENS SERUM INST, DEPT TOXOPLASMOSIS, DK-2300 COPENHAGEN, DENMARK	University of Copenhagen; University of Copenhagen; Statens Serum Institut			Lundgren, Jens/AAE-6876-2019	Lundgren, Jens/0000-0001-8901-7850				CASEMORE DP, 1990, EPIDEMIOL INFECT, V104, P1, DOI 10.1017/S0950268800054480; CONNOLLY GM, 1988, GUT, V29, P593, DOI 10.1136/gut.29.5.593; CURRENT WL, 1988, AM SOC MICROBIOLOGY, V54, P604; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; HOJLYNG N, 1986, J CLIN MICROBIOL, V23, P1109; HOLTENANDERSEN W, 1984, J INFECTION, V9, P277, DOI 10.1016/S0163-4453(84)90618-2; HORNICK RB, 1970, NEW ENGL J MED, V283, P686, DOI 10.1056/NEJM197009242831306; JANOFF EN, 1990, ANN INTERN MED, V112, P75, DOI 10.7326/0003-4819-112-1-75; JOKIPII AMM, 1985, LANCET, V2, P487; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; MARTINO P, 1988, J INFECT DIS, V158, P647, DOI 10.1093/infdis/158.3.647; NAVIN TR, 1987, J INFECT DIS, V155, P150, DOI 10.1093/infdis/155.1.150; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PEDERSEN C, 1990, AIDS, V4, P233, DOI 10.1097/00002030-199003000-00009; ROLSTON KVI, 1989, J ACQ IMMUN DEF SYND, V2, P426; UNGAR BLP, 1990, GASTROENTEROLOGY, V98, P486, DOI 10.1016/0016-5085(90)90842-O; ZAR F, 1985, J INFECT DIS, V151, P195, DOI 10.1093/infdis/151.1.195	17	61	66	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	1991	302	6771					277	280		10.1136/bmj.302.6771.277	http://dx.doi.org/10.1136/bmj.302.6771.277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998796	Green Published, Bronze			2022-12-28	WOS:A1991EX91900024
J	HOLMEN, J; FORSEN, L; HJORT, PF; MIDTHJELL, K; WAALER, HT; BJORNDAL, A				HOLMEN, J; FORSEN, L; HJORT, PF; MIDTHJELL, K; WAALER, HT; BJORNDAL, A			DETECTING HYPERTENSION - SCREENING VERSUS CASE FINDING IN NORWAY	BRITISH MEDICAL JOURNAL			English	Article							POPULATION-SAMPLE; CONTROL PROGRAM; COMMUNITY	Objective-Evaluation of detection of hypertension in adults in the county of Nord-Trondelag, Norway. Design-Cross sectional survey with clinical follow up examinations. Setting-Health survey by screening teams from the national health screening service, and examinations by all 106 general practitioners in the county. Subject-During 1984-6, 74977 persons (88.1% of those aged 20 years and over) participated in the health survey. Main outcome measures-Hypertension (when assessed by standardised recording and by questionnaires on drug treatment for hypertension) according to the blood pressure thresholds used in the Norwegian treatment programme. Subjects positive on screening were grouped after clinical examination into treatment groups. Results-In all, 2399 subjects were positive for hypertension. Before screening 6210 (8.3%) patients reported taking antihypertensive drugs and another 3849 (5.1%) had their blood pressure monitored regularly. All who screened positive were referred to their general practitioner and evaluated according to a standard programme. As a result, drug treatment was started in 406 (0.5%) participants screened and blood pressure monitoring in another 1007 (1.3%). Of all patients taking antihypertensive drugs after the screening, 6399 (94.0%) had been diagnosed before screening, and of those whose blood pressure was monitored after the screening, 79.3% had been diagnosed before screening. Conclusions-At the blood pressure screening threshold used, and when hypertension is defined by an overall clinical diagnosis, the results indicate that general practitioners can find and diagnose hypertensive patients with the case finding strategy.	NATL INST PUBL HLTH,HLTH SERV RES UNIT,OSLO 1,NORWAY		HOLMEN, J (corresponding author), NATL INST PUBL HLTH,COMMUNITY MED RES CTR,POB 234,N-7651 VERDALSORA,NORWAY.							AROMAA A, 1979, NORD MED, V92, P204; Berglund G, 1978, Lakartidningen, V75, P4253; BERGLUND G, 1974, ACTA MED SCAND, V196, P301; BERGLUND G, 1977, S52 SWED PLANN RAT I; DANNENBERG AL, 1988, AM J PUBLIC HEALTH, V78, P676, DOI 10.2105/AJPH.78.6.676; EILERTSEN E, 1968, ACTA MED SCAND, V183, P293; GROSS F, 1984, MANAGEMENT ARTERIAL; HART JT, 1980, HYPERTENSION; Hines E, 1981, J Med Assoc Ga, V70, P353; HOLMEN J, 1989, 1 STAT I FOLK AVD HE; HOLMEN J, 1981, BLODTRYKKSPROGRAM NO; HOLMEN J, 1989, 5 STAT I FOLK AVD HE; HOLMEN J, 1983, 10 GRUPP HELS FORSKN; HOLMEN J, 1986, 11 GRUPP HELS EFF RA; HOLMEN J, 1990, 4 NAT I PUBL HLTH; KRISHAN I, 1981, MAYO CLIN PROC, V56, P3; KVAMME JI, 1980, HYPERTENSJON DISTRIK, V3; LABARTHE DR, 1979, MAYO CLIN PROC, V54, P289; MOSER M, 1977, JAMA-J AM MED ASSOC, V237, P255; NISSINEN A, 1980, SCAND J SOC MED, V8, P17, DOI 10.1177/140349488000800103; RASTAM L, 1986, ACTA MED SCAND, V219, P249; SIGURDSSON JA, 1981, SCAND J SOC MED, V9, P41, DOI 10.1177/140349488100900106; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STAMLER J, 1976, JAMA-J AM MED ASSOC, V235, P2299, DOI 10.1001/jama.235.21.2299; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; TUOMILEHTO J, 1980, SCAND J SOC MED, V8, P9, DOI 10.1177/140349488000800102; WAALER HT, 1978, 5 GRUPP HELS FORSKN; WILBER JA, 1972, AM J MED, V52, P653, DOI 10.1016/0002-9343(72)90055-1; 1989, BMJ, V298, P694; 1985, HYPERTENSION, V7, P457; 1981, PREVENTION ARTERIAL; 1988, ARCH INTERN MED, V148, P1023; 1989, J HYPERTENS, V7, P689	33	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					219	222		10.1136/bmj.302.6770.219	http://dx.doi.org/10.1136/bmj.302.6770.219			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998765	Green Published, Bronze			2022-12-28	WOS:A1991EV22800030
J	PETERS, BS; BECK, EJ; COLEMAN, DG; WADSWORTH, MJH; MCGUINNESS, O; HARRIS, JRW; PINCHING, AJ				PETERS, BS; BECK, EJ; COLEMAN, DG; WADSWORTH, MJH; MCGUINNESS, O; HARRIS, JRW; PINCHING, AJ			CHANGING DISEASE PATTERNS IN PATIENTS WITH AIDS IN A REFERRAL CENTER IN THE UNITED-KINGDOM - THE CHANGING FACE OF AIDS	BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; TRIMETHOPRIM; EXPERIENCE; EFFICACY; SURVIVAL	Objective-To study the changes in morbidity, mortality, and survival patterns in a population of patients with AIDS in the United Kingdom from 1982 to 1989. Design-A retrospective analysis of inpatient and outpatient records of patients with AIDS. Subjects-347 Patients with AIDS, predominantly homosexual or bisexual men. Setting-Department of immunology and genitourinary medicine, St Mary's Hospital, London. Main outcome measures-Presenting diagnosis of AIDS, occurrence of other opportunist diseases, cause of death, and survival since AIDS was diagnosed, in particular for those patients with Pneumocystis carinii pneumonia or Kaposi's sarcoma. Results-The overall proportion of patients who developed P carinii pneumonia dropped from 56% (20/36) in 1984 to 24% (46/194) in 1989, although it has remained the index diagnosis in about half of new patients. Kaposi's sarcoma has decreased as index diagnosis from 30% (20/67) to 20% (15/74) over the same period, though the prevalance has remained constant at around 35%. P carinii pneumonia accounted for 46% (16/35) of known causes of death in 1986 but only 3% (1/31) in 1989. Conversely, deaths due to Kaposi's sarcoma rose from 14% (1/7) to 32% (10/31) between 1984 and 1989. Lymphoma accounted for an increased proportion of deaths among these patients with 16% (5/31) of deaths in 1989. Their median survival increased from 10 months in 1984-6 to 20 months in 1987. Conclusions-The changing patterns of disease in patients with AIDS have important implications both for health care provision and future medical research. Medical and nursing provision must be made for the increased morbidity of these diseases and the increased survival of these patients. Research should now be directed towards developing effective treatments for the opportunist infections which are currently more difficult to treat, the secondary malignancies of AIDS, as well as more effective immunorestorative treatments. Future changes in disease patterns must be recognised at an early stage so that resources can be adequately planned and allocated.	ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED,LONDON W2 1PG,ENGLAND	Imperial College London; Imperial College London	PETERS, BS (corresponding author), ST MARYS HOSP,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND.							ARMITAGE P, 1987, STATISTICAL METHODS, P429; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GARDNER TD, 1989, J INFECTION, V18, P111, DOI 10.1016/S0163-4453(89)91038-4; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; LEOUNG GS, 1986, ANN INTERN MED, V105, P45, DOI 10.7326/0003-4819-105-1-45; MACFADDEN DK, 1987, LANCET, V1, P1477, DOI 10.1016/S0140-6736(87)92219-7; PENN I, 1986, PROG ALLERGY, V37, P259; PETERS BS, 1990, LANCET, V335, P545, DOI 10.1016/0140-6736(90)90782-Z; PETERS BS, 1990, AIDS, V4, P367, DOI 10.1097/00002030-199004000-00016; PETERS BS, IN PRESS Q J MED; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; RUTHERFORD GW, 1989, J INFECT DIS, V159, P567; SELIK RM, 1987, AIDS, V1, P175; STAMBUK D, 1989, Q J MED, V262, P161; SWART AM, 1990, BRIT MED J, V301, P825, DOI 10.1136/bmj.301.6756.825; THOMAS S, 1990, BRIT MED J, V300, P211, DOI 10.1136/bmj.300.6719.211; 1987, MMWR S1S, V36, pS1	21	160	160	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					203	207		10.1136/bmj.302.6770.203	http://dx.doi.org/10.1136/bmj.302.6770.203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998759	Bronze, Green Published			2022-12-28	WOS:A1991EV22800023
J	FLANAGAN, PM; KELLEHER, RJ; SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD				FLANAGAN, PM; KELLEHER, RJ; SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD			A MEDIATOR REQUIRED FOR ACTIVATION OF RNA POLYMERASE-II TRANSCRIPTION INVITRO	NATURE			English	Article							PREINITIATION COMPLEX; GAL4 DERIVATIVES; FACTOR ATF; YEAST; GENE; INITIATION; MECHANISM; BINDING; PROMOTERS; INTERACTS	ACTIVATOR proteins bind to enhancer DNA elements and stimulate the initiation of transcription. It has been proposed 1-3 that activators contact general initiation factors at a promoter, and evidence for such direct interaction has been obtained 4-10. Studies of transcription in vitro, however, have suggested that activators might function through an intermediary molecule(s) distinct from the general factors. In the first of these studies 11,12, we exploited the finding that one activator could inhibit transcription stimulated by a second activator (activator interference or 'squelching') 13-15. This inhibition, which is attributed to competition between the activators for a common target factor, could not be relieved by addition of a large excess of general initiation factors, suggesting that the target for which activators compete is distinct from these factors. Similar conclusions came from the observation that TFIID's expressed from cloned genes 16-18 fail to replace partially purified 'natural' TFIID fractions in supporting activation, evidently because they lacked some component present in the impure fractions. While these lines of evidence for a novel 'mediator' of activation were negative, we also showed that a partially purified fraction from yeast would reverse activator interference 12. This positive effect of a presumptive mediator provided an assay for its activity, but its role in activation was still only inferred. We now present direct evidence for a mediator which is required for stimulation of transcription in vitro by the activators GAL4-VP16 and GCN4, but which has no effect on transcription in the absence of activator protein.			FLANAGAN, PM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,FAIRCHILD CTR,DEPT CELL BIOL,STANFORD,CA 94305, USA.							BRANDL CJ, 1989, P NATL ACAD SCI USA, V86, P2652, DOI 10.1073/pnas.86.8.2652; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GUARENTE L, 1988, CELL, V52, P303, DOI 10.1016/S0092-8674(88)80020-5; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KORNBERG RD, 1989, GENE REGULATION AIDS, P9; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718	27	296	308	3	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					436	438		10.1038/350436a0	http://dx.doi.org/10.1038/350436a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011193				2022-12-28	WOS:A1991FF04200055
J	TURK, E; ZABEL, B; MUNDLOS, S; DYER, J; WRIGHT, EM				TURK, E; ZABEL, B; MUNDLOS, S; DYER, J; WRIGHT, EM			GLUCOSE GALACTOSE MALABSORPTION CAUSED BY A DEFECT IN THE NA+/GLUCOSE COTRANSPORTER	NATURE			English	Article							HUMAN INTESTINAL NA+/GLUCOSE; POLYMERASE CHAIN-REACTION; SINGLE-STRANDED-DNA; TRANSPORTER; EXPRESSION; NUMBERS; CELLS; CDNA	GLUCOSE/galactose malabsorption (GGM) is an autosomal recessive disease manifesting within the first weeks of life and characterized by a selective failure to absorb dietary glucose and galactose from the intestine 1. The consequent severe diarrhoea and dehydration are usually fatal unless these sugars are eliminated from the diet. Intestinal biopsies of GGM patients have revealed a specific defect in Na+-dependent absorption of glucose in the brush border 2-4. Normal glucose absorption is mediated by the Na+/glucose cotransporter in the brush border membrane of the intestinal epithelium 5. Cellular influx is driven by the transmembrane Na+ electrochemical potential gradient; thereafter the sugar moves to the blood across the basolateral membrane via the facilitated glucose carrier. We have previously cloned and sequenced a Na+/glucose cotransporter from normal human ileum 6 and shown that this gene, SGLT1, resides on the distal q arm of chromosome 22 7. We have now amplified SGLT1 complementary DNA and genomic DNA from members of a family affected with GGM by the polymerase chain reaction 8. Sequence analysis of the amplified products has revealed a single missense mutation in SGLT1 which cosegregates with the GGM phenotype and results in a complete loss of Na+-dependent glucose transport in Xenopus oocytes injected with this complementary RNA.	UNIV MAINZ,DEPT PEDIAT,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz	TURK, E (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024, USA.		Mundlos, Stefan/ABH-9585-2020					BOOTH IW, 1988, GUT, V29, P1661, DOI 10.1136/gut.29.12.1661; Desjeux JF, 1989, METABOLIC BASIS INHE, P2463; ELSAS L J, 1970, Journal of Clinical Investigation, V49, P576, DOI 10.1172/JCI106268; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1989, GENOMICS, V4, P297, DOI 10.1016/0888-7543(89)90333-9; HEDIGER MA, IN PRESS BIOCH BIOPH; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; KIMMICH GA, 1981, AM J PHYSIOL, V241, pC227, DOI 10.1152/ajpcell.1981.241.5.C227; KIMMICH GA, 1981, PHYSL GASTROINTESTIN, P1035; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; STIRLING CE, 1972, J CLIN INVEST, V51, P438, DOI 10.1172/JCI106830; YANG JL, 1989, GENE, V83, P347, DOI 10.1016/0378-1119(89)90121-2	17	297	320	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					354	356		10.1038/350354a0	http://dx.doi.org/10.1038/350354a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008213				2022-12-28	WOS:A1991FD83800097
J	HOLLEY, HP				HOLLEY, HP			SUCCESSFUL TREATMENT OF CAT-SCRATCH DISEASE WITH CIPROFLOXACIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; BACTERIAL-INFECTION; CULTURE; LESIONS	Cat-scratch disease is usually a benign, self-limited disease. Infection may be asymptomatic but is commonly associated with painful regional lymphadenitis. Occasionally, disease may result in systemic symptoms and dissemination. Five adult patients, aged 24 to 57 years, were diagnosed as having cat-scratch disease, based on a positive history of cat scratches followed by typical symptoms including painful regional lymphadenitis, malaise, and positive cat-scratch skin tests. Diagnostic evaluations revealed no other cause for the lymphadenitis. Three patients had not received prior treatment with antibiotics, and two patients had failed to improve on other antibiotics. All five were treated with oral ciprofloxacin, 500 mg by mouth, twice daily. All patients had dramatic improvement in symptoms within a few days and none has relapsed during follow-up. This is the first report of successful treatment of cat-scratch disease with ciprofloxacin, which appears to be an effective therapy for cat-scratch disease in adults.			HOLLEY, HP (corresponding author), MED UNIV S CAROLINA,DIV INFECT DIS,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.							BLACK JR, 1986, ARCH INTERN MED, V146, P394, DOI 10.1001/archinte.146.2.394; BOGUE CW, 1989, JAMA-J AM MED ASSOC, V1262, P813; CAMPOLIRICHARDS DM, 1988, DRUGS, V35, P373, DOI 10.2165/00003495-198835040-00003; CARITHERS HA, 1969, J AMER MED ASSOC, V207, P312, DOI 10.1001/jama.207.2.312; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; COLLIPP PJ, 1989, AM J DIS CHILD, V143, P1261, DOI 10.1001/archpedi.1989.02150230019008; DANIELS WB, 1954, JAMA-J AM MED ASSOC, V154, P1247, DOI 10.1001/jama.1954.02940490011003; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; FISCHER GW, 1990, PRINCIPLES PRACTICE, P1874; FLESSNER MF, 1989, JAMA-J AM MED ASSOC, V261, P991, DOI 10.1001/jama.1989.03420070041019; KOEHLER JE, 1988, ANN INTERN MED, V109, P449, DOI 10.7326/0003-4819-109-6-449; Korbitz B C, 1973, Rocky Mt Med J, V70, P23; LEFKOWITZ M, 1989, ARCH PATHOL LAB MED, V113, P473; LENOIR AA, 1988, LANCET, V1, P1132; MARGILETH AM, 1987, J INFECT DIS, V155, P390, DOI 10.1093/infdis/155.3.390; MARGILETH AM, 1968, PEDIATRICS, V42, P803; MARGILETH AM, 1987, INFECT SURG, V6, P572; MARGILETH AM, 1985, CECIL TXB MED, P1618; RIZKALLAH MF, 1988, PEDIATR INFECT DIS J, V7, P191, DOI 10.1097/00006454-198803000-00011; ROCCO VK, 1985, GASTROENTEROLOGY, V89, P1400, DOI 10.1016/0016-5085(85)90661-4; SCHLOSSBERG D, 1989, ARCH INTERN MED, V149, P1437, DOI 10.1001/archinte.149.6.1437; WEAR DJ, 1983, SCIENCE, V221, P1403, DOI 10.1126/science.6612349	22	56	57	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1563	1565		10.1001/jama.265.12.1563	http://dx.doi.org/10.1001/jama.265.12.1563			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999905				2022-12-28	WOS:A1991FC60400032
J	HEITZ, D; ROUSSEAU, F; DEVYS, D; SACCONE, S; ABDERRAHIM, H; LEPASLIER, D; COHEN, D; VINCENT, A; TONIOLO, D; DELLAVALLE, G; JOHNSON, S; SCHLESSINGER, D; OBERLE, I; MANDEL, JL				HEITZ, D; ROUSSEAU, F; DEVYS, D; SACCONE, S; ABDERRAHIM, H; LEPASLIER, D; COHEN, D; VINCENT, A; TONIOLO, D; DELLAVALLE, G; JOHNSON, S; SCHLESSINGER, D; OBERLE, I; MANDEL, JL			ISOLATION OF SEQUENCES THAT SPAN THE FRAGILE-X AND IDENTIFICATION OF A FRAGILE-X RELATED CPG ISLAND	SCIENCE			English	Article							CHROMOSOME; DNA; EXPRESSION; SEGMENTS; SITES; YEAST; LOCUS	Yeast artificial chromosomes (YACs) were obtained from a 550-kilobase region that contains three probes previously mapped as very close to the locus of the fragile X syndrome. These YACs spanned the fragile site in Xq27.3 as shown by fluorescent in situ hybridization. An internal 200-kilobase segment contained four chromosomal breakpoints generated by induction of fragile X expression. A single CpG island was identified in the cloned region between markers DXS463 and DXS465 that appears methylated in mentally retarded fragile X males, but not in nonexpressing male carriers of the mutation nor in normal males. This CpG island may indicate the presence of a gene involved in the clinical phenotype of the syndrome.	UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL, I-27100 PAVIA, ITALY; CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE; CNR, IST GENET BIOCHIM & EVOLUT, I-27100 PAVIA, ITALY; WASHINGTON UNIV, SCH MED, CTR GENET MED, ST LOUIS, MO 63110 USA	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Washington University (WUSTL)	HEITZ, D (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Toniolo, Daniela/AAE-2969-2019; Saccone, Salvatore/H-1548-2012	Toniolo, Daniela/0000-0001-9545-6032; Saccone, Salvatore/0000-0001-7568-5823; Devys, Didier/0000-0001-9655-3512; Le Paslier, Denis/0000-0003-4335-9956				ABIDI FE, 1990, GENOMICS, V7, P363, DOI 10.1016/0888-7543(90)90170-Y; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; FUJITA R, 1990, P NATL ACAD SCI USA, V87, P1796, DOI 10.1073/pnas.87.5.1796; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HARRISON CJ, 1983, J MED GENET, V20, P280, DOI 10.1136/jmg.20.4.280; HEITZ D, UNPUB; KANDPAL RP, 1990, NUCLEIC ACIDS RES, V18, P3081, DOI 10.1093/nar/18.10.3081; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1987, GENETICS, V117, P587; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MAESTRINI E, 1990, GENOMICS, V8, P664, DOI 10.1016/0888-7543(90)90253-Q; MONTANARO V, IN PRESS AM J HUM GE; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; POUSTKA A, 1988, GENET ENG, V10, P169; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, UNPUB; SHAW J, 1990, CYTOGENET CELL GENET, V53, P221, DOI 10.1159/000132936; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SOUTHERN EM, 1987, NUCLEIC ACIDS RES, V15, P5925, DOI 10.1093/nar/15.15.5925; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERLAND GR, 1985, AM J MED GENET, V22, P433, DOI 10.1002/ajmg.1320220234; SVED JA, 1990, AM J HUM GENET, V46, P443; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; Vincent A. C., UNPUB; WADA M, 1990, AM J HUM GENET, V46, P95; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WILLARD HF, 1983, NUCLEIC ACIDS RES, V11, P2017, DOI 10.1093/nar/11.7.2017; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806	33	176	180	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1236	1239		10.1126/science.2006411	http://dx.doi.org/10.1126/science.2006411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006411				2022-12-28	WOS:A1991FA69100043
J	LIN, YS; GREEN, MR				LIN, YS; GREEN, MR			MECHANISM OF ACTION OF AN ACIDIC TRANSCRIPTIONAL ACTIVATOR INVITRO	CELL			English	Article							RNA-POLYMERASE-II; PREINITIATION COMPLEX; INITIATION-FACTOR; FUNCTIONAL-ANALYSIS; GENE-TRANSCRIPTION; FACTOR ATF; PROMOTER; PURIFICATION; PROTEIN; GAL4	Transcription of a eukaryotic structural gene by RNA polymerase II requires the ordered assembly of general transcription factors on the promoter to form a preinitiation complex. Here we analyze affinity-purified complexes at various stages of assembly to determine the mechanism of action of an acidic transcriptional activator. We show that the activator can function in the absence of ATP and stimulates transcription by increasing the number of functional preinitiation complexes. The activator effects this increase by recruiting the general transcription factor TFIIB to the promoter. Using protein affinity chromatography we demonstrate a specific interaction between an acidic activating region and TFIIB. Based on these combined results, we propose that TFIIB is a direct target of an acidic activator.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University								ALBRECHT G, 1988, MOL CELL BIOL, V8, P1534, DOI 10.1128/MCB.8.4.1534; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEVAUX B, 1987, MOL CELL BIOL, V7, P4560, DOI 10.1128/MCB.7.12.4560; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V341, P279, DOI 10.1038/341279a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TSUNG K, 1990, P NATL ACAD SCI USA, V87, P5940, DOI 10.1073/pnas.87.15.5940; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; ZINN K, 1986, CELL, V45, P611, DOI 10.1016/0092-8674(86)90293-X	47	490	499	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					971	981		10.1016/0092-8674(91)90321-O	http://dx.doi.org/10.1016/0092-8674(91)90321-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001592				2022-12-28	WOS:A1991FA94000014
J	ADEBONOJO, FO				ADEBONOJO, FO			INFANT HEAD SHAPING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ADEBONOJO, FO (corresponding author), E TENNESSEE STATE UNIV,JOHNSON CITY,TN 37614, USA.							EPSTEIN F, 1973, LANCET, V1, P634; HENSHEN P, 1966, HUMAN SKULL CULTURAL; MARSHALL DS, 1956, AM J PHYS ANTHROPOL, V13, P405; McGibbon Walter, 1912, LARYNGOSCOPE, V22, P1165; NICHTER LS, 1986, PLAST RECONSTR SURG, V77, P325; SCHENDEL SA, 1986, PLAST RECONSTR SURG, V78, P267, DOI 10.1097/00006534-198608000-00038; SHAPIRO HL, 1928, ANTHR PAPERS MUSEU 1, P30; TROPINARD P, 1878, ANTHROPOLOGY	8	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1179	1179						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996005				2022-12-28	WOS:A1991EZ47400037
J	RAUB, W				RAUB, W			IMMUNOGENETIC DISTINCTION FOUND BETWEEN PAUCIARTICULAR AND POLYARTICULAR JUVENILE ARTHRITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, ARTHRITIS RHEUM, V33, P1787	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-28	WOS:A1991EZ47400006
J	ERZURUM, SC; LEFF, JA; COCHRAN, JE; ACKERSON, LM; SZEFLER, SJ; MARTIN, RJ; COTT, GR				ERZURUM, SC; LEFF, JA; COCHRAN, JE; ACKERSON, LM; SZEFLER, SJ; MARTIN, RJ; COTT, GR			LACK OF BENEFIT OF METHOTREXATE IN SEVERE, STEROID-DEPENDENT ASTHMA - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						METHOTREXATE; ASTHMA, SEVERE; STEROIDS; IGE; RESPIRATORY FUNCTION TESTS; PATIENT COMPLIANCE	LOW-DOSE METHOTREXATE; RHEUMATOID-ARTHRITIS; BRONCHIAL-ASTHMA; THERAPY; CROSSOVER; EFFICACY; SAFETY	Objective: To determine the effect of low-dose methotrexate in asthmatic patients on steroid use, asthma symptom scores, pulmonary function, airway reactivity, blood cellular components, and immunoglobulin E levels. Design: A randomized, double-blind, parallel, placebo-controlled, 13-week clinical trial with follow-up of patients in an open trial of methotrexate at the conclusion of the double-blind study. Setting: An asthma care outpatient clinic. Patients: From February 1988 to March 1990, 19 patients with severe, steroid-dependent asthma were enrolled in the study. Two of these patients were excluded from analysis. Results: Patients on methotrexate and placebo both significantly decreased their steroid dose by 39.6% (95% CI, 25.1% to 54.1%, P = 0.001) a nd 40.2% (CI, 17.9% to 67.4%, P = 0.003), respectively. Pulmonary function did not differ significantly between the methnotrexate and placebo groups. In addition, airway reactivity and symptom scores were unchanged on methotrexate or placebo. No significant toxicites were seen during the course of the 13-week blinded study, but one patient on methotrexate and prednisone in the follow-up period developed Pneumocystis carinii pneumonia and died. Despite continuing methotrexate for up to 1 year, and increasing methotrexate to 30 mg weekly, no significant benefit of methotrexate on asthma control could be shown. Conclusion: Our study does not support the use of methotrexate in the treatment of severe asthma. Conclusion: Our study does not support the use of methotrexate in the treatment of severe asthma.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, ROOM K613, DENVER, CO 80206 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT BIOSTAT, DENVER, CO 80206 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, T32HL007085] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07085, HL-36577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1986, Standards for the Diagnosis and Care of Patients with Chronic Pulmonary Disease (COPD) and Asthma, V136, P225; AXELROD L, 1976, MEDICINE, V55, P39, DOI 10.1097/00005792-197601000-00003; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; CLUSS PA, 1984, J CONSULT CLIN PSYCH, V52, P909, DOI 10.1037/0022-006X.52.5.909; CROPP GJA, 1980, ATS NEWS         SPR, P11; DYKEWICZ MS, 1986, ARCH INTERN MED, V146, P2369, DOI 10.1001/archinte.146.12.2369; EPSTEIN LH, 1982, J CONSULT CLIN PSYCH, V50, P950, DOI 10.1037/0022-006X.50.6.950; EPSTEIN LH, 1984, HEALTH PSYCHOL, V3, P385, DOI 10.1037/0278-6133.3.4.385; FURST DE, 1985, J RHEUMATOL, V12, P11; HOFFMEISTER RT, 1983, AM J MED, V75, P69, DOI 10.1016/0002-9343(83)90477-1; KHANINA S B, 1971, Terapevticheskii Arkhiv, V43, P100; KLAUSTERMEYER WB, 1987, J ALLERGY CLIN IMMUN, V79, P720, DOI 10.1016/0091-6749(87)90202-8; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; LOUIS TA, 1984, NEW ENGL J MED, V310, P24, DOI 10.1056/NEJM198401053100106; MULLARKEY MF, 1990, ANN INTERN MED, V112, P577, DOI 10.7326/0003-4819-112-8-577; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MULLARKEY MF, 1986, ANN ALLERGY, V56, P347; MURANAKA M, 1978, ANN ALLERGY, V40, P132; PERRUQUET JL, 1983, ARTHRITIS RHEUM, V26, P1291, DOI 10.1002/art.1780261021; ROMANOVA EV, 1987, TERAPEVT ARKH, V59, P56; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; SNAPPER JR, 1990, AM REV RESPIR DIS, V141, P531, DOI 10.1164/ajrccm/141.3.531; TUGWELL P, 1987, ANN INTERN MED, V107, P358, DOI 10.7326/0003-4819-107-2-358; WALD JA, 1986, J ALLERGY CLIN IMMUN, V78, P36, DOI 10.1016/0091-6749(86)90112-0; WALLIS PJW, 1989, ANN RHEUM DIS, V48, P247, DOI 10.1136/ard.48.3.247; WILLIAMS MH, 1989, NEW ENGL J MED, V320, P1015; WOODS JR, 1989, ANN INTERN MED, V110, P560, DOI 10.7326/0003-4819-110-7-560; WOOLCOCK AJ, 1985, CHEST, V87, pS209, DOI 10.1378/chest.87.5_Supplement.209S	29	129	135	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					353	360		10.7326/0003-4819-114-5-353	http://dx.doi.org/10.7326/0003-4819-114-5-353			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992876				2022-12-28	WOS:A1991EZ17400002
J	CANTOR, JC; COHEN, AB; BARKER, DC; SHUSTER, AL; REYNOLDS, RC				CANTOR, JC; COHEN, AB; BARKER, DC; SHUSTER, AL; REYNOLDS, RC			MEDICAL EDUCATORS VIEWS ON MEDICAL-EDUCATION REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								To determine whether medical educators perceive a need for change in medical student education, we analyzed data from a 1989 survey of 1369 respondents from all US schools of allopathic medicine. Except for basic sciences faculty, a majority of educators stated that "fundamental changes" are needed in medical student education in the United States. Nearly three fourths of deans and associated deans reported the need for "fundamental changes" or "thorough reform." At least 79% of educators voiced support for six specific reforms, such as rewarding teaching excellence and increasing clinical education in ambulatory and community settings. While slight majorities supported reducing class size and centralizing governance, substantial proportions stated that they would "work against" such reforms. Most educators reported that a broad base of support within the school would be essential for change. The survey suggests a restlessness among the leaders of medical education.			CANTOR, JC (corresponding author), ROBERT WOOD JOHNSON FDN,OFF HLTH STAT & ANAL,POB 2316,PRINCETON,NJ 08543, USA.			Cohen, Alan B./0000-0002-5232-8927				BLOOM SW, 1988, J HEALTH SOC BEHAV, V29, P294, DOI 10.2307/2136864; Cox B, 1985, METHODOLOGICAL ISSUE; EBERT RH, 1988, HEALTH AFFAIR, V7, P5, DOI 10.1377/hlthaff.7.2.5; GASTEL B, 1989, 1988 P J MAC F NAT S; IGLEHART JK, 1988, HEALTH AFFAIR, V7, P108; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Starr P, 1982, SOCIAL TRANSFORMATIO; 1988, JAMA-J AM MED ASSOC, V260, P1136; 1984, J MED ED 2, V59, P193; 1989, DIRECTORY AM MED ED	10	78	78	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					1002	1006		10.1001/jama.265.8.1002	http://dx.doi.org/10.1001/jama.265.8.1002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1992193				2022-12-28	WOS:A1991EY43200029
J	FIELDING, C				FIELDING, C			AUDIT IN PERSON - THE ROLE OF THE AUDIT ANALYST	BRITISH MEDICAL JOURNAL			English	Editorial Material											FIELDING, C (corresponding author), CHESTERFIELD & N DERBYSHIRE ROYAL HOSP,CHESTERFIELD S44 5BL,DERBY,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					453	455		10.1136/bmj.302.6774.453	http://dx.doi.org/10.1136/bmj.302.6774.453			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004175	Green Published, Bronze			2022-12-28	WOS:A1991EZ03300025
J	GOODBURN, E; MATTOSINHO, S; MONGI, P; WATERSTON, T				GOODBURN, E; MATTOSINHO, S; MONGI, P; WATERSTON, T			MANAGEMENT OF CHILDHOOD DIARRHEA BY PHARMACISTS AND PARENTS - IS BRITAIN LAGGING BEHIND THE THIRD-WORLD	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GASTROENTERITIS; CHILDREN; DRUGS	Objective-To investigate the role of community pharmacists in providing advice and treatment for children with diarrhoea; to investigate mothers' responses to diarrhoea in their children. Design-Cross sectional questionnaire study of a random selection of community pharmacists and of mothers attending child health clinics. Pharmacists were interviewed and given a questionnaire and a separate group was visited by a researcher posing as a parent; mothers were interviewed at the clinic. Setting-Newcastle upon Tyne. Subjects-20 pharmacists were interviewed and visits by a researcher posing as a parent were carried out to 10 different pharmacists; 58 mothers were interviewed. Main outcome measures-Advice given by pharmacists was contrasted with standard advice on management of diarrhoea in children. Results-Half the pharmacists interviewed and 70% of pharmacists visited by a researcher posing as a parent recommended inappropriate treatment of childhood diarrhoea (such as antidiarrhoeal drugs and withholding breast milk), and only 30% at interview stated that they would ask for the age of the child. Mothers' knowledge of home treatment was inadequate. All pharmacists in the posed visits recommended a purchased treatment. Conclusion-Pharmacists are widely used by parents for consultation for children's ailments but their advice is not always appropriate; hence they should be given more consistent training in recognising and managing clinical problems. Medical advice on management of diarrhoea is also inconsistent and should be modified to conform to the guidelines of the World Health Organisation.	NEWCASTLE GEN HOSP, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND; INST CHILD HLTH, TROP CHILD HLTH UNIT, LONDON WC1N 1EH, ENGLAND	Newcastle General Hospital; University of London; University College London								CONWAY SP, 1989, ARCH DIS CHILD, V64, P87, DOI 10.1136/adc.64.1.87; CUNNINGHAMBURLEY S, 1987, SOC SCI MED, V24, P371, DOI 10.1016/0277-9536(87)90155-9; CUTTING WAM, 1989, LANCET, V1, P1080; EDWARDS C, 1982, MINOR ILLNESS MAJOR; GALLAGER F, 1983, BMJ-BRIT MED J, V287, P397; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; MOBEY N, 1986, PHARM J, V3, P807; MORRELL DC, 1981, UPDATE, V1, P1187; PAUNCEFOR Z, 1989, PHARM HLTH CARE REPO; RYLANCE GW, 1988, BMJ-BRIT MED J, V297, P445, DOI 10.1136/bmj.297.6646.445; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P917, DOI 10.1136/adc.65.9.917; WATERSTON T, 1981, J MATERNAL CHILD HLT, V1, P34; WHARTON BA, 1988, BMJ-BRIT MED J, V296, P450, DOI 10.1136/bmj.296.6620.450; 1980, WHO CDDSER802; 1989, MED ETHICS GUIDE PHA	15	52	54	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 23	1991	302	6774					440	443		10.1136/bmj.302.6774.440	http://dx.doi.org/10.1136/bmj.302.6774.440			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004171	Green Published, Bronze			2022-12-28	WOS:A1991EZ03300020
J	BAUMGARTNER, M; DUTRILLAUX, B; LEMIEUX, N; LILIENBAUM, A; PAULIN, D; VIEGASPEQUIGNOT, E				BAUMGARTNER, M; DUTRILLAUX, B; LEMIEUX, N; LILIENBAUM, A; PAULIN, D; VIEGASPEQUIGNOT, E			GENES OCCUPY A FIXED AND SYMMETRICAL POSITION ON SISTER CHROMATIDS	CELL			English	Article							INSITU HYBRIDIZATION; NUCLEOTIDE-SEQUENCE; HUMAN-CHROMOSOMES; HUMAN VIMENTIN; DNA LIBRARIES; SV40 DNA; METAPHASE; CELLS; MICROSCOPY; ASSIGNMENT	A high-resolution fluorescence methodology for non-isotopic in situ hybridization was applied to determine the positions occupied by several single-copy genes, DNA sequences, and integrated viral genomes on sister chromatids. The lateral and longitudinal mapping of the probes was performed on prometaphase and metaphase chromosomes. A fixed lateral position, exterior or median in relation to the longitudinal axis of the chromatids, was observed for a given probe, with a symmetrical position of the double fluorescent spots. This position appears to be independent of chromosome condensation stage from prometaphase to metaphase. These observations suggest an opposite helical-handedness conformation of DNA on both chromatids with a mirror symmetry. They support the model of chromosome packaging recently proposed by Boy de la Tour and Laemmli. Moreover, our results indicate that the last stages of chromosome condensation occur by packing down the coils without further coiling.	UNIV PARIS 07, BIOL MOLEC DIFFERENTIAT LAB, F-75724 PARIS 15, FRANCE	UDICE-French Research Universities; Universite Paris Cite	BAUMGARTNER, M (corresponding author), INST CURIE, CNRS, URA CNRS, BIOL STRUCT & MUTAGENESE CHROMOSOM SECT, 26 RUE ULM, F-75231 PARIS 05, FRANCE.							BAK AL, 1977, P NATL ACAD SCI USA, V74, P1595, DOI 10.1073/pnas.74.4.1595; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DUPRAW EJ, 1965, NATURE, V206, P338, DOI 10.1038/206338a0; DUPRAW EJ, 1966, NATURE, V209, P577, DOI 10.1038/209577a0; FERRARI S, 1987, AM J HUM GENET, V41, P616; FUSCOE JC, 1989, GENOMICS, V5, P100, DOI 10.1016/0888-7543(89)90092-X; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LI ZL, 1989, GENE, V78, P243; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LILIENBAUM A, 1986, EMBO J, V5, P2809, DOI 10.1002/j.1460-2075.1986.tb04572.x; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; OHNUKI Y, 1968, CHROMOSOMA, V25, P402, DOI 10.1007/BF02327721; PERREAU J, 1988, GENE, V62, P7, DOI 10.1016/0378-1119(88)90575-6; QUAXJEUKEN Y, 1985, CYTOGENET CELL GENET, V40, P727; RUDDLE FH, 1989, CYTOGENET CELL GENET, V51, P1, DOI 10.1159/000132773; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; VELLARD M, 1991, IN PRESS ONCOGENE; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; WRAY W, 1977, COLD SPRING HARB SYM, V42, P361; ZEHNER ZE, 1983, P NATL ACAD SCI-BIOL, V80, P911, DOI 10.1073/pnas.80.4.911	27	52	52	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					761	766		10.1016/0092-8674(91)90505-S	http://dx.doi.org/10.1016/0092-8674(91)90505-S			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997205				2022-12-28	WOS:A1991EZ47800011
J	RAMACHANDRAN, VS				RAMACHANDRAN, VS			FORM, MOTION, AND BINOCULAR-RIVALRY	SCIENCE			English	Article									UNIV CALIF SAN DIEGO,NEUROSCI PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego	RAMACHANDRAN, VS (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL,LA JOLLA,CA 92093, USA.							BARINAGA M, 1990, SCIENCE, V249, P856, DOI 10.1126/science.2392677; BLAKE R, 1974, NATURE, V249, P488, DOI 10.1038/249488a0; Crick F., 1990, Seminars in the Neurosciences, V2, P263; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Kaufman L., 1974, SIGHT MIND, DOI [10.1097/00006324-197411000, DOI 10.1097/00006324-197411000]; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MYERSON J, 1981, BEHAV ANAL LETT, V1, P149; RAMACHANDRAN VS, 1973, NATURE, V242, P412, DOI 10.1038/242412a0; RAMACHANDRAN VS, IN PRESS ARTFUL BRAI; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; TREISMAN A, 1962, Q J EXP PSYCHOL, V14, P23, DOI 10.1080/17470216208416507; VONHELMHOLTZ H, 1925, PHYSL OPTICS	13	10	10	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					950	951		10.1126/science.2000497	http://dx.doi.org/10.1126/science.2000497			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000497				2022-12-28	WOS:A1991EY62900049
J	SHIBUTANI, S; TAKESHITA, M; GROLLMAN, AP				SHIBUTANI, S; TAKESHITA, M; GROLLMAN, AP			INSERTION OF SPECIFIC BASES DURING DNA-SYNTHESIS PAST THE OXIDATION-DAMAGED BASE 8-OXODG	NATURE			English	Article							POLYMERASE-DELTA; CALF THYMUS; 8-HYDROXY-2'-DEOXYGUANOSINE	OXIDATIVE damage to DNA, reflected in the formation of 8-oxo-7-hydrodeoxyguanosine (8-oxodG) 1, 2, may be important in mutagenesis, carcinogenesis and the ageing process 3,4. Kuchino et al. studied DNA synthesis on oligodeoxynucleotide templates containing 8-oxodG, concluding that the modified base lacked base pairing specificity and directed misreading of pyrimidine residues neighbouring the lesion 5. Here we report different results, using an approach in which the several products of a DNA polymerase reaction can be measured. In contrast to the earlier report 5, we find that dCMP and dAMP are incorporated selectively opposite 8-oxodG with transient inhibition of chain extension occurring 3' to the modified base. The potentially mutagenic insertion of dAMP is targeted exclusively to the site of the lesion. The ratio of dCMP to dAMP incorporated varies, depending on the DNA polymerase involved. Chain extension from the dA . 8-oxodG pair was efficiently catalysed by all polymerases tested.			SHIBUTANI, S (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.			Shibutani, Shinya/0000-0003-4190-9512				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; AIDA M, 1987, MUTAT RES, V192, P83, DOI 10.1016/0165-7992(87)90101-1; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BODEPUDI V, IN PRESS NUCLEOSIDES; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; KARAWYA EM, 1982, J BIOL CHEM, V257, P3129; KASAI H, 1987, B CHEM SOC JPN, V60, P3799, DOI 10.1246/bcsj.60.3799; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KOUCHAKDIJAN M, IN PRESS J BIOCH; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MORIYA M, IN PRESS MUT RES; Sambrook J., 1989, MOL CLONING; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; TAN CK, 1986, J BIOL CHEM, V261, P2310; UESUGI S, 1977, J AM CHEM SOC, V99, P3250, DOI 10.1021/ja00452a008; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	23	2044	2073	1	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					431	434		10.1038/349431a0	http://dx.doi.org/10.1038/349431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992344				2022-12-28	WOS:A1991EV51400057
J	RILEY, DJ; MUGHAL, MZ; ROLAND, J				RILEY, DJ; MUGHAL, MZ; ROLAND, J			IMMUNIZATION STATE OF YOUNG-CHILDREN ADMITTED TO HOSPITAL AND EFFECTIVENESS OF A WARD BASED OPPORTUNISTIC IMMUNIZATION POLICY	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION	Objective - To study the need for an effectiveness of a ward based opportunistic immunisation policy. Design - A six month prospective study. Setting - An acute medical paediatric ward of an inner city teaching hospital. Subjects - 296 children admitted to the ward who lived within central Manchester Health Authority boundaries and were aged from 5 months to 6 years. Main outcome measures - Completion of immunisation schedule appropriate for age. Results - 56 children were three or more months behind with immunisations. The parent's history was not reliable for 18 children. Accessing health authority immunisation records was not difficult. The main reasons for falling behind were the mobility of the families (15 children), lack of motivation (14), and frequent minor illnesses (9). 40 children were immunised before discharge, but three could not be because of valid contraindications. Of the 16 children requiring more immunisations after discharge, only four obtained them at the correct time and five children not at all. Conclusion - An opportunistic immunisation policy is an important means of immunising a vulnerable group of children who would often default on routine immunisations, and such policies should operate however possible. Our ward based policy can achieve immunisation of three quarters of possible children without change or inconvenience to the daily ward work, but efficacy relies on adequate levels of enthusiastic staff. The system can be improved by having accurate and updated immunisation records available in the hospital, and by encouraging nursing staff to participate.	ST MARYS HOSP,DEPT PAEDIAT,MANCHESTER M13 0JH,LANCS,ENGLAND; CENT MANCHESTER DIST HLTH AUTHOR,DEPT PUBL HLTH MED,MANCHESTER,ENGLAND	University of Manchester			MUGHAL, Zulf/AAA-1230-2021					BEGG NT, 1985, BRIT MED J, V291, P1370, DOI 10.1136/bmj.291.6506.1370; BLACK J, 1985, NEW PAEDIATRICS CHIL; FERSON MJ, 1990, ARCH DIS CHILD, V65, P763, DOI 10.1136/adc.65.7.763; FULGINITI VA, 1988, AM J DIS CHILD, V142, P704, DOI 10.1001/archpedi.1988.02150070018013; HULL D, 1988, BRIT MED J, V297, P755; JAMES J, 1986, ARCH DIS CHILD, V61, P630; JARMAN B, 1988, BRIT MED J, V296, P1775, DOI 10.1136/bmj.296.6639.1775; NICOLL A, 1989, BRIT MED J, V299, P808, DOI 10.1136/bmj.299.6703.808; TIFFT CJ, 1988, AM J DIS CHILD, V142, P719, DOI 10.1001/archpedi.1988.02150070033019; 1990, IMMUNISATION INFECTI; 1988, IMMUNISATION INFECTI	11	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					31	33		10.1136/bmj.302.6767.31	http://dx.doi.org/10.1136/bmj.302.6767.31			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991185	Bronze, Green Published			2022-12-28	WOS:A1991ER37200024
J	SCHMIDT, PJ; NIEMAN, LK; GROVER, GN; MULLER, KL; MERRIAM, GR; RUBINOW, DR				SCHMIDT, PJ; NIEMAN, LK; GROVER, GN; MULLER, KL; MERRIAM, GR; RUBINOW, DR			LACK OF EFFECT OF INDUCED MENSES ON SYMPTOMS IN WOMEN WITH PREMENSTRUAL-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENSTRUAL-CYCLE; PROLACTIN RESPONSES; ANTI-PROGESTERONE; TENSION SYNDROME; RU-486; MOOD; PITUITARY; HORMONES; PRIMATES	Background. No physiologic abnormality of the luteal phase has been consistently demonstrated in women with premenstrual syndrome (PMS). Using the progesterone antagonist mifepristone, we truncated the late luteal phase of the menstrual cycle in a blinded fashion to evaluate the relation of the events of the late luteal phase to the symptoms of PMS. Methods. Fourteen women with PMS were given mifepristone (12.5 or 25 mg per kilogram of body weight) by mouth on the seventh day after the surge of luteinizing hormone. On the sixth through the eighth days after the surge, they also received injections of either placebo or human chorionic gonadotropin (2000 IU). Seven women with PMS received placebo instead of both mifepristone and human chorionic gonadotropin. All the women completed daily questionnaires measuring a variety of mood-related and somatic symptoms. Results. Mifepristone consistently induced menses. The women receiving only mifepristone had plasma progesterone levels like those of the follicular phase (< 3 nmol per liter) within four days, whereas all the other women had plasma progesterone levels characteristic of the luteal phase (> 8 nmol per liter) for at least seven days after treatment. In all three groups, the severity of symptoms was significantly higher after treatment than before, according to an analysis of variance with repeated measures. The level and pattern of the ratings of symptom severity were similar in all treatment groups. Conclusions. Neither the timing nor the severity of PMS symptoms was altered by mifepristone-induced menses or luteolysis. The temporal association of typical PMS symptoms with an artificially induced follicular phase suggests that endocrine events during the late luteal phase do not directly generate the symptoms of PMS.	NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	SCHMIDT, PJ (corresponding author), NIMH,BIOL PSYCHIAT BRANCH,BEHAV ENDOCRINOL SECT,BLDG 10,RM 3N238,BETHESDA,MD 20892, USA.							ABRAHAM GE, 1971, J CLIN ENDOCR METAB, V32, P619, DOI 10.1210/jcem-32-5-619; BACKSTROM T, 1983, PSYCHOSOM MED, V45, P503, DOI 10.1097/00006842-198312000-00004; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; CASPER RF, 1990, AM J OBSTET GYNECOL, V162, P105, DOI 10.1016/0002-9378(90)90831-Q; CASPER RF, 1989, J CLIN ENDOCR METAB, V68, P608, DOI 10.1210/jcem-68-3-608; CASSON P, 1990, AM J OBSTET GYNECOL, V162, P99, DOI 10.1016/0002-9378(90)90830-Z; Endicott J, 1982, PSYCHOPHARMACOL BULL, V18, P109; GAILLARD RC, 1984, P NATL ACAD SCI-BIOL, V81, P3879, DOI 10.1073/pnas.81.12.3879; HALBREICH U, 1985, CAN J PSYCHIAT, V30, P489, DOI 10.1177/070674378503000706; HAMMARBACK S, 1988, ACTA OBSTET GYN SCAN, V67, P159, DOI 10.3109/00016348809004191; HEALY DL, 1983, J CLIN ENDOCR METAB, V57, P863, DOI 10.1210/jcem-57-4-863; HEALY DL, 1983, FERTIL STERIL, V40, P253; HERRMANN W, 1982, CR ACAD SCI III-VIE, V294, P933; JIANG NS, 1969, MAYO CLIN PROC, V44, P461; LI TC, 1988, FERTIL STERIL, V50, P732; MOGUILEWSKY M, 1981, J STEROID BIOCHEM, V15, P329, DOI 10.1016/0022-4731(81)90293-4; MUSE KN, 1984, NEW ENGL J MED, V311, P1345, DOI 10.1056/NEJM198411223112104; NIEMAN LK, 1987, NEW ENGL J MED, V316, P187, DOI 10.1056/NEJM198701223160404; PHILIBERT D, 1982, 64TH END SOC ANN M S; RABIN DS, 1990, J CLIN ENDOCR METAB, V71, P1158, DOI 10.1210/jcem-71-5-1158; ROYBYRNE PP, 1987, AM J PSYCHIAT, V144, P480, DOI 10.1176/ajp.144.4.480; ROYBYRNE PP, 1986, NEUROPSYCHOBIOLOGY, V16, P61, DOI 10.1159/000118298; RUBINOW DR, 1988, AM J OBSTET GYNECOL, V158, P5, DOI 10.1016/0002-9378(88)90765-X; RUBINOW DR, 1984, AM J PSYCHIAT, V141, P684; Schnurr PP, 1989, PSYCHOL ASSESSMENT, V1, P277; Spielberger CD, 1970, STAI MANUAL STATETRA; Spitzer R.L., 1975, SCHEDULE AFFECTIVE D; STEINER M, 1980, ACTA PSYCHIAT SCAND, V62, P177, DOI 10.1111/j.1600-0447.1980.tb00605.x; 1987, DIAGNOSTIC STATISTIC	29	138	140	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1174	1179		10.1056/NEJM199104253241705	http://dx.doi.org/10.1056/NEJM199104253241705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH572	2011161				2022-12-28	WOS:A1991FH57200005
J	SANAZARO, PJ; MILLS, DH				SANAZARO, PJ; MILLS, DH			A CRITIQUE OF THE USE OF GENERIC SCREENING IN QUALITY ASSESSMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSURANCE; MORTALITY; CARE	This article summarizes available information on the efficiency and effectiveness of generic occurrence screening when used in quality assessment. Generic screening is relatively inefficient because of its multitiered review system and high rates of errors and false positives. Overall sensitivity may approach 70% to 80%, but specificity is estimated to range from about 22% to 73%. Effectiveness of generic screening in identifying problems in quality is limited by variability in peer review. Other limitations of generic screens include their lack of inherent relationship to the quality of patient care and their inability to provide direct performance measures for use in the periodic reappraisal of clinical privileges of medical staff members. We propose the monitoring of specific adverse surgical and medical clinical outcomes and related risk factors to increase efficiency in quality assessment and provide a more adequate database for the continual improvement of patient care and clinical performance.	PROFESS RISK MANAGEMENT GRP,LONG BEACH,CA; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033	University of California System; University of California San Francisco; University of Southern California								BADER BS, 1986, PATIENT SAFETY MANUA; Barnes C, 1988, Top Health Rec Manage, V9, P72; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; CAPLAN R A, 1988, Anesthesiology (Hagerstown), V69, pA722, DOI 10.1097/00000542-198809010-00722; Codman EA, 1914, T AM GYNECOLOGICAL S, V39, P60; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; ESCOVITZ GH, 1978, MED CARE, V16, P941, DOI 10.1097/00005650-197811000-00004; GILBERT J, 1980, HELTH CARE DELIVERY, P93; Goldman R, 1989, QRB Qual Rev Bull, V15, P315; GORAN MJ, 1975, MED CARE, V13, P1; HULKA BS, 1979, MED CARE, V17, P1; KAHN KL, 1988, JAMA-J AM MED ASSOC, V260, P3625, DOI 10.1001/jama.260.24.3625; LEMBCKE PA, 1956, JAMA-J AM MED ASSOC, V162, P646, DOI 10.1001/jama.1956.72970240010009; MILLS DH, 1978, WESTERN J MED, V128, P360; MILLS DH, 1988, WESTERN J MED, V149, P611; MILLS DH, 1977, CALIFORNIA MED ASS C; MORLOCK L, 1989, PROVIDING QUALITY CA, P225; PONTON TR, 1953, MED STAFF HOSPITAL, P169; RHODES RS, 1986, NEW ENGL J MED, V314, P153, DOI 10.1056/NEJM198601163140305; RICHARDS T, 1988, MED CARE S5, V26, pS45; Richardson F M, 1972, Med Care, V10, P29, DOI 10.1097/00005650-197201000-00004; ROOS LL, 1985, AM J PUBLIC HEALTH, V75, P1288, DOI 10.2105/AJPH.75.11.1288; SANAZARO PJ, 1985, MED CARE, V23, P1097, DOI 10.1097/00005650-198509000-00007; SANAZARO PJ, 1978, NEW ENGL J MED, V298, P1171, DOI 10.1056/NEJM197805252982104; SANAZARO PJ, 1980, ANN REV PUBLIC HLTH, V11, P37; SANAZARO PJ, 1978, PRIVATE INITIATIVE P, P87; SICHER CM, 1987, APPROACHES PATIENT C; SOPER K, 1980, HLTH CARE DELIVERY A, P99; WARD GG, 1920, B AM COLL SURG, V4, P7; WILLIAMSON JW, 1978, ASSESSING IMPROVING; 1976, SURGERY US SUMMARY R, P2131; 1952, HIPPOCRATIC WRITINGS, P46; 1976, ASSESSING QUALITY HL; 1986, QUALITY MANAGEMENT R; 1979, CALIFORNIA HOSPITAL; 1989, JOINT COMMISSION ACC, P213; 1988, OTAH386 PUBL, P112; 1974, PEP PRIMER PERFORMAN	40	66	67	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1977	1981		10.1001/jama.265.15.1977	http://dx.doi.org/10.1001/jama.265.15.1977			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008027				2022-12-28	WOS:A1991FF76800024
J	FYE, WB				FYE, WB			THE ORIGIN OF THE FULL-TIME FACULTY SYSTEM - IMPLICATIONS FOR CLINICAL RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICINE	Clinical research has long been viewed as a fragile pursuit requiring special nurturing. The full-time clinical faculty system was introduced in the early 20th century to provide a milieu that would foster clinical investigation. This article, based on extensive archival research, will show that the main goal of the architects of the full-time system was to stimulate research by removing the incentive for medical professors to devote their main energy to practice. The plan was developed by preclinical scientists at The Johns Hopkins Medical School (Baltimore, Md) and was inaugurated there in 1913 with the financial assistance of the Rockefeller General Education Board. As other medical schools adopted traditional academic criteria for appointment and advancement, there were additional incentives for faculty members to undertake research. In the 1920s, the General Education Board yielded to pressure to liberalize its definition of full time and began to support medical schools that implemented what came to be known as the "geographic full-time plan." Increased government support and other factors encouraged the expansion of full-time plans and led to an impressive increase in the output of research. Today, growing pressure on full-time clinical faculty members to generate income from practice for themselves and their institutions threatens the future of clinical research in this country.	UNIV WISCONSIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	FYE, WB (corresponding author), MARSHFIELD CLIN FDN MED RES & EDUC,DEPT CARDIOL,1000 N OAK AVE,MARSHFIELD,WI 54449, USA.							[Anonymous], 1963, AM DOCTORS GERMAN U; Barker LF, 1907, B JOHNS HOPKINS HOSP, V18, P193; BARKER LF, 1911, JAMA-J AM MED ASSOC, V56, P613; BARKER LF, 1911, COMMUNICATION   0307; BARKER LF, 1914, COMMUNICATION   0117; BARKER LF, 1903, NOTES PRESIDENT HARP; BARKER LF, 1901, COMMUNICATION   0713; BARKER LF, 1904, COMMUNICATION   0221; BARKER LF, 1902, AM MED, V4, P143; BARKER LF, 1913, COMMUNICATION   0307; BARKER LF, 1942, TIME PHYSICIAN AUTOB; BARKER LF, 1913, COMMUNICATION   1118; Benison S, 1987, WB CANNON LIFE TIMES; BENNETT HS, 1962, J MED EDUC, V37, P581; Bevan AD, 1908, J AMER MED ASSOC, V51, P566; BONIFIELD CL, 1922, CINCINNATI J MED, V3, P1; BONNER TN, 1989, MED HIST, V33, P472, DOI 10.1017/S0025727300049942; Brown E. Richard, 1979, ROCKEFELLER MED MEN; BUTTRICK W, 1913, COMMUNICATION   1029; CHESNEY AM, 1943, J HOPKINS HOSPITAL J; CHIN D, 1985, NEW ENGL J MED, V312, P1029, DOI 10.1056/NEJM198504183121605; CHRISTIAN HA, 1913, COMMUNICATION   1101; CLUFF LE, 1983, JAMA-J AM MED ASSOC, V250, P2931; CLUFF LE, 1986, DAEDALUS, V115, P137; Cole R, 1920, Science, V51, P329, DOI 10.1126/science.51.1318.329; COLE R, 1919, COMMUNICATION   1016; COLE R, 1920, COMMUNICATION   0323; COLE R, 1919, COMMUNICATION   1219; Corner George Washington, 1964, HIST ROCKEFELLER I 1; De Solla Price D. J., 1963, LITTLE SCI BIG SCI, DOI 10.7312/pric91844; EBERT RH, 1983, NEW ENGL J MED, V308, P1200, DOI 10.1056/NEJM198305193082006; FLEMING D, 1954, WH WELCH RISE MED; Fleming D, 1955, J MED EDUC, V30, P398; Flexner A, 1924, J AMER MED ASSOC, V82, P833, DOI 10.1001/jama.1924.02650370001001; FLEXNER A, 1919, MED ED US CANADA; FLEXNER A, 1927, HIST FULL TIME CLINI; FLEXNER A, 1980, B HIST MED, V54, P475; Flexner A, 1940, I REMEMBER AUTOBIOGR; FLEXNER A, 1919, COMMUNICATION    DEC; Flexner A., 1910, FLEXNER REPORT; FLEXNER A, 1946, DC GILMAN CREATOR AM; FLEXNER A, 1931, COMMUNICATION   1125; FLEXNER A, 1963, J HOPKINS HOSPITAL J, V3, P287; FLEXNER A, 1919, COMMUNICATION   1218; FLEXNER JT, 1984, AM SAGA STORY H TOMA; Flexner S, 1941, WH WELCH HEROIC AGE; FOSDICK RB, 1952, STORY ROCKEFELLER F; Fox Daniel M., 1986, HLTH POLICIES HLTH P; FYE WB, 1989, NEW ENGL J MED, V320, P1425, DOI 10.1056/NEJM198905253202123; FYE WB, 1990, ANN INTERN MED, V113, P317, DOI 10.7326/0003-4819-113-4-317; FYE WB, 1987, DEV AM PHYSIOLOGY F; Gates F., 1977, CHAPTERS MY LIFE; GATES FT, 1897, COMMUNICATION   0619; GATES FT, 1924, SUGGESTIONS REGARDIN; GATES FT, 1902, COMMUNICATION   0304; GATES FT, 1963, J HOPKINS HOSPITAL J, V3, P133; GATES FT, 1916, COMMUNICATION   1225; GATES FT, 1911, MEMORANDUM       AUG; Ginzberg E., 1989, FINANCING BIOMEDICAL; Harden V.A., 1986, INVENTING NIH FEDERA; Harvey A. McGehee, 1981, SCI BEDSIDE CLIN RES; HATFIELD HD, 1931, COMMUNICATION   0303; HOWELL WH, 1911, COMMUNICATION   1005; JANEWAY TC, 1917, COMMUNICATION   1104; JANEWAY TC, 1918, B J HOPKINS HOSP, V29, P142; JANEWAY TC, 1915, COMMUNICATION   0420; JANEWAY TC, 1917, COMMUNICATION   1203; JANEWAY TC, 1928, JJAMA, V90, P1315; JONAS HS, 1990, JAMA-J AM MED ASSOC, V264, P801, DOI 10.1001/jama.264.7.801; KELLY HA, 1913, COMMUNICATION   1021; LUDMERER KM, 1985, LEARNING HEAL; MALL FP, 1905, COMMUNICATION   0304; MALL FP, 1905, COMMUNICATION    MAR; MALL FP, 1934, FRANKLIN PAINE MALL, P260; MALL FP, 1902, COMMUNICATION   0803; MALL FP, 1902, COMMUNICATION   1107; MALL FP, 1905, COMMUNICATION   0310; MCLEAN FC, 1924, COMMUNICATION   0314; OSLER W, 1914, COMMUNICATION   0325; OSLER W, 1911, COMMUNICATION   0523; OSLER W, 1911, WHOLE TIME CLIN PROF; PRITCHETT HS, 1910, AMA B, V5, P289; PRITCHETT HS, 1919, COMMUNICATION   1111; RANSDELL J, 1930, PUBLIC HLTH REP, V45, P1411; RELMAN AS, 1969, J CLIN INVEST, V48, P1169, DOI 10.1172/JCI106074; ROBERTS S, 1921, S MED J, V15, P1013; ROCKEFELLER JD, 1903, COMMUNICATION   1010; ROCKEFELLER JD, 1958, J HOPKINS HOSPITAL J, V3, P391; Sabin F. R., 1934, FRANKLIN PAINE MALL; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; SHRYOCK RH, 1953, UNIQUE INFLUENCE J H; Starr P, 1982, SOCIAL TRANSFORMATIO; Stengel A, 1933, J ASSOC AM MED COLL, V8, P257; STOKES AP, 1924, COMMUNICATION   0823; Strickland S. P., 1972, POLITICS SCI DREAD D; THAYER WS, 1919, COMMUNICATION    JAN; TURNER TB, 1974, HERITAGE EXCELLENCE; VAUGHAN VC, 1910, AMA B, V5, P307; WEED LH, 1931, REPORT SURVEY COMMIT; WELCH WH, 1910, JAMA-J AM MED ASSOC, V54, P2011; WELCH WH, 1891, COMMUNICATION   1107; WELCH WH, 1899, PAPERS WELCH, P63; WELCH WH, 1911, COMMUNICATION   0602; WELCH WH, 1920, MED ED HIST MISCELLA; WELCH WH, 1892, PAPERS WELCH, P41; WELCH WH, 1941, WH WELCH HEROIC AGE, P112; WELCH WH, 1934, FRANKLIN PAINE MALL, P113; Wheatly S.C., 1988, POLITICS PHILANTHROP; WIEBE RH, 1967, SEARCH ORDER 1877-19; WILLIAMS JW, 1913, J HOPKINS ALUMNI MAG, V2, P81; WYNGAARDEN JB, 1981, B NEW YORK ACAD MED, V57, P415; WYNGAARDEN JB, 1987, AM REV RESPIR DIS, V136, P541, DOI 10.1164/ajrccm/136.3.541; [No title captured]; 1930, PUBLIC HLTH REP, V45, P1409	114	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1555	1562		10.1001/jama.265.12.1555	http://dx.doi.org/10.1001/jama.265.12.1555			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999904				2022-12-28	WOS:A1991FC60400031
J	QUILL, TE				QUILL, TE			DEATH AND DIGNITY - A CASE OF INDIVIDUALIZED DECISION-MAKING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											QUILL, TE (corresponding author), GENESEE HOSP,ROCHESTER,NY 14607, USA.								0	290	292	1	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					691	694		10.1056/NEJM199103073241010	http://dx.doi.org/10.1056/NEJM199103073241010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FA144	1994255				2022-12-28	WOS:A1991FA14400010
J	GOLDSTEIN, AO				GOLDSTEIN, AO			COMING HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1099	1099		10.1001/jama.265.9.1099	http://dx.doi.org/10.1001/jama.265.9.1099			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995991				2022-12-28	WOS:A1991EZ47400010
J	TUNICK, PA; CULLIFORD, AT; LAMPARELLO, PJ; KRONZON, I				TUNICK, PA; CULLIFORD, AT; LAMPARELLO, PJ; KRONZON, I			ATHEROMATOSIS OF THE AORTIC-ARCH AS AN OCCULT SOURCE OF MULTIPLE SYSTEMIC EMBOLI	ANNALS OF INTERNAL MEDICINE			English	Note						ATHEROSCLEROSIS; AORTA, THORACIC; EMBOLISM; CEREBRAL EMBOLISM AND THROMBOSIS; ENDARTERECTOMY	STROKE	Atheroemboli are a well-known cause of arterial of microcirculatory obstruction, especially after a catheter is passed through the abdominal or thoracic aorta. We previously reported the cases of three patients with embolization in whom transesophageal echocardiography showed a new finding: protruding atherosclerotic masses, with mobile components, in the aortic arch and descending thoracic aorta. We subsequently evaluated the currently reported patient, who had had four cerebral and peripheral emboli within a short period. She also had protruding plaque in her aortic arch, which was removed surgically because of her repeated episodes. Pathologic examination showed it to be atherosclerotic plaque with superimposed thrombus. We believe that this is the first time that aortic arch endarterectomy has been done as a result of this new transesophageal echocardiographic finding and that this process may be responsible for embolization in some patients in whom the cause had been previously unexplained.			TUNICK, PA (corresponding author), NYU MED CTR, 560 1ST AVE, 2-E, NEW YORK, NY 10016 USA.			Lamparello, MD, Patrick/0000-0003-4000-0104				BAUNWALD E, 1988, HEART DISEASE TXB CA, P1571; CULLIFORD AT, 1986, ANN THORAC SURG, V41, P27, DOI 10.1016/S0003-4975(10)64492-X; GREENLAND P, 1981, ANN INTERN MED, V95, P51, DOI 10.7326/0003-4819-95-1-51; MOLDVEEN.M, 1967, CIRCULATION, V35, P946, DOI 10.1161/01.CIR.35.5.946; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442	8	107	107	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					391	392		10.7326/0003-4819-114-5-391	http://dx.doi.org/10.7326/0003-4819-114-5-391			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992882				2022-12-28	WOS:A1991EZ17400008
J	CARAMAZZA, A; HILLIS, AE				CARAMAZZA, A; HILLIS, AE			LEXICAL ORGANIZATION OF NOUNS AND VERBS IN THE BRAIN	NATURE			English	Article							CATEGORY; IMPAIRMENT; LANGUAGE; APHASIA	THE analysis of neuropsychological disorders of lexical processing has provided important clues about the general organization of the lexical system and the internal structure of the processing components 1-3. Reports of patients with selective dysfunction of specific semantic categories such as abstract versus concrete words 4-6, living things versus inanimate objects 7-11, animals 12-14, fruits and vegetables 15, proper names 16,17 and so forth, support the hypothesis that the neural organization of the semantic processing component is organized in these categories. There are reports of selective dysfunction of the grammatical categories noun and verb 18-21, suggesting that a dimension of lexical organization is the grammatical class of words. But the results reported in these studies have not provided unambiguous evidence concerning two fundamental questions about the nature and the locus of this organization within the lexical system. Is the noun-verb distinction represented in the semantic or in the phonological and orthographic lexicons? Is grammatical-class knowledge represented independently of lexical forms or is it represented separately and redundantly within each modality-specific lexicon? Here we report the performance of two brain-damaged subjects with modality-specific deficits restricted principally (H.W.) or virtually only (S.J.D) to verbs in oral and written production, respectively. The contrasting performance suggests that grammatical-class distinctions are redundantly represented in the phonological and orthographic output lexical components.	HEALTHSOUTH REHABIL CORP,BALTIMORE,MD 21234		CARAMAZZA, A (corresponding author), JOHNS HOPKINS UNIV,DEPT COGNIT SCI,BALTIMORE,MD 21218, USA.							BASSO A, 1988, J NEUROL NEUROSUR PS, V51, P1201, DOI 10.1136/jnnp.51.9.1201; CARAMAZZA A, 1988, ANNU REV NEUROSCI, V11, P395, DOI 10.1146/annurev.neuro.11.1.395; Ellis A, 1988, HUMAN COGNITIVE NEUR; GOODGLASS H, 1988, NEUROPSYCHOLOGIA, V26, P67, DOI 10.1016/0028-3932(88)90031-0; HART J, 1985, NATURE, V316, P338; HILLIS AE, IN PRESS BRAIN; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MCKENNA P, 1978, J NEUROL NEUROSUR PS, V41, P571, DOI 10.1136/jnnp.41.6.571; SARTORI G, 1988, COGNITIVE NEUROPSYCH, V5, P105, DOI 10.1080/02643298808252928; SEMENZA C, 1989, NATURE, V342, P678, DOI 10.1038/342678a0; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SILVERI MC, 1988, COGNITIVE NEUROPSYCH, V5, P677, DOI 10.1080/02643298808253278; WARRINGTON EK, 1981, PHILOS T ROY SOC B, V295, P411, DOI 10.1098/rstb.1981.0149; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; WARRINGTON EK, 1975, Q J EXP PSYCHOL, V27, P635, DOI 10.1080/14640747508400525	17	501	508	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					788	790		10.1038/349788a0	http://dx.doi.org/10.1038/349788a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EZ666	2000148				2022-12-28	WOS:A1991EZ66600055
J	PAPADAKIS, MA; MANGIONE, CM; LEE, KK; KRISTOF, M				PAPADAKIS, MA; MANGIONE, CM; LEE, KK; KRISTOF, M			TREATABLE ABDOMINAL PATHOLOGICAL CONDITIONS AND UNSUSPECTED MALIGNANT NEOPLASMS AT AUTOPSY IN VETERANS WHO RECEIVED MECHANICAL VENTILATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Study Objective: To determine, in medical patients who received mechanical ventilation, the frequency and types of major unexpected diagnoses at autopsy that, if known before death, would probably have led to improved survival (class I errors) or substantively changed management but not survival (class IIB errors). Design: Retrospective cohort study. Setting: Six medical intensive care units in a Department of Veterans Affairs Cooperative Study. Patients: One hundred seventy-two autopsied patients of the 401 veterans who received mechanical ventilation and died in the hospital. Results: The class I error rate was 12%. Abdominal pathologic conditions-abscesses, bowel perforations, or infarction-were as frequent as pulmonary emboli as a cause of class I errors. While patients with abdominal pathologic conditions generally complained of abdominal pain, results of examination of the abdomen were considered unremarkable in most patients, and the symptom was not pursued. Six percent of patients had extensive malignant neoplasms (class IIb errors). Conclusions: Atypical presentation of potentially treatable abdominal pathologic conditions is a common cause of class I errors in veterans who receive mechanical ventilation. Conversely, several patients with unrecognized terminal conditions underwent intensive intervention. If the information gained at autopsy had been known before death, management would have probably changed substantively in 18% of patients.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; VET AFFAIRS MED CTR,DEPT BIOSTAT,PALO ALTO,CA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	PAPADAKIS, MA (corresponding author), DEPT VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,4150 CLEMENT ST 111A1,SAN FRANCISCO,CA 94121, USA.							Fleiss JL, 1981, STAT METHODS RATES P; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANDEFELD CS, 1988, NEW ENGL J MED, V318, P1249, DOI 10.1056/NEJM198805123181906; LUNDBERG GD, 1988, JAMA-J AM MED ASSOC, V260, P3488; MCPHEE SJ, 1985, AM J MED, V78, P107, DOI 10.1016/0002-9343(85)90470-X; Reichert C M, 1985, Health Aff (Millwood), V4, P82, DOI 10.1377/hlthaff.4.2.82; ROBERTS WC, 1978, NEW ENGL J MED, V299, P332, DOI 10.1056/NEJM197808172990704; 1988, MMWR, V37, P191	10	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					885	887		10.1001/jama.265.7.885	http://dx.doi.org/10.1001/jama.265.7.885			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992186	Green Submitted			2022-12-28	WOS:A1991EX58700040
J	COVERLEY, D; KENNY, MK; MUNN, M; RUPP, WD; LANE, DP; WOOD, RD				COVERLEY, D; KENNY, MK; MUNN, M; RUPP, WD; LANE, DP; WOOD, RD			REQUIREMENT FOR THE REPLICATION PROTEIN SSB IN HUMAN DNA EXCISION REPAIR	NATURE			English	Article							HUMAN CELL-EXTRACTS; SIMIAN VIRUS-40 DNA; PURIFIED PROTEINS; POLYMERASE-DELTA; HELICASE-II; INVITRO; COMPLEX; ALPHA	REPLICATION and repair are essential processes that maintain the continuity of the genetic material. Dissection of simian virus 40 (SV40) DNA replication has resulted in the identification of many eukaryotic replication proteins, but the biochemistry of the multienzyme process of DNA excision repair is less well defined. One protein that is absolutely required for semiconservative replication of SV40 DNA in vitro is human single-stranded DNA-binding protein (SSB, also called RF-A and RP-A) 1-3. SSB consists of three polypeptides of relative molecular mass 70,000, 34,000 and 13,000, and acts with T antigen and topoisomerases to unwind DNA, allowing the access of other replication proteins. Human SSB can also stimulate the activity of polymerases- alpha and delta, suggesting a further role in elongation during DNA replication 4-6. We have now found a role for human SSB in DNA excision repair using a cell-free system that can carry out nucleotide excision repair in vitro 7. Monoclonal antibodies against human SSB caused extensive inhibition of DNA repair in plasmid molecules damaged by ultraviolet light or acetylaminofluorene. Addition of purified SSB reversed this inhibition and further stimulated repair synthesis by increasing the number of repair events. These results show that a mammalian DNA replication protein is also essential for repair.	YALE UNIV, SCH MED, RADIOBIOL LABS, NEW HAVEN, CT 06510 USA	Yale University	COVERLEY, D (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, BLANCHE LANE, S MIMMS EN6 3LD, HERTS, ENGLAND.		Wood, Richard D/M-6319-2018; Lane, David P/C-4920-2008	Wood, Richard D/0000-0002-9495-6892; Coverley, Dawn/0000-0001-8262-7023; Lane, David/0000-0003-0551-3545				CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; MANLEY JL, 1988, P NATN ACAD SCI US, V77; NISHIDA C, 1988, J BIOL CHEM, V263, P501; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TOULME JJ, 1983, EMBO J, V2, P505, DOI 10.1002/j.1460-2075.1983.tb01454.x; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1988, MECHANISMS CONSEQUEN, P57	23	233	234	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					538	541		10.1038/349538a0	http://dx.doi.org/10.1038/349538a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992355				2022-12-28	WOS:A1991EW57100072
J	BARLOW, DH; BROCKIE, JA; REES, CMP				BARLOW, DH; BROCKIE, JA; REES, CMP			STUDY OF GENERAL-PRACTICE CONSULTATIONS AND MENOPAUSAL PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT THERAPY	Objective-To investigate the nature of work related to the menopause in general practice. Design-Questionnaire study over six months among general practitioners after each consultation with a woman aged 40-69 at which issues related to the climacteric had been discussed. Setting-9 General practices in the Oxford area. Subjects-416 Women who had 572 consultations. Main outcome measures-Age, menopausal state, and first or subsequent consultation. Symptoms were classified together with the treatment and the outcome of the consultation. Results-The consultation rate varied greatly between practices, the overall rate being 4.4%. There were many premenopausal women and women in their 60s presenting; women with hysterectomies presented more often-36% (37/103) of women with hysterectomies had more than one consultation compared with 26% (38/144) for premenopausal women and 24% (38/155) for postmenopausal women. 409 women had symptoms and 218 were prescribed oestrogen treatment. 156 of the consultations involved discussion and advice only. Only four women were referred to a local specialist clinic. Conclusion-There is a low overall use of hormone replacement therapy in the general postmenopausal population despite the recent media coverage of its benefits in the prevention of osteoporosis and subsequent fractures.			BARLOW, DH (corresponding author), UNIV OXFORD,JOHN RADCLIFFE MATERN HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Barlow, David/F-8738-2011					AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; BALLINGER CB, 1975, BRIT MED J, V3, P344, DOI 10.1136/bmj.3.5979.344; BARLOW DH, 1989, BRIT J OBSTET GYNAEC, V96, P1192, DOI 10.1111/j.1471-0528.1989.tb03195.x; BELCHETZ P, 1989, BMJ-BRIT MED J, V298, P1467, DOI 10.1136/bmj.298.6686.1467; DRAPER J, 1990, BRIT MED J, V300, P786, DOI 10.1136/bmj.300.6727.786; SHEARS MR, 1989, PRACTITIONER, V233, P146; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; THOMPSON B, 1973, J BIOSOC SCI, V5, P71, DOI 10.1017/S0021932000008956	8	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					274	276		10.1136/bmj.302.6771.274	http://dx.doi.org/10.1136/bmj.302.6771.274			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998795	Green Published, Bronze			2022-12-28	WOS:A1991EX91900023
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS .6. ATTENDANCE ALLOWANCE	BRITISH MEDICAL JOURNAL			English	Article											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					228	230		10.1136/bmj.302.6770.228	http://dx.doi.org/10.1136/bmj.302.6770.228			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998768	Green Published, Bronze			2022-12-28	WOS:A1991EV22800034
J	RICHARDS, C				RICHARDS, C			IMPACT OF MEDICAL AUDIT ADVISORY GROUPS	BRITISH MEDICAL JOURNAL			English	Article									SW REG HLTH AUTHOR,LONDON,ENGLAND		RICHARDS, C (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,HLTH CARE EVALUAT UNIT,CANYNGE HALL,BRISTOL BS8 2PR,ENGLAND.							BAKER R, 1990, PRACTICE AUDIT PLAN; HUGHES J, 1990, MED AUDIT GENEAL PRA; IRVINE D, 1990, MED AUDIT SERIES, V2; LOHR KN, 1990, NEW ENGL J MED, V322, P707, DOI 10.1056/NEJM199003083221031; MARINKER M, 1990, MED AUDIT GENERAL PR; 1990, QUALITY MED CARE	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					153	155		10.1136/bmj.302.6769.153	http://dx.doi.org/10.1136/bmj.302.6769.153			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995136	Bronze, Green Published			2022-12-28	WOS:A1991EU02000024
J	ROBERTS, J				ROBERTS, J			THE NHS OBSERVED - A MEDICAL MALAISE IN HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									MUHIMBILI MED CTR,DAR ES SAALAAM,TANZANIA									AARON HJ, 1984, PAINFUL PRESCRIPTION; BRINDLE D, 1990, GUARDIAN        1018, P2; BRINDLE D, 1990, GUARDIAN        1005, P3; Cartwright F.F., 1977, SOCIAL HIST MED; DENNIER C, 1987, OXFORD MAIL     1211, P7; EBELL ME, 1988, JAMA-J AM MED ASSOC, V26, P1630; HARRISON S, 1990, DYNAMICS BRIT HLTH P; HEWSER RL, 1989, BMJ, V298, P1219; LAING W, 1988, REVIEW PRIVATE HEALT; MIHILL C, 1990, GUARDIAN        1011, P7; 1988, HLTH US 1988; 1989, WORKING PATIENTS; 1989, COMPENDIUM HLTH STAT	13	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					163	166		10.1136/bmj.302.6769.163	http://dx.doi.org/10.1136/bmj.302.6769.163			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995138	Green Published, Bronze			2022-12-28	WOS:A1991EU02000027
J	JANKOVIC, J; BRIN, MF				JANKOVIC, J; BRIN, MF			THERAPEUTIC USES OF BOTULINUM TOXIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							A TOXIN; HEMIFACIAL SPASM; NEUROMUSCULAR-JUNCTION; TORSION DYSTONIA; DOUBLE-BLIND; LARYNGEAL DYSTONIA; INHIBITORY-ACTION; INJECTIONS; BLEPHAROSPASM; DYSPHONIA		COLUMBIA UNIV COLL PHYS & SURG, INST NEUROL, NEW YORK, NY 10032 USA	Columbia University	JANKOVIC, J (corresponding author), BAYLOR UNIV, MOVEMENT DISORDERS CLIN, DEPT NEUROL, 6550 FANNIN 1801, HOUSTON, TX 77030 USA.				FDA HHS [FD-R-000195] Funding Source: Medline	FDA HHS		[Anonymous], 1990, Neurology, V40, P1332; ARONSON AE, 1983, LARYNGOSCOPE, V93, P1; ASHTON AC, 1988, J NEUROCHEM, V50, P1808, DOI 10.1111/j.1471-4159.1988.tb02482.x; AVILA OL, 1989, J NEUROSCI, V9, P2902; Bertrand C M, 1988, Adv Neurol, V50, P637; BIGLAN AW, 1989, OPHTHALMOLOGY, V96, P935; BLACKIE JD, 1990, J NEUROL NEUROSUR PS, V53, P640, DOI 10.1136/jnnp.53.8.640; BLITZER A, 1988, LARYNGOSCOPE, V98, P636; BLITZER A, IN PRESS ANN OTOL RH; BLITZER A, 1989, 1989 T AM LAR ASS SA, V110, P206; BORODIC GE, 1991, OPHTHALMIC PLAST REC, V7, P54, DOI 10.1097/00002341-199103000-00007; BRIN M F, 1990, Neurology, V40, P381; BRIN MF, 1987, MOVEMENT DISORD, V2, P237, DOI 10.1002/mds.870020402; BRIN MF, 1989, MOVEMENT DISORD, V4, P287, DOI 10.1002/mds.870040401; BURKE RE, 1986, NEUROLOGY, V36, P160, DOI 10.1212/WNL.36.2.160; CARTER JB, 1990, ARCH OPHTHALMOL-CHIC, V108, P249, DOI 10.1001/archopht.1990.01070040101040; CLARKE JR, 1988, BRIT J OPHTHALMOL, V72, P361, DOI 10.1136/bjo.72.5.361; COHEN LG, 1989, J NEUROL NEUROSUR PS, V52, P355, DOI 10.1136/jnnp.52.3.355; COMELLA C L, 1990, Neurology, V40, P382; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DasGupta BR, 1989, BOTULINUM NEUROTOXIN, P53; DEDO HH, 1976, ANN OTO RHINOL LARYN, V85, P451, DOI 10.1177/000348947608500405; DEZFULIAN M, 1984, J CLIN MICROBIOL, V19, P645, DOI 10.1128/JCM.19.5.645-648.1984; Digre K, 1988, Adv Neurol, V49, P151; DUBINSKY RM, 1989, ANN NEUROL, V26, P123; DUNN WJ, 1986, OPHTHALMOLOGY, V93, P470; DUTTON JJ, 1988, OPHTHALMOLOGY, V95, P1529; DYKSTRA DD, 1990, ARCH PHYS MED REHAB, V71, P24; DYKSTRA DD, 1988, J UROLOGY, V139, P919, DOI 10.1016/S0022-5347(17)42717-0; Elston J S, 1988, Adv Neurol, V50, P579; ELSTON JS, 1986, J NEUROL NEUROSUR PS, V49, P827, DOI 10.1136/jnnp.49.7.827; FITZSIMONS R, 1989, EYE, V3, P391, DOI 10.1038/eye.1989.58; FRUEH BR, 1988, AM J OPHTHALMOL, V106, P45, DOI 10.1016/S0002-9394(14)76386-X; GELB DJ, 1989, NEUROLOGY, V39, P80, DOI 10.1212/WNL.39.1.80; GELLER BD, 1989, MUSCLE NERVE, V12, P716, DOI 10.1002/mus.880120904; GONNERING RS, 1988, AM J OPHTHALMOL, V105, P313, DOI 10.1016/0002-9394(88)90016-5; GRANDAS F, 1988, J NEUROL NEUROSUR PS, V51, P767, DOI 10.1136/jnnp.51.6.767; GREENE P, 1990, NEUROLOGY, V40, P1213, DOI 10.1212/WNL.40.8.1213; GREENE P, 1988, MOVEMENT DISORD, V3, P46, DOI 10.1002/mds.870030107; HABERMANN E, 1974, N-S ARCH PHARMACOL, V281, P47, DOI 10.1007/BF00500611; HAGENAH R, 1977, N-S ARCH PHARMACOL, V299, P267, DOI 10.1007/BF00500319; HALLAN RI, 1988, LANCET, V2, P714; HATHEWAY CH, 1984, J INFECT DIS, V150, P407, DOI 10.1093/infdis/150.3.407; HELVESTON EM, 1988, AM J OPHTHALMOL, V106, P584, DOI 10.1016/0002-9394(88)90590-9; HERRERO BA, 1967, EXP MOL PATHOL, V6, P84, DOI 10.1016/0014-4800(67)90007-X; Hornykiewicz O, 1988, Adv Neurol, V50, P157; JAHANSHAHI M, 1990, ARCH NEUROL-CHICAGO, V47, P548, DOI 10.1001/archneur.1990.00530050070014; JANKOVIC J, 1990, ADV NEUROL, V53, P293; JANKOVIC J, 1987, NEW ENGL J MED, V316, P278; Jankovic J, 1988, Adv Neurol, V49, P103; JANKOVIC J, 1987, NEUROLOGY, V37, P616, DOI 10.1212/WNL.37.4.616; JANKOVIC J, 1986, ARCH NEUROL-CHICAGO, V43, P866, DOI 10.1001/archneur.1986.00520090006004; JANKOVIC J, 1988, J NEUROL NEUROSUR PS, V51, P1512, DOI 10.1136/jnnp.51.12.1512; JANKOVIC J, 1990, J NEUROL NEUROSUR PS, V53, P633, DOI 10.1136/jnnp.53.8.633; JANKOVIC J, 1990, NEUROLOGY, V40, P277, DOI 10.1212/WNL.40.2.277; JANKOVIC J, 1988, NEUROLOGY, V38, P391, DOI 10.1212/WNL.38.3.391; JANKOVIC J, 1989, SEMIN NEUROL, V9, P131, DOI 10.1055/s-2008-1041316; JANKOVIC J, IN PRESS NEUROLOGY; Jankovic J, 1988, PARKINSONS DIS MOVEM, P283; JANNETTA PJ, 1977, J NEUROSURG, V47, P321, DOI 10.3171/jns.1977.47.3.0321; JORDAN DR, 1989, OPHTHALMIC SURG LAS, V20, P280; KAO I, 1976, SCIENCE, V193, P1256, DOI 10.1126/science.785600; KATZ B, 1987, AM J OPHTHALMOL, V103, P718, DOI 10.1016/S0002-9394(14)74342-9; KIRKNESS CM, 1988, OPHTHALMOLOGY, V95, P473; KRAFT SP, 1988, CAN J NEUROL SCI, V15, P276, DOI 10.1017/S0317167100027748; LOU JS, 1991, NEUROLOGY, V41, P234, DOI 10.1212/WNL.41.2_Part_1.234; LUDLOW C L, 1989, Neurology, V39, P353; LUDLOW CL, 1988, NEUROLOGY, V38, P1220, DOI 10.1212/WNL.38.8.1220; LUDLOW CL, 1990, JAMA-J AM MED ASSOC, V264, P2671, DOI 10.1001/jama.264.20.2671; LUDLOW CL, 1990, OTOLARYNG HEAD NECK, V102, P122, DOI 10.1177/019459989010200205; MAGOON EH, 1989, OPHTHALMOLOGY, V96, P931; MAGOON EH, 1985, AM ORTHOPT J, V35, P48; MANNING KA, 1990, ANN NEUROL, V28, P653, DOI 10.1002/ana.410280509; MARSDEN CD, 1990, TRENDS NEUROSCI, V13, P148, DOI 10.1016/0166-2236(90)90007-W; MAURIELLO JA, 1987, OPHTHALMOLOGY, V94, P976; MELLING J, 1988, EYE, V2, P16, DOI 10.1038/eye.1988.5; MILLER LG, 1990, CURR NEUROL, V10, P321; MILLER RH, 1987, ARCH OTOLARYNGOL, V113, P603; NYGAARD TG, 1991, NEUROLOGY, V41, P174, DOI 10.1212/WNL.41.2_Part_1.174; OZELIUS L, 1989, NEURON, V2, P1427, DOI 10.1016/0896-6273(89)90188-8; PAMPHLETT R, 1989, J NEUROL SCI, V92, P181, DOI 10.1016/0022-510X(89)90135-4; PESTRONK A, 1976, NATURE, V264, P787, DOI 10.1038/264787a0; QUINN N, 1989, LANCET, V1, P964; RIVEST J, 1991, MOVEMENT DISORD, V6, P55, DOI 10.1002/mds.870060110; ROSENBAUM AL, 1989, ARCH OPHTHALMOL-CHIC, V107, P820, DOI 10.1001/archopht.1989.01070010842025; ROSENBAUM F, 1988, NEUROLOGY, V38, P522, DOI 10.1212/WNL.38.4.522; SAVINO PJ, 1985, ARCH OPHTHALMOL-CHIC, V103, P1305; SCHANTZ EJ, 1990, LANCET, V335, P421, DOI 10.1016/0140-6736(90)90263-5; SCHWARTZ K S, 1990, Neurology, V40, P382; Scott A B, 1989, Trans Am Ophthalmol Soc, V87, P174; SCOTT AB, 1973, INVEST OPHTH VISUAL, V12, P924; SCOTT AB, 1988, MOVEMENT DISORD, V3, P333, DOI 10.1002/mds.870030409; SCOTT AB, 1980, OPHTHALMOLOGY, V87, P1044; SCOTT AB, 1985, ARCH OPHTHALMOL-CHIC, V103, P347; SELLIN LC, 1981, MED BIOL, V59, P11; SHANNON K M, 1989, Neurology, V39, P352; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SIMPSON LL, 1989, BOTULINUM NEUROTOXIN, P153; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; STANLEY EF, 1983, BRAIN RES, V261, P172, DOI 10.1016/0006-8993(83)91300-8; STELL R, 1988, J NEUROL NEUROSUR PS, V51, P920, DOI 10.1136/jnnp.51.7.920; Tolosa E, 1988, Adv Neurol, V49, P479; Tsui J K, 1988, Adv Neurol, V49, P473; TSUI JK, 1988, ANN NEUROL, V24, P181; TSUI JK, 1987, ANN NEUROL, V22, P147; TSUI JKC, 1986, LANCET, V2, P245; VANERMENGEM E, 1979, REV INFECT DIS, V1, P701; WIEGAND H, 1977, N-S ARCH PHARMACOL, V298, P235, DOI 10.1007/BF00500893; WIEGAND H, 1976, N-S ARCH PHARMACOL, V292, P161, DOI 10.1007/BF00498587; WOOTEN M P, 1990, Neurology, V40, P142; 1989, OPHTHALMOLOGY 2, V96, P37; 1990, ARCH OTOLARYNGOL, V9, P8; 1990, MED LETT DRUGS THER, V32, P100; IN PRESS JAMA	114	648	691	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1186	1194		10.1056/nejm199104253241707	http://dx.doi.org/10.1056/nejm199104253241707			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011163				2022-12-28	WOS:A1991FH57200007
J	ELKAYAM, U				ELKAYAM, U			TOLERANCE TO ORGANIC NITRATES - EVIDENCE, MECHANISMS, CLINICAL RELEVANCE, AND STRATEGIES FOR PREVENTION	ANNALS OF INTERNAL MEDICINE			English	Review							CONGESTIVE HEART-FAILURE; STABLE ANGINA-PECTORIS; VASCULAR SMOOTH-MUSCLE; INTERMITTENT TRANSDERMAL NITROGLYCERIN; ACUTE MYOCARDIAL-INFARCTION; ORAL ISOSORBIDE DINITRATE; DOSE-RESPONSE RELATION; GLYCERYL TRINITRATE; INTRAVENOUS NITROGLYCERIN; N-ACETYLCYSTEINE	Objective: To review the available information about nitrate tolerance, its potential mechanisms, clinical implications, and strategies for prevention. Data Identification: A survey of the National Library of Medicine MEDLINE database and bibliographies of the reviewed articles. Study Selection and Data Extraction: Studies were selected from the English language literature with an emphasis on recent studies and, when available, randomized placebo-controlled studies. Old studies were selected on the basis of their historical value and originality. A total of 134 retrieved articles were considered relevant and were reviewed in depth. Results: The available information about the experimental as well as the clinical evidence for tolerance to organic nitrates has been summarized. In addition, information related to potential mechanisms, clinical implications, and possible methods for prevention have been reviewed. Conclusions: Evidence indicates that prolonged in-vitro exposure to organic nitrates, continuous intravenous or topical administration of nitrates, and frequent in-vivo oral dosing result in the rapid development of tolerance to the peripheral as well as to the coronary vasodilatory effects of the drugs. This phenomenon leads to the rapid attenuation of the hemodynamic and anti-ischemic effects of nitrates in patients with ischemic heart disease or congestive heart failure, or both. Tolerance development seems to be dose- and time-dependent, and its main mechanism seems to be a depletion of sulfhydryl groups at the vascular cell. Although the repletion of sulfhydryl groups with the use of sulfhydryl-containing drugs may help to prevent tolerance, the efficacy and safety of this approach requires further evaluation. Intermittent therapy allowing a sufficiently long, daily nitrate-washout interval seems to be the most effective and the most safe strategy currently available for the prevention of nitrate tolerance.			ELKAYAM, U (corresponding author), UNIV SO CALIF, SCH MED, DIV CARDIOL, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA.							ABRAMS J, 1989, AM J CARDIOL, V64, P931, DOI 10.1016/0002-9149(89)90844-8; AHLNER J, 1986, ACTA PHARMACOL TOX, V59, P123; AMIDI M, 1989, CIRCULATION S2, V80, P214; ARONOW WS, 1970, CIRCULATION, V42, P61, DOI 10.1161/01.CIR.42.1.61; AXELSSON KL, 1982, ACTA PHARMACOL TOX, V50, P350; AXELSSON KL, 1983, EUR J PHARMACOL, V88, P71, DOI 10.1016/0014-2999(83)90393-X; AXELSSON KL, 1984, ACTA PHARMACOL TOX, V55, P203; BENNETT BM, 1988, CIRC RES, V63, P693, DOI 10.1161/01.RES.63.4.693; BENSON H, 1979, NEW ENGL J MED, V300, P1424; BERNSTEIN LM, 1955, CIRCULATION, V12, P353, DOI 10.1161/01.CIR.12.3.353; BERTEL O, 1987, CIRCULATION, V76, P254; BOERTZ A, 1986, Z KARDIOL, V75, P57; BOLOGNESE L, 1988, CLIN CARDIOL, V11, P79, DOI 10.1002/clc.4960110206; BRIEN JF, 1986, J PHARMACOL EXP THER, V237, P608; BRIEN JF, 1988, J PHARMACOL EXP THER, V244, P322; CHIEN YW, 1984, AM HEART J, V108, P207, DOI 10.1016/0002-8703(84)90577-5; COLUCCI WS, 1981, AM J MED, V71, P89, DOI 10.1016/0002-9343(81)90263-1; COWAN JC, 1987, AM J CARDIOL, V60, P271, DOI 10.1016/0002-9149(87)90226-8; Crandall LA, 1931, J PHARMACOL EXP THER, V41, P103; Crandall LA, 1933, J PHARMACOL EXP THER, V48, P127; CREAN PA, 1984, AM HEART J, V108, P1494, DOI 10.1016/0002-8703(84)90697-5; CROME P, 1976, J INT MED RES, V4, P105, DOI 10.1177/14732300760040S419; DAKAK N, 1990, AM J CARDIOL, V66, P608, DOI 10.1016/0002-9149(90)90489-N; DALAL JJ, 1984, AM J CARDIOL, V54, P286, DOI 10.1016/0002-9149(84)90184-X; DALAL JJ, 1983, J AM COLL CARDIOL, V2, P115, DOI 10.1016/S0735-1097(83)80383-0; DANAHY DT, 1977, CIRCULATION, V56, P205, DOI 10.1161/01.CIR.56.2.205; DEGRAEFF PA, 1989, CIRCULATION S2, V80, P214; DEMOTS H, 1989, J AM COLL CARDIOL, V13, P786, DOI 10.1016/0735-1097(89)90216-7; DUPUIS J, 1990, AM HEART J, V120, P625, DOI 10.1016/0002-8703(90)90021-O; EBRIGHT GE, 1914, JAMA-J AM MED ASSOC, V62, P201; ELKAYAM U, 1987, CIRCULATION, V76, P256; ELKAYAM U, 1989, Journal of the American College of Cardiology, V13, p178A; ELKAYAM U, 1982, DRUGS, V23, P165, DOI 10.2165/00003495-198223030-00001; ELKAYAM U, 1987, CIRCULATION, V76, P577, DOI 10.1161/01.CIR.76.3.577; ELKAYAM URI, 1985, AM J CARDIOL, V56, P555, DOI 10.1016/0002-9149(85)91184-1; FLAHERTY JT, 1983, CIRCULATION, V68, P576, DOI 10.1161/01.CIR.68.3.576; FRANCIOSA JA, 1980, AM J CARDIOL, V45, P648, DOI 10.1016/S0002-9149(80)80018-X; FRISHMAN WH, 1989, J CLIN PHARMACOL, V29, P1097, DOI 10.1002/j.1552-4604.1989.tb03285.x; FUNG H-L, 1989, European Heart Journal, V10, P2; GRECO R, 1988, AM J CARDIOL, V61, pE44; HEEPE W, 1987, J INT MED RES, V15, P198, DOI 10.1177/030006058701500402; HOROWITZ JD, 1988, CIRCULATION, V77, P787, DOI 10.1161/01.CIR.77.4.787; HOROWITZ JD, 1983, CIRCULATION, V68, P1247, DOI 10.1161/01.CIR.68.6.1247; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IRVINE RF, 1986, BRIT MED BULL, V42, P369, DOI 10.1093/oxfordjournals.bmb.a072154; JAMES MA, 1985, BRIT HEART J, V53, P631; JORDAN RA, 1985, CIRCULATION, V71, P980, DOI 10.1161/01.CIR.71.5.980; JORDAN RA, 1986, ANN INTERN MED, V104, P295, DOI 10.7326/0003-4819-104-3-295; JUGDUTT BI, 1988, CIRCULATION, V78, P906, DOI 10.1161/01.CIR.78.4.906; KAPLAN K, 1983, AM J CARDIOL, V51, P694, DOI 10.1016/S0002-9149(83)80117-9; KAPOOR AS, 1985, CLIN THER, V7, P674; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KEITH RA, 1983, J PHARMACOL EXP THER, V225, P29; KLOCK JC, 1975, AM HEART J, V89, P510, DOI 10.1016/0002-8703(75)90159-3; KOHLI RS, 1986, AM J CARDIOL, V58, P727, DOI 10.1016/0002-9149(86)90345-0; KUKOVETZ W R, 1987, Cardiology, V74, P12, DOI 10.1159/000174258; KUKOVETZ WR, 1986, Z KARDIOL, V75, P8; Laws CE, 1910, J AMER MED ASSOC, V54, P793; Laws G, 1898, JAMA-J AM MED ASSOC, V31, P793; LEE G, 1978, AM J CARDIOL, V41, P82, DOI 10.1016/0002-9149(78)90136-4; LEIER CV, 1983, CIRCULATION, V67, P817, DOI 10.1161/01.CIR.67.4.817; LEVY WS, 1988, CIRCULATION, V78, P640, DOI 10.1161/01.CIR.78.3.640; LEVY WS, 1989, CIRCULATION S2, V80, P214; LIN SG, 1985, AM J CARDIOL, V56, P742, DOI 10.1016/0002-9149(85)91126-9; LUKE R, 1987, J AM COLL CARDIOL, V10, P642, DOI 10.1016/S0735-1097(87)80208-5; MANTHEY J, 1980, CIRCULATION, V62, P259; MANYARI DE, 1985, AM J CARDIOL, V55, P927, DOI 10.1016/0002-9149(85)90719-2; MAY DC, 1987, NEW ENGL J MED, V317, P805, DOI 10.1056/NEJM198709243171305; MCGUINNESS B, 1961, BRIT MED J, V2, P745, DOI 10.1136/bmj.2.5254.745; MILLER LF, 1983, SEMIN ONCOL, V10, P76; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MUIESAN G, 1986, AM HEART J, V112, P233, DOI 10.1016/0002-8703(86)90713-1; MULLER P, 1982, EUR J CLIN PHARMACOL, V22, P473, DOI 10.1007/BF00609617; MULSCH A, 1988, EUR J PHARMACOL, V158, P191, DOI 10.1016/0014-2999(88)90066-0; NAAFS MAB, 1984, EUR HEART J, V5, P705, DOI 10.1093/oxfordjournals.eurheartj.a061730; NATARAJAN D, 1988, AM J CARDIOL, V62, P319, DOI 10.1016/0002-9149(88)90236-6; NEEDLEMA.P, 1970, J PHARMACOL EXP THER, V171, P98; NEEDLEMAN P, 1973, J PHARMACOL EXP THER, V184, P709; NEUBERG GW, 1989, CIRCULATION S2, V80, P213; OLIVARI MT, 1983, J AM COLL CARDIOL, V2, P872, DOI 10.1016/S0735-1097(83)80234-4; PACKER M, 1981, CIRCULATION, V64, P506, DOI 10.1161/01.CIR.64.3.506; PACKER M, 1986, AM J CARDIOL, V57, P260, DOI 10.1016/0002-9149(86)90902-1; PACKER M, 1987, NEW ENGL J MED, V317, P799, DOI 10.1056/NEJM198709243171304; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARISI AF, 1982, CIRCULATION, V65, pI38; PARKER JO, 1984, AM J CARDIOL, V54, P471, DOI 10.1016/0002-9149(84)90233-9; PARKER JO, 1987, NEW ENGL J MED, V316, P1440, DOI 10.1056/NEJM198706043162303; PARKER JO, 1987, CIRCULATION, V76, P572, DOI 10.1161/01.CIR.76.3.572; PARKER JO, 1985, AM J CARDIOL, V56, P724, DOI 10.1016/0002-9149(85)91123-3; PARKER JO, 1984, AM J CARDIOL, V54, P8, DOI 10.1016/0002-9149(84)90296-0; PARKER JO, 1989, J AM COLL CARDIOL, V13, P794, DOI 10.1016/0735-1097(89)90217-9; PRESCOTT LF, 1976, J INT MED RES, V4, P112, DOI 10.1177/14732300760040S420; RAJFER SI, 1984, AM J CARDIOL, V54, P120, DOI 10.1016/0002-9149(84)90315-1; RAPOPORT RM, 1983, J CYCLIC NUCL PROT, V9, P281; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; REICHEK N, 1974, CIRCULATION, V50, P348, DOI 10.1161/01.CIR.50.2.348; REICHEK N, 1984, AM J CARDIOL, V54, P1, DOI 10.1016/0002-9149(84)90295-9; ROTH A, 1987, J AM COLL CARDIOL, V9, P858, DOI 10.1016/S0735-1097(87)80242-5; ROTH A, 1986, CLIN RES, V34, pA13; RUSH ML, 1971, EUR J PHARMACOL, V16, P148, DOI 10.1016/0014-2999(71)90004-5; SCARDI S, 1985, AM HEART J, V110, P546, DOI 10.1016/0002-8703(85)90073-0; SCHAER DH, 1988, AM J CARDIOL, V61, P46, DOI 10.1016/0002-9149(88)91302-1; SCHELLING JL, 1967, CLIN PHARMACOL THER, V8, P256; SCHNEIDER WU, 1984, AM J CARDIOL, V53, P700, DOI 10.1016/0002-9149(84)90389-8; SCHWARTZ AM, 1946, NEW ENGL J MED, V235, P541, DOI 10.1056/NEJM194610102351503; SHARPE DN, 1984, J CARDIOVASC PHARM, V6, P76; SHARPE N, 1987, AM J CARDIOL, V59, P895, DOI 10.1016/0002-9149(87)91115-5; SILBER S, 1987, AM J MED, V83, P860, DOI 10.1016/0002-9343(87)90643-7; SLACK CJ, 1988, CAN J PHYSIOL PHARM, V66, P1344, DOI 10.1139/y88-220; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; Stewart DD, 1905, J AMER MED ASSOC, V44, P1678; STEWART DJ, 1986, CIRCULATION, V74, P573, DOI 10.1161/01.CIR.74.3.573; STEWART DJ, 1987, CIRCULATION, V75, P847, DOI 10.1161/01.CIR.75.4.847; SULLIVAN M, 1985, J AM COLL CARDIOL, V5, P1220, DOI 10.1016/S0735-1097(85)80028-0; Tauchert M, 1983, Z Kardiol, V72 Suppl 3, P218; THADANI U, 1987, CIRCULATION, V76, P128; THADANI U, 1982, AM J CARDIOL, V49, P411, DOI 10.1016/0002-9149(82)90518-5; THADANI U, 1980, CIRCULATION, V61, P526, DOI 10.1161/01.CIR.61.3.526; THADANI U, 1987, AM J CARDIOL, V59, P756, DOI 10.1016/0002-9149(87)91087-3; THADANI U, 1986, ANN INTERN MED, V105, P485, DOI 10.7326/0003-4819-105-4-485; THADANI U, 1988, CURR PROB CARDIOLOGY, V13, P731; THADANI U, 1989, CIRCULATION, V80, P216; THOMPSON R, 1986, ANGIOLOGY, V37, P448, DOI 10.1177/000331978603700604; TORRESI J, 1985, J CARDIOVASC PHARM, V7, P777, DOI 10.1097/00005344-198507000-00024; TREMBLAY G, 1975, AM HEART J, V89, P521, DOI 10.1016/0002-8703(75)90161-1; VALE JA, 1981, ARCH INTERN MED, V141, P394, DOI 10.1001/archinte.141.3.394; WEBSTER M, 1989, CIRCULATION, V80, P215; WINNIFORD MD, 1986, CIRCULATION, V73, P138, DOI 10.1161/01.CIR.73.1.138; YEATES RA, 1985, MOL PHARMACOL, V28, P555; YUSUF S, 1988, LANCET, V1, P1088; ZELIS R, 1975, JAMA-J AM MED ASSOC, V234, P166, DOI 10.1001/jama.234.2.166; ZIMRIN D, 1988, CIRCULATION, V77, P1376, DOI 10.1161/01.CIR.77.6.1376	133	138	138	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					667	677		10.7326/0003-4819-114-8-667	http://dx.doi.org/10.7326/0003-4819-114-8-667			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003715				2022-12-28	WOS:A1991FG03100010
J	MIRANDA, CP; LEHMANN, KG; LACHTERMAN, B; COODLEY, EM; FROELICHER, VF				MIRANDA, CP; LEHMANN, KG; LACHTERMAN, B; COODLEY, EM; FROELICHER, VF			COMPARISON OF SILENT AND SYMPTOMATIC ISCHEMIA DURING EXERCISE TESTING IN MEN	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL ISCHEMIA; TREADMILL EXERCISE; CHEST PAIN; INFARCTION; PROGNOSIS; DEATH; ANGIOPLASTY	Objective: To compare angina and ST-segment depression during exercise testing, as markers for coronary artery disease. Design: Retrospective analysis of exercise test responses and cardiac catheterization results. Setting: A U.S. Veterans Affairs medical center. Patients: Four hundred and sixteen men who were referred for the evaluation of symptoms, postmyocardial infarction testing, or both. Two hundred patients had no clinical or electrocardiographic evidence of previous myocardial infarction, whereas 216 were survivors of a previous myocardial infarction. Interventions: All patients did a standard exercise test and had diagnostic coronary angiography with ventriculography within an average of 32 days (range, 0 to 90 days) of their exercise test. Results: Two hundred patients without a previous myocardial infarction were divided into four groups: the no ischemia group had 80 patients; the angina pectoris only group had 23 patients; the silent ischemia group had 40 patients; and the ST-segment depression and angina pectoris group had 57 patients. In patients without a previous myocardial infarction, exercise-induced ST-segment depression was a better marker than exercise-induced angina for the presence of any coronary artery disease (P < 0.005). Patients with symptomatic exercise-induced ischemia had a higher prevalence of severe coronary artery disease than did those with only silent ischemia (30% compared with 20%; 95% CI, - 7.3% to 27.0%; P = 0.005). For the 216 survivors of a myocardial infarction, divided into the same four groups, ST-segment depression again was a better marker for the presence of severe coronary artery disease compared with angina alone (P = 0.08). The prevalence rates of severe coronary artery disease in the no ischemia plus myocardial infarction group, the angina pectoris only plus myocardial infarction group, the silent ischemia plus myocardial infarction group, and the ST-segment depression and angina pectoris plus myocardial infarction group were 10%, 9%, 23%, and 32%, respectively (P < 0.01). Conclusions: Exercise-induced ST-segment depression is a better marker for coronary artery disease than is exercise-induced angina. Symptomatic ischemia during the exercise test is a better marker for severe coronary artery disease than is silent ischemia.	UNIV CALIF IRVINE, IRVINE, CA 92717 USA	University of California System; University of California Irvine	MIRANDA, CP (corresponding author), LONG BEACH VET AFFAIRS MED CTR, 5901 E 7TH ST, LONG BEACH, CA 90822 USA.			Froelicher, Victor/0000-0001-8831-4853				AMSTERDAM EA, 1986, AM J CARDIOL, V58, pB43, DOI 10.1016/0002-9149(86)90409-1; CALLAHAM PR, 1989, J AM COLL CARDIOL, V14, P1175, DOI 10.1016/0735-1097(89)90413-0; COHN PF, 1981, AM J CARDIOL, V47, P233, DOI 10.1016/0002-9149(81)90391-X; COLE JP, 1978, AM J CARDIOL, V41, P227, DOI 10.1016/0002-9149(78)90161-3; DELIGONUL U, 1989, AM J CARDIOL, V64, P1, DOI 10.1016/0002-9149(89)90643-7; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; ERIKSSEN J, 1976, CIRCULATION, V54, P371, DOI 10.1161/01.CIR.54.3.371; FALCONE C, 1987, J AM COLL CARDIOL, V9, P295, DOI 10.1016/S0735-1097(87)80378-9; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P62; FROELICHER VF, 1988, DM-DIS MON, V34, P682, DOI 10.1016/0011-5029(88)90011-9; Gardner MJ, 1989, STAT CONFIDENCE, P28; HAUSER AM, 1985, J AM COLL CARDIOL, V5, P193, DOI 10.1016/S0735-1097(85)80036-X; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; MARK DB, 1989, J AM COLL CARDIOL, V14, P885, DOI 10.1016/0735-1097(89)90459-2; MCCLISH DK, 1987, MED DECIS MAKING, V7, P149, DOI 10.1177/0272989X8700700305; OUYANG P, 1987, AM J CARDIOL, V59, P730, DOI 10.1016/0002-9149(87)91082-4; STERN S, 1988, J CARDIOPULM REHABIL, V12, P507; UPTON MT, 1980, CIRCULATION, V62, P341, DOI 10.1161/01.CIR.62.2.341; VISSER FC, 1990, INT J CARDIOL, V27, P71, DOI 10.1016/0167-5273(90)90193-9; WARNES CA, 1984, AM J CARDIOL, V54, P65, DOI 10.1016/0002-9149(84)90305-9; WEINER DA, 1987, AM J CARDIOL, V59, P725, DOI 10.1016/0002-9149(87)91081-2; WEINER DA, 1978, AM HEART J, V96, P458, DOI 10.1016/0002-8703(78)90155-2; WEINER DA, 1988, AM J CARDIOL, V62, P1155, DOI 10.1016/0002-9149(88)90251-2	24	27	28	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					649	656		10.7326/0003-4819-114-8-649	http://dx.doi.org/10.7326/0003-4819-114-8-649			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003711				2022-12-28	WOS:A1991FG03100006
J	BARRETTCONNOR, E; BUSH, TL				BARRETTCONNOR, E; BUSH, TL			ESTROGEN AND CORONARY HEART-DISEASE IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-CONTRACEPTIVE ESTROGENS; PRACTITIONERS ORAL CONTRACEPTION; NONFATAL MYOCARDIAL-INFARCTION; LONG-TERM ESTROGEN; RISK-FACTORS; CARDIOVASCULAR-DISEASE; REPLACEMENT THERAPY; POSTMENOPAUSAL ESTROGEN; YOUNG-WOMEN; REPRODUCTIVE HISTORY	We review herein the evidence that estrogen is protective against the development of cardiovascular disease in women. To our knowledge, no studies in women have looked at endogenous estrogen levels as predictors of cardiovascular disease. Studies of surrogate measures of endogenous estrogen such as parity, age at menarche, and age at menopause have provided inconsistent results. Current use of oral contraceptives increases risk in older women who smoke cigarettes, but most studies of past use show no increased risk. Most, but not all, studies of hormone replacement therapy in postmenopausal women show around a 50% reduction in risk of a coronary event in women using unopposed oral estrogen. These important observations need to be confirmed in a double-blind, randomized clinical trial, since the protection is biologically plausible and the magnitude of the benefit would be quite large if selection factors can be excluded.	JOHNS HOPKINS UNIV,DEPT EPIDEMIOL,BALTIMORE,MD 21218	Johns Hopkins University	BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED M-007,LA JOLLA,CA 92093, USA.							ABRAHAM GE, 1975, OBSTET GYNECOL, V45, P271; ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; ADAMS MR, 1987, CARDIOVASCULAR DISEA, P381; ASKUPMARK E, 1962, ACTA MED SCAND, V172, P129; AVILA MH, 1990, EPIDEMIOLOGY, V1, P128; BARRETTCONNOR E, 1986, WOMEN HEALTH, V11, P179; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, ARTERIOSCLEROSIS, V10, P531, DOI 10.1161/01.ATV.10.4.531; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BEARD CM, 1984, AM J EPIDEMIOL, V120, P108, DOI 10.1093/oxfordjournals.aje.a113859; BEARD CM, 1986, MAYO CLIN PROC, V61, P186, DOI 10.1016/S0025-6196(12)61847-3; BEARD CM, 1989, MAYO CLIN PROC, V64, P1471, DOI 10.1016/S0025-6196(12)65702-4; BENGTSSON C, 1973, ACTA MED SCAND, V549, P75; BERAL V, 1985, J EPIDEMIOL COMMUN H, V39, P343, DOI 10.1136/jech.39.4.343; BURCH JC, 1974, AM J OBSTET GYNECOL, V118, P778, DOI 10.1016/0002-9378(74)90487-6; BUSH TL, 1985, EPIDEMIOL REV, V7, P80, DOI 10.1093/oxfordjournals.epirev.a036287; BUSH TL, 1988, CLIN CHEM, V34, pB60; BUSH TL, 1987, CIRCULATION, V75, P1002; BUSH TL, 1987, MENOPAUSE PHYSL PHAR, P187; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P861, DOI 10.1093/oxfordjournals.aje.a114723; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; EAKER ED, 1987, CORONARY HEART DISEA, P122; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; Glendy RE, 1937, J AMER MED ASSOC, V109, P1775, DOI 10.1001/jama.1937.02780480007002; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HAHN RG, 1989, AM J OBSTET GYNECOL, V61, P1854; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HUBERT HB, 1987, AM J EPIDEMIOL, V125, P812, DOI 10.1093/oxfordjournals.aje.a114598; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1407, DOI 10.1001/jama.239.14.1407; JOHANSSON BW, 1975, ACTA OBSTET GYN SCAN, V54, P449, DOI 10.3109/00016347509157108; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KAY CR, 1984, CLIN OBSTET GYNAECOL, V11, P759; KNOPP RH, 1988, AM J OBSTET GYNECOL, V158, P1630, DOI 10.1016/0002-9378(88)90201-3; KRITZSILVERSTEIN D, 1990, CIRCULATION, V81, P718; LAFFERTY FW, 1985, MATURITAS, V7, P47; LAVECCHIA C, 1987, AM J OBSTET GYNECOL, V157, P1108, DOI 10.1016/S0002-9378(87)80271-5; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; LIPPMAN ME, 1987, J LAB CLIN MED, V109, P230; MACMAHON B, 1978, CORONARY HEART DISEA; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; MANN JI, 1975, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5965.245; MANN JI, 1976, BRIT MED J, V2, P445, DOI 10.1136/bmj.2.6033.445; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; MCGILL HC, 1989, POSTGRAD MED     APR, P64; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOVACK ER, 1966, AM J OBSTET GYNECOL, V80, P863; OLIVER MF, 1959, LANCET, V2, P690; OLIVER MF, 1974, BMJ-BRIT MED J, V4, P253, DOI 10.1136/bmj.4.5939.253; PARRISH HM, 1967, AM J OBSTET GYNECOL, V97, P1087, DOI 10.1016/0002-9378(67)90469-3; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; RITTERBAND AB, 1963, CIRCULATION, V26, P237; RIVIN AU, 1954, CIRCULATION, V9, P533, DOI 10.1161/01.CIR.9.4.533; ROBINSON RW, 1959, ARCH INTERN MED, V104, P908, DOI 10.1001/archinte.1959.00270120064010; ROSENBERG L, 1976, NEW ENGL J MED, V294, P1256, DOI 10.1056/NEJM197606032942302; ROSENBERG L, 1980, JAMA-J AM MED ASSOC, V244, P339, DOI 10.1001/jama.244.4.339; ROSENBERG L, 1980, AM J EPIDEMIOL, V111, P59, DOI 10.1093/oxfordjournals.aje.a112874; SHAPIRO S, 1979, LANCET, V1, P743; SLONE D, 1981, NEW ENGL J MED, V305, P420, DOI 10.1056/NEJM198108203050802; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAMLER J, 1953, CIRC RES, V1, P94, DOI 10.1161/01.RES.1.1.94; STAMLER J, 1956, ANN NY ACAD SCI, V64, P596, DOI 10.1111/j.1749-6632.1956.tb36834.x; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; STEINLEITNER A, 1989, AM J OBSTET GYNECOL, V161, P1677, DOI 10.1016/0002-9378(89)90949-6; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; SZKLO M, 1984, PREV MED, V13, P510, DOI 10.1016/0091-7435(84)90019-7; SZNAJDERMAN M, 1963, LANCET, V1, P962; TALBOTT E, 1977, AM J CARDIOL, V39, P858, DOI 10.1016/S0002-9149(77)80040-4; TALBOTT EO, 1989, INT J EPIDEMIOL, V18, P589, DOI 10.1093/ije/18.3.589; TALBOTT EO, 1981, AM J EPIDEMIOL, V114, P672; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; TIKKANEN MJ, 1982, J CLIN ENDOCR METAB, V54, P1113, DOI 10.1210/jcem-54-6-1113; TIKKANEN MJ, 1986, METABOLISM, V35, P99, DOI 10.1016/0026-0495(86)90107-1; VERMEULEN A, 1983, HORM RES, V18, P37, DOI 10.1159/000179777; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; WILSON PWF, 1986, NEW ENGL J MED, V315, P135; WINKELSTEIN W, 1964, AM HEART J, V67, P481, DOI 10.1016/0002-8703(64)90094-8; WINKELSTEIN W Jr, 1958, J Chronic Dis, V7, P273, DOI 10.1016/0021-9681(58)90085-7; WUEST JH, 1953, CIRCULATION, V7, P801, DOI 10.1161/01.CIR.7.6.801; 1980, NIH801527 US DEP HLT, P1; 1981, LANCET, V1, P541; 1980, NEW ENGL J MED, V303, P1038	92	1150	1164	0	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1861	1867		10.1001/jama.265.14.1861	http://dx.doi.org/10.1001/jama.265.14.1861			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005736				2022-12-28	WOS:A1991FE86200029
J	ALBRIGHT, GA; COHEN, H; FORSTER, RM; GLASSENBERG, R; BRUNNER, EA				ALBRIGHT, GA; COHEN, H; FORSTER, RM; GLASSENBERG, R; BRUNNER, EA			ANESTHESIA FOR PATIENTS WITH PREECLAMPSIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University	ALBRIGHT, GA (corresponding author), NW MEM HOSP,CHICAGO,IL 60611, USA.							1986, SURV ANESTHESIOL, V30, P306	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1587	1587		10.1001/jama.265.12.1587	http://dx.doi.org/10.1001/jama.265.12.1587			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999909				2022-12-28	WOS:A1991FC60400038
J	PANLILIO, AL; FOY, DR; EDWARDS, JR; BELL, DM; WELCH, BA; PARRISH, CM; CULVER, DH; LOWRY, PW; JARVIS, WR; PERLINO, CA				PANLILIO, AL; FOY, DR; EDWARDS, JR; BELL, DM; WELCH, BA; PARRISH, CM; CULVER, DH; LOWRY, PW; JARVIS, WR; PERLINO, CA			BLOOD CONTACTS DURING SURGICAL-PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPERATIONS; RISK; AIDS	Operating room personnel are at risk for infection with blood-borne pathogens through blood contact. To describe the nature and frequency of blood contact and its risk factors, trained observers monitored a sample of operations performed by six surgical services at Grady Memorial Hospital, Atlanta, Ga, for 6 months. In 62 (30.1%) of 206 operations, at least one blood contact was observed. Of 1828 operating room person-procedures observed, 96 (5.3%) had 147 blood contacts (133 skin contacts [90%], 10 percutaneous injuries [7%], and four eye splashes [3%]). The mean number of blood contacts per 100 person-procedures was highest for surgeons (18.6). The frequency of percutaneous injury was similar among surgeons and scrub staff (mean, 1.2 per 100 worker-procedures for each group). Risk factors for surgeons' blood contacts were (1) performing a trauma, burn, or orthopedic emergency procedure (odds ratio [OR], 4.1; 95% confidence interval [Cl], 2.0 to 8.7); (2) patient blood loss exceeding 250mL (OR, 2.1; 95% Cl, 1.2 to 3.7); and (3) being in the operating room longer than 1 hour (OR, 3.3; 95% Cl, 1.6 to 7.1). Of 110 blood contacts among surgeons, 81 (74%) were potentially preventable by additional barrier precautions, such as face shields and fluid-resistant gowns. Twenty-one (84%) of 25 blood contacts among surgeons in procedures in which all three risk factors were present were potentially preventable by additional barriers. Of 29 blood contacts among anesthesia and circulating personnel, 20 (69%) would have been prevented by glove use. For surgical procedures in which operating room personnel are at increased risk of blood contact, reevaluation of surgical technique, use of appropriate barrier precautions, and development of puncture-resistant glove materials are indicated.	GRADY MEM HOSP,DEPT EPIDEMIOL,ATLANTA,GA; EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA 30322	Emory University	PANLILIO, AL (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP C-10,ATLANTA,GA 30333, USA.							ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; Breslow N.E., 1980, STAT METHODS CANC RE, P192; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GRAVES EJ, 1989, VITAL HLTH STAT, V13, P99; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; MCNICHOLAS TA, 1989, BRIT J UROL, V63, P565, DOI 10.1111/j.1464-410X.1989.tb05246.x; PANLILIO AL, 1990, 6TH INT C AIDS SAN F; POPEJOY SL, IN PRESS SURG GYNECO; TELFORD GL, 1987, SURG ROUNDS, V10, P30; TOKARS JI, 1990, 30TH INT C ANT AG CH; 1987, MMWR, V36, P285; 1987, MMWR, V36, P1; 1989, RECOMMENDATIONS PREV; 1987, MMWR, V36, P509	15	147	154	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1533	1537		10.1001/jama.265.12.1533	http://dx.doi.org/10.1001/jama.265.12.1533			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999903				2022-12-28	WOS:A1991FC60400027
J	KNOWLES, JR				KNOWLES, JR			ENZYME CATALYSIS - NOT DIFFERENT, JUST BETTER	NATURE			English	Review							SITE-DIRECTED MUTAGENESIS; ALPHA-HELIX DIPOLE; TRIOSEPHOSPHATE ISOMERASE; ACTIVE-SITE; LACTATE-DEHYDROGENASE; PHOSPHATE; MECHANISM; STABILIZATION; SPECTROSCOPY; ENERGETICS	Where are we in our understanding of enzyme catalysis? The gloomier view is that protein structure and enzyme function are the finely balanced end-products of many weak interactions that can be summed only by massive computing power, and more precise parameterization than we enjoy at present. The cheerier position is that proteins are built on definable principles, and that enzymes use recognizable catalytic devices that will allow us to understand how existing enzymes work and to design new ones. To assess which interpretation is the more realistic, the simple reaction catalysed by triosephosphate isomerase is considered here. This examination illustrates some of the catalytic features of enzymes that are understood, and exposes a few that are not. But overall, the question turns out to have an optimistic answer.	HARVARD UNIV,DEPT BIOCHEM,CAMBRIDGE,MA 02138	Harvard University	KNOWLES, JR (corresponding author), HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138, USA.							ADAMS MJ, 1973, P NATL ACAD SCI USA, V70, P1968, DOI 10.1073/pnas.70.7.1968; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ALBER TC, 1987, COLD SPRING HARB SYM, V52, P603, DOI 10.1101/SQB.1987.052.01.069; ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5627, DOI 10.1021/bi00670a031; BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BELASCO JG, 1978, BIOCHEMISTRY-US, V17, P2971, DOI 10.1021/bi00608a005; BELASCO JG, 1980, BIOCHEMISTRY-US, V19, P472, DOI 10.1021/bi00544a012; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BLACKLOW SC, 1990, BIOCHEMISTRY-US, V29, P4099, DOI 10.1021/bi00469a012; BLOW DM, 1975, PHILOS T ROY SOC B, V272, P87, DOI 10.1098/rstb.1975.0072; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; COREY EJ, 1956, J AM CHEM SOC, V78, P6269, DOI 10.1021/ja01605a013; DAVENPORT RC, 1986, THESIS MIT CAMBRIDGE; Fischer E., 1894, BER DTSCH CHEM GES, V27, P2985, DOI DOI 10.1002/CBER.18940270364; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; HALDANE JBS, 1930, ENZYMES, P182; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HUFF JB, 1988, J AM CHEM SOC, V110, P5908, DOI 10.1021/ja00225a057; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KOMIVES EA, IN PRESS BIOCHEMISTR; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LUDWIG ML, 1967, P NATL ACAD SCI USA, V57, P511, DOI 10.1073/pnas.57.3.511; MAISTER SG, 1976, BIOCHEMISTRY-US, V15, P5607, DOI 10.1021/bi00670a027; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; PICKOVER CA, 1979, J BIOL CHEM, V254, P1323; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RAINES RT, 1986, BIOCHEMISTRY-US, V25, P7142, DOI 10.1021/bi00370a057; REDFIELD AG, 1990, BIOCHEMISTRY-US, V29, P3509, DOI 10.1021/bi00466a013; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RICHARD JP, 1984, J AM CHEM SOC, V106, P4926, DOI 10.1021/ja00329a050; RIEDER SV, 1959, J BIOL CHEM, V234, P1007; ROSE I A, 1962, Brookhaven Symp Biol, V15, P293; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; TIDOR BB, IN PRESS BIOCHEMISTR; WEBB MR, 1974, BIOCHEM J, V141, P589, DOI 10.1042/bj1410589; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066; ZIMMERMAN SC, 1988, J AM CHEM SOC, V110, P5906, DOI 10.1021/ja00225a056	45	496	509	0	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					121	124		10.1038/350121a0	http://dx.doi.org/10.1038/350121a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005961				2022-12-28	WOS:A1991FB64500046
J	BUCHI, K				BUCHI, K			RADIATION PROCTITIS - THERAPY AND PROGNOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							LASER THERAPY; ENTERITIS				BUCHI, K (corresponding author), UNIV UTAH,HLTH SCI CTR,SALT LAKE CITY,UT 84112, USA.							AHLQUIST DA, 1986, MAYO CLIN PROC, V61, P927, DOI 10.1016/S0025-6196(12)62631-7; BLOOMER WD, 1975, NEW ENGL J MED, V293, P80, DOI 10.1056/NEJM197507102930206; BUCHI KN, 1987, GASTROINTEST ENDOSC, V33, P27, DOI 10.1016/S0016-5107(87)71481-3; GALLAND RB, 1986, SURGERY, V99, P133; GOLDSTEIN F, 1976, AM J GASTROENTEROL, V65, P201; LEUCHTER RS, 1982, OBSTET GYNECOL, V59, pS65; NOVAK JM, 1979, J CLIN GASTROENTEROL, V1, P9, DOI 10.1097/00004836-197903000-00003; Walsh D, 1897, Br Med J, V2, P272	8	41	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1180	1180		10.1001/jama.265.9.1180	http://dx.doi.org/10.1001/jama.265.9.1180			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996006				2022-12-28	WOS:A1991EZ47400039
J	GENBERG, L; RICHARD, L; MCLENDON, G; MILLER, RJD				GENBERG, L; RICHARD, L; MCLENDON, G; MILLER, RJD			DIRECT OBSERVATION OF GLOBAL PROTEIN MOTION IN HEMOGLOBIN AND MYOGLOBIN ON PICOSECOND TIME SCALES	SCIENCE			English	Article							ENERGY RELAXATION PROCESSES; HEME-PROTEINS; GEMINATE RECOMBINATION; RESONANCE RAMAN; LIGAND-BINDING; EXCITED-STATE; SPECTROSCOPY; DYNAMICS; (CARBONMONOXY)HEMOGLOBIN; CARBOXYMYOGLOBIN	Picosecond phase-grating spectroscopy is highly sensitive to density changes and provides a new holographic approach to the study of protein dynamics. Photodissociation of carbon monoxide from heme proteins induces a well-defined transition from a ligated to a deoxy structure that is important to hemoglobin and myoglobin functionality. Grating spectroscopy was used to observe protein-driven density waves on a picosecond time scale after carbon monoxide dissociation. This result demonstrates that global tertiary structure changes of proteins occur on an extremely fast time scale and provides new insight into the biomechanics of deterministic protein motion.	UNIV ROCHESTER,INST OPT,ROCHESTER,NY 14627	University of Rochester	GENBERG, L (corresponding author), UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627, USA.				NIGMS NIH HHS [1 R01 GM41909-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041909] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; [Anonymous], 1986, LASER INDUCED DYNAMI; ANSARI A, 1986, BIOCHEMISTRY-US, V25, P3139, DOI 10.1021/bi00359a011; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; CUSACK S, 1990, BIOPHYS J, V58, P243, DOI 10.1016/S0006-3495(90)82369-9; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; FINDSEN EW, 1985, SCIENCE, V229, P661, DOI 10.1126/science.4023704; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; GENBERG L, 1989, CHEM PHYS, V131, P81, DOI 10.1016/0301-0104(89)87082-X; GENBERG L, 1987, J PHYS CHEM-US, V91, P5521, DOI 10.1021/j100306a002; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; JANES SM, 1988, BIOPHYS J, V54, P545, DOI 10.1016/S0006-3495(88)82987-4; KOGELNIK H, 1969, AT&T TECH J, V48, P2909, DOI 10.1002/j.1538-7305.1969.tb01198.x; LEUNG WP, 1987, CHEM PHYS LETT, V141, P220, DOI 10.1016/0009-2614(87)85013-3; MILLER RJD, 1989, TIME RESOLVED SPECTR, V18, P1; MURRAY LP, 1988, BIOPHYS CHEM, V29, P63, DOI 10.1016/0301-4622(88)87025-X; NELSON KA, 1982, J CHEM PHYS, V77, P1144, DOI 10.1063/1.443979; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PETRICH JW, 1987, BIOCHEMISTRY-US, V26, P7914, DOI 10.1021/bi00398a056; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; REYNOLDS AH, 1981, P NATL ACAD SCI-BIOL, V78, P2292, DOI 10.1073/pnas.78.4.2292; SIEGMAN AE, 1977, J OPT SOC AM, V67, P545, DOI 10.1364/JOSA.67.000545; WESTRICK JA, 1990, BIOCHEMISTRY-US, V29, P6741, DOI 10.1021/bi00480a026; ZIMMT MB, 1989, CHEM PHYS LETT, V160, P564, DOI 10.1016/0009-2614(89)80064-8	24	99	99	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1051	1054		10.1126/science.1998121	http://dx.doi.org/10.1126/science.1998121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1998121				2022-12-28	WOS:A1991EZ66500042
J	WILLIAMS, T; TJIAN, R				WILLIAMS, T; TJIAN, R			CHARACTERIZATION OF A DIMERIZATION MOTIF IN AP-2 AND ITS FUNCTION IN HETEROLOGOUS DNA-BINDING PROTEINS	SCIENCE			English	Article							LEUCINE ZIPPER; TRANSCRIPTION FACTOR; ENHANCER-BINDING; SEQUENCE; JUN; SPECIFICITY; ELEMENTS; COMMON; DOMAIN; C/EBP	The mammalian transcription factor AP-2 is a retinoic acid inducible sequence-specific DNA-binding protein that is developmentally regulated. In this report, the functional domains necessary for AP-2 DNA binding were studied. AP-2 required a dimerization domain and an adjacent region of net basic charge to achieve a sequence-specific protein: DNA interaction. The sequences responsible for dimerization consisted of two putative amphipathic alpha helices separated by a large intervening span region. This helix-span-helix (HSH) domain was unable to bind DNA when separated from the basic region, but was still capable of dimerization. The ability of the HSH domain to function as a module that promotes DNA binding through dimerization was further demonstrated by attaching it to the heterologous basic region of the c-Jun proto-oncogene product. The resulting chimeric protein specifically recognized an AP-1 DNA-binding site in the absence of an intact c-Jun leucine repeat and in a manner that was dependent on the presence of a functional AP-2 dimerization domain.			WILLIAMS, T (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WILLIAMS T, IN PRESS GENES DEV; Williams T. J., UNPUB	31	196	204	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1067	1071		10.1126/science.1998122	http://dx.doi.org/10.1126/science.1998122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1998122				2022-12-28	WOS:A1991EZ66500049
J	GANNON, JV; LANE, DP				GANNON, JV; LANE, DP			PROTEIN-SYNTHESIS REQUIRED TO ANCHOR A MUTANT P53 PROTEIN WHICH IS TEMPERATURE-SENSITIVE FOR NUCLEAR TRANSPORT	NATURE			English	Article							TRANSFORMED-CELLS; GENE-PRODUCT; MUTATIONS; EXPRESSION; ANTIGEN; CANCER	THE p53 protein is rendered temperature-sensitive by a point mutation 1. Rat cells transformed by this mutant p53 and an activated ras oncogene grow well at 37-degrees-C but cease DNA synthesis and cell division when shifted to 32-degrees-C (ref. 1). Immunostaining demonstrates that the mutant p53 protein is in the nucleus of the arrested cells at 32-degrees-C but in the cytoplasm of the growing cells at 37-degrees-C. This is the first example of a protein which is temperature-sensitive for nuclear transport. The translocation from cytoplasm to nucleus and vice versa occurs 6 h after temperature shift and is coincident with the inhibition of DNA synthesis; transport from cytoplasm to nucleus does not require protein synthesis. Remarkably, inhibition of protein synthesis at 37-degrees-C also results in the rapid appearance of mutant p53 in the cell nucleus. These results suggest the presence of a short-lived protein responsible for holding p53 in the cytoplasm at 37-degrees-C but not at 32-degrees-C. Analysis of a non-temperature-sensitive mutant p53 protein shows that its cytoplasmic location is sensitive to protein synthesis inhibitors but not to temperature.			GANNON, JV (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ANDENBERG FM, 1989, J PATHOL, V157, P193; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; Crawford L V, 1984, Mol Biol Med, V2, P261; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1988, ANTIBODIES LABORATOR; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WASEEM NH, 1990, J CELL SCI, V96, P121; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	29	200	203	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					802	806						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000149				2022-12-28	WOS:A1991EZ66600060
J	PENN, ND				PENN, ND			EVERYDAY AIDS AND APPLIANCES - CALIPERS	BRITISH MEDICAL JOURNAL			English	Article											PENN, ND (corresponding author), ST JAMES UNIV HOSP,DEPT MED ELDERLY,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							GOODWILL J, 1988, REHABILITATION PHYSI, P741; McHugh B, 1987, PHYSIOTHERAPY, V73, P380; REDFORD JB, 1980, ORTHOTICS ETCETERA	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					402	403		10.1136/bmj.302.6773.402	http://dx.doi.org/10.1136/bmj.302.6773.402			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	2004148	Bronze, Green Published			2022-12-28	WOS:A1991EX85800033
J	KLEIN, CB; CONWAY, K; WANG, XW; BHAMRA, RK; LIN, XH; COHEN, MD; ANNAB, L; BARRETT, JC; COSTA, M				KLEIN, CB; CONWAY, K; WANG, XW; BHAMRA, RK; LIN, XH; COHEN, MD; ANNAB, L; BARRETT, JC; COSTA, M			SENESCENCE OF NICKEL-TRANSFORMED CELLS BY AN X-CHROMOSOME - POSSIBLE EPIGENETIC CONTROL	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENES; CHINESE-HAMSTER; RETINOBLASTOMA; LOCALIZATION; CANCER; REGION; MOUSE; DNA	Transfer of a normal Chinese hamster X chromosome (carried in a mouse A9 donor cell line) to a nickel-transformed Chinese hamster cell line with an Xq chromosome deletion resulted in senescence of these previously immortal cells. At early passages of the A9/CX donor cells, the hamster X chromosome was highly active, inducing senescence in 100% of the colonies obtained after its transfer into the nickel-transformed cells. However, senescence was reduced to 50% when Chinese hamster X chromosomes were transferred from later passage A9 cells. Full senescing activity of the intact hamster X chromosome was restored by treatment of the donor mouse cells with 5-azacytidine, which induced demethylation of DNA. These results suggest that a senescence gene or genes, which may be located on the Chinese hamster X chromosome, can be regulated by DNA methylation, and that escape from senescence and possibly loss of tumor suppressor gene activity can occur by epigenetic mechanisms.	NYU MED CTR,INST ENVIRONM MED,NEW YORK,NY 10016; UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	New York University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			costa, max/H-1754-2012; Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Klein, Catherine/0000-0001-8588-3751	NIEHS NIH HHS [ES 04895, ES 05512, ES 04715] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004715, P42ES004895] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGGART NW, 1986, MUTAT RES, V175, P209, DOI 10.1016/0165-7992(86)90056-4; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROWN CJ, 1990, AM J HUM GENET, V46, P273; CONWAY K, 1989, CANCER RES, V49, P6032; CONWAY K, 1989, THESIS NEW YORK U GR; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FENWICK RG, 1980, SOMAT CELL GENET, V6, P477, DOI 10.1007/BF01539151; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOCKEY AJ, 1989, SOMAT CELL MOLEC GEN, V15, P421, DOI 10.1007/BF01534893; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HUEBNER K, 1986, AM J HUM GENET, V38, P819; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1989, P NATL ACAD SCI USA, V86, P8733; LIMON J, 1986, CANCER GENET CYTOGEN, V23, P87, DOI 10.1016/0165-4608(86)90152-4; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NISHIOKA H, 1975, MUTAT RES, V31, P185, DOI 10.1016/0165-1161(75)90088-6; PERIERASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SEN P, 1986, TOXICOL APPL PHARM, V84, P278, DOI 10.1016/0041-008X(86)90135-3; SEN P, 1985, CANCER RES, V45, P2320; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P9099, DOI 10.1073/pnas.84.24.9099; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WANG X, UNPUB; YAMADA H, 1990, ONCOGENE, V5, P141	35	167	168	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					796	799		10.1126/science.1990442	http://dx.doi.org/10.1126/science.1990442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990442				2022-12-28	WOS:A1991EX57500045
J	NIGGLI, E; LEDERER, WJ				NIGGLI, E; LEDERER, WJ			MOLECULAR OPERATIONS OF THE SODIUM CALCIUM EXCHANGER REVEALED BY CONFORMATION CURRENTS	NATURE			English	Article							GUINEA-PIG; VOLTAGE DEPENDENCE; VENTRICULAR CELLS; MECHANISM; VESICLES; PUMPS	THE sodium-calcium exchanger is critical in the normal functioning of many cells 1,2. In heart muscle, it is the principal way by which the cells keep the concentration of intracellular calcium low, pumping out the Ca2+ that enters the cytosol through L-type Ca2+ channels 3,4. The exchanger may also contribute to the triggering of Ca2+ release during voltage-activated excitation-contraction coupling in heart 5,6. Time resolved examination of the conformational changes of macromolecules in living cells has so far been largely restricted to ion-channel proteins whose gating is voltage-dependent 7,8. We have now directly measured electrical currents arising from the molecular rearrangements of the sarcolemmal Na-Ca exchanger. Changes in the conformation of the exchanger protein were activated by a rapid increase in the intracellular calcium concentration produced by flash photolysis of caged calcium 9 in voltage-clamped heart cells. Two components of membrane current were produced, reflecting a calcium-dependent conformational change of the transporter proteins and net transport of ions by the exchanger. The properties of these components provide evidence that the Na-Ca exchanger protein undergoes two consecutive membrane-crossing molecular transitions that each move charge, and that there are at least 250 exchangers per mu-m2 turning over up to 2,500 times per second.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; MED BIOTECHNOL CTR,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Niggli, Ernst/C-4884-2015; Lederer, William/B-1285-2010; Niggli, Ernst/AAL-4351-2020	Niggli, Ernst/0000-0003-4670-4903; Niggli, Ernst/0000-0003-4670-4903				ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CALLEWAERT G, 1986, PFLUG ARCH EUR J PHY, V406, P424, DOI 10.1007/BF00590947; CHEON J, 1988, J BIOL CHEM, V263, P2309; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; EHARA T, 1989, J PHYSIOL-LONDON, V410, P227, DOI 10.1113/jphysiol.1989.sp017530; EHARA T, 1988, J PHYSIOL-LONDON, V403, P117, DOI 10.1113/jphysiol.1988.sp017242; EISNER DA, 1985, AM J PHYSIOL, V248, pC189, DOI 10.1152/ajpcell.1985.248.3.C189; HILGEMANN DW, 1988, PROG BIOPHYS MOL BIO, V51, P1, DOI 10.1016/0079-6107(88)90009-0; HODGKIN AL, 1987, J PHYSIOL-LONDON, V391, P371, DOI 10.1113/jphysiol.1987.sp016743; HOROWICZ P, 1981, J PHYSIOL-LONDON, V314, P595, DOI 10.1113/jphysiol.1981.sp013726; KAPLAN JH, 1990, REV PHYSL, V52, P897; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; LAUGER P, 1984, BIOCHIM BIOPHYS ACTA, V779, P307, DOI 10.1016/0304-4157(84)90015-7; LAUGER P, 1987, J MEMBRANE BIOL, V99, P1, DOI 10.1007/BF01870617; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LIPP P, 1988, J PHYSIOL-LONDON, V403, P355, DOI 10.1113/jphysiol.1988.sp017253; MULLINS LJ, 1977, J GEN PHYSIOL, V70, P681, DOI 10.1085/jgp.70.6.681; REUTER H, 1968, J PHYSL, V218, P908; SLAUGHTER RS, 1988, BIOCHEMISTRY-US, V27, P2403, DOI 10.1021/bi00407a023	27	130	132	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					621	624		10.1038/349621a0	http://dx.doi.org/10.1038/349621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000135				2022-12-28	WOS:A1991EX57000063
J	EELES, RA; TAN, S; WILTSHAW, E; FRYATT, I; AHERN, RP; SHEPHERD, JH; HARMER, CL; BLAKE, PR; CHILVERS, CED				EELES, RA; TAN, S; WILTSHAW, E; FRYATT, I; AHERN, RP; SHEPHERD, JH; HARMER, CL; BLAKE, PR; CHILVERS, CED			HORMONE REPLACEMENT THERAPY AND SURVIVAL AFTER SURGERY FOR OVARIAN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT; POSTMENOPAUSAL WOMEN; MENOPAUSE; EPIDEMIOLOGY; CARCINOMA; RISK	Objective - To evaluate whether hormone replacement therapy affects survival in women who have undergone bilateral salpingo-oophorectomy because of epithelial ovarian cancer. Design - Retrospective analysis by review of patients' notes and questionnaires completed by general practitioners to compare the overall survival and disease free survival in patients with ovarian cancer who did or did not receive hormone replacement therapy after diagnosis. Data were analysed by Cox regression, with hormone replacement therapy as a time dependent covariate because patients who received hormone replacement did so at different times after diagnosis. Setting - Gynaecological oncology unit of Royal Marsden Hospital. Patients - 373 patients aged 50 years or younger who attended the hospital from 1972 to 1988. All of the women had undergone bilateral salpingo-oophorectomy for epithelial ovarian cancer. In all, 78 had received hormone replacement therapy, starting at a median of four months after diagnosis. Intervention - A questionnaire was sent to the general practitioners of all patients who were not recorded as having received hormone replacement therapy. Main outcome measures - Overall survival and disease free survival. Results - There was no significant difference in survival between women receiving hormone replacement therapy and those not receiving it after accounting for the effects of other known prognostic factors (stage of cancer, differentiation of tumour, histological results, and time to relapse). The relative risk of dying in those who received hormone replacement therapy was 0.73 (95% confidence interval 0.44 to 1.20). In addition, there was no significant difference in disease free survival (relative risk in those receiving hormone replacement therapy was 0.90; 95% confidence interval 0.52 to 1.54). Conclusions - This study shows that hormone replacement therapy is unlikely to have a detrimental effect on the prognosis of patients with ovarian cancer, but this would be shown conclusively only by a randomised controlled trial.	ROYAL MARSDEN HOSP,DEPT MED,GYNAECOL ONCOL UNIT,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,DEPT COMP,LONDON SW3 6JJ,ENGLAND; UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2RD,ENGLAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Nottingham				Eeles, Rosalind/0000-0002-3698-6241; A'Hern, Roger/0000-0003-0593-8391				ANDERSON JR, 1985, CANCER TREAT REP, V69, P1139; BARRETTCONNOR E, 1989, NEW ENGL J MED, V321, P319, DOI 10.1056/NEJM198908033210510; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; HORSMAN A, 1977, BRIT MED J, V2, P789, DOI 10.1136/bmj.2.6090.789; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KUHNEL R, 1987, INT J GYNECOL PATHOL, V6, P248; LAVECCHIA C, 1982, J NATL CANCER I, V69, P1207; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; TOBIAS JS, 1976, NEW ENGL J MED, V294, P818, DOI 10.1056/NEJM197604082941506; TZONOU A, 1984, EUR J CANCER CLIN ON, V20, P1045, DOI 10.1016/0277-5379(84)90107-X; WEISS NS, 1982, J NATL CANCER I, V68, P95; WHITEHEAD M, 1988, LANCET, V2, P1243	20	105	124	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					259	262		10.1136/bmj.302.6771.259	http://dx.doi.org/10.1136/bmj.302.6771.259			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998789	Green Published, Bronze			2022-12-28	WOS:A1991EX91900017
J	LYNCH, TH; WAYMONT, B; BEACOCK, CJM; DUNN, JA; HUGHES, MA; WALLACE, DMA				LYNCH, TH; WAYMONT, B; BEACOCK, CJM; DUNN, JA; HUGHES, MA; WALLACE, DMA			FOLLOW-UP AFTER TRANSURETHRAL RESECTION OF PROSTATE - WHO NEEDS IT	BRITISH MEDICAL JOURNAL			English	Article											LYNCH, TH (corresponding author), QUEEN ELIZABETH MED CTR,DEPT UROL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.			Dunn, Janet/0000-0001-7313-4446				DORFLINGER T, 1988, J UROLOGY, V140, P1487, DOI 10.1016/S0022-5347(17)42081-7; Singh M, 1973, Br J Urol, V45, P93, DOI 10.1111/j.1464-410X.1973.tb00050.x; 1985, SERIES MB4 27; 1988, BMDP STATISTICAL SOF, V2; 1988, BMDP STATISTICAL SOF, V1	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					27	27		10.1136/bmj.302.6767.27	http://dx.doi.org/10.1136/bmj.302.6767.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991183	Bronze, Green Published			2022-12-28	WOS:A1991ER37200021
J	HAYWARD, RSA; STEINBERG, EP; FORD, DE; ROIZEN, MF; ROACH, KW				HAYWARD, RSA; STEINBERG, EP; FORD, DE; ROIZEN, MF; ROACH, KW			PREVENTIVE CARE GUIDELINES - 1991	ANNALS OF INTERNAL MEDICINE			English	Review							PERIODIC HEALTH EXAMINATION; ASYMPTOMATIC ADULTS; BREAST-CANCER; RISK-FACTORS; MAINTENANCE; RECOMMENDATIONS; DISEASES; SERVICES	Clinicians increasingly are urged to integrate preventive services into their clinical practices. To facilitate this process, several groups have developed practice guidelines for preventing disease in asymptomatic patients. In this paper, we compare and contrast preventive guidelines from the American College of Physicians (ACP), the Canadian Task Force on the Periodic Health Examination (CTF), the United States Preventive Services Task Force (USPSTF), and other well-known authorities. We chose these groups because they based their recommendations on explicit methods that include critical appraisal of the pertinent literature. Recommendations from these authorities usually are consistent with each other. Moreover, the ACP, CTF, and USPSTF all favor a shift away from the relatively simple classification of patients by age and sex for general preventive interventions to the more complex stratification of patients by additional risk factors and the formulation of a selective prevention strategy that is specific to each risk profile. Some guidelines, particularly the criteria used to define patients who are at increased risk for preventable disease and who should have more intensive surveillance, are difficult to interpret. Further research is needed to address some areas of disagreement and ambiguity. In addition, new tools must be developed to help physicians apply preventive guidelines, particularly those that require noting many patient-specific characteristics.	UNIV CHICAGO, CHICAGO, IL 60637 USA	University of Chicago	HAYWARD, RSA (corresponding author), JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA.							ALMY TP, 1988, ANN INTERN MED, V109, P70, DOI 10.7326/0003-4819-109-1-70; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1981, Ann Intern Med, V95, P729; [Anonymous], MMWR MORB MORTAL WKL; [Anonymous], COMMON SCREENING TES; [Anonymous], 1989, GUIDE CLIN PREVENTIV; [Anonymous], MMWR MORB MORTAL WKL; BECKER MH, 1990, ANN INTERN MED, V113, P419, DOI 10.7326/0003-4819-113-6-419; BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V258, P3411; BRESLOW L, 1977, NEW ENGL J MED, V296, P601, DOI 10.1056/NEJM197703172961104; DAVIDSON RA, 1984, ARCH INTERN MED, V144, P2167, DOI 10.1001/archinte.144.11.2167; Eddy D., 1980, CA-CANCER J CLIN, V30, P194; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P389, DOI 10.1001/jama.264.3.389; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; FEUSSNER JR, 1988, ANN INTERN MED, V109, P835; Field MJ, 1990, CLIN PRACTICE GUIDEL; FIELDING JE, 1990, PREVENTING DISEASE R; FINK DJ, 1988, CA-CANCER J CLIN, V38, P127, DOI 10.3322/canjclin.38.2.127; Fleming D M, 1981, J R Coll Gen Pract, V31, P615; Frame P S, 1975, J Fam Pract, V2, P189; Frame P S, 1975, J Fam Pract, V2, P283; Frame P S, 1975, J Fam Pract, V2, P123; Frame P S, 1975, J Fam Pract, V2, P29; FRAME P S, 1990, Journal of General Internal Medicine, V5, pS112, DOI 10.1007/BF02600855; FRAME PS, 1986, J FAM PRACTICE, V22, P341; FRAME PS, 1986, J FAM PRACTICE, V22, P511; FRAME PS, 1986, J FAM PRACTICE, V22, P417; FRAME PS, 1986, J FAM PRACTICE, V23, P29; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GEMSON DH, 1986, AM J PREV MED, V2, P226; GOLDBLOOM R, 1986, CAN MED ASSOC J, V134, P721; GOLDBLOOM R, 1991, CAN MED ASSOC J, V144, P425; GOLDBLOOM R, 1989, CAN MED ASSOC J, V141, P209; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P618; GOLDBLOOM RB, 1990, CAN MED ASSOC J, V143, P259; GOLDBLOOM RB, 1990, PREVENTING DISEASE R, P407; GORDILLO C, 1989, JAMA-J AM MED ASSOC, V262, P1155, DOI 10.1001/jama.262.9.1155; GREENE JC, 1990, JAMA-J AM MED ASSOC, V263, P421, DOI 10.1001/jama.263.3.421; GREENE JC, 1989, JAMA-J AM MED ASSOC, V262, P3459, DOI 10.1001/jama.262.24.3459; GROSS G, 1990, PREVENTING DISEASE R; GRUNDY SM, 1987, CIRCULATION, V75, pA1339; HARRIS RP, 1990, AM J PREV MED, V6, P145, DOI 10.1016/S0749-3797(18)31019-5; HARRIS SS, 1989, JAMA-J AM MED ASSOC, V261, P3588, DOI 10.1001/jama.261.24.3588; HART G, 1990, COMMON DIAGNOSTIC TE, P302; HAYNES MA, 1990, PREVENTING DISEASE T; HAYNES RB, 1987, ARCH INTERN MED, V147, P1297, DOI 10.1001/archinte.147.7.1297; HELFAND M, 1990, ANN INTERN MED, V112, P840, DOI 10.7326/0003-4819-112-11-840; HORSBURGH CR, 1987, JAMA-J AM MED ASSOC, V258, P815; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; KOMAROFF AL, 1990, COMMON DIAGNOSTIC TE, P286; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; LAFORCE FM, 1987, JAMA-J AM MED ASSOC, V257, P2464, DOI 10.1001/jama.257.18.2464; LAWRENCE RS, 1987, JAMA-J AM MED ASSOC, V257, P2205, DOI 10.1001/jama.257.16.2205; LEDERLE FA, 1990, J CLIN EPIDEMIOL, V43, P101, DOI 10.1016/0895-4356(90)90062-T; LEWIS CE, 1988, AM J PREV MED S, V4, pS9; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MANN K, 1990, PREVENTING DISEASE R; MCGINNIS J M, 1990, Journal of General Internal Medicine, V5, pS11, DOI 10.1007/BF02600832; MCPHEE S J, 1990, Journal of General Internal Medicine, V5, pS116, DOI 10.1007/BF02600856; MEDALIE JH, 1990, PREVENTING DISEASE R; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; OBOLER SK, 1989, ANN INTERN MED, V110, P214, DOI 10.7326/0003-4819-110-3-214; OMALLEY MS, 1987, JAMA-J AM MED ASSOC, V257, P2197; PELS RJ, 1990, PREVENTING DISEASE R; POLEN MR, 1988, JAMA-J AM MED ASSOC, V259, P76, DOI 10.1001/jama.259.1.76; ROMM FJ, 1981, SOUTHERN MED J, V74, P265, DOI 10.1097/00007611-198103000-00004; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SCHLANT RC, 1986, J AM COLL CARDIOL, V8, P725; SCHOENBAUM S C, 1990, Journal of General Internal Medicine, V5, pS123, DOI 10.1007/BF02600857; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; SHAPIRO MF, 1990, COMMON DIAGNOSTIC TE, P183; SINGER DE, 1988, ANN INTERN MED, V109, P639, DOI 10.7326/0003-4819-109-8-639; SINGER DE, 1990, PREVENTING DISEASE R; SKINNER HA, 1985, BRIT MED J, V290, P212, DOI 10.1136/bmj.290.6463.212; SOX HC, 1989, ANN INTERN MED, V110, P456, DOI 10.7326/0003-4819-110-6-456; SOX HC, 1989, ANN INTERN MED, V111, P489, DOI 10.7326/0003-4819-111-6-489; STEINBERG EP, 1988, QUALITY CARE TECHNOL, P79; WHITE LJ, 1986, ANN INTERN MED, V105, P281, DOI 10.7326/0003-4819-105-2-295; WHITE LJ, 1988, ANN INTERN MED, V108, P460, DOI 10.7326/0003-4819-108-3-460; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; WOOLHANDLER S, 1990, PREVENTING DISEASE R; 1990, CAN MED ASSOC J, V143, P269; 1984, CHEM DEPENDENCE; 1990, CAN MED ASSOC J, V142, P955; 1984, B WORLD HEALTH ORGAN, V62, P861; 1984, MEN ONLY TESTICULAR; 1989, CA, V39, P317; 1989, PREFERRED PRACTICE P; 1990, GUIDE ADULT IMMUNIZA; 1988, SUMMARY CURRENT GUID; 1989, MMWR S9, V38, P1; 1985, NUTRITION; 1991, CAN MED ASSOC J, V144, P665; 1991, IN PRESS CAN MED ASS; 1979, CAN MED ASS J, V121, P1193; 1989, J AM GERIATR SOC, V37, P883; 1984, HLTH PROMOTION DISEA; [No title captured]; 1991, COMMON SCREENING TES; 1987, CLIN EFFICACY REPORT; 1957, CHRONIC ILLNESS US; 1986, TESTICULAR SELF EXAM; 1991, POSITIONS CLIN ASPEC; 1989, CAN MED ASSOC J, V141, P1136; 1990, CAN MED ASSOC J, V142, P1233; 1989, J AM GERIATR SOC, V37, P885; 1984, CAN MED ASSOC J, V130, P1278; 1986, GUIDELINES EXERCISE; 1989, STANDARDS OBSTETRIC, P97; 1987, WORKING GUIDELINES E; 1989, DIABETES CARE, V12, P588; 1990, AM CANCER SOC GUIDEL; 1986, CAN MED ASSOC J, V134, P724; 1986, CLIN EFFICACY ASSESS; 1988, FA88 AM MED ASS COUN; 1985, MMWR S, V34, pS53; 1989, CAN MED ASSOC J, V141, P1233; 1988, REPORT EXPERT PANEL; 1990, MMWR, V39, P1; 1989, NUTR REV, V47, P142; 1989, JAMA-J AM MED ASSOC, V261, P2535; 1987, MMWR, V36, P509	129	196	197	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					758	+		10.7326/0003-4819-114-9-758	http://dx.doi.org/10.7326/0003-4819-114-9-758			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012359				2022-12-28	WOS:A1991FJ11700010
J	YOUNG, S; LESOUEF, PN; GEELHOED, GC; STICK, SM; CHIR, B; TURNER, KJ; LANDAU, LI				YOUNG, S; LESOUEF, PN; GEELHOED, GC; STICK, SM; CHIR, B; TURNER, KJ; LANDAU, LI			THE INFLUENCE OF A FAMILY HISTORY OF ASTHMA AND PARENTAL SMOKING ON AIRWAY RESPONSIVENESS IN EARLY INFANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHIAL RESPONSIVENESS; INHALED HISTAMINE; CHILDHOOD ASTHMA; NEWBORN-INFANTS; ATOPIC DISEASE; REACTIVITY; IGE; CHILDREN; ALLERGY	Background. Airway responsiveness to inhaled nonspecific bronchoconstrictive agents has been demonstrated in normal, healthy infants. However, it is unknown whether airway responsiveness is present from birth or if it develops as a result of subsequent insults to the respiratory tract. To investigate this question, we assessed airway responsiveness in 63 normal infants at a mean age of 4 1/2 weeks. Methods. Respiratory function was measured with use of the partial forced expiratory flow-volume technique to determine the maximal flow at functional residual capacity (V(maxFRC)). The infants inhaled nebulized histamine at sequentially doubled concentrations (0.125 to 8.0 g per liter), until a concentration was reached at which the V(maxFRC) fell by 40 percent from the base-line value (PC40) or until a concentration of 8.0 g per liter was reached. We also assessed maternal serum levels of IgE, cord-serum levels of IgE, the infants' skin reactivity to several allergens, and the parents' responsiveness to histamine and obtained family histories of asthma and smoking. Results. Airway responsiveness was increased in infants with a family history of asthma (n = 19; median PC40, 0.78 g per liter; 95 percent confidence interval, 0.44 to 1.15; P < 0.01), parental smoking (n = 13; median PC40, 0.52 g per liter; 95 percent confidence interval, 0.43 to 5.40; P < 0.05), or both (n = 20; median PC40, 0.69 g per liter; 95 percent confidence interval, 0.37 to 2.10; P < 0.05), as compared with the infants with no family history of asthma or smoking. The infants with no family history of asthma or smoking had a median PC40 of 2.75 g per liter (95 percent confidence interval, 1.48 to 4.00). No significant relations were detected between the immunologic variables and the PC40 in the infants. Conclusions. This study indicates that airway responsiveness can be present early in life and suggests that a family history of asthma or parental smoking contributes to elevated levels of airway responsiveness at an early age.	PRINCESS MARGARET HOSP,CLIN IMMUNOL RES UNIT,PERTH,WA 6001,AUSTRALIA		YOUNG, S (corresponding author), PRINCESS MARGARET HOSP,DEPT RESP MED,POB D184,PERTH,WA 6001,AUSTRALIA.		Le Souef, Peter N/H-5256-2014; Stick, Stephen/AAA-5945-2021; Stick, Stephen/O-5683-2014; Stick, Stephen/GZG-7584-2022	Stick, Stephen/0000-0002-5386-8482; Le Souef, Peter/0000-0003-0930-1654				BENSON MK, 1977, J APPL PHYSIOL, V43, P643, DOI 10.1152/jappl.1977.43.4.643; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; CADE JF, 1971, LANCET, V2, P186; CAMPBELL MJ, 1989, STATISTICS CONFIDENC, P71; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; GARDNER MJ, 1989, CONFIDENCE INTERVAL; GELLER DE, 1988, PEDIATR PULM, V4, P90, DOI 10.1002/ppul.1950040206; GELLERBERNSTEIN G, 1987, ALLERGY, V42, P85, DOI 10.1111/j.1398-9995.1987.tb02364.x; GERRARD JW, 1974, J PEDIATR, V5, P660; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P601, DOI 10.1111/j.1651-2227.1976.tb04939.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; ORGEL HA, 1977, ANN ALLERGY, V39, P161; PRENDIVILLE A, 1987, THORAX, V42, P92, DOI 10.1136/thx.42.2.92; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P489, DOI 10.1111/j.1651-2227.1982.tb09457.x; Schwartz M, 1952, ACTA ALLERGOL S2, V5, P1; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SILVERMAN M, 1985, NEONATAL PEDIATRIC R, P161; STICK S M, 1990, American Review of Respiratory Disease, V141, pA283; TAUSSIG LM, 1982, J APPL PHYSIOL, V53, P1220, DOI 10.1152/jappl.1982.53.5.1220; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; TEPPER RS, 1987, J APPL PHYSIOL, V62, P1155, DOI 10.1152/jappl.1987.62.3.1155; TEPPER RS, 1987, AM REV RESPIR DIS, V136, P800; TURNER KJ, 1981, CLIN EXP IMMUNOL, V43, P458; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZAR JH, 1974, BIOSTAT ANAL, P109; [No title captured]	34	349	354	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1168	1173		10.1056/NEJM199104253241704	http://dx.doi.org/10.1056/NEJM199104253241704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011160				2022-12-28	WOS:A1991FH57200004
J	KLEINMAN, LC				KLEINMAN, LC			HEALTH-CARE IN CRISIS - A PROPOSED ROLE FOR THE INDIVIDUAL PHYSICIAN AS ADVOCATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; INSURANCE; ACCESS				KLEINMAN, LC (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,DIV GEN INTERNAL MED,B-973 LOUIS FACTOR BLDG,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.		Kleinman, Lawrence/AAS-6934-2021					BRAVEMAN P, 1988, WESTERN J MED, V149, P708; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; GINZBERG E, 1988, JAMA-J AM MED ASSOC, V259, P3309; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; HOGUE CJR, 1989, JAMA-J AM MED ASSOC, V262, P548, DOI 10.1001/jama.262.4.548; Kleinman L C, 1989, Conn Med, V53, P305; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; 1990, JAMA-J AM MED ASSOC, V263, P2344	9	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1991	1992						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008029				2022-12-28	WOS:A1991FF76800027
J	MATON, PN				MATON, PN			DRUG-THERAPY - OMEPRAZOLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ZOLLINGER-ELLISON SYNDROME; GASTRIC-ACID SECRETION; DUODENAL-ULCER PATIENTS; BLIND COMPARATIVE TRIAL; SHORT-TERM TREATMENT; PERNICIOUS-ANEMIA; CARCINOID-TUMORS; REFLUX ESOPHAGITIS; 20 MG; PLASMA GASTRIN				MATON, PN (corresponding author), OKLAHOMA FDN DIGEST RES, 711 STANTON L YOUNG BLVD, SUITE 501, OKLAHOMA CITY, OK 73104 USA.							ALLEN JM, 1984, HEPATO-GASTROENTEROL, V31, P44; ANDERSSON T, 1990, CLIN PHARMACOL THER, V47, P79, DOI 10.1038/clpt.1990.12; ARCHAMBAULT AP, 1988, GASTROENTEROLOGY, V94, P1130, DOI 10.1016/0016-5085(88)90003-0; ARNOLD R, 1989, DIGESTION, V44, P77, DOI 10.1159/000200107; BADER JP, 1986, SCAND J GASTROENTERO, V21, P177, DOI 10.3109/00365528609090936; BARBARA L, 1987, GUT, V28, pA1341; BARBARA L, 1987, HEPATO-GASTROENTEROL, V34, P229; BARDHAN KD, 1987, GUT, V28, pA1375; BARDHAN KD, 1986, J CLIN GASTROENTEROL, V8, P408, DOI 10.1097/00004836-198608000-00005; BARDHAN KD, 1988, GASTROENTEROLOGY, V94, pA22; BARDRAM L, 1986, DIGESTION, V35, P116, DOI 10.1159/000199387; BARDRAM L, 1986, SCAND J GASTROENTERO, V21, P374, DOI 10.3109/00365528609003090; BARDRAM L, 1989, SCAND J GASTROENTERO, V24, P95, DOI 10.3109/00365528909091253; BATE CM, 1989, GUT, V30, P1323, DOI 10.1136/gut.30.10.1323; BENFIELD P, 1986, DRUGS, V31, P376, DOI 10.2165/00003495-198631050-00002; BIANCHI A, 1982, LANCET, V2, P1223; BIGARD MA, 1987, GASTROEN CLIN BIOL, V11, P753; BORCH K, 1985, GASTROENTEROLOGY, V88, P638, DOI 10.1016/0016-5085(85)90131-3; BRINTON LA, 1989, BRIT J CANCER, V59, P810, DOI 10.1038/bjc.1989.169; BROOK CW, 1987, MED J AUSTRALIA, V147, P595, DOI 10.5694/j.1326-5377.1987.tb133696.x; BRUNNER G, 1988, DIGESTION, V39, P80, DOI 10.1159/000199610; BRUNNER G, 1990, DIGESTION, V45, P217, DOI 10.1159/000200249; BRUNNER G, 1989, SCAND J GASTROENTERO, V24, P101, DOI 10.3109/00365528909091254; BURGET DW, 1990, GASTROENTEROLOGY, V99, P345, DOI 10.1016/0016-5085(90)91015-X; CADRANEL JF, 1989, GASTROEN CLIN BIOL, V13, P654; CARLSSON E, 1986, SCAND J GASTROENTERO, V21, P31, DOI 10.3109/00365528609090884; CARNEY JA, 1983, ANN INTERN MED, V99, P761, DOI 10.7326/0003-4819-99-6-761; CEDERBERG C, 1989, SCAND J GASTROENTERO, V24, P33, DOI 10.3109/00365528909091241; CHALMERS TC, 1988, DATA ANAL CLIN MED Q, P75; CLASSEN M, 1985, DEUT MED WOCHENSCHR, V110, P210, DOI 10.1055/s-2008-1068800; CLASSEN M, 1985, DEUT MED WOCHENSCHR, V110, P628, DOI 10.1055/s-2008-1068876; CLISSOLD SP, 1986, DRUGS, V32, P15, DOI 10.2165/00003495-198632010-00002; CORLETO V, 1988, GASTROENTEROLOGY, V94, pA79; CREUTZFELDT W, 1986, DIGESTION, V35, P84, DOI 10.1159/000199384; CREUTZFELDT W, 1988, DIGESTION, V39, P61, DOI 10.1159/000199609; CROBACH LFSJ, 1988, SCAND J GASTROENTERO, V23, P407, DOI 10.3109/00365528809093887; CROWE JP, 1989, ALIMENT PHARM THERAP, V3, P83; DAHLGREN S, 1988, Alimentary Pharmacology and Therapeutics, V2, P483; DAMMANN HG, 1986, DEUT MED WOCHENSCHR, V111, P123, DOI 10.1055/s-2008-1068412; DAYAL Y, 1989, Gastroenterology, V96, pA113; DEHN TCB, 1990, GUT, V31, P509, DOI 10.1136/gut.31.5.509; DELCHIER JC, 1989, GUT, V30, P1173, DOI 10.1136/gut.30.9.1173; DELCHIER JC, 1986, DIGEST DIS SCI, V31, P693, DOI 10.1007/BF01296445; DENT J, 1986, SCAND J GASTROENTERO, V21, P181, DOI 10.3109/00365528609090939; DIAZ D, 1990, GASTROENTEROLOGY, V99, P737, DOI 10.1016/0016-5085(90)90963-2; DOCKRAY GJ, 1989, HDB PHYSL 6, V2, P311; DOWIE LJ, 1988, EUR J CLIN PHARMACOL, V35, P625, DOI 10.1007/BF00637598; EKMAN L, 1985, SCAND J GASTROENTERO, V20, P53, DOI 10.3109/00365528509095819; FARUP PG, 1989, SCAND J GASTROENTERO, V24, P1107, DOI 10.3109/00365528909089263; FARUP PG, 1988, CURR THER RES CLIN E, V43, P872; FAUSA O, 1987, SCAND J GASTROENTERO, V22, P38; FELLENIUS E, 1981, NATURE, V290, P159, DOI 10.1038/290159a0; FESTEN HPM, 1986, DIGEST DIS SCI, V31, P561, DOI 10.1007/BF01318685; FESTEN HPM, 1989, SCAND J GASTROENTE S, V166, P156; FRANCAVILLA A, 1986, DIGEST DIS SCI, V31, pS335; FRYKLUND J, 1988, AM J PHYSIOL, V254, pG399, DOI 10.1152/ajpgi.1988.254.3.G399; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; GRAHAM DY, 1990, DIGEST DIS SCI, V35, P66, DOI 10.1007/BF01537225; GRANT SM, 1989, DRUGS, V37, P801, DOI 10.2165/00003495-198937060-00003; GUERREIRO AS, 1990, ALIMENT PHARM THERAP, V4, P309; GUGLER R, 1987, PHARMACOL THERAPEUT, V33, P133, DOI 10.1016/0163-7258(87)90041-6; GUGLER R, 1985, GASTROENTEROLOGY, V89, P1235, DOI 10.1016/0016-5085(85)90638-9; GUSTAVSSON S, 1987, GASTROENTEROLOGY, V92, P1420; GUSTAVSSON S, 1983, LANCET, V2, P124, DOI 10.1016/S0140-6736(83)90114-9; HALLBERG D, 1986, DIGEST DIS SCI, V31, pS280; HAMEETEMAN W, 1986, AM J GASTROENTEROL, V81, P764; HARVEY RF, 1985, LANCET, V1, P951; HAVELUND T, 1988, BRIT MED J, V296, P89, DOI 10.1136/bmj.296.6615.89; HAVU N, 1986, DIGESTION, V35, P42, DOI 10.1159/000199381; HAVU N, 1990, DIGESTION, V45, P189, DOI 10.1159/000200245; HELANDER HF, 1986, DIGESTION, V35, P123, DOI 10.1159/000199388; HELANDER HF, 1974, GASTROENTEROLOGY, V67, P447; HENRY D, 1987, EUR J CLIN PHARMACOL, V33, P369, DOI 10.1007/BF00637632; HENRY DA, 1984, BRIT J CLIN PHARMACO, V18, P195, DOI 10.1111/j.1365-2125.1984.tb02452.x; HETZEL DJ, 1986, AUST NZ J MED, V16, P595; HETZEL DJ, 1986, AUST NZ J MED, V16, P226, DOI 10.1111/j.1445-5994.1986.tb01156.x; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; HEWSON EG, 1988, GUT, V29, P1715, DOI 10.1136/gut.29.12.1715; HIRSCHOWITZ B I, 1990, Gastroenterology, V98, pA286; HIRSCHOWITZ BI, 1988, GASTROENTEROLOGY, V94, pA188; HODGES JR, 1981, GUT, V22, P237, DOI 10.1136/gut.22.3.237; HOROWITZ M, 1984, BRIT J CLIN PHARMACO, V18, P791, DOI 10.1111/j.1365-2125.1984.tb02544.x; HOWDEN CW, 1985, EUR J CLIN PHARMACOL, V28, P637, DOI 10.1007/BF00607907; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; HUI WM, 1987, GASTROENTEROLOGY, V92, P1443; HUTTEMANN W, 1986, DIGESTION, V33, P117, DOI 10.1159/000199283; HUTTEMANN W, 1986, SCAND J GASTROENTERO, V21, P179; IM WB, 1985, BIOCHEM BIOPH RES CO, V126, P78, DOI 10.1016/0006-291X(85)90573-X; ISAL J P, 1990, Gastroenterology, V98, pA63; JANSEN JBMJ, 1990, GASTROENTEROLOGY, V99, P621, DOI 10.1016/0016-5085(90)90946-X; JANSEN JBMJ, 1988, GUT, V29, P75, DOI 10.1136/gut.29.1.75; JENSEN JC, 1986, BRIT J CLIN PHARMACO, V21, P328, DOI 10.1111/j.1365-2125.1986.tb05199.x; KARVONEN AL, 1986, SCAND J GASTROENTERO, V21, P449, DOI 10.3109/00365528609015161; KAUNITZ JD, 1986, J BIOL CHEM, V261, P14005; KITTANG E, 1987, SCAND J GASTROENTERO, V22, P156, DOI 10.3109/00365528708991873; KITTANG E, 1985, GUT, V26, P594, DOI 10.1136/gut.26.6.594; KLINKENBERGKNOL EC, 1988, GASTROENTEROLOGY, V94, pA230; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; LAMBERTS R, 1988, DIGESTION, V39, P126, DOI 10.1159/000199615; LAMERS CBHW, 1984, NEW ENGL J MED, V310, P758, DOI 10.1056/NEJM198403223101205; LANZON-MILLER S, 1987, Alimentary Pharmacology and Therapeutics, V1, P239; LANZON-MILLER S, 1987, Alimentary Pharmacology and Therapeutics, V1, P225; LARSSON H, 1988, GASTROENTEROLOGY, V95, P1477, DOI 10.1016/S0016-5085(88)80066-0; LARSSON H, 1988, TOXICOL PATHOL, V16, P267, DOI 10.1177/019262338801600220; LAURITSEN K, 1989, Gastroenterology, V96, pA289; LAURITSEN K, 1988, GUT, V29, P249, DOI 10.1136/gut.29.2.249; LAURITSEN K, 1985, NEW ENGL J MED, V312, P958, DOI 10.1056/NEJM198504113121505; LAURITSEN K, 1989, ALIMENT PHARM THERAP, V3, P59; LEHTOLA J, 1985, HEPATO-GASTROENTEROL, V32, P72; LEHY T, 1989, GASTROENTEROLOGY, V96, P1029, DOI 10.1016/0016-5085(89)91620-X; LIND T, 1988, SCAND J GASTROENTERO, V23, P1259, DOI 10.3109/00365528809090202; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; LINDBERG P, 1986, J MED CHEM, V29, P1327, DOI 10.1021/jm00158a001; LLOYD-DAVIES K A, 1988, Alimentary Pharmacology and Therapeutics, V2, P13; LORENTZON P, 1987, BIOCHIM BIOPHYS ACTA, V897, P41, DOI 10.1016/0005-2736(87)90313-0; LOSEC, 1989, 1989 P GASTR DRUGS A, V1, P151; LUNDELL L, 1990, ALIMENT PHARM THERAP, V4, P145; MACDONALD RA, 1956, AM J MED, V21, P867, DOI 10.1016/0002-9343(56)90101-2; Marks I N, 1988, S Afr Med J, V74 Suppl, P54; MATON PN, 1989, ENDOCRIN METAB CLIN, V18, P519, DOI 10.1016/S0889-8529(18)30380-3; MATON PN, 1990, GASTROENTEROLOGY, V99, P943, DOI 10.1016/0016-5085(90)90611-4; MATON PN, 1989, GASTROENTEROLOGY, V97, P827, DOI 10.1016/0016-5085(89)91485-6; MATON PN, 1988, GASTROENTEROLOGY, V94, P294, DOI 10.1016/0016-5085(88)90415-5; MATTSSON H, 1991, GASTROENTEROLOGY, V100, P311, DOI 10.1016/0016-5085(91)90197-S; MCARTHUR KE, 1985, GASTROENTEROLOGY, V88, P939, DOI 10.1016/S0016-5085(85)80011-1; MCFARLAND RJ, 1990, GASTROENTEROLOGY, V98, P278, DOI 10.1016/0016-5085(90)90815-I; MCKEE RF, 1988, ALIMENT PHARM THERAP, V2, P429; MCLEAN AJ, 1988, DRUGS, V35, P329, DOI 10.2165/00003495-198835040-00001; MEIJER JL, 1989, DIGESTION, V44, P31, DOI 10.1159/000200102; MILLER LS, 1990, GASTROENTEROLOGY, V98, P341, DOI 10.1016/0016-5085(90)90823-J; MULDER CJJ, 1989, ALIMENT PHARM THERAP, V3, P445; NAESDAL J, 1985, SCAND J GASTROENTERO, V20, P691, DOI 10.3109/00365528509089196; NAESDAL J, 1986, CLIN PHARMACOL THER, V40, P344, DOI 10.1038/clpt.1986.186; NAESDAL J, 1987, SCAND J GASTROENTERO, V22, P5, DOI 10.3109/00365528708991848; OBERG K, 1983, LANCET, V1, P66; OLBE L, 1988, GASTROENTEROL INT S1, V1, P340; PEDERSEN SA, 1987, SCAND J GASTROENTERO, V22, P725, DOI 10.3109/00365528709011150; PEN JH, 1988, GASTROENTEROLOGY, V94, pA348; PENSTON J, 1987, GUT, V28, P488, DOI 10.1136/gut.28.4.488; POYNTER D, 1985, GUT, V26, P1284, DOI 10.1136/gut.26.12.1284; PRICHARD PJ, 1987, BRIT J CLIN PHARMACO, V24, P543, DOI 10.1111/j.1365-2125.1987.tb03209.x; PRICHARD PJ, 1985, BRIT MED J, V290, P601, DOI 10.1136/bmj.290.6468.601; PRICHARD PJ, 1985, GASTROENTEROLOGY, V88, P64, DOI 10.1016/S0016-5085(85)80133-5; REGARDH CG, 1986, SCAND J GASTROENTERO, V21, P99, DOI 10.3109/00365528609090907; RICHARDS AT, 1987, S AFR MED J, V72, P51; RICHTER JE, 1986, J CLIN GASTROENTEROL, V8, P72, DOI 10.1097/00004836-198606001-00011; RINETTI M, 1986, DRUG EXP CLIN RES, V12, P701; RYBERG B, 1990, GASTROENTEROLOGY, V98, P33, DOI 10.1016/0016-5085(90)91287-G; SACHS G, 1976, J BIOL CHEM, V251, P7690; SACHS G, 1988, ANNU REV PHARMACOL, V28, P269; SACHS G, 1986, SCAND J GASTROENTERO, V21, P1, DOI 10.3109/00365528609090880; SANDMARK S, 1988, SCAND J GASTROENTERO, V23, P625, DOI 10.3109/00365528809093923; SHARMA BK, 1984, BRIT MED J, V289, P717, DOI 10.1136/bmj.289.6447.717; SHARMA BK, 1984, GUT, V25, P957, DOI 10.1136/gut.25.9.957; SMOLKA A, 1983, AM J PHYSIOL, V245, pG589, DOI 10.1152/ajpgi.1983.245.4.G589; SOLCIA E, 1989, SCAND J GASTROENTERO, V24, P129, DOI 10.3109/00365528909091260; SOLCIA E, 1989, GASTROENTEROL CLIN N, V18, P671; SOLVELL L, 1989, SCAND J GASTROENTERO, V24, P106, DOI 10.3109/00365528909091255; SPENCER AJ, 1989, TOXICOL PATHOL, V17, P7, DOI 10.1177/01926233890171P102; STOCKBRUGGER RW, 1983, GUT, V24, P1141, DOI 10.1136/gut.24.12.1141; SUTFIN T, 1989, THER DRUG MONIT, V11, P176, DOI 10.1097/00007691-198903000-00010; TALLEY NJ, 1989, ANN INTERN MED, V111, P738, DOI 10.7326/0003-4819-111-9-738; TYTGAT G N J, 1987, Alimentary Pharmacology and Therapeutics, V1, P31; VANDEVENTER GM, 1988, GASTROENTEROLOGY, V94, pA476; VANTRAPPEN G, 1988, DIGEST DIS SCI, V33, P523, DOI 10.1007/BF01798351; VEZZADINI P, 1984, CURR THER RES CLIN E, V35, P772; VINAYEK R, 1990, GASTROENTEROLOGY, V99, P10, DOI 10.1016/0016-5085(90)91223-S; WALAN A, 1989, NEW ENGL J MED, V320, P69, DOI 10.1056/NEJM198901123200201; WALLMARK B, 1989, SCAND J GASTROENTERO, V24, P12, DOI 10.3109/00365528909091237; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; WALSH JH, 1988, AM J GASTROENTEROL, V83, P1042; WILANDER E, 1981, VIRCHOWS ARCH A, V394, P151, DOI 10.1007/BF00431673; WOLOSIN JM, 1985, AM J PHYSIOL, V248, pG595, DOI 10.1152/ajpgi.1985.248.6.G595; WORMSLEY KG, 1984, GUT, V25, P1416, DOI 10.1136/gut.25.12.1416; ZEITOUN P, 1989, GASTROEN CLIN BIOL, V13, P457; 1984, SCAND J GASTROENTERO, V19, P882; 1984, BMJ, V289, P525; 1989, SCAND J GASTROENTERO, V24, P557; 1989, BMJ, V298, P645; 1986, SCAND J GASTROENTE S, V118, P175	180	290	294	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					965	975						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	2002819				2022-12-28	WOS:A1991FE37600006
J	BLUM, A				BLUM, A			THE MARLBORO GRAND-PRIX - CIRCUMVENTION OF THE TELEVISION BAN ON TOBACCO ADVERTISING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BLUM, A (corresponding author), BAYLOR UNIV,HOUSTON,TX 77005, USA.							BLUM A, 1985, NEW YORK STATE J MED, V85, P458; BUCHANAN DR, 1990, BEER FAST CARS BREWE, P25; DRAPE J, 1990, ATLANTA J CONST 0729, pA1; DRAPE J, 1990, ATLANTA J CONST 0729, pA12; FORKAN JP, 1986, ADVERTISING AGE 0324, P45; HARVEY P, 1991, RACETIME         NOV, P34; JOHNSON ME, 1990, ADVERTISING AGE 1105, P36; KING W, 1975, NY TIMES        0713, P36; KOTEN J, 1990, WALL STREET J   0524, pA1; KOTEN J, 1990, WALL STREET J   0524, P9; MILLER C, 1983, MED J AUSTRALIA, V1, P242; RAEBURN P, 1990, IDAHO STATESMAN 0115, pD1; WALTZ K, 1990, NATIONAL SPEED  1128, P8; 1989, TNN, V2, P1; 1991, RACETIME         NOV, P10; 1990, WHO REGIONAL PUBLICA, V30, P43; 1990, NATIONAL DRAGST 1207, P29; 1990, AUSTR HIGH COURT UPH; 1990, MMWR, V39, P261; 1989, CART, V7, P1	20	50	50	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					913	916		10.1056/NEJM199103283241310	http://dx.doi.org/10.1056/NEJM199103283241310			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000115				2022-12-28	WOS:A1991FD11100010
J	CLINTON, JJ				CLINTON, JJ			PHYSICIAN INPUT INVITED ON CLINICAL GUIDELINE DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AGCY HLTH CARE POLICY & RES,ROCKVILLE,MD 20857	Agency for Healthcare Research & Quality								1990, FED REG         1210, P55	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1508	1508		10.1001/jama.265.12.1508	http://dx.doi.org/10.1001/jama.265.12.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999893				2022-12-28	WOS:A1991FC60400005
J	SHIVER, JW; HENKART, PA				SHIVER, JW; HENKART, PA			A NONCYTOTOXIC MAST-CELL TUMOR LINE EXHIBITS POTENT IGE-DEPENDENT CYTOTOXICITY AFTER TRANSFECTION WITH THE CYTOLYSIN PERFORIN GENE	CELL			English	Article							PURIFIED CYTOPLASMIC GRANULES; TOXIC LYMPHOCYTES-T; KILLER CELLS; LYSIS; INHIBITION; ANTIBODIES; EXPRESSION; INDUCTION; MECHANISM; SECRETION	To test the granule exocytosis model for lymphocyte cytotoxicity, we have expressed the gene for the cytotoxic lymphocyte granule protein cytolysin (perforin) in the noncytotoxic rat basophilic leukemia (RBL) cell line, which undergoes granule exocytosis when its high affinity IgE receptor is cross-linked. Homogenates of RBL-cytolysin (RBL-cy) transfectants showed a calcium-dependent hemolytic activity in dense granule fractions, demonstrating that the expressed cytolysin protein was correctly targeted to secretory granules. RBL-cy transfectants showed a potent and calcium-dependent cytolytic activity against IgE-coated RBCs, while the parental RBL line was not cytotoxic under these conditions. RBL-cy cells did not lyse non-IgE-coated RBCs copelleted with targets: this sparing of "innocent bystanders" parallels cytotoxic T lymphocyte lysis and suggests a polarized secretion of cytolysin. In contrast to RBC targets, IgE-coated tumor cells were much less sensitive to lysis by RBL-cy transfectants.			SHIVER, JW (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BLDG 10,ROOM 4B17,BETHESDA,MD 20892, USA.							ACHAORBEA H, 1990, EMBO J, V9, P3815, DOI 10.1002/j.1460-2075.1990.tb07599.x; Battey, 1986, BASIC METHODS MOL BI; BLOOM BR, 1971, ADV IMMUNOL, V13, P102; CERROTINI JC, 1974, ADV IMMUNOL, V18, P67; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNERT G, 1983, J EXP MED, V157, P1483, DOI 10.1084/jem.157.5.1483; DOURMASHKIN RR, 1980, CLIN EXP IMMUNOL, V43, P554; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HENKART PA, 1986, J IMMUNOL, V137, P2611; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P1073, DOI 10.1002/eji.1830170727; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; LIU FT, 1980, J IMMUNOL, V124, P2728; MASSON D, 1985, EMBO J, V4, P2533, DOI 10.1002/j.1460-2075.1985.tb03967.x; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; REYNOLDS CW, 1987, J LEUKOCYTE BIOL, V42, P642, DOI 10.1002/jlb.42.6.642; RUSSELL JH, 1983, IMMUNOL REV, V72, P92; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TEMPLETON D, 1984, MOL CELL BIOL, V4, P817, DOI 10.1128/MCB.4.5.817; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; TSCHOPP J, 1986, J IMMUNOL, V137, P1950; WEI WZ, 1981, J IMMUNOL, V126, P513; YUE CC, 1987, MOL IMMUNOL, V24, P647, DOI 10.1016/0161-5890(87)90046-0	31	85	87	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1175	1181		10.1016/0092-8674(91)90272-Z	http://dx.doi.org/10.1016/0092-8674(91)90272-Z			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004423				2022-12-28	WOS:A1991FD55800015
J	KORULA, J; HARMA, C				KORULA, J; HARMA, C			A SIMPLE AND INEXPENSIVE METHOD OF REMOVAL OR REPLACEMENT OF GASTROSTOMY TUBES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PERCUTANEOUS ENDOSCOPIC GASTROSTOMY	The safety of removal or replacement of gastrostomy tubes by simply cutting the tube and allowing the inner components to be eliminated intestinally was prospectively studied in 64 patients. In only one patient was the internal component lodged at the pylorus; it required endoscopic removal. Abdominal radiographs obtained in 57 patients confirmed complete elimination of internal percutaneous endoscopic gastrostomy components in 48 patients (84%) and identified these components in the colon in eight (14%). In two patients, the internal components were identified in the stool, and in one, radiographs were not obtained. Six patients who did not have abdominal radiographs had no problems during a mean follow-up period of 153.3 +/- 37.2 days. This simple method is safe, inexpensive, can be offered to the large majority of patients with percutaneous endoscopic gastrostomy tubes, and avoids the need for endoscopic removal.			KORULA, J (corresponding author), UNIV SO CALIF,SCH MED,LOS AMIGOS MED CTR,LIVER UNIT,7601 E IMPERIAL HWY,DOWNEY,CA 90242, USA.							LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; PONSKY JL, 1981, GASTROINTEST ENDOSC, V27, P9, DOI 10.1016/S0016-5107(81)73133-X; RUSSELL TR, 1984, AM J SURG, V148, P132, DOI 10.1016/0002-9610(84)90300-3; SHALLMAN RW, 1988, GASTROINTEST ENDOSC, V34, P367, DOI 10.1016/S0016-5107(88)71384-X; WILSON WCM, 1990, GASTROINTEST ENDOSC, V36, P62, DOI 10.1016/S0016-5107(90)70927-3	5	61	62	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1426	1428		10.1001/jama.265.11.1426	http://dx.doi.org/10.1001/jama.265.11.1426			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999884				2022-12-28	WOS:A1991FB55000025
J	BRANCH, WT; ARKY, RA; WOO, B; STOECKLE, JD; LEVY, DB; TAYLOR, WC				BRANCH, WT; ARKY, RA; WOO, B; STOECKLE, JD; LEVY, DB; TAYLOR, WC			TEACHING MEDICINE AS A HUMAN-EXPERIENCE - A PATIENT-DOCTOR RELATIONSHIP COURSE FOR FACULTY AND 1ST-YEAR MEDICAL-STUDENTS	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL CORRELATION COURSE; RESIDENT-MATCHING-PROGRAM; INTERNAL MEDICINE; LEARNING PROJECTS; HUMAN-VALUES; 1ST YEAR; EDUCATION; CURRICULUM; PHYSICIAN; ETHICS	We developed a required, longitudinal course for first-year medical students that addressed the patient-doctor relationship. Our course linked understanding patients' experiences and perspectives on illness with listening to, talking with, and establishing a rapport with patients while obtaining their medical histories. Learning was enhanced by use of an interdisciplinary faculty and by small-group continuity and faculty mentoring. Our curriculum adapted problem-based, self-directed educational methods to convey medical humanism. We focused on bedside interviewing as the means for exploring patients' social, emotional, and ethical concerns.	MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MT AUBURN HOSP, CAMBRIDGE, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Mount Auburn Hospital	BRANCH, WT (corresponding author), BRIGHAM & WOMENS HOSP, 75 FRANCIS ST, BOSTON, MA 02115 USA.							ALPER PR, 1987, NEW ENGL J MED, V316, P337, DOI 10.1056/NEJM198702053160611; AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; ARNOLD RM, 1987, ANN INTERN MED, V106, P313, DOI 10.7326/0003-4819-106-2-313; BARNES HN, 1987, ALCOHOLISM GUIDE PRI, P3; Barrows H., 1980, PROBLEM BASED LEARNI; BARROWS HS, 1983, JAMA-J AM MED ASSOC, V250, P3077, DOI 10.1001/jama.250.22.3077; BERRIEN R, 1987, NEW ENGL J MED, V316, P334, DOI 10.1056/NEJM198702053160610; BICKEL J, 1987, J MED EDUC, V62, P369; BILLINGS JA, 1989, CLIN ENCOUNTER GUIDE, P117; BLUMGART HL, 1964, NEW ENGL J MED, V270, P449, DOI 10.1056/NEJM196402272700906; BOK D, 1984, HARV MAG         JUN, V86, P32; BOK D, 1984, HARVARD MAG, V86, P70; BRANCH WT, 1990, J GEN INTERN MED, V5, pS15, DOI 10.1007/BF02600434; BRANCH WT, 1987, J GEN INTERN MED, V2, P356, DOI 10.1007/BF02596175; BRANCH WT, 1989, J GEN INTERN MED, V4, P359, DOI 10.1007/BF02597413; BRANCH WT, 1990, AM J MED, V88, P56, DOI 10.1016/0002-9343(90)90128-Z; BRANCH WT, 1989, HARVARD MED ALUM WIN, P12; BRICE JA, 1986, HARV MED ALUM B, V60, P28; BROOKFIELD S, 1987, UNDERSTANDING FACILI; Cassell EJ, 1984, PLACE HUMANITIES MED; COHENCOLE SA, 1986, QUALITY LIFE CARDIOV, V3, P53; Cross K.P., 1981, ADULTS LEARNERS; CULVER CM, 1985, NEW ENGL J MED, V312, P253, DOI 10.1056/NEJM198501243120430; EMOND S, 1989, PATIENT DOCTOR GUIDE; ENDE J, 1983, JAMA-J AM MED ASSOC, V250, P777, DOI 10.1001/jama.250.6.777; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; ENGEL GL, 1985, MED HUMAN EXPERIENCE, P61; FRIEDLAND GH, 1989, DAEDALUS, V118, P59; FRIEDMAN CP, 1990, ACAD MED, V65, P8, DOI 10.1097/00001888-199001000-00002; GLICK SM, 1981, NEW ENGL J MED, V304, P1036, DOI 10.1056/NEJM198104233041711; GONDA TA, 1984, DYING DIGNIFIED HLTH, P28; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; GRAETTINGER JS, 1988, ANN INTERN MED, V108, P761, DOI 10.7326/0003-4819-108-5-761; GRAETTINGER JS, 1988, ANN INTERN MED, V108, P101, DOI 10.7326/0003-4819-108-1-101; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; KAHN GS, 1979, J MED EDUC, V54, P29; KAY J, 1990, JAMA-J AM MED ASSOC, V263, P572, DOI 10.1001/jama.263.4.572; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kleinman A., 1988, ILLNESS NARRATIVES; Knowles M., 1980, MODERN PRACTICE ADUL; KOLODNY RC, 1987, SEXUALITY MED, V1, P3; KRALEWSKI JE, 1987, NEW ENGL J MED, V316, P339, DOI 10.1056/NEJM198702053160612; LAMBIE AT, 1981, MED EDUC, V15, P209, DOI 10.1111/j.1365-2923.1981.tb02634.x; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; LIPOWSKI ZJ, 1970, PSYCHIAT MED, V1, P91, DOI 10.2190/19Q3-9QL8-XYV1-8XC2; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MCCARTY DJ, 1987, NEW ENGL J MED, V317, P567, DOI 10.1056/NEJM198708273170909; MCCORMICK D, 1985, 838625 HARV BUS SCH; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MCKINLEY J, 1983, HELPING ADULTS LEARN, P13; MILES SH, 1989, ACAD MED, V64, P705, DOI 10.1097/00001888-198912000-00004; MULLER S, 1984, J MED EDUC, V59, P1; NEUFELD VR, 1984, ANDRAGOGY ACTION APP, P207; NEUFIELD VR, 1984, J MED EDUC, V49, P1040; ODEGAARD CE, 1986, COMMUNICATION; ORT RS, 1964, J HEALTH HUM BEHAV, V5, P25, DOI 10.2307/2948757; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; PELLEGRINO ED, 1974, JAMA-J AM MED ASSOC, V227, P1288, DOI 10.1001/jama.227.11.1288; PLATT FW, 1979, ANN INTERN MED, V91, P898, DOI 10.7326/0003-4819-91-6-898; PUCKETT AC, 1989, ACAD MED, V64, P231, DOI 10.1097/00001888-198905000-00002; RAPHAEL B, 1983, ANATOMY BEREAVEMENT, P352; REISER DE, 1980, PATIENT INTERVIEWING, P3; RELMAN AS, 1987, NEW ENGL J MED, V316, P333, DOI 10.1056/NEJM198702053160609; REYNOLDS RC, 1976, J MED EDUC, V51, P142; SANTOSGOMEZ L, 1990, MED EDUC, V24, P366, DOI 10.1111/j.1365-2923.1990.tb02453.x; SCHERR L, 1987, ACP OBSERVER, P7; Schmidt H. G, 1989, NEW DIRECTIONS MED E, P105; SCHMIDT HG, 1983, MED EDUC, V17, P11, DOI 10.1111/j.1365-2923.1983.tb01086.x; Schoen Donald, 1987, ED REFLECTIVE PRACTI; Self D J, 1988, Theor Med, V9, P227, DOI 10.1007/BF00489414; SHEEHAN KH, 1990, JAMA-J AM MED ASSOC, V263, P533, DOI 10.1001/jama.263.4.533; SHORTER R, 1985, BEDSIDE MANNERS TROU; SIEGLER M, 1978, JAMA-J AM MED ASSOC, V239, P951, DOI 10.1001/jama.239.10.951; SILVER HK, 1990, JAMA-J AM MED ASSOC, V263, P527, DOI 10.1001/jama.263.4.527; STOECKLE JD, 1987, ANN INTERN MED, V107, P250, DOI 10.7326/0003-4819-107-2-250; STOECKLE JD, 1987, J GEN INTERN MED, V2, P119, DOI 10.1007/BF02596310; STOECKLE JD, 1980, RELEVANCE SOCIAL SCI, P223; Stokes J 3rd, 1988, Adv Intern Med, V33, P431; SWICK T, 1987, ACP OBSERVER, V7, P12; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; TAYLOR WC, 1989, ACAD MED, V64, P673, DOI 10.1097/00001888-198911000-00015; THOMASMA DC, 1982, MOBIUS, V2, P72; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405; VEATCH R, 1989, MED ETHICS, P3; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WAITZKIN H, 1984, LANCET, V2, P1144; WILSON F, 1982, HLTH SERVICES US, P99; WOODWARD CA, 1983, MED EDUC, V17, P54, DOI 10.1111/j.1365-2923.1983.tb01094.x; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1987, NRMP 1987 RESULTS; 1983, ANN INTERN MED, V9, P720	91	73	77	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					482	489		10.7326/0003-4819-114-6-482	http://dx.doi.org/10.7326/0003-4819-114-6-482			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994796				2022-12-28	WOS:A1991FB64000009
J	HUANG, S; LEE, WH; LEE, EYHP				HUANG, S; LEE, WH; LEE, EYHP			A CELLULAR PROTEIN THAT COMPETES WITH SV40 T-ANTIGEN FOR BINDING TO THE RETINOBLASTOMA GENE-PRODUCT	NATURE			English	Article							SUSCEPTIBILITY GENE; EXPRESSION; CELLS	TUMOUR-suppressor genes, such as the human retinoblastoma susceptibility gene (Rb), are widely recognized as being vital in the control of cell growth and tumour formation 1. This role is indicated, in part, by the suppression of tumorigenicity of human tumour cells after retrovirus-mediated Rb replacement 2-4. How Rb acts to bring about this suppression is not clear 5 but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses 6-8, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells 9,10. These observations suggest that endogenous cellular proteins might exist that bind to the same regions of Rb and thereby mediate its function. We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46). Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb. The apparent targeting of the RbAP46-Rb interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.			HUANG, S (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093, USA.							BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; Lee W.-H., 1990, TUMOR SUPPRESSOR GEN, P169; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807	18	145	165	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					160	162		10.1038/350160a0	http://dx.doi.org/10.1038/350160a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005966				2022-12-28	WOS:A1991FB64500061
J	RAUB, W				RAUB, W			COMBINED AGENTS ELIMINATE HUMAN HIV-1 FROM T-CELL CULTURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, P NATL ACAD SCI USA, V87, P8889	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-28	WOS:A1991EZ47400005
J	EPSTEIN, HF; FISCHMAN, DA				EPSTEIN, HF; FISCHMAN, DA			MOLECULAR ANALYSIS OF PROTEIN ASSEMBLY IN MUSCLE DEVELOPMENT	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; CAENORHABDITIS-ELEGANS; SKELETAL-MUSCLE; THICK FILAMENTS; CONTRACTILE PROTEINS; ACTIN-FILAMENTS; HEAVY-CHAIN; C-PROTEIN; MYOSIN MINIFILAMENTS; ELECTRON-MICROSCOPY	The challenge presented by myofibril assembly in striated muscle is to understand the molecular mechanisms by which its protein components are arranged at each level of organization. Recent advances in the genetics and cell biology of muscle development have shown that in vivo assembly of the myofilaments requires a complex array of structural and associated proteins and that organization of whole sarcomeres occurs initially at the cell membrane. These studies have been complemented by in vitro analyses of the renaturation, polymerization, and three-dimensional structure of the purified proteins.	BAYLOR UNIV,DEPT HYG & MED MIKROBIOL,HOUSTON,TX 77030; BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030; CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021	Baylor University; Baylor University; Cornell University	EPSTEIN, HF (corresponding author), BAYLOR UNIV,DEPT NEUROL,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033223] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42267] Funding Source: Medline; NIAMS NIH HHS [AR-32147] Funding Source: Medline; NIGMS NIH HHS [GM-33223] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RD, 1981, CELL MOTIL CYTOSKEL, V1, P275, DOI 10.1002/cm.970010302; ANDERSON P, 1989, ANNU REV GENET, V23, P507, DOI 10.1146/annurev.ge.23.120189.002451; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ANTIN PB, 1981, J CELL BIOL, V90, P300, DOI 10.1083/jcb.90.2.300; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BENNETT P, 1986, J MUSCLE RES CELL M, V7, P550, DOI 10.1007/BF01753571; BRACKEN WC, 1988, BIOPOLYMERS, V27, P1223, DOI 10.1002/bip.360270804; Briggs MM, 1989, CELLULAR MOL BIOL MU, P597; BRONSON DD, 1982, J BIOL CHEM, V257, P3937; BROWN HR, 1985, P NATL ACAD SCI USA, V82, P2359, DOI 10.1073/pnas.82.8.2359; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1980, CELL, V19, P587, DOI 10.1016/S0092-8674(80)80035-3; CAPLAN AI, 1983, SCIENCE, V221, P921, DOI 10.1126/science.6348946; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CASJENS S, 1974, Journal of Supramolecular Structure, V2, P202, DOI 10.1002/jss.400020215; CHOWRASHI PK, 1986, J MUSCLE RES CELL M, V7, P413, DOI 10.1007/BF01753584; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIS JS, 1985, BIOCHEMISTRY-US, V24, P5263, DOI 10.1021/bi00340a046; DAVIS JS, 1988, ANNU REV BIOPHYS BIO, V17, P217; DAVIS JS, 1976, FEBS LETT, V72, P199, DOI 10.1016/0014-5793(76)80971-4; DECHESNE CA, 1987, J CELL BIOL, V105, P3031, DOI 10.1083/jcb.105.6.3031; DENNIS JE, 1984, J CELL BIOL, V98, P1514, DOI 10.1083/jcb.98.4.1514; DIBB NJ, 1989, J MOL BIOL, V205, P602; DLUGOSZ AA, 1984, J CELL BIOL, V99, P2268, DOI 10.1083/jcb.99.6.2268; EDELMAN GM, 1987, IMMUNOL REV, V100, P11, DOI 10.1111/j.1600-065X.1987.tb00526.x; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; EPSTEIN HF, 1988, BIOESSAYS, V9, P197, DOI 10.1002/bies.950090604; EPSTEIN HF, 1985, J CELL BIOL, V100, P904, DOI 10.1083/jcb.100.3.904; EPSTEIN HF, 1986, J CELL BIOL, V103, P985, DOI 10.1083/jcb.103.3.985; EPSTEIN HF, 1974, J MOL BIOL, V90, P291, DOI 10.1016/0022-2836(74)90374-X; EPSTEIN HF, 1990, MOL NEUROBIOL, V4, P1, DOI 10.1007/BF02935583; EPSTEIN HF, 1986, UCLA S MOL CELL BIOL, V29, P653; FISCHMAN DA, 1986, MYOLOGY BASIC CLIN, P5; FISCHMAN DA, IN PRESS FRONTIERS M; FRANCIS GR, 1985, J CELL BIOL, V101, P1532, DOI 10.1083/jcb.101.4.1532; FRYBERG EA, 1980, CELL, V19, P365; FURST DO, 1989, J CELL BIOL, V105, P1563; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; FYRBERG E, 1989, CELL MOTIL CYTOSKEL, V14, P118, DOI 10.1002/cm.970140121; GEISTERFERLOWRA.AA, 1990, CELL, V62, P99; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P894, DOI 10.1021/bi00806a026; GOLDBERG AL, 1975, MED SCI SPORT EXER, V7, P248; GREENWALD IS, 1980, GENETICS, V96, P147; HERZBERG O, 1985, NATURE, V313, P655; HITCHCOCKDEGREGORI SE, 1989, CELL MOTIL CYTOSKEL, V14, P12, DOI 10.1002/cm.970140105; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLTZER H, 1957, J BIOPHYS BIOCHEM CY, V3, P705, DOI 10.1083/jcb.3.5.705; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; INOUE S, 1981, J CELL BIOL, V89, P346, DOI 10.1083/jcb.89.2.346; JOHNSON CS, 1988, J CELL BIOL, V107, P2213, DOI 10.1083/jcb.107.6.2213; JOSEPHS R, 1966, BIOCHEMISTRY-US, V5, P3473; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAGAWA H, 1989, J MOL BIOL, V207, P311, DOI 10.1016/0022-2836(89)90257-X; KENSLER RW, 1982, J CELL BIOL, V92, P443, DOI 10.1083/jcb.92.2.443; KETTELHUT IC, 1988, DIABETES METAB REV, V4, P751, DOI 10.1002/dmr.5610040805; Klug A, 1980, Harvey Lect, V74, P141; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P2268, DOI 10.1073/pnas.71.6.2268; LEHRER SS, 1989, SCIENCE, V246, P926, DOI 10.1126/science.2814515; LEINWAND LA, 1989, CELL MOTIL CYTOSKEL, V14, P3, DOI 10.1002/cm.970140104; LEVINE RJC, 1973, J CELL BIOL, V57, P591, DOI 10.1083/jcb.57.2.591; MACKENZIE JM, 1978, CELL, V15, P751, DOI 10.1016/0092-8674(78)90261-1; MAHAFFEY JW, 1985, CELL, V40, P101, DOI 10.1016/0092-8674(85)90313-7; MCKEOWN M, 1981, CELL, V24, P799, DOI 10.1016/0092-8674(81)90105-7; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MCLACHLAN AD, 1984, ANNU REV BIOPHYS BIO, V13, P167; MENETRET JF, 1990, J MUSCLE RES CELL M, V11, P1, DOI 10.1007/BF01833321; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MOEMAN DG, 1982, CELL, V29, P773; NIEDERMAN R, 1982, J MOL BIOL, V161, P505, DOI 10.1016/0022-2836(82)90404-1; NOMURA M, 1973, SCIENCE, V179, P864, DOI 10.1126/science.179.4076.864; ODONNELL PT, 1988, J CELL BIOL, V107, P2601, DOI 10.1083/jcb.107.6.2601; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; OFFER G, 1985, J MOL BIOL, V186, P393; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; PINSETHARSTROM I, 1985, J MOL BIOL, V182, P159, DOI 10.1016/0022-2836(85)90034-8; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; REISLER E, 1982, BIOCHEMISTRY-US, V21, P701, DOI 10.1021/bi00533a018; REISLER E, 1980, J MOL BIOL, V143, P129, DOI 10.1016/0022-2836(80)90127-8; SAAD AD, 1986, P NATL ACAD SCI USA, V83, P9483, DOI 10.1073/pnas.83.24.9483; SCHACHAT FH, 1985, J BIOL CHEM, V260, P1108; SCHULTHEISS T, 1990, J CELL BIOL, V110, P1159, DOI 10.1083/jcb.110.4.1159; STARR R, 1971, FEBS LETT, V15, P40, DOI 10.1016/0014-5793(71)80075-3; STEWART M, 1986, J MOL BIOL, V192, P831, DOI 10.1016/0022-2836(86)90032-X; TAKANOOHMURO H, 1989, J MUSCLE RES CELL M, V10, P369, DOI 10.1007/BF01758433; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; TIDBALL JG, 1986, J CELL BIOL, V103, P1465, DOI 10.1083/jcb.103.4.1465; TRINICK J, 1980, J MOL BIOL, V141, P315, DOI 10.1016/0022-2836(80)90183-7; TWITCHIN GM, 1989, NATURE, V342, P45; VENOLIA L, 1990, GENETICS, V126, P345; VIBERT P, 1983, J MOL BIOL, V165, P303, DOI 10.1016/S0022-2836(83)80259-9; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; WANG K, 1984, P NATL ACAD SCI-BIOL, V81, P3685, DOI 10.1073/pnas.81.12.3685; WANG YL, 1979, J CELL BIOL, V82, P672; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Waterston R., 1988, NEMATODE C ELEGANS, P281; WATERSTON RH, 1984, J MOL BIOL, V180, P473, DOI 10.1016/0022-2836(84)90023-8; WATERSTON RH, 1989, CELL MOTIL CYTOSKEL, V14, P136, DOI 10.1002/cm.970140123; WATERSTON RH, 1980, DEV BIOL, V77, P271, DOI 10.1016/0012-1606(80)90475-3; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WHITING A, 1989, J MOL BIOL, V205, P263, DOI 10.1016/0022-2836(89)90381-1; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINKELMANN DA, 1985, J MOL BIOL, V181, P487, DOI 10.1016/0022-2836(85)90422-X; WOOD WB, 1978, HARVEY LECT, V73, P203; WRAY JS, 1979, NATURE, V277, P37, DOI 10.1038/277037a0; ZEMAN RJ, 1987, AM J PHYSIOL, V252, pE152, DOI 10.1152/ajpendo.1987.252.1.E152; ZENGEL JM, 1980, CELL MOTIL CYTOSKEL, V1, P73, DOI 10.1002/cm.970010107; 1990, NY TIMES        0606, pA1	121	128	130	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1039	1044		10.1126/science.1998120	http://dx.doi.org/10.1126/science.1998120			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1998120				2022-12-28	WOS:A1991EZ66500040
J	KEMPER, P; MURTAUGH, CM				KEMPER, P; MURTAUGH, CM			LIFETIME USE OF NURSING-HOME CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM CARE; RISK; INSTITUTIONALIZATION; POPULATION; STATISTICS; MORTALITY; FALLACY	Background and Methods. Despite the growth in the number of Americans in nursing homes, there are only limited data on the total amount of time that people spend in such facilities. We estimate the amount of time the average person spends in nursing homes over his or her lifetime (lifetime nursing home use), using data from the National Mortality Followback Survey of the next of kin of a sample of persons 25 years of age or older who died in 1986. On the basis of these data, we estimated the likelihood that Americans will use nursing home care during the course of their lifetimes and the total duration of such care. Current data on life expectancy were then used to reweight the sample to project lifetime nursing home use for those who became 65 years old in 1990. Results. Of those who died in 1986 at 25 years of age or older, 29 percent had at some time been residents in a nursing home, and almost half of those who entered a nursing home spent a cumulative total of at least one year there. The probability of nursing home use increased sharply with age at death: 17 percent for age 65 to 74, 36 percent for age 75 to 84, and 60 percent for age 85 to 94. For persons who turned 65 in 1990, we project that 43 percent will enter a nursing home at some time before they die. Of those who enter nursing homes, 55 percent will have total lifetime use of at least one year, and 21 percent will have total lifetime use of five years or more. We also project that more women than men will enter nursing homes (52 percent vs. 33 percent), and among them, more women than men will have total lifetime nursing home use of five years or more (25 percent vs. 13 percent). Conclusions. Our projections indicate that over a lifetime, the risk of entering a nursing home and spending a long time there is substantial. With the elderly population growing, this has important implications for both medical practice and the financing of long-term care.			KEMPER, P (corresponding author), AGCY HLTH CARE POLICY RES,CTR INTRAMURAL RES,DIV LONG TERM CARE STUDIES,ROCKVILLE,MD 20857, USA.							BALL RM, 1989, WERE ALL TOGETHER CA; BLUMENTHAL D, 1988, RENEWING PROMISE MED, P176; BRANCH LG, 1988, GERONTOLOGIST, V28, P648, DOI 10.1093/geront/28.5.648; BURWELL BO, 1990, MED CARE, V28, P349, DOI 10.1097/00005650-199004000-00006; Carpenter L, 1988, Health Care Financ Rev, V10, P67; COHEN MA, 1986, MED CARE, V24, P1161, DOI 10.1097/00005650-198612000-00008; DAVIS K, 1986, MEDICARE POLICY NEW; FRIES JF, 1986, HOME HLTH CARE S FAL, P51; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; HAYFLICK L, 1986, HLTH CARE ELDERLY RE, P75; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; INGRAM DK, 1977, GERONTOLOGIST, V17, P303, DOI 10.1093/geront/17.4.303; Institute of Medicine report, 1986, IMPROVING QUALITY CA; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KASTENBAUM R, 1973, INT J AGING HUM DEV, V4, P15, DOI 10.2190/28NK-ENPJ-M7PT-GKTK; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KEELER EB, 1981, MED CARE, V19, P363, DOI 10.1097/00005650-198103000-00011; LESNOFFCARAVAGLIA G, 1978, INT J AGING HUM DEV, V9, P187, DOI 10.2190/5WJR-1JFB-FGAG-MN9X; Letsch S W, 1988, Health Care Financ Rev, V10, P109; LIANG J, 1986, GERONTOLOGIST, V26, P560, DOI 10.1093/geront/26.5.560; LIU K, 1983, MED CARE, V21, P1211, DOI 10.1097/00005650-198312000-00008; LIU K, 1990, GERONTOLOGIST, V30, P7, DOI 10.1093/geront/30.1.7; Liu K, 1981, Health Care Financ Rev, V3, P15; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; MARQUIS KH, 1978, RECORD CHECK VALIDIT; MATHIOWETZ NA, 1988, J BUS ECON STAT, V6, P221, DOI 10.2307/1391559; MATHIOWETZ NA, 1985, AM J PUBLIC HEALTH, V75, P639, DOI 10.2105/AJPH.75.6.639; MEINERS MR, 1984, MED CARE, V22, P901, DOI 10.1097/00005650-198410000-00003; Moore J.C., 1988, J OFF STAT, V4, P155; MORRISEY MA, 1988, MED CARE, V26, P685, DOI 10.1097/00005650-198807000-00004; MOSES SA, 1990, GERONTOLOGIST, V30, P21, DOI 10.1093/geront/30.1.21; MURTAUGH CM, 1990, MED CARE, V28, P952, DOI 10.1097/00005650-199010000-00009; PALMORE E, 1976, GERONTOLOGIST, V16, P504, DOI 10.1093/geront/16.6.504; ROGERS A, 1990, GERONTOLOGIST, V30, P640, DOI 10.1093/geront/30.5.640; ROGERS RG, 1989, MILBANK Q, V67, P370, DOI 10.2307/3350221; SEEMAN I, 1989, PUBLIC HEALTH REP, V104, P183; SHAH BV, 1981, RTI52500001S RES TRI; SHAUGHNESSY PW, 1990, NEW ENGL J MED, V322, P21, DOI 10.1056/NEJM199001043220105; SMEEDING TM, 1990, GERONTOLOGIST, V30, P5, DOI 10.1093/geront/30.1.5; SOMERS AR, 1982, NEW ENGL J MED, V307, P221, DOI 10.1056/NEJM198207223070404; SPENCE DA, 1990, GERONTOLOGIST, V30, P16, DOI 10.1093/geront/30.1.16; VANGELDER S, 1991, LONG TERM CARE INSUR; VICENTE L, 1979, GERONTOLOGIST, V19, P361, DOI 10.1093/geront/19.4.361; Vladeck B.C., 1980, UNLOVING CARE NURSIN; WADE A, 1988, SSA1111549 SOC SEC A; Weissert W G, 1985, Health Care Financ Rev, V6, P83; 1989, CURRENT POPULATI P25, V1018; 1989, VITAL HLTH STATIS 13, V97; 1981, VITAL HLTH STATIS 13, V54; 1978, IOM7804 NAT AC SCI P; 1970, VITAL HLTH STATIS 12, V13; [No title captured]; 1990, RECOMMENDATIONS C AC	53	273	274	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 28	1991	324	9					595	600		10.1056/NEJM199102283240905	http://dx.doi.org/10.1056/NEJM199102283240905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY886	1992320	Bronze			2022-12-28	WOS:A1991EY88600005
J	SORIANO, P; MONTGOMERY, C; GESKE, R; BRADLEY, A				SORIANO, P; MONTGOMERY, C; GESKE, R; BRADLEY, A			TARGETED DISRUPTION OF THE C-SRC PROTOONCOGENE LEADS TO OSTEOPETROSIS IN MICE	CELL			English	Article							AVIAN-SARCOMA VIRUSES; DEVELOPING RAT-BRAIN; GENE-PRODUCT; STEM-CELLS; HOMOLOGOUS RECOMBINATION; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; SPLEEN-CELLS; PP60C-SRC; EXPRESSION	To understand the normal, physiological role of the c-src proto-oncogene, a null mutation was introduced into the gene by homologous recombination in mouse embryonic stem cells. Two independent targeted clones were used to generate chimeras that transmitted the mutated allele to their offspring. Intercrossing of heterozygotes gave rise to live born homozygotes, but most of these mice died within the first few weeks of birth. Histological and hematological examination of the homozygous mutants did not reveal detectable abnormalities in the brain or platelets, where src is most highly expressed. However, these mutants were deficient in bone remodeling, indicating impaired osteoclast function, and developed osteopetrosis. These results demonstrate that src is not required for general cell viability (possibly because of functional overlap with other tyrosine kinases related to src) and uncover an essential role for src in bone formation.	BAYLOR UNIV, INST MOLEC GENET, HOUSTON, TX 77030 USA; BAYLOR UNIV, CTR COMPARAT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor University; Baylor University	SORIANO, P (corresponding author), BAYLOR UNIV, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Bradley, Allan/0000-0002-2349-8839	NICHD NIH HHS [HD24875, HD25326] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875, R37HD025326, R01HD025326] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAIR GM, 1989, P NATL ACAD SCI USA, V86, P4574, DOI 10.1073/pnas.86.12.4574; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOLDEN A, 1988, ONCOGENE HDB, V7; Green MC., 1989, GENETIC VARIANTS STR, P12; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JONES KL, 1988, SMITHS RECOGNIZABLE, P353; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	51	1852	1923	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					693	702		10.1016/0092-8674(91)90499-O	http://dx.doi.org/10.1016/0092-8674(91)90499-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997203				2022-12-28	WOS:A1991EZ47800005
J	MIRKIN, G				MIRKIN, G			ESTROGEN IN YAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MIRKIN, G (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20057, USA.							BLUNDEN G, 1967, J PHARM SCI, V56, P948, DOI 10.1002/jps.2600560804; BLUNDEN G, 1968, J PHARM SCI, V57, P602, DOI 10.1002/jps.2600570411; Chakravarti R N, 1966, Bull Calcutta Sch Trop Med, V14, P45; CURNOW DH, 1954, BIOCHEM J, V58, P283, DOI 10.1042/bj0580283	4	13	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					912	912						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992191				2022-12-28	WOS:A1991EX58700048
J	TALBOT, RJ				TALBOT, RJ			UNDERPRIVILEGED AREAS AND HEALTH-CARE PLANNING - IMPLICATIONS OF USE OF JARMAN INDICATORS OF URBAN DEPRIVATION	BRITISH MEDICAL JOURNAL			English	Article							SCORES	Objective-To analyse critically the use of the Jarman underprivileged area index in health care planning and distribution of resources. Design-The original derivation of the score was examined and evidence to support criticisms of the use of underprivileged area scores examined. Main outcome measures-Discrepancies between areas classified as deprived according to the index and areas known to require government funding; the extent of the bias towards family practitioner areas in London; and how the results of using the Jarman index compared with those when another deprivation index based on different indicators was used. Results-The use of electoral wards as geographical areas for which deprivation payments are made is unsatisfactory as the wards vary considerably in size. Of the 20 district health authorities with the highest underprivileged area scores in England, 12 were in London, and four of the six family practitioner committee areas with the highest scores were in London. No health authority or family practitioner committee area in the Northern region had one of the top 20 or 10 scores respectively. When an alternative deprivation index was used to determine the allocation of resources to doctors there was considerable variation compared with the Jarman index. Conclusion-The Jarman index underprivileged area score is an inappropriate measure to use for health care planning and distribution of resources. There is a need for a revised measure for allocating deprivation payments to general practitioners.			TALBOT, RJ (corresponding author), DONCASTER COLL,DIV CONTINUING EDUC,DONCASTER DN5 7SZ,ENGLAND.							ACHESON D, 1981, PRIMARY HLTH CARE IN; BRINDLE D, 1990, GUARDIAN        1018, P2; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; CARSTAIRS V, 1989, COMMUNITY MED, V11, P364; CHURCH AP, 1989, SOCIAL PROBLEMS CITY; Collins R., 1975, CONFLICT SOCIOLOGY; COOPERS, 1988, INTEGRATED ANAL REV; Hamnett C., 1979, SOCIAL PROBLEMS CITY; HATCH S, 1973, POLICY POLIT, V1, P223; HUTCHINSON A, 1989, BRIT MED J, V299, P1142, DOI 10.1136/bmj.299.6708.1142; IRVING D, 1984, INFORMATION HLTH SER; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JARMAN B, 1985, UNDERPRIVILEGED AREA; PAHL RE, 1979, SOCIAL PROBLEMS CITY; Smith D.M., 1979, SOCIAL PROBLEMS CITY, P13; THURNHURST C, 1985, STATISTICIAN, V34, P93; Townsend P., 1986, INEQUALITIES HLTH NO; Townsend PP., 1988, HLTH DEPRIVATION INE; WHITEHEAD M, 1988, HLTH DIVIDE INEQUALI; 1989, GENERAL PRACTICE NAT; 1983, DONCASTER METROPOLIT; 1990, FPCL4690 DEP HLTH; 1987, CMND249; 1990, DOCTOR          0201, P18; 1989, CMND555; 1990, LOADING DEPRIVED ARE	27	50	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					383	386		10.1136/bmj.302.6773.383	http://dx.doi.org/10.1136/bmj.302.6773.383			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EX858	2004143	Bronze, Green Published			2022-12-28	WOS:A1991EX85800026
J	WOOD, WB				WOOD, WB			EVIDENCE FROM REVERSAL OF HANDEDNESS IN C-ELEGANS EMBRYOS FOR EARLY CELL-INTERACTIONS DETERMINING CELL FATES	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LINEAGES; GLP-1	MANY animals with overall bilateral symmetry also exhibit some left-right asymmetries with generally invariant handedness. Therefore, the left-right embryonic axis must have a consistent polarity, whose origins and subsequent effects on development are not understood (reviewed in ref. 1). Caenorhabditis elegans exhibits such left-right asymmetries at all developmental stages. The embryonic cell lineage is asymmetric as well: although the animal is generally bilaterally symmetric, many of its contralaterally analogous cells arise from different lineages on the two sides of the embryo 2,3. I accomplished reversal of embryonic handedness by micromanipulation at the 6-cell stage, which resulted in mirror-image but otherwise normal development into healthy, fertile animals with all the usual left-right asymmetries reversed. This result demonstrates that in the 6-cell embryo the pair of anterior (AB) blastomeres on the right is equivalent to the pair on the left, and that the extensive differences in fates between lineally homologous derivatives of these cells on the two sides of the animals must be dictated by cell interactions, most of which are likely to occur early in embryogenesis.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	WOOD, WB (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOX 347,BOULDER,CO 80309, USA.							Bonfig R, 1925, Z WISS ZOOL ABT A, V124, P407; BROWN NA, 1990, DEVELOPMENT, V109, P1; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; DEPPE U, 1978, P NATL ACAD SCI USA, V75, P376, DOI 10.1073/pnas.75.1.376; Dunschen F., 1929, Archiv fuer Entwicklungsmechanik der Organismen Berlin, V115, P237; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; STRASSEN OZ, 1896, ARCH ENTWICKLUNGSMEC, V3, P27; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1983, COLD SPRING HARB SYM, V48, P443, DOI 10.1101/SQB.1983.048.01.049; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	18	147	148	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					536	538		10.1038/349536a0	http://dx.doi.org/10.1038/349536a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992354				2022-12-28	WOS:A1991EW57100071
J	ROBINSON, GE; BURREN, T; MACKIE, IJ; BOUNDS, W; WALSHE, K; FAINT, R; GUILLEBAUD, J; MACHIN, SJ				ROBINSON, GE; BURREN, T; MACKIE, IJ; BOUNDS, W; WALSHE, K; FAINT, R; GUILLEBAUD, J; MACHIN, SJ			CHANGES IN HEMOSTASIS AFTER STOPPING THE COMBINED CONTRACEPTIVE PILL - IMPLICATIONS FOR MAJOR SURGERY	BRITISH MEDICAL JOURNAL			English	Article							ORAL-CONTRACEPTIVES; COAGULATION; THROMBOSIS; DISEASE	Objective-To investigate the changes in haemostasis in the three months immediately after stopping the combined contraceptive pill. Design-Prospective randomised study. Setting-Family planning centre in London. Subjects-24 women aged 35-45 investigated before, during, and after six months' use of combined oral contraceptives containing 30-mu-g ethinyl oestradiol together with the progestogens desogestrel or gestodene. Main outcome measures and results-Blood samples were taken immediately before and after six months of oral contraceptive use and one, two, four, six, eight, and 12 weeks after the pill had been stopped. During the six months of oral contraceptive use the plasma concentration of factor X and fibrinogen increased and that of antithrombin III decreased. Between two and six weeks after stopping the pill a rebound phenomenon occurred with plasma concentrations of antithrombin III increasing (mean change from baseline at two weeks 0.06 IU/l and at six weeks 0.10 IU/l) and fibrinogen decreasing (0.26 g/l change at two weeks and 0.40 g/l at six weeks). Factor X concentrations fell gradually and the values at eight weeks were not significantly different from those found before the combined pill was started. Conclusion-The combined pill should be stopped at least four weeks before major surgery, which carries the risk of postoperative thrombosis, to allow the potentially prothrombotic haemostatic changes that occur during its use to be corrected.	MARGARET PYKE CTR STUDY & TRAINING FAMILY PLANNING,15 BATEMANS BLDG,SOHO SQ,LONDON W1V 5TW,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT HAEMATOL,LONDON W1,ENGLAND	University of London; University College London			MACKIE, Ian J/C-1587-2008					BONNAR J, 1987, AM J OBSTET GYNECOL, V157, P1042, DOI 10.1016/S0002-9378(87)80129-1; BOTTIGER LE, 1980, LANCET, V1, P1097; COHEN H, 1988, BRIT J HAEMATOL, V69, P259, DOI 10.1111/j.1365-2141.1988.tb07631.x; GALLUS AS, 1984, THROMB RES, V35, P513, DOI 10.1016/0049-3848(84)90283-4; GIDDINGS JC, 1980, BLOOD COAGULATION HA, P138; GUILLEBAUD J, 1988, BRIT MED J, V296, P786, DOI 10.1136/bmj.296.6624.786-a; GUILLEBAUD J, 1985, BRIT MED J, V291, P498, DOI 10.1136/bmj.291.6494.498; HAWKINS DF, 1979, HUMAN FERTILITY CONT; KOCH GG, 1980, INT STAT REV, V48, P249, DOI 10.2307/1402940; MACHIN SJ, 1989, LABORATORY HAEMATOLO, P263; MAMMEN EF, 1982, AM J OBSTET GYNECOL, V142, P781; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; SAGAR S, 1976, LANCET, V1, P509; SUELING H, 1988, BRIT MED J, V296, P447, DOI 10.1136/bmj.296.6620.447; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; VONCLAUSS A, 1957, ACTA HAEMAT, V17, P237; 1989, OUTLOOK, V7, P10	18	49	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					269	271		10.1136/bmj.302.6771.269	http://dx.doi.org/10.1136/bmj.302.6771.269			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998792	Green Published, Bronze			2022-12-28	WOS:A1991EX91900020
J	CAPSTICK, B; EDWARDS, P; MASON, D				CAPSTICK, B; EDWARDS, P; MASON, D			FOR DEBATE - COMPENSATION FOR MEDICAL ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Editorial Material											CAPSTICK, B (corresponding author), CAPSTICKS,LONDON SW15 2TT,ENGLAND.							CAPSTICK B, 1991, QUALITY COUNTS; CAPSTICK B, 1990, LANCET, V336, P931	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					230	232		10.1136/bmj.302.6770.230	http://dx.doi.org/10.1136/bmj.302.6770.230			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998769	Bronze, Green Published			2022-12-28	WOS:A1991EV22800035
J	HARDING, GKM; NICOLLE, LE; RONALD, AR; PREIKSAITIS, JK; FORWARD, KR; LOW, DE; CHEANG, M				HARDING, GKM; NICOLLE, LE; RONALD, AR; PREIKSAITIS, JK; FORWARD, KR; LOW, DE; CHEANG, M			HOW LONG SHOULD CATHETER-ACQUIRED URINARY-TRACT INFECTION IN WOMEN BE TREATED - A RANDOMIZED CONTROLLED-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							SINGLE-DOSE THERAPY; TRIMETHOPRIM-SULFAMETHOXAZOLE; NOSOCOMIAL INFECTION; NO THERAPY; BACTERIURIA; CYSTITIS	Objective: To determine the optimal management of catheter-acquired bacteriuria after short-term catheter use in women. Patients: Asymptomatic patients (119) with catheter-acquired bacteriuria were randomly assigned to receive no therapy, a single dose (320-1600 mg) of therapy with trimethoprim-sulfamethoxazole, or 10 days (160-800 mg twice daily) of therapy. Thirty-two patients with lower tract symptoms alone received a single dose or 10 days of therapy, and 10 patients with upper tract symptoms or signs received 10 days of therapy. Main Results: The mean and median durations of catheter use were 6 and 4 days, respectively. Bacteriuria resolved within 14 days without therapy in 15 of 42 (36%; 95% CI, 21% to 51%) asymptomatic patients. Seven of the remaining patients developed symptoms. Single-dose therapy resolved infection in 30 of 37 patients (81%; CI, 68% to 94%); 10 days of therapy resolved infection in 26 of 33 (79%; CI, 65% to 93%). For patients with lower tract symptoms alone, resolution rates with single-dose therapy or 10 days of therapy were similar (11 of 14 [79%] and 13 of 16 [81%], respectively). Ten days of therapy resolved infection in 6 of 9 (67%) patients with upper tract symptoms. Infection was resolved more often in women who were less-than-or-equal-to 65 years than in older women (62 of 70 [89%] versus 24 of 39 [62%]; P < 0.001). Bacteriuria resolved spontaneously more frequently in younger (14 of 19 [74%] compared with 1 of 23 older women [4%]; P < 0.001). Single-dose therapy resolved infection in 31 of 33 (94%) patients who were less-than-or-equal-to 65 years. Conclusions: Asymptomatic bacteriuria after short-term catheter use frequently becomes symptomatic and should be treated. For asymptomatic patients and patients with lower tract symptoms alone, single-dose therapy was as effective as 10 days of therapy; it was very effective in women who were less-than-or-equal-to 65 years. Bacteriuria resolved spontaneously within 14 days after catheter removal more commonly in women who were less-than-or-equal-to 65 years and both types of therapy were less effective in older women.	HLTH SCI CTR, INFECT CONTROL UNIT, WINNIPEG R3A 1R9, MANITOBA, CANADA; ST BONIFACE GEN HOSP, DEPT MICROBIOL, WINNIPEG R3K 0R1, MANITOBA, CANADA; UNIV MANITOBA, STAT PROGRAMMING, WINNIPEG R3E 0W3, MANITOBA, CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	HARDING, GKM (corresponding author), ST BONIFACE GEN HOSP, INFECT DIS SECT, ROOM A1105-409, TACHE AVE, WINNIPEG R2H 2A6, MANITOBA, CANADA.		Low, Donald/B-1726-2012	Ronald, Allan/0000-0002-5746-3490				BOSCIA JA, 1987, JAMA-J AM MED ASSOC, V257, P1067, DOI 10.1001/jama.257.8.1067; BUCKWOLD FJ, 1982, JAMA-J AM MED ASSOC, V247, P1839, DOI 10.1001/jama.247.13.1839; BUCKWOLD FJ, 1979, J CLIN MICROBIOL, V10, P275, DOI 10.1128/JCM.10.3.275-278.1979; BUTLER HK, 1968, J UROLOGY, V100, P567, DOI 10.1016/S0022-5347(17)62572-2; COUNTS GW, 1982, REV INFECT DIS, V4, P484; FIHN SD, 1988, ANN INTERN MED, V108, P350, DOI 10.7326/0003-4819-108-3-350; GARIBALDI RA, 1974, NEW ENGL J MED, V291, P215, DOI 10.1056/NEJM197408012910501; GARIBALDI RA, 1980, NEW ENGL J MED, V303, P316, DOI 10.1056/NEJM198008073030605; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HARDING GKM, 1978, JAMA-J AM MED ASSOC, V240, P1147, DOI 10.1001/jama.240.11.1147; HOOTON TM, 1985, JAMA-J AM MED ASSOC, V253, P387, DOI 10.1001/jama.253.3.387; KUNIN CM, 1966, NEW ENGL J MED, V274, P1155, DOI 10.1056/NEJM196605262742101; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; MORRISON AJ, 1986, ARCH INTERN MED, V146, P1549, DOI 10.1001/archinte.146.8.1549; NICOLLE LE, 1983, NEW ENGL J MED, V309, P1420, DOI 10.1056/NEJM198312083092304; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; NORRBY SR, 1990, REV INFECT DIS, V12, P458; PHILBRICK JT, 1985, ARCH INTERN MED, V145, P1672, DOI 10.1001/archinte.145.9.1672; PLATT R, 1983, LANCET, V1, P893; TOLKOFFRUBIN NE, 1982, REV INFECT DIS, V4, P444; TURCK M, 1981, AM J MED, V70, P651, DOI 10.1016/0002-9343(81)90590-8; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WARREN JW, 1978, NEW ENGL J MED, V299, P570, DOI 10.1056/NEJM197809142991103; WARREN JW, 1982, JAMA-J AM MED ASSOC, V248, P454; 1984, PERFORMANCE STANDARD	25	102	104	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					713	719		10.7326/0003-4819-114-9-713	http://dx.doi.org/10.7326/0003-4819-114-9-713			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012351				2022-12-28	WOS:A1991FJ11700001
J	WILENSKY, GR				WILENSKY, GR			MEDICARES PROPOSAL TO PAY HOSPITALS FOR CAPITAL COSTS UNDER THE PROSPECTIVE PAYMENT SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											WILENSKY, GR (corresponding author), HLTH CARE FINANCING ADM,BALTIMORE,MD, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1927	1927						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008017				2022-12-28	WOS:A1991FF76800005
J	RAHN, DW; MALAWISTA, SE				RAHN, DW; MALAWISTA, SE			LYME-DISEASE - RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT	ANNALS OF INTERNAL MEDICINE			English	Article							ERYTHEMA CHRONICUM MIGRANS; NERVOUS-SYSTEM MANIFESTATIONS; LINKED IMMUNOSORBENT-ASSAY; BORRELIA-BURGDORFERI; NEUROLOGIC MANIFESTATIONS; PENICILLIN; ARTHRITIS; TICK; ABNORMALITIES; SPIROCHETE	The incidence and the endemic range of Lyme disease in the United States have increased steadily since the disease was originally recognized in Lyme, Connecticut, in 1975. Because of the varied clinical manifestations of this illness and the use of unstandardized serologic testing methods, diagnosis is often uncertain and treatment outcomes are often difficult to evaluate. The antibiotic regimens that are commonly used in clinical practice have changed rapidly. They show much regional variation with little critical comparison of treatment results. The clinical diagnosis and the literature on the treatment of the various stages of Lyme disease are reviewed. The reported data are supplemented with recommendations based on 15 years of clinical experience with this illness.			RAHN, DW (corresponding author), YALE UNIV, SCH MED, RHEUMATOL SECT, POB 3333, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.				NIAMS NIH HHS [AR 40452, AR 07107] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040452, T32AR007107] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; BERGER BW, 1988, ANN NY ACAD SCI, V539, P346, DOI 10.1111/j.1749-6632.1988.tb31868.x; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; BURGDORFER W, 1989, RHEUM DIS CLIN N AM, V15, P775; CLARK JR, 1985, LARYNGOSCOPE, V95, P1341; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; DATTWYLER R J, 1990, Arthritis and Rheumatism, V33, pS85; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DINERMAN H, 1990, Arthritis and Rheumatism, V33, pS136; DIRINGER MN, 1987, ARTHRITIS RHEUM, V30, P705; DOTEVALL L, 1988, SCAND J INFECT DIS, P74; FAWCETT PT, 1989, ARTHRITIS RHEUM, V32, P1041, DOI 10.1002/anr.1780320814; GERBER MA, 1990, 4 INT C LYM BORR STO, P131; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HALPERIN JJ, 1990, NEUROLOGY, V40, P1340, DOI 10.1212/WNL.40.9.1340; HALPERIN JJ, 1989, NEUROLOGY, V39, P753, DOI 10.1212/WNL.39.6.753; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANSEN K, 1989, J CLIN MICROBIOL, V27, P545, DOI 10.1128/JCM.27.3.545-551.1989; HYDE FW, 1989, J CLIN MICROBIOL, V27, P58, DOI 10.1128/JCM.27.1.58-61.1989; JOHNSON RC, 1987, ANTIMICROB AGENTS CH, V31, P164, DOI 10.1128/AAC.31.2.164; LIU NY, 1989, ARTHRITIS RHEUM S, V32, pS32; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MACDONALD AB, 1987, NEW YORK STATE J MED, V87, P615; MAGNARELLI LA, 1989, JAMA-J AM MED ASSOC, V262, P3464, DOI 10.1001/jama.262.24.3464; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MARKOWITZ LE, 1986, JAMA-J AM MED ASSOC, V255, P3394, DOI 10.1001/jama.255.24.3394; MASSAROTTI E, 1990, Arthritis and Rheumatism, V33, pS37; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; NISHIO MJ, 1990, ARTHRITIS RHEUM S, V33, pR6; PACHNER AR, 1989, ARCH NEUROL-CHICAGO, V46, P790, DOI 10.1001/archneur.1989.00520430086023; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PERSING D H, 1990, Arthritis and Rheumatism, V33, pS36; PERSING DH, 1990, J CLIN MICROBIOL, V28, P566, DOI 10.1128/JCM.28.3.566-572.1990; PFISTER HW, 1989, ARCH NEUROL-CHICAGO, V46, P1190, DOI 10.1001/archneur.1989.00520470044025; PFISTER HW, 1990, 4 INT C LYM BORR STO, P165; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; RAHN DW, 1991, IN PRESS SEMIN ARTHR; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; REIK L, 1985, NEUROLOGY, V35, P267, DOI 10.1212/WNL.35.2.267; SCHLESINGER PA, 1985, ANN INTERN MED, V103, P67, DOI 10.7326/0003-4819-103-1-67; SCHOEN R T, 1990, Arthritis and Rheumatism, V33, pS85; SCHUTZER SE, 1990, LANCET, V335, P312, DOI 10.1016/0140-6736(90)90606-6; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; SIGAL LH, 1988, NEUROLOGY, V38, P1439, DOI 10.1212/WNL.38.9.1439; SIGAL LH, 1989, SEMIN ARTHRITIS RHEU, V18, P151, DOI 10.1016/0049-0172(89)90058-9; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STANEK G, 1990, NEW ENGL J MED, V322, P249, DOI 10.1056/NEJM199001253220407; STEER AC, 1983, ANN INTERN MED, V99, P767, DOI 10.7326/0003-4819-99-6-767; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1978, AM J EPIDEMIOL, V108, P312, DOI 10.1093/oxfordjournals.aje.a112625; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; TSAI TF, 1990, 4 INT C LYM BORR STO, P13; VANDERLINDE MR, 1990, BRIT HEART J, V63, P162, DOI 10.1136/hrt.63.3.162; WEBER K, 1988, PEDIATR INFECT DIS J, V7, P286, DOI 10.1097/00006454-198804000-00010; WEISS N L, 1990, Arthritis and Rheumatism, V33, pS37; WEYAND CM, 1989, ARTHRITIS RHEUM, V32, P1057, DOI 10.1002/anr.1780320902; WILLIAMS CL, 1988, ANN NY ACAD SCI, V539, P504, DOI 10.1111/j.1749-6632.1988.tb31922.x; 1990, CONNECTICUT EPIDEMIO, P10	72	219	225	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					472	481		10.7326/0003-4819-114-6-472	http://dx.doi.org/10.7326/0003-4819-114-6-472			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994795				2022-12-28	WOS:A1991FB64000008
J	PELLEGRINO, ED				PELLEGRINO, ED			FAMILIES SELF-INTEREST AND THE CADAVERS ORGANS - WHAT PRICE CONSENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											PELLEGRINO, ED (corresponding author), GEORGETOWN UNIV,CTR ADV STUDY ETH,WASHINGTON,DC 20057, USA.							BEAUCHAMP TL, 1989, PRINCIPLES BIOETHICS, P110; Blum L, 1980, FRIENDSHIP ALTRUISM; FRANKFURT H, 1989, IMPORTANCE WHAT WE C, P26; NAGEL T, 1978, POSSIBILITY ALTRUISM, P144; TITMUSS R, 1971, GIFT RELATIONSHIP HU, P245	5	48	49	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1305	1306		10.1001/jama.265.10.1305	http://dx.doi.org/10.1001/jama.265.10.1305			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995980				2022-12-28	WOS:A1991FA51100029
J	GOLINO, P; PISCIONE, F; WILLERSON, JT; CAPPELLIBIGAZZI, M; FOCACCIO, A; VILLARI, B; INDOLFI, C; RUSSOLILLO, E; CONDORELLI, M; CHIARIELLO, M				GOLINO, P; PISCIONE, F; WILLERSON, JT; CAPPELLIBIGAZZI, M; FOCACCIO, A; VILLARI, B; INDOLFI, C; RUSSOLILLO, E; CONDORELLI, M; CHIARIELLO, M			DIVERGENT EFFECTS OF SEROTONIN ON CORONARY-ARTERY DIMENSIONS AND BLOOD-FLOW IN PATIENTS WITH CORONARY ATHEROSCLEROSIS AND CONTROL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; VASOCONSTRICTOR ACTIVITY; SUBSELECTIVE MEASUREMENT; RECEPTOR ANTAGONISTS; THROMBOXANE; KETANSERIN; DOGS; 5-HYDROXYTRYPTAMINE; VASODILATOR; RESPONSES	Background. Studies in animals have shown that serotonin constricts coronary arteries if the endothelium is damaged, but in vitro studies have revealed a vasodilating effect on isolated coronary segments with an intact endothelium. To investigate the effect of serotonin in humans, we studied coronary-artery cross-sectional area and blood flow before and after the infusion of serotonin in seven patients with angiographically normal coronary arteries and in seven with coronary artery disease. Methods. We measured the cross-sectional area of the coronary artery by quantitative angiography and coronary blood flow with an intracoronary Doppler catheter. Measurements were obtained at base line and during intracoronary infusions of serotonin (0.1, 1, and 10-mu-g per kilogram of body weight per minute, for two minutes). We repeated the measurements after an infusion of ketanserin, an antagonist of serotonin receptors that is thought to block the effect of serotonin on receptors in the arterial wall but not in the endothelium. Results. In patients with normal coronary arteries, the highest dose of serotonin increased cross-sectional area by 52 percent (P < 0.001) and blood flow by 58 percent (P < 0.01). The effect was significantly potentiated by administration of ketanserin. In patients with coronary-artery atherosclerosis, serotonin reduced cross-sectional area by 64 percent (P < 0.001) and blood flow by 59 percent (P < 0.001). Ketanserin prevented this effect. Conclusions. Serotonin has a vasodilating effect on normal human coronary arteries; when the endothelium is damaged, as in coronary artery disease, serotonin has a direct, unopposed vasoconstricting effect. When considered with other evidence, these data suggest that platelet-derived factors such as serotonin may have a role in certain acute coronary ischemic syndromes.	NAPLES UNIV, SCH MED 2, DEPT INTERNAL MED, I-80131 NAPLES, ITALY; UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, HOUSTON, TX 77225 USA; TEXAS HEART INST, HOUSTON, TX 77025 USA	University of Naples Federico II; University of Texas System; University of Texas Health Science Center Houston; Texas Heart Institute	GOLINO, P (corresponding author), NAPLES UNIV, SCH MED 2, DIV CARDIOL, VIA SERGIO PANSINI 5, I-80131 NAPLES, ITALY.			GOLINO, Paolo/0000-0002-3590-6983; INDOLFI, Ciro/0000-0003-1241-6487				ASHTON JH, 1986, CIRCULATION, V73, P572, DOI 10.1161/01.CIR.73.3.572; ASHTON JH, 1987, CIRCULATION, V76, P952, DOI 10.1161/01.CIR.76.4.952; ASHTON JH, 1986, CIRC RES, V59, P568, DOI 10.1161/01.RES.59.5.568; AWOUTERS F, 1985, DRUG DEVELOP RES, V6, P263, DOI 10.1002/ddr.430060402; BENEDICT CR, 1986, CIRC RES, V58, P58, DOI 10.1161/01.RES.58.1.58; BRAZENOR RM, 1982, EUR J PHARMACOL, V81, P569, DOI 10.1016/0014-2999(82)90346-6; BRUM JM, 1984, CIRCULATION, V70, P1066, DOI 10.1161/01.CIR.70.6.1066; BUSH LR, 1984, CIRCULATION, V69, P1161, DOI 10.1161/01.CIR.69.6.1161; CAPPELLIBIGAZZI M, 1990, AM J PHYSIOL, V259, pH1161, DOI 10.1152/ajpheart.1990.259.4.H1161; CHU A, 1987, CIRC RES, V61, P81; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; COHEN ML, 1988, J CARDIOVASC PHARM, V11, pS25; COHEN RA, 1983, AM J PHYSIOL, V245, P1077; COHEN RA, 1983, SCIENCE, V221, P273, DOI 10.1126/science.6574604; DECATERINA R, 1984, CIRCULATION, V69, P889, DOI 10.1161/01.CIR.69.5.889; GOLINO P, 1990, J AM COLL CARDIOL, V15, P718, DOI 10.1016/0735-1097(90)90652-6; GOLINO P, 1989, CIRCULATION, V79, P154, DOI 10.1161/01.CIR.79.1.154; GOLINO P, 1988, CIRCULATION, V78, P701, DOI 10.1161/01.CIR.78.3.701; HEISTAD DD, 1984, CIRC RES, V54, P711, DOI 10.1161/01.RES.54.6.711; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; HOUSTON DS, 1985, AM J PHYSIOL, V248, pH389, DOI 10.1152/ajpheart.1985.248.3.H389; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; RUBANYI GM, 1987, J AM COLL CARDIOL, V9, P1243, DOI 10.1016/S0735-1097(87)80462-X; SCHMITZ JM, 1985, CIRC RES, V57, P223, DOI 10.1161/01.RES.57.2.223; SIBLEY DH, 1986, J AM COLL CARDIOL, V8, P1332, DOI 10.1016/S0735-1097(86)80305-9; SPEARS JR, 1983, CIRCULATION, V68, P453, DOI 10.1161/01.CIR.68.2.453; VANDENBERG EK, 1989, CIRCULATION, V79, P116, DOI 10.1161/01.CIR.79.1.116; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; VANNUETEN JM, 1981, J PHARMACOL EXP THER, V218, P217; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82; WILSON RF, 1986, CIRCULATION, V73, P444, DOI 10.1161/01.CIR.73.3.444	33	414	430	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					641	648		10.1056/NEJM199103073241001	http://dx.doi.org/10.1056/NEJM199103073241001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA144	1994246				2022-12-28	WOS:A1991FA14400001
J	APPLEBY, L				APPLEBY, L			SUICIDE DURING PREGNANCY AND IN THE 1ST POSTNATAL YEAR	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDER	Objectives-To calculate age adjusted mortality ratios for suicide by women in the first year after childbirth and during pregnancy, and to identify characteristics of postnatal suicide in childbearing women. Design-Retrospective study based on population data for England and Wales from 1973 to 1984. Subjects-Women aged 15-44 who committed suicide in the year after childbirth or during pregnancy. Main outcome measures-Observed to expected mortality ratios for the total postnatal sample, for five year age groups, for unmarried mothers, and for suicide after stillbirth; observed to expected mortality ratios for all suicides during pregnancy and for five year age groups; the timing of suicides in relation to delivery; and the frequency of the various methods of suicide. Results-The standardised mortality ratio for postnatal suicide was calculated to be 0.17-that is, the actual total was only one sixth of that expected. The low ratio was not found after stillbirth, which was associated with a rate six times that in all women after childbirth. The low ratio was less pronounced, but still present, in teenage mothers and in unmarried mothers. Women who committed suicide after childbirth most often did so in the first month, and there was a tendency to use violent methods. The standardised mortality ratio for suicide during pregnancy was calculated to be 0.05 of all pregnant women. Teenagers were at substantially increased risk. Conclusions-Women in the first year after childbirth and during pregnancy have a low risk of suicide despite their high rate of psychiatric morbidity. Underreporting of maternal suicides is unlikely to explain the findings, though it may affect their magnitude. Motherhood seems to protect against suicide. Concern for dependants may be an important focus for suicide prevention in clinical practice.			APPLEBY, L (corresponding author), INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND.							BECK AT, 1979, COGNITIVE THERAPY DE; Breslow N. E., 1987, STATISTICAL METHODS, VII; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KLEINER GJ, 1984, SUICIDE PREGNANCY; KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; O'Hara M. W., 1988, MOTHERHOOD MENTAL IL, P17; PAFFENBARGER RS, 1964, BRIT J PREV SOC MED, V18, P189; WATSON JP, 1984, BRIT J PSYCHIAT, V144, P453, DOI 10.1192/bjp.144.5.453; 1990, REPORT CONFIDENTIAL; [No title captured]; 1982, REPORT CONFIDENTIAL; ANN PUBLICATION OFFI; 1979, REPORT CONFIDENTIAL; 1973, ANN PUBLICATION OFFI; 1986, REPORT CONFDENTIAL E	17	185	189	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					137	140		10.1136/bmj.302.6769.137	http://dx.doi.org/10.1136/bmj.302.6769.137			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995132	Green Published, Bronze			2022-12-28	WOS:A1991EU02000018
J	SONIES, BC; DALAKAS, MC				SONIES, BC; DALAKAS, MC			DYSPHAGIA IN PATIENTS WITH THE POSTPOLIO SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROMUSCULAR SYMPTOMS; OLD POLIOMYELITIS	Background and Methods. Dysphagia may develop in some patients many years after an attack of acute paralytic poliomyelitis. To identify clinical or subclinical signs of oropharyngeal dysfunction, we examined 32 patients (mean age, 48.9 years) with the post-polio syndrome (defined by new weakness in the limbs). Of the 32 patients, 14 had symptoms of new swallowing difficulties, and 18 were asymptomatic in this respect; 12 had a history of bulbar involvement during acute poliomyelitis. Swallowing function was assessed objectively by ultrasonography, videofluoroscopy, and an oral motor index score for 10 components of oral function. Results. All but 1 of the 32 patients, regardless of whether they had new symptoms or previous bulbar involvement, had some abnormality on detailed testing of oropharyngeal function; only 2 patients had any signs of aspiration. The mean oral motor index score (a quantitative measure of oral sensorimotor function) in the patients was higher than that in age-matched normal subjects (P < 0.001). Videofluoroscopy showed abnormalities of varying severity, including unilateral bolus transport through the pharynx, pooling in the valleculae or pyriform sinuses, delayed pharyngeal constriction, and impaired tongue movements. On ultrasonography, the mean (+/- SD) duration of wet swallows was significantly longer in the symptomatic patients than in the asymptomatic patients (2.67 +/- 0.70 vs. 1.65 +/- 0.42 seconds). The four patients who were reexamined two years later had objective signs of worsening oropharyngeal function and corresponding new symptoms. Conclusions. In patients with the post-polio syndrome, the bulbar muscles often have clinical or subclinical signs of dysfunction. These abnormalities suggest that in bulbar neurons there is a slowly progressive deterioration similar to that in the muscles of the limbs.	NINCDS,NEUROMUSCULAR DIS SECT,RM 4N248,BLDG 10,BETHESDA,MD 20892; WARREN G MAGNUSON CLIN CTR,DEPT REHABIL MED,SPEECH PATHOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								BAKER AB, 1950, ARCH NEURO PSYCHIATR, V63, P257, DOI 10.1001/archneurpsyc.1950.02310200065007; BODIAN D, 1949, POLIOMYELITIS PAPERS, P62; BOSMA JF, 1976, PHYSL ORAL TISSUES, V2, P78; BROWN S, 1987, RES CLIN ASPECTS LAT, V23, P83; BUCHHOLZ D, 1987, RES CLIN ASPECTS LAT, V23, P55; CASHMAN NR, 1987, NEW ENGL J MED, V317, P7, DOI 10.1056/NEJM198707023170102; DALAKAS M, 1990, Current Opinion in Rheumatology, V2, P901; DALAKAS MC, 1984, REV INFECT DIS, V6, pS562; DALAKAS MC, 1986, NEW ENGL J MED, V314, P959, DOI 10.1056/NEJM198604103141505; DALAKAS MC, 1986, EUR NEUROL, V25, P381, DOI 10.1159/000116038; DALAKAS MC, 1988, NEUROLOGY, V38, P99, DOI 10.1212/WNL.38.1.99; DALAKAS MC, 1988, ADV CONT NEUROLOGY, V29, P51; DALAKAS MC, 1984, MIAMI S F, P73; DALAKAS MC, 1990, POSTPOLIO SYNDROME, P31; DALAKAS MC, 1987, RES CLIN ASPECTS LAT, V23, P241; Darley FL, 1975, MOTOR SPEECH DISORDE; Groher M, 1984, DYSPHAGIA DIAGNOSIS; HALSTEAD LS, 1987, RES CLIN ASPECTS LAT, V23; Logemann JA, 1986, DYSPHAGIA, V1, P34, DOI 10.1007/bf02408238; LOGEMANN JA, 1985, EVALUATION TREATMENT; LOGEMANN JA, 1983, MANUAL VIDEO FLUOROG; MUNSAAT TL, 1987, RES CLIN ASPECTS LAT, V23, P329; MUNSAT TL, 1990, POSTPOLIO SYNDROME; PEZESHKPOUR GH, 1988, ARCH NEUROL-CHICAGO, V45, P505, DOI 10.1001/archneur.1988.00520290033010; RAVITS J, 1990, MUSCLE NERVE, V13, P667, DOI 10.1002/mus.880130802; SHAWKER TH, 1984, ULTRASOUND ANN, P237; Sonies B C, 1988, Dysphagia, V3, P1, DOI 10.1007/BF02406274; SONIES BC, 1988, OTOLARYNG CLIN N AM, V21, P637; SONIES BC, 1987, DYSPHAGIA, V1, P178	29	61	61	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1162	1167		10.1056/NEJM199104253241703	http://dx.doi.org/10.1056/NEJM199104253241703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011159	Bronze			2022-12-28	WOS:A1991FH57200003
J	BURNUM, JF				BURNUM, JF			SECRETS ABOUT PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P309; BOK S, 1983, SECRETS ETHICS CONCE, P3; BOK S, 1979, LYING MORAL CHOICE P, P232; JONSEN AR, 1986, CLIN ETHICS PRACTICA, P65; MAPPES TA, 1986, BIOMEDICAL ETHICS, P51; PUMA JL, 1989, J GEN INTERN MED, V4, P413; VEATCH RM, 1981, THEORY MED ETHICS, P214	7	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1130	1133		10.1056/NEJM199104183241611	http://dx.doi.org/10.1056/NEJM199104183241611			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008187				2022-12-28	WOS:A1991FG91200010
J	LEVINSKY, NG; RETTIG, RA				LEVINSKY, NG; RETTIG, RA			THE MEDICARE END-STAGE RENAL-DISEASE PROGRAM - A REPORT FROM THE INSTITUTE-OF-MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NATL ACAD SCI,WASHINGTON,DC 20418	National Academies of Sciences, Engineering & Medicine	LEVINSKY, NG (corresponding author), BOSTON UNIV,MED CTR,BOSTON,MA 02118, USA.							EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GARCIA JR, 1990, STAFFING DIALYSIS UN; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1990, PRICE DIALYSIS HOSPI; HELD PJ, 1990, MORTALITY PRICE DIAL; Lohr K.N., 1990, MEDICARE STRATEGY QU, V1; Lohr KN, 1990, MEDICARE STRATEGY QU, V2; RENNIE D, 1981, NEW ENGL J MED, V304, P351, DOI 10.1056/NEJM198102053040609; RETTIG RA, IN PRESS KIDNEY FAIL; 1990, 1990 NAT I DIAB DIG; 1990, UNITED NETWORK ORGAN; 1990, HLTH CARE FINANCING; 1990, DISTRIBUTION ORGANS	14	63	63	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1143	1148		10.1056/NEJM199104183241628	http://dx.doi.org/10.1056/NEJM199104183241628			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008193	Bronze			2022-12-28	WOS:A1991FG91200027
J	GERN, JE; YANG, E; EVRARD, HM; SAMPSON, HA				GERN, JE; YANG, E; EVRARD, HM; SAMPSON, HA			ALLERGIC REACTIONS TO MILK-CONTAMINATED NONDAIRY PRODUCTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							FOOD ALLERGY; HYPERSENSITIVITY; CHILDREN		MT SINAI MED CTR,DIV CLIN IMMUNOL,NEW YORK,NY 10029; JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT ALLERGY IMMUNOL,BALTIMORE,MD 21205	Icahn School of Medicine at Mount Sinai; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00052] Funding Source: Medline; NIAID NIH HHS [AI-24439, AI-07007-11A2] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BOCK SA, 1987, PEDIATRICS, V79, P683; DEWDNEY JM, 1984, J ROY SOC MED, V77, P866, DOI 10.1177/014107688407701013; FREEDMAN AM, 1989, WALL STREET J, P1; FRIEND BA, 1983, XENOBIOTICS FOODS FE, P47; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; PASTORELLO EA, 1989, J ALLERGY CLIN IMMUN, V84, P475, DOI 10.1016/0091-6749(89)90360-6; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1989, J ALLERGY CLIN IMMUN, V84, P1062; SAMPSON HA, IN PRESS J PEDIATR; SAMPSON HA, IN PRESS ADVERSE REA; SEIGEL BB, 1959, B WORLD HEALTH ORGAN, V21, P703; 1969, WHO TECH REP SER, V430, P5; 1990, FED REGISTER, V55, P7289; 1990, FED REGISTER, V55, P26422	17	118	119	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					976	979		10.1056/NEJM199104043241407	http://dx.doi.org/10.1056/NEJM199104043241407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	2002820				2022-12-28	WOS:A1991FE37600007
J	WILSON, ME; VONREYN, CF; FINEBERG, HV				WILSON, ME; VONREYN, CF; FINEBERG, HV			INFECTIONS IN HIV-INFECTED TRAVELERS - RISKS AND PREVENTION	ANNALS OF INTERNAL MEDICINE			English	Review							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; ISOSPORA-BELLI INFECTION; AIDS-RELATED COMPLEX; VISCERAL LEISHMANIASIS; VIRUS HIV; UNITED-STATES; SALMONELLA BACTEREMIA; CAMPYLOBACTER-JEJUNI; INTERNATIONAL TRAVEL	Objective: To review risks for infection and to outline strategies to protect the health of travelers infected with human immunodeficiency virus (HIV). Data Sources: Original reports and summaries of the geographic distribution and frequency of infections as well as of special risks these infections impose on HIV-infected persons. The recommendations incorporate guidelines published by the Centers for Disease Control (CDC) and the World Health Organization. Study Selection: Sources containing the most recent, pertinent information. Data Synthesis: Infections of the gastrointestinal tract are common in all travelers to developing countries and are likely to be more frequent, severe, and difficult to treat in HIV-infected persons. Prominent among the respiratory tract infections that pose special risks to HIV-infected travelers are influenza, measles, and fungal infections with geographically focal distributions. The most common vector-borne infection, malaria, appears to present relatively little, if any, incremental risk to the HIV-infected traveler. Persons with HIV infection respond less vigorously to vaccines and have a higher frequency of adverse reactions to antimicrobial agents. Nevertheless, immunizations and chemoprophylaxis can reduce the risk for many travel-related infections. Additionally, there are protective measures that travelers can take to minimize exposure to pathogens. Conclusions: By understanding the risks for disease in different destinations, assessing patients' HIV status, counseling patients about travel plans and personal protective measures, appropriately using vaccines and chemoprophylaxis, as well as instituting early treatment of infection, physicians can help HIV-infected patients to preserve their health during travel.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, HANOVER, NH 03756 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Dartmouth College	WILSON, ME (corresponding author), MT AUBURN HOSP, DIV INFECT DIS, 330 MT AUBURN ST, CAMBRIDGE, MA 02238 USA.							AMPEL NM, 1989, REV INFECT DIS, V11, P897; ANTUNES F, 1987, T ROY SOC TROP MED H, V81, P595, DOI 10.1016/0035-9203(87)90419-6; ARNDT KA, 1976, JAMA-J AM MED ASSOC, V235, P918, DOI 10.1001/jama.235.9.918; BASKIN DH, 1987, AM J GASTROENTEROL, V82, P338; BATTEGAY M, 1989, LANCET, V2, P1100; BENEZRA D, 1987, ANN INTERN MED, V107, P944, DOI 10.7326/0003-4819-107-6-944_1; BERENGUER J, 1989, ANN INTERN MED, V111, P129, DOI 10.7326/0003-4819-111-2-129; BERNARD E, 1989, J INFECT DIS, V159, P143, DOI 10.1093/infdis/159.1.143; BLACK RE, 1990, REV INFECT DIS, V12, pS73; BLASER MJ, 1989, AM J MED, V86, P105, DOI 10.1016/0002-9343(89)90239-8; BOLIVAR R, 1978, J INFECT DIS, V137, P324, DOI 10.1093/infdis/137.3.324; BOUDES P, 1989, JAMA-J AM MED ASSOC, V262, P2386, DOI 10.1001/jama.1989.03430170046020; BRONNIMANN DA, 1987, ANN INTERN MED, V106, P372, DOI 10.7326/0003-4819-106-3-372; Bryan R. T., 1990, Principles and practice of infectious diseases., P2130; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CLAUVEL JP, 1986, T ROY SOC TROP MED H, V80, P1010, DOI 10.1016/0035-9203(86)90310-X; COHEN JP, 1989, JAMA-J AM MED ASSOC, V261, P245, DOI 10.1001/jama.1989.03420020097023; COLEBUNDERS R, 1987, AM J GASTROENTEROL, V82, P859; COSTEL EE, 1984, SOUTHERN MED J, V77, P927, DOI 10.1097/00007611-198407000-00035; CUNNINGHAM AL, 1988, J INFECT DIS, V158, P386, DOI 10.1093/infdis/158.2.386; CURRAN WJ, 1900, WORLDWIDE SURVEY AID; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; DICK GWA, 1952, J HYG-CAMBRIDGE, V50, P376, DOI 10.1017/S0022172400019653; DUBOIS EL, 1978, SEMIN ARTHRITIS RHEU, V8, P33; DUCKETT M, 1989, AIDS, V3, pS231, DOI 10.1097/00002030-198901001-00034; DWORKIN B, 1986, AM J MED, V80, P965, DOI 10.1016/0002-9343(86)90646-7; ELSSER KA, 1986, CAN MED ASSOC J, V135, P211; FEELEY JC, 1980, CHOLERA RELATED DIAR, P204; FERNANDEZGUERRERO ML, 1987, AM J MED, V83, P1098, DOI 10.1016/0002-9343(87)90948-X; FISCHL MA, 1986, ARCH INTERN MED, V146, P113, DOI 10.1001/archinte.146.1.113; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FREESTONE DS, 1988, VACCINES, P387; GIANNELLA RA, 1973, ANN INTERN MED, V78, P271, DOI 10.7326/0003-4819-78-2-271; GILMORE N, 1989, AIDS, V3, pS225, DOI 10.1097/00002030-198901001-00033; GLASER JB, 1985, ANN INTERN MED, V102, P189, DOI 10.7326/0003-4819-102-2-189; GODIWALA T, 1987, ANN INTERN MED, V106, P908, DOI 10.7326/0003-4819-106-6-908_2; GORBACH S, 1986, INFECTIVE DIARRHOEA, P179; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GOSTIN LO, 1990, NEW ENGL J MED, V322, P1743, DOI 10.1056/NEJM199006143222411; GRAYBILL JR, 1988, J INFECT DIS, V158, P623, DOI 10.1093/infdis/158.3.623; HADLER SC, 1988, ANN INTERN MED, V109, P92, DOI 10.7326/0003-4819-109-2-92; HILL DR, 1989, ANN INTERN MED, V111, P699, DOI 10.7326/0003-4819-111-9-699; HILL DR, 1988, ANN INTERN MED, V108, P839, DOI 10.7326/0003-4819-108-6-839; HOOK EW, 1989, J INFECT DIS, V160, P530, DOI 10.1093/infdis/160.3.530; HRDY DB, 1987, REV INFECT DIS, V9, P461; HURVITZ D, 1965, NEW ENGL J MED, V273, P23, DOI 10.1056/NEJM196507012730105; JACOBS JL, 1985, ANN INTERN MED, V102, P186, DOI 10.7326/0003-4819-102-2-186; JACOBSON MA, 1988, AM J MED, V85, P172, DOI 10.1016/S0002-9343(88)80337-1; JANOFF EN, 1988, J INFECT DIS, V157, P798, DOI 10.1093/infdis/157.4.798; JOKIPII AMM, 1985, LANCET, V2, P487; KUBLI D, 1987, BRIT MED J, V295, P169, DOI 10.1136/bmj.295.6591.169; LABRO MT, 1988, ANTIMICROB AGENTS CH, V32, P1124, DOI 10.1128/AAC.32.8.1124; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P502, DOI 10.7326/0003-4819-109-6-502; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEVINE MM, 1989, PEDIATR INFECT DIS J, V8, P374, DOI 10.1097/00006454-198906000-00010; MAAYAN S, 1987, AM J MED, V83, P945, DOI 10.1016/0002-9343(87)90656-5; MALEBRANCHE R, 1983, LANCET, V2, P873; MANDELL W, 1986, JAMA-J AM MED ASSOC, V255, P3116, DOI 10.1001/jama.1986.03370220078021; MARKOWITZ LE, 1988, INT J EPIDEMIOL, V17, P187, DOI 10.1093/ije/17.1.187; MCLAUGHLIN M, 1988, PEDIATRICS, V82, P229; MENDEZ H, 1988, 4TH INT C AIDS STOCK; MIOTTI PG, 1989, JAMA-J AM MED ASSOC, V262, P779, DOI 10.1001/jama.262.6.779; MIRO JM, 1988, ANN INTERN MED, V109, P342, DOI 10.7326/0003-4819-109-4-342; MONTALBAN C, 1989, REV INFECT DIS, V11, P655; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; MORROW RH, 1989, AIDS, V3, pS79, DOI 10.1097/00002030-198901001-00012; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; MVULA M, 1988, 4TH INT C AIDS STOCK, V6; NADELMAN RB, 1985, ARCH INTERN MED, V145, P1968, DOI 10.1001/archinte.145.11.1968; NAVIN TR, 1984, REV INFECT DIS, V6, P313; NELSON KE, 1988, ANN INTERN MED, V109, P383, DOI 10.7326/0003-4819-109-5-383; NGUYENDINH P, 1987, B WORLD HEALTH ORGAN, V65, P607; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; OSEASOHN R, 1988, VACCINES, P362; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; PATCHEN LC, 1989, NEW ENGL J MED, V321, P1415; PERLMAN DM, 1988, ANN INTERN MED, V108, P540, DOI 10.7326/0003-4819-108-4-540; PHILLIPSHOWARD PA, 1990, LANCET, V335, P119, DOI 10.1016/0140-6736(90)90596-W; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; RAVIGLIONE MC, 1988, ARCH INTERN MED, V148, P2683, DOI 10.1001/archinte.148.12.2683; RIZZI M, 1988, T ROY SOC TROP MED H, V82, P565, DOI 10.1016/0035-9203(88)90509-3; RYAN CA, 1989, REV INFECT DIS, V11, P1; SALMERON G, 1983, AM J MED, V75, P19, DOI 10.1016/0002-9343(83)91266-4; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SHAFFER N, 1989, J INFECT DIS, V159, P596, DOI 10.1093/infdis/159.3.596; SHERIDAN JF, 1981, INFECT IMMUN, V31, P419, DOI 10.1128/IAI.31.1.419-429.1981; SMITH DE, 1988, T ROY SOC TROP MED H, V82, P654; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; SNYDER JD, 1982, JAMA-J AM MED ASSOC, V247, P2268, DOI 10.1001/jama.1982.03320410050031; SORVILLO F, 1990, NEW ENGL J MED, V322, P131; SPERBER SJ, 1987, REV INFECT DIS, V9, P925; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; STURCHLER D, 1990, NEW ENGL J MED, V322, P1752; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; TSAI TF, 1986, J INFECT DIS, V154, P726, DOI 10.1093/infdis/154.4.726; ULLRICH R, 1989, ANN INTERN MED, V111, P15, DOI 10.7326/0003-4819-111-1-15; UNGAR BLP, 1989, ARCH INTERN MED, V149, P894, DOI 10.1001/archinte.149.4.894; VOLLET JJ, 1979, J MED VIROL, V4, P81, DOI 10.1002/jmv.1890040202; VONREYN CF, 1990, B WORLD HEALTH ORGAN, V68, P251; VONREYN CF, 1987, LANCET, V2, P669; WABWIREMANGEN F, 1989, AM J TROP MED HYG, V41, P504, DOI 10.4269/ajtmh.1989.41.504; WHIMBEY E, 1986, ANN INTERN MED, V104, P511, DOI 10.7326/0003-4819-104-4-511; WILSON M, 1991, WORLD GUIDE INFECTIO; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; YEBRA M, 1988, ANN INTERN MED, V108, P490, DOI 10.7326/0003-4819-108-3-490_2; 1989, WEEKLY EPIDEMIOLOGIC, V64, P247; IN PRESS MMWR; 1988, MMWR, V37, P3; 1990, MMWR, V39, P14; 1988, MMWR, V37, P183; 1988, MMWR, V37, P64; 1990, HHS CDC908290 PUBL; 1987, MMWR, V36, P795; 1966, JAMA-J AM MED ASSOC, V198, P671; SUMMARY HLTH INFORMA; 1990, INT TRAVEL HLTH VACC; 1988, MMWR, V37, P181; 1990, MED LETT DRUGS THER, V32, P13; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1; 1985, MMWR, V34, P227; 1987, WEEKLY EPIDEMIOLOGIC, V62, P281	124	50	52	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					582	592		10.7326/0003-4819-114-7-582	http://dx.doi.org/10.7326/0003-4819-114-7-582			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001092				2022-12-28	WOS:A1991FD66100012
J	WIERSMA, SR; ORTEGA, J; SOBEL, E; WEINBERG, KI				WIERSMA, SR; ORTEGA, J; SOBEL, E; WEINBERG, KI			CLINICAL IMPORTANCE OF MYELOID-ANTIGEN EXPRESSION IN ACUTE LYMPHOBLASTIC-LEUKEMIA OF CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER-STUDY-GROUP; PROGNOSTIC-SIGNIFICANCE; LINEAGE LEUKEMIA; DISCRETE STAGES; DIFFERENTIATION; LYMPHOMA; CLASSIFICATION; TRANSLOCATION; PHENOTYPES; PROTOCOL	Background. Leukemic cells in 15 to 25 percent of patients with acute lymphoblastic leukemia (ALL) express myeloid antigens as well as lymphoid antigens (the latter reflecting B-cell or T-cell lineage). The relations of myeloid-antigen expression to other features of ALL and to prognosis have been controversial. Methods. We analyzed clinical and laboratory features present at diagnosis in 236 consecutive cases of ALL in children. Immunophenotyping, including single- and dual-fluorescence analyses, was used to classify leukemic cells as B or T lymphoblasts and also to identify myeloid-antigen expression - the simultaneous expression of lymphoid-associated antigens and at least one of three myeloid-associated antigens and at least one of three myeloid-associated antigens (CD33, CD13, and CD14) on cells classified as L1 or L2 according to the French-American-British system. Results. Forty-five of 185 patients with B-lineage ALL had myeloid-antigen expression, as did 8 of 41 patients with T-lineage ALL. In 10 patients, the lineage could not be determined. Myeloid-antigen expression was associated with L2 morphology (P < 0.05), but it did not correlate with other prognostic features recognized previously. Multivariate analysis showed that myeloid-antigen expression was an important predictor of relapse in childhood ALL and the most significant prognostic factor statistically (P < 0.0001). A white-cell count greater-than-or-equal-to 50 x 10(9) per liter at diagnosis was also an important and highly significant prognostic feature (P < 0.001). After 40 months, the estimated disease-free survival for patients with ALL was 84 percent for those without myeloid-antigen expression and with a low white-cell count, 57 percent for those without myeloid-antigen expression and with a high white-cell count, 47 percent for those with myeloid-antigen expression and a low white-cell count, and 26 percent for those with myeloid-antigen expression and a high white-cell count (P < 0.00001). Conclusions. Myeloid-antigen expression is an important independent predictor of a poor response to chemotherapy in childhood ALL.	UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90089; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California								ARTHUR DC, 1982, BLOOD, V59, P96; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BLEYER WA, 1986, MED PEDIATR ONCOL, V14, P271, DOI 10.1002/mpo.2950140506; CIVIN CI, 1990, EXP HEMATOL, V18, P461; COX DR, 1972, J R STAT SOC B, V34, P187; CROCE CM, 1985, BLOOD, V65, P1; DUQUEHAMMERSHAIMB L, 1983, CANCER, V52, P39, DOI 10.1002/1097-0142(19830701)52:1<39::AID-CNCR2820520109>3.0.CO;2-S; FOON KA, 1986, BLOOD, V68, P1; GAYNON P, 1985, P AM SOC CLIN ONCOL, V4, P173; GAYNON PS, 1988, LANCET, V2, P921; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GREAVES MF, 1986, BLOOD, V67, P1; GRIESINGER F, 1989, J EXP MED, V169, P1101, DOI 10.1084/jem.169.3.1101; HANECAK R, 1989, MOL CELL BIOL, V9, P2264, DOI 10.1128/MCB.9.5.2264; HERSHFIELD MS, 1984, P NATL ACAD SCI-BIOL, V81, P253, DOI 10.1073/pnas.81.1.253; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERSEY JH, 1979, AM J CLIN PATHOL, V72, P746; LAWLESS JF, 1982, STATISTICAL MODELS M; MCCULLOCH EA, 1983, BLOOD, V62, P1; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; MIRRO J, 1985, BLOOD, V66, P1115; MIRRO J, 1986, BLOOD, V67, P689; NADLER LM, 1984, J CLIN INVEST, V74, P332, DOI 10.1172/JCI111428; NEAME PB, 1985, BLOOD, V65, P142; PUI CH, 1990, BLOOD, V75, P198; PUI CH, 1984, BRIT J HAEMATOL, V56, P121, DOI 10.1111/j.1365-2141.1984.tb01277.x; REAMAN G, 1989, P AN M AM SOC CLIN, V8, P211; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RIEHM H, 1983, LEUKEMIA RES ADV CEL, P251; ROBISON LL, 1980, AM J PEDIAT HEMATOL, V2, P5; SALLAN SE, 1980, BLOOD, V55, P395; SMITH LJ, 1983, BLOOD, V61, P1138; SOBOL RE, 1987, NEW ENGL J MED, V316, P111; STASS S, 1984, BLOOD, V64, P701; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; STOCKINGER H, 1984, J NATL CANCER I, V73, P7	36	172	176	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					800	808		10.1056/NEJM199103213241204	http://dx.doi.org/10.1056/NEJM199103213241204			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997852				2022-12-28	WOS:A1991FC44200004
J	SEPKOWITZ, KA; TELZAK, EE; GOLD, JWM; BERNARD, EM; BLUM, S; CARROW, M; DICKMEYER, M; ARMSTRONG, D				SEPKOWITZ, KA; TELZAK, EE; GOLD, JWM; BERNARD, EM; BLUM, S; CARROW, M; DICKMEYER, M; ARMSTRONG, D			PNEUMOTHORAX IN AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; FEATURES	Objective: To determine risk factors for the development of pneumothorax in p Design: Prospective cohort study. Setting: Tertiary care center. Patients: Of 1030 patients with AIDS who were followed at Memorial Sloan-Kettering Cancer Center between 1 January 1980 and 30 September 1989, 20 (2%) developed pneumothorax that was unrelated to trauma or a pulmonary procedure. Results: Of 20 patients with AIDS who presented with pneumothorax, 19 had compelling evidence of concurrent Pneumocystis carinii pneumonia. Using bivariate analysis, patients receiving aerosol pentamidine prophylaxis (relative risk, 17.6) and those with a history of P. carinii pneumonia (relative risk, 14.5) were more likely to develop pneumothorax. By Mantel-Haenszel stratified analysis, aerosol pentamidine use was a statistically significant risk factor independent of a history of P. carinii pneumonia. The pneumothorax-related mortality rate was 10% and there was considerable morbidity. Conclusions: Patients with AIDS at the highest risk for developing pneumothorax are those with a history of P. carinii pneumonia who are receiving aerosol pentamidine prophylaxis but who nevertheless develop P. carinii pneumonia. The benefits of aerosol pentamidine prophylaxis in these patients far outweigh this risk. Pneumocystis carinii pneumonia should be considered as the most likely diagnosis in any patient with AIDS who develops a pneumothorax.	MEM SLOAN KETTERING CANC CTR, INFECT DIS SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	Memorial Sloan Kettering Cancer Center; New York City Department of Health & Mental Hygiene					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027669] Funding Source: NIH RePORTER; NIAID NIH HHS [5 UO1 AI27669-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFESSA B, 1988, ARCH INTERN MED, V148, P2651, DOI 10.1001/archinte.148.12.2651; BERNARD EM, 1989, 5 P INT C AIDS MONTR; BYRNES TA, 1989, J THORAC CARDIOV SUR, V98, P546; DELORENZO LJ, 1987, CHEST, V91, P323, DOI 10.1378/chest.91.3.323; DOPPMAN JL, 1975, RADIOLOGY, V114, P39, DOI 10.1148/114.1.39; ENG RHK, 1987, ARCH INTERN MED, V147, P746, DOI 10.1001/archinte.147.4.746; FELZENBERG JD, 1987, CHEST, V91, P934, DOI 10.1378/chest.91.6.934a; FEUERSTEIN IM, 1990, RADIOLOGY, V174, P697, DOI 10.1148/radiology.174.3.2305052; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEISHER AG, 1988, ANN THORAC SURG, V45, P21, DOI 10.1016/S0003-4975(10)62388-0; GOODMAN PC, 1986, AM J ROENTGENOL, V147, P29, DOI 10.2214/ajr.147.1.29; HOPEWELL PC, 1985, CHEST, V87, P104, DOI 10.1378/chest.87.1.104; JACOBSON SJ, 1989, 5 P INT C AIDS MONTR; JOE L, 1986, ARCH INTERN MED, V146, P1816, DOI 10.1001/archinte.146.9.1816; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; LEE M, 1990, CHEST, V97, P510, DOI 10.1378/chest.97.2.510-c; LEOUNG GS, 1989, 5 P INT C AIDS MONTR; LOVE L, 1954, ANN INTERN MED, V40, P153, DOI 10.7326/0003-4819-40-1-153; MARTINEZ CM, 1988, CHEST, V94, P1317, DOI 10.1378/chest.94.6.1317b; MELTON LJ, 1979, AM REV RESPIR DIS, V120, P1379; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; NEWSOME GS, 1989, 5 P INT C AIDS MONTR; SANDHU JS, 1989, RADIOLOGY, V173, P33, DOI 10.1148/radiology.173.1.2789413; SCANNELL KA, 1990, CHEST, V97, P479, DOI 10.1378/chest.97.2.479; SELIK RM, 1987, AIDS, V1, P175; SEPKOWITZ KA, 1989, 5 P INT C AIDS MONTR; SHERMAN M, 1986, CHEST, V90, P609, DOI 10.1378/chest.90.4.609; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WOLLSCHLAGER CM, 1984, CHEST, V85, P197, DOI 10.1378/chest.85.2.197; 1990, CHEST, V97, P510	30	104	106	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					455	459		10.7326/0003-4819-114-6-455	http://dx.doi.org/10.7326/0003-4819-114-6-455			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994791				2022-12-28	WOS:A1991FB64000004
J	BREO, DL				BREO, DL			AIDS WARRIOR WALLACE,JOYCE HOPES TO SHELTER HOMELESS HOOKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1313	&		10.1001/jama.265.10.1313	http://dx.doi.org/10.1001/jama.265.10.1313			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995983				2022-12-28	WOS:A1991FA51100032
J	FRIEDMAN, HD; DRACKER, RA				FRIEDMAN, HD; DRACKER, RA			INTRAVASCULAR ERYTHROPHAGOCYTOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NEUTROPHILS				FRIEDMAN, HD (corresponding author), SUNY HLTH SCI CTR, DEPT PATHOL, 750 E ADAMS ST, SYRACUSE, NY 13210 USA.							Connal A, 1912, J PATHOL BACTERIOL, V16, P502; COOPER MB, 1950, BLOOD, V5, P678, DOI 10.1182/blood.V5.7.678.678; DACIE JV, 1962, HAEMOLYTIC ANAEMIA 1, P98; FORSLID J, 1985, IMMUNOLOGY, V55, P97; GASSER C, 1952, SCHWEIZ MED WSCHR, V82, P42; HERNANDEZ JA, 1984, AM J CLIN PATHOL, V81, P787, DOI 10.1093/ajcp/81.6.787; HOPKINS JG, 1910, ARCH INTERN MED, V6, P270; Huber O, 1912, DEUT MED WOCHENSCHR, V38, P1923, DOI 10.1055/s-0029-1189869; Huck JG, 1923, B JOHNS HOPKINS HOSP, V34, P335; MacKay I, 1939, BRIT MED J, V1, P494, DOI 10.1136/bmj.1.4079.494; REINER AP, 1988, MEDICINE, V67, P369, DOI 10.1097/00005792-198811000-00002; SCHUBOTHE H, 1955, KLIN WOCHENSCHR, V33, P272, DOI 10.1007/BF01467553; ZINKHAM WH, 1952, BLOOD, V7, P592, DOI 10.1182/blood.V7.6.592.592; ZUELZER WW, 1949, JAMA-J AM MED ASSOC, V141, P185, DOI 10.1001/jama.1949.02910030015004	14	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1082	1082		10.1001/jama.265.9.1082	http://dx.doi.org/10.1001/jama.265.9.1082			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995990				2022-12-28	WOS:A1991EZ47400009
J	CAINE, N; HARRISON, SCW; SHARPLES, LD; WALLWORK, J				CAINE, N; HARRISON, SCW; SHARPLES, LD; WALLWORK, J			PROSPECTIVE-STUDY OF QUALITY-OF-LIFE BEFORE AND AFTER CORONARY-ARTERY BYPASS-GRAFTING	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURGERY; HEALTH	Objectives - Measurement of changes in patients' perceptions of how differing states of health affect their lives and determination of the ability of preoperative variables to predict outcome after coronary artery bypass grafting. Design - Prospective study with completion of questionnaires before coronary artery bypass grafting and at three months, one year, and five years afterwards. Setting - Regional cardiothoracic centre. Patients - 100 Male patients all aged below 60 at the time of operation, who were patients of two cardiothoracic surgeons. Main outcome measures - Patients' assessment of their health state in terms of functional capacity and aspects of distress, according to the Nottingham health profile and outcome of operation in terms of changes in symptoms, working life, and daily activities determined by self completed study questionnaires before operation and at three and six months afterwards. Results - Intermediate one year results are reported. The differences between the Nottingham health profile scores before operation and at three months afterwards were significantly different (p < 0.01), indicating an appreciable improvement in general health state, and at one year compared favourably with those from a normal male population. Analysis of responses to the study questionnaire showed that 65 of 89 patients (73%) were working at one year after operation with a further seven (8%) maintaining that they were fit to work but unable to find employment. The proportion of patients complaining of chest pain fell from 90% (88/98) before grafting to 19% (17/89) at one year after coronary artery bypass grafting, when 91% (81/89) patients maintained that their condition was either completely better or definitely improved. The significant positive factors affecting return to work and home activities were working before operation, short wait for operation, absence of breathlessness, and low physical mobility score in the Nottingham health profile (all p < 0.001). Conclusions - Improvements were evident in general health state, symptoms, and activity at three months and one year after coronary artery bypass graft surgery. Interventions likely to influence outcomes included reduction in waiting times for operation; rehabilitation initiatives; and more attention to the quality of information given to patients, their relatives, and the community.	PAPWORTH HOSP, CAMBRIDGE CB3 8RE, ENGLAND; UNIV CAMBRIDGE, DEPT COMMUNITY MED, CAMBRIDGE, ENGLAND; MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	Papworth Hospital; University of Cambridge; MRC Biostatistics Unit				Sharples, Linda/0000-0003-0894-966X				BUXTON MR, 1985, COSTS BENEFITS HEART; CAY E L, 1988, European Heart Journal, V9, P74; DANCHIN N, 1988, EUR HEART J, V9, P454, DOI 10.1093/oxfordjournals.eurheartj.a062524; ENGLISH TAH, 1984, BRIT MED J, V289, P1205, DOI 10.1136/bmj.289.6453.1205; GEHRING J, 1988, European Heart Journal, V9, P109; HUNT SM, 1984, J EPIDEMIOL COMMUN H, V38, P156, DOI 10.1136/jech.38.2.156; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JENKINS CD, 1983, JAMA-J AM MED ASSOC, V250, P782, DOI 10.1001/jama.250.6.782; KORNFELD DS, 1982, CIRCULATION, V66, P24; LAIRDMEETER K, 1989, EUR HEART J, V10, P917, DOI 10.1093/oxfordjournals.eurheartj.a059402; MAYOU R, 1987, Q J MED, V62, P239; MCEWEN J, 1985, MEASURING SOCIAL BEN, P75; MONPERE C, 1988, European Heart Journal, V9, P48; MORTON JR, 1982, AM J SURG, V143, P417, DOI 10.1016/0002-9610(82)90189-1; MYERS WO, 1985, ANN THORAC SURG, V40, P245, DOI 10.1016/S0003-4975(10)60037-9; OAKLEY CM, 1987, Q J MED, V62, P181; SPIEGELHALTER DJ, 1982, STATISTICIAN, V31, P19; WALLWORK J, 1985, QUALITY LIFE CARDIOV, V1, P317; WALTER P J, 1988, European Heart Journal, V9, P58	19	135	137	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1991	302	6775					511	516		10.1136/bmj.302.6775.511	http://dx.doi.org/10.1136/bmj.302.6775.511			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012849	Green Published, Bronze			2022-12-28	WOS:A1991FB05500024
J	JACOBS, KM; DONOGHUE, JP				JACOBS, KM; DONOGHUE, JP			RESHAPING THE CORTICAL MOTOR MAP BY UNMASKING LATENT INTRACORTICAL CONNECTIONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NMDA RECEPTORS; CORTEX; INHIBITION; NEURONS; INVITRO	The primary motor cortex (MI) contains a map organized so that contralateral limb or facial movements are elicited by electrical stimulation within separate medial to lateral MI regions. Within hours of a peripheral nerve transection in adult rats, movements represented in neighboring MI areas are evoked from the cortical territory of the affected body part. One potential mechanism for reorganization is that adjacent cortical regions expand when preexisting lateral excitatory connections are unmasked by decreased intracortical inhibition. During pharmacological blockade of cortical inhibition in one part of the MI representation, movements of neighboring representations were evoked by stimulation in adjacent MI areas. These results suggest that intracortical connections form a substrate for reorganization of cortical maps and that inhibitory circuits are critically placed to maintain or readjust the form of cortical motor representations.			JACOBS, KM (corresponding author), BROWN UNIV,CTR NEURAL SCI,BOX 1953,PROVIDENCE,RI 02912, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022517, R01NS025074, R37NS025074] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22517, NS25074] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKHTAR N D, 1987, Society for Neuroscience Abstracts, V13, P77; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; Brown TG, 1912, P R SOC LOND B-CONTA, V85, P250, DOI 10.1098/rspb.1912.0050; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; CRAGGS MD, 1976, BRAIN, V99, P575, DOI 10.1093/brain/99.3.575; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; DONOGHUE JP, 1987, BRAIN RES, V408, P367, DOI 10.1016/0006-8993(87)90407-0; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P492; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; HENDRY SHC, 1986, NATURE, V320, P750, DOI 10.1038/320750a0; IRIKI A, 1989, SCIENCE, V245, P1385, DOI 10.1126/science.2551038; KRNJEVIC K, 1963, J PHYSIOL-LONDON, V166, P296, DOI 10.1113/jphysiol.1963.sp007106; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; METHERATE R, 1988, J NEUROPHYSIOL, V59, P1231, DOI 10.1152/jn.1988.59.4.1231; STELZER A, 1987, NATURE, V326, P698, DOI 10.1038/326698a0; WELKER E, 1989, EXP BRAIN RES, V74, P441, DOI 10.1007/BF00247346; WHITE EL, 1989, CORTICAL CIRCUITS SY, P46; WIGSTROM H, 1986, J PHYSIOL-PARIS, V81, P228; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x	19	749	761	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					944	947		10.1126/science.2000496	http://dx.doi.org/10.1126/science.2000496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000496				2022-12-28	WOS:A1991EY62900047
J	TAYLOR, JE; HENDERSON, IS; MACTIER, RA; STEWART, WK				TAYLOR, JE; HENDERSON, IS; MACTIER, RA; STEWART, WK			EFFECTS OF WITHDRAWING ERYTHROPOIETIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article											TAYLOR, JE (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, RENAL UNIT, DUNDEE DD1 9SY, SCOTLAND.							COTES PM, 1989, Q J MED, V70, P113; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; SUNDAL E, 1989, NEPHROL DIAL TRANSPL, V4, P979, DOI 10.1093/ndt/4.11.979; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6	4	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	1991	302	6771					272	273		10.1136/bmj.302.6771.272-a	http://dx.doi.org/10.1136/bmj.302.6771.272-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998794	Green Published, Bronze			2022-12-28	WOS:A1991EX91900022
J	GASSER, RA; MAGILL, AJ; OSTER, CN; TRAMONT, EC				GASSER, RA; MAGILL, AJ; OSTER, CN; TRAMONT, EC			THE THREAT OF INFECTIOUS-DISEASE IN AMERICANS RETURNING FROM OPERATION DESERT STORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGO HEMORRHAGIC-FEVER; SAUDI-ARABIA; CUTANEOUS LEISHMANIASIS; NOSOCOMIAL OUTBREAK; TYPHOID-FEVER; WILD ANIMALS; CLINICAL EFFICACY; DRUG-RESISTANCE; WESTERN REGION; KUWAIT		WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	GASSER, RA (corresponding author), WALTER REED ARMY MED CTR, INFECT DIS SERV, WASHINGTON, DC 20307 USA.							ABDELHAFEZ MMA, 1986, ANN TROP MED PARASIT, V80, P631, DOI 10.1080/00034983.1986.11812078; AHMED M M, 1989, Journal of the Egyptian Society of Parasitology, V19, P583; ALAWADI AR, 1982, B WORLD HEALTH ORGAN, V60, P283; ALMOFLEH IA, 1990, ANN SAUDI MED, V10, P620, DOI 10.5144/0256-4947.1990.620; ALNAKIB W, 1984, T ROY SOC TROP MED H, V78, P474, DOI 10.1016/0035-9203(84)90065-8; ALORAINEY IO, 1989, TUBERCLE, V70, P207, DOI 10.1016/0041-3879(89)90052-4; ALTIKRITI SK, 1981, B WORLD HEALTH ORGAN, V59, P85; ALTIKRITI SK, 1981, J TROP MED HYG, V84, P117; ALZAHRANI MA, 1989, T ROY SOC TROP MED H, V83, P621, DOI 10.1016/0035-9203(89)90376-3; ALZAHRANI MA, 1989, T ROY SOC TROP MED H, V83, P503, DOI 10.1016/0035-9203(89)90267-8; ASHI J, 1989, J TROP MED HYG, V92, P27; ASPERILLA MO, 1990, REV INFECT DIS, V12, P873; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BADARO R, 1986, LANCET, V1, P647; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BAHMANYAR M, 1972, AM J TROP MED HYG, V21, P123, DOI 10.4269/ajtmh.1972.21.123; BARTELLONI PJ, 1976, AM J TROP MED HYG, V25, P456, DOI 10.4269/ajtmh.1976.25.456; BASSILY S, 1970, T ROY SOC TROP MED H, V64, P723, DOI 10.1016/0035-9203(70)90013-1; BERMAN JD, 1988, REV INFECT DIS, V10, P560; BIENZLE U, 1978, TROPENMED PARASITOL, V29, P188; BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941; CHUGH TD, 1983, TROP GEOGR MED, V35, P37; CHUGH TD, 1985, J HYG-CAMBRIDGE, V95, P391, DOI 10.1017/S0022172400062811; DAMJANOVIC V, 1984, J HYG-CAMBRIDGE, V92, P205, DOI 10.1017/S0022172400064226; EITREM R, 1990, AM J TROP MED HYG, V43, P207, DOI 10.4269/ajtmh.1990.43.207; ELBIHARI S, 1987, TROP MED PARASITOL, V38, P89; ELHAZMI MAF, 1989, J TROP MED HYG, V92, P427; ELHAZMI MAF, 1989, J TROP MED HYG, V92, P56; FARID Z, 1970, J TROP MED HYG, V73, P153; GAMRA EMA, 1983, J EGYPT SOC PARASITO, V13, P227; GILMAN RH, 1975, LANCET, V1, P1211; GUERRACACERES JG, 1979, T ROY SOC TROP MED H, V73, P680, DOI 10.1016/0035-9203(79)90020-8; GUNN RA, 1981, B WORLD HEALTH ORGAN, V59, P61; HATHOUT SED, 1967, AM J TROP MED HYG, V16, P462, DOI 10.4269/ajtmh.1967.16.462; Hertig M., 1964, PREVENTIVE MED WORLD, V7, P109; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203; HUGGINS JW, 1989, REV INFECT DIS, V11, pS750; ISLAM A, 1988, J INFECT DIS, V158, P742, DOI 10.1093/infdis/158.4.742; JOPLING WH, 1955, BRIT MED J, V2, P1013, DOI 10.1136/bmj.2.4946.1013-a; KAPLAN M M, 1955, Bull World Health Organ, V13, P829; KARAWYA EM, 1990, ANN SAUDI MED, V10, P165, DOI 10.5144/0256-4947.1990.165; KASIM AA, 1983, ACTA TROP, V40, P155; KASSIMI MA, 1985, J HOSP INFECT, V6, P234; KHAIRY N, 1980, ANN TROP MED PARASIT, V74, P29, DOI 10.1080/00034983.1980.11687307; Khuffash F A, 1982, Ann Trop Paediatr, V2, P123; KIEL FW, 1987, J CLIN MICROBIOL, V25, P1384, DOI 10.1128/JCM.25.8.1384-1387.1987; KILLICKKENDRICK R, 1985, T ROY SOC TROP MED H, V79, P252, DOI 10.1016/0035-9203(85)90350-5; Marrie T. J., 1988, Biology of rickettsial diseases. Volume II., P1; MATOSSIAN RM, 1963, AM J TROP MED HYG, V12, P82, DOI 10.4269/ajtmh.1963.12.82; MCKEE K, 1990, DIAGNOSIS TREATMENT; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; MOORE PS, 1989, LANCET, V2, P260; MOUSA ARM, 1988, REV INFECT DIS, V10, P211; MURPHY C, 1991, WASHINGTON POST 0126, pA1; MURPHY C, 1991, WASHINGTON POST 0126, pA15; NEVES J, 1967, T ROY SOC TROP MED H, V61, P541, DOI 10.1016/0035-9203(67)90105-8; NEVES J, 1969, T ROY SOC TROP MED H, V63, P79, DOI 10.1016/0035-9203(69)90070-4; NOAH MS, 1986, ANN TROP MED PARASIT, V80, P607, DOI 10.1080/00034983.1986.11812075; OLDFIELD EC, 1991, REV INFECT DIS, V13, pS199; PETERS W, 1987, SAUDI MED J, V8, P333; PETERS W, 1988, T ROY SOC TROP MED H, V82, P179, DOI 10.1016/0035-9203(88)90400-2; QADRI MH, 1990, ANN SAUDI MED, V10, P280, DOI 10.5144/0256-4947.1990.280; QADRI SMH, 1989, J NATL MED ASSOC, V81, P1061; RAMIA S, 1987, T ROY SOC TROP MED H, V81, P317, DOI 10.1016/0035-9203(87)90251-3; RAMIA S, 1986, TROP GEOGR MED, V38, P63; RAMIREZ CA, 1985, ANTIMICROB AGENTS CH, V28, P128, DOI 10.1128/AAC.28.1.128; SALIH SY, 1977, J TROP MED HYG, V80, P14; SCHIOTT CR, 1985, SAUDI MED J, V6, P375; SCOTT DA, 1990, T ROY SOC TROP MED H, V84, P288, DOI 10.1016/0035-9203(90)90290-U; SEBAI ZA, 1988, TROP DOCT, V18, P183, DOI 10.1177/004947558801800415; SETHI S K, 1989, Journal of Diarrhoeal Diseases Research, V7, P85; SETHI SK, 1989, PEDIATR INFECT DIS J, V8, P593, DOI 10.1097/00006454-198909000-00005; SHOBOKSHI OA, 1987, T ROY SOC TROP MED H, V81, P219, DOI 10.1016/0035-9203(87)90220-3; SULEIMAN MNEH, 1980, LANCET, V2, P939; TESH RB, 1989, ISRAEL J MED SCI, V25, P214; VANDEWAL BW, 1985, S AFR MED J, V68, P729; VANEEDEN PJ, 1985, S AFR MED J, V68, P718; VANEEDEN PJ, 1985, S AFR MED J, V68, P711; VASSALLO L, 1985, ANN TROP MED PARASIT, V79, P349, DOI 10.1080/00034983.1985.11811931; WATTS DM, 1989, AM J TROP MED HYG, V41, P581, DOI 10.4269/ajtmh.1989.41.581; WEINRAUCH L, 1987, BRIT J DERMATOL, V117, P666, DOI 10.1111/j.1365-2133.1987.tb07504.x; WILSON HG, 1976, CIRCULATION, V53, P680, DOI 10.1161/01.CIR.53.4.680; YOUSIF AA, 1989, J BAHRAIN MED SOC, V1, P52; 1985, WHO TECH REP SER, V721, P1; 1990, MED LETT DRUGS THER, V32, P23; 1990, WORLD HLTH STAT Q, V43, P68; 1990, WKLY EPIDEMIOL REC, V65, P321; 1987, MMWR, V36, P559; 1990, WKLY EPIDEMIOL REC, V65, P337	89	41	41	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					859	864		10.1056/NEJM199103213241229	http://dx.doi.org/10.1056/NEJM199103213241229			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997866	Bronze			2022-12-28	WOS:A1991FC44200036
J	WING, S; SHY, CM; WOOD, JL; WOLF, S; CRAGLE, DL; FROME, EL				WING, S; SHY, CM; WOOD, JL; WOLF, S; CRAGLE, DL; FROME, EL			MORTALITY AMONG WORKERS AT OAK RIDGE NATIONAL LABORATORY - EVIDENCE OF RADIATION EFFECTS IN FOLLOW-UP THROUGH 1984	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RATES; COHORT; MISCLASSIFICATION; SELECTION; SURVIVAL; EXPOSURE; PLANT	White men hired at the Oak Ridge (Tenn) National Laboratory between 1943 and 1972 were followed up for vital status through 1984 (N = 8318, 1524 deaths). Relatively low mortality compared with that in US white men was observed for most causes of death, but leukemia mortality was elevated in the total cohort (63% higher, 28 deaths) and in workers who had at some time been monitored for internal radionuclide contamination (123% higher, 16 deaths). Median cumulative dose of external penetrating radiation was 1.4 mSv; 638 workers had cumulative doses above 50 mSv (5 rem). After accounting for age, birth cohort, a measure of socioeconomic status, and active worker status, external radiation with a 20-year exposure lag was related to all causes of death (2.68% increase per 10 mSv) primarily due to an association with cancer mortality (4.94% per 10 mSv). Studies of this population through 1977 did not find radiation-cancer mortality associations, and identical analyses using the shorter follow-up showed that associations with radiation did not appear until after 1977. The radiation-cancer dose response is 10 times higher than estimates from the follow-up of survivors of the bombings of Hiroshima and Nagasaki, Japan, but similar to one previous occupational study. Dose-response estimates are subject to uncertainties due to potential problems, including measurement of radiation doses and cancer outcomes. Longer-term follow-up of this and other populations with good measurement of protracted low-level exposures will be critical to evaluating the generalizability of the results reported herein.	OAK RIDGE TENN ASSOCIATED UNIV,CTR EPIDEMIOL RES,OAK RIDGE,TN; OAK RIDGE NATL LAB,MATH SCI SECT,OAK RIDGE,TN 37830	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory	WING, S (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CB 7400,CHAPEL HILL,NC 27599, USA.							[Anonymous], 1990, HLTH EFFECTS EXPOSUR; AXELSON O, 1989, BRIT J IND MED, V46, P505; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHECKOWAY H, 1985, BRIT J IND MED, V42, P525; CLAPP RW, 1987, LANCET, V2, P1324; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; DEVESA SS, 1989, J NATL CANCER I, V81, P1568, DOI 10.1093/jnci/81.20.1568; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GILBERT ES, 1990, AM J EPIDEMIOL, V131, P917, DOI 10.1093/oxfordjournals.aje.a115581; GILBERT ES, 1983, BIOMETRICS, V39, P161, DOI 10.2307/2530816; GILBERT ES, 1989, RADIAT RES, V120, P19, DOI 10.2307/3577633; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; LAND CE, 1980, SCIENCE, V209, P1197, DOI 10.1126/science.7403879; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; MCMICHAEL AJ, 1976, J OCCUP ENVIRON MED, V18, P165, DOI 10.1097/00043764-197603000-00009; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MORRIS M, 1990, INVESTIGATION LEUKEM; PEARCE N, 1986, SCAND J WORK ENV HEA, V12, P97, DOI 10.5271/sjweh.2161; SHORE RE, 1990, HEALTH PHYS, V59, P63, DOI 10.1097/00004032-199007000-00007; SHY CM, 1978, B NEW YORK ACAD MED, V54, P1155; TORNQVIST L, 1985, AM STAT, V39, P43, DOI 10.2307/2683905; UPTON AC, 1990, JNCI-J NATL CANCER I, V82, P448, DOI 10.1093/jnci/82.6.448; WILCOSKY T, 1987, SCAND J WORK ENV HEA, V13, P70, DOI 10.5271/sjweh.2078; WING S, 1988, AM J PUBLIC HEALTH, V78, P1415, DOI 10.2105/AJPH.78.11.1415; WOOLHANDLER S, 1985, LANCET, V1, P1375; 1985, NIH852748 PUBL	29	153	156	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1397	1402		10.1001/jama.265.11.1397	http://dx.doi.org/10.1001/jama.265.11.1397			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999879				2022-12-28	WOS:A1991FB55000019
J	DOUGLAS, SE; MURPHY, CA; SPENCER, DF; GRAY, MW				DOUGLAS, SE; MURPHY, CA; SPENCER, DF; GRAY, MW			CRYPTOMONAD ALGAE ARE EVOLUTIONARY CHIMERAS OF 2 PHYLOGENETICALLY DISTINCT UNICELLULAR EUKARYOTES	NATURE			English	Article							SUBUNIT RIBOSOMAL-RNA; C-CONTAINING ALGA; ORGANELLES; ORIGINS; DNA	ALTHOUGH it is widely accepted that the plastids of plants and algae originated as endosymbionts 1, the details of this evolutionary process are unclear 2,3. It has been proposed that in organisms whose plastids are surrounded by more than two membranes, the endosymbiont was a eukaryotic alga rather than a photosynthetic prokaryote 4. The DNA-containing 5 nucleomorph 6 of cryptomonad algae appears to be the vestigial nucleus of such an algal endosymbiont 7. Eukaryotic-type ribosomal RNA sequences have been localized to a nucleolus-like structure in the nucleomorph 8. In support of the hypothesis that cryptomonads are evolutionary chimaeras of two distinct eukaryotic cells, we show here that Cryptomonas PHI contains two phylogenetically separate, nuclear-type small-subunit rRNA genes, both of which are transcriptionally active. We incorporate our rRNA sequence data into phylogenetic trees, from which we infer the evolutionary ancestry of the host and symbiont components of Cryptomonas PHI. Such trees do not support the thesis 3 that chromophyte algae evolved directly from a cryptomonad-like ancestor.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX B3H 4H7,NS,CANADA	Dalhousie University	DOUGLAS, SE (corresponding author), NATL RES COUNCIL CANADA,ATLANTIC REG LAB,INST MARINE BIOSCI,1411 OXFORD ST,HALIFAX B3H 3Z1,NS,CANADA.			Gray, Michael/0000-0001-7125-2625				BHATTACHARYA D, 1990, J PHYCOL, V26, P181, DOI 10.1111/j.0022-3646.1990.00181.x; BIRD CJ, 1990, NUCLEIC ACIDS RES, V18, P4023, DOI 10.1093/nar/18.13.4023; Cavalier-Smith T., 1986, Progress phycol. Res., V4, P309; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; DOUGLAS SE, 1989, PLANT MOL BIOL, V13, P13, DOI 10.1007/BF00027331; DOUGLAS SE, 1988, CURR GENET, V14, P591, DOI 10.1007/BF00434085; Felsenstein J., 1990, PHYLIP MANUAL VERSIO; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; GRAY MW, 1984, NUCLEIC ACIDS RES, V12, P5837, DOI 10.1093/nar/12.14.5837; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; GREENWOOD A D, 1977, British Phycological Journal, V12, P119; GUNDERSON JH, 1987, P NATL ACAD SCI USA, V84, P5823, DOI 10.1073/pnas.84.16.5823; HENDRIKS L, 1989, SYST APPL MICROBIOL, V12, P223, DOI 10.1016/S0723-2020(89)80066-9; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; LUDWIG M, 1987, ANN NY ACAD SCI, V503, P198, DOI 10.1111/j.1749-6632.1987.tb40609.x; LUDWIG M, 1985, PROTOPLASMA, V127, P9, DOI 10.1007/BF01273697; Maxam A M, 1980, Methods Enzymol, V65, P499; MCFADDEN GI, 1990, J CELL SCI, V95, P303; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; PERASSO R, 1989, NATURE, V339, P142, DOI 10.1038/339142a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNARE MN, 1986, J BIOL CHEM, V261, P5187; Sogin ML, 1990, PCR PROTOCOLS GUIDE, P307, DOI DOI 10.1016/B978-0-12-372180-8.50041-X; SWOFFORD DL, 1989, PAUP VERSION 3 0 ILL; WHATLEY JM, 1981, NEW PHYTOL, V87, P233, DOI 10.1111/j.1469-8137.1981.tb03195.x	27	244	246	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					148	151		10.1038/350148a0	http://dx.doi.org/10.1038/350148a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005963				2022-12-28	WOS:A1991FB64500056
J	KUHLBRANDT, W; WANG, DN				KUHLBRANDT, W; WANG, DN			3-DIMENSIONAL STRUCTURE OF PLANT LIGHT-HARVESTING COMPLEX DETERMINED BY ELECTRON CRYSTALLOGRAPHY	NATURE			English	Article							A/B-PROTEIN COMPLEX; PHOTOSYNTHETIC REACTION CENTER; RHODOPSEUDOMONAS-VIRIDIS; SENSITIVE SPECIMENS; PURPLE MEMBRANE; CHLOROPHYLL; RESOLUTION; MICROGRAPHS; CRYSTALS; BEAM	The structure of the light-harvesting chlorophyll a/b-protein complex, a membrane protein serving as the major antenna of solar energy in plant photosynthesis, has been determined at 6 angstrom resolution by electron crystallography. Within the complex, three membrane-spanning alpha-helices and 15 chlorophyll molecules are resolved. There is an intramolecular diad relating two of the alpha-helices and some of the chlorophylls. The spacing of the chlorophylls suggests energy transfer by delocalized exciton coupling and Forster mechanisms.			KUHLBRANDT, W (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.			Kuhlbrandt, Werner/0000-0002-2013-4810; Wang, Da-Neng/0000-0002-6496-4699				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; BALDWIN J, 1984, ULTRAMICROSCOPY, V14, P319, DOI 10.1016/0304-3991(84)90217-1; BRODY SS, 1957, REV SCI INSTRUM, V28, P1021, DOI 10.1063/1.1715792; BULLOUGH P, 1987, ULTRAMICROSCOPY, V21, P223, DOI 10.1016/0304-3991(87)90147-1; BURGI R, 1987, BIOCHIM BIOPHYS ACTA, V890, P346, DOI 10.1016/0005-2728(87)90162-9; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHOTHIA C, 1985, REV BIOCH, V53, P537; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DOWNING KH, 1986, ULTRAMICROSCOPY, V20, P269, DOI 10.1016/0304-3991(86)90191-9; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GLAESER RM, 1989, ULTRAMICROSCOPY, V27, P307, DOI 10.1016/0304-3991(89)90021-1; HAYWARD SB, 1980, ULTRAMICROSCOPY, V5, P3, DOI 10.1016/0304-3991(80)90005-4; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HENDERSON R, 1985, ULTRAMICROSCOPY, V16, P139, DOI 10.1016/0304-3991(85)90069-5; HOFFMANN NE, 1986, P NATL ACAD SCI USA, V84, P8844; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; KARLINNEUMANN GA, 1985, J MOL APPL GENET, V3, P45; KUHLBRANDT W, 1984, NATURE, V307, P478, DOI 10.1038/307478a0; KUHLBRANDT W, 1983, J CELL BIOL, V96, P1414, DOI 10.1083/jcb.96.5.1414; KUHLBRANDT W, 1989, J MOL BIOL, V207, P823, DOI 10.1016/0022-2836(89)90247-7; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; MICHEL H, 1986, ENCY PLANT PHYSL PHO, V19, P371; MULLET JE, 1983, J BIOL CHEM, V258, P9941; SAUER K, 1986, ENCY PLANT PHYSL, V19, P85; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SHIPMAN LL, 1976, J AM CHEM SOC, V98, P8222, DOI 10.1021/ja00441a056; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; SIMPSON DJ, 1979, CARLSBERG RES COMMUN, V44, P305, DOI 10.1007/BF02906493; STARK W, 1984, EMBO J, V3, P777, DOI 10.1002/j.1460-2075.1984.tb01884.x; VANGRONDELLE R, 1985, BIOCHIM BIOPHYS ACTA, V811, P147, DOI 10.1016/0304-4173(85)90017-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG DN, 1991, IN PRESS J MOL BIOL; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	39	425	432	5	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					130	134						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005962				2022-12-28	WOS:A1991FB64500048
J	RAYMOND, M; CALLAGHAN, A; FORT, P; PASTEUR, N				RAYMOND, M; CALLAGHAN, A; FORT, P; PASTEUR, N			WORLDWIDE MIGRATION OF AMPLIFIED INSECTICIDE RESISTANCE GENES IN MOSQUITOS	NATURE			English	Article							ORGANO-PHOSPHATE RESISTANCE; CULEX-PIPIENS L; DROSOPHILA-MELANOGASTER; L DIPTERA; QUINQUEFASCIATUS DIPTERA; DETOXIFYING ESTERASES; ALCOHOL-DEHYDROGENASE; CULICIDAE; COMPLEX; POPULATIONS	IN Culex pipiens, overproduction of nonspecific esterases is a common mechanism of resistance to organophosphate insecticides 1,2. The esterases are attributed to closely linked loci named A and B according to substrate preference 3-6, and overproduction of all esterases B is due to gene amplification 7,8. Distribution of electrophoretically distinct variants of overproduced esterases A and B is geographically restricted, with the exception of esterases A2 and B2, always found together throughout at least three continents (Fig. 1). To determine whether this situation is due to migration or to a high mutation rate, esterase B structural genes and their flanking regions were compared by sequence and/or restriction fragment length polymorphism analysis. Whereas structural genes were similar, flanking regions of electrophoretically dissimilar esterases B varied considerably. In contrast, flanking sequences of esterases B2 from different geographical locations (Africa, Asia, North America) were identical. These results suggest that amplified esterase B2 genes originated from an initial event that has subsequently spread organophosphate insecticide resistance by migration.	UNIV MONTPELLIER 2,BIOL MOLEC LAB,URA 1191,F-34095 MONTPELLIER,FRANCE	Universite de Montpellier	RAYMOND, M (corresponding author), INST SCI EVOLUT,GENET & ENVIRONM LAB,URA 327,CASE COURRIER 64,F-34095 MONTPELLIER,FRANCE.		Raymond, Michel/C-9049-2015; Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722; Callaghan, Amanda/0000-0002-2731-3352; Raymond, Michel/0000-0002-1714-6984				AGUADE M, 1988, GENETICS, V119, P135; ANDREADIS TG, 1988, J AM MOSQUITO CONTR, V4, P256; AQUADRO CF, 1986, GENETICS, V114, P1165; ASAHINA S, 1970, JPN J MED SCI BIOL, V23, P255, DOI 10.7883/yoken1952.23.255; BEYSSATARNAOUTY V, 1989, J AM MOSQUITO CONTR, V5, P196; BEYSSATARNAOUTY V, 1989, THESIS U MONTPELLIER; CALLAGHAN A, 1989, THESIS U LONDON; CURTIS CF, 1981, B ENTOMOL RES, V71, P153, DOI 10.1017/S0007485300051129; DESTORDEUR E, 1976, BIOCHEM GENET, V14, P481, DOI 10.1007/BF00486128; FOURNIER D, 1987, PESTIC BIOCHEM PHYS, V27, P211, DOI 10.1016/0048-3575(87)90048-4; GEORGHIOU GP, 1980, J ECON ENTOMOL, V73, P489, DOI 10.1093/jee/73.4.489; GEORGHIOU GP, 1966, B WORLD HEALTH ORGAN, V35, P691; HEMINGWAY J, 1989, MED VET ENTOMOL, V3, P445; HIGHTON RB, 1970, B WORLD HEALTH ORGAN, V42, P334; KREITMAN M, 1986, P NATL ACAD SCI USA, V83, P3562, DOI 10.1073/pnas.83.10.3562; MAGNIN M, 1988, J MED ENTOMOL, V25, P99, DOI 10.1093/jmedent/25.2.99; MAGNIN M, 1986, THESIS U PARIS 6; MOUCHES C, 1990, P NATL ACAD SCI USA, V87, P2574, DOI 10.1073/pnas.87.7.2574; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; MOUCHES C, 1987, P NATL ACAD SCI USA, V84, P2113, DOI 10.1073/pnas.84.8.2113; PASTEUR N, 1981, BIOCHEM GENET, V19, P499, DOI 10.1007/BF00484622; PASTEUR N, 1981, BIOCHEM GENET, V19, P909, DOI 10.1007/BF00504256; PASTEUR N, 1989, J ECON ENTOMOL, V82, P347, DOI 10.1093/jee/82.2.347; RAYMOND M, 1987, J MED ENTOMOL, V24, P24, DOI 10.1093/jmedent/24.1.24; RAYMOND M, 1985, CR ACAD SCI III-VIE, V300, P509; RAYMOND M, 1989, BIOCHEM GENET, V27, P417, DOI 10.1007/BF02399670; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONS GM, 1989, EVOLUTION, V43, P393, DOI 10.1111/j.1558-5646.1989.tb04235.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; URBANELLI S, 1985, B ENTOMOL RES, V75, P291, DOI 10.1017/S0007485300014383; VILLANI F, 1987, PESTIC BIOCHEM PHYS, V27, P218, DOI 10.1016/0048-3575(87)90049-6; VILLANI F, 1983, B ENTOMOL RES, V73, P153, DOI 10.1017/S0007485300013882; WIRTH MC, 1990, J MED ENTOMOL, V27, P202, DOI 10.1093/jmedent/27.2.202	33	262	290	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					151	153		10.1038/350151a0	http://dx.doi.org/10.1038/350151a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005964				2022-12-28	WOS:A1991FB64500057
J	COHEN, C; BENJAMIN, M				COHEN, C; BENJAMIN, M			ALCOHOLICS AND LIVER-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Two arguments underlie a widespread unwillingness to consider patients with alcoholic cirrhosis of the liver as candidates for transplantation. First, alcoholics are morally blameworthy, their condition the result of their own misconduct; such blameworthiness disqualifies alcoholics in unavoidable competition for organs with others who are equally sick but blameless. Second, because of their habits, alcoholics will not exhibit satisfactory rates of survival after transplantation; good stewardship of a scarce lifesaving resource therefore requires that alcoholics not be considered for liver transplantation. These arguments are carefully analyzed and shown to be defective. There is not good moral or medical reason for categorically precluding alcoholics as candidates for liver transplantation. It would, in addition, be unjust to implement such a preclusion simply because others might respond negatively if we do not.			COHEN, C (corresponding author), TRANSPLANT & HLTH POLICY CTR,115 WASHTENAW PL,BOX 0716,ANN ARBOR,MI 48109, USA.							BERESFORD TP, 1990, PSYCHOSOMATICS, V31, P241, DOI 10.1016/S0033-3182(90)72160-3; BERGLUND M, 1984, ACTA PSYCHIAT SCAND, V70, P407, DOI 10.1111/j.1600-0447.1984.tb01228.x; Childress JF., 1970, SOUNDINGS, V53, P339; FINGARETTE H, 1988, PUBLIC INTEREST, V91, P3; FINGARETTE H, 1989, PUBLIC INTEREST, V95, P118; Gordon R D, 1987, Clin Transpl, P43; GORDON RD, 1988, ORGAN TRANSPLANTATIO, P511; JELLINEK EM, 1960, DISEASE CONCEPT ALCO; KLERMAN GL, 1989, NEW ENGL J MED, V320, P394, DOI 10.1056/NEJM198902093200611; MADSEN W, 1989, PUBLIC INTEREST, V95, P112; ROSE RM, 1988, ALCOHOLISM ORIGINS O; SCHARSCHMIDT BF, 1984, HEPATOLOGY, V4, P95; SCHENKER S, 1990, HEPATOLOGY, V11, P314, DOI 10.1002/hep.1840110223; STARZL TE, 1988, JAMA-J AM MED ASSOC, V260, P2542, DOI 10.1001/jama.260.17.2542; STARZL TE, 1988, TRANSPLANT P, V20, P131; Vaillant G.E., 1995, WISDOM EGO; 1987, DHHS ADM871519 US DE; 1983, JAMA-J AM MED ASSOC, V250, P2961	18	94	94	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1299	1301		10.1001/jama.265.10.1299	http://dx.doi.org/10.1001/jama.265.10.1299			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FA511	1995978				2022-12-28	WOS:A1991FA51100027
J	BLACKWOOD, EM; EISENMAN, RN				BLACKWOOD, EM; EISENMAN, RN			MAX - A HELIX-LOOP-HELIX ZIPPER PROTEIN THAT FORMS A SEQUENCE-SPECIFIC DNA-BINDING COMPLEX WITH MYC	SCIENCE			English	Article							HUMAN C-MYC; AVIAN MYELOCYTOMATOSIS VIRUS; LEUCINE-ZIPPER; DIFFERENTIAL EXPRESSION; NUCLEAR-LOCALIZATION; MOLECULAR-CLONING; NEOPLASTIC-CELLS; ESCHERICHIA-COLI; ENHANCER BINDING; GENE-EXPRESSION	The myc protooncogene family has been implicated in cell proliferation, differentiation, and neoplasia, but its mechanism of function at the molecular level is unknown. The carboxyl terminus of Myc family proteins contains a basic region helix-loop-helix leucine zipper motif (bHLH-Zip), which has DNA-binding activity and has been predicted to mediate protein-protein interactions. The bHLH-Zip region of c-Myc was used to screen a complementary DNA (cDNA) expression library, and a bHLH-Zip protein, termed Max, was identified. Max specifically associated with c-Myc, N-Myc, and L-Myc proteins, but not with a number of other bHLH, bZip, or bHLH-Zip proteins. The interaction between Max and c-Myc was dependent on the integrity of the c-Myc HLH-Zip domain, but not on the basic region or other sequences outside the domain. Furthermore, the Myc-Max complex bound to DNA in a sequence-specific manner under conditions where neither Max nor Myc exhibited appreciable binding. The DNA-binding activity of the complex was dependent on both the dimerization domain and the basic region of c-Myc. These results suggest that Myc family proteins undergo a restricted set of interactions in the cell and may belong to the more general class of eukaryotic DNA-binding transcription factors.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	BLACKWOOD, EM (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104, USA.				NCI NIH HHS [P01 CA28151, R01 CA20525, T32 CA09437] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009437, R01CA020525, P01CA028151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, UNPUB; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUREE C, 1989, CELL, V58, P537; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKAJIMA H, 1989, ONCOGENE, V4, P999; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SAWADOGO M, 1987, EMBO J, V6, P3027; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AR, UNPUB; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	72	1704	1745	3	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1211	1217		10.1126/science.2006410	http://dx.doi.org/10.1126/science.2006410			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006410				2022-12-28	WOS:A1991FA69100035
J	JEWETT, ME; KRONAUER, RE; CZEISLER, CA				JEWETT, ME; KRONAUER, RE; CZEISLER, CA			LIGHT-INDUCED SUPPRESSION OF ENDOGENOUS CIRCADIAN AMPLITUDE IN HUMANS	NATURE			English	Article							RHYTHM; OSCILLATOR; INDUCTION; GONYAULAX; PULSES; CLOCK	WINFREE reported 20 years ago the intriguing finding that a light stimulus of a critical strength applied at a critical circadian phase could essentially stop the circadian clock in Drosophila pseudo-obscura by resetting the circadian oscillator close to its singularity (a phaseless position at which the amplitude of circadian oscillation is zero) 1. Since then, similar observations of attenuated circadian amplitude in response to critical stimuli have been limited to unicells, insects and plants 2-7. Our recent demonstration that the phase of the human circadian pacemaker could be inverted using an unconventional three-cycle stimulus 8,9 led us to investigate whether critically timed exposure to a more moderate stimulus could drive that oscillator towards its singularity. Here we report that exposure of humans to fewer cycles of bright light, centred around the time at which the human circadian pacemaker is most sensitive to light-induced phase shifts, can markedly attenuate endogenous circadian amplitude. In some cases this results in an apparent loss of rhythmicity, as expected to occur in the region of singularity.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CIRCADIAN & SLEEP DISORDERS MED LAB,BOSTON,MA 02115; HARVARD UNIV,DIV APPL SCI,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University								BROWN EN, 1987, THESIS HARVARD U, P1; CZEISLER CA, 1990, NEW ENGL J MED, V322, P1253, DOI 10.1056/NEJM199005033221801; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; ENGELMANN W, 1978, PHYSIOL PLANTARUM, V43, P68, DOI 10.1111/j.1399-3054.1978.tb01569.x; ENRIGHT JT, 1986, LECT MATH LIFE SCI, V19, P121; Eskin A., 1971, P55; GANDER PH, 1983, AM J PHYSIOL, V245, pR10, DOI 10.1152/ajpregu.1983.245.1.R10; Kronauer R.E., 1990, SLEEP 90 P 10 EUR C, P295; MALINOWSKI JR, 1985, J COMP PHYSIOL B, V155, P257, DOI 10.1007/BF00685221; MILLS JN, 1978, J PHYSIOL-LONDON, V285, P455, DOI 10.1113/jphysiol.1978.sp012582; PETERSON EL, 1980, J COMP PHYSIOL, V138, P201, DOI 10.1007/BF00657038; SAUNDERS DS, 1978, J COMP PHYSIOL, V124, P75, DOI 10.1007/BF00656393; STROGATZ SH, 1990, J BIOL RHYTHM, V5, P169, DOI 10.1177/074873049000500208; TAYLOR W, 1982, J COMP PHYSIOL, V148, P11, DOI 10.1007/BF00688883; WALZ B, 1979, P NATL ACAD SCI USA, V76, P6443, DOI 10.1073/pnas.76.12.6443; Winfree A.T., 1987, TIMING BIOL CLOCKS; WINFREE AT, 1973, J COMP PHYSIOL, V85, P105, DOI 10.1007/BF00696471; WINFREE AT, 1970, J THEOR BIOL, V28, P327, DOI 10.1016/0022-5193(70)90075-5	18	200	203	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					59	62		10.1038/350059a0	http://dx.doi.org/10.1038/350059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002845				2022-12-28	WOS:A1991FA69300064
J	JACOBY, GA; ARCHER, GL				JACOBY, GA; ARCHER, GL			MECHANISMS OF DISEASE - NEW MECHANISMS OF BACTERIAL-RESISTANCE TO ANTIMICROBIAL AGENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PENICILLIN-BINDING PROTEIN; GRAM-NEGATIVE BACILLI; PLASMID-DETERMINED RESISTANCE; SPECTRUM BETA-LACTAMASES; OUTER-MEMBRANE PROTEINS; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; AMINOGLYCOSIDE RESISTANCE; METHICILLIN RESISTANCE		VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV INFECT DIS, RICHMOND, VA 23298 USA	Virginia Commonwealth University	JACOBY, GA (corresponding author), MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, BOSTON, MA 02114 USA.		Jacoby, George A/G-2604-2011		NIAID NIH HHS [AI-20415, AI-21772] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020415, R01AI021772] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALOBEID S, 1990, ANTIMICROB AGENTS CH, V34, P252, DOI 10.1128/AAC.34.2.252; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AOYAMA H, 1988, ANTIMICROB AGENTS CH, V32, P922, DOI 10.1128/AAC.32.6.922; ARCHER GL, 1985, J INFECT DIS, V151, P243, DOI 10.1093/infdis/151.2.243; ARCHER GL, 1990, ANTIMICROB AGENTS CH, V34, P1720, DOI 10.1128/AAC.34.9.1720; BARBERISMAINO L, 1987, GENE, V59, P107, DOI 10.1016/0378-1119(87)90271-X; BELLIDO F, 1990, J ANTIMICROB CHEMOTH, V25, P57, DOI 10.1093/jac/25.1.57; BENVENISTE R, 1973, P NATL ACAD SCI USA, V70, P2276, DOI 10.1073/pnas.70.8.2276; BERGERBACHI B, 1983, FEMS MICROBIOL LETT, V20, P305; BERGERBACHI B, 1989, MOL GEN GENET, V219, P263; BREUIL J, 1989, PLASMID, V21, P151, DOI 10.1016/0147-619X(89)90060-7; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; BRUNTON J, 1986, J BACTERIOL, V168, P374, DOI 10.1128/jb.168.1.374-379.1986; BRYAN LE, 1984, ANTIMICROB AGENTS CH, V26, P250, DOI 10.1128/AAC.26.2.250; BRYAN LE, 1989, HDB EXPT PHARM, V91; CHAMBERLAND S, 1989, ANTIMICROB AGENTS CH, V33, P624, DOI 10.1128/AAC.33.5.624; Chambers H.F., 1988, CLIN MICROBIOL REV, V1, P173, DOI DOI 10.1128/CMR.1.2.173; CHAMBERS HF, 1987, ANTIMICROB AGENTS CH, V31, P1982, DOI 10.1128/AAC.31.12.1982; CHAMBERS HF, 1989, ANTIMICROB AGENTS CH, V33, P424, DOI 10.1128/AAC.33.4.424; CLEWELL DB, 1981, MICROBIOL REV, V45, P409, DOI 10.1128/MMBR.45.3.409-436.1981; COHEN SP, 1988, ANTIMICROB AGENTS CH, V32, P1187, DOI 10.1128/AAC.32.8.1187; COHEN SP, 1989, ANTIMICROB AGENTS CH, V33, P1318, DOI 10.1128/AAC.33.8.1318; COOKSON BD, 1990, J ANTIMICROB CHEMOTH, V25, P497, DOI 10.1093/jac/25.4.497; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P681, DOI 10.1128/AAC.34.5.681; CUCHURAL GJ, 1986, ANTIMICROB AGENTS CH, V30, P645, DOI 10.1128/AAC.30.5.645; DAIKOS GL, 1988, ANTIMICROB AGENTS CH, V32, P785, DOI 10.1128/AAC.32.5.785; DANGOR Y, 1990, ANTIMICROB AGENTS CH, V34, P1303, DOI 10.1128/AAC.34.7.1303; DATTA N, 1983, NATURE, V306, P616, DOI 10.1038/306616a0; DAVIES J, 1978, ANNU REV MICROBIOL, V32, P469, DOI 10.1146/annurev.mi.32.100178.002345; Davies J. E., 1986, ANTIBIOTICS LABORATO, P790; DOERN GV, 1988, ANTIMICROB AGENTS CH, V32, P180, DOI 10.1128/AAC.32.2.180; DOUGHERTY TJ, 1986, ANTIMICROB AGENTS CH, V30, P649, DOI 10.1128/AAC.30.5.649; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; DUFRESNE J, 1988, ANTIMICROB AGENTS CH, V32, P819, DOI 10.1128/AAC.32.6.819; ELIOPOULOS G M, 1988, Clinical Microbiology Reviews, V1, P139; EZEKIEL DH, 1968, NATURE, V220, P276, DOI 10.1038/220276a0; Facklam RR, 1985, MANUAL CLIN MICROBIO, V4th, P154; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; FINLAND M, 1955, NEW ENGL J MED, V253, P909, DOI [10.1056/NEJM195512082532306, 10.1056/NEJM195512012532206]; FONTANA R, 1990, EUR J CLIN MICROBIOL, V9, P103, DOI 10.1007/BF01963633; FONTANALS D, 1989, EUR J CLIN MICROBIOL, V8, P90, DOI 10.1007/BF01964130; FORBES BA, 1983, J BACTERIOL, V153, P627, DOI 10.1128/JB.153.2.627-634.1983; FOSTER TJ, 1983, MICROBIOL REV, V47, P361, DOI 10.1128/MMBR.47.3.361-409.1983; FROGGATT JW, 1989, ANTIMICROB AGENTS CH, V33, P460, DOI 10.1128/AAC.33.4.460; GAYNES R, 1988, ANTIMICROB AGENTS CH, V32, P1379, DOI 10.1128/AAC.32.9.1379; GEORGE AM, 1983, J BACTERIOL, V155, P531, DOI 10.1128/JB.155.2.531-540.1983; GERDING DN, 1985, AM J MED, V79, P1, DOI 10.1016/0002-9343(85)90184-6; GILLESPIE MT, 1987, FEMS MICROBIOL LETT, V43, P165, DOI 10.1111/j.1574-6968.1987.tb02117.x; GOLDMAN RC, 1990, ANTIMICROB AGENTS CH, V34, P1973, DOI 10.1128/AAC.34.10.1973; GOOTZ TD, 1990, CLIN MICROBIOL REV, V3, P13, DOI 10.1128/CMR.3.1.13-31.1990; GUTMANN L, 1988, REV INFECT DIS, V10, P860; GUTMANN L, 1985, J INFECT DIS, V151, P501, DOI 10.1093/infdis/151.3.501; HANDWERGER S, 1990, REV INFECT DIS, V12, P602; HARDER KJ, 1981, ANTIMICROB AGENTS CH, V20, P549, DOI 10.1128/AAC.20.4.549; HEDGES RW, 1974, MOL GEN GENET, V132, P31, DOI 10.1007/BF00268228; HODELCHRISTIAN SL, 1990, ANTIMICROB AGENTS CH, V34, P1278, DOI 10.1128/AAC.34.6.1278; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; HOOPER DC, 1989, ANTIMICROB AGENTS CH, V33, P283, DOI 10.1128/AAC.33.3.283; HOOPER DC, 1986, ANTIMICROB AGENTS CH, V29, P639, DOI 10.1128/AAC.29.4.639; HOPKINS JM, 1990, J ANTIMICROB CHEMOTH, V25, P49, DOI 10.1093/jac/25.1.49; Horan T C, 1986, MMWR CDC Surveill Summ, V35, p17SS; HORODNICEANU T, 1982, ANTIMICROB AGENTS CH, V21, P176, DOI 10.1128/AAC.21.1.176; HSU CCS, 1988, ARCH INTERN MED, V148, P569, DOI 10.1001/archinte.148.3.569; HUMMEL H, 1989, HDB EXPT PHARM, V91, P193; HUOVINEN P, 1987, ANTIMICROB AGENTS CH, V31, P1451, DOI 10.1128/AAC.31.10.1451; JABES D, 1989, J INFECT DIS, V159, P16, DOI 10.1093/infdis/159.1.16; JACOBY GA, 1990, ANTIMICROB AGENTS CH, V34, P858, DOI 10.1128/AAC.34.5.858; JACOBY GA, 1990, ANTIMICROB AGENTS CH, V34, P2381, DOI 10.1128/AAC.34.12.2381; Jacoby GA, 1986, BACTERIA TREATISE ST, V10, P265; JACOBY GA, 1980, SEMINARS INFECTIOUS, V3, P1; JAFFE A, 1983, ANTIMICROB AGENTS CH, V23, P622, DOI 10.1128/AAC.23.4.622; JOLYGUILLOU ML, 1987, J ANTIMICROB CHEMOTH, V20, P773, DOI 10.1093/jac/20.6.773; JONES RN, 1989, DIAGN MICR INFEC DIS, V12, P385, DOI 10.1016/0732-8893(89)90108-9; KERNODLE DS, 1989, J INFECT DIS, V159, P103, DOI 10.1093/infdis/159.1.103; KERNODLE DS, 1990, JAMA-J AM MED ASSOC, V263, P961, DOI 10.1001/jama.263.7.961; KETTNER M, 1988, J ANTIMICROB CHEMOTH, V22, P82, DOI 10.1093/jac/22.1.82; KETTNER M, 1989, INFECTION, V17, P100, DOI 10.1007/BF01646887; KLECKNER N, 1981, ANNU REV GENET, V15, P341, DOI 10.1146/annurev.ge.15.120181.002013; KLIEBE C, 1985, ANTIMICROB AGENTS CH, V28, P302, DOI 10.1128/AAC.28.2.302; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; KORFMANN G, 1988, REV INFECT DIS, V10, P793; KOTILAINEN P, 1990, J INFECT DIS, V161, P41, DOI 10.1093/infdis/161.1.41; KRESKEN M, 1988, ANTIMICROB AGENTS CH, V32, P1285, DOI 10.1128/AAC.32.8.1285; KRISTIANSEN BE, 1990, ANTIMICROB AGENTS CH, V34, P2277, DOI 10.1128/AAC.34.11.2277; LAMBERT T, 1990, ANTIMICROB AGENTS CH, V34, P1244, DOI 10.1128/AAC.34.6.1244; LAMBERT T, 1988, ANTIMICROB AGENTS CH, V32, P15, DOI 10.1128/AAC.32.1.15; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LESTER SC, 1990, NEW ENGL J MED, V323, P285, DOI 10.1056/NEJM199008023230501; LEVINE JF, 1985, J INFECT DIS, V151, P295, DOI 10.1093/infdis/151.2.295; LEVY SB, 1989, J ANTIMICROB CHEMOTH, V24, P1, DOI 10.1093/jac/24.1.1; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; LEVY SB, 1987, REV INFECT DIS S3, V9; LOWBURY EJL, 1972, LANCET, V2, P941; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MAGILAT C, 1990, ANTIMICROB AGENTS CH, V34, P2210; MALONEY J, 1989, ARCH INTERN MED, V149, P630, DOI 10.1001/archinte.149.3.630; MANAVATHU EK, 1990, ANTIMICROB AGENTS CH, V34, P71, DOI 10.1128/AAC.34.1.71; MAPLE PAC, 1989, LANCET, V1, P537; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MARTINEZ E, 1990, EMBO J, V9, P1275, DOI 10.1002/j.1460-2075.1990.tb08236.x; MASSANARI RM, 1988, J INFECT DIS, V158, P702, DOI 10.1093/infdis/158.4.702; MCDOUGAL LK, 1986, J CLIN MICROBIOL, V23, P832, DOI 10.1128/JCM.23.5.832-839.1986; MEDEIROS AA, 1989, HDB EXPT PHARM, V91, P101; MENDELMAN PM, 1988, ANTIMICROB AGENTS CH, V32, P706, DOI 10.1128/AAC.32.5.706; MENDELMAN PM, 1990, J ANTIMICROB CHEMOTH, V25, P525, DOI 10.1093/jac/25.4.525; MERCIER J, 1990, J BACTERIOL, V172, P3745, DOI 10.1128/jb.172.7.3745-3757.1990; MORAN JS, 1990, REV INFECT DIS, V12, pS633; MORSE SA, 1986, ANTIMICROB AGENTS CH, V30, P664, DOI 10.1128/AAC.30.5.664; MURRAY BE, 1983, J CLIN INVEST, V72, P1168, DOI 10.1172/JCI111042; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; MURRAY BE, 1986, J CLIN INVEST, V77, P289, DOI 10.1172/JCI112289; NAKAMURA S, 1989, ANTIMICROB AGENTS CH, V33, P254, DOI 10.1128/AAC.33.2.254; NEEDHAM C A, 1988, Clinical Microbiology Reviews, V1, P218; NIKAIDO H, 1989, HDB EXPT PHARM, V91, P1; OLSSON O, 1983, P NATL ACAD SCI-BIOL, V80, P7556, DOI 10.1073/pnas.80.24.7556; OUNISSI H, 1990, ANTIMICROB AGENTS CH, V34, P2164, DOI 10.1128/AAC.34.11.2164; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; PAPANICOLAOU GA, 1990, ANTIMICROB AGENTS CH, V34, P2200, DOI 10.1128/AAC.34.11.2200; PARK BH, 1987, ANTIMICROB AGENTS CH, V31, P1739, DOI 10.1128/AAC.31.11.1739; PATTERSON JE, 1990, ANTIMICROB AGENTS CH, V34, P302, DOI 10.1128/AAC.34.2.302; PATTERSON JE, 1990, REV INFECT DIS, V12, P644; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; PHILIPPON A, 1989, INFECTION, V17, P347, DOI 10.1007/BF01650727; PIERRE J, 1990, ANTIMICROB AGENTS CH, V34, P1691, DOI 10.1128/AAC.34.9.1691; PIERRE J, 1990, ANTIMICROB AGENTS CH, V34, P1695, DOI 10.1128/AAC.34.9.1695; PRINCE A, 1988, ANTIMICROB AGENTS CH, V32, P838, DOI 10.1128/AAC.32.6.838; REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563; ROBERTS MC, 1987, J BACTERIOL, V169, P3836, DOI 10.1128/jb.169.8.3836-3839.1987; ROBERTS MC, 1990, ANTIMICROB AGENTS CH, V34, P476, DOI 10.1128/AAC.34.3.476; ROBILLARD NJ, 1988, ANTIMICROB AGENTS CH, V32, P535, DOI 10.1128/AAC.32.4.535; ROOD JI, 1989, ANTIMICROB AGENTS CH, V33, P1569, DOI 10.1128/AAC.33.9.1569; RUOFF KL, 1988, J CLIN MICROBIOL, V26, P2064, DOI 10.1128/JCM.26.10.2064-2068.1988; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; SANDERS CC, 1984, ANTIMICROB AGENTS CH, V26, P797, DOI 10.1128/AAC.26.6.797; SANDERS CC, 1986, J INFECT DIS, V153, P617, DOI 10.1093/infdis/153.3.617; SANDERS CC, 1989, HDB EXPT PHARM, V91, P129; SANDERS WE, 1988, REV INFECT DIS, V10, P830; SAREEN M, 1990, ANTIMICROB AGENTS CH, V34, P1773, DOI 10.1128/AAC.34.9.1773; SCHAEFLER S, 1989, J CLIN MICROBIOL, V27, P335, DOI 10.1128/JCM.27.2.335-336.1989; SCHWALBE RS, 1987, NEW ENGL J MED, V316, P927, DOI 10.1056/NEJM198704093161507; SCHWARCZ SK, 1990, JAMA-J AM MED ASSOC, V264, P1413, DOI 10.1001/jama.264.11.1413; SHAW WV, 1983, CRC CR REV BIOCH MOL, V14, P1, DOI 10.3109/10409238309102789; SHIMIZU K, 1985, ANTIMICROB AGENTS CH, V28, P282, DOI 10.1128/AAC.28.2.282; SHLAES DM, 1989, ANTIMICROB AGENTS CH, V33, P198, DOI 10.1128/AAC.33.2.198; SILVER L, 1990, EUR J CLIN MICROBIOL, V9, P455, DOI 10.1007/BF01964283; SIMBERKOFF MS, 1986, J INFECT DIS, V153, P78, DOI 10.1093/infdis/153.1.78; SONG MD, 1987, FEBS LETT, V221, P167, DOI 10.1016/0014-5793(87)80373-3; SOUGAKOFF W, 1988, REV INFECT DIS, V10, P879; SPRATT BG, 1988, NATURE, V332, P173, DOI 10.1038/332173a0; SPRATT BG, 1989, P NATL ACAD SCI USA, V86, P8988, DOI 10.1073/pnas.86.22.8988; SPRATT BG, 1989, HDB EXPT PHARM, V91, P77; SREEDHARAN S, 1990, J BACTERIOL, V172, P7260, DOI 10.1128/jb.172.12.7260-7262.1990; STOKES HW, 1989, MOL MICROBIOL, V3, P1669, DOI 10.1111/j.1365-2958.1989.tb00153.x; TAYLOR DE, 1988, ANTIMICROB AGENTS CH, V32, P1107, DOI 10.1128/AAC.32.8.1107; TESCH W, 1990, ANTIMICROB AGENTS CH, V34, P1703, DOI 10.1128/AAC.34.9.1703; THEN RL, 1982, ANTIMICROB AGENTS CH, V21, P711, DOI 10.1128/AAC.21.5.711; THOMAS WD, 1989, ANTIMICROB AGENTS CH, V33, P1335, DOI 10.1128/AAC.33.8.1335; THOMPSON CJ, 1983, P NATL ACAD SCI-BIOL, V80, P5190, DOI 10.1073/pnas.80.17.5190; THORBJARNARDOTTIR SH, 1978, MOL GEN GENET, V161, P89, DOI 10.1007/BF00266619; TOMASZ A, 1989, ANTIMICROB AGENTS CH, V33, P1869, DOI 10.1128/AAC.33.11.1869; TRIAS J, 1990, ANTIMICROB AGENTS CH, V34, P52, DOI 10.1128/AAC.34.1.52; TRIEUCUOT P, 1986, J ANTIMICROB CHEMOTH, V18, P93, DOI 10.1093/jac/18.Supplement_C.93; UBUKATA K, 1989, J BACTERIOL, V171, P2882, DOI 10.1128/jb.171.5.2882-2885.1989; UBUKATA K, 1984, ANTIMICROB AGENTS CH, V25, P754, DOI 10.1128/AAC.25.6.754; UTTLEY AHC, 1988, LANCET, V1, P57; VANHOOF R, 1988, EUR J CLIN MICROBIOL, V7, P183, DOI 10.1007/BF01963076; VANNHIEU GT, 1988, ANTIMICROB AGENTS CH, V32, P1289, DOI 10.1128/AAC.32.8.1289; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; VU H, 1985, ANTIMICROB AGENTS CH, V27, P393, DOI 10.1128/AAC.27.3.393; WALLACE RJ, 1990, AM J MED, V88, pS46, DOI 10.1016/0002-9343(90)90262-C; WEXLER HM, 1987, J ANTIMICROB CHEMOTH, V19, P143, DOI 10.1093/jac/19.2.143; WISE EM, 1975, P NATL ACAD SCI USA, V72, P2621, DOI 10.1073/pnas.72.7.2621; WOLFSON JS, 1989, CLIN MICROBIOL REV, V2, P378, DOI 10.1128/CMR.2.4.378-424.1989; YANG YJ, 1990, ANTIMICROB AGENTS CH, V34, P755, DOI 10.1128/AAC.34.5.755; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990; YOUNG EJ, 1985, AM J MED SCI, V290, P223, DOI 10.1097/00000441-198512000-00001; 1989, HUMAN HLTH RISKS SUB	180	241	264	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 28	1991	324	9					601	612						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY886	1992321				2022-12-28	WOS:A1991EY88600006
J	KLAMBT, C; JACOBS, JR; GOODMAN, CS				KLAMBT, C; JACOBS, JR; GOODMAN, CS			THE MIDLINE OF THE DROSOPHILA CENTRAL-NERVOUS-SYSTEM - A MODEL FOR THE GENETIC-ANALYSIS OF CELL FATE, CELL-MIGRATION, AND GROWTH CONE GUIDANCE	CELL			English	Article							AXON PATHWAYS; EMBRYONIC-DEVELOPMENT; NEURONAL DEVELOPMENT; LARVAL CUTICLE; ZYGOTIC LOCI; MELANOGASTER; GRASSHOPPER; EXPRESSION; PATTERN; CNS	A row of mesectodermal cells separates the two lateral neurogenic regions in the Drosophila embryo and generates a discrete set of glia and neurons. Most CNS growth cones initially head straight toward the midline, suggesting that these midline cells play a key role in the formation of the axon commissures. We have used antibodies that stain the first axons, beta-galactosidase enhancer trap lines that selectively stain the different midline cells, and electron microscopic studies to elucidate the cells and interactions that mediate the normal formation of the two major commissures in each segment. This analysis has led to a model that proposes a series of sequential cell interactions controlling the development of the axon commissures. A genetic test of this model has utilized a number of mutations that, by either eliminating or altering the differentiation of various midline cells, perturb the development of the axon commissures in a predictable fashion.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	KLAMBT, C (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			jacobs, j roger/0000-0002-5878-5416	NINDS NIH HHS [NS18366] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BATE CM, 1981, J EMBRYOL EXP MORPH, V61, P317; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; Bridges CB., 1919, CARNEGIE I WASH PUBL, V278, P123; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERDIEU JR, 1989, DEVELOPMENT, V106, P749; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FOE VE, 1989, DEVELOPMENT, V107, P1; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HOYLE G, 1986, J COMP NEUROL, V246, P85, DOI 10.1002/cne.902460106; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JESSELL TM, 1989, CIBA F SYMP, V144, P255; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KLAMBT C, 1991, IN PRESS GLIA; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MEYER MR, 1987, J NEUROSCI, V7, P512; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Poulson D. F., 1950, BIOL DROSOPHILA, P168; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; ZAK NB, 1990, DEVELOPMENT, V109, P865	43	457	457	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					801	815		10.1016/0092-8674(91)90509-W	http://dx.doi.org/10.1016/0092-8674(91)90509-W			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997208				2022-12-28	WOS:A1991EZ47800015
J	MEYER, T				MEYER, T			CELL SIGNALING BY 2ND MESSENGER WAVES	CELL			English	Review							CYCLIC-AMP WAVES; DICTYOSTELIUM-DISCOIDEUM; CALCIUM; OSCILLATIONS; AGGREGATION				MEYER, T (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.			Meyer, Tobias/0000-0003-4339-3804				BACKX PH, 1989, J GEN PHYSIOL, V93, P963, DOI 10.1085/jgp.93.5.963; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; DINAUER MC, 1980, J CELL BIOL, V86, P537, DOI 10.1083/jcb.86.2.537; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; GOLDBETER A, 1975, NATURE, V253, P540, DOI 10.1038/253540a0; Goldbeter A, 1989, CELL CELL SIGNALLING; GRAF P, 1987, BIOCHEM J, V241, P933, DOI 10.1042/bj2410933; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JACOB R, 1990, CELL CALCIUM, V11, P241, DOI 10.1016/0143-4160(90)90075-6; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; Meinhardt H., 1982, MODELS BIOL PATTERN; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SAGE SO, 1989, J BIOL CHEM, V264, P6; SANDERSON MJ, 1988, AM J PHYSIOL, V254, pC63, DOI 10.1152/ajpcell.1988.254.1.C63; SPEKSNIJDER JE, 1990, J CELL BIOL, V110, P1589, DOI 10.1083/jcb.110.5.1589; TAKAMATSU T, 1990, FASEB J, V4, P1519, DOI 10.1096/fasebj.4.5.2307330; TYSON JJ, 1989, DEVELOPMENT, V106, P421; WINFREE AT, 1984, NATURE, V311, P611, DOI 10.1038/311611a0; WWAKUI M, 1990, CELL, V63, P1025	25	120	120	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					675	678		10.1016/0092-8674(91)90496-L	http://dx.doi.org/10.1016/0092-8674(91)90496-L			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997202				2022-12-28	WOS:A1991EZ47800003
J	GURURAJAN, R; PERRYOKEEFE, H; MELTON, DA; WEEKS, DL				GURURAJAN, R; PERRYOKEEFE, H; MELTON, DA; WEEKS, DL			THE XENOPUS LOCALIZED MESSENGER-RNA AN3 MAY ENCODE AN ATP-DEPENDENT RNA HELICASE	NATURE			English	Article							UNWINDING ACTIVITY; FACTOR EIF-4A; PROTEIN; CLONING; EGGS; GENES; VASA	THE maternal messenger RNA An3 was originally identified localized to the animal hemisphere of Xenopus laevis oocytes, eggs and early embryos 1,2. Xenopus embryos depend on mRNA and protein present in the egg before fertilization (maternal molecules) to provide the information needed for early development. Localization of maternal mRNA gives cells derived from different regions of the egg distinctive capacities for protein synthesis. We show here that An3 mRNA encodes a protein with 74% identity to a protein encoded by the testes-specific mRNA PL10 found in mouse 3, which is proposed to have RNA helicase activity. Because the gene encoding An3 mRNA is reactivated after gastrulation and remains active throughout embryogenesis 1,2, we have examined its distribution in embryonic and adult tissues. Unlike PL10 mRNA, which is primarily restricted to the testes, An3 mRNA is broadly distributed in later development.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	University of Iowa; Harvard University			Young, Richard A/F-6495-2012; Weeks, Daniel/F-6216-2010	Young, Richard A/0000-0001-8855-8647; Weeks, Daniel/0000-0002-4977-2410				BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOER D, 1990, NUCLEIC ACIDS RES, V18, P5489; DUMONT JN, 1972, J MORPHOL, V136, P155; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; KREIG PA, 1989, DEV BIOL, V133, P93; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; PERRYOKEEFE H, 1990, IN SITU HYBRIDISATIO, P115; RAY BK, 1985, J BIOL CHEM, V260, P7651; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHTER JD, 1984, J MOL BIOL, V173, P227, DOI 10.1016/0022-2836(84)90191-8; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WEEKS DL, 1985, COLD SPRING HARB SYM, V50, P21, DOI 10.1101/SQB.1985.050.01.005	25	78	81	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					717	719		10.1038/349717a0	http://dx.doi.org/10.1038/349717a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996140				2022-12-28	WOS:A1991EY62700055
J	RATNER, J; LISBONA, A; ROSENBLOOM, M; PALAYEW, M; SZABOLCSI, S; TUPAZ, T				RATNER, J; LISBONA, A; ROSENBLOOM, M; PALAYEW, M; SZABOLCSI, S; TUPAZ, T			THE PREVALENCE OF GALLSTONE DISEASE IN VERY OLD INSTITUTIONALIZED PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							POPULATION; SYMPTOMS; AUTOPSY	We present the results of a study that was undertaken at a large geriatric nursing home to assess the prevalence of gallstone disease in very old institutionalized persons. One hundred seventeen residents underwent ultrasound examination of the gallbladder. Two thirds of 82 women and half of 35 men had gallstone disease. When stratified for age, 80% of women and men over the age of 90 years were positive for the disease. In summary, the prevalence of gallstone disease in our very old nursing home population was found to be unexpectedly high.	SIR MORTIMER B DAVIS JEWISH HOSP,MONTREAL H3T 1E2,QUEBEC,CANADA	McGill University	RATNER, J (corresponding author), MAIMONIDES HOSP,CTR GERIATR,PROFESS SERV,5795 CALDWELL AVE,MONTREAL H4W 1W3,QUEBEC,CANADA.							BATESON MC, 1975, BMJ-BRIT MED J, V4, P427; CLINCH D, 1984, AGE AGEING, V13, P120, DOI 10.1093/ageing/13.2.120; EINARSSON K, 1985, NEW ENGL J MED, V313, P277, DOI 10.1056/NEJM198508013130501; FENYO G, 1982, AM J SURG, V143, P751, DOI 10.1016/0002-9610(82)90052-6; GILAT T, 1985, AM J CLIN NUTR, V41, P336, DOI 10.1093/ajcn/41.2.336; GLAMBEK I, 1989, SCAND J GASTROENTERO, V24, P277, DOI 10.3109/00365528909093046; GLAMBEK I, 1987, SCAND J GASTROENTERO, V22, P1089, DOI 10.3109/00365528708991963; GRUNDY SM, 1987, HEPATOLOGY, V7, P946, DOI 10.1002/hep.1840070526; JANZON L, 1985, SCAND J GASTROENTERO, V20, P706, DOI 10.3109/00365528509089199; LICHTAROWICZ AM, 1987, J ROY SOC MED, V80, P692, DOI 10.1177/014107688708001111; LONGINO CF, 1988, GERONTOLOGIST, V28, P515, DOI 10.1093/geront/28.4.515; LOWBEER TS, 1985, RECENT ADV GERIATRIC, P37; MOGENSEN NB, 1984, SURG GYNECOL OBSTET, V159, P353; ROSENWAIKE I, 1987, GERONTOLOGIST, V27, P275, DOI 10.1093/geront/27.3.275; Strom BL, 1985, GALLSTONES, P1; VITETTA L, 1988, AUST NZ J SURG, V58, P561; ZAHOR Z, 1974, SCAND J GASTROENTERO, V9, P3	17	36	38	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					902	903		10.1001/jama.265.7.902	http://dx.doi.org/10.1001/jama.265.7.902			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992189				2022-12-28	WOS:A1991EX58700044
J	BHOPAL, RS; FALLON, RJ; BUIST, EC; BLACK, RJ; URQUHART, JD				BHOPAL, RS; FALLON, RJ; BUIST, EC; BLACK, RJ; URQUHART, JD			PROXIMITY OF THE HOME TO A COOLING-TOWER AND RISK OF NON-OUTBREAK LEGIONNAIRES-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							LEGIONELLA-PNEUMOPHILA; TRANSMISSION; INFECTIONS; ANTIGEN	Objective-To study the source of non-outbreak legionnaires' disease, particularly the role of cooling towers, by comparing the locations of patients' homes in relation to the location of cooling towers. Design-Retrospective, descriptive study of a case series of patients with legionnaires' disease ill between 1978 and 1986 and, for comparison, a case series of patients with lung cancer. A prospectively developed register and interview based survey provided data on the location of cooling towers. Setting-The city of Glasgow. Patients-134 patients aged 14-84 with legionnaires' disease during 1978-86 and 10 159 patients with lung cancer during the same period. Main outcome measures-The locations of patients' homes and cooling towers as defined by postcodes, which provided map grid references accurate to 10 m; numbers of expected and observed cases of legionnaires' disease in census enumeration districts; and distance of enumeration districts from the nearest cooling tower as defined by five distance categories. Results-Most cooling towers were in or near the city centre or close to the River Clyde, as were the places of residence of patients with community acquired, non-travel, non-outbreak legionnaires' disease (n = 107). There was an inverse association between the distance of residence from any cooling tower and the risk of infection, the population living within 0.5 km of any tower having a relative risk of infection over three times that of people living more than 1 km away. There was no such association with respect to travel related legionnaires' disease, and for lung cancer the association was weak (relative risk less-than-or-equal-to 1.2 in any distance group). Conclusion-In Glasgow cooling towers have been a source of infection in two outbreaks of legionnaires' disease and, apparently, a source of non-outbreak infection also. Better maintenance of cooling towers should help prevent non-outbreak cases. This method of inquiry should be applied elsewhere to study the source of this and other environmentally acquired disease.	RUCHILL HOSP,DEPT LAB MED,GLASGOW G20 9NB,SCOTLAND; SCOTTISH HLTH SERV COMMON SERV AGCY,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,SCOTLAND		BHOPAL, RS (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.							ADDISS DG, 1989, J INFECT DIS, V159, P572, DOI 10.1093/infdis/159.3.572; ADDISS DG, 1989, AM J EPIDEMIOL, V130, P557, DOI 10.1093/oxfordjournals.aje.a115370; BAND JD, 1982, RECENT ADV INFECTION, V2, P101; BARTLETT CLR, 1986, LEGIONELLA INFECTION; BHOPAL R S, 1990, Health Bulletin (Edinburgh), V48, P288; BHOPAL RS, 1990, EPIDEMIOL INFECT, V104, P29, DOI 10.1017/S0950268800054492; BHOPAL RS, IN PRESS EPIDEMIOL I; BHOPAL RS, 1988, COMMUNICABLE DISEASE, V22, P7; BHOPAL RS, 1988, COMMUNICABLE DISEASE, V22, P2; BOLLIN GE, 1985, APPL ENVIRON MICROB, V50, P1128, DOI 10.1128/AEM.50.5.1128-1131.1985; Bovallius A, 1980, Ann N Y Acad Sci, V353, P186, DOI 10.1111/j.1749-6632.1980.tb18922.x; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; DEVENAY WT, WATER SUPPLY LOCH KA; DONDERO TJ, 1980, NEW ENGL J MED, V302, P365, DOI 10.1056/NEJM198002143020703; FALLON RJ, 1982, J CLIN PATHOL, V35, P434, DOI 10.1136/jcp.35.4.434; FALLON RJ, 1982, J HYG-CAMBRIDGE, V89, P439, DOI 10.1017/S002217240007100X; FALLON RJ, 1981, LABORATORY DIAGNOSIS; KLAUCKE DN, 1984, AM J EPIDEMIOL, V119, P382, DOI 10.1093/oxfordjournals.aje.a113756; KURITSKY JN, 1984, 2ND P INT S, P243; MUDER RR, 1986, ARCH INTERN MED, V146, P1607, DOI 10.1001/archinte.146.8.1607; NIMMO A W, 1989, Health Bulletin (Edinburgh), V47, P40; PASTORIS MC, 1984, J CLIN MICROBIOL, V20, P780, DOI 10.1128/JCM.20.4.780-783.1984; REDD SC, 1987, JAMA-J AM MED ASSOC, V27, P1221; STOUT JE, 1987, JAMA-J AM MED ASSOC, V257, P1215, DOI 10.1001/jama.257.9.1215; TIMBURY MC, 1986, J HYG-CAMBRIDGE, V97, P393, DOI 10.1017/S0022172400063580; WILKINSON HW, 1982, J CLIN MICROBIOL, V16, P979, DOI 10.1128/JCM.16.5.979-981.1982; 1987, 2ND COMM INQ OUTBR L; 1988, BROADCASTING HOUSE L; 1983, LANCET, V1, P103; 1986, POSTCODE DIRECTORY U, V1; 1986, LANCET, V2, P380	31	68	69	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					378	383		10.1136/bmj.302.6773.378	http://dx.doi.org/10.1136/bmj.302.6773.378			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	2004142	Green Published, Bronze			2022-12-28	WOS:A1991EX85800025
J	JENNINGS, M				JENNINGS, M			AUDIT OF A NEW APPOINTMENTS SYSTEM IN A HOSPITAL OUTPATIENT-CLINIC	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the effect of a new appointments system on patients' waiting time. Design-Replacement of an existing system of regularly spaced appointments at 10 minute intervals with one in which the doctor arranged appointments according to his perception of individual patients' requirements, from December 1988 to June 1989. Setting-One general medical outpatient clinic. Patients-All (436) patients under regular review with fixed appointment times during six months; those arriving for blood testing before the start of the clinic and those requiring ambulance transport were excluded. Main outcome measures-Mean waiting time (mean of difference between appointment time and start of consultation), maximum waiting time, number of patients, and total duration of clinics. Results-Mean waiting time was reduced by about 30 minutes (from 39.6 to 9.5 mins) over the six months. There was no change in the number of patients attending (mean 15.8 upsilon 15.4) or the duration of the clinics (mean 187 upsilon 160 mins). Conclusion-Efficiency was improved by simple adjustment to the appointments system used in the hospital outpatient clinic.			JENNINGS, M (corresponding author), UNIV SHEFFIELD,DEPT MED & PHARMACOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							HARRISON AT, 1987, BMJ-BRIT MED J, V294, P1465, DOI 10.1136/bmj.294.6585.1465	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					148	149		10.1136/bmj.302.6769.148	http://dx.doi.org/10.1136/bmj.302.6769.148			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	2009103	Bronze, Green Published			2022-12-28	WOS:A1991EU02000022
J	BIGIANI, AR; ROPER, SD				BIGIANI, AR; ROPER, SD			MEDIATION OF RESPONSES TO CALCIUM IN TASTE CELLS BY MODULATION OF A POTASSIUM CONDUCTANCE	SCIENCE			English	Article							RECEPTOR-CELLS; MEMBRANE-PROPERTIES; K+ CHANNELS; TRANSDUCTION; MUDPUPPY; SOUR	Calcium salts are strong taste stimuli in vertebrate animals. However, the chemosensory transduction mechanisms for calcium are not known. In taste buds of Necturus maculosus (mud puppy), calcium evokes depolarizing receptor potentials by acting extracellularly on the apical ends of taste cells to block a resting potassium conductance. Therefore, divalent cations elicit receptor potentials in taste cells by modulating a potassium conductance rather than by permeating the cell membrane, the mechanism utilized by monovalent cations such as sodium and potassium ions.	UNIV COLORADO,HLTH SCI CTR,ROCKY MT TASTE & SMELL CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	BIGIANI, AR (corresponding author), COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523, USA.		Bigiani, Albertino/G-3024-2015	Bigiani, Albertino/0000-0001-6987-488X; Roper, Stephen/0000-0001-6049-8320	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020486, R01NS024107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006557] Funding Source: NIH RePORTER; NIA NIH HHS [5 RO1 AG06557] Funding Source: Medline; NINDS NIH HHS [2 RO1 NS24107, 2 POI NS 20486] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; AKAIKE N, 1976, J PHYSIOL-LONDON, V254, P87, DOI 10.1113/jphysiol.1976.sp011223; ARMSTRONG CM, 1986, J GEN PHYSIOL, V87, P817, DOI 10.1085/jgp.87.5.817; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; AVENET P, 1987, J MEMBRANE BIOL, V95, P265, DOI 10.1007/BF01869488; AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; JUNGE D, 1970, COMP BIOCHEM PHYSIOL, V35, P623, DOI 10.1016/0010-406X(70)90979-5; KINNAMON SC, 1987, J PHYSIOL-LONDON, V383, P601; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1989, ANN NY ACAD SCI, V560, P112, DOI 10.1111/j.1749-6632.1989.tb24085.x; KINNAMON SC, 1988, CHEM SENSES, V13, P115, DOI 10.1093/chemse/13.1.115; KINNAMON SC, 1988, J GEN PHYSIOL, V91, P351, DOI 10.1085/jgp.91.3.351; KITADA Y, 1978, JPN J PHYSIOL, V28, P413; KURIHARA K, 1989, BIOSIGNAL RANSDUCTIO, P181; MCPHEETERS M, 1985, CHEM SENSES, V10, P341, DOI 10.1093/chemse/10.3.341; Moncrieff R.W., 1967, CHEM SENSES, V3rd; ROPER SD, 1989, J MEMBRANE BIOL, V109, P29, DOI 10.1007/BF01870788; ROPER SD, 1989, ANNU REV NEUROSCI, V12, P329, DOI 10.1146/annurev.ne.12.030189.001553; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SAND O, 1986, ACTA PHYSIOL SCAND, V126, P173, DOI 10.1111/j.1748-1716.1986.tb07803.x; SATO T, 1980, PROG NEUROBIOL, V14, P25, DOI 10.1016/0301-0082(80)90003-9; SCHIFFMAN SS, 1990, CHEM SENSES, V15, P129, DOI 10.1093/chemse/15.1.129; SPIELMAN AI, 1989, BRAIN RES, V503, P326, DOI 10.1016/0006-8993(89)91684-3; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0; VANDEMORTEL JBJ, 1990, BIOCHIM BIOPHYS ACTA, V1026, P220, DOI 10.1016/0005-2736(90)90067-X	25	41	41	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					126	128		10.1126/science.2011748	http://dx.doi.org/10.1126/science.2011748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011748				2022-12-28	WOS:A1991FE95200050
J	WEBER, JM; LEUNG, JO; SWANSON, SJ; IDLER, KB; MCALPINE, JB				WEBER, JM; LEUNG, JO; SWANSON, SJ; IDLER, KB; MCALPINE, JB			AN ERYTHROMYCIN DERIVATIVE PRODUCED BY TARGETED GENE DISRUPTION IN SACCHAROPOLYSPORA-ERYTHRAEA	SCIENCE			English	Article							RAT MAMMARY-GLAND; STREPTOMYCES-ERYTHREUS; MACROLIDE ANTIBIOTICS; MYCOBACTERIUM-AVIUM; NUCLEOTIDE-SEQUENCE; INVITRO ACTIVITIES; BIOSYNTHESIS; CLONING; IDENTIFICATION; HYDROLASE	Derivatives of erythromycin with modifications at their C-6 position are generally sought for their increased stability at acid pH, which in turn may confer improved pharmacological properties. A recombinant mutant of the erythromycin-producing bacterium, Saccharopolyspora erythraea, produced an erythromycin derivative, 6-deoxyerythromycin A, that could not be obtained readily by chemical synthesis. This product resulted from targeted disruption of the gene, designated eryF (systematic nomenclature, CYP107), that apparently codes for the cytochrome P450, 6-deoxyerythronolide B (DEB) hydroxylase, which converts DEB to erythronolide B (EB). Enzymes normally acting on EB can process the alternative substrate DEB to form the biologically active erythromycin derivative lacking the C-6 hydroxyl group.	ABBOTT LABS,ANTIINFECT RES,ABBOTT PK,IL 60064; ABBOTT LABS,CORP MOLEC BIOL,ABBOTT PK,IL 60064	Abbott Laboratories; Abbott Laboratories	WEBER, JM (corresponding author), ABBOTT LABS,DEPT 451-R5,BIOPROC DEV,N CHICAGO,IL 60064, USA.		Weber, J. Mark/AAF-5739-2020					Corcoran JW, 1981, ANTIBIOTICS, P132; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; EPP JK, 1989, GENE, V85, P293, DOI 10.1016/0378-1119(89)90421-6; FERNANDES PB, 1989, ANTIMICROB AGENTS CH, V33, P1531, DOI 10.1128/AAC.33.9.1531; FERNANDES PB, 1986, ANTIMICROB AGENTS CH, V30, P865, DOI 10.1128/AAC.30.6.865; HARDY DJ, 1988, ANTIMICROB AGENTS CH, V32, P1710, DOI 10.1128/AAC.32.11.1710; HARDY DR, UNPUB; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HOPWOOD DA, 1989, GENETICS MOL BIOL IN, P12; ISHIZAKI T, 1989, J BACTERIOL, V171, P596, DOI 10.1128/jb.171.1.596-601.1989; KANEMOTO RH, 1989, J BACTERIOL, V171, P2506, DOI 10.1128/jb.171.5.2506-2512.1989; KIRST HA, 1989, ANTIMICROB AGENTS CH, V33, P1413, DOI 10.1128/AAC.33.9.1413; MARTIN JR, 1974, J ANTIBIOT, V27, P570, DOI 10.7164/antibiotics.27.570; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; MCALPINE JR, UNPUB; NAGGERT J, 1987, BIOCHEM J, V243, P597, DOI 10.1042/bj2430597; NAIK S, 1989, ANTIMICROB AGENTS CH, V33, P1614, DOI 10.1128/AAC.33.9.1614; NEBERT DW, 1987, DNA-J MOLEC CELL BIO, V6, P1, DOI 10.1089/dna.1987.6.1; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OMER CA, 1990, J BACTERIOL, V172, P3335, DOI 10.1128/jb.172.6.3335-3345.1990; PAULUS TJ, 1990, J BACTERIOL, V172, P2541, DOI 10.1128/jb.172.5.2541-2546.1990; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; RINEHART KL, 1977, PURE APPL CHEM, V49, P1361, DOI 10.1351/pac197749091361; SAFFORD R, 1987, BIOCHEMISTRY-US, V26, P1358, DOI 10.1021/bi00379a023; SAKAKIBARA H, 1984, MACROLIDE ANTIBIOTIC, P85; SANGLARD D, 1989, GENE, V76, P121, DOI 10.1016/0378-1119(89)90014-0; SHAFIEE A, 1987, BIOCHEMISTRY-US, V26, P6204, DOI 10.1021/bi00393a037; SHIER WT, 1969, BIOCHEMISTRY-US, V63, P198; SWANSON RN, UNPUB; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WEBER JM, 1989, GENE, V75, P235, DOI 10.1016/0378-1119(89)90269-2; ZALKIN H, 1988, J BIOL CHEM, V263, P1595	34	138	156	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					114	117		10.1126/science.2011746	http://dx.doi.org/10.1126/science.2011746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011746				2022-12-28	WOS:A1991FE95200046
J	CIESIELSKI, SD; SEED, JR; ESPOSITO, DH; HUNTER, N				CIESIELSKI, SD; SEED, JR; ESPOSITO, DH; HUNTER, N			THE EPIDEMIOLOGY OF TUBERCULOSIS AMONG NORTH-CAROLINA MIGRANT FARM-WORKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULMONARY TUBERCULOSIS; BCG VACCINATION; SKIN-TEST; INFECTION; PRISON; SENSITIVITY; REACTIVITY; COMMUNITY; SHELTERS; FEATURES	Although tuberculosis (TB) has been recognized as a significant health problem of migrant farm workers, the nature and extent of the problem have been poorly defined. We report the first population-based study of TB in a random sample of farm workers (n = 543) and the first use of recall antigens in an epidemiologic study of TB. Purified protein derivative positivity ranged from 33% in Hispanics to 54% in US-born blacks and 76% in Haitians. Active tubercular disease occurred in 3.6% of US-born blacks and 0.47% of Hispanics. Among US-born blacks, risk factors associated with farm work were most significant. Blacks born in the United States also had the highest prevalence of anergy. The use of recall antigens made possible a better description of the epidemiology of TB by excluding false negatives and clarifying associations between infection and risk factors. We conclude that TB among farm workers represents a serious public health problem with previously unrecognized risk factors. Additional resources for migrant health care, improvements in health care access, and fundamental changes in the system of migrant labor are all necessary to reduce the transmission of TB.	N CAROLINA STATE LAB PUBL HLTH,DIV LAB SERV,MICROBIOL BRANCH,RALEIGH,NC; UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC 27514; UNIV N CAROLINA,SCH PUBL HLTH,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	CIESIELSKI, SD (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT PARASITOL & LAB PRACTICE,CHAPEL HILL,NC 27599, USA.							ABELES H, 1970, AM REV RESPIR DIS, V101, P706; American Thoracic Society, 1981, AM REV RESPIR DIS, V124, P356; [Anonymous], 1988, MMWR, V36, P817; BARRY MA, 1986, PUBLIC HEALTH REP, V101, P487; BATTERSHILL JH, 1980, CHEST, V77, P188, DOI 10.1378/chest.77.2.188; BHATNAGAR R, 1977, AM REV RESPIR DIS, V115, P207; BLEIKER MA, 1983, TUBERCLE, V64, P255, DOI 10.1016/0041-3879(83)90022-3; BONANNO G, 1983, DRUG ALCOHOL DEPEN, V12, P189, DOI 10.1016/0376-8716(83)90044-3; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CAPEWELL S, 1986, BRIT J DIS CHEST, V80, P37, DOI 10.1016/0007-0971(86)90007-0; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAPARAS SD, 1982, CRIT REV MICROBIOL, V9, P193; COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363, DOI 10.1093/oxfordjournals.aje.a112105; COMSTOCK GW, 1986, AM J EPIDEMIOL, V124, P1; HERSHFIELD L, 1977, CHEST, V76, P805; HOLDEN M, 1971, NEW ENGL J MED, V285, P1506, DOI 10.1056/NEJM197112302852704; JACOBSON ML, 1987, AM J PUBLIC HEALTH, V77, P29, DOI 10.2105/AJPH.77.1.29; JONCAS JH, 1975, CAN MED ASSOC J, V113, P127; Kent PT, 1985, GUIDE LEVEL 3 LAB; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; KIRKPATRICK CH, 1964, J EXP MED, V119, P727, DOI 10.1084/jem.119.5.727; MCKEOWN T, 1976, ROLE MED; MCMURRAY DN, 1978, AM REV RESPIR DIS, V118, P827; MORLAND B, 1982, ACTA PHARMACOL TOX, V50, P221; NASH DR, 1980, CHEST, V77, P32, DOI 10.1378/chest.77.1.32; PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7; PEREZSTABLE EJ, 1986, AM J PUBLIC HEALTH, V76, P643, DOI 10.2105/AJPH.76.6.643; PIO A, 1976, B OFIC SANIT PANAM, V80, P281; PITCHENIK AE, 1982, NEW ENGL J MED, V307, P162, DOI 10.1056/NEJM198207153070306; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; RUST GS, 1990, AM J PUBLIC HEALTH, V80, P1213, DOI 10.2105/AJPH.80.10.1213; SALIMUDDIN A, 1985, TUBERCLE, V66, P133; SHAH BV, 1986, SURVEY DATA ANAL SOF; SHANNON DC, 1966, NEW ENGL J MED, V275, P690, DOI 10.1056/NEJM196609292751302; SHOTLAND J, 1989, FULL FIELDS EMPTY CU; SLUTKIN G, 1986, PUBLIC HEALTH REP, V101, P481; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; STEINER P, 1980, AM J DIS CHILD, V134, P747, DOI 10.1001/archpedi.1980.02130200017007; TERRIS M, 1948, AM J PUBLIC HEALTH, V38, P1061; TRACHTMAN L, 1978, JAMA-J AM MED ASSOC, V240, P739, DOI 10.1001/jama.1978.03290080029014; WATSON H, 1984, ARIZ MED, V41, P665; WEBER DJ, 1989, SOUTHERN MED J, V82, P1204, DOI 10.1097/00007611-198910000-00003; ZEITZ SJ, 1974, J ALLERGY CLIN IMMUN, V53, P20, DOI 10.1016/0091-6749(74)90095-5; 1979, TUBERCLE, V60, P191; 1987, MMWR, V36, P212; 1988, MMWR, V37, P517; 1987, MMWR, V36, P785; 1982, TUBERCULOSIS US 1979; 1987, MMWR, V36, P493; 1985, ALCOHOL ALCOHOLISM, V20, P89; 1989, MMWR, V38, P236; 1982, MMWR, V31, P237; 1987, MMWR, V36, P257; 1987, MMWR, V36, P795; 1977, RECOMMENDATIONS COUN; 1986, 1985 TUBERCULOSIS ST; 1987, MMWR, V34, P429; 1986, JAMA-J AM MED ASSOC, V256, P977; 1989, MMWR, V38, P313; 1961, RECOMMENDATIONS REPO; 1985, TUBERCULOSIS MIGRANT; 1989, MMWR, V38, pS3; 1987, MMWR, V36, P77	63	59	59	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1715	1719		10.1001/jama.265.13.1715	http://dx.doi.org/10.1001/jama.265.13.1715			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD659	2002573				2022-12-28	WOS:A1991FD65900028
J	LOBOS, E; WEISS, N; KARAM, M; TAYLOR, HR; OTTESEN, EA; NUTMAN, TB				LOBOS, E; WEISS, N; KARAM, M; TAYLOR, HR; OTTESEN, EA; NUTMAN, TB			AN IMMUNOGENIC ONCHOCERCA-VOLVULUS ANTIGEN - A SPECIFIC AND EARLY MARKER OF INFECTION	SCIENCE			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI; SEQUENCE	Onchocerciasis (river blindness) is a serious health problem and a severe obstacle to social and economic development, especially in Africa. A complementary DNA fragment coding for an Onchocerca volvulus antigen (OV-16) was cloned and expressed in the plasmid vector pCG808fx. Immune responses to this O. volvulus-specific recombinant antigen were detectable in patients with documented onchocerciasis; the antibody response was also detectable at 3 months and at more than 1 year before infection could otherwise be detected in humans and in chimpanzees experimentally infected with O. volvulus third-stage larvae.	JOHNS HOPKINS UNIV,WILMER OPHTHALMOL INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205; SWISS TROP INST,CH-4051 BASEL,SWITZERLAND; WHO,ONCHOCERCIASIS CONTROL PROGRAMME,OUAGADOUGOU,BURKINA FASO	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of Basel; Swiss Tropical & Public Health Institute; World Health Organization	LOBOS, E (corresponding author), NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.			Taylor, Hugh/0000-0002-9437-784X				AZIZ M A, 1986, Parasitology Today, V2, P233, DOI 10.1016/0169-4758(86)90001-3; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; GUAN C, 1987, GENE, V67, P21; KARAM M, 1985, AM J TROP MED HYG, V40, P261; LOBOS E, 1986, PARASITOLOGY, V93, P389, DOI 10.1017/S0031182000051556; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; LOBOS E, UNPUB; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MORT JS, 1988, BIOL CHEM H-S, V369, P163; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; TAYLOR HR, 1990, SCIENCE, V250, P116, DOI 10.1126/science.2218502; TAYLOR HR, 1988, AM J TROP MED HYG, V39, P86, DOI 10.4269/ajtmh.1988.39.86; VERNET T, 1989, GENE, V77, P229, DOI 10.1016/0378-1119(89)90071-1; WALSH J, 1986, SCIENCE, V232, P922, DOI 10.1126/science.3754652; WEISS N, UNPUB; WEISS N, 1987, CIBA F S, V27, P180; 1976, WHO TECH REP SER, V597; 1987, WHO TECH REP SER, V752	18	123	125	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1603	1605		10.1126/science.2011741	http://dx.doi.org/10.1126/science.2011741			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011741				2022-12-28	WOS:A1991FD89000035
J	SATO, J; PERL, ER				SATO, J; PERL, ER			ADRENERGIC EXCITATION OF CUTANEOUS PAIN RECEPTORS INDUCED BY PERIPHERAL-NERVE INJURY	SCIENCE			English	Article							REFLEX SYMPATHETIC DYSTROPHY; UNMYELINATED C FIBERS; POLYMODAL NOCICEPTORS; STIMULATION; SENSITIVITY; CAUSALGIA; RAT; MECHANISMS; ACTIVATION; UNITS	The mechanisms by which peripheral nerve injuries sometimes lead to causalgia, aberrant burning pain peripheral to the site of nerve damage, are uncertain, although the sympathetic nervous system is known to be involved. Whether such syndromes could be the result of the development of responsiveness by some cutaneous pain receptors (C-fiber nociceptors) to sympathetic efferent activity as a consequence of the nerve injury was tested in an animal model. After nerve damage but not in its absence, sympathetic stimulation and norepinephrine were excitatory for a subset of skin C-fiber nociceptors and enhanced the responsiveness of these nociceptors to tissue-damaging stimulation. These effects were demonstrable within days after nerve lesions, occurred at the cutaneous receptive terminal region, were manifest in sensory fibers that had not degenerated after the injury, and were mediated by alpha-2-adrenergic-like receptors.	UNIV N CAROLINA,DEPT PHYSIOL,CB 7545,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014899] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10321, NS14899] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARASI S, 1986, BRAIN RES, V378, P21, DOI 10.1016/0006-8993(86)90282-9; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; BESSOU P, 1969, J NEUROPHYSIOL, V32, P1025, DOI 10.1152/jn.1969.32.6.1025; CANNON WB, 1949, SUPERSENSITIVITY DEN, P25; COHEN RH, 1990, J NEUROPHYSIOL, V64, P457, DOI 10.1152/jn.1990.64.2.457; DAVIES B, 1982, J CLIN INVEST, V69, P779, DOI 10.1172/JCI110516; DEVOR M, 1983, J AUTONOM NERV SYST, V7, P371, DOI 10.1016/0165-1838(83)90090-5; DEVOR M, 1981, NEUROSCI LETT, V24, P43, DOI 10.1016/0304-3940(81)90356-6; ECKER A, 1984, PSYCHIAT ANN, V14, P787, DOI 10.3928/0048-5713-19841101-08; Feldberg W, 1926, J PHYSIOL-LONDON, V61, P518, DOI 10.1113/jphysiol.1926.sp002313; HANNINGTONKIFF JG, 1974, PAIN RELIEF, P75; HU SJ, 1989, PAIN, V38, P85, DOI 10.1016/0304-3959(89)90077-8; KORENMAN EMD, 1981, EXP NEUROL, V72, P63, DOI 10.1016/0014-4886(81)90127-8; Levitzki A, 1978, Rev Physiol Biochem Pharmacol, V82, P1, DOI 10.1007/BFb0030496; Mitchell SW., 1864, GUNSHOT WOUNDS OTHER; NATHAN PW, 1947, BRAIN, V70, P145, DOI 10.1093/brain/70.2.145; OCHOA J, 1983, ADV PAIN RES THER, V5, P99; RICHARDS RL, 1967, ARCH NEUROL-CHICAGO, V16, P339, DOI 10.1001/archneur.1967.00470220003001; ROBERTS WJ, 1985, SOMATOSENS RES, V3, P33, DOI 10.3109/07367228509144575; ROBERTS WJ, 1986, PAIN, V24, P297, DOI 10.1016/0304-3959(86)90116-8; SCADDING JW, 1981, EXP NEUROL, V73, P345, DOI 10.1016/0014-4886(81)90271-5; SCHOTT GD, 1986, BRAIN, V109, P717, DOI 10.1093/brain/109.4.717; SCHWARTZMAN RJ, 1987, ARCH NEUROL-CHICAGO, V44, P555, DOI 10.1001/archneur.1987.00520170081028; SHEA VK, 1985, J NEUROPHYSIOL, V54, P502, DOI 10.1152/jn.1985.54.3.502; SHEA VK, 1985, J NEUROPHYSIOL, V54, P491, DOI 10.1152/jn.1985.54.3.491; SHEA VK, 1985, J NEUROPHYSIOL, V54, P513, DOI 10.1152/jn.1985.54.3.513; TOREBJOR.HE, 1974, ACTA PHYSIOL SCAND, V92, P374, DOI 10.1111/j.1748-1716.1974.tb05755.x; WALLIN G, 1976, SENSORY FUNCTIONS SK, P489; WIESENFELDHALLIN Z, 1984, HUM NEUROBIOL, V3, P41	29	480	492	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1608	1610		10.1126/science.2011742	http://dx.doi.org/10.1126/science.2011742			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011742				2022-12-28	WOS:A1991FD89000037
J	HAMILTON, DP				HAMILTON, DP			COLD FUSION - BATTLE OF THE BOOKS	SCIENCE			English	Editorial Material																		FIRE ICE SEARCHING T; TOO HOT HANDLE RACE	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1415	1415						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006415				2022-12-28	WOS:A1991FC85300015
J	ORCI, L; TAGAYA, M; AMHERDT, M; PERRELET, A; DONALDSON, JG; LIPPINCOTTSCHWARTZ, J; KLAUSNER, RD; ROTHMAN, JE				ORCI, L; TAGAYA, M; AMHERDT, M; PERRELET, A; DONALDSON, JG; LIPPINCOTTSCHWARTZ, J; KLAUSNER, RD; ROTHMAN, JE			BREFELDIN-A, A DRUG THAT BLOCKS SECRETION, PREVENTS THE ASSEMBLY OF NON-CLATHRIN-COATED BUDS ON GOLGI CISTERNAE	CELL			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; VESICULAR TRANSPORT; INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; FUSION PROTEIN; STACK; YEAST; RECONSTITUTION; COMPLEX	We report that brefeldin A prevents the assembly of non-clathrin-coated vesicles from Golgi cisternae in a cell-free system. This finding provides a simple molecular explanation for the primary effect of this remarkable compound in blocking constitutive secretion. We further report that when coated vesicle assembly is blocked, extensive tubule networks form that connect previously separate cisternae and stacks into a single topological unit, allowing the intermixing of contents of Golgi cisternae, presumably by lateral diffusion. Formation of the tubule networks requires ATP, cytosol, and the general fusion protein NSF. Tubule networks may be related to the membrane tubules mediating retrograde transport in vivo.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544; NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	Princeton University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	ORCI, L (corresponding author), UNIV GENEVA,SCH MED,INST HISTOL & EMBRYOL,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027044, R37DK027044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ARMBRUSTER BL, 1982, J MICROSC-OXFORD, V126, P77, DOI 10.1111/j.1365-2818.1982.tb00358.x; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; COREY E J, 1976, Tetrahedron Letters, V51, P4701; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, IN PRESS J CELL BIOL; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; LEDRIAN C, 1982, J AM CHEM SOC, V104, P5473, DOI 10.1021/ja00384a038; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P215; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; TANDLER B, 1990, J ELECTRON MICR TECH, V16, P81, DOI 10.1002/jemt.1060160110; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	40	439	447	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1183	1195						13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004424				2022-12-28	WOS:A1991FD55800016
J	EDDY, DM				EDDY, DM			THE INDIVIDUAL VS SOCIETY - IS THERE A CONFLICT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									DUKE UNIV,DURHAM,NC 27706	Duke University								CANELLOS GP, 1990, J CLIN ONCOL, V8, P1775, DOI 10.1200/JCO.1990.8.11.1775; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1161, DOI 10.1001/jama.264.9.1161; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1169; EDDY DM, 1986, NCI MONOGRAPHS, V2, P75; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1165; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1170	7	39	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1446	&		10.1001/jama.265.11.1446	http://dx.doi.org/10.1001/jama.265.11.1446			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB550	1999888				2022-12-28	WOS:A1991FB55000029
J	SCHILLER, PH; LEE, KM				SCHILLER, PH; LEE, KM			THE ROLE OF THE PRIMATE EXTRASTRIATE AREA V4 IN VISION	SCIENCE			English	Article							MONKEY VISUAL-CORTEX; STATE DEPENDENT ACTIVITY; DISCRIMINATION; MACAQUE; COLOR; HUE	Area V4 is a part of the primate visual cortex. Its role in vision has been extensively debated. Inferences about the functions of this area have now been made by examination of a broad range of visual capacities after ablation of V4 in rhesus monkeys. The results obtained suggest that this area is involved in more complex aspects of visual information processing than had previously been suggested. Monkeys had particularly severe deficits in situations where the task was to select target stimuli that had a lower contrast, smaller size, or slower rate of motion than the array of comparison stimuli from which they had to be discriminated. Extensive training on each specific task resulted in improved performance. However, after V4 ablation, the monkeys could not generalize the specific task to new stimulus configurations and to new spatial locations.			SCHILLER, PH (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139, USA.		Lee, Kyoung Min/J-2775-2012		NATIONAL EYE INSTITUTE [R01EY000676, R37EY000676] Funding Source: NIH RePORTER; NEI NIH HHS [EY00676] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Blake R., 1990, PERCEPTION; CAVANAGH P, 1990, J EXP PSYCHOL HUMAN, V16, P479, DOI 10.1037/0096-1523.16.3.479; DEAN P, 1979, EXP BRAIN RES, V35, P69; DESIMONE R, 1985, VISION RES, V25, P441, DOI 10.1016/0042-6989(85)90069-0; DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; GROSS CG, 1973, PROGR PHYSL PSYCHOL; GROSS CG, 1977, LATERAL NERVOUS SYST; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; HAENNY PE, 1988, EXP BRAIN RES, V69, P245, DOI 10.1007/BF00247570; HEYWOOD CA, 1987, J NEUROSCI, V7, P2601; LOGOTHETIS NK, 1990, SCIENCE, V247, P214, DOI 10.1126/science.2294602; MAGUIRE WM, 1984, J NEUROSCI, V4, P1690; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; ROBINSON DA, 1963, IEEE T BIOMED ENG, V101, P131; SCHEIN SJ, 1990, J NEUROSCI, V10, P3369; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; TREISMAN A, 1988, PSYCHOL REV, V95, P15, DOI 10.1037/0033-295X.95.1.15; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; WILD HM, 1985, NATURE, V313, P133, DOI 10.1038/313133a0; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0	24	173	174	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1251	1253		10.1126/science.2006413	http://dx.doi.org/10.1126/science.2006413			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006413				2022-12-28	WOS:A1991FA69100048
J	FERRARA, JLM; DEEG, HJ				FERRARA, JLM; DEEG, HJ			GRAFT-VERSUS-HOST DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; T-CELL DEPLETION; LYMPHOCYTES-T; CYCLOSPORINE; ACTIVATION; CLONES; MOUSE		CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA; FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA	Harvard University; Boston Children's Hospital; Fred Hutchinson Cancer Center	FERRARA, JLM (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV PEDIAT ONCOL, 44 BINNEY ST, BOSTON, MA 02115 USA.				NCI NIH HHS [CA18221, CA39542, CA31787] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA039542, P01CA018221, R01CA031787] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; Billingham R E, 1966, Harvey Lect, V62, P21; CULPEPPER J, 1987, LYMPHOKINES, V13, P275; Deeg HJ, 1990, GRAFT VS HOST DISEAS, P311; FERRARA JLM, 1989, TRANSPLANTATION, V47, P50, DOI 10.1097/00007890-198901000-00012; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FISCHER AC, 1989, J EXP MED, V169, P1031, DOI 10.1084/jem.169.3.1031; GALE RP, 1986, LANCET, V1, P1468; GHAYUR T, 1987, TRANSPLANTATION, V44, P261, DOI 10.1097/00007890-198708000-00017; GHAYUR T, 1990, GRAFT VS HOST DISEAS, P109; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GOWANS JL, 1962, ANN NY ACAD SCI, V99, P432, DOI 10.1111/j.1749-6632.1962.tb45326.x; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HERVE P, 1990, BLOOD, V75, P1017; HESS AD, 1985, J EXP MED, V161, P718, DOI 10.1084/jem.161.4.718; HESS AD, 1989, TRANSPLANTATION, V48, P895, DOI 10.1097/00007890-198912000-00001; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; JUJI T, 1989, NEW ENGL J MED, V321, P56; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KERNAN NA, 1986, BLOOD, V68, P770; KORNGOLD R, 1990, GRAFT VERSUS HOST DI, P31; KRENSKY AM, 1990, NEW ENGL J MED, V322, P510, DOI 10.1056/NEJM199002223220805; MAIER T, 1986, IMMUNOL TODAY, V7, P312, DOI 10.1016/0167-5699(86)90069-1; MARTIN PJ, 1988, AM J KIDNEY DIS, V11, P149, DOI 10.1016/S0272-6386(88)80201-4; MARTIN PJ, 1990, CLIN ASPECTS AUTOIMM, V4, P8; MCGREGOR DD, 1968, J EXP MED, V127, P953, DOI 10.1084/jem.127.5.953; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARKMAN R, 1986, J IMMUNOL, V136, P3543; PIGUET PF, 1990, GRAFT VS HOST DISEAS, P225; POYNTON CH, 1988, BONE MARROW TRANSPL, V3, P265; RAPPEPORT J, 1979, LANCET, V2, P717; SALE GE, 1985, AM J PATHOL, V118, P278; SALE GE, 1984, PATHOLOGY BONE MARRO; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; SOSMAN JA, 1990, BLOOD, V75, P2005; SPITZER TR, 1990, GRAFT VERSUS HOST DI, P539; STORB R, 1983, NEW ENGL J MED, V308, P302, DOI 10.1056/NEJM198302103080602; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1990, TRANSPL P, V22, P1336; SYKES M, 1990, J EXP MED, V171, P645, DOI 10.1084/jem.171.3.645; SYMINGTON FW, 1989, J IMMUNOL IMMUNOPHAR, V9, P214; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TRUITT RL, 1990, GRAFT VS HOST DISEAS, P177; TUTSCHKA PJ, 1986, INT J CELL CLONING, V4, P181, DOI 10.1002/stem.5530040718; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; VALLERA DA, 1989, TRANSPLANTATION, V47, P751, DOI 10.1097/00007890-198905000-00001; VANBEKKUM DW, 1967, RAD CHIMERAS; VOGELSANG GB, 1990, BONE MARROW TRANSPL, P55; Vossen J, 1990, GRAFT VS HOST DISEAS, P403; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359; WINGARD JR, 1989, BLOOD, V74, P1428	56	1131	1161	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					667	674						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA144	1994250				2022-12-28	WOS:A1991FA14400005
J	ITO, N; PHILLIPS, SEV; STEVENS, C; OGEL, ZB; MCPHERSON, MJ; KEEN, JN; YADAV, KDS; KNOWLES, PF				ITO, N; PHILLIPS, SEV; STEVENS, C; OGEL, ZB; MCPHERSON, MJ; KEEN, JN; YADAV, KDS; KNOWLES, PF			NOVEL THIOETHER BOND REVEALED BY A 1.7-A CRYSTAL-STRUCTURE OF GALACTOSE-OXIDASE	NATURE			English	Article							RIBONUCLEOTIDE REDUCTASE; SUPEROXIDE-DISMUTASE; RADICAL SITE; COPPER; RESOLUTION; ENZYME; IDENTIFICATION; INVOLVEMENT; CATALYSIS; SYSTEM	GALACTOSE oxidase is an extracellular enzyme secreted by the fungus Dactylium dendroides. It is monomeric, with a relative molecular mass of 68,000, catalyses the stereospecific oxidation of a broad range of primary alcohol substrates and possesses a unique mononuclear copper site essential for catalysing a two-electron transfer reaction during the oxidation of primary alcohols to corresponding aldehydes 1. Recent evidence 2 arguing against a Cu(III)-Cu(I) couple 3 implies the existence of a second redox-active site proposed to involve pyrroloquinoline quinone 4 or a tyrosine radical 5,6. We now report the crystal structure of galactose oxidase at 1.7 angstrom resolution. This reveals a unique structural feature at the copper site with a novel thioether bond linking Cys 228 and Tyr 272 in a stacking interaction with Trp 290. We propose that these molecular components stabilize the protein free-radical species essential for catalysis and thus provide a 'built-in' secondary cofactor. This feature may represent a new mechanism for mediating electron transfer in metalloenzymes in the absence of exogenous cofactors.			ITO, N (corresponding author), UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			McPherson, Michael/0000-0002-0719-6427; Phillips, Simon/0000-0001-8922-0250				BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BLACKBURN NJ, 1984, BIOCHEM J, V219, P985, DOI 10.1042/bj2190985; DOOLEY DM, 1987, LIFE CHEM REPORTS, V5, P91; GUSS JM, 1983, J MOL BIOL, V169, P521; HAMILTON GA, 1978, J AM CHEM SOC, V100, P1899, DOI 10.1021/ja00474a042; JACOBSON RR, 1988, J AM CHEM SOC, V110, P3690, DOI 10.1021/ja00219a071; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KOSMAN DJ, 1974, ARCH BIOCHEM BIOPHYS, V165, P456, DOI 10.1016/0003-9861(74)90271-9; KOSMAN DJ, 1984, COPPER PROTEINS COPP, V1, P1; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LERCH K, 1982, J BIOL CHEM, V257, P6414; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; POULOS TL, 1980, J BIOL CHEM, V255, P8199; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PRINCE RC, 1990, TRENDS BIOCHEM SCI, V15, P170, DOI 10.1016/0968-0004(90)90152-2; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TRESSEL P, 1980, BIOCHEM BIOPH RES CO, V92, P781, DOI 10.1016/0006-291X(80)90771-8; VANDERMEER RA, 1989, J BIOL CHEM, V264, P7792; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104	30	694	706	2	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					87	90		10.1038/350087a0	http://dx.doi.org/10.1038/350087a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002850				2022-12-28	WOS:A1991FA69300073
J	MCFADDEN, EP; CLARKE, JG; DAVIES, GJ; KASKI, JC; HAIDER, AW; MASERI, A				MCFADDEN, EP; CLARKE, JG; DAVIES, GJ; KASKI, JC; HAIDER, AW; MASERI, A			EFFECT OF INTRACORONARY SEROTONIN ON CORONARY VESSELS IN PATIENTS WITH STABLE ANGINA AND PATIENTS WITH VARIANT ANGINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISOLATED CANINE; ARTERIES; RESPONSES; ENDOTHELIUM; DISEASE; 5-HYDROXYTRYPTAMINE; INHIBITION; ANTAGONIST; PLATELETS; RECEPTOR	Background. Serotonin, a major product of platelet activation, has potent vasoactive effects in animal models, but its role in human coronary artery disease remains largely speculative. Methods. Using quantitative coronary angiography, we compared the effects of the intracoronary infusion of graded concentrations of serotonin (10(-7) to 10(-4) mol per liter) on coronary vessels in two groups of patients with different clinical presentations of coronary disease (nine with stable angina and five with variant angina), with the effects in a control group of eight subjects with normal vessels on angiography. Results. Normal coronary vessels had a biphasic response to intracoronary serotonin: dilation at concentrations up to 10(-5) mol per liter, but constriction at 10(-4) mol per liter. Vessels in patients with stable angina constricted at all concentrations, with mean (+/- SEM) maximal decreases in diameter of 23.9 +/- 3.6, 33.1 +/- 3.9, and 41.7 +/- 3.1 percent from base line in proximal, middle, and distal segments at a serotonin concentration of 10(-4) mol per liter. Smooth segments constricted more than irregular segments (42.0 +/- 4.6 vs. 21.1 +/- 1.6 percent). Four patients with stable angina had a marked reduction in collateral filling. All the patients with stable angina had angina during the intracoronary infusion of serotonin, and electrocardiographic changes were noted in six. All the patients with variant angina had angina, electrocardiographic changes, and localized occlusive epicardial coronary-artery spasm at concentrations of 10(-6) (n = 2) or 10(-5) (n = 3) mol per liter. Conclusions. Patients with stable coronary disease do not have the normal vasodilator response to intracoronary serotonin, but rather have progressive constriction, which is particularly intense in small distal and collateral vessels. Patients with variant angina have occlusive coronary-artery spasm at a dose that dilates normal vessels and causes only slight constriction in vessels from patients with stable angina. These findings suggest that serotonin, released after the intracoronary activation of platelets, may contribute to or cause myocardial ischemia in patients with coronary artery disease.			MCFADDEN, EP (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,CARDIOVASC RES UNIT,DUCANE RD,LONDON W12 0NN,ENGLAND.							Austen W G, 1975, Circulation, V51, P5; BENEDICT CR, 1986, CIRC RES, V58, P58, DOI 10.1161/01.RES.58.1.58; BERKENBOOM G, 1989, CARDIOVASC RES, V23, P780, DOI 10.1093/cvr/23.9.780; BERTHOLD H, 1989, N-S ARCH PHARMACOL, V339, P259; BOLLI R, 1989, J AM COLL CARDIOL, V14, P460, DOI 10.1016/0735-1097(89)90202-7; BOLLI R, 1984, J AM COLL CARDIOL, V3, P1417, DOI 10.1016/S0735-1097(84)80280-6; BRUCE RA, 1971, ANN CLIN RES, V3, P323; DECLERCK F, 1984, AGENTS ACTIONS, V15, P627; DEHMER GJ, 1989, CIRCULATION, V79, P116; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; GINSBURG R, 1984, CIRCULATION, V69, P430, DOI 10.1161/01.CIR.69.2.430; HEISTAD DD, 1984, CIRC RES, V54, P711, DOI 10.1161/01.RES.54.6.711; HIRSH P D, 1981, New England Journal of Medicine, V304, P685, DOI 10.1056/NEJM198103193041201; HOUSTON DS, 1986, J CLIN INVEST, V78, P539, DOI 10.1172/JCI112606; KASKI JC, 1986, CIRCULATION, V74, P1255, DOI 10.1161/01.CIR.74.6.1255; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; MACALPIN RN, 1980, CIRCULATION, V61, P296, DOI 10.1161/01.CIR.61.2.296; MASERI A, 1990, CIRCULATION, V81, P1983, DOI 10.1161/01.CIR.81.6.1983; MASERI A, 1987, J AM COLL CARDIOL, V9, P249, DOI 10.1016/S0735-1097(87)80372-8; NEWMAN CM, 1990, AM J CARDIOL, V66, P1070, DOI 10.1016/0002-9149(90)90507-W; ORLANDI C, 1986, MICROVASC RES, V32, P121, DOI 10.1016/0026-2862(86)90048-8; PUPITA G, 1990, NEW ENGL J MED, V323, P514, DOI 10.1056/NEJM199008233230804; RENTROP KP, 1985, J AM COLL CARDIOL, V5, P587; RUBANYI GM, 1987, J AM COLL CARDIOL, V9, P1243, DOI 10.1016/S0735-1097(87)80462-X; SHIMOKAWA H, 1988, CIRCULATION, V78, P1421, DOI 10.1161/01.CIR.78.6.1421; SHIMOKAWA H, 1987, CIRC RES, V61, P256, DOI 10.1161/01.RES.61.2.256; VANHOUTTE PM, 1983, BIOCHEM PHARMACOL, V32, P3671, DOI 10.1016/0006-2952(83)90134-X; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198	28	348	348	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					648	654		10.1056/NEJM199103073241002	http://dx.doi.org/10.1056/NEJM199103073241002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA144	1994247				2022-12-28	WOS:A1991FA14400002
J	RIGOTTI, NA; NEER, RM; SKATES, SJ; HERZOG, DB; NUSSBAUM, SR				RIGOTTI, NA; NEER, RM; SKATES, SJ; HERZOG, DB; NUSSBAUM, SR			THE CLINICAL COURSE OF OSTEOPOROSIS IN ANOREXIA-NERVOSA - A LONGITUDINAL-STUDY OF CORTICAL BONE MASS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY HYPERPARATHYROIDISM; GROWTH-HORMONE; FRACTURE RISK; SOMATOMEDIN-C; WOMEN; OSTEOPENIA; DENSITY; AMENORRHEA; PREDICTION; CALCIUM	Women with anorexia nervosa have reduced bone mass and may develop fractures. Neither the pathophysiology of this osteoporosis nor its natural history is known. To study the clinical course of osteoporosis, we followed up 27 women with anorexia nervosa for a median of 25 months (range, 9 to 53 months). At study entry, cortical bone density, measured by single-photon absorptiometry of the radial shaft, was low (mean +/- SD, 0.63 +/- 0.07 g/cm2) and inversely related to the duration of amenorrhea (r = -0.49). During follow-up, most patients gained weight (n = 19), took calcium supplements (n = 16), and exercised regularly (n = 22), but fewer than half reached 80% or more of ideal body weight (n = 11), resumed menses (n = 6), or received estrogen (n = 4). Cortical bone density was stable during follow-up for the group as a whole; the mean annual change (+/-SD) was +0.005 (+/- .015) g/cm2 (95% confidence interval, -0.0009 to +0.0109). There was no significant difference in the mean change in bone density between women who attained 80% of ideal weight and those who did not or between groups who did or did not regain menses, take estrogen or calcium, or exercise vigorously. Four fractures were clinically observed in three women during follow-up. The rate of 0.05 nonspine fractures per person-year (95% confidence interval, 0.02 to 0.13) exceeds that of normal women in this age range (relative risk, 7.1; 95% confidence interval, 2.3 to 18.5). We conclude that reductions in cortical bone density appear not to be rapidly reversed recovery from anorexia nervosa and that anorectic women may have an increased risk of fracture.	MASSACHUSETTS GEN HOSP,MED SERV,ENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PSYCHIAT SERV,EATING DISORDERS UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	RIGOTTI, NA (corresponding author), MASSACHUSETTS GEN HOSP,MED SERV,GEN INTERNAL MED UNIT,BULFINCH 1,FRUIT ST,BOSTON,MA 02114, USA.				NCRR NIH HHS [RR-1066] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AYERS JWT, 1984, FERTIL STERIL, V41, P224; BACHRACH LK, 1990, PEDIATRICS, V86, P440; BILLER BMK, 1989, J CLIN ENDOCR METAB, V68, P548, DOI 10.1210/jcem-68-3-548; BLOCK G, 1982, AM J EPIDEMIOL, V115, P492, DOI 10.1093/oxfordjournals.aje.a113331; Cameron J R, 1968, Invest Radiol, V3, P141, DOI 10.1097/00004424-196805000-00001; CANN CE, 1985, BONE, V6, P1, DOI 10.1016/8756-3282(85)90399-0; CHOLST IN, 1984, NEW ENGL J MED, V310, P1221, DOI 10.1056/NEJM198405103101904; CLEMMONS DR, 1979, NEW ENGL J MED, V301, P1138, DOI 10.1056/NEJM197911223012102; CLEMMONS DR, 1981, J CLIN ENDOCR METAB, V53, P1247, DOI 10.1210/jcem-53-6-1247; CROSBY LO, 1985, CLIN ORTHOP RELAT R, V201, P271; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DAVIES KM, 1990, BONE, V11, P143, DOI 10.1016/8756-3282(90)90207-F; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; DRINKWATER BL, 1986, JAMA-J AM MED ASSOC, V256, P380, DOI 10.1001/jama.256.3.380; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; FONESCA VA, 1988, J CLIN PATHOL, V41, P195; GARDSELL P, 1989, CALCIFIED TISSUE INT, V44, P235, DOI 10.1007/BF02553757; GARRAWAY WM, 1979, MAYO CLIN PROC, V54, P701; GRANDE F, 1980, MODERN NUTRITION HLT, P7; HINTZ RL, 1978, J PEDIATR-US, V92, P153, DOI 10.1016/S0022-3476(78)80099-7; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem-67-4-701; JOYCE JM, 1990, J NUCL MED, V31, P325; KAPLAN FS, 1986, CLIN ORTHOP RELAT R, V212, P250; KLIBANSKI A, 1980, NEW ENGL J MED, V303, P1511, DOI 10.1056/NEJM198012253032605; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; LINDBERG JS, 1984, ANN INTERN MED, V101, P647, DOI 10.7326/0003-4819-101-5-647; MARCUS R, 1985, ANN INTERN MED, V102, P158, DOI 10.7326/0003-4819-102-2-158; MARTIN P, 1986, ARCH INTERN MED, V146, P689, DOI 10.1001/archinte.146.4.689; MAZESS RB, 1974, AT1111422 U WISC MED; MELTON LJ, 1983, OSTEOPOROTIC SYNDROM, P45; MERIMEE TJ, 1982, J CLIN ENDOCR METAB, V55, P999, DOI 10.1210/jcem-55-5-999; NEWMAN MM, 1989, PSYCHIAT RES, V29, P105, DOI 10.1016/0165-1781(89)90190-X; PHILLIPS LS, 1978, ENDOCRINOLOGY, V103, P121, DOI 10.1210/endo-103-1-121; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RIGOTTI NA, 1986, JAMA-J AM MED ASSOC, V256, P385, DOI 10.1001/jama.256.3.385; RIGOTTI NA, 1984, NEW ENGL J MED, V311, P601; SZMUKLER GI, 1985, BRIT MED J, V290, P26, DOI 10.1136/bmj.290.6461.26; TREASURE J, 1986, SCOT MED J, V31, P206; TREASURE JL, 1987, BRIT MED J, V295, P474, DOI 10.1136/bmj.295.6596.474-a; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WYSHAK G, 1989, J ORTHOPAED RES, V7, P91, DOI 10.1002/jor.1100070113; 1987, DIAGNOSTIC STATISTIC; 1986, NEW ENGL J MED, V314, P39	46	287	288	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1133	1138		10.1001/jama.265.9.1133	http://dx.doi.org/10.1001/jama.265.9.1133			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995999				2022-12-28	WOS:A1991EZ47400030
J	NELSON, HE; THRASHER, S; BARNES, TRE				NELSON, HE; THRASHER, S; BARNES, TRE			PRACTICAL WAYS OF ALLEVIATING AUDITORY HALLUCINATIONS	BRITISH MEDICAL JOURNAL			English	Article											NELSON, HE (corresponding author), HORTON HOSP,CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT,EPSOM KT19 8PZ,SURREY,ENGLAND.							COLLINS MN, 1989, BRIT MED J, V229, P431; DONE DJ, 1986, BRIT J CLIN PSYCHOL, V25, P151, DOI 10.1111/j.2044-8260.1986.tb00687.x; MARGO A, 1981, BRIT J PSYCHIAT, V139, P122, DOI 10.1192/bjp.139.2.122; Slade P. D., 1988, SENSORY DECEPTION SC	4	34	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					327	327		10.1136/bmj.302.6772.327	http://dx.doi.org/10.1136/bmj.302.6772.327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EX569	2001507	Green Published, Bronze			2022-12-28	WOS:A1991EX56900023
J	JOHNSTON, IH				JOHNSTON, IH			WHAT WILL THE MEDICAL DIRECTOR DO	BRITISH MEDICAL JOURNAL			English	Article											JOHNSTON, IH (corresponding author), GEN INFIRM,LEEDS WESTERN HLTH AUTHOR,GREAT GEORGE ST,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.							1990, NHS TRUSTS WORKING G; 1989, 1 SECR STAT HLTH WAL; 1990, 2ND STEER GROUP UND	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					280	281		10.1136/bmj.302.6771.280	http://dx.doi.org/10.1136/bmj.302.6771.280			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998797	Green Published, Bronze			2022-12-28	WOS:A1991EX91900025
J	GORE, SM; TAYLOR, RMR; WALLWORK, J				GORE, SM; TAYLOR, RMR; WALLWORK, J			AVAILABILITY OF TRANSPLANTABLE ORGANS FROM BRAIN-STEM DEAD DONORS IN INTENSIVE-CARE UNITS	BRITISH MEDICAL JOURNAL			English	Article								Objective-By audit from January to June 1989 to quantify, separately for hearts, kidneys, liver, lungs and corneas, the possible increases in transplantable organs from brain stem dead potential donors in intensive care units and to compare them with the increases achieved in October-November 1989, during intense, national publicity about transplantation. Design-Prospective audit of all deaths in intensive care units in England from 1 January to 30 June 1989 and subsequent case study of the impact of publicity on offers and donations during October-November 1989. Setting-15 regional and special health authorities in England. Patients-5803 patients dying in intensive care units, of whom 497 were confirmed as brain stem dead and had no general medical contraindication to organ donation. Main outcome measures-Organ specific suitability for transplantation (as reported by intensive care units); consent for donation of specific suitable organs; and procurement of specific organs reported as suitable for transplantation and offered. Results-In the 497 (8.6%) brain stem dead potential donors we estimated the organ specific suitability for heart as 63%, kidneys 95%, liver 70%, lungs 29%, and corneas 91%. Refusal of relatives (30%) accounted for major losses of suitable organs of all types. For kidneys the loss was equivalent to 44% of brain stem dead actual kidney donors. No discussion of organ donation was the second most important reason for missed kidney donors, the loss being equivalent to 10% of brain stem dead actual donors. Non-procurement or difficulties with allocating organs was the second most notable cause of missed suitable liver and lung donors; 29% (55) of the offered total of 189 liver donors and 27% (21) of 78 offered suitable lung donors in six months. Non-procurement of suitable, offered organs was rare for kidneys and modest, of the order of 13% and 10% respectively, for heart and corneas. Corneal donation from brain stem dead potential donors might be improved nearly as much (that is, a 78% increase in brain stem dead actual corneal donors) by specific measures to promote corneal donation when other organs are offered as by reducing the overall refusal rate. Restricted offers, non-procurement, and no discussion of donation accounted for nearly equal numbers of lost donations of hearts (each equivalent to 15% of donated hearts). During October-November 1989 when there was intense, positive publicity about transplantation the rates of refusal and non-discussion fell compared with during January-June (22%, 36/163 upsilon 30%, 138/460; 7%, 33/497 upsilon 2%, 4/167 respectively). Offers of suitable donors increased significantly (p < 0.02) compared with the first six months of 1989, most notably for heart donors (80 upsilon 60.1 expected) and kidney donors (122 upsilon 102.1 expected) but only for kidneys was there a noticeable 17% increase in actual donors (118 actual audited donors upsilon 100.8 expected donors; p = 0.09). Conclusions-Four strategies to increase the supply of transplantable organs from brain stem dead potential donors in intensive care units were identified: (a) reducing refusal of relatives (b) avoiding non-procurement of actually suitable organs (by logistical initiatives) and deterioration of initially suitable organs (by donor care initiatives); (c) converting restricted offers to unrestricted offers; and (d) ensuring discussion with families. Early referral to the transplant team or coordinator gives time for discussion about donor care and agreement on medical suitability for donation of specific organs. Solving some of the logistical problems of non-procurement may be a prerequisite for increased offers to be translated into increased donations. The impact of publicity therefore needs to be measured on offers of suitable donors as well as by actual donations.	ROYAL VICTORIA INFIRM,ORGAN GRAFTING UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; PAPWORTH HOSP,THORAC SURG UNIT,CAMBRIDGE CB3 8RE,ENGLAND	Newcastle University - UK; Papworth Hospital	GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND.							GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; GREBENCK CR, 1987, BR J HOSP MED    JUL, P62; JENNETT B, 1981, BRIT J ANAESTH, V53, P1111, DOI 10.1093/bja/53.11.1111; KEMP G, 1989, SUNDAY EXPRESS  0827, P1; ODOM NJ, 1990, BMJ-BRIT MED J, V300, P1571, DOI 10.1136/bmj.300.6739.1571; WALLWORK J, 1989, BRIT MED J, V299, P1291, DOI 10.1136/bmj.299.6711.1291; 1987, REPORT	7	54	55	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					149	153		10.1136/bmj.302.6769.149	http://dx.doi.org/10.1136/bmj.302.6769.149			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995135	Green Published, Bronze			2022-12-28	WOS:A1991EU02000023
J	LINDBERG, G; EKLUND, GA; GULLBERG, B; RASTAM, L				LINDBERG, G; EKLUND, GA; GULLBERG, B; RASTAM, L			SERUM SIALIC-ACID CONCENTRATION AND CARDIOVASCULAR MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							CANCER; CHOLESTEROL; FIBRINOGEN	Objective - To determine whether serum sialic acid concentration may be used to predict short and long term cardiovascular mortality. Design - Prospective study on all men and women who had their serum sialic acid concentration measured as part of a general health survey in 1964 or in 1965. All were followed up for an average of 20.5 years. Setting - Geographical part of the county of Varmland, Sweden. Subjects - Residents in the area participating in a health check up in 1964-5 (27 065 men and 28 037 women), of whom 372 men (169 with incomplete data and 203 lost to follow up) and 345 women (143 and 202 respectively) were excluded; thus 26 693 men and 27 692 women entered the study. The study sample was restricted to subjects aged 40-74 during any of the 20 years' follow up. Main outcome measures - Serum sialic acid concentration, serum cholesterol concentration, diastolic blood pressure, body mass index at the general health survey visit; cardiovascular and noncardiovascular deaths during three periods of follow up (0-6 years, 7-13 years, and 14-20 years), according to the Swedish mortality register, in subjects aged 45-74. Results - Mean serum sialic acid concentration (mg/100 ml) was 68.8 (SD 8.0) for men and 69.2 (8.0) for women; the average concentration increasing with age in both sexes. A total of 5639 (21%) men and 3307 (12%) women died during the follow up period, in whom death in 3052 (54%) men and 1368 (41%) women was from cardiovascular causes. During short (0-6 years), medium (7-13 years), and long (14-20 years) term follow up the relative risk of death from cardiovascular disease increased with increasing serum sialic acid concentration. The relative risk (95% confidence interval) associated with the highest quartile of sialic acid concentration compared with the lowest quartile was 2.38 (2.01 to 2.83) in men and 2.62 (1.93 to 3.57) in women. Similar results were found for deaths from noncardiovascular disease with relative risks of 1.50 (1.34 to 2.68) in men and 1.89 (1.57 to 2.28) in women, but these relative risks were significantly lower than those for deaths from cardiovascular disease (p < 0.001 and p < 0.005 respectively). In multivariate analysis of total mortality and of cardiovascular mortality with sialic acid concentration, serum cholesterol concentration, diastolic blood pressure, and body mass index as independent variables the impact of sialic acid concentration was virtually the same as in univariate analysis. Conclusion - Serum sialic acid concentration is a strong predictor of cardiovascular mortality. A possible explanation of these findings is that the serum sialic acid concentration may reflect the existence or the activity of an atherosclerotic process, and this may warrant further investigation.	KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Lund University	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							BOLANDER AM, 1981, MED ASPECTS MORTALIT, P236; Hrncir Z, 1975, Vnitr Lek, V21, P436; KROLIKOWSKI FJ, 1976, PHARMACOLOGY, V14, P47, DOI 10.1159/000136578; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MEADE TW, 1980, LANCET, V1, P1050; Ng S.-S., 1976, BIOL ROLES SIALIC AC, P59; PETREN S, 1989, BIOCHIM BIOPHYS ACTA, V994, P161, DOI 10.1016/0167-4838(89)90155-6; RADHAKRISHNAMURTHY B, 1976, LAB INVEST, V34, P159; SCHWICK HG, 1986, BEHRING I MITT, V80, P1; SHANBERGER RJ, 1984, J CLIN CHEM CLIN BIO, V22, P647; SHVARTS L S, 1971, Problemy Endokria, V17, P37; STUART J, 1981, J CLIN PATHOL, V34, P464, DOI 10.1136/jcp.34.5.464; SUCCARI M, 1982, PATHOL BIOL, V30, P151; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SWAHN E, 1989, SCAND J CLIN LAB INV, V49, P49, DOI 10.3109/00365518909089077; TANIUCHI K, 1981, Kobe Journal of Medical Sciences, V27, P91; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VARMA R, 1983, J CLIN CHEM CLIN BIO, V21, P273; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; 1967, MANUAL INT STATISTIC; 1955, MANUAL INT STATISTIC; 1971, VARMLAND SURVEY	24	205	209	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					143	146		10.1136/bmj.302.6769.143	http://dx.doi.org/10.1136/bmj.302.6769.143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995133	Green Published, Bronze			2022-12-28	WOS:A1991EU02000020
J	SELLAR, C; FERGUSON, JA; GOLDACRE, MJ				SELLAR, C; FERGUSON, JA; GOLDACRE, MJ			OCCURRENCE AND REPETITION OF HOSPITAL ADMISSIONS FOR ACCIDENTS IN PRESCHOOL-CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD INJURIES; EPIDEMIOLOGY; RATES	Objectives - To examine trends over time in the rates of admission to hospital for accidents of preschool children and to study patterns of repeated admissions for accidents in these children. Design - Analysis of linked, routine abstracts of hospital inpatient records for accidents. Setting - Six districts in the Oxford Regional Health Authority covered by the Oxford record linkage study. Subjects - Records for 19 427 children aged 5 years and under at the time of first recorded admission to hospital. Main outcome measure - Number of admissions to hospital. Results - Records were analysed in three groups: person based annual admission rates were calculated for each calendar year; each child's first recorded admission in 1976-85 was identified, and the child's record was followed up by linkage for one year from that admission; each child's first recorded admission in 1976-81 was identified and followed up for five years. Overall, 19 427 children from an average annual resident population of 163 000 children in 1976-86 had 20 657 admissions for accidents before they were 6 years of age. Of these admissions 13 983 were for injuries, 5717 for poisonings, and 957 for burns. Admission rates declined after 1976 for poisoning, but no substantial changes over time were found in admission rates for injuries or burns. A total of 17 724 children were followed up for one year and 10 889 for five years; 470 (2.6%) of the children who were followed up for one year and 926 (8.5%) of those followed up for five years had at least one further admission for an accident. Of those followed up for one year the 4 and 5 year old children were least likely and those under 1 and 1 year old were most likely to have a further admission for an accident. The number of children who had more than one accident was greater than would be expected if accidents were random occurrences. Those who had a poisoning at first admission were more likely to have another poisoning than an injury or burn; and those who had a burn at first admission were more likely to have another burn. Conclusions - Hospital admissions for accidents in children are common: on average 1 child in 88 in this population was admitted each year. Multiple admissions are uncommon but none the less occur more often than would be expected by chance.			SELLAR, C (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CLIN EPIDEMIOL UNIT,HEADINGTON,OXFORD OX3 7LF,ENGLAND.							AGASS M, 1990, BRIT J GEN PRACT, V40, P202; ARMITAGE P, 1987, STATISTICAL METHODS, P371; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BIJUR PE, 1988, PEDIATRICS, V82, P707; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BOYCE WT, 1989, AM J DIS CHILD, V143, P338, DOI 10.1001/archpedi.1989.02150150096024; EMINSON CJ, 1986, J EPIDEMIOL COMMUN H, V40, P170, DOI 10.1136/jech.40.2.170; GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; HUSBAND P, 1973, PRACTITIONER, V211, P335; JACKSON RH, 1983, BRIT MED J, V287, P1468, DOI 10.1136/bmj.287.6403.1468-a; JACKSON RH, 1983, HUM TOXICOL, V2, P285, DOI 10.1177/096032718300200218; RIVARA FP, 1982, AM J DIS CHILD, V136, P399, DOI 10.1001/archpedi.1982.03970410017003; RIVARA FP, 1982, AM J DIS CHILD, V136, P502, DOI 10.1001/archpedi.1982.03970420026004; STEWARTBROWN S, 1986, INT J EPIDEMIOL, V15, P352, DOI 10.1093/ije/15.3.352; 1989, BASIC PRINCIPLES CHI; 1990, ELM901 DEP HLTH; 1967, MANUAL INT STATISTIC; 1990, ACTION ACCIDENT UNIQ; HOSPITAL PATIENT ENQ; MORTALITY STATISTICS; 1989, EL89P96 DEP HLTH SOC; [No title captured]	22	25	25	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					16	19		10.1136/bmj.302.6767.16	http://dx.doi.org/10.1136/bmj.302.6767.16			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER372	1991180	Bronze, Green Published			2022-12-28	WOS:A1991ER37200018
J	WELLER, PF; MOSES, A; WEINBERGER, S; FLIER, J				WELLER, PF; MOSES, A; WEINBERGER, S; FLIER, J			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - THE IMMUNOBIOLOGY OF EOSINOPHILS	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							MAJOR BASIC-PROTEIN; PLATELET-ACTIVATING FACTOR; COLONY-STIMULATING FACTOR; AMINO-ACID SEQUENCE; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; GRANULE CATIONIC PROTEINS; CYTOPLASMIC LIPID BODIES; MATURE HUMAN EOSINOPHILS; CHARCOT-LEYDEN CRYSTALS; CELL HISTAMINE-RELEASE				WELLER, PF (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV INFECT DIS, DANA 617, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.		Flier, jeffrey/AAG-6223-2019		NIAID NIH HHS [AI20241, AI22571] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022571, R01AI020241] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ACKERMAN SJ, 1985, AM J TROP MED HYG, V34, P735, DOI 10.4269/ajtmh.1985.34.735; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; BAINTON DF, 1970, J CELL BIOL, V45, P54, DOI 10.1083/jcb.45.1.54; BARKER RL, 1990, GENE, V86, P285, DOI 10.1016/0378-1119(90)90292-Y; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BARKER RL, 1989, J EXP MED, V170, P1057; BARKER RL, 1989, J IMMUNOL, V143, P952; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; BROFMAN JD, 1989, J APPL PHYSIOL, V66, P1867, DOI 10.1152/jappl.1989.66.4.1867; BUTTERWORTH AE, 1984, ADV PARASIT, V23, P143, DOI 10.1016/S0065-308X(08)60287-0; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; CAPRON M, 1985, J IMMUNOL, V134, P3013; CAPRON M, 1984, J IMMUNOL, V132, P462; CAPRON M, 1981, J IMMUNOL, V126, P2087; CHANGELIAN PS, 1986, J EXP MED, V163, P101, DOI 10.1084/jem.163.1.101; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; DVORAK AM, 1988, BLOOD, V72, P150; DVORAK AM, 1990, BLOOD CELL BIOCH, V2, P237; EGESTEN A, 1986, J HISTOCHEM CYTOCHEM, V34, P1399, DOI 10.1177/34.11.3772075; ELOVIC A, 1990, AM J PATHOL, V137, P1425; ENOKIHARA H, 1989, BLOOD, V73, P1809; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FOEGH ML, 1986, SCAND J IMMUNOL, V23, P599, DOI 10.1111/j.1365-3083.1986.tb01993.x; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GRANGETTE C, 1989, J IMMUNOL, V143, P3580; GRAZIANO RF, 1989, J IMMUNOL, V142, P230; HALLGREN R, 1989, AM J MED, V86, P56, DOI 10.1016/0002-9343(89)90230-1; HAMADA A, 1987, J IMMUNOL, V138, P1240; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HARTNELL A, 1990, IMMUNOLOGY, V69, P264; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; HENDERSON WR, 1987, J ALLERGY CLIN IMMUN, V79, P543, DOI 10.1016/S0091-6749(87)80146-X; HODGES MK, 1988, AM REV RESPIR DIS, V138, P799, DOI 10.1164/ajrccm/138.4.799; JONG EC, 1981, J IMMUNOL, V126, P468; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; KANOFSKY JR, 1988, J BIOL CHEM, V263, P9692; KHALIFE J, 1986, J IMMUNOL, V137, P1659; KROEGEL C, 1989, BIOCHEM BIOPH RES CO, V162, P511, DOI 10.1016/0006-291X(89)92027-5; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LAMAS AM, 1989, J IMMUNOL, V142, P3978; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEE TH, 1986, ADV IMMUNOL, V39, P145; LEHRER RI, 1989, J IMMUNOL, V142, P4428; LIMAYE AP, 1990, J EXP MED, V172, P399, DOI 10.1084/jem.172.1.399; LIU LX, 1990, J EXP MED, V172, P993, DOI 10.1084/jem.172.3.993; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; LUCEY DR, 1989, J EXP MED, V169, P327, DOI 10.1084/jem.169.1.327; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NOGUEIRA NM, 1982, J IMMUNOL, V128, P1705; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; OLSSON I, 1986, BLOOD, V67, P498; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PARMLEY RT, 1974, LAB INVEST, V30, P557; PETERS MS, 1986, LAB INVEST, V54, P656; PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283, DOI 10.1002/jlb.41.4.283; PINCUS SH, 1981, BLOOD, V58, P1175; RAND TH, 1990, BLOOD S, V76, pA191; RAND TH, IN PRESS J EXP MED; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SERHAN CN, 1987, FEBS LETT, V217, P242, DOI 10.1016/0014-5793(87)80671-3; SHER A, 1990, P NATL ACAD SCI USA, V87, P61, DOI 10.1073/pnas.87.1.61; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V150, P376, DOI 10.1016/0006-291X(88)90531-1; SILBERSTEIN DS, 1989, J IMMUNOL, V143, P979; SONODA Y, 1989, LEUKEMIA, V3, P14; SPRY CJF, 1988, EOSINOPHILS GUIDE SC, P28; STEINHILBER D, 1989, FEBS LETT, V255, P143, DOI 10.1016/0014-5793(89)81078-6; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; VANCHERI C, 1989, AM J RESP CELL MOL, V1, P289, DOI 10.1165/ajrcmb/1.4.289; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WASMOEN TL, 1988, J BIOL CHEM, V263, P12559; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WEINSTOCK JV, 1988, J IMMUNOL, V141, P961; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WELLER PF, 1982, J IMMUNOL, V128, P1346; WELLER PF, 1984, J BIOL CHEM, V259, P5100; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELLER PF, 1980, P NATL ACAD SCI-BIOL, V77, P7440, DOI 10.1073/pnas.77.12.7440; WELLER PF, 1985, BLOOD, V65, P1269; WELLER PF, 1991, AM J PATHOL, V138, P141; WELLER PF, 1988, J LEUKOCYTE BIOL, V43, P1; WELLER PF, 1989, AM J PATHOL, V135, P947; WELLER PF, 1988, ARTHRITIS ALLIED CON, P366; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; YAZDANBAKHSH M, 1987, J IMMUNOL, V138, P3443; YUKAWA T, 1989, IMMUNOLOGY, V68, P140; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180; [No title captured]	116	596	605	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1110	1118						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008184				2022-12-28	WOS:A1991FG91200007
J	GILSTRAP, LC				GILSTRAP, LC			ELECTIVE APPENDECTOMY DURING ABDOMINAL-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GILSTRAP, LC (corresponding author), UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DALLAS,TX 75235, USA.							PARSONS AK, 1986, OBSTET GYNECOL, V68, P479; WATERS EG, 1977, OBSTET GYNECOL, V50, P511; WESTERMANN C, 1986, SURG GYNECOL OBSTET, V162, P307	3	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1736	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002579				2022-12-28	WOS:A1991FD65900034
J	BASLER, K; CHRISTEN, B; HAFEN, E				BASLER, K; CHRISTEN, B; HAFEN, E			LIGAND-INDEPENDENT ACTIVATION OF THE SEVENLESS RECEPTOR TYROSINE KINASE CHANGES THE FATE OF CELLS IN THE DEVELOPING DROSOPHILA EYE	CELL			English	Article							PROTO-ONCOGENE PRODUCT; PUTATIVE RECEPTOR; POINT MUTATION; OPSIN GENE; RETINA; MELANOGASTER; DOMAIN; EXPRESSION; PATTERN; MUTANT	Cell fate in the developing eye is determined by a cascade of inductive interactions. In this process, the sevenless protein-a receptor tyrosine kinase-is required for the specification of the R7 photoreceptor cell fate. We have constructed a gain-of-function sevenless mutation (Sev(S11)) by overexpressing a truncated sevenless protein in the cells where sevenless is normally expressed. In Sev(S11) mutant flies, all sevenless-expressing cells initiate neural development. This results in the formation of multiple R7-like photoreceptors per ommatidium. Therefore, sevenless activity appears to be necessary and sufficient for the determination of R7 cell fate. These results illustrate the central role receptor tyrosine kinases can play in the specification of cell fate during development.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich				Basler, Konrad/0000-0003-3534-1529				BALLINGER DG, 1988, P NATL ACAD SCI USA, V85, P3960, DOI 10.1073/pnas.85.11.3960; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, IN PRESS GENES DEV; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; JARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MISMER D, 1987, GENETICS, V116, P565; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONTELL C, 1987, J NEUROSCI, V7, P1558; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SNYDER M, 1982, CELL, V29, P1027, DOI 10.1016/0092-8674(82)90466-4; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STARK WS, 1987, J NEUROGENET, V4, P227, DOI 10.3109/01677068709102343; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOMILINSON A, 1989, CIBA F S, V144, P281; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; ZUKER CS, 1987, J NEUROSCI, V7, P1550	51	223	225	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1069	1081		10.1016/0092-8674(91)90262-W	http://dx.doi.org/10.1016/0092-8674(91)90262-W			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004416	Green Accepted			2022-12-28	WOS:A1991FD55800005
J	HALLAM, L				HALLAM, L			ORGANIZATION OF TELEPHONE SERVICES AND PATIENTS ACCESS TO DOCTORS BY TELEPHONE IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							HOURS CALLS; RECEPTIONIST; DRAGON; DESK	Objectives-To assess how accessible general practitioners are to patients by telephone and to examine the relations between organisation, number of lines, and number of patient-doctor calls. Design-Postal survey of a random sample of general practitioners stratified by rural and urban practice areas, with differential sampling fractions. Setting-General practices in England and Wales. Subjects-2000 general practitioners, of whom 1459 (74%) responded. Main outcome measures-Number of calls received by general practitioner a day, time reserved for patients' calls, and communication of availability of telephone contact. Results-1421 general practitioners said that they accepted non-emergency calls from patients during the day and 285 reported reserving specific times of the day for this purpose. 848 estimated that they received four or fewer patient calls a day. The number of calls was significantly related to reserving time for calls (p < 0.001), informing patients that the doctor was accessible by telephone (p < 0.00001), and the number of periods when calls were accepted (p < 0.00001). On average there were 3659 patients per incoming line; the number of patients per incoming line rose significantly as practice size increased (p < 0.00001). Conclusions-The apparent willingness of general practitioners to accept calls was not reflected in the number of calls received. Reserving time, increasing periods of availability, and publicising telephone access increased the number of doctor-patient telephone contacts. Line congestion may be a problem, and impartial advice and guidance on telephone organisation and line requirements would be helpful.			HALLAM, L (corresponding author), UNIV MANCHESTER,CTR PRIMARY CARE,MANCHESTER M14 5NP,ENGLAND.							ALLEN D, 1988, J ROY COLL GEN PRACT, V38, P163; ALLEN D, 1988, PRACTITIONER, V232, P1380; ARBER S, 1985, SOC SCI MED, V20, P911, DOI 10.1016/0277-9536(85)90347-8; BHOPAL JS, 1988, UPDATE, V37, P848; CROWE MGF, 1976, BRIT MED J, V1, P1582, DOI 10.1136/bmj.1.6025.1582; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; HALLAM L, 1989, FAM PRACT, V6, P47, DOI 10.1093/fampra/6.1.47; HOBDAY PJ, 1988, J ROY COLL GEN PRACT, V38, P35; LEAVEY R, 1988, ORG PRACTICE RESOURC; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; RUSSELL T, 1976, PRACTITIONER S, V197, P3; WATTS CAH, 1971, BRIT MED J, V3, P419, DOI 10.1136/bmj.3.5771.419; 1986, GENERAL PRACTIT 1128, P1; 1987, PULSE, V47, P67; 1990, HLTH PERSONAL SOCIAL; 1978, BMJ, V2, P1106; 1989, GMSC NEWS REV    JAN, pR5; 1987, GENERAL HOUSEHOLD SU	18	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					629	632		10.1136/bmj.302.6777.629	http://dx.doi.org/10.1136/bmj.302.6777.629			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012879	Bronze, Green Published			2022-12-28	WOS:A1991FC07100025
J	YELLAND, A; GRAHAM, MD; TROTT, PA; FORD, HT; COOMBES, RC; GAZET, JC; POLSON, NG				YELLAND, A; GRAHAM, MD; TROTT, PA; FORD, HT; COOMBES, RC; GAZET, JC; POLSON, NG			DIAGNOSING BREAST-CARCINOMA IN YOUNG-WOMEN	BRITISH MEDICAL JOURNAL			English	Article							ASPIRATION CYTOLOGY; MAMMOGRAPHY; MANAGEMENT; CANCER	Objective-To assess the individual and combined diagnostic accuracy of clinical examination, mammography, and fine needle aspiration biopsy in young women with breast cancer. Design-Analysis based on case notes of patients presenting with breast cancer during 1971-89. Setting-A combined breast clinic. Patients-Consecutive series of 81 women aged < 36 with histologically proved breast cancer presenting with a discrete mass over 19 years. Main outcome measures-Results of clinical examination, xeromammography or conventional mammography, fine needle aspiration biopsy, and examination of tissue removed by surgery. Results-The clinical diagnosis was correct in 47 women and radiography in 35. Fine needle aspiration biopsy was correct in 47 of the 63 women in whom it was successfully performed. Fine needle aspiration was significantly more accurate than mammography (78% v 45%, p < 0.01). Ten (16%) patients had negative results on clinical examination, mammography, and fine needle aspiration. Conclusion-Mammography alone seems inadequately sensitive to detect breast cancer in young patients. When all investigations give negative results excision biopsy is the only way of obtaining a definitive diagnosis.	ST GEORGE HOSP,COMBINED BREAST CLIN,LONDON SW17 0QT,ENGLAND	St Georges University London				Coombes, Raoul Charles/0000-0002-4811-1100				ASHLEY S, 1989, BRIT J SURG, V76, P835, DOI 10.1002/bjs.1800760825; CAHILL CJ, 1981, BRIT J SURG, V68, P882, DOI 10.1002/bjs.1800681215; CANT PJ, 1987, BRIT J SURG, V74, P857, DOI 10.1002/bjs.1800740936; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; SMALLWOOD J, 1985, BRIT J SURG, V72, P841, DOI 10.1002/bjs.1800721022; TEIXIDOR HS, 1977, AM J ROENTGENOL, V128, P409, DOI 10.2214/ajr.128.3.409; THOMAS MJ, 1978, BMJ, V2, P1139; TROTT PA, 1981, DIAGNOSIS PRIMARY BR, P1; WARWICK DJ, 1988, BRIT J SURG, V75, P243, DOI 10.1002/bjs.1800750319; WILKINSON S, 1985, BRIT J SURG, V72, P838, DOI 10.1002/bjs.1800721021; 1989, LANCET, V1, P973	11	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					618	620		10.1136/bmj.302.6777.618	http://dx.doi.org/10.1136/bmj.302.6777.618			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012873	Bronze, Green Published			2022-12-28	WOS:A1991FC07100018
J	ASBURY, CH				ASBURY, CH			THE ORPHAN DRUG-ACT - THE 1ST 7 YEARS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The 1983 Orphan Drug Act sought to increase market incentives and decrease regulatory barriers for products used to treat rare ("orphan") diseases. Major provisions included market exclusivity, tax credits, and regulatory process clarifications. This analysis compares pre- and post-Act industry and government data to examine changes associated with the law. While industry sponsored 34 marketed and 24 experimental orphan drugs in the 17 years prior to the Act, it has sponsored 39 of 42 marketed orphan products in the 7 years since the Act. An additional 301 experimental products have orphan designation. While 25 of 40 marketed orphan products reportedly had annual sales of less than $1 million, product sales for three conditions are more than $100 million annually. This prompted changes in the law, passed by Congress in 1990, but vetoed. Overall, the law has been associated with an increase in orphan product development. The law's costs and benefits to companies, patients, and the public should be examined if future changes are proposed.			ASBURY, CH (corresponding author), ROBERT WOOD JOHNSON FDN,POB 2316,PRINCETON,NJ 08543, USA.							ASBURY CH, 1981, ANN INTERN MED, V95, P221, DOI 10.7326/0003-4819-95-2-221; ASBURY CH, 1981, INT J HEALTH SERV, V11, P451, DOI 10.2190/NELD-FBM5-FFN3-0FLC; ASBURY CH, 1982, SYSTEMS APPROACH ORP, P232; ASBURY CH, 1985, ORPHAN DRUGS MED VS; ATLHIUS T, 1980, NEW ENGL J MED, V303, P1004; BLOOM B, 1976, IMPACT PUBLIC POLICY, P344; CRAWFORD M, 1988, SCIENCE, V239, P723, DOI 10.1126/science.3340852; DEVITA VT, 1979, CANCER CLIN TRIALS, V2, P195; DIMASI J, IN PRESS J HLTH EC; FINKEL MJ, 1980, NEW ENGL J MED, V302, P643, DOI 10.1056/NEJM198003133021134; FINKEL MJ, 1986, ORPHAN DIS ORPHAN DR, P159; FRAIER SD, 1989, NEW ENGL J MED, V321, P1124; GIBBONS A, 1990, SCIENCE, V248, P678, DOI 10.1126/science.2333518; HANSEN RW, 1980, ISSUE SPHARM EC, P151; HARRIS R, 1964, REAL VOICE, P21; KARCH F, 1982, ORPHAN DRUGS; LASAGNA L, 1979, REGULATION, V3, P27; LEWIN R, 1989, SCIENCE, V245, P467, DOI 10.1126/science.2502841; MCLEOD DC, 1989, DICP ANN PHARMAC, V23, P605, DOI 10.1177/1060028089023007-819; MILLER D, 1990, PMA NEWSLETT, V32, P2; MILLER D, 1990, PMA NEWSLETT, V32, P3; MILLER D, 1990, PMA NEWSLETT, V32, P6; MILLR D, 1989, PMA NEWSLETT, V31, P2; MOSSINGHOFF GJ, 1989, ORPHAN DRUGS DEV; RAWLINS M, 1977, BMJ, V2, P1076; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; RUSSO JB, 1978, NEW ENGL J MED, V299, P156; SCHARF SF, 1985, AM J LAW MED, V10, P491; SCHONDELMEYER S, 1990, DEC HLTH POL FOR WAS; SCHWARTZMAN D, 1976, INNOVATION PHARM IND, P106; SHAFFR M, 1984, DRUGS BIOL APPROVED; TEMIN P, 1979, B J EC, V10, P427; VANCE ML, 1990, NEW ENGL J MED, V323, P52; VANWOERT MH, 1978, NEW ENGL J MED, V298, P903, DOI 10.1056/NEJM197804202981608; Waxman Henry A., 1986, ORPHAN DIS ORPHAN DR, p[135, 136]; 1988, HLTH CARE FINANCING, P68; 1990, REPORT PHARM MANUFAC, P3; 1979, REPORT SECRETARY DHE; NMES APPROVED 1983 8; 1976, LANCET, V2, P835; 1987, M PHARM MANUFACTURER; 1982, PRELIMINARY REPORT S; 1981, FEDERAL DRUG DEV PRO; 1990, OTAH451 US C OFF TEC, P72; 1981, PATENT TERM EXTENSIO; 1990, APPROVED DESIGNATED	46	30	30	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					893	897						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992188				2022-12-28	WOS:A1991EX58700042
J	BLUMBERG, H; SILVER, PA				BLUMBERG, H; SILVER, PA			A HOMOLOG OF THE BACTERIAL HEAT-SHOCK GENE DNAJ THAT ALTERS PROTEIN SORTING IN YEAST	NATURE			English	Article							ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; BACTERIOPHAGE-LAMBDA; REPLICATION; INITIATION; TRANSLOCATION; SEQUENCE; CELLS	HEAT-shock proteins have been implicated in assembly of protein complexes 1, correct protein folding 2 and uptake of proteins into organelles 3,4. In Escherichia coli, the heat-shock protein DnaJ and the Hsp70 homologue, DnaK, act together to disassemble a protein complex involved in bacteriophage-lambda replication 5. We report the identification of SCJ1, a gene in the yeast Saccharomyces cerevisiae that encodes a homologue of the bacterial DnaJ protein. SCJ1 was identified by a genetic screen in which increased expression of candidate genes results in missorting of a nuclear-targeted test protein. The predicted amino-acid sequence of SCJ1 is 37% identical to the entire E. coli DnaJ protein. Hybridization experiments indicate that there is a family of yeast genes related to SCJ1. These findings suggest that the Hsp70 DnaK-DnaJ interaction is general to eukaryotes.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University								BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; Georgopoulos C., 1971, BACTERIOPHAGE LAMBDA, P553; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LATHIGRA RB, 1988, NUCLEIC ACIDS RES, V16, P1636, DOI 10.1093/nar/16.4.1636; LEBOWITZ JH, 1985, P NATL ACAD SCI USA, V82, P3988, DOI 10.1073/pnas.82.12.3988; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; Maniatis T., 1982, MOL CLONING; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OHKI M, 1986, J BIOL CHEM, V261, P1778; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; VONHEIJNE G, 1985, CURR TOP MEMBR TRANS, V24, P151; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	25	112	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					627	630		10.1038/349627a0	http://dx.doi.org/10.1038/349627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000136				2022-12-28	WOS:A1991EX57000065
J	NIGRO, JM; CHO, KR; FEARON, ER; KERN, SE; RUPPERT, JM; OLINER, JD; KINZLER, KW; VOGELSTEIN, B				NIGRO, JM; CHO, KR; FEARON, ER; KERN, SE; RUPPERT, JM; OLINER, JD; KINZLER, KW; VOGELSTEIN, B			SCRAMBLED EXONS	CELL			English	Article							MESSENGER-RNA PRECURSORS; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; ENZYMATIC AMPLIFICATION; SPLICING INVITRO; LEADER SEQUENCE; DNA-POLYMERASES; CDNA LIBRARIES; EVOLUTION; GENES; INTERMEDIATE	Using a sensitive assay for RNA expression, we identified several abnormally spliced transcripts in which exons from a candidate tumor suppressor gene (DCC) were scrambled during the splicing process in vivo. Cloning and sequencing of PCR-amplified segments of the abnormally spliced transcripts showed that exons were joined accurately at consensus splice sites, but in an order different from that present in the primary transcript. Four scrambled transcripts were identified, each involving a different pair of exons. The scrambled transcripts were found at relatively low levels in a variety of normal and neoplastic cells of rodent and human origin, primarily in the nonpolyadenylated component of cytoplasmic RNA. These results demonstrate that the splicing process does not always pair sequential exons in the order predicted from their positions in genomic DNA, thus creating a novel type of RNA product.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN GENET,BALTIMORE,MD 21231	Johns Hopkins University; Johns Hopkins University	NIGRO, JM (corresponding author), JOHNS HOPKINS UNIV,CTR ONCOL,SCH MED,BALTIMORE,MD 21231, USA.			Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [R37CA043460, R01CA043460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460] Funding Source: Medline; NIGMS NIH HHS [GM07309, GM07184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW LT, 1977, CELL, V12, P1, DOI 10.1016/0092-8674(77)90180-5; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; EDELMANN P, 1977, CELL, V10, P131, DOI 10.1016/0092-8674(77)90147-7; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAUER A, 1983, NUCLEIC ACIDS RES, V11, P3503, DOI 10.1093/nar/11.11.3503; HAYMERLE H, 1986, NUCLEIC ACIDS RES, V14, P8615, DOI 10.1093/nar/14.21.8615; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KOLLER B, 1987, CELL, V48, P111, DOI 10.1016/0092-8674(87)90361-8; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; REANNEY D, 1979, NATURE, V277, P598, DOI 10.1038/277598b0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; VAESSEN RTMJ, 1987, SCIENCE, V235, P1486, DOI 10.1126/science.3823900; VANDOREN K, 1988, NATURE, V335, P556; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215	41	704	754	6	68	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					607	613		10.1016/0092-8674(91)90244-S	http://dx.doi.org/10.1016/0092-8674(91)90244-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991322	hybrid			2022-12-28	WOS:A1991EX36100016
J	WILKIE, AOM; HIGGS, DR; RACK, KA; BUCKLE, VJ; SPURR, NK; FISCHELGHODSIAN, N; CECCHERINI, I; BROWN, WRA; HARRIS, PC				WILKIE, AOM; HIGGS, DR; RACK, KA; BUCKLE, VJ; SPURR, NK; FISCHELGHODSIAN, N; CECCHERINI, I; BROWN, WRA; HARRIS, PC			STABLE LENGTH POLYMORPHISM OF UP TO 260 KB AT THE TIP OF THE SHORT ARM OF HUMAN CHROMOSOME-16	CELL			English	Article							GLOBIN GENE-CLUSTER; MOUSE ERYTHROLEUKEMIA-CELLS; REPETITIVE DNA-SEQUENCE; SACCHAROMYCES-CEREVISIAE; PSEUDOAUTOSOMAL REGION; RECOMBINATION NODULES; HUMAN TELOMERE; HUMAN MEIOSIS; HUMAN GENOME; LINKAGE MAP	We have completed a long-range restriction map of the terminal region of the short arm of human chromosome 16 (16p13.3) by physically linking a distal genetic locus (alpha-globin) with two recently isolated probes to telomere-associated repeats (TelBam3.4 and TelBam-11). Comparison of 47 chromosomes has revealed major polymorphic length variation in this region: we have identified three alleles in which the alpha-globin genes lie 170 kb, 350 kb, or 430 kb from the telomere. The two most common alleles contain different terminal segments, starting 145 kb distal to the alpha-globin genes. Beyond this boundary these alleles are nonhomologous, yet each contains sequences related to other (different) chromosome termini. This chromosome size polymorphism has probably arisen by occasional exchanges between the subtelomeric regions of nonhomologous chromosomes; analogous length variation is likely to be present at other human telomeres.	IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND; CEDARS SINAI MED CTR,LOS ANGELES,CA 90048; INST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	Cedars Sinai Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Oxford	WILKIE, AOM (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Ceccherini, Isabella/P-8195-2014; Wilkie, Andrew/AAC-3820-2020	Ceccherini, Isabella/0000-0001-8732-1955; Wilkie, Andrew/0000-0002-2972-5481; Brown, William RA/0000-0001-5340-3645	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALTHERR MR, 1989, GENOMICS, V5, P581, DOI 10.1016/0888-7543(89)90026-8; BATES GP, 1990, AM J HUM GENET, V46, P762; BERNARDI G, 1989, ANNU REV GENET, V23, P637, DOI 10.1146/annurev.genet.23.1.637; BOJKO M, 1983, CARLSBERG RES COMMUN, V48, P457, DOI 10.1007/BF02911920; Bond D, 1983, OXFORD MONOGRAPHS ME, P198; BROWN WRA, 1990, J CELL SCI, V95, P521; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BUCAN M, 1990, GENOMICS, V6, P1; BUCKLE VJ, 1989, NEURON, V3, P647, DOI 10.1016/0896-6273(89)90275-4; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHANDLEY AC, 1989, J MED GENET, V26, P546, DOI 10.1136/jmg.26.9.546; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHENG JF, 1989, NUCLEIC ACIDS RES, V17, P6109, DOI 10.1093/nar/17.15.6109; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; DANIEL A, 1989, AM J MED GENET, V31, P14; DEISSEROTH A, 1978, CELL, V15, P55, DOI 10.1016/0092-8674(78)90082-X; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P6197, DOI 10.1093/nar/15.15.6197; GERMINO GG, 1990, AM J HUM GENET, V46, P925; HARRIS PC, 1990, GENOMICS, V7, P195, DOI 10.1016/0888-7543(90)90541-2; HATTON CSR, 1990, BLOOD, V76, P221; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HELDER J, 1987, P NATL ACAD SCI USA, V84, P2387, DOI 10.1073/pnas.84.8.2387; HIGGS DR, 1989, BLOOD, V73, P1081; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; JEFFREYS AJ, 1984, NUCLEIC ACIDS RES, V12, P3235, DOI 10.1093/nar/12.7.3235; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LAMB J, 1989, LANCET, V2, P819; LAURIE DA, 1985, ANN HUM GENET, V49, P203, DOI 10.1111/j.1469-1809.1985.tb01694.x; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; MARCUS M, 1976, NATURE, V262, P63, DOI 10.1038/262063a0; MATTEI MG, 1982, HUM GENET, V61, P295; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURRAY AW, 1986, MOL CELL BIOL, V6, P3166, DOI 10.1128/MCB.6.9.3166; Old JM., 1983, METHODS HEMATOLOGY T, V6, P74; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; RAPPOLD GA, 1988, NUCLEIC ACIDS RES, V16, P5361, DOI 10.1093/nar/16.12.5361; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; ROUYER F, 1990, EMBO J, V9, P505, DOI 10.1002/j.1460-2075.1990.tb08137.x; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SPEED RM, 1988, HUM GENET, V78, P260, DOI 10.1007/BF00291673; SPEED RM, 1990, HUM GENET, V84, P547; SPURR NK, 1988, HUM GENET, V78, P333, DOI 10.1007/BF00291730; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; WEBER B, 1990, NUCLEIC ACIDS RES, V18, P3353, DOI 10.1093/nar/18.11.3353; WELLS RA, 1990, GENOMICS, V8, P699, DOI 10.1016/0888-7543(90)90257-U; WELLS RA, 1989, GENOMICS, V5, P761, DOI 10.1016/0888-7543(89)90118-3; WILKIE AOM, 1990, AM J HUM GENET, V46, P1127; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILKIE AOM, 1990, AM J HUM GENET, V46, P1112; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; ZAKIAN VA, 1988, MOL CELL BIOL, V8, P2257, DOI 10.1128/MCB.8.5.2257; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; Zeitlin H C, 1983, Mol Biol Med, V1, P489	64	157	157	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					595	606		10.1016/0092-8674(91)90243-R	http://dx.doi.org/10.1016/0092-8674(91)90243-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991321				2022-12-28	WOS:A1991EX36100015
J	DIXON, AK; SOUTHERN, JP; TEALE, A; FREER, CEL; HALL, LD; WILLIAMS, A; SIMS, C				DIXON, AK; SOUTHERN, JP; TEALE, A; FREER, CEL; HALL, LD; WILLIAMS, A; SIMS, C			MAGNETIC-RESONANCE-IMAGING OF THE HEAD AND SPINE - EFFECTIVE FOR THE CLINICIAN OR THE PATIENT	BRITISH MEDICAL JOURNAL			English	Article							COMPUTED-TOMOGRAPHY; POOR QUALITY	Objectives - To test how the results of magnetic resonance imaging influence clinicians' diagnoses and management plans for patients with cranial and spinal problems and to assess changes in the quality of life of these patients. Design - Survey of patients undergoing cranial and spinal magnetic resonance imaging with questionnaires about diagnoses and intended management plans before and after imaging and quality of life questionnaires at the time of imaging and again four months later. Setting - Regional magnetic resonance imaging and spectroscopy unit. Subjects - 100 consecutive patients referred for cranial imaging in early 1989; 100 similar patients referred for spinal imaging. Main outcome measures - Changes in clinicians' leading diagnoses after magnetic resonance imaging and their confidence in these diagnoses;changes in intended management plans; assessment of the contribution to the future management of the patient; changes in patients' quality of life. Results - Magnetic resonance imaging altered the clinicians' leading diagnoses in 35 of 169 (21%) cases. The clinicians became more confident about their leading diagnoses in 90 of 167 (54%). There was a change in management plan in 113 of 182 (62%). The clinicians considered that magnetic resonance imaging made an important contribution to management in 119 of 162 (73%) patients. Overall, the patients' quality of life was unchanged at the four month assessment. Conclusions - Magnetic resonance imaging of patients with cranial and spinal problems influences clinicians' diagnoses and management plans, but the quality of life of these patients remains unchanged.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	DIXON, AK (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND.							COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; DIXON AK, 1981, LANCET, V1, P1199; DOLLERY C, 1978, END AGE OPTIMISM, P59; FRANKEN EA, 1986, RADIOLOGY, V161, P377, DOI 10.1148/radiology.161.2.3763904; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; GUDEX C, 1988, 38 U YORK CTR HLTH E; Hillman B J, 1986, Invest Radiol, V21, P289, DOI 10.1097/00004424-198603000-00019; HILLMAN BJ, 1988, AM J ROENTGENOL, V151, P858, DOI 10.2214/ajr.151.5.858; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; Moore A T, 1987, Health Trends, V19, P8; SHUMAN WP, 1988, AM J ROENTGENOL, V151, P857, DOI 10.2214/ajr.151.5.857; SIEGEL S, 1988, NONPARAMETRIC STAT, P298; STLEGER AS, 1989, BRIT MED J, V299, P1017, DOI 10.1136/bmj.299.6706.1017; TEASDALE GM, 1989, BRIT MED J, V299, P349, DOI 10.1136/bmj.299.6695.349; 1984, LANCET, V2, P961; [No title captured]; [No title captured]; 1979, LANCET, V1, P809	18	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					79	82		10.1136/bmj.302.6768.79	http://dx.doi.org/10.1136/bmj.302.6768.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995119	Bronze, Green Published			2022-12-28	WOS:A1991ER95100016
J	PERROTTA, AT; BEEN, MD				PERROTTA, AT; BEEN, MD			A PSEUDOKNOT-LIKE STRUCTURE REQUIRED FOR EFFICIENT SELF-CLEAVAGE OF HEPATITIS DELTA-VIRUS RNA	NATURE			English	Article							GENOME; SITE	HEPATITIS delta virus genomic and antigenomic RNAs contain a self-cleavage site hypothesized to function in processing the viral RNA during replication 1-3. Self-cleavage requires only a divalent cation 1-3 and is mediated at the genomic site by a sequence of less than 85 nucleotides 4. We propose that the genomic self-cleaving sequence element 4 and a corresponding sequence from the antigenomic RNA could generate related secondary structures. The region of the antigenomic sequence, predicted from the proposed structure, was synthesized and shown to be sufficient for self-cleavage. Evidence for two stems which form a tertiary interaction was obtained by site-specific mutagenesis of the antigenomic sequence. Efficient self-cleavage in 10 M formamide or 5 M urea, also a property of the genomic sequence 5, was dependent on base-pairing in both stems. But in the absence of denaturants, the stem distal to the site of cleavage was not required, suggesting that the tertiary interaction stabilizes the structure required for self-cleavage.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University								FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; PERROTTA AT, 1990, NUCLEIC ACIDS RES, V18, P6821, DOI 10.1093/nar/18.23.6821; PFEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143; ROSENSTEIN SP, 1990, BIOCHEMISTRY-US, V29, P8011, DOI 10.1021/bi00487a002; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; VEIRIA J, 1987, METHOD ENZYMOL, V154, P3; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831	14	300	346	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					434	436		10.1038/350434a0	http://dx.doi.org/10.1038/350434a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011192				2022-12-28	WOS:A1991FF04200054
J	MOMOSE, H; LEE, S				MOMOSE, H; LEE, S			PNEUMOCYSTIS-CARINII AS FOAMY EXUDATE IN BONE-MARROW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACQUIRED IMMUNODEFICIENCY SYNDROME; PENTAMIDINE; PNEUMONIA				MOMOSE, H (corresponding author), CEDARS SINAI MED CTR,DEPT PATHOL & LAB MED,8700 BEVERLY BLVD,ROOM 4533,LOS ANGELES,CA 90048, USA.							BEDROSSIAN CWM, 1989, SEMIN DIAGN PATHOL, V6, P212; BERMAN SM, 1990, WESTERN J MED, V153, P82; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; MONTGOMERY AB, 1987, LANCET, V2, P480; MONTGOMERY AB, 1988, AM REV RESPIR DIS, V137, P477, DOI 10.1164/ajrccm/137.2.477; RADIO SJ, 1990, MODERN PATHOL, V3, P462	6	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1672	1672		10.1001/jama.265.13.1672	http://dx.doi.org/10.1001/jama.265.13.1672			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002563				2022-12-28	WOS:A1991FD65900009
J	JUST, U; STOCKING, C; SPOONCER, E; DEXTER, TM; OSTERTAG, W				JUST, U; STOCKING, C; SPOONCER, E; DEXTER, TM; OSTERTAG, W			EXPRESSION OF THE GM-CSF GENE AFTER RETROVIRAL TRANSFER IN HEMATOPOIETIC STEM-CELL LINES INDUCES SYNCHRONOUS GRANULOCYTE-MACROPHAGE DIFFERENTIATION	CELL			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTORS; AUTOCRINE STIMULATION; AUTONOMOUS GROWTH; SELF-RENEWAL; EGF RECEPTOR; INTERLEUKIN-3; MICROENVIRONMENT; IDENTIFICATION; TUMORIGENICITY	Multipotent murine stem cell lines (FDC-Pmix) depend on IL-3 for self-renewal and proliferation and can be induced to differentiate into multiple hematopoietic lineages. Single FDC-Pmix cells infected with retroviral vectors expressing GM-CSF are induced to differentiate into granulocytes and macrophages. This results in a complete loss of clonogenic cells if IL-3 is not exogenously supplied; however, multipotent variants can be selected that do not terminally differentiate if cells are kept in the presence of IL-3. Unidirectional and synchronous granulocyte and macrophage differentiation accompanied with loss of self-renewal capacity is induced when IL-3 is removed. Our data indicate that activation of the GM-CSF receptor induces differentiation of stem cells by an instructive mechanism that can be blocked by the activated IL-3 receptor. A model of how receptors can induce proliferation and cell-specific differentiation by two separate pathways is discussed.	PATERSON INST CANC RES,MANCHESTER M20 9BX,ENGLAND	Paterson Institute for Cancer Research	JUST, U (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Just, Ursula/E-6992-2010					ALLEN TD, 1984, EXP HEMATOL, V12, P517; BOETTIGER D, 1984, CELL, V36, P763, DOI 10.1016/0092-8674(84)90356-8; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; EISEN H, 1978, COLD SPRING HARBOR C, V5, P277; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; Hayhoe FGJ, 1988, HAEMATOLOGICAL CYTOC; HEYWORTH CM, 1988, J CELL SCI, V91, P239; HOUSMAN D, 1978, COLD SPRING HARBOR C, V5, P193; IHLE JN, 1983, J IMMUNOL, V131, P282; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAKER C, 1989, MOL CELL BIOL, V9, P5746, DOI 10.1128/MCB.9.12.5746; LAKER C, 1989, MOD TRENDS HUM LEUK, V8, P188; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1984, HEMOPOIETIC COLONIES; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; QUESENBERRY P, 1988, BLOOD S, V1, P116; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SPOONCER E, 1989, CURR TOP MICROBIOL, V149, P109; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	39	77	80	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1163	1173		10.1016/0092-8674(91)90271-Y	http://dx.doi.org/10.1016/0092-8674(91)90271-Y			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004422				2022-12-28	WOS:A1991FD55800014
J	RICHARDSON, JP				RICHARDSON, JP			PREVENTING THE SYNTHESIS OF UNUSED TRANSCRIPTS BY RHO-FACTOR	CELL			English	Review							ESCHERICHIA-COLI; TERMINATION; SITES; OPERON; GENE		INDIANA UNIV,PROGRAM MOLEC CELLULAR & DEV BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	RICHARDSON, JP (corresponding author), INDIANA UNIV,DEPT CHEM,PROGRAM BIOCHEM,BLOOMINGTON,IN 47405, USA.							ALIFANO P, 1991, CELL, V64, P553; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BIVILLE F, 1985, J GEN MICROBIOL, V131, P2953; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PLATT T, 1991, IN PRESS TRANSCRIPTI; REYNOLDS RR, 1991, IN PRESS J MOL BIOL; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; RUTESHOUSER EC, 1989, J MOL BIOL, V208, P23, DOI 10.1016/0022-2836(89)90085-5; SHIMOTSU H, 1986, GENE, V43, P85; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; TSURUSHITA N, 1989, J MOL BIOL, V210, P23, DOI 10.1016/0022-2836(89)90288-X; WEK RC, 1987, J BIOL CHEM, V262, P15256; WRIGHT JJ, 1987, EMBO J, V6, P1115, DOI 10.1002/j.1460-2075.1987.tb04866.x; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, V1, P1241	17	111	111	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1047	1049		10.1016/0092-8674(91)90257-Y	http://dx.doi.org/10.1016/0092-8674(91)90257-Y			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004415				2022-12-28	WOS:A1991FD55800002
J	SAVITZ, DA				SAVITZ, DA			POWER-LINES AND CANCER RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SAVITZ, DA (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,CHAPEL HILL,NC 27514, USA.		Savitz, David A/I-2211-2014					AHLBOM A, 1988, SCAND J WORK ENV HEA, V14, P337, DOI 10.5271/sjweh.1909; COLEMAN M, 1988, INT J EPIDEMIOL, V17, P1, DOI 10.1093/ije/17.1.1; MORGAN M, 1988, PUBLIC UTILITIES MAR, P49; WILSON BW, 1990, EXTREMELY LOW FREQUE	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1458	1458						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999890				2022-12-28	WOS:A1991FB55000030
J	ZACHARIAH, PK; SHEPS, SG; BAILEY, KR; WILTGEN, CM; MOORE, AG				ZACHARIAH, PK; SHEPS, SG; BAILEY, KR; WILTGEN, CM; MOORE, AG			AGE-RELATED CHARACTERISTICS OF AMBULATORY BLOOD-PRESSURE LOAD AND MEAN BLOOD-PRESSURE IN NORMOTENSIVE SUBJECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTENSIVE PATIENTS; BORDERLINE; MEN	Ambulatory blood pressure monitoring has become increasingly popular for diagnosing and treating hypertension. However, data from normotensive subjects are needed for interpretation of hypertensive readings. Ambulatory blood pressure was monitored in 126 normotensive subjects (age range, 20 to 84 years). Mean systolic and diastolic blood pressures and blood pressure loads (percentage of systolic readings > 140 mm Hg and diastolic readings > 90 mm Hg) were obtained and interpreted. Mean awake systolic and diastolic pressures ranged from 125 +/- 10 to 137 +/- 17 mm Hg and 70 +/- 8 to 71 +/- 9 mm Hg, respectively. The systolic and diastolic trends of subjects' blood pressures taken during office visits and the 24-hour measurements were similar. Ranges for systolic and diastolic blood pressure loads from youngest to oldest ages were 9% +/- 14% to 25% +/- 20% and 3% +/- 7% to 4% +/- 7%, respectively. A comparison of blood pressure means from our sample that were taken during office visits and blood pressure means from a 2122-patient community survey demonstrated that our sample was reflective of an unselected population.	MAYO CLIN & MAYO FDN,DIV HYPERTENS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	ZACHARIAH, PK (corresponding author), MAYO CLIN,HYPERTENS & NEPHROL SECT,4500 SAN PABLO RD,JACKSONVILLE,FL 32224, USA.							BEVAN AT, 1969, CLIN SCI, V36, P329; CRUICKSHANK JM, 1987, LANCET, V1, P581; DRAYER JIM, 1985, ARCH INTERN MED, V145, P271, DOI 10.1001/archinte.145.2.271; DRAYER JIM, 1982, AM J MED, V73, P493, DOI 10.1016/0002-9343(82)90327-8; DRAYER JIM, 1985, AM HEART J, V109, P1334, DOI 10.1016/0002-8703(85)90361-8; *GOULD BA, 1982, BMJ, V285, P1691; HARSHFIELD GA, 1988, J HYPERTENS, V6, P913, DOI 10.1097/00004872-198811000-00010; IRVING JB, 1976, POSTGRAD MED J, V52, P137; Kannel WB, 1980, EPIDEMIOLOGY ARTERIA, P265; KENNEDY HL, 1983, AM HEART J, V106, P717, DOI 10.1016/0002-8703(83)90093-5; MESSERLI FH, 1982, AM HEART J, V104, P109, DOI 10.1016/0002-8703(82)90649-4; MILLARCRAIG MW, 1978, LANCET, V1, P795; PHILLIPS SJ, 1988, MAYO CLIN PROC, V63, P691, DOI 10.1016/S0025-6196(12)65531-1; PICKERING TG, 1982, CLIN EXP HYPERTENS, V4, P675, DOI 10.3109/10641968209061606; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; PICKERING TG, 1985, HYPERTENSION, V7, P171, DOI 10.1161/01.HYP.7.2.171; WALLACE JM, 1984, AMBULATORY BLOOD PRE, P117; WEBER MA, 1984, AM J CARDIOL, V54, P115, DOI 10.1016/0002-9149(84)90314-X; WHITE WB, 1989, AM HEART J, V118, P782, DOI 10.1016/0002-8703(89)90593-0; ZACHARIAH PK, 1988, MAYO CLIN PROC, V63, P1085, DOI 10.1016/S0025-6196(12)65503-7; ZACHARIAH PK, 1988, PRACTICAL CARDIOL, V14, P79; 1985, HYPERTENSION, V7, P457; 1988, ARCH INTERN MED, V148, P1023	23	46	46	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1414	1417		10.1001/jama.265.11.1414	http://dx.doi.org/10.1001/jama.265.11.1414			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999882				2022-12-28	WOS:A1991FB55000022
J	DUNEA, G				DUNEA, G			LETTER FROM CHICAGO - VOICES OF THE MOON	BRITISH MEDICAL JOURNAL			English	Article											DUNEA, G (corresponding author), COOK CTY HOSP,CHICAGO,IL 60612, USA.							Fraser M., 1990, Promerops, P12; MARCHASIN, 1990, WALL STREET J   0626	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					650	651		10.1136/bmj.302.6777.650	http://dx.doi.org/10.1136/bmj.302.6777.650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012885	Bronze, Green Published			2022-12-28	WOS:A1991FC07100031
J	MUNOZ, DP; PELISSON, D; GUITTON, D				MUNOZ, DP; PELISSON, D; GUITTON, D			MOVEMENT OF NEURAL ACTIVITY ON THE SUPERIOR COLLICULUS MOTOR MAP DURING GAZE SHIFTS	SCIENCE			English	Article							SACCADIC EYE-MOVEMENTS; RETICULO-SPINAL NEURONS; VESTIBULO-OCULAR REFLEX; ALERT CAT; HEAD COORDINATION; PRIMATE; STIMULATION; ORIENTATION; HUMANS	The superior colliculus contains neurons that cause displacements of the visual axis (gaze shifts). These cells are arranged topographically in a motor map on which the vector (amplitude and direction) of the coded movement varies continuously with location. How this spatial representation becomes a temporal code (frequency and duration) in the motoneurons is unknown. During a gaze shift, a zone of neural activity moved continuously on the map from an initial location, defining the vector of the desired gaze shift, to a final "zero" position containing neurons that were active during fixation. Thus, the spatial-temporal transformation may be accomplished by control of gaze throughout the spatial trajectory of activity on the motor map.	MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,3801 UNIV,MONTREAL H3A 2B4,QUEBEC,CANADA	McGill University			Pelisson, Denis/H-2916-2017	Pelisson, Denis/0000-0002-9114-7758				BERTHOZ A, 1986, NEUROSCI LETT, V72, P289, DOI 10.1016/0304-3940(86)90528-8; CROMMELINCK M, 1990, Society for Neuroscience Abstracts, V16, P1082; DROULEZ J, 1988, NEURAL COMPUTERS, P345; DROULEZ J, IN PRESS P NATL ACAD; FULLER JH, 1983, BRAIN RES, V271, P241, DOI 10.1016/0006-8993(83)90286-X; GRANTYN A, 1985, EXP BRAIN RES, V57, P417; GRANTYN A, 1982, EXP BRAIN RES, V46, P243; GUITTON D, 1980, EXP BRAIN RES, V39, P63; GUITTON D, 1987, J NEUROPHYSIOL, V58, P427, DOI 10.1152/jn.1987.58.3.427; GUITTON D, 1984, J NEUROPHYSIOL, V52, P1030, DOI 10.1152/jn.1984.52.6.1030; GUITTON D, 1990, J NEUROPHYSIOL, V64, P509, DOI 10.1152/jn.1990.64.2.509; GUITTON D, IN PRESS EYE MOVEMEN; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; LEFEVRE P, 1990, Society for Neuroscience Abstracts, V16, P1084; MEREDITH MA, 1986, J NEUROPHYSIOL, V56, P640, DOI 10.1152/jn.1986.56.3.640; MOSCHOVAKIS AK, 1985, J COMP NEUROL, V239, P276, DOI 10.1002/cne.902390304; MUNOZ D, UNPUB; MUNOZ D P, 1988, Society for Neuroscience Abstracts, V14, P956; MUNOZ D P, 1990, Society for Neuroscience Abstracts, V16, P1084; MUNOZ DP, 1986, BRAIN RES, V398, P185, DOI 10.1016/0006-8993(86)91267-9; MUNOZ DP, 1989, REV NEUROL-FRANCE, V145, P567; MUNOZ DP, 1988, THESIS MCGILL U MONT; PELISSON D, 1986, BRAIN RES, V380, P397, DOI 10.1016/0006-8993(86)90244-1; PELISSON D, 1988, J NEUROPHYSIOL, V59, P997, DOI 10.1152/jn.1988.59.3.997; PELISSON P, 1989, EXP BRAIN RES, V78, P654; Pitts Walter, 1947, BULL MATH BIOPHYS, V9, P127, DOI 10.1007/BF02478291; ROUCOUX A, 1980, EXP BRAIN RES, V39, P75; SPARKS DL, 1990, ANNU REV NEUROSCI, V13, P309, DOI 10.1146/annurev.ne.13.030190.001521; SPARKS DL, 1986, PHYSIOL REV, V66, P118, DOI 10.1152/physrev.1986.66.1.118; TOMLINSON RD, 1986, J NEUROPHYSIOL, V56, P1558, DOI 10.1152/jn.1986.56.6.1558; WURTZ RH, 1980, ANNU REV NEUROSCI, V3, P189, DOI 10.1146/annurev.ne.03.030180.001201	31	129	129	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1358	1360		10.1126/science.2003221	http://dx.doi.org/10.1126/science.2003221			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003221				2022-12-28	WOS:A1991FB73300044
J	DALLOS, P; EVANS, BN; HALLWORTH, R				DALLOS, P; EVANS, BN; HALLWORTH, R			NATURE OF THE MOTOR ELEMENT IN ELECTROKINETIC SHAPE CHANGES OF COCHLEAR OUTER HAIR-CELLS	NATURE			English	Article							MECHANICAL RESPONSES	IT is the prevailing notion that cochlear outer hair cells function as mechanical effectors as well as sensory receptors 1-3. Electrically induced changes in the shape of mammalian outer hair cells 4,5, studied in vitro, are commonly assumed to represent an aspect of their effector process that may occur in vivo. The nature of the motile process is obscure, even though none of the established cellular motors can be involved 6. Although it is known that the motile response is under voltage control 7, it is uncertain whether the stimulus is a drop in the voltage along the long axis of the cell or variation in the transmembrane potential. We have now performed experiments with cells partitioned in differing degrees between two chambers. Applied voltage stimulates the cell membrane segments in opposite polarity to an amount dependent on the partitioning. The findings show, in accordance with previous suggestions 6,8, that the driving stimulus is a local transmembrane voltage drop and that the cellular motor consists of many independent elements, distributed along the cell membrane and its associated cortical structures. We further show that the primary action of the motor elements is along the longitudinal dimension of the cell without necessarily involving changes in intracellular hydrostatic pressure. This establishes the outer hair cell motor as unique among mechanisms that control cell shape 9.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University	DALLOS, P (corresponding author), NORTHWESTERN UNIV,HUGH KNOWLES CTR,AUDITORY PHYSIOL LAB,EVANSTON,IL 60208, USA.		Dallos, Peter/Q-9360-2019	Dallos, Peter/0000-0002-9731-6591				ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; Bannister L H, 1988, Prog Brain Res, V74, P213; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; BROWNELL WE, 1990, EAR HEARING, V11, P82, DOI 10.1097/00003446-199004000-00003; BROWNELL WE, 1986, PERIPHERAL AUDITORY, P369; BROWNELL WE, 1983, MECHANISMS HEARING, P5; CLARK BA, 1990, PFLUG ARCH EUR J PHY, V415, P490, DOI 10.1007/BF00373629; DALLOS P, 1985, P207; DALLOS P, 1978, J NEUROPHYSIOL, V41, P365, DOI 10.1152/jn.1978.41.2.365; DALLOS P, 1988, AUDITORY FUNCTION NE, P153; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; EVANS BN, 1990, HEARING RES, V45, P265, DOI 10.1016/0378-5955(90)90126-A; EVANS BN, 1988, THESIS U TEXAS HLTH; FLOCK A, 1986, ARCH OTO-RHINO-LARYN, V243, P83, DOI 10.1007/BF00453755; GUINAN JJ, 1983, J COMP NEUROL, V221, P358, DOI 10.1002/cne.902210310; HOLLEY MC, 1988, NATURE, V335, P635, DOI 10.1038/335635a0; HOLLEY MC, 1990, J CELL SCI, V96, P283; HOLLEY MC, 1988, PROC R SOC SER B-BIO, V232, P413, DOI 10.1098/rspb.1988.0004; JEN DH, 1987, J ACOUST SOC AM, V82, P1667, DOI 10.1121/1.395158; KIM DO, 1986, HEARING RES, V22, P105, DOI 10.1016/0378-5955(86)90088-2; Lackie J.M., 1986, CELL MOVEMENT CELL B, P253, DOI [10.1007/978-94-009-4071-0_10, DOI 10.1007/978-94-009-4071-0_10]; SAITO K, 1983, CELL TISSUE RES, V229, P467; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SMITH CA, 1957, AM J ANAT, V100, P337, DOI 10.1002/aja.1001000304; SPOENDLIN H, 1969, ACTA OTO-LARYNGOL, V67, P239, DOI 10.3109/00016486909125448	26	190	196	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					155	157		10.1038/350155a0	http://dx.doi.org/10.1038/350155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005965				2022-12-28	WOS:A1991FB64500059
J	CALLAHAM, M; BARTON, CW; KAYSER, S				CALLAHAM, M; BARTON, CW; KAYSER, S			POTENTIAL COMPLICATIONS OF HIGH-DOSE EPINEPHRINE THERAPY IN PATIENTS RESUSCITATED FROM CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT VASOPRESSOR RESPONSE; MYOCARDIAL OXYGEN DELIVERY; CARDIOPULMONARY RESUSCITATION; HUMAN-BEINGS; CPR	Adults resuscitated from nontraumatic cardiac arrest who received intravenous epinephrine in doses chosen by the treating physician and who survived at least 6 hours were studied to determine if high-dose epinephrine produced more complications than standard-dose. A total of 68 patients were enrolled and evaluated for postresuscitation complications attributable to epinephrine, using a two-tailed t test, and contingency analysis. The 33 patients receiving high-dose epinephrine and 35 patients receiving standard-dose epinephrine were similar in demographics and variables known to affect outcome. There was no difference in potential complications between groups except serum calcium, which was 1.97 mmol/L (SD, 0.20) in the high-dose epinephrine group and 2.10 (SD, 0.20) in the standard-dose group. Hospital discharge rates (18% in the high-dose vs 30% in the standard-dose group) and neurological status on discharge were not significantly different. High-dose epinephrine did not produce increased direct complications in this cardiac arrest population compared with standard-dose epinephrine.	UNIV CALIF SAN FRANCISCO,DIV CLIN PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CALLAHAM, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,DIV EMERGENCY MED,SAN FRANCISCO,CA 94143, USA.			Callaham, Michael/0000-0003-2284-256X				BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1988, CRIT CARE MED, V16, P536, DOI 10.1097/00003246-198805000-00013; BROWN DD, 1988, SKELETAL RADIOL, V17, P302, DOI 10.1007/BF00401818; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; ERSOZ N, 1971, BRIT J ANAESTH, V43, P709, DOI 10.1093/bja/43.7.709; FRIEDMAN B, 1955, LANCET, P575; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HALL AH, 1987, AM J EMERG MED, V5, P64, DOI 10.1016/0735-6757(87)90293-2; KARCH SB, 1987, AM J FOREN MED PATH, V8, P3, DOI 10.1097/00000433-198703000-00002; KELLNER M, 1966, ACTA MED HUNG, V23, P37; KELLNER M, 1966, ACTA MED HUNG, V22, P335; KIRIMLI B, 1969, ANESTH ANAL CURR RES, V48, P649; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KURACHEK SC, 1985, JAMA-J AM MED ASSOC, V253, P1441, DOI 10.1001/jama.253.10.1441; LONGSTRETH WT, 1987, WESTERN J MED, V147, P175; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; MARTIN D, 1990, ANN EMERG MED, V19, P322, DOI 10.1016/S0196-0644(05)82055-4; MARTIN GB, 1985, ANN EMERG MED, V14, P293, DOI 10.1016/S0196-0644(85)80089-5; MUSCH W, 1987, ANN EMERG MED, V16, P514; NOVEY HS, 1969, J AMER MED ASSOC, V207, P2435, DOI 10.1001/jama.207.13.2435; PARADIS N A, 1990, Critical Care Medicine, V18, pS221, DOI 10.1097/00003246-199012001-00087; PARADIS NA, 1990, ANN EMERG MED, V19, P491; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; SALERNO DM, 1989, CRIT CARE MED, V17, P1181, DOI 10.1097/00003246-198911000-00016; STEINGRUB J, 1990, Critical Care Medicine, V18, pS223, DOI 10.1097/00003246-199012001-00090; URBAN P, 1988, ANN INTERN MED, V109, P110, DOI 10.7326/0003-4819-109-2-110; 1986, JAMA-J AM MED ASSOC, V255, P2905	29	35	35	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1117	1122		10.1001/jama.265.9.1117	http://dx.doi.org/10.1001/jama.265.9.1117			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995996				2022-12-28	WOS:A1991EZ47400027
J	CHARLESWORTH, B				CHARLESWORTH, B			THE EVOLUTION OF SEX-CHROMOSOMES	SCIENCE			English	Article							DOSAGE COMPENSATION; ACCUMULATION; ALLOCATION; PLANTS; GENES; POPULATIONS	Structurally distinct sex chromosomes (X and Y) are the most familiar mode of genetic sex determination and have evolved independently in many different taxa. The evolutionary paths by which their characteristic properties may have evolved are reviewed. These properties include the failure of X and Y to recombine through much or all of their length, the genetic inertness of much of the Y chromosome, dosage compensation of the activity of X chromosomal loci, and the accumulation of repeated DNA sequences on the Y chromosome.			CHARLESWORTH, B (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637, USA.							Bull J.J., 1983, EVOLUTION SEX DETERM; CASPER BB, 1982, J THEOR BIOL, V96, P143, DOI 10.1016/0022-5193(82)90217-X; CHARLESWORTH B, 1986, GENETICS, V112, P359; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; CHARLESWORTH B, 1989, ANNU REV GENET, V23, P251, DOI 10.1146/annurev.ge.23.120189.001343; CHARLESWORTH D, 1987, EVOLUTION, V41, P948, DOI 10.1111/j.1558-5646.1987.tb05869.x; CHARLESWORTH D, 1979, PROC R SOC SER B-BIO, V205, P513, DOI 10.1098/rspb.1979.0082; CHARLESWORTH D, 1989, J THEOR BIOL, V139, P327, DOI 10.1016/S0022-5193(89)80212-7; Charlesworth D., 1985, EVOLUTION ESSAYS HON, P237; CHARLESWORTH D, UNPUB; Darlington CD., 1958, EVOLUTION GENETIC SY; Darwin C, 1877, EFFECTS CROSS SELF F; Dobzhansky T, 1935, GENETICS, V20, P0366; EICHER EM, 1989, GENETICS, V122, P181; ELLIS N, 1989, TRENDS GENET, V5, P406, DOI 10.1016/0168-9525(89)90199-6; Endler J.A., 1986, P109; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; Fisher RA, 1935, AM NAT, V69, P446, DOI 10.1086/280618; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; John B, 1988, HETEROCHROMATIN MOL, P1; LLOYD DG, 1979, PLANT SYST EVOL, V131, P71, DOI 10.1007/BF00984123; Lohe A., 1988, HETEROCHROMATIN MOL, P148; LUCCHESI JC, 1978, SCIENCE, V202, P711, DOI 10.1126/science.715437; LUCCHESI JC, 1990, NATURE, V344, P721; MAYNARD SMITH J., 1978, EVOLUTION SEX; Muller HJ, 1918, GENETICS, V3, P422; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; NEI M, 1970, AM NAT, V104, P311, DOI 10.1086/282665; RICE WR, 1987, GENETICS, V116, P161; RICE WR, 1987, EVOLUTION, V41, P911, DOI 10.1111/j.1558-5646.1987.tb05864.x; STEINEMANN M, 1982, CHROMOSOMA, V86, P59, DOI 10.1007/BF00330730; STEPHAN W, 1989, MOL BIOL EVOL, V6, P198, DOI 10.1093/oxfordjournals.molbev.a040542; STROBEL E, 1978, P NATL ACAD SCI USA, V75, P931, DOI 10.1073/pnas.75.2.931; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL	36	581	598	5	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1030	1033		10.1126/science.1998119	http://dx.doi.org/10.1126/science.1998119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1998119				2022-12-28	WOS:A1991EZ66500038
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - BENEFITS FOR PEOPLE IN HOSPITAL, NURSING-HOMES, AND RESIDENTIAL CARE HOMES	BRITISH MEDICAL JOURNAL			English	Editorial Material											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					463	465		10.1136/bmj.302.6774.463	http://dx.doi.org/10.1136/bmj.302.6774.463			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004176	Green Published, Bronze			2022-12-28	WOS:A1991EZ03300029
J	THOMAS, KJ; CARR, J; WESTLAKE, L; WILLIAMS, BT				THOMAS, KJ; CARR, J; WESTLAKE, L; WILLIAMS, BT			USE OF NON-ORTHODOX AND CONVENTIONAL HEALTH-CARE IN GREAT-BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							MEDICINE	Objective-To describe the characteristics of patients using non-orthodox health care and their pattern of use of conventional health care with respect to a particular problem. Design-Postal survey of all 2152 practitioners of acupuncture, chiropractic, homoeopathy, naturopathy, and osteopathy identified from 11 national professional association registers. Patients attending a representative sample of 101 responding practitioners completed questionnaires covering demographic characteristics, presenting problems, and use of the health service. Setting-Practices of practitioners of non-orthodox health care in England, Scotland, and Wales. Subjects-Qualified, non-medical practitioners of non-orthodox health care working in Great Britian and 2473 patients who had attended one of the sampled practitioners in an allocated time period between August 1987 and July 1988. Results-An estimated 1909 practitioners were actively practising one of the study treatments in Great Britian in 1987. Of the estimated 70 600 patients seen by this group of practitioners in an average week, most (78%) were attending with a musculoskeletal problem. Two thirds of the patients were women. Only 2% were aged under 16, but 15% were aged 65 or over. One in three patients had not received previous conventional care for their main problem; 18% were receiving concurrent non-orthodox and conventional care. Twenty two per cent of the patients reported having seen their general practitioner for any reason in the two weeks before the surveyed consultation. Conclusions-Patients of non-orthodox health care, as provided by this group of practitioners, had not turned their backs on conventional health care. Non-orthodox treatment was sought for a limited range of problems and used most frequently as a supplement to orthodox medicine.			THOMAS, KJ (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							DAVIES P, 1987, REPORT TRENDS COMPLE; FULDER SJ, 1986, LANCET, V2, P542; INGLIS B, 1985, LANCET, V1, P95; Lamberts H., 1987, ICPC INT CLASSIFICAT; MURRAY J, 1988, J ROY COLL GEN PRACT, V38, P511; 1984, GENERAL HOUSEHOLD SU; 1987, PROFESSIONAL CONDUCT; 1986, WHICH            OCT, P443; 1986, ALTERNATIVE THERAPIE	9	159	160	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					207	210		10.1136/bmj.302.6770.207	http://dx.doi.org/10.1136/bmj.302.6770.207			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV228	1998760	Bronze, Green Published			2022-12-28	WOS:A1991EV22800024
J	BRUNS, FJ; ADLER, S; FRALEY, DS; SEGEL, DP				BRUNS, FJ; ADLER, S; FRALEY, DS; SEGEL, DP			SUSTAINED REMISSION OF MEMBRANOUS GLOMERULONEPHRITIS AFTER CYCLOPHOSPHAMIDE AND PREDNISONE	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; FOLLOW-UP; UNTREATED PATIENTS; NEPHROTIC SYNDROME; NATURAL-HISTORY; RENAL-FUNCTION; NEPHROPATHY; CHLORAMBUCIL; ADULTS; METHYLPREDNISOLONE	Objective: To determine the effect of cyclophosphamide and prednisone on progressive renal failure and on nephrotic features in patients with membranous glomerulonephritis. Design: Prospective, nonrandomized time series. Setting: Outpatient clinic at a university medical center. Patients: Eleven consecutive patients with biopsy-proven membranous glomerulonephritis and rising plasma creatinine levels over at least 6 months. Intervention: Cyclophosphamide and prednisone in ten patients and cyclophosphamide alone in one patient. Measurements and Main Results: In ten patients treated with both agents, the median plasma creatinine rose 53-mu-mol/L (0.6 mg/dL) over the months before treatment from 141 to 194-mu-mol/L (1.6 to 2.2 mg/dL) (95% CI, 27 to 141-mu-mol/L; P = 0.002). After combined therapy for 6 months, the median plasma creatinine fell to 133-mu-mol/L (1.5 mg/dL) for a median decline of 62-mu-mol/L (0.7 mg/dL) (CI, 44 to 150-mu-mol/L; P = 0.006). Pretreatment plasma creatinine levels, which ranged from 159 to 371-mu-mol/L (1.8 to 4.2 mg/dL), decreased in the ten patients by 6 months and remained stable in seven of the eight patients followed 24 to 54 months after therapy was completed. The median urine protein excretion decreased by 9.6 g/d with 12 months of therapy in the ten patients from 11.9 to 2.3 g/d (CI, 6.0 to 15.1 g/d; P < 0.001). The median plasma albumin rose by 14 g/L from 24 to 38 g/L (CI, 11 to 19 g/L; P < 0.001). The median plasma cholesterol fell by 3.26-mu-mol/L (140 mg/dL) from 10.45 to 6.52-mu-mol/L (405 to 252 mg/dL) (CI, 1.42 to 7.16-mu-mol/L; P = 0.01). One patient who had a relapse 30 months after completing therapy responded to re-treatment with renal function and nephrotic variables returning toward normal. The eleventh patient received cyclophosphamide alone and had a course similar to that of the combined therapy group. Conclusion: Cyclophosphamide plus prednisone can promote prolonged remissions in membranous glomerulonephritis even when renal function is already declining.	UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BRUNS, FJ (corresponding author), MONTEFIORE UNIV HOSP, 3459 5TH AVE, PITTSBURGH, PA 15213 USA.							BAILAR JC, 1984, NEW ENGL J MED, V311, P156, DOI 10.1056/NEJM198407193110306; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BLACK DAK, 1970, BRIT MED J, V3, P421, DOI 10.1136/bmj.3.5720.421; BRUNS FJ, 1989, AM J MED, V86, P400, DOI 10.1016/0002-9343(89)90336-7; CAMERON JS, 1979, KIDNEY INT, V15, P88; CAMERON JS, 1982, AM J KIDNEY DIS, V1, P371; CATTRAN D, 1984, 9TH P INT C NEPHR A, V74; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COGGINS CH, 1979, NEW ENGL J MED, V301, P1301; DAVISON AM, 1984, CLIN NEPHROL, V22, P61; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; DONADIO JV, 1974, KIDNEY INT, V6, P431, DOI 10.1038/ki.1974.129; Ehrenreich T., 1968, PATHOL ANNU, V3, P145; EVANOFF GV, 1987, ARCH INTERN MED, V147, P492, DOI 10.1001/archinte.147.3.492; FRANKLIN WA, 1973, KIDNEY INT, V4, P36, DOI 10.1038/ki.1973.78; GARTNER HV, 1974, NEPHRON, V13, P288, DOI 10.1159/000180405; GLASSOCK RJ, 1982, AM J KIDNEY DIS, V1, P376, DOI 10.1016/S0272-6386(82)80011-5; HONKANEN E, 1986, CLIN NEPHROL, V25, P122; IDELSON BA, 1977, ARCH INTERN MED, V137, P891, DOI 10.1001/archinte.137.7.891; LAVORI PW, 1983, NEW ENGL J MED, V309, P1291, DOI 10.1056/NEJM198311243092105; LOUIS TA, 1984, NEW ENGL J MED, V310, P24, DOI 10.1056/NEJM198401053100106; MANOS J, 1982, CLIN NEPHROL, V18, P286; MATHIESON PW, 1988, LANCET, V2, P869; MOSES LE, 1985, NEW ENGL J MED, V312, P890, DOI 10.1056/NEJM198504043121405; NOEL LH, 1979, AM J MED, V66, P82, DOI 10.1016/0002-9343(79)90486-8; PIERIDES AM, 1977, Q J MED, V46, P163; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; Ponticelli C, 1987, Adv Nephrol Necker Hosp, V16, P195; RANDALL RE, 1970, AM SOC NEPHROL, V4, P65; RELMAN AS, 1989, NEW ENGL J MED, V320, P248, DOI 10.1056/NEJM198901263200411; RYAN BF, 1985, MINITAB HDB, P292; SUKI WN, 1981, AM J NEPHROL, V1, P11, DOI 10.1159/000166481; TAGUMA Y, 1985, NEW ENGL J MED, V313, P1617, DOI 10.1056/NEJM198512263132601; TILLER DJ, 1981, 8TH P INT C NEPHR, P345; TU WH, 1984, NEPHRON, V36, P118, DOI 10.1159/000183130; WEST ML, 1987, KIDNEY INT, V32, P579, DOI 10.1038/ki.1987.247	37	72	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					725	730		10.7326/0003-4819-114-9-725	http://dx.doi.org/10.7326/0003-4819-114-9-725			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012353				2022-12-28	WOS:A1991FJ11700003
J	PIPER, JM; RAY, WA; DAUGHERTY, JR; GRIFFIN, MR				PIPER, JM; RAY, WA; DAUGHERTY, JR; GRIFFIN, MR			CORTICOSTEROID USE AND PEPTIC-ULCER DISEASE - ROLE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS	ANNALS OF INTERNAL MEDICINE			English	Article							GASTRIC-ULCER; ADRENOCORTICOSTEROID THERAPY; ASPIRIN; ASSOCIATION; PREVENTION; SECRETION	Objective: To estimate the relative risk for peptic ulcer disease that is associated with the use of oral corticosteroids. Design: A nested case-control study. Setting: Tennessee Medicaid program. Participants: The case patients (n = 1415) were hospitalized between 1984 and 1986 for gastric or duodenal ulcer or for upper gastrointestinal hemorrhage of unknown cause. The controls (n = 7063) were randomly selected from Medicaid enrollees not meeting the study criteria for inclusion as case patients. Measurements and Main Results: The estimated relative risk for the development of peptic ulcer disease among current users of oral corticosteroids was 2.0 (95% CI, 1.3 to 3.0). However, the risk was increased only in those who concurrently received nonsteroidal anti-inflammatory drugs (NSAIDS); these persons had an estimated relative risk associated with current corticosteroid use of 4.4 (CI, 2.0 to 9.7). In contrast, the estimated relative risk for those corticosteroid users not receiving corticosteroids and NSAIDs had a risk for peptic ulcer disease that was 15 times greater than that of nonusers of either drug. Conclusion: Discrepant findings among earlier studies regarding steroids and the risk for peptic ulcer disease could in part be due to differences in the use of NSAIDs among study participants. The high risk for peptic ulcer disease associated with combined use of NSAIDs and corticosteroids indicates the need to prescribe this drug combination cautiously.			PIPER, JM (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT PREVENT MED, MED CTR N A-1112, NASHVILLE, TN 37232 USA.				FDA HHS [FD-U-000073] Funding Source: Medline	FDA HHS		BECK JC, 1950, CAN MED ASSOC J, V62, P423; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; CONN HO, 1976, NEW ENGL J MED, V294, P473, DOI 10.1056/NEJM197602262940905; DAVIS TA, 1952, JAMA-J AM MED ASSOC, V150, P31, DOI 10.1001/jama.1952.63680010004008c; DEAN AG, 1988, AM J EPIDEMIOL, V127, P654, DOI 10.1093/oxfordjournals.aje.a114840; DELANEY JP, 1979, GASTROENTEROLOGY, V76, P913; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P469, DOI 10.1056/NEJM197402282900901; GRAHAM DY, 1988, LANCET, V2, P1277; GRAY SJ, 1951, JAMA-J AM MED ASSOC, V147, P1529, DOI 10.1001/jama.1951.03670330021007; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HAWLEY CJ, 1990, BMJ-BRIT MED J, V300, P278; JANOWITZ HD, 1958, GASTROENTEROLOGY, V34, P11; KAHN DS, 1961, AM J PATHOL, V38, P177; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P379; LANZA FL, 1989, SCAND J GASTROENTERO, V24, P24, DOI 10.3109/00365528909091171; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MALONE DE, 1986, BRIT J RHEUMATOL, V25, P342; MCINTOSH JH, 1988, AM J EPIDEMIOL, V128, P761, DOI 10.1093/oxfordjournals.aje.a115029; MCINTOSH JH, 1985, GUT, V26, P789, DOI 10.1136/gut.26.8.789; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; MOE AE, 1952, GASTROENTEROLOGY, V20, P343; PAYNE CD, 1986, GLIM SYSTEM RELEASE; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROBERT A, 1964, ARCH PATHOL, V77, P407; SEINO S, 1978, GUT, V19, P10, DOI 10.1136/gut.19.1.10; SELLING JA, 1987, ANN INTERN MED, V106, P368, DOI 10.7326/0003-4819-106-3-368; SOMERVILLE K, 1986, LANCET, V1, P462; SPIRO HM, 1983, NEW ENGL J MED, V309, P45, DOI 10.1056/NEJM198307073090110; SPIRO HM, 1950, J LAB CLIN MED, V35, P899; STRUM WB, 1986, ANN INTERN MED, V105, P757, DOI 10.7326/0003-4819-105-5-757; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; 1985, CLIN MODIFICATION, V2	35	426	434	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					735	740		10.7326/0003-4819-114-9-735	http://dx.doi.org/10.7326/0003-4819-114-9-735			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012355				2022-12-28	WOS:A1991FJ11700005
J	CASSILETH, BR; LUSK, EJ; GUERRY, D; BLAKE, AD; WALSH, WP; KASCIUS, L; SCHULTZ, DJ				CASSILETH, BR; LUSK, EJ; GUERRY, D; BLAKE, AD; WALSH, WP; KASCIUS, L; SCHULTZ, DJ			SURVIVAL AND QUALITY-OF-LIFE AMONG PATIENTS RECEIVING UNPROVED AS COMPARED WITH CONVENTIONAL CANCER-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMYGDALIN; MEDICINE	Background. Cancer treatments without proved efficacy have achieved new levels of popularity, particularly among well-educated patients. The value of these therapies is vigorously debated. Methods. We compared the length of survival and quality of life in patients who received treatment at a prominent unorthodox cancer clinic in addition to conventional treatment and in matched control patients from an academic cancer center who received only conventional treatment. All the patients had documented extensive malignant disease associated with a predicted median survival time of less than one year. The study sample consisted of 78 pairs of patients matched according to sex, race, age, diagnosis, and time from the diagnosis of metastatic or recurrent disease, who were enrolled over a period of 3 1/2 years. Periodic follow-up (approximately every two months) continued until death. Results. There was no difference between the two patient groups in length of survival. Median survival for both groups was 15 months (P = 0.22; relative risk, 1.23; 95 percent confidence interval, 0.88 to 1.72). Quality-of-life scores were consistently better among conventionally treated patients from enrollment on. Conclusions. For this sample of patients with extensive disease and for this particular unorthodox treatment regimen, conventional and unorthodox treatments produced similar results.	UNIV PENN,PSYCHOSOCIAL RES PROGRAMS,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA042260] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWMAN BB, 1984, J CLIN ONCOL, V2, P702, DOI 10.1200/JCO.1984.2.6.702; CASSILETH B R, 1989, Journal of Psychosocial Oncology, V7, P47; CASSILETH BR, 1986, CANCER INVEST, V4, P591, DOI 10.3109/07357908609039837; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CURT GA, 1986, JAMA-J AM MED ASSOC, V255, P505, DOI 10.1001/jama.255.4.505; DEVERELL D, 1978, I HEALED MY CANCER H; DIPALMA JR, 1982, B NEW YORK ACAD MED, V58, P254; EISELE JW, 1980, JAMA-J AM MED ASSOC, V244, P1608, DOI 10.1001/jama.244.14.1608; GERSON M, 1977, CANCER THERAPY RESUL; HERBERT V, 1980, NUTRITION CULTISM FA; HINDMARSH W, 1980, CLIN TOXICOL, V17, P85; ISTRE GR, 1982, NEW ENGL J MED, V307, P339, DOI 10.1056/NEJM198208053070603; LIVINGSTONWHEEL.V, 1984, CONQUEST CANCER; MASTRANGELO MJ, 1985, CANCER PRINCIPLES PR, V2, P1371; MINNA JD, 1985, CANCER PRINCIPLES PR, V1, P507; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; MOERTEL CG, 1982, NEW ENGL J MED, V306, P201, DOI 10.1056/NEJM198201283060403; MOERTEL CG, 1981, JAMA-J AM MED ASSOC, V245, P591, DOI 10.1001/jama.245.6.591; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; OBRIEN PC, 1987, BIOMETRICS, V43, P169, DOI 10.2307/2531957; PORTLOCK CS, 1980, MANUAL CLIN PROBLEMS, P168; SCHAUMBURG H, 1983, NEW ENGL J MED, V309, P445, DOI 10.1056/NEJM198308253090801; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; SINDELAR WF, 1985, CANCER PRINCIPLES PR, V1, P691; WHEELER VL, 1980, COMPENDIUM MICROBIOL; WUERTHELE-CASPE V, 1947, J Med Soc N J, V44, P256; 1983, CA, V33, P252; 1990, OTAH405 PUBL; 1983, CA, V33, P57; 1984, CA, V34, P232	30	133	137	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1180	1185		10.1056/NEJM199104253241706	http://dx.doi.org/10.1056/NEJM199104253241706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011162				2022-12-28	WOS:A1991FH57200006
J	Wassertheilsmoller, S; Blaufox, MD; Oberman, A; Davis, BR; Swencionis, C; Knerr, MO; Hawkins, CM; Langford, HG				Wassertheilsmoller, S; Blaufox, MD; Oberman, A; Davis, BR; Swencionis, C; Knerr, MO; Hawkins, CM; Langford, HG			EFFECT OF ANTIHYPERTENSIVES ON SEXUAL FUNCTION AND QUALITY-OF-LIFE - THE TAIM STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIAL; THERAPY; IMPACT; MEN	Objective: To evaluate treatment of mild hypertension using combinations of diet and low-dose pharmacologic therapies. Design: Multicenter, randomized, placebo-controlled clinical trial. Setting: Three university-based tertiary care centers. Patients: Patients (697) 21 to 65 years of age with diastolic blood pressure between 90 and 100 mm Hg as well as weight between 110% and 160% of ideal weight. Intervention: Patients were stratified by clinical center and race and were randomly assigned to one of three diets (usual, low-sodium and high-potassium, weight loss) and one of three agents (placebo, chlorthalidone, and atenolol). Measurements: Changes in measures of sexual problems, distress, and well-being after 6 months of therapy were analyzed. Main Results: Low-dose chlorthalidone and atenolol produced few side effects, except in men. Erection-related problems worsened in 28% (95% CI, 15% to 41%) of men receiving chlorthalidone and usual diet compared with 3% (CI, 0% to 9%) of those receiving placebo and usual diet (P = 0.009) and 11% (CI, 2% to 20%) of those receiving atenolol and usual diet (P > 0.05). The weight loss diet ameliorated this effect. The low-sodium diet with placebo was associated with greater fatigue (34%; CI, 23% to 45%) than was either usual diet (18%; CI, 10% to 27%; P = 0.04) or weight reduction (15%; CI, 7% to 23%; P = 0.009). The low-sodium diet with chlorthalidone increased problems with sleep (32%; CI, 22% to 42%) compared with chlorthalidone and usual diet (16%; CI, 8% to 24%; P = 0.04). The weight loss diet benefited quality of life most, reducing total physical complaints (P < 0.001) and increasing satisfaction with health (P < 0.001). Total physical complaints decreased in 57% to 76% of patients depending on drug and diet group, and were markedly decreased by weight loss. Conclusion: In general, low-dose antihypertensive drug therapy (with chlorthalidone or atenolol) improves rather than impairs the quality of life; however, chlorthalidone with usual diet increases sexual problems in men.	Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Wassertheilsmoller, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Blaufox, MDonald/AAF-6965-2020	Blaufox, MDonald/0000-0002-4148-6866	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030171, R01HL024369, R01HL030163] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30163, HL 24369, HL 30171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1981, LANCET, V2, P539; BANSAL S, 1988, HYPERTENSION, V12, P1; BLUMENTHAL JA, 1988, CLIN PHARMACOL THER, V43, P429, DOI 10.1038/clpt.1988.54; Cohen J., 1988, STATISTICAL POWER AN, DOI DOI 10.1234/12345678; CROOG SH, 1988, ARCH INTERN MED, V148, P788, DOI 10.1001/archinte.148.4.788; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; CURB J D, 1985, American Journal of Preventive Medicine, V1, P36; CURB JD, 1985, JAMA-J AM MED ASSOC, V253, P3263, DOI 10.1001/jama.253.22.3263; DAVIS BR, 1989, CONTROL CLIN TRIALS, V10, P11; DEROGATIS L, 1990, DESCRIPTION BIBLIO S; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; EGAN KJ, 1983, J HUM STRESS, V9, P4, DOI 10.1080/0097840X.1983.9935024; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; GENGO FM, 1988, ARCH INTERN MED, V148, P779, DOI 10.1001/archinte.148.4.779; LANGFORD HG, 1991, IN PRESS HYPERTENSIO; LICHTER I, 1986, BRIT J CLIN PHARMACO, V21, P641, DOI 10.1111/j.1365-2125.1986.tb05228.x; OBERMAN A, 1990, ANN INTERN MED, V112, P89, DOI 10.7326/0003-4819-112-2-89; SMOLLER JW, 1987, J PSYCHOSOM RES, V31, P429, DOI 10.1016/0022-3999(87)90001-8; TESTA MA, 1987, J HYPERTENS, V5, pS9; WARE JE, 1984, AM PSYCHOL, V39, P1090; WILLIAMS GH, 1987, J HYPERTENS, V5, pS29; 1989, PHYSICIANS DESK REFE	22	194	197	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					613	620		10.7326/0003-4819-114-8-613	http://dx.doi.org/10.7326/0003-4819-114-8-613			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003706				2022-12-28	WOS:A1991FG03100001
J	BARONDESS, JA				BARONDESS, JA			THE RISK OF CONTRACTING HIV-INFECTION IN THE COURSE OF HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BARONDESS, JA (corresponding author), NEW YORK ACAD MED,2 E 103RD ST,NEW YORK,NY 10029, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1872	1873						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005738				2022-12-28	WOS:A1991FE86200031
J	GAWIN, FH				GAWIN, FH			COCAINE ADDICTION - PSYCHOLOGY AND NEUROPHYSIOLOGY	SCIENCE			English	Article							ABSTINENCE SYMPTOMATOLOGY; PSYCHIATRIC-DIAGNOSIS; CLINICAL OBSERVATIONS; DOPAMINE; ABUSE; WITHDRAWAL; BRAIN; STIMULANTS; DEPENDENCE; RECEPTORS	Cocaine was considered incapable of producing dependence in 1980 but was recently proclaimed the drug of greatest national health concern. Recent clinical and preclinical investigations demonstrate that cocaine produces unique abuse and withdrawal patterns that differ from those of other major abused drugs and suggest that long-term cocaine abuse produces neurophysiological alterations in specific systems in the central nervous system that regulate the capacity to experience pleasure. It will be necessary to develop clinically pertinent research models before these findings can be considered definitive, but these evolving ideas have already led to applications of promising experimental treatments for cocaine abuse.			GAWIN, FH (corresponding author), UNIV CALIF LOS ANGELES,DEPT PSYCHIAT STIMULANT ABUSE TREATMENT & RES,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006289, R18DA006082] Funding Source: NIH RePORTER; NIDA NIH HHS [R18-DA06082, R01-DA06289] Funding Source: Medline; PHS HHS [P50-04060] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS EH, 1985, NIDA RES MONOGR, V61, P35; BLACKBURN JR, 1989, BEHAV NEUROSCI, V103, P15, DOI 10.1037/0735-7044.103.1.15; BROWN E E, 1990, Society for Neuroscience Abstracts, V16, P251; CARROLL ME, 1990, PHARMACOL BIOCHEM BE, V35, P237, DOI 10.1016/0091-3057(90)90232-7; CARROLL ME, 1990, PSYCHOPHARMACOLOGY, V100, P293, DOI 10.1007/BF02244596; CARROLL ME, 1987, LIFE SCI, V40, P2183, DOI 10.1016/0024-3205(87)90009-9; Childress A, 1988, NIDA Res Monogr, V81, P74; CONNELL PH, 1970, DRUGS YOUTH; DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3; DWOSKIN LP, 1988, LIFE SCI, V42, P255, DOI 10.1016/0024-3205(88)90634-0; ELLINWOOD EH, 1974, DRUG USE EPIDEMIOLOG, P303; ELLINWOOD EH, 1977, PSYCHOPHARMACOLOGY P, P467; ELLINWOOD EH, 1977, DRUG ABUSE CLIN BASI, P248; EXTEIN I, 1987, 140TH M AM PSYCH ASS; FAWCETT JA, COMMUNICATION; Freud S, 1884, CENTRALBLATT GESAMMT, V2, P289; GAWIN F, 1989, TREATMENT PSYCHIATRI; Gawin F H, 1985, NIDA Res Monogr, V61, P182; GAWIN FH, 1989, ARCH GEN PSYCHIAT, V46, P322; GAWIN FH, 1985, BRIT J PSYCHIAT, V147, P569, DOI 10.1192/bjp.147.5.569; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GAWIN FH, 1984, ARCH GEN PSYCHIAT, V41, P903; GAWIN FH, 1986, PSYCHOPHARMACOLOGY, V90, P142; GAWIN FH, 1986, COCAINE CLIN BIOBEHA, P169; GAWIN FH, UNPUB; GIANNINI AJ, 1986, J CLIN PHARMACOL, V26, P211, DOI 10.1002/j.1552-4604.1986.tb02936.x; GIANNINI AJ, 1985, INT J PSYCHIAT MED, V15, P415; GRABOWSKI J, 1984, NIDA RES MONOGR, V50, pR8; GRINSPOON L, 1980, COMPREHENSIVE TXB PS; GRINSPOON L, 1973, DRUG USE AM PROBLEMS; HENRY DJ, 1989, J PHARMACOL EXP THER, V251, P901; HOLLANDER S, 1990, PSYCHIAT RES, V33, P1611; JEKEL JF, 1986, LANCET, V1, P459; JOHANSON CE, 1989, PHARMACOL REV, V41, P3; JONES R, 1984, NIDA RES MONOGRAPH S, V50, P182; KALIVAS PW, 1990, SYNAPSE, V5, P48, DOI 10.1002/syn.890050104; KALSA H, UNPUB; KOKKINIDIS L, 1990, PHARMACOL BIOCHEM BE, V36, P463, DOI 10.1016/0091-3057(90)90242-A; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LEWIN, 1924, PHANTASTICA, P80; MARKOU A, 1988, Society for Neuroscience Abstracts, V14, P660; MARTIN SD, 1989, BIOL PSYCHIAT, V26, P356, DOI 10.1016/0006-3223(89)90051-6; McElroy S L, 1989, NIDA Res Monogr, V95, P57; MEIER HW, 1926, KOKAINISMUS; MELLO NK, 1989, SCIENCE, V245, P859, DOI 10.1126/science.2772637; MEMO M, 1981, NEUROPHARMACOLOGY, V20, P1145, DOI 10.1016/0028-3908(81)90055-1; MENDELSON J, 1988, AM J PSYCHIAT, V145, P553; MODELL JG, 1989, J CLIN PSYCHOPHARM, V9, P347; NUNES N, 1989, ARCH GEN PSYCHIAT, V46, P117; O'Brien C P, 1989, NIDA Res Monogr, V95, P78; OBRIEN CP, 1988, J CLIN PSYCHIAT, V49, P17; PILOTTE NS, 1990, BRAIN RES, V512, P107, DOI 10.1016/0006-8993(90)91177-I; REITH MEA, 1987, J PHARMACOL EXP THER, V243, P281; REITH MEA, 1983, MOL PHARMACOL, V23, P600; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROUNSAVILLE BJ, 1986, AM J PSYCHIAT, V143, P463; SATEL SA, IN PRESS AM J PSYCHI; SCHERER M, 1988, ARCH GEN PSYCHIAT, V45, P673; SCHWARTZ CM, 1990, AM J PSYCHIAT, V147, P777; SHERER MA, 1989, PSYCHIAT RES, V27, P117, DOI 10.1016/0165-1781(89)90127-3; Siegel R. K, 1982, J PSYCHOACTIVE DRUGS, V14, P321; SPYRAKI C, 1982, BRAIN RES, V253, P195, DOI 10.1016/0006-8993(82)90686-2; TRULSON ME, 1986, EXP NEUROL, V94, P744, DOI 10.1016/0014-4886(86)90252-9; UTENA H, 1962, PROG BRAIN RES, V21, P1902; VANDYKE C, 1982, INT J PSYCHIAT MED, V12, P1; VOLKOW ND, 1988, BRIT J PSYCHIAT, V152, P641, DOI 10.1192/bjp.152.5.641; VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719; WATSON R, 1972, AM J PSYCHIAT, V129, P263, DOI 10.1176/ajp.129.3.263; WEDDINGTON WW, 1990, ARCH GEN PSYCHIAT, V47, P861; WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118; WOLVERTON W, 1988, PSYCHOPHARMACOLOGY, V94, P288; WOOD DM, 1987, LIFE SCI, V41, P1431, DOI 10.1016/0024-3205(87)90619-9; WYATT RJ, 1987, 26TH ANN M AM COLL N; 1981, B WORLD HEALTH ORGAN, V39, P225	75	636	649	0	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1580	1586		10.1126/science.2011738	http://dx.doi.org/10.1126/science.2011738			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD890	2011738				2022-12-28	WOS:A1991FD89000028
J	HILL, CP; YEE, J; SELSTED, ME; EISENBERG, D				HILL, CP; YEE, J; SELSTED, ME; EISENBERG, D			CRYSTAL-STRUCTURE OF DEFENSIN HNP-3, AN AMPHIPHILIC DIMER - MECHANISMS OF MEMBRANE PERMEABILIZATION	SCIENCE			English	Article							NATURAL PEPTIDE ANTIBIOTICS; NUCLEAR MAGNETIC-RESONANCE; 3-DIMENSIONAL STRUCTURE; ANTIMICROBIAL PEPTIDES; RABBIT GRANULOCYTES; NEUTROPHIL DEFENSIN; DIRECT INACTIVATION; ESCHERICHIA-COLI; PURIFICATION; CONFORMATION	Defensins (molecular weight 3500 to 4000) act in the mammalian immune response by permeabilizing the plasma membranes of a broad spectrum of target organisms, including bacteria, fungi, and enveloped viruses. The high-resolution crystal structure of defensin HNP-3 (1.9 angstrom resolution, R factor 0.19) reveals a dimeric beta-sheet that has an architecture very different from other lytic peptides. The dimeric assembly suggests mechanisms by which defensins might bind to and permeabilize the lipid bilayer.	UNIV CALIF LOS ANGELES,DEPT BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	HILL, CP (corresponding author), UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.							BACH AC, 1987, BIOCHEMISTRY-US, V26, P4389, DOI 10.1021/bi00388a030; CHOTHIA C, 1973, J MOL BIOL, V75, P295, DOI 10.1016/0022-2836(73)90022-3; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; DAWSON CR, 1978, BIOCHIM BIOPHYS ACTA, V510, P75, DOI 10.1016/0005-2736(78)90131-1; EISENHAUER PB, 1989, INFECT IMMUN, V57, P2021, DOI 10.1128/IAI.57.7.2021-2027.1989; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1981, TRENDS BIOCHEM SCI, V6, P291, DOI 10.1016/0968-0004(81)90105-5; FOX RO, 1982, NATURE, V300, P325, DOI 10.1038/300325a0; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GREENWALD GI, 1987, INFECT IMMUN, V55, P1365, DOI 10.1128/IAI.55.6.1365-1368.1987; HAYDON DA, 1963, J THEOR BIOL, V4, P281, DOI 10.1016/0022-5193(63)90007-9; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; HULL SE, 1978, NATURE, V275, P206, DOI 10.1038/275206a0; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LEE KH, 1987, BIOCHIM BIOPHYS ACTA, V911, P144, DOI 10.1016/0167-4838(87)90003-3; LEHRER RI, 1988, HEMATOL ONCOL CLIN N, V2, P159; LEHRER RI, 1985, J VIROL, V54, P467, DOI 10.1128/JVI.54.2.467-472.1985; LEHRER RI, 1985, INFECT IMMUN, V49, P207, DOI 10.1128/IAI.49.1.207-211.1985; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEHRER RI, 1988, BLOOD, V72, pA149; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; MANDERSLOOT JG, 1975, BIOCHIM BIOPHYS ACTA, V382, P22, DOI 10.1016/0005-2736(75)90368-5; MASSEFSKI W, 1990, SCIENCE, V249, P521, DOI 10.1126/science.1696395; OOSAWA K, 1986, P NATL ACAD SCI USA, V83, P6930, DOI 10.1073/pnas.83.18.6930; PARDI A, 1988, J MOL BIOL, V201, P625, DOI 10.1016/0022-2836(88)90643-2; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; Poon A., COMMUNICATION; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1987, INFECT IMMUN, V55, P2281, DOI 10.1128/IAI.55.9.2281-2286.1987; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; STANFIELD RL, 1988, J BIOL CHEM, V263, P5933; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6010; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS MS, 1989, FEBS LETT, V256, P143, DOI 10.1016/0014-5793(89)81735-1; WHITE CJ, 1986, CLIN IMMUNOL IMMUNOP, V40, P50, DOI 10.1016/0090-1229(86)90068-1; WILDE CG, 1989, J BIOL CHEM, V264, P11200; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	50	441	462	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1481	1485		10.1126/science.2006422	http://dx.doi.org/10.1126/science.2006422			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006422				2022-12-28	WOS:A1991FC85300047
J	PETITTO, LA; MARENTETTE, PF				PETITTO, LA; MARENTETTE, PF			BABBLING IN THE MANUAL MODE - EVIDENCE FOR THE ONTOGENY OF LANGUAGE	SCIENCE			English	Article							AMERICAN SIGN LANGUAGE; SPEECH-PERCEPTION; CONTINUITY	Infant vocal babbling has been assumed to be a speech-based phenomenon that reflects the maturation of the articulatory apparatus responsible for spoken language production. Manual babbling has now been reported to occur in deaf children exposed to signed languages from birth. The similarities between manual and vocal babbling suggest that babbling is a product of an amodal, brain-based language capacity under maturational control, in which phonetic and syllabic units are produced by the infant as a first step toward building a mature linguistic system. Contrary to prevailing accounts of the neurological basis of babbling in language ontogeny, the speech modality is not critical in babbling. Rather, babbling is tied to the abstract linguistic structure of language and to an expressive capacity capable of processing different types of signals (signed or spoken).			PETITTO, LA (corresponding author), MCGILL UNIV,DEPT PSYCHOL,MONTREAL H3A 1B1,QUEBEC,CANADA.		Marentette, Paula/D-2888-2011	Marentette, Paula/0000-0002-4098-0571				CHOMSKY N, 1980, BEHAV BRAIN SCI, V3, P1, DOI 10.1017/S0140525X00001515; ELBERS L, 1982, COGNITION, V12, P45, DOI 10.1016/0010-0277(82)90029-4; GLEITMAN LR, 1981, COGNITION, V10, P103; HUTTENLOCHER J, 1987, COGNITIVE PSYCHOL, V19, P63, DOI 10.1016/0010-0285(87)90004-1; JUSCZYK PW, 1986, INVARIANCE VARIABILI, P1; Klima E., 1979, SIGNS LANGUAGE; LENNEBERG EH, 1967, BIOL F LANGUAGE; LIBERMAN AM, 1989, SCIENCE, V243, P489, DOI 10.1126/science.2643163; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; LIDDELL SK, 1984, LANGUAGE, V60, P372, DOI 10.2307/413645; Lieberman P., 1984, BIOL EVOLUTION LANGU; Locke J., 1983, PHONOLOGICAL ACQUISI, DOI DOI 10.2307/414500; MARENTETTE PF, UNPUB; MEHLER J, 1986, CR ACAD SCI III-VIE, V303, P637; Oller D. K., 1980, CHILD PHONOLOGY, V1, P93, DOI [10.1016/B978-0-12-770601-6.50011-5, DOI 10.1016/B978-0-12-770601-6.50011-5]; OLLER DK, 1988, CHILD DEV, V59, P441, DOI 10.1111/j.1467-8624.1988.tb01479.x; PETITTO LA, 1987, COGNITION, V27, P1, DOI 10.1016/0010-0277(87)90034-5; PETITTO LA, 1988, DEV LANGUAGE LANGUAG, P187; SHATZ M, 1985, MERRILL PALMER QUART, V31, P211; Stokoe W. C., 1976, DICT AM SIGN LANGUAG; van der Stelt J. M., 1986, WENNER GREN CTR IN B, P163; VIHMAN MM, 1985, LANGUAGE, V61, P397, DOI 10.2307/414151; VIHMAN MM, 1986, APPL PSYCHOLINGUIST, V7, P3, DOI 10.1017/S0142716400007165	23	242	248	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1493	1496		10.1126/science.2006424	http://dx.doi.org/10.1126/science.2006424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC853	2006424				2022-12-28	WOS:A1991FC85300051
J	JUNG, LJ; SCHELLER, RH				JUNG, LJ; SCHELLER, RH			PEPTIDE PROCESSING AND TARGETING IN THE NEURONAL SECRETORY PATHWAY	SCIENCE			English	Article							EGG-LAYING HORMONE; BAG CELL NEURONS; LARGE HERMAPHRODITIC DUCT; ATRIAL GLAND PEPTIDES; SEMLIKI FOREST VIRUS; APLYSIA-CALIFORNICA; BEHAVIORAL-PATTERNS; ELICITED BEHAVIORS; PROLONGED ACTIONS; ENDOCRINE CELLS	The abdominal ganglion of the marine mollusk Aplysia contains a pair of identified neuronal clusters, the bag cells, which control egg laying by means of a number of unique regulatory mechanisms. Each neuron in the bag cell clusters synthesizes several peptides derived from a single prohormone and packages them into separate vesicles. These vesicles are then differentially localized in specific neuronal processes, thus segregating peptides destined for autocrine and hormonal release sites. Therefore in this system, protein trafficking through the secretory pathway organizes multiple peptide neurochemical messengers to efficiently regulate simple behaviors.			JUNG, LJ (corresponding author), STANFORD UNIV, BECKMAN CTR, DEPT MOLEC & CELLULAR PHYSIOL, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.							ARCH S, 1977, BEHAV BIOL, V19, P45, DOI 10.1016/S0091-6773(77)91331-1; ARCH S, 1980, J COMP PHYSIOL, V141, P131, DOI 10.1007/BF00611886; ARCH S, 1978, J COMP PHYSIOL, V128, P67, DOI 10.1007/BF00668374; ARCH S, 1976, AM ZOOL, V16, P167; AUDESIRK TE, 1977, BEHAV BIOL, V20, P235, DOI 10.1016/S0091-6773(77)90799-4; BEARD M, 1982, TISSUE CELL, V14, P297, DOI 10.1016/0040-8166(82)90028-3; BERRY RW, 1986, PEPTIDES, V7, P637, DOI 10.1016/0196-9781(86)90039-2; BLANKENSHIP JE, 1979, J NEUROPHYSIOL, V42, P347, DOI 10.1152/jn.1979.42.2.347; BRANTON WD, 1978, P NATL ACAD SCI USA, V75, P5732, DOI 10.1073/pnas.75.11.5732; BRANTON WD, 1978, NATURE, V274, P70, DOI 10.1038/274070a0; CAREFOOT TH, 1967, J MAR BIOL ASSOC UK, V47, P565, DOI 10.1017/S0025315400035190; CHIU AY, 1979, P NATL ACAD SCI USA, V76, P6656, DOI 10.1073/pnas.76.12.6656; COBBS JS, 1982, J COMP PHYSIOL, V147, P523, DOI 10.1007/BF00612018; COBBS JS, 1982, J COMP PHYSIOL, V147, P537, DOI 10.1007/BF00612019; COGGESHALL RE, 1967, J NEUROPHYSIOL, V30, P1263, DOI 10.1152/jn.1967.30.6.1263; COGGESHALL RE, 1972, AM ZOOL, V12, P521; DALE HENRY, 1935, PROC ROY SOC MED, V28, P319; DUDEK FE, 1977, J NEUROPHYSIOL, V40, P1301, DOI 10.1152/jn.1977.40.6.1301; EALES NB, 1921, LIVERPOOL MARINE BIO, V24, P183; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; FINK LA, 1988, J NEUROSCI, V8, P2544; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FRAZIER WT, 1967, J NEUROPHYSIOL, V30, P1288, DOI 10.1152/jn.1967.30.6.1288; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HAND AR, 1977, J CELL BIOL, V74, P399, DOI 10.1083/jcb.74.2.399; HASKINS JT, 1981, J NEUROCYTOL, V10, P729, DOI 10.1007/BF01262650; HELLER E, 1980, P NATL ACAD SCI-BIOL, V77, P2328, DOI 10.1073/pnas.77.4.2328; JOHNSON DC, 1980, VIROLOGY, V103, P407, DOI 10.1016/0042-6822(80)90200-7; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KACZMAREK LK, 1978, P NATL ACAD SCI USA, V75, P5200, DOI 10.1073/pnas.75.10.5200; KACZMAREK LK, 1979, J NEUROBIOL, V10, P535, DOI 10.1002/neu.480100604; KACZMAREK LK, 1982, BRAIN RES, V238, P105, DOI 10.1016/0006-8993(82)90774-0; Kandel ER., 1976, CELLULAR BASIS BEHAV; KANDEL ER, 1979, BEHAVIORAL BIOL APLY; KAUER JA, 1987, J NEUROSCI, V7, P3623; KUPFERMA.I, 1974, BEHAV BIOL, V12, P317, DOI 10.1016/S0091-6773(74)91503-X; KUPFERMANN I, 1976, J GEN PHYSIOL, V67, P113, DOI 10.1085/jgp.67.1.113; KUPFERMANN I, 1967, NATURE, V216, P814, DOI 10.1038/216814a0; LEVITAN ES, 1987, P NATL ACAD SCI USA, V84, P6307, DOI 10.1073/pnas.84.17.6307; LOECHNER KJ, 1990, J NEUROPHYSIOL, V63, P738, DOI 10.1152/jn.1990.63.4.738; Macginitie GE, 1934, BIOL BULL-US, V67, P300, DOI 10.2307/1537166; MAHON AC, 1985, J NEUROSCI, V5, P1872; Mayeri E., 1985, P285; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1165, DOI 10.1152/jn.1979.42.4.1165; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1185, DOI 10.1152/jn.1979.42.4.1185; MAYERI E, 1981, NEUROSECRETION MOL C, P305; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NAGLE GT, 1986, J BIOL CHEM, V261, P7853; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; NAMBU JR, 1986, J NEUROSCI, V6, P2026; NEWCOMB R, 1988, J BIOL CHEM, V263, P12514; NEWCOMB R, 1987, J NEUROSCI, V7, P854; NEWCOMB RW, 1990, BRAIN RES, V521, P229, DOI 10.1016/0006-8993(90)91547-T; NOVIKOFF PM, 1971, J CELL BIOL, V50, P859, DOI 10.1083/jcb.50.3.859; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PAINTER SD, 1985, J MORPHOL, V186, P167, DOI 10.1002/jmor.1051860204; PAINTER SD, 1989, BEHAV NEURAL BIOL, V51, P222, DOI 10.1016/S0163-1047(89)90857-1; PINSKER HM, 1977, SCIENCE, V197, P490, DOI 10.1126/science.197.4302.490; ROCK MK, 1986, J NEUROBIOL, V17, P273, DOI 10.1002/neu.480170403; ROSEN SC, 1979, J NEUROPHYSIOL, V42, P954, DOI 10.1152/jn.1979.42.4.954; ROTHMAN BS, 1986, J BIOL CHEM, V261, P1616; ROTHMAN BS, 1983, P NATL ACAD SCI-BIOL, V80, P5753, DOI 10.1073/pnas.80.18.5753; ROTHMAN BS, 1983, GEN COMP ENDOCR, V52, P134, DOI 10.1016/0016-6480(83)90166-1; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SMITH RE, 1966, J CELL BIOL, V31, P319, DOI 10.1083/jcb.31.2.319; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; SOSSIN WS, 1990, P NATL ACAD SCI USA, V87, P4845, DOI 10.1073/pnas.87.12.4845; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; SUSSWEIN AJ, 1984, BEHAV NEURAL BIOL, V41, P7, DOI 10.1016/S0163-1047(84)90667-8; SUSSWEIN AJ, 1984, BEHAV NEURAL BIOL, V42, P127, DOI 10.1016/S0163-1047(84)90968-3; SUSSWEIN AJ, 1985, NEUROSCI LETT, V59, P325, DOI 10.1016/0304-3940(85)90153-3; SWEETCORDERO A, 1990, J NEUROCHEM, V55, P1933, DOI 10.1111/j.1471-4159.1990.tb05779.x; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS G, 1986, SCIENCE, V232, P1641, DOI 10.1126/science.3754979; THOMPSON T E, 1969, Malacologia, V7, P347; TOOZE J, 1987, J CELL BIOL, V105, P155, DOI 10.1083/jcb.105.1.155; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551	90	101	105	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1991	251	4999					1330	1335		10.1126/science.2003219	http://dx.doi.org/10.1126/science.2003219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003219				2022-12-28	WOS:A1991FB73300037
J	WICKNER, S; HOSKINS, J; MCKENNEY, K				WICKNER, S; HOSKINS, J; MCKENNEY, K			FUNCTION OF DNAJ AND DNAK AS CHAPERONES IN ORIGIN-SPECIFIC DNA-BINDING BY REPA	NATURE			English	Article							P1 PLASMID REPLICATION; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; GENE	HEAT-shock proteins are normal constituents of cells whose synthesis is increased on exposure to various forms of stress. They are interesting because of their ubiquity and high conservation during evolution. Two families of heat-shock proteins, hsp60s and hsp70s, have been implicated in accelerating protein folding and oligomerization and also in maintaining proteins in an unfolded state, thus facilitating membrane transport 1-5. The Escherichia coli hsp70 analogue, DnaK, and two other heat-shock proteins, DnaJ and GrpE, are required for cell viability at high temperatures and are involved in DNA replication of phage-lambda and plasmids P1 and F 6-10. These three proteins are involved in replication in vitro of P1 DNA along with many host replication proteins and the P1 RepA initiator protein 11,12. RepA exists in a stable protein complex with DnaJ containing a dimer each of RepA and DnaJ 11. We report here that DnaK and DnaJ mediate an alteration in the P1 initiator protein, rendering it much more active for oriP1 DNA binding.	NATL INST STAND & TECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850	National Institute of Standards & Technology (NIST) - USA	WICKNER, S (corresponding author), NCI,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; ABELES AL, 1986, J BIOL CHEM, V261, P3548; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MORIMOTO R I, 1990, P1; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; TILLY K, 1990, NEW BIOL, V2, P1; WICKNER SH, 1987, P NATL ACAD SCI USA, V84, P3668, DOI 10.1073/pnas.84.11.3668; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	16	199	201	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					165	167		10.1038/350165a0	http://dx.doi.org/10.1038/350165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005967				2022-12-28	WOS:A1991FB64500063
J	CARPENTER, ATC				CARPENTER, ATC			DISTRIBUTIVE SEGREGATION - MOTORS IN THE POLAR WIND	CELL			English	Review							DROSOPHILA-MELANOGASTER; CHROMOSOME SEGREGATION; CLARET LOCUS; KINETOCHORE; MOVEMENT; MEIOSIS; KINESIN; SPINDLE		UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								Baker BS, 1976, GENETICS BIOL DROS B, P351; CARPENTER AT, 1973, GENETICS, V73, P393; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; Grell R. F., 1976, GENET BIOL DROSOPHIL, VIa, P435; GRELL RF, 1962, P NATL ACAD SCI USA, V48, P165, DOI 10.1073/pnas.48.2.165; KIMBLE M, 1983, J CELL SCI, V62, P301; KUBAI DF, 1981, J CELL BIOL, V88, P281, DOI 10.1083/jcb.88.2.281; LESLIE RJ, 1987, P NATL ACAD SCI USA, V84, P2771, DOI 10.1073/pnas.84.9.2771; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; MITCHISON TJ, 1986, J CELL SCI, P121; NEIGHBORS BW, 1988, J CELL BIOL, V106, P1193, DOI 10.1083/jcb.106.4.1193; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NICKLAS RB, 1985, CHROMOSOMA, V92, P313, DOI 10.1007/BF00329815; NOVITSKI E, 1975, GENETICS, V79, P63; OTOUSA J, 1980, DROS INF SERV, V55, P119; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PURO J, 1977, CHROMOSOMA, V63, P273, DOI 10.1007/BF00327454; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; SEQUEIRA W, 1989, GENETICS, V123, P511; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; van Beneden E., 1883, ARCH BIOL, V4, P265; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; YAMAMOTO AH, 1989, EMBO J, V8, P3543, DOI 10.1002/j.1460-2075.1989.tb08526.x; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115	28	54	55	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1991	64	5					885	890		10.1016/0092-8674(91)90313-N	http://dx.doi.org/10.1016/0092-8674(91)90313-N			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001589				2022-12-28	WOS:A1991FA94000006
J	DSOUZA, SE; GINSBERG, MH; MATSUEDA, GR; PLOW, EF				DSOUZA, SE; GINSBERG, MH; MATSUEDA, GR; PLOW, EF			A DISCRETE SEQUENCE IN A PLATELET INTEGRIN IS INVOLVED IN LIGAND RECOGNITION	NATURE			English	Article							IIB-IIIA COMPLEX; MEMBRANE GLYCOPROTEIN-IIB; CELL-BINDING DOMAIN; FIBRINOGEN BINDING; GAMMA-CHAIN; SYNTHETIC PEPTIDES; ALPHA-SUBUNITS; ACID SEQUENCES; FIBRONECTIN; RECEPTOR	PLATELET membrane glycoprotein IIb-IIIa (gpIIb-IIIa; alpha-IIb-beta-3), the most prominent member of the integrin family of adhesion receptors on these cells, mediates platelet aggregation by binding fibrinogen and is critical in thrombosis and haemostasis 1-5. A short amino-acid sequence at the carboxy terminus of the gamma-chain of fibrinogen is recognized by gpIIb-IIIa (ref. 6) and peptides containing this sequence are selectively crosslinked to residues 294-314 of gpIIb (ref. 7). Here we show that an 11-residue peptide from this region of gpIIb inhibits platelet aggregation and binding of fibrinogen to platelets and to purified gpIIb-IIIa, and that it interacts directly with fibrinogen. These results implicate this segment of gpIIb-IIIa in the ligand-binding function of the receptor. Moreover, as this region is highly conserved among integrins, it may have a general function in ligand recognition by this broadly distributed family of adhesion receptors.	PRINCETON UNIV, SQUIBB LABS BIOL, PRINCETON, NJ 08544 USA	Princeton University	DSOUZA, SE (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; CHARO IF, 1989, BLOOD, V74, pA497; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; HAVERSTICK DM, 1985, BLOOD, V66, P946; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KOBAYASHI T, 1989, J BIOL CHEM, V264, P18247; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MATSUEDA GR, 1988, FASEB J, V2, P6480; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1987, BLOOD, V70, P110; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446	29	197	202	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					66	68		10.1038/350066a0	http://dx.doi.org/10.1038/350066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002847				2022-12-28	WOS:A1991FA69300066
J	HELLMAN, S				HELLMAN, S			HODGKIN,THOMAS AND HODGKINS-DISEASE - 2 PARADIGMS APPROPRIATE TO MEDICINE TODAY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Thomas Hodgkin was an investigator whose contributions extended over a wide range of medicine. While he is known for Hodgkin's disease, this was not his major interest. That this is so has more to do with his successors than him. He had a highly committed social conscience and was outspoken in advocacy of his positions. This greatly limited his professional career. The history of Hodgkin's disease is one of hypothesis generation, which allowed for its effective treatment even without an understanding of its etiology, illustrating the approximate nature of scientific discovery and the importance of chance in historical attribution. Hodgkin, as a scientist, healer, and socially committed individual, embodied the many characteristics that are desirable for today's physician, while the evolution of knowledge about Hodgkin's disease and its treatment is an instructive model for future medical advances.			HELLMAN, S (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DIV BIOL SCI,CHICAGO,IL 60637, USA.							BRIGHT R, 1838, GUYS HOSP REP, V3, P401; DEVITA VT, 1973, NEW ENGL J MED, V289, P801, DOI 10.1056/NEJM197310112891510; DEVITA VT, 1970, ANN INTERN MED, V73, P891; Easson EC, 1963, BRIT MED J, V1, P1704; Gilbert R, 1939, AM J ROENTGENOL RADI, V41, P198; Greenfield WS, 1878, T PATHOL SOC LOND, V29, P272; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; Hodgkin, 1832, Med Chir Trans, V17, P68; HODGKIN T, 1835, PROMOTING PRESERVING; Hodgkin Thomas, 1829, CATALOGUE PREPARATIO; Kaplan H.S., 1980, HODGKINS DISEASE; KAPLAN HS, 1975, CANCER, V36, P796, DOI 10.1002/1097-0142(197508)36:2+<796::AID-CNCR2820360825>3.0.CO;2-N; KAPLAN HS, 1959, LANCET, V2, P1; Kass Amalie M., 1988, PERFECTING WORLD LIF; KASS EH, 1980, MED HIST, V24, P197, DOI 10.1017/S0025727300040163; MALPIGHI M, 1925, ANN MED HIST, V7, P245; NULAND SB, 1981, B NEW YORK ACAD MED, V57, P776; ORDER SE, 1972, LANCET, V1, P571; PETERS MV, 1950, AM J ROENTGENOL, V63, P299; PETERS MV, 1960, 4 P NAT CANC C, P571; PUSEY WA, 1902, JAMA-J AM MED ASSOC, V28, P166; Reed D., 1902, JOHNS HOPKINS HOS RE, V10, P133; Rosenbloom Jacob, 1921, Ann Med Hist, V3, P381; SAKULA S, 1979, J R SOC MED, V72, P382; Sternberg C. U., 1898, Z HEILK, V19, P21; Wilks S, 1865, GUYS HOSP REP, V11, P56	26	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					1007	1010		10.1001/jama.265.8.1007	http://dx.doi.org/10.1001/jama.265.8.1007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992194				2022-12-28	WOS:A1991EY43200030
J	HARTMANN, HA; KIRSCH, GE; DREWE, JA; TAGLIALATELA, M; JOHO, RH; BROWN, AM				HARTMANN, HA; KIRSCH, GE; DREWE, JA; TAGLIALATELA, M; JOHO, RH; BROWN, AM			EXCHANGE OF CONDUCTION PATHWAYS BETWEEN 2 RELATED K+ CHANNELS	SCIENCE			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNEL; RAT-BRAIN; TETRAETHYLAMMONIUM; MEMBRANE; NEURONS	The structure of the ion conduction pathway or pore of voltage-gated ion channels is unknown, although the linker between the membrane spanning segments S5 and S6 has been suggested to form part of the pore in potassium channels. To test whether this region controls potassium channel conduction, a 21-amino acid segment of the S5-S6 linker was transplanted from the voltage-activated potassium channel NGK2 to another potassium channel DRK1, which has very different pore properties. In the resulting chimeric channel, the single channel conductance and blockade by external and internal tetraethylammonium (TEA) ion were characteristic of the donor NGK2 channel. Thus, this 21-amino acid segment controls the essential biophysical properties of the pore and may form the conduction pathway of these potassium channels.	BAYLOR UNIV,DEPT ANESTHESIOL,HOUSTON,TX 77030	Baylor University	HARTMANN, HA (corresponding author), BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/A-2062-2019; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/ABH-4262-2020	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; 	NINDS NIH HHS [NS08805, NS23877, NS28407] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028407, F32NS008805, R01NS023877] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Erlich H.A., 1989, PCR TECHNOLOGY; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HERMANN A, 1979, NEUROSCI LETT, V12, P87, DOI 10.1016/0304-3940(79)91485-X; Hille B, 1984, IONIC CHANNELS EXCIT; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KOPPENHOFER E, 1969, PFLUG ARCH EUR J PHY, V313, P361, DOI 10.1007/BF00593959; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; TAGLIALATELA M, UNPUB; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THOMPSON SH, 1977, J PHYSIOL-LONDON, V265, P465, DOI 10.1113/jphysiol.1977.sp011725; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	25	373	377	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					942	944		10.1126/science.2000495	http://dx.doi.org/10.1126/science.2000495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000495				2022-12-28	WOS:A1991EY62900046
J	PARKS, GD; LAMB, RA				PARKS, GD; LAMB, RA			TOPOLOGY OF EUKARYOTIC TYPE-II MEMBRANE-PROTEINS - IMPORTANCE OF N-TERMINAL POSITIVELY CHARGED RESIDUES FLANKING THE HYDROPHOBIC DOMAIN	CELL			English	Article							PARAMYXOVIRUS SIMIAN VIRUS-5; ENDOPLASMIC-RETICULUM MEMBRANE; CLEAVABLE SIGNAL SEQUENCE; INFLUENZA-VIRUS; INVARIANT CHAIN; MESSENGER-RNA; CELL-SURFACE; NH2 TERMINUS; AMINO-ACID; TRANSLOCATION	We have tested the role of different charged residues flanking the sides of the signal/anchor (S/A) domain of a eukaryotic type II (N(cyt)C(exo)) integral membrane protein in determining its topology. The removal of positively charged residues on the N-terminal side of the S/A yields proteins with an inverted topology, while the addition of positively charged residues to only the C-terminal side has very little effect on orientation. Expression of chimeric proteins composed of domains from a type II protein (HN) and the oppositely oriented membrane protein M2 indicates that the HN N-terminal domain is sufficient to confer a type II topology and that the M2 N-terminal ectodomain can direct a type II topology when modified by adding positively charged residues. These data suggest that eukaryotic membrane protein topology is governed by the presence or absence of an N-terminal signal for retention in the cytoplasm that is composed in part of positive charges.	NORTHWESTERN UNIV,HOWARD HUGHES MED INST,EVANSTON,IL 60208	Howard Hughes Medical Institute; Northwestern University	PARKS, GD (corresponding author), NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI023173, R01AI020201] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20201, AI-23173] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; AKITA M, 1990, J BIOL CHEM, V265, P8164; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1985, J VIROL, V55, P744, DOI 10.1128/JVI.55.3.744-751.1985; HIEBERT SW, 1985, J VIROL, V54, P1; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; LAMB RA, 1982, VIROLOGY, V123, P237, DOI 10.1016/0042-6822(82)90258-6; LAMB RA, 1978, VIROLOGY, V91, P60, DOI 10.1016/0042-6822(78)90355-0; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 1981, VIROLOGY, V112, P746, DOI 10.1016/0042-6822(81)90319-6; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NGDTW, 1989, J CELL BIOL, V109, P3273; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PARKS GD, 1989, J CELL BIOL, V109, P2023, DOI 10.1083/jcb.109.5.2023; PATERSON RG, 1985, P NATL ACAD SCI USA, V82, P7520, DOI 10.1073/pnas.82.22.7520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WEINSTEIN JN, 1982, J MEMBRANE BIOL, V66, P203, DOI 10.1007/BF01868495; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	49	149	152	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					777	787		10.1016/0092-8674(91)90507-U	http://dx.doi.org/10.1016/0092-8674(91)90507-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997206				2022-12-28	WOS:A1991EZ47800013
J	GERSHON, D				GERSHON, D			GENE-THERAPY - CANCER TRIAL STARTS	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					445	445		10.1038/349445c0	http://dx.doi.org/10.1038/349445c0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992346	Bronze			2022-12-28	WOS:A1991EW57100008
J	SEATON, D; YOGANATHAN, K; COADY, T; BARKER, R				SEATON, D; YOGANATHAN, K; COADY, T; BARKER, R			SPONTANEOUS PNEUMOTHORAX - MARKER GAS TECHNIQUE FOR PREDICTING OUTCOME OF MANUAL ASPIRATION	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether in a patient with spontaneous pneumothorax the presence or absence of a pleural leak can be shown at the time of manual aspiration by use of a marker gas. Also, to find out if the technique can predict whether manual aspiration will be successful, hence avoiding the need for intercostal tube drainage. Design-Prospective study of 25 episodes of pneumothorax during which patients breathed air from a Douglas bag that contained chlorofluorocarbon gases from a metered dose inhaler while the pneumothorax was aspirated. Setting-Medical unit of a district general hospital. Patients-22 patients who presented over nine months with acute pneumothorax. Main outcome measures-Presence or absence of chlorofluorocarbon marker gases in the aspirate. Presence or absence of sustained re-expansion of the affected lung in the chest radiograph. Results-Marker gas was detected in the aspirate from 16 out of 25 pneumothoraces. Of these, 13 required intercostal tube drainage because of failure of the lung to re-expand. Marker gas was not detected in nine cases, and in all of these cases manual aspiration resulted in sustained re-expansion of the lung. Conclusions-The presence or absence of a pleural leak during manual aspiration of spontaneous pneumothorax can be shown by using this technique. The absence of marker gas in the aspirate implies that manual aspiration will be successful, whereas its presence predicts, in most cases, either failure of manual aspiration to expand the lung or early recollapse of the lung.			SEATON, D (corresponding author), IPSWICH HOSP,DEPT THORAC MED,IPSWICH IP4 5PD,SUFFOLK,ENGLAND.							BEVELAQUA FA, 1982, CHEST, V81, P693, DOI 10.1378/chest.81.6.693; COADY TJ, 1988, LANCET, V2, P1286; CUMMINGS JH, 1988, RECENT ADV GASTROENT, V7, P328; HAMILTON AAD, 1983, THORAX, V38, P934, DOI 10.1136/thx.38.12.934; JONES JS, 1985, THORAX, V40, P66, DOI 10.1136/thx.40.1.66; RAJA OG, 1981, BR J DIS CHEST, V75, P27; Seaton A, 1989, CROFTON DOUGLASS RES, P761	7	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					262	265		10.1136/bmj.302.6771.262	http://dx.doi.org/10.1136/bmj.302.6771.262			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998790	Green Published, Bronze			2022-12-28	WOS:A1991EX91900018
J	TIERNEY, AJ; LEONARD, RCF; TAYLOR, J; CLOSS, SJ; CHETTY, U; RODGER, A				TIERNEY, AJ; LEONARD, RCF; TAYLOR, J; CLOSS, SJ; CHETTY, U; RODGER, A			SIDE-EFFECTS EXPECTED AND EXPERIENCED BY WOMEN RECEIVING CHEMOTHERAPY FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									LONGMORE HOSP,BREAST UNIT,EDINBURGH,SCOTLAND; WESTERN GEN HOSP,CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	TIERNEY, AJ (corresponding author), UNIV EDINBURGH,DEPT NURSING STUDIES,NURSING RES UNIT,EDINBURGH EH8 9JT,SCOTLAND.			Closs, Susan Jose/0000-0002-3257-5277				TIERNEY AJ, 1989, STUDY INFORM NURSING	1	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					272	272		10.1136/bmj.302.6771.272	http://dx.doi.org/10.1136/bmj.302.6771.272			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998793	Bronze, Green Published			2022-12-28	WOS:A1991EX91900021
J	KOLCH, W; HEIDECKER, G; LLOYD, P; RAPP, UR				KOLCH, W; HEIDECKER, G; LLOYD, P; RAPP, UR			RAF-1 PROTEIN-KINASE IS REQUIRED FOR GROWTH OF INDUCED NIH/3T3 CELLS	NATURE			English	Article							SIGNAL TRANSDUCTION; V-RAF; ONCOGENE; PHOSPHORYLATION	MANY growth factors regulate the cytoplasmic RAF-1 protein kinase 1-10, consistent with its having a central role in transduction of growth signals. The kinase is ubiquitously expressed 11 and can promote proliferation 12, presumably in a manner dependent on growth-factor receptors and membrane-associated oncogenes 13-15. We have now examined the dependence of serum- and TPa (12-O-tetradecanoylphorbol-13-acetate)-regulated NIH/3T3 cell growth on RAF-1 kinase to determine whether Raf-1 is essential for receptor signalling. We inhibited Raf-1 function by expressing c-raf-1 antisense RNA or kinase-defective c-raf-1 mutants. Antisense RNA for c-raf-1 interferes with proliferation of normal NIH/3T3 cells and reverts raf-transformed cells. In revertant cells, DNA replication induced by serum or TPA was eliminated or reduced proportionately to the reduction in Raf protein levels. Expression of a kinase-defective Raf-1 mutant (craf301) or a regulatory domain fragment (HCR) inhibited serum-induced NIH/3T3-cell proliferation and raf transformation even more efficiently. Inhibition by antisense RNA or craf301 blocked proliferation and transformation by Ki- and Ha-ras oncogenes. We conclude that raf functions as an essential signal transducer downstream of serum growth factor receptors, protein kinase C and ras.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016				APP H, IN PRESS MOLEC CELL; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; KOLCH W, 1990, ONCOGENE, V5, P713; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STORM SM, 1990, ONCOGENE, V5, P345; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TURNER BC, IN PRESS P NATN ACAD; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	26	472	512	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					426	428		10.1038/349426a0	http://dx.doi.org/10.1038/349426a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992343	Green Published			2022-12-28	WOS:A1991EV51400055
J	ROBLES, L; RUGGERO, MA; RICH, NC				ROBLES, L; RUGGERO, MA; RICH, NC			2-TONE DISTORTION IN THE BASILAR-MEMBRANE OF THE COCHLEA	NATURE			English	Article							MECHANICS; NONLINEARITY; RESPONSES; 2F1-F2; MOTION; TONES; NERVE	WHEN humans listen to pairs of thnes they hear additional tones, or distortion products, that are not present in the stimulus 1. Two-tone distortion products are also known as combination tones, because their pitches match combinations of the primary frequencies (f1 and f2,f2 > f1), such as f2 - f1, (n+1)f1 - nf2 and (n + 1)f2 - nf1 (n = 1,2,3...) (refs 2-4). Physiological correlates of the perceived distortion products exist in responses of auditory-nerve fibres 5-8 and inner hair cells 9 and in otoacoustic emissions (sounds generated by the cochlea, recordable at the ear canal) 7, 10-12. Because the middle ear responds linearly to sound 13, 14 and neural responses to distortion products can be abolished by damage to hair cells at cochlear sites preferentially tuned to the frequencies of the primary tones 8, it was hypothesized that distortion products are generated at these sites and propagate mechanically along the basilar membrane to the location tuned to the distortion-product frequency 7,8. But until now, efforts to confirm this hypothesis have failed 15,16. Here we report the use of a new laser-velocimetry technique 17 to demonstrate two-tone distortion in basilar-membrane motion at low and moderate stimulus intensities.	UNIV CHILE,FAC MED,DEPT FISIOL & BIOFIS,SANTIAGO,CHILE	Universidad de Chile	ROBLES, L (corresponding author), UNIV MINNESOTA,DEPT OTOLARYNGOL,2630 UNIV AVE SE,MINNEAPOLIS,MN 55414, USA.		Ruggero, Mario A/A-9860-2009	Ruggero, Mario A/0000-0001-8240-3644	NIDCD NIH HHS [R01 DC000419] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000419] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BUUNEN TJF, 1978, J ACOUST SOC AM, V64, P772, DOI 10.1121/1.382042; BUUNEN TJF, 1981, J ACOUST SOC AM, V69, P744, DOI 10.1121/1.385574; GOLDSTEI.JL, 1968, PR INST ELECTR ELECT, V56, P981, DOI 10.1109/PROC.1968.6449; GOLDSTEIN JL, 1967, J ACOUST SOC AM, V41, P676, DOI 10.1121/1.1910396; GUINAN JJ, 1967, J ACOUST SOC AM, V41, P1237, DOI 10.1121/1.1910465; Jones AT., 1935, AM J PHYS, V3, P49, DOI [10.1119/1.1992920, DOI 10.1119/1.1992920]; KEMP DT, 1979, ARCH OTO-RHINO-LARYN, V224, P37, DOI 10.1007/BF00455222; KIM DO, 1980, J ACOUST SOC AM, V67, P1704, DOI 10.1121/1.384297; MOUNTAIN DC, 1980, SCIENCE, V210, P71, DOI 10.1126/science.7414321; NUTTALL AL, 1990, J ACOUST SOC AM, V87, P782, DOI 10.1121/1.398890; NUTTALL AL, IN PRESS MECHANICS B; PATUZZI R, 1984, HEARING RES, V13, P19, DOI 10.1016/0378-5955(84)90091-1; Rhode WS., 1977, PSYCHOPHYSICS PHYSL, P27; ROBLES L, 1986, J ACOUST SOC AM, V80, P1364, DOI 10.1121/1.394389; ROBLES L, IN PRESS MECHANICS B; Robles L, 1989, COCHLEAR MECHANISMS, P369; RUGGERO MA, IN PRESS HEAR RES; RUGGERO MA, IN PRESS J NEUROSCI; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SIEGEL JH, 1982, J NEUROPHYSIOL, V47, P303, DOI 10.1152/jn.1982.47.2.303; SIEGEL JH, 1982, HEARING RES, V6, P171, DOI 10.1016/0378-5955(82)90052-1; SMOORENBURG GF, 1972, J ACOUST SOC AM, V52, P615, DOI 10.1121/1.1913152; WILSON JP, 1973, NATURE, V241, P206, DOI 10.1038/241206a0; ZUREK PM, 1979, SCIENCE, V205, P600, DOI 10.1126/science.451625	24	136	145	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					413	414		10.1038/349413a0	http://dx.doi.org/10.1038/349413a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992342	Green Accepted			2022-12-28	WOS:A1991EV51400050
J	RAWLINS, MD; JEFFERYS, DB				RAWLINS, MD; JEFFERYS, DB			STUDY OF UNITED-KINGDOM PRODUCT LICENSE APPLICATIONS CONTAINING NEW ACTIVE SUBSTANCES, 1987-9	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate the fate of product licence applications containing new active substances in relation to their degree of innovation and therapeutic category. To assess the numbers of volunteers and patients exposed to a new active substance when marketing authorisation is first sought. Design and setting-Observational study of records for each licence application submitted to the United Kingdom licensing authority for marketing authorisation from 1987 to 1989. Subjects-118 product licence applications containing one or more new active substances. Main outcome measures-Success of application for product licence as assessed by the decision of the Committee on Safety of Medicines to advise the granting of a licence (with or without conditions) or provisionally advise its refusal on the grounds of quality, safety, or efficacy. Assessment of numbers of volunteers and patients exposed to each substance during premarketing studies and clinical trials, and the numbers of treated patients available for an assessment of safety. Results-118 relevant product licence applications were submitted during the review. Although 60% (52/86) of semi-innovative products fell into one of three therapeutic categories (cardiovascular, central nervous system, or anti-infective agents), only 41% (13/32) of fully innovative products fell into these categories. 47 applications were granted (conditionally or unconditionally) but the success rate for fully innovative products (56%, 18/32) was greater than that for semi-innovative products (34%, 29/86). The number of volunteers and patients exposed to a new product at submission varied widely and tended to be greater for successful applications. Conclusion-The results suggest a broadening of the pharmaceutical industry's research and development programmes and that a more liberal licensing policy exists for fully innovative products than for semi-innovative products. The relatively limited exposure of patients to new active substances at licensing underlines the importance of rigorous postmarketing surveillance.	MED CONTROL AGCY,DEPT HLTH,LONDON SW8 5NQ,ENGLAND		RAWLINS, MD (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.							GRIFFIN JP, 1981, BRIT J CLIN PHARMACO, V12, P453, DOI 10.1111/j.1365-2125.1981.tb01251.x; LUNDE I, 1980, IND SANTE, V49, P37; 1989, RULES GOVERNING MED, V33	3	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					223	225		10.1136/bmj.302.6770.223	http://dx.doi.org/10.1136/bmj.302.6770.223			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998766	Green Published, Bronze			2022-12-28	WOS:A1991EV22800031
J	FLEISSIG, A				FLEISSIG, A			UNINTENDED PREGNANCIES AND THE USE OF CONTRACEPTION - CHANGES FROM 1984 TO 1989	BRITISH MEDICAL JOURNAL			English	Article											FLEISSIG, A (corresponding author), INSTITUTE SOCIAL STUDIES MED CARE,14 S HILL PK,LONDON NW3 2SB,ENGLAND.							CARTWRIGHT A, 1988, SOC SCI MED, V27, P249, DOI 10.1016/0277-9536(88)90128-1; Griffiths M, 1990, BRIT J FAM PLANN, V16, P16; Guillebaud J, 2017, CONTRACEPTION YOUR Q; SMITH T, 1990, BRIT MED J, V300, P1154, DOI 10.1136/bmj.300.6733.1154	4	50	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					147	147		10.1136/bmj.302.6769.147	http://dx.doi.org/10.1136/bmj.302.6769.147			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995134	Green Published, Bronze			2022-12-28	WOS:A1991EU02000021
J	WEISS, JN; NADEMANEE, K; STEVENSON, WG; SINGH, B				WEISS, JN; NADEMANEE, K; STEVENSON, WG; SINGH, B			VENTRICULAR ARRHYTHMIAS IN ISCHEMIC-HEART-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Discussion							ACUTE MYOCARDIAL-INFARCTION; SUDDEN CARDIAC DEATH; PROGRAMMED ELECTRICAL-STIMULATION; SIGNAL-AVERAGED ELECTROCARDIOGRAM; REPERFUSION-INDUCED ARRHYTHMIAS; BETA-ADRENERGIC-BLOCKADE; SLOW CONDUCTION; SYMPATHETIC DENERVATION; CORONARY-ARTERY; GUINEA-PIG	Ventricular arrhythmias remain the leading cause of death from coronary artery disease. This review summarizes current thinking in several areas relating to the pathophysiology, prognosis, and therapy of ventricular arrhythmias associated with acute and chronic coronary artery disease syndromes. The experimental basis of arrhythmias in the setting of acute myocardial ischemia and chronic myocardial infarction is described, stressing the important pathophysiologic differences between these two conditions. The effects of the autonomic nervous system as a key modulator of ischemic arrhythmogenesis are discussed. Insights, derived from endocardial mapping studies, into the nature of ventricular tachycardia in humans with chronic myocardial infarction are described, including implications for risk stratification and therapy to prevent arrhythmia recurrence. Current therapeutic principles are discussed in the management of ventricular arrhythmias associated with coronary artery disease, including pharmacologic approaches, surgical and catheter ablation, and automatic implantable cardioverting and defibrillating devices.			WEISS, JN (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV CARDIOL, LOS ANGELES, CA 90024 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL001890] Funding Source: NIH RePORTER; NHLBI NIH HHS [1K04 HLO1890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBER MJ, 1983, CIRCULATION, V67, P787, DOI 10.1161/01.CIR.67.4.787; BARBER MJ, 1985, CIRCULATION, V72, P623, DOI 10.1161/01.CIR.72.3.623; BHANDARI AK, 1985, AM J CARDIOL, V56, P737, DOI 10.1016/0002-9149(85)91125-7; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BIGGER JT, 1989, J AM COLL CARDIOL, V14, P1511, DOI 10.1016/0735-1097(89)90390-2; BOLICK DR, 1986, CIRCULATION, V74, P1266, DOI 10.1161/01.CIR.74.6.1266; BRAAT SH, 1983, AM J CARDIOL, V52, P686, DOI 10.1016/0002-9149(83)90398-3; BRUGADA P, 1986, J AM COLL CARDIOL, V8, P1035, DOI 10.1016/S0735-1097(86)80379-5; BURKART F, 1989, CIRCULATION S2, V80, P119; CORR PB, 1984, CIRC RES, V55, P135, DOI 10.1161/01.RES.55.2.135; CORR PB, 1987, CIRCULATION, V76, P208; CORR PB, 1978, CIRC RES, V43, P1; DEBAKKER JMT, 1988, CIRCULATION, V77, P589, DOI 10.1161/01.CIR.77.3.589; DEMELLO WC, 1982, CIRC RES, V51, P1, DOI 10.1161/01.RES.51.1.1; DENNISS AR, 1986, CIRCULATION, V74, P731, DOI 10.1161/01.CIR.74.4.731; DENNISS AR, 1987, AM J CARDIOL, V60, P580, DOI 10.1016/0002-9149(87)90309-2; DENNISS AR, 1989, CIRC RES, V64, P155, DOI 10.1161/01.RES.64.1.155; DESILVA RA, 1982, ANN NY ACAD SCI, V382, P143, DOI 10.1111/j.1749-6632.1982.tb55213.x; DILLON SM, 1988, CIRC RES, V63, P182, DOI 10.1161/01.RES.63.1.182; DIMSDALE JE, 1987, CIRCULATION, V76, P198; DOWNAR E, 1988, J AM COLL CARDIOL, V11, P783, DOI 10.1016/0735-1097(88)90212-4; ELSHERIF N, 1975, CIRCULATION, V51, P1003, DOI 10.1161/01.CIR.51.6.1003; EVANS GT, 1986, PACE, V9, P1391, DOI 10.1111/j.1540-8159.1986.tb06729.x; FEDIDA D, 1987, J PHYSIOL-LONDON, V392, P523, DOI 10.1113/jphysiol.1987.sp016795; FENOGLIO JJ, 1983, CIRCULATION, V68, P518, DOI 10.1161/01.CIR.68.3.518; FRISHMAN WH, 1984, NEW ENGL J MED, V310, P830; FURBERG CD, 1983, AM J CARDIOL, V52, pC32, DOI 10.1016/0002-9149(83)90629-X; GANG ES, 1989, NEW ENGL J MED, V321, P712, DOI 10.1056/NEJM198909143211104; GARDNER PI, 1985, CIRCULATION, V72, P596, DOI 10.1161/01.CIR.72.3.596; GILMOUR RF, 1983, AM J CARDIOL, V51, P137, DOI 10.1016/S0002-9149(83)80024-1; GOLDMAN L, 1982, CIRCULATION, V65, P936, DOI 10.1161/01.CIR.65.5.936; GOMES JA, 1989, J AM COLL CARDIOL, V13, P377, DOI 10.1016/0735-1097(89)90515-9; Gorgels A, 1987, CARDIAC ARRHYTHMIAS, P147; HALL PAX, 1989, PROG CARDIOVASC DIS, V31, P295, DOI 10.1016/0033-0620(89)90035-2; HARRIS AS, 1943, EXP MED SURG, V1, P105; HARRIS L, 1987, J AM COLL CARDIOL, V10, P1040, DOI 10.1016/S0735-1097(87)80344-3; HAUSWIRTH O, 1978, PHARMACOL REV, V30, P5; HEARSE DJ, 1987, CIRC RES, V60, P375, DOI 10.1161/01.RES.60.3.375; HOROWITZ LN, 1981, ANN INTERN MED, V95, P88, DOI 10.7326/0003-4819-95-1-88; IDEKER RE, 1983, PACE, V6, P908, DOI 10.1111/j.1540-8159.1983.tb04412.x; INOUE H, 1988, AM J PHYSIOL, V255, pH26, DOI 10.1152/ajpheart.1988.255.1.H26; INOUE H, 1988, CIRC RES, V62, P1111, DOI 10.1161/01.RES.62.6.1111; INOUE H, 1987, CIRCULATION, V75, P877, DOI 10.1161/01.CIR.75.4.877; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; JANSE MJ, 1980, CIRC RES, V47, P151, DOI 10.1161/01.RES.47.2.151; JOSEPHSON ME, 1984, CIRCULATION, V70, P529, DOI 10.1161/01.CIR.70.4.529; KAMMERLING JJ, 1987, CIRCULATION, V76, P383, DOI 10.1161/01.CIR.76.2.383; KENNEDY HL, 1985, NEW ENGL J MED, V312, P193, DOI 10.1056/NEJM198501243120401; KENT KM, 1973, CIRCULATION, V47, P291, DOI 10.1161/01.CIR.47.2.291; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; KLEBER AG, 1984, J MOL CELL CARDIOL, V16, P389, DOI 10.1016/S0022-2828(84)80610-0; KLEBER AG, 1983, CIRC RES, V52, P442, DOI 10.1161/01.RES.52.4.442; KLEBER AG, 1987, CIRC RES, V61, P271, DOI 10.1161/01.RES.61.2.271; KLEIN GJ, 1987, PROG CARDIOL, V15, P139; KUCHAR DL, 1987, J AM COLL CARDIOL, V9, P531, DOI 10.1016/S0735-1097(87)80045-1; KULLER LH, 1980, PROG CARDIOVASC DIS, V23, P1, DOI 10.1016/0033-0620(80)90002-X; LEE HC, 1988, CIRCULATION, V78, P1047, DOI 10.1161/01.CIR.78.4.1047; LEVY MN, 1984, FED PROC, V43, P2598; LOMBARDI F, 1983, AM HEART J, V105, P958, DOI 10.1016/0002-8703(83)90397-6; LOWN B, 1976, NEW ENGL J MED, V294, P1165; MALLIANI A, 1980, AM HEART J, V100, P705, DOI 10.1016/0002-8703(80)90238-0; MANNING AS, 1984, J MOL CELL CARDIOL, V16, P497, DOI 10.1016/S0022-2828(84)80638-0; MARBAN E, 1987, P NATL ACAD SCI USA, V84, P6005, DOI 10.1073/pnas.84.16.6005; MARCHLINSKI FE, 1983, AM J CARDIOL, V52, P1190, DOI 10.1016/0002-9149(83)90572-6; MARTINS JB, 1980, CIRC RES, V47, P33, DOI 10.1161/01.RES.47.1.33; MASON JW, 1989, CIRCULATION, V79, P1354; MEINERTZ T, 1984, AM J CARDIOL, V53, P902, DOI 10.1016/0002-9149(84)90522-8; MINARDO JD, 1988, CIRCULATION, V78, P1008, DOI 10.1161/01.CIR.78.4.1008; MITCHELL LB, 1987, NEW ENGL J MED, V317, P1681, DOI 10.1056/NEJM198712313172701; MORAD M, 1986, OPTICAL METHODS CELL, P211; MORADY F, 1988, J AM COLL CARDIOL, V11, P775, DOI 10.1016/0735-1097(88)90211-2; OKUMURA K, 1985, CIRCULATION, V72, P1293, DOI 10.1161/01.CIR.72.6.1293; OKUMURA K, 1987, CIRCULATION, V75, P369, DOI 10.1161/01.CIR.75.2.369; OPIE LH, 1979, AM J CARDIOL, V43, P131, DOI 10.1016/0002-9149(79)90055-9; PANTRIDGE JF, 1981, PROG CARDIOVASC DIS, V23, P265, DOI 10.1016/0033-0620(81)90016-5; POGWIZD SM, 1987, CIRC RES, V61, P352, DOI 10.1161/01.RES.61.3.352; PRATT CM, 1990, AM J CARDIOL, V65, P103, DOI 10.1016/0002-9149(90)90034-X; REA RF, 1988, CIRCULATION, V78, P1072, DOI 10.1161/01.CIR.78.4.1072; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; SAMAN S, 1984, J MOL CELL CARDIOL, V16, P659, DOI 10.1016/S0022-2828(84)80629-X; SATO R, 1985, CIRC RES, V57, P553, DOI 10.1161/01.RES.57.4.553; SCHWARTZ PJ, 1988, CIRCULATION, V78, P969, DOI 10.1161/01.CIR.78.4.969; SCHWARTZ PJ, 1984, CIRCULATION, V69, P790, DOI 10.1161/01.CIR.69.4.790; SCHWARTZ PJ, 1987, CIRCULATION, V76, P215; SHINE KI, 1977, AM J PHYSIOL, V232, pH564, DOI 10.1152/ajpheart.1977.232.6.H564; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; SINGH BN, 1990, AM J CARDIOL, V66, pC9, DOI 10.1016/0002-9149(90)90757-R; SINGH BN, 1989, AM J CARDIOL, V63, P867, DOI 10.1016/0002-9149(89)90059-3; SINGH BN, 1988, CONTROL CARDIAC ARRH, P1; SINGH BN, 1990, CARDIAC ELECTROPHYSI, P882; SINGH BN, 1989, AM J CARDIOL, pA1; SKINNER JE, 1981, AM J PHYSIOL, V240, pH156, DOI 10.1152/ajpheart.1981.240.2.H156; SKINNER JE, 1975, CIRCULATION, V51, P656, DOI 10.1161/01.CIR.51.4.656; SPACH MS, 1981, CIRC RES, V48, P39, DOI 10.1161/01.RES.48.1.39; SPEAR JF, 1979, CIRCULATION, V59, P247, DOI 10.1161/01.CIR.59.2.247; STANTON MS, 1989, J AM COLL CARDIOL, V14, P1519, DOI 10.1016/0735-1097(89)90391-4; STEENBERGEN C, 1987, CIRC RES, V60, P700, DOI 10.1161/01.RES.60.5.700; STEVENSON WG, 1989, CIRCULATION, V80, P793, DOI 10.1161/01.CIR.80.4.793; STEVENSON WG, 1989, J AM COLL CARDIOL, V13, P369, DOI 10.1016/0735-1097(89)90514-7; STEVENSON WG, 1989, AM HEART J, V117, P452, DOI 10.1016/0002-8703(89)90792-8; STEVENSON WG, 1988, J AM COLL CARDIOL, V11, P522, DOI 10.1016/0735-1097(88)91526-4; STEVENSON WG, 1987, CARDIAC ARRHYTHMIAS, P367; TAKAHASHI N, 1985, AM J PHYSIOL, V248, pH89, DOI 10.1152/ajpheart.1985.248.1.H89; WEBB SW, 1972, BMJ-BRIT MED J, V3, P89, DOI 10.1136/bmj.3.5818.89; WEISS J, 1982, AM J PHYSIOL, V242, pH619, DOI 10.1152/ajpheart.1982.242.4.H619; WEISS JN, 1987, CARDIAC ARRHYTHMIAS, P83; WELLENS HJJ, 1989, J AM COLL CARDIOL, V14, P1417, DOI 10.1016/0735-1097(89)90375-6; WELLENS HJJ, 1986, PROG CARDIOVASC DIS, V29, P165, DOI 10.1016/0033-0620(86)90040-X; WIENER I, 1984, AM HEART J, V107, P86, DOI 10.1016/0002-8703(84)90138-8; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; WIT AL, 1986, HEART CARDIOVASCULAR, P1449; YAMADA KA, 1987, HEART BRAIN BRAIN HE, P79; YUSUF S, 1987, Cardiovascular Drugs and Therapy, V1, P343, DOI 10.1007/BF02209073; ZIPES DP, 1987, CIRCULATION, V76, P202; 1989, NEW ENGL J MED, V321, P331; 1986, 1987 HEART FACTS, P2	116	35	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					784	797		10.7326/0003-4819-114-9-784	http://dx.doi.org/10.7326/0003-4819-114-9-784			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012360				2022-12-28	WOS:A1991FJ11700011
J	HIRSCHEL, B; LAZZARIN, A; CHOPARD, P; OPRAVIL, M; FURRER, HJ; RUTTIMANN, S; VERNAZZA, P; CHAVE, JP; ANCARANI, F; GABRIEL, V; HEALD, A; KING, R; MALINVERNI, R; MARTIN, JL; MERMILLOD, B; NICOD, L; SIMONI, L; VIVIRITO, MC; ZERBONI, R				HIRSCHEL, B; LAZZARIN, A; CHOPARD, P; OPRAVIL, M; FURRER, HJ; RUTTIMANN, S; VERNAZZA, P; CHAVE, JP; ANCARANI, F; GABRIEL, V; HEALD, A; KING, R; MALINVERNI, R; MARTIN, JL; MERMILLOD, B; NICOD, L; SIMONI, L; VIVIRITO, MC; ZERBONI, R			A CONTROLLED-STUDY OF INHALED PENTAMIDINE FOR PRIMARY PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; SULFAMETHOXAZOLE; CHEMOPROPHYLAXIS; PROPHYLAXIS; AEROSOL; AIDS	Background. Current recommendations for prophylaxis of Pneumocystis carinii pneumonia (PCP) are based on data from patients who have had at least one episode of PCP (secondary prevention). We designed a study to determine the efficacy and side effects of inhaled pentamidine in the primary prevention of PCP. Methods. Two hundred twenty-three patients sero-positive for human immunodeficiency virus (HIV) who had the acquired immunodeficiency syndrome (AIDS) but not PCP, who had advanced AIDS-related complex, or who had less than 0.2 x 10(9) CD4-positive lymphocytes per liter received either 300 mg of pentamidine isethionate or 300 mg of sodium isethionate every 28 days by inhaler. The proportion of patients surviving without PCP was analyzed with the log-rank test as a function of time spent in the trial, according to the intention to treat with either placebo or pentamidine. Results. The third of five planned interim analyses showed a significant difference in the occurrence of PCP, with 8 cases in the pentamidine group and 23 in the placebo group (nominal P value = 0.0021). There were no deaths within 60 days of the diagnosis of PCP and no significant differences in survival between groups. Approximately 53 inhalations were needed to prevent one episode of pneumonia. Thirty-eight of 114 patients given pentamidine (33 percent) and 7 of 109 given placebo (6 percent) had moderate-to-severe coughing during inhalations (two-tailed P < 0.00001), which caused 4 patients given pentamidine (3.5 percent) to discontinue taking it. Conclusions. A dose of 300 mg of aerosolized pentamidine given every four weeks was well tolerated and 60 to 70 percent effective in preventing a first episode of PCP in patients with HIV infection.	HOP CANTONAL LAUSANNE,POLICLIN MED,CH-1011 LAUSANNE,SWITZERLAND; HOP CANTONAL LAUSANNE,CTR INFORMAT HOSP,CH-1011 LAUSANNE,SWITZERLAND; UNIV HOSP ZURICH,DEPT MED,DIV INFECT DIS,CH-8091 ZURICH,SWITZERLAND; INSELSPITAL BERN,MED OUTPATIENT CLIN,CH-3010 BERN,SWITZERLAND; KANTONSSPITAL,MED OUTPATIENT CLIN,BASEL,SWITZERLAND; KANTONSSPITAL,CH-9006 ST GALLEN,SWITZERLAND; CHU VAUDOIS,CH-1011 LAUSANNE,SWITZERLAND; UNIV ANCONA,INFECT DIS CLIN,I-60100 ANCONA,ITALY; UNIV MILAN,BIANCHI BONOMI HEMOPHILIA & THROMBOSIS CTR,I-20122 MILAN,ITALY; CLIN DERMATOL 1,CTR AIDS,MILAN,ITALY; HOP CANTONAL LAUSANNE,DIV PULM MED,CH-1011 LAUSANNE,SWITZERLAND; OSPED L SACCO,DIV INFECT DIS,MILAN,ITALY; OSPED L SACCO,INFECT DIS CLIN,MILAN,ITALY	University of Zurich; University Zurich Hospital; University of Bern; University Hospital of Bern; Kantonsspital Aarau AG (KSA); University of Basel; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Marche Polytechnic University; University of Milan; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital	HIRSCHEL, B (corresponding author), HOP CANTONAL UNIV,DIV MALAD INFECT,CH-1211 GENEVA 4,SWITZERLAND.		Nicod, Laurent/ABD-3360-2020; chopard, pierre/L-8697-2014; Furrer, Hansjakob/G-6768-2013; LAZZARIN, Adriano/K-3607-2018	Furrer, Hansjakob/0000-0002-1375-3146; LAZZARIN, Adriano/0000-0003-2551-7754				CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; DEVITA VT, 1987, ANN INTERN MED, V106, P568, DOI 10.7326/0003-4819-106-4-568; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1986, ANN INTERN MED, V105, P629, DOI 10.7326/0003-4819-105-4-629_1; Fleiss JL, 1981, STAT METHODS RATES P; GIRARD PM, 1987, ANTIMICROB AGENTS CH, V31, P978, DOI 10.1128/AAC.31.7.978; GIRARD PM, 1989, LANCET, V1, P1348; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; KEMPER CA, 1990, AIDS, V4, P1145, DOI 10.1097/00002030-199011000-00015; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MASUR H, 1989, REV INFECT DIS    S7, V11, pS1664; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; SANDE MA, 1990, MED MANAGEMENT AIDS; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SMALDONE GC, 1988, J AEROSOL MED, V1, P113; SPILKER B, 1984, GUIDE CLIN STUDIES D, P37; WEBER R, 1990, DEUT MED WOCHENSCHR, V115, P1619, DOI 10.1055/s-2008-1065200; 1988, MMWR, V37, P571; 1989, MMWR, V38, P1	25	182	182	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1079	1083		10.1056/NEJM199104183241602	http://dx.doi.org/10.1056/NEJM199104183241602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008181	Bronze			2022-12-28	WOS:A1991FG91200002
J	DAVIDSON, MH; DUGAN, LD; BURNS, JH; BOVA, J; STORY, K; DRENNAN, KB				DAVIDSON, MH; DUGAN, LD; BURNS, JH; BOVA, J; STORY, K; DRENNAN, KB			THE HYPOCHOLESTEROLEMIC EFFECTS OF BETA-GLUCAN IN OATMEAL AND OAT BRAN - A DOSE-CONTROLLED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; HYPERCHOLESTEROLEMIC MEN; DIETARY FIBER; ATHEROSCLEROSIS	Oat cereals rich in the water-soluble fiber beta-glucan have been studied as a dietary therapy for hypercholesterolemia. To determine the hypocholesterolemic response of beta-glucan in the diet, 156 adults with low-density lipoprotein cholesterol (LDL-C) levels above 4.14 mmol/L (160 mg/dL) or between 3.37 and 4.14 mmol/L (130 and 160 mg/dL) with multiple risk factors were randomized to one of seven groups. Six groups received either oatmeal or oat bran at doses (dry weight) of 28 g (1 oz), 56 g (2 oz), and 84 g (3 oz). A seventh group received 28 g of farina (beta-glucan control). At week 6 of treatment, significant differences were found for both total cholesterol and LDL-C levels among the farina control and the treatment groups who were receiving 84 g of oatmeal, 56 g of oat bran, and 84 g of oat bran, with decreases in LDL-C levels of 10.1%, 15.9%, and 11.5%, respectively. Fifty-six grams of oat bran resulted in significantly greater reductions in LDL-C levels than 56 g of oatmeal. Nutrient analysis shows no difference in dietary fat content between these treatment groups; therefore, the higher beta-glucan content of oat bran most likely explains the significantly greater LDL-C reductions. A dose-dependent reduction in LDL-C levels with oat cereals supports the independent hypocholesterolemic effects of beta-glucan.			DAVIDSON, MH (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,CHICAGO CTR CLIN RES,800 S WELLS,SUITE M-25,CHICAGO,IL 60607, USA.							ANDERSON JW, 1988, ARCH INTERN MED, V148, P292, DOI 10.1001/archinte.148.2.292; ANDERSON JW, 1985, FED PROC, V44, P2902; ANDERSON JW, 1984, AM J CLIN NUTR, V40, P1146, DOI 10.1093/ajcn/40.6.1146; BELL LP, 1989, JAMA-J AM MED ASSOC, V261, P3419, DOI 10.1001/jama.261.23.3419; CHEN WJL, 1984, P SOC EXP BIOL MED, V175, P215, DOI 10.3181/00379727-175-41791; CHEN WJL, 1986, DIETARY FIBER BASIC, P275; FADEL JG, 1987, NUTR REP INT, V35, P1049; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; JUDD PA, 1981, AM J CLIN NUTR, V34, P2061, DOI 10.1093/ajcn/34.10.2061; KEENAN JM, 1990, CIRCULATION, V82, P1889; KIRBY RW, 1981, AM J CLIN NUTR, V34, P824, DOI 10.1093/ajcn/34.5.824; KRITCHEVSKY D, 1987, J AM OIL CHEM SOC, V64, P1167, DOI 10.1007/BF02612995; MARSTON R, 1987, NATL FOOD REV, V36, P18; QURESHI AA, 1986, J BIOL CHEM, V261, P544; REMMELL PS, 1980, J AM DIET ASSOC, V76, P351; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHINNICK FL, 1990, J NUTR, V120, P561, DOI 10.1093/jn/120.6.561; STORER GB, 1983, NUTR RES, V3, P514; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; VAHOUNY GV, 1982, FED PROC, V41, P2801; VANHORN L, 1991, AM J PUBLIC HEALTH, V81, P183, DOI 10.2105/AJPH.81.2.183; VANHORN LV, 1986, J AM DIET ASSOC, V86, P759; 1985, SAS USERS GUIDE STAT; 1988, ARCH INTERN MED, V148, P36	25	211	223	3	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1833	1839						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005733				2022-12-28	WOS:A1991FE86200023
J	RUBEN, SM; DILLON, PJ; SCHRECK, R; HENKEL, T; CHEN, CH; MAHER, M; BAEUERLE, PA; ROSEN, CA				RUBEN, SM; DILLON, PJ; SCHRECK, R; HENKEL, T; CHEN, CH; MAHER, M; BAEUERLE, PA; ROSEN, CA			ISOLATION OF A REL-RELATED HUMAN CDNA THAT POTENTIALLY ENCODES THE 65-KD SUBUNIT OF NF-KAPPA-B	SCIENCE			English	Article							RECEPTOR-ALPHA-GENE; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; C-REL; ENZYMATIC AMPLIFICATION; EXPRESSION; SEQUENCES; ENHANCER; NUCLEAR; ACTIVATION	A DNA probe that spanned a domain conserved among the proto-oncogene c-rel, the Drosophila morphogen dorsal, and the p50 DNA binding subunit of NF-KB was generated from Jurkat T cell complementary DNA with the polymerase chain reaction (PCR) and degenerate oligonucleotides. This probe was used to identify a rel-related complementary DNA that hybridized to a 2.6-kilobase messenger RNA present in human T and B lymphocytes. In vitro transcription and translation of the complementary DNA resulted in the synthesis of a protein with an apparent molecular size of 65 kilodaltons (kD). The translated protein showed weak DNA binding with a specificity for the KB binding motif. This protein-DNA complex comigrated with the complex obtained with the purified human p65 NF-KB subunit and binding was inhibited by IKB-alpha and -beta-proteins. In addition, the 65-kD protein associated with the p50 subunit of NF-KB and the KB probe to form a complex with the same electrophoretic mobility as the NF-KB-DNA complex. Therefore the rel-related 65-kD protein may represent the p65 subunit of the active NF-KB transcription factor complex.	GENZENTRUM,MOLEK BIOL LAB,W-8033 MARTINSRIED,GERMANY		RUBEN, SM (corresponding author), ROCHE RES CTR,ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110, USA.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BROWNELL E, 1989, ONCOGENE, V4, P935; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; KERR LK, UNPUB; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINK E, UNPUB; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN S, UNPUB; RUBEN S M, 1989, New Biologist, V1, P275; RUBEN S M, 1990, New Biologist, V2, P894; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; URBAN M, UNPUB; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	36	428	443	3	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1490	1493		10.1126/science.2006423	http://dx.doi.org/10.1126/science.2006423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006423				2022-12-28	WOS:A1991FC85300050
J	LIPSHULTZ, SE; COLAN, SD; GELBER, RD; PEREZATAYDE, AR; SALLAN, SE; SANDERS, SP				LIPSHULTZ, SE; COLAN, SD; GELBER, RD; PEREZATAYDE, AR; SALLAN, SE; SANDERS, SP			LATE CARDIAC EFFECTS OF DOXORUBICIN THERAPY FOR ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTHRACYCLINE CARDIOTOXICITY; INTENSIVE ASPARAGINASE; BICYCLE EXERCISE; CHILDREN; ADRIAMYCIN; GROWTH; INDUCTION; TREADMILL; FAILURE; HEART	Background. Cardiotoxicity is a recognized complication of doxorubicin therapy, but the long-term effects of doxorubicin are not well documented. We therefore-assessed the cardiac status of 115 children who had been treated for acute lymphoblastic leukemia with doxorubicin 1 to 15 years earlier in whom the disease was in continuous remission. Methods. Eighteen patients received one dose of doxorubicin (45 mg per square meter of body-surface area), and 97 received multiple doses totaling 228 to 550 mg per square meter (median, 360). The median interval between the end of treatment and the cardiac evaluation was 6.4 years. Our evaluation consisted of a history, 24-hour ambulatory electrocardiographic recording, exercise testing, and echocardiography. Results. Fifty-seven percent of the patients had abnormalities of left ventricular afterload (measured as end-systolic wall stress) or contractility (measured as the stress-velocity index). The cumulative dose of doxorubicin was the most significant predictor of abnormal cardiac function (P < 0.002). Seventeen percent of patients who received one dose of doxorubicin had slightly elevated-age-adjusted afterload, and none had decreased contractility. In contrast, 65 percent of patients who received at least 228 mg of doxorubicin per square meter had increased afterload (59 percent of patients), decreased contractility (23 percent), or both. Increased afterload was due to reduced ventricular wall thickness, not to hypertension or ventricular dilatation. In multivariate analyses restricted to patients who received at least 228 mg of doxorubicin per square meter, the only significant predictive factors were a higher cumulative dose (P = 0.01), which predicted decreased contractility, and an age of less than four years at treatment (P = 0.003), which predicted increased afterload. Afterload increased progressively in 24 of 34 patients evaluated serially (71 percent). Reported symptoms correlated poorly with indexes of exercise tolerance or ventricular function. Eleven patients had congestive heart failure within one year of treatment with doxorubicin; five of them had recurrent heart failure 3.7 to 10.3 years after completing doxorubicin treatment, and two required heart transplantation. No patient had late heart failure as a new event. Conclusions. Doxorubicin therapy in childhood impairs myocardial growth in a dose-related fashion and results in a progressive increase in left ventricular afterload, sometimes accompanied by reduced contractility. We hypothesize that the loss of myocytes during doxorubicin therapy in childhood might result in inadequate left ventricular mass and clinically important heart disease in later years.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NATIONAL CANCER INSTITUTE [P01CA034183, P30CA006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001816] Funding Source: NIH RePORTER; NCI NIH HHS [CA06516, CA34183] Funding Source: Medline; NHLBI NIH HHS [HL01816] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOROW KM, 1985, CIRCULATION, V72, P515, DOI 10.1161/01.CIR.72.3.515; BRISTOW MR, 1978, AM J MED, V65, P823, DOI 10.1016/0002-9343(78)90802-1; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; BRUCE R A, 1963, Pediatrics, V32, P742; CAULFIELD JB, 1988, AM J PATHOL, V133, P298; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; CLUBB FJ, 1987, LAB INVEST, V56, P189; CLUBB FJ, 1984, LAB INVEST, V50, P571; COLAN SD, 1984, J AM COLL CARDIOL, V4, P715, DOI 10.1016/S0735-1097(84)80397-6; Cox DR., 1989, ANAL BINARY DATA; CUMMING GR, 1978, AM J CARDIOL, V41, P69, DOI 10.1016/0002-9149(78)90134-0; DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144; FURMAN L, 1976, Medical and Pediatric Oncology, V2, P157, DOI 10.1002/mpo.2950020205; GILLADOGA AC, 1976, CANCER, V37, P1070, DOI 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6; GOORIN AM, 1990, J PEDIATR-US, V116, P144, DOI 10.1016/S0022-3476(05)81668-3; HAUSDORF G, 1988, BRIT HEART J, V60, P309; HITCHCOCKBRYAN S, 1986, MED PEDIATR ONCOL, V14, P211, DOI 10.1002/mpo.2950140405; JAMES FW, 1980, CIRCULATION, V61, P902, DOI 10.1161/01.CIR.61.5.902; KANTROWITZ NE, 1984, PROG CARDIOVASC DIS, V27, P195, DOI 10.1016/0033-0620(84)90004-5; KOH E, 1988, PEDIATR HEMAT ONCOL, V5, P245, DOI 10.3109/08880018809031275; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; LEWIS AB, 1978, MED PEDIATR ONCOL, V5, P167, DOI 10.1002/mpo.2950050123; LIPSHULTZ SE, 1990, PEDIATR RES, V27, pA145; LIPSHULTZ SE, 1989, AM J CARDIOL, V64, P416; LIPSHULTZ SE, 1989, PEDIATR RES S, V25, pA53; LIPSHULTZ SE, 1987, BLOOD, V70, pA234; LOWN B, 1977, AM J CARDIOL, V39, P910, DOI 10.1016/S0002-9149(77)80046-5; NAG AC, 1980, CYTOBIOS, V28, P41; Riehm H, 1990, Haematol Blood Transfus, V33, P439; SALLAN SE, 1978, BLOOD, V51, P425; SALLAN SE, 1983, CANCER RES, V43, P5601; SALLAN SE, 1989, BLOOD S, V74, pA79; SALLAN SE, 1984, LEUKAMIEBEHANDLUNG K, P35; STEINHERZ LJ, 1988, AM J CARDIOL, V62, P505; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WETHERBEE JN, 1988, J AM COLL CARDIOL, V11, P330, DOI 10.1016/0735-1097(88)90098-8; ZAK R, 1974, CIRC RES, V35, P17	37	1095	1113	1	45	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					808	815		10.1056/NEJM199103213241205	http://dx.doi.org/10.1056/NEJM199103213241205			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997853	Bronze			2022-12-28	WOS:A1991FC44200005
J	STEWART, DJ; LEVY, RD; CERNACEK, P; LANGLEBEN, D				STEWART, DJ; LEVY, RD; CERNACEK, P; LANGLEBEN, D			INCREASED PLASMA ENDOTHELIN-1 IN PULMONARY-HYPERTENSION - MARKER OR MEDIATOR OF DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							RELAXING FACTOR; RELEASE; CELLS; SHOCK	Objective: To explore the role of endothelin-1, a potent endothelial-derived vasoconstrictor peptide, in pulmonary hypertension, by measuring its concentration in arterial and venous plasma. Design: A survey, case series study. Setting: University-affiliated hospitals and outpatient clinics. Patients: Twenty-seven patients with pulmonary hypertension: 7 with primary, and 20 with secondary pulmonary hypertension of various causes. The control groups (n = 16) comprised 8 healthy volunteers and 8 patients with coronary artery disease but without evidence of pulmonary hypertension. Measurements and Main Results: Pulmonary artery pressure was markedly increased (94/43 +/- 23/13 mm Hg) in the patients with pulmonary hypertension. Venous plasma immunoreactive endothelin-1, measured by a specific radioimmunoassay, was significantly higher in patients with pulmonary hypertension (3.5 +/- 2.5 pg/mL, P < 0.001) than in normal subjects (1.45 +/- 0.45 pg/mL), or patients with coronary disease (0.75 +/- 0.64 pg/mL). The arterial-to-venous ratio of immunoreactive endothelin-1 was significantly greater than unity in primary pulmonary hypertension (2.21 +/- 0.72, P = 0.01), whereas the patients with secondary pulmonary hypertension had a mean ratio not different from 1 (0.97 +/- 0.42). In contrast, the mean arterial-to-venous ratios were significantly less than unity in both control groups (0.59 +/- 0.35, and 0.54 +/- 0.64; P < 0.02, for normal subjects and coronary disease patients, respectively), indicating a possible clearance of endothelin-1 across the healthy lung. Conclusions: Patients with pulmonary hypertension have substantial alterations in plasma immunoreactive endothelin-1, which may reflect changes in net release or clearance of endothelin-1 by the lung. In patients with primary pulmonary hypertension, the high levels in arterial compared with venous plasma suggest pulmonary production of endothelin-1, which may contribute to elevated pulmonary vascular resistance.	SIR MORTIMER B DAVIS JEWISH HOSP, MONTREAL H3T 1E2, QUEBEC, CANADA	McGill University	STEWART, DJ (corresponding author), ROYAL VICTORIA HOSP, DIV CARDIOL, ROOM M476, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA.		Langleben, David/AAJ-9152-2020					ANGGARD E, 1989, J CARDIOVASC PHARM, V13, pS46; BRAQUET P, 1989, J CARDIOVASC PHARM, V13, pS143, DOI 10.1097/00005344-198900135-00036; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DINH XUAN AT, 1989, EUR RESPIR J, V2, P409; DRESDALE DT, 1951, AM J MED, V11, P686, DOI 10.1016/0002-9343(51)90020-4; Dubin D, 1989, J VASC MED BIOL, V1, P150; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HEATH D, 1987, BRIT HEART J, V58, P204; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HILEY CR, 1989, J CARDIOVASC PHARM, V13, pS197, DOI 10.1097/00005344-198900135-00055; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; LIPPTON HL, 1989, J APPL PHYSIOL, V66, P1008, DOI 10.1152/jappl.1989.66.2.1008; Meyrick B, 1989, Prog Clin Biol Res, V308, P91; MONCADA S, 1978, PHARMACOL REV, V30, P293; MOON DG, 1989, P NATL ACAD SCI USA, V86, P9529, DOI 10.1073/pnas.86.23.9529; MOREL DR, 1989, EUR J PHARMACOL, V167, P427, DOI 10.1016/0014-2999(89)90454-8; NEWMAN JH, 1989, J AM COLL CARDIOL, V14, P551, DOI 10.1016/0735-1097(89)90091-0; NICOD P, 1989, CIRCULATION, V80, P1486, DOI 10.1161/01.CIR.80.5.1486; OHTSUKA M, 1989, American Review of Respiratory Disease, V139, pA51; PERNOW J, 1989, ACTA PHYSIOL SCAND, V137, P317, DOI 10.1111/j.1748-1716.1989.tb08756.x; RAE GA, 1989, J CARDIOVASC PHARM, V13, pS89, DOI 10.1097/00005344-198900135-00022; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RIMAR S, 1989, CIRCULATION S2, V80, P213; RYAN US, 1989, J CARDIOVASC PHARM, V13, pS57, DOI 10.1097/00005344-198900135-00014; RYAN US, 1987, PULMONARY ENDOTHELIU, P3; SIRVIO ML, 1990, BIOCHEM BIOPH RES CO, V167, P1191, DOI 10.1016/0006-291X(90)90649-8; STELZNER TJ, 1990, FASEB J, V4, pA1147; STEWART DJ, 1990, CARDIOVASC RES, V24, P7, DOI 10.1093/cvr/24.1.7; SUGIURA M, 1989, BIOCHEM BIOPH RES CO, V161, P1220, DOI 10.1016/0006-291X(89)91372-7; VIERHAPPER H, 1990, CIRCULATION, V81, P1415, DOI 10.1161/01.CIR.81.4.1415; VOELKEL NF, 1989, PULMONARY VASCULAR P, P513; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; WOOD P, 1958, BRIT HEART J, V20, P557; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	40	843	889	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					464	469		10.7326/0003-4819-114-6-464	http://dx.doi.org/10.7326/0003-4819-114-6-464			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994793				2022-12-28	WOS:A1991FB64000006
J	SCHNORR, TM; GRAJEWSKI, BA; HORNUNG, RW; THUN, MJ; EGELAND, GM; MURRAY, WE; CONOVER, DL; HALPERIN, WE				SCHNORR, TM; GRAJEWSKI, BA; HORNUNG, RW; THUN, MJ; EGELAND, GM; MURRAY, WE; CONOVER, DL; HALPERIN, WE			VIDEO DISPLAY TERMINALS AND THE RISK OF SPONTANEOUS-ABORTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINNISH CASE-REFERENT; BIRTH-DEFECTS; PREGNANCY; WORK; EXPOSURE; SCREENS	Background. The relation between spontaneous abortion and the use of video display terminals (VDTs) is of great public health concern. Previous investigators of this issue have reported inconsistent findings. Methods. To determine whether electromagnetic fields emitted by VDTs are associated with an increased risk of spontaneous abortion, a cohort of female telephone operators who used VDTs at work was compared with a cohort of operators who did not use VDTs. To obtain reliable estimates of exposure, we determined the number of hours of VDT use per week from company records and measured electromagnetic fields at VDT workstations and, for purposes of comparison, at workstations without VDTs. Operators who used VDTs had higher abdominal exposure to very-low-frequency (15 kHz) electromagnetic fields (workstations without VDTs did not emit very-low-frequency energy). Abdominal exposure to extremely-low-frequency fields (45 to 60 Hz) was similar for both operators who used VDTs and those who did not. Among 2430 women interviewed, there were 882 pregnancies that met our criteria for inclusion in the study. Results. We found no excess risk of spontaneous abortion among women who used VDTs during the first trimester of pregnancy (odds ratio = 0.93; 95 percent confidence interval, 0.63 to 1.38), and no dose-response relation was apparent when we examined the women's hours of VDT use per week (odds ratio for 1 to 25 hours per week = 1.04; 95 percent confidence interval, 0.61 to 1.79; odds ratio for >25 hours per week = 1.00; 95 percent confidence interval, 0.61 to 1.64). There continued to be no risk associated with the use of VDTs when we accounted for multiple pregnancies, conducted separate analyses of early abortion, late abortion, and all fetal losses, or limited our analyses to spontaneous abortions for which a physician was consulted. Conclusions. The use of VDTs and exposure to the accompanying electromagnetic fields were not associated with an increased risk of spontaneous abortion in this study.	AMER CANC SOC,ATLANTA,GA	American Cancer Society	SCHNORR, TM (corresponding author), NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,CINCINNATI,OH 45226, USA.							BARNES FS, 1985, JUN ANN M BIOEL SOC; Bergquist U.O., 1984, SCAND J WORK ENV S2, V10, P62; Bowman JD, 1988, APPL IND HYG, V3, P189; BRANDT LPA, 1990, SCAND J WORK ENV HEA, V16, P329, DOI 10.5271/sjweh.1776; BRYANT HE, 1989, INT J EPIDEMIOL, V18, P132, DOI 10.1093/ije/18.1.132; ERICSON A, 1986, AM J IND MED, V9, P459, DOI 10.1002/ajim.4700090507; ERICSON A, 1986, AM J IND MED, V9, P447, DOI 10.1002/ajim.4700090506; GOLDHABER MK, 1988, AM J IND MED, V13, P695, DOI 10.1002/ajim.4700130608; GUY AW, 1987, MEASUREMENT ANAL ELE; GUY AW, 1987, WORK DISPLAY UNITS 8, P69; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; HARRELL FE, 1986, LOGIST PROCEDURE SUG; KLINE J, 1980, LANCET, V2, P176, DOI 10.1016/S0140-6736(80)90062-8; Kline J, 1989, MONOGRAPHS EPIDEMIOL, V14; KURPPA K, 1985, SCAND J WORK ENV HEA, V11, P353, DOI 10.5271/sjweh.2213; MCDONALD AD, 1988, BRIT J IND MED, V45, P509; NIELSEN CV, 1990, SCAND J WORK ENV HEA, V16, P323, DOI 10.5271/sjweh.1777; NURMINEN T, 1988, SCAND J WORK ENV HEA, V14, P293, DOI 10.5271/sjweh.1917; POTTER JD, 1980, SURG GYNECOL OBSTET, V150, P251; SCHNORR TM, 1991, INVSTIGATION SPONTAN; SCHNORR TM, 1985, CURRENT CONCEPTS, V8; STUCHLY MA, 1983, HEALTH PHYS, V45, P713, DOI 10.1097/00004032-198309000-00013; TELL R, 1990, PB91130500; TELL RA, 1983, BIOL EFFECTS DOSIMET, P95; WERTHEIMER N, 1986, BIOELECTROMAGNETICS, V7, P13, DOI 10.1002/bem.2250070103; WERTHEIMER N, 1989, AM J EPIDEMIOL, V129, P220, DOI 10.1093/oxfordjournals.aje.a115112; WESTERHOLM P, 1987, WORK DISPLAY UNITS 8, P104; WINDHAM GC, 1990, AM J IND MED, V18, P675, DOI 10.1002/ajim.4700180606; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1983, DHHS NIOSH833291498; 1984, DHHS NIOSH842971609; 1984, 84191 NAT I OCC SAF	32	107	106	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					727	733		10.1056/NEJM199103143241104	http://dx.doi.org/10.1056/NEJM199103143241104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997838				2022-12-28	WOS:A1991FB55600004
J	MERCER, JA; SEPERACK, PK; STROBEL, MC; COPELAND, NG; JENKINS, NA				MERCER, JA; SEPERACK, PK; STROBEL, MC; COPELAND, NG; JENKINS, NA			NOVEL MYOSIN HEAVY-CHAIN ENCODED BY MURINE DILUTE COAT COLOR LOCUS	NATURE			English	Article							INTESTINAL MICROVILLUS; MESSENGER-RNA; SEQUENCE; PROTEIN; GENE; COMPLEX; CLONING; ACTIN; DNA; PHENOTYPE	HUNDREDS of murine dilute mutations have been identified and analysed, making dilute one of the best genetically characterized of all mammalian loci. The recessive dilute (d) coat colour mutation carried by many inbred strains of mice produces a lightening of coat colour, caused by an abnormal adendritic melanocyte morphology that results in an uneven release of pigment granules into the developing hair shaft 1,2. Most dilute alleles (dilute-lethal) also produce a neurological defect, characterized by convulsions and opisthotonus, apparent at 8-10 days of age and continuing until the death of the animal at 2-3 weeks of age 3. The discovery that the original dilute allele (now termed dilute-viral or d(V)) is the result of the integration of an ecotropic murine leukaemia provirus 4 has allowed the cloning of genomic DNA 5,6 and in this study complementary DNA, from the dilute locus. The predicted dilute amino-acid sequence indicates that dilute encodes a novel type of myosin heavy chain, with a tail, or C-terminal, region that has elements of both type II (alpha-helical coiled-coil) and type I (non-coiled-coil) myosin heavy chains. Dilute transcripts are differentially expressed in both embryonic and adult tissues and are very abundant in neurons of the central nervous system, cephalic ganglia, and spinal ganglia. These results suggest an important role for the dilute gene product in the elaboration, maintenance, or function of cellular processes of melanocytes and neurons.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Mercer, John/0000-0003-0307-4438				BRAY D, 1989, NATURE, V338, P203, DOI 10.1038/338203a0; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLUCCIO LM, 1987, J CELL BIOL, V105, P325, DOI 10.1083/jcb.105.1.325; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COPELAND NG, 1983, CELL, V33, P379, DOI 10.1016/0092-8674(83)90419-1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAASE AT, 1982, VIROLOGY, V119, P399, DOI 10.1016/0042-6822(82)90099-X; HAYDEN SM, 1990, J CELL BIOL, V111, P433; HOSHIMARU M, 1989, J BIOCHEM-TOKYO, V106, P455, DOI 10.1093/oxfordjournals.jbchem.a122873; HOSHIMARU M, 1987, J BIOL CHEM, V262, P14625; JENKINS NA, 1981, NATURE, V293, P370, DOI 10.1038/293370a0; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; MARKERT CL, 1956, GENETICS, V41, P429; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MOORE KJ, 1988, P NATL ACAD SCI USA, V85, P8131, DOI 10.1073/pnas.85.21.8131; MOORE KJ, 1988, GENETICS, V119, P933; RUSSELL ES, 1949, GENETICS, V34, P146; SEARLE AG, 1952, HEREDITY, V6, P395, DOI 10.1038/hdy.1952.48; SHEETZ MP, 1990, CELL, V61, P231, DOI 10.1016/0092-8674(90)90804-N; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; STROBEL MC, 1990, MOL CELL BIOL, V10, P501, DOI 10.1128/MCB.10.2.501; TAKAHASHI N, 1985, CELL, V42, P139, DOI 10.1016/S0092-8674(85)80109-4; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433	32	489	492	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					709	713		10.1038/349709a0	http://dx.doi.org/10.1038/349709a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996138				2022-12-28	WOS:A1991EY62700052
J	DIXON, JM; ELTON, RA; RAINEY, JB; MACLEOD, DAD				DIXON, JM; ELTON, RA; RAINEY, JB; MACLEOD, DAD			RECTAL EXAMINATION IN PATIENTS WITH PAIN IN THE RIGHT LOWER QUADRANT OF THE ABDOMEN	BRITISH MEDICAL JOURNAL			English	Article							APPENDICITIS	Objective-To determine whether rectal examination provides any diagnostic information in patients admitted to hospital with pain in the right lower quadrant of the abdomen. Design-Casualty officer or surgical registrar recorded symptoms and signs on admission on detailed forms. Final diagnosis was noted on discharge from hospital. Setting-District general hospital. Patients-1204 Consecutive patients admitted to hospital with pain in the right lower quadrant of the abdomen as their major complaint; 1028 had a rectal examination on admission. Main outcome measures-Odds ratio for each symptom and sign related to final diagnosis. Results of multiple logistic regression analysis for acute appendicitis. Results-Right sided rectal tenderness, present in 309 of those examined, was more common in patients with acute appendicitis (odds ratio 1.34, p < 0.05). This odds ratio was considerably less than that for other clinical signs-namely, tenderness in the right lower quadrant (odds ratio 5.09), rebound tenderness (3.34), guarding (3.07), and muscular rigidity in the abdomen (5.03). In the logistic regression analysis of patients with acute appendicitis, when allowance was made for the presence or absence of rebound tenderness, rectal tenderness on the right lost its significance. Six patients had masses palpable rectally, of which three were palpable on abdominal examination; the other three patients had acute appendicitis. No other unexpected diagnoses were established, and no useful additional diagnostic information was obtained by routine rectal examination. Conclusion-If patients presenting with pain in the right lower quadrant of the abdomen are tested for rebound tenderness then rectal examination does not give any further diagnostic information.	UNIV EDINBURGH,MED STAT UNIT,EDINBURGH,SCOTLAND; ST JOHNS HOSP HOWDEN,DEPT SURG,LIVINGSTON,W LOTHIAN,SCOTLAND	University of Edinburgh	DIXON, JM (corresponding author), UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							Armitage P., 1987, STATISTICAL METHODS, P386; BONNELLO JC, 1979, DIS COLON RECTUM, V22, P97; CAIN A, 1986, H BAILEYS DEMONSTRAT, P297; CONDON R, 1986, TXB SURG, P971; DICKSON AP, 1985, ARCH DIS CHILD, V60, P666, DOI 10.1136/adc.60.7.666; KAZARIAN KK, 1970, AM J SURG, V119, P681, DOI 10.1016/0002-9610(70)90239-4; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; Magee R B, 1967, Pa Med, V70, P47; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; NAUTA RJ, 1986, AM J SURG, V151, P746, DOI 10.1016/0002-9610(86)90057-7; OSLER W, 1901, PRINCIPLES PRACTICES, P525; SMITH PH, 1965, POSTGRAD MED J, V41, P2, DOI 10.1136/pgmj.41.471.2; TEICHER I, 1983, ANN SURG, V198, P753, DOI 10.1097/00000658-198312000-00014	13	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					386	388		10.1136/bmj.302.6773.386	http://dx.doi.org/10.1136/bmj.302.6773.386			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	2004144	Bronze, Green Published			2022-12-28	WOS:A1991EX85800027
J	GOTTFRIED, DS; STEFFEN, MA; BOXER, SG				GOTTFRIED, DS; STEFFEN, MA; BOXER, SG			LARGE PROTEIN-INDUCED DIPOLES FOR A SYMMETRICAL CAROTENOID IN A PHOTOSYNTHETIC ANTENNA COMPLEX	SCIENCE			English	Article							ELECTROCHROMIC ABSORBANCE CHANGES; RHODOPSEUDOMONAS-SPHAEROIDES; RHODOBACTER-SPHAEROIDES; ABSORPTION-SPECTRUM; REACTION CENTERS; ELECTRIC-FIELDS; DYE MOLECULES; LIPID LAYERS; STATE; MEMBRANES	Unusually large electric field effects have been measured for the absorption spectra of carotenoids (spheroidene) in the B800-850 light-harvesting complex from the photosynthetic bacterium Rhodobacter sphaeroides. Quantitative analysis shows that the difference in the permanent dipole moment between the ground state and excited states in this protein complex is substantially larger than for pure spheroidene extracted from the protein. The results demonstrate the presence of a large perturbation on the electronic structure of this nearly symmetric carotenoid due to the organized environment in the protein. This work also provides an explanation for the seemingly anomalous dependence of carotenoid band shifts on transmembrane potential and a generally useful approach for calibrating electric field-sensitive dyes that are widely used to probe potentials in biological systems.			GOTTFRIED, DS (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.			Boxer, Steven/0000-0001-9167-4286; Gottfried, David/0000-0002-2729-2504	NIGMS NIH HHS [GM07365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1985, ANTENNAS REACTION CT, P82; BOXER SG, 1989, J PHYS CHEM-US, V93, P8280, DOI 10.1021/j100363a004; BRETON J, 1987, TOP PHOTOSYNTH, V8, P159; CHANCE B, 1955, NATURE, V175, P803, DOI 10.1038/175803b0; CHANCE BRITTON, 1958, BROOKHAVEN SYMPOSIA IN BIOL, V11, P74; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; COGDELL RJ, 1978, BIOCHIM BIOPHYS ACTA, V502, P409, DOI 10.1016/0005-2728(78)90074-9; COGDELL RJ, 1985, ANTENNAS REACTION CT, P85; CRIELAARD W, 1988, BIOCHIM BIOPHYS ACTA, V973, P505; DEGROOTH BG, 1977, BIOCHIM BIOPHYS ACTA, V462, P237, DOI 10.1016/0005-2728(77)90122-0; DEGROOTH BG, 1980, BIOCHIM BIOPHYS ACTA, V589, P299, DOI 10.1016/0005-2728(80)90046-8; EVANS MB, 1988, BIOCHIM BIOPHYS ACTA, V935, P292, DOI 10.1016/0005-2728(88)90224-1; Goodwin T. W., 1988, Plant pigments., P61; GOTTFRIED DS, UNPUB; HAYASHI H, 1989, PHOTOCHEM PHOTOBIOL, V49, P337, DOI 10.1111/j.1751-1097.1989.tb04116.x; JACKSON JB, 1969, FEBS LETT, V4, P185, DOI 10.1016/0014-5793(69)80230-9; JUNGE W, 1982, PHOTOSYNTHESIS ENERG, V1, P589; KAKITANI T, 1982, BIOPHYS J, V39, P57, DOI 10.1016/S0006-3495(82)84490-1; KRAMER HJM, 1984, BIOCHIM BIOPHYS ACTA, V765, P156, DOI 10.1016/0005-2728(84)90009-4; LIPTAY W, 1988, CHEM PHYS, V120, P439, DOI 10.1016/0301-0104(88)87230-6; LIPTAY W, 1974, EXCITED STATES, P129; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P2958; LOCKHART DJ, 1988, P NATL ACAD SCI USA, V85, P107, DOI 10.1073/pnas.85.1.107; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P664, DOI 10.1021/bi00377a001; LOCKHART DJ, UNPUB; MANTELE W, 1985, ANTENNAS REACTION CT, P88; MATHIES R, 1976, P NATL ACAD SCI USA, V73, P2169, DOI 10.1073/pnas.73.7.2169; MYERS AB, 1981, J AM CHEM SOC, V103, P1881, DOI 10.1021/ja00398a001; PONDER M, 1983, J PHYS CHEM-US, V87, P5090, DOI 10.1021/j150643a010; Rau W., 1988, PLANT PIGMENTS, P231; REICH R, 1972, BERICH BUNSEN GESELL, V76, P589; REICH R, 1976, BIOCHIM BIOPHYS ACTA, V449, P285, DOI 10.1016/0005-2728(76)90140-7; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; SYMONS M, 1977, BIOCHIM BIOPHYS ACTA, V462, P706, DOI 10.1016/0005-2728(77)90112-8; SYMONS M, 1983, BIOCHIM BIOPHYS ACTA, V723, P454, DOI 10.1016/0005-2728(83)90052-X; TRAUTMAN JK, 1990, P NATL ACAD SCI USA, V87, P215, DOI 10.1073/pnas.87.1.215; WRAIGHT CA, 1978, PHOTOSYNTHETIC BACTE, P471; ZUBER H, 1986, TRENDS BIOCHEM SCI, V11, P414, DOI 10.1016/0968-0004(86)90175-1	38	68	69	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					662	665		10.1126/science.1992518	http://dx.doi.org/10.1126/science.1992518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1992518				2022-12-28	WOS:A1991EW39900042
J	KNEKT, P; REUNANEN, A; TEPPO, L				KNEKT, P; REUNANEN, A; TEPPO, L			SERUM-CHOLESTEROL CONCENTRATION AND RISK OF PRIMARY BRAIN-TUMORS	BRITISH MEDICAL JOURNAL			English	Article							CANCER		FINNISH CANC REGISTRY,SF-00170 HELSINKI,FINLAND	Finnish Cancer Registry	KNEKT, P (corresponding author), SOCIAL INSURANCE INST,SOCIAL SECUR RES INST,SF-00380 HELSINKI,FINLAND.							ABRAMSON ZH, 1985, BRIT J CANCER, V52, P93, DOI 10.1038/bjc.1985.154; BASU TK, 1974, INT J VITAM NUTR RES, V44, P14; DAVEYSMITH G, 1989, BMJ-BRIT MED J, V299, P26; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; NEUGUT AI, 1989, INT J EPIDEMIOL, V18, P798, DOI 10.1093/ije/18.4.798	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					90	90		10.1136/bmj.302.6768.90	http://dx.doi.org/10.1136/bmj.302.6768.90			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995123	Bronze, Green Published			2022-12-28	WOS:A1991ER95100021
J	SPIELBERG, SP; SHEAR, NH; CANNON, M; HUTSON, NJ; GUNDERSON, K				SPIELBERG, SP; SHEAR, NH; CANNON, M; HUTSON, NJ; GUNDERSON, K			INVITRO ASSESSMENT OF A HYPERSENSITIVITY SYNDROME ASSOCIATED WITH SORBINIL	ANNALS OF INTERNAL MEDICINE			English	Article							DIABETIC NEUROPATHY; REGENERATION; SORBITOL	Sorbinil is a hydantoin aldose reductase inhibitor that has shown promise as therapy for patients with diabetic complications such as neuropathy and retinopathy. However, as many as 10% of patients receiving sorbinil have had adverse reactions characterized by fever, skin rash, and myalgia. Our previous studies of phenytoin suggested that susceptibility to reactions might result from an inherited detoxification defect. We did the current study to determine if sorbinil is metabolized to reactive intermediates and if cells from patients with a history of a reaction to sorbinil are appropriate for the in-vitro investigation of susceptibility. Microsome-generated metabolites of sorbinil (50-mu-M) were toxic to normal peripheral blood lymphocytes (7.9% +/- 0.3% dead cells [mean +/- SE]). Toxicity was increased in the presence of an epoxide hydrolase inhibitor (17.5% +/- 0.3% dead cells) and abolished by an inhibitor of cytochrome P-450. In contrast to cells from healthy controls and diabetics who tolerated sorbinil (7.9% +/- 0.7% and 7.8% +/- 0.4% dead cells, respectively), cells from the six patients who had sorbinil reactions showed significantly increased toxicity from metabolites of sorbinil and phenytoin (19.7% +/- 2.3% dead cells, P < 0.001). Cells from three patients who had reactions to phenytoin were similarly sensitive to sorbinil metabolites (23.4% +/- 0.3% dead cells). We conclude that sorbinil is oxidatively metabolized to a potentially toxic intermediate. Certain patients may be at increased risk for developing hypersensitivity reactions. Development of this important new drug has been hampered by uncommon but potentially severe reactions. An increased understanding of the steps involved in the development of adverse reactions could lead to screening tests or to the development of safer compounds.	SUNNYBROOK HLTH SCI CTR A3, DIV CLIN PHARMACOL, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ONTARIO, CANADA; UNIV TORONTO, CTR DRUG SAFETY RES, TORONTO M5S 1A1, ONTARIO, CANADA; PFIZER INC, CENT RES, DEPT METAB DIS, GROTON, CT 06340 USA; HOSP SICK CHILDREN, CLIN PHARMACOL & TOXICOL, TORONTO M5G 1X8, ONTARIO, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Pfizer; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BURG MB, 1988, J CLIN INVEST, V81, P635, DOI 10.1172/JCI113366; DYCK PJ, 1988, NEW ENGL J MED, V319, P542, DOI 10.1056/NEJM198809013190904; JUDZEWITSCH RG, 1983, NEW ENGL J MED, V308, P119, DOI 10.1056/NEJM198301203080302; KALOW W, 1984, BANBURY REPORT, V16; PITTS NE, 1986, METABOLISM, V35, P96, DOI 10.1016/0026-0495(86)90195-2; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; RULL JA, 1969, DIABETOLOGIA, V5, P215, DOI 10.1007/BF01212087; SHEAR NH, 1988, J CLIN INVEST, V82, P1826, DOI 10.1172/JCI113798; SIMA AAF, 1988, NEW ENGL J MED, V319, P548, DOI 10.1056/NEJM198809013190905; SPIELBERG SP, 1981, J PHARMACOL EXP THER, V217, P386; UETRECHT J, 1988, CHEM RES TOXICOL, V1, P148, DOI 10.1021/tx00003a004; VESELL ES, 1984, BANBURY REPORT, V16, P117	12	49	49	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					720	724		10.7326/0003-4819-114-9-720	http://dx.doi.org/10.7326/0003-4819-114-9-720			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012352				2022-12-28	WOS:A1991FJ11700002
J	HAMILTON, DP				HAMILTON, DP			DOOMED DETECTOR	SCIENCE			English	Editorial Material																		1991, SCIENCE, V251, P24	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1415	1415						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006415				2022-12-28	WOS:A1991FC85300014
J	HEITZLER, P; SIMPSON, P				HEITZLER, P; SIMPSON, P			THE CHOICE OF CELL FATE IN THE EPIDERMIS OF DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; NEURONAL PRECURSOR CELLS; CAENORHABDITIS-ELEGANS; C-ELEGANS; EARLY NEUROGENESIS; NOTCH LOCUS; GROWTH-FACTOR; GENE-PRODUCT; MELANOGASTER; LIN-12	In Drosophila, neural precursors are formed in a spaced pattern separated by intervening epidermal cells. Segregation of neural and epidermal lineages relies on cellular interactions. Failure of this cell communication, as in the mutants Notch (N), Delta, and shaggy, results in most or all of the cells becoming neural. Cells mutant for N and shaggy, but not Delta, autonomously adopt the neural fate when adjacent to wild-type cells in mosaics. Furthermore, wild-type cells adopt the epidermal fate if adjacent cells express a lower level of N activity than themselves, but produce neural precursors if adjacent cells express a higher level of N activity. This shows that there is competition between the cells and that the N protein is required for the mechanism whereby the cells choose between alternative fates. It also suggests that N acts as a receptor for an inhibitory signal emanating from the neural precursors.			HEITZLER, P (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL, CNRS, GENET MOLEC EUCARYOTES LAB, INSERM, F-67085 STRASBOURG, FRANCE.							AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1986, ROUX ARCH DEV BIOL, V195, P210, DOI 10.1007/BF02438953; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAWRENCE PA, 1966, J CELL SCI, V1, P475; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MITCHELL HK, 1990, DEV GENET, V11, P133, DOI 10.1002/dvg.1020110203; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIMPSON P, 1990, TRENDS GENET, V6, P343, DOI 10.1016/0168-9525(90)90260-D; SIMPSON P, 1989, DEVELOPMENT, V106, P57; STERN CURT, 1954, AMER SCI, V42, P213; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TECHNAU GM, 1987, P NATL ACAD SCI USA, V84, P4500, DOI 10.1073/pnas.84.13.4500; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILCOX M, 1973, J CELL SCI, V12, P707; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	655	664	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1083	1092		10.1016/0092-8674(91)90263-X	http://dx.doi.org/10.1016/0092-8674(91)90263-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004417				2022-12-28	WOS:A1991FD55800006
J	RUDEN, DM; MA, J; LI, Y; WOOD, K; PTASHNE, M				RUDEN, DM; MA, J; LI, Y; WOOD, K; PTASHNE, M			GENERATING YEAST TRANSCRIPTIONAL ACTIVATORS CONTAINING NO YEAST PROTEIN SEQUENCES	NATURE			English	Article								WE previously reported that roughly 1% of the short peptides encoded by Escherichia coli genomic DNA fragments act as transcriptional activating regions in yeast when fused to GAL4(1-147), a DNA-binding portion of the yeast transcriptional activator GAL4 (ref. 1). Struhl questioned the conclusion that we had identified new transcriptional activating sequences that function in the absence of yeast transcriptional activating sequences 2. His criticism was based on two considerations: first, GAL4(1-147) contains an acidic segment (and subsequent experiments have shown that this region contains a weak activating region in vitro 3); second, attempts to isolate new activating regions failed when the DNA-binding domain of a bacterial repressor, LexA(1-87), was used as the DNA-binding unit 2. We report here a repeat of our original experiment using the complete LexA molecule LexA(1-202) as the DNA-binding region, instead of GAL4(1-147) or LexA(1-87). We find that, as in the original experiment, about 1% of the short peptides encoded by E. coli genomic fragments act as transcriptional activating regions when fused to intact LexA. All of the new activating regions whose sequences we determined bore an excess of acidic amino acids (see Table 1).	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138	Harvard University			Ma, Jun/GLT-4809-2022; Ruden, Douglas/ABE-1418-2021; Ruden, Douglas/A-5008-2016	Ma, Jun/0000-0002-1609-3294; Ruden, Douglas/0000-0002-0070-437X				BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0	8	136	143	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					250	252		10.1038/350250a0	http://dx.doi.org/10.1038/350250a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005981				2022-12-28	WOS:A1991FC77900064
J	LESTINA, DC; WILLIAMS, AF; LUND, AK; ZADOR, P; KUHLMANN, TP				LESTINA, DC; WILLIAMS, AF; LUND, AK; ZADOR, P; KUHLMANN, TP			MOTOR-VEHICLE CRASH INJURY PATTERNS AND THE VIRGINIA SEAT-BELT LAW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SAFETY BELTS; SEVERITY; CARE	Injuries to front seat occupants in tow-away crashes in the Charlottesville, Va, area were compared for 1 year before and 1 year after Virginia's seat belt use law took effect. Vehicle and occupant data were combined to examine crash and injury patterns. Reported seat belt use in crashes increased after the law, and there were substantial decreases in injuries. Front seat occupants were less likely to receive medical treatment following a crash in the postlaw period. The reduction in the number of injuries was greater for passengers in the right front seat than for drivers and for frontal crashes than for other types of crashes. The injury reduction effects occurred primarily through reductions in the number of head and face injuries, particularly those that occur from contact with windshields and instrument panels.	INSURANCE INST HIGHWAY SAFETY,ARLINGTON,VA; UNIV VIRGINIA,EMERGENCY MED SERV,CHARLOTTESVILLE,VA 22903	University of Virginia								BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARANCIK JI, 1988, B NEW YORK ACAD MED, V64, P742; BERNSTEIN E, 1989, AM J EMERG MED, V7, P271, DOI 10.1016/0735-6757(89)90168-X; Campbell B, 1988, PREVENTING AUTOMOBIL, P24; CAMPBELL BJ, 1987, J TRAUMA, V27, P733, DOI 10.1097/00005373-198707000-00007; CRUBUIB JD, 1975, ACCIDENT ANAL PREV, V7, P81; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P229, DOI 10.1016/0001-4575(86)90007-2; GLOYNS PF, 1990, 12TH P EXP SAF C WAS, P529; LUND AK, 1987, SAE870224 SOC AUT EN; ORSAY EM, 1988, JAMA-J AM MED ASSOC, V260, P3598, DOI 10.1001/jama.260.24.3598; Partyka SC, 1990, COMP BELT EFFECTIVEN; Preusser D F, 1986, J Public Health Policy, V7, P470, DOI 10.2307/3342236; RUTHERFORD WH, 1985, MED EFFECTS SEAT BEL; SAALBERG JH, 1990, IMPACT MICHIGAN SAFE; SKINNER D, 1988, DOTTSC81570PM885 NAT; STATES JD, 1989, 33RD P AM ASS AUT ME, P265; WILLIAMS AF, 1988, PREVENTING AUTOMOBIL, P51; 1986, NASS DATA COLLECTION; 1988, INSURANCE INJURY LOS; 1985, SAS USERS GUIDE STAT; 1982, COLLISION DEFORMATIO; 1985, COMPULSORY SEAT BELT; 1985, ABBREVIATED INJURY S	23	23	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1409	1413		10.1001/jama.265.11.1409	http://dx.doi.org/10.1001/jama.265.11.1409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999881				2022-12-28	WOS:A1991FB55000021
J	GELLERT, GA; KAZNADY, SI				GELLERT, GA; KAZNADY, SI			MELTING THE IRON CURTAIN - OPPORTUNITIES FOR PUBLIC-HEALTH COLLABORATION THROUGH INTERNATIONAL JOINT VENTURES	BRITISH MEDICAL JOURNAL			English	Article							USSR		KIEV INT MANAGEMENT INST,KIEV,UKRAINE,USSR		GELLERT, GA (corresponding author), ORANGE CTY HLTH CARE AGCY,515 N SYCAMORE,SANTA ANA,CA 92701, USA.							[Anonymous], 1988, FUTURE PUBLIC HLTH; BELETSKAYA V, 1988, OGONYOK, V51, P20; CHAZOV E, 1989, PEOPLES HLTH SOC WEA; De Schryver A, 1989, World Health Stat Q, V42, P90; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; FORSTER DP, 1990, LANCET, V335, P458, DOI 10.1016/0140-6736(90)90678-X; GELLERT G A, 1989, Journal of Public Health Policy, V10, P421, DOI 10.2307/3342515; GELLERT GA, 1990, JAMA-J AM MED ASSOC, V264, P610; GELLERT GA, 1990, NEW ENGL J MED, V323, P1843; GOLDSMITH MF, 1988, JAMA-J AM MED ASSOC, V259, P1917, DOI 10.1001/jama.259.13.1917; Hall R. D., 1984, INT JOINT VENTURE; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; KNOX JDE, 1989, LANCET, V2, P732; MEDVEDEV ZA, 1985, GERONTOLOGIST, V25, P201, DOI 10.1093/geront/25.2.201; MOYER ME, 1989, HEALTH AFFAIR, V8, P102, DOI 10.1377/hlthaff.8.2.102; PARKHOMOVSKII E, 1989, IZVESTYA        0119, P2; ROWLAND D, 1990, JAMA-J AM MED ASSOC, V263, P2646; RYAN M, 1989, BRIT MED J, V299, P383, DOI 10.1136/bmj.299.6695.383; SHORT PF, 1987, UNINSURED AM 1987 PR; SILVER GA, 1988, LANCET, V1, P817; 1989, LANCET, V2, P1208; 1990, AIDS CASES REPORT SU; 1989, LANCET, V2, P1385; 1989, SOCIAL INDICATORS DE; 1989, WORLD HLTH STATISTIC	25	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					633	635		10.1136/bmj.302.6777.633	http://dx.doi.org/10.1136/bmj.302.6777.633			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC071	2012880	Bronze, Green Published			2022-12-28	WOS:A1991FC07100026
J	THORPEBEESTON, JG; NICOLAIDES, KH; GOSDEN, CM; MCGREGOR, AM				THORPEBEESTON, JG; NICOLAIDES, KH; GOSDEN, CM; MCGREGOR, AM			THYROID-FUNCTION IN FETUSES WITH CHROMOSOMAL-ABNORMALITIES	BRITISH MEDICAL JOURNAL			English	Article							FETAL		KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	University of London; King's College London; University of Edinburgh; University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				CUTLER AT, 1986, AM J DIS CHILD, V140, P479, DOI 10.1001/archpedi.1986.02140190089034; DEESCOBAR GM, 1987, HORM RES, V26, P12, DOI 10.1159/000180681; NICOLAIDES KH, 1986, LANCET, V1, P1065; PUESCHEL SM, 1985, AM J DIS CHILD, V139, P636, DOI 10.1001/archpedi.1985.02140080106045; THORPEBEESTON JG, 1991, NEW ENGL J MED, V324, P532, DOI 10.1056/NEJM199102213240805	5	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					628	628		10.1136/bmj.302.6777.628	http://dx.doi.org/10.1136/bmj.302.6777.628			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012878	Bronze, Green Published			2022-12-28	WOS:A1991FC07100024
J	LAITINEN, K; LAMBERG-ALLARDT, C; TUNNINEN, R; KARONEN, SL; TAHTELA, R; YLIKAHRI, R; VALIMAKI, M				LAITINEN, K; LAMBERG-ALLARDT, C; TUNNINEN, R; KARONEN, SL; TAHTELA, R; YLIKAHRI, R; VALIMAKI, M			TRANSIENT HYPOPARATHYROIDISM DURING ACUTE ALCOHOL-INTOXICATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAGNESIUM-DEFICIENCY; PARATHYROID-HORMONE; MINERAL METABOLISM; CALCIUM; ETHANOL; SERUM; BONE; SECRETION; OSTEOPOROSIS; ABSORPTION	Background. Persons with chronic alcoholism frequently have hypocalcemia, hypomagnesemia, and osteoporosis. The short-term effects of alcohol ingestion on calcium and magnesium metabolism are poorly understood, however. Methods. We measured serum calcium, magnesium, and phosphate concentrations in 17 normal men and 7 normal women before and at intervals up to 16 hours after the ingestion of 1.2 to 1.5 g of alcohol per kilogram of body weight over a 3-hour period (doses sufficient to cause acute intoxication). Urinary excretion of calcium, magnesium, and phosphate and serum calciotropic hormone levels were measured in 16 of these subjects. As a control, the same measurements were made after the ingestion of fruit juice instead of alcohol. Results. The mean (+/- SE) peak blood alcohol level in the men was 37.5 +/- 1.6 mmol per liter, and in the women it was 38.0 +/- 3.2 mmol per liter. In the men the mean serum parathyroid hormone concentration decreased from 16.1 +/- 2.1 to 6.8 +/- 0.9 ng per liter at the end of the three-hour drinking period. The value at this time was 30 percent of that at the end of the three-hour session during which the men drank fruit juice (P = 0.004). The serum concentration of ionized calcium reached a nadir eight hours after the beginning of alcohol administration (decreasing from 1.18 +/- 0.01 to 1.15 +/- 0.01 mmol per liter; P < 0.001 as compared with values during the fruit-juice study), and urinary excretion of calcium increased from 0.34 +/- 0.08 to 0.36 +/- 0.08 mmol per hour (P < 0.01 as compared with values during the fruit-juice study). Serum parathyroid hormone levels exceeded base-line values during the last 4 hours of the 16-hour study period; this increase was accompanied by a decrease in the urinary excretion of calcium. Both serum levels of magnesium (in the first 6 hours) and urinary levels (in the first 12 hours) increased after the ingestion of alcohol. In the women, serum parathyroid hormone levels decreased from 29.2 +/- 2.8 to 17.3 +/- 2.6 ng per liter two hours after the administration of alcohol was begun (P < 0.001) and increased above base-line values during the last four hours of the study period. The serum concentration of ionized calcium decreased from 1.20 +/- 0.01 to 1.16 +/- 0.01 mmol per liter, reaching a nadir 8 to 12 hours after alcohol administration was begun (P < 0.001). Conclusions. Short-term alcohol administration causes transitory hypoparathyroidism. This decline in the secretion of parathyroid hormone accounts at least in part for the transient hypocalcemia, hypercalciuria, and hypermagnesuria that follow alcohol ingestion.	UNIV HELSINKI, ALCOHOL DIS RES UNIT, SF-00100 HELSINKI 10, FINLAND; UNITED LABS, HELSINKI, FINLAND; MINERVA FDN, INST MED RES, HELSINKI, FINLAND; ALKO LTD, FINNISH STATE ALCOHOL CO, RES LABS, HELSINKI, FINLAND; UNIV HELSINKI, DEPT MED 3, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT CLIN CHEM, SF-00100 HELSINKI 10, FINLAND	University of Helsinki; University of Helsinki; University of Helsinki								AVERY DH, 1983, J STUD ALCOHOL, V44, P205, DOI 10.15288/jsa.1983.44.205; BETHUNE JE, 1968, J CLIN ENDOCR METAB, V28, P673, DOI 10.1210/jcem-28-5-673; BIKLE DD, 1985, ANN INTERN MED, V103, P42, DOI 10.7326/0003-4819-103-1-42; BJORNEBOE GEA, 1988, ALCOHOL CLIN EXP RES, V12, P229, DOI 10.1111/j.1530-0277.1988.tb00185.x; BJORNEBOE GEA, 1986, AM J CLIN NUTR, V44, P678, DOI 10.1093/ajcn/44.5.678; BOHMER T, 1982, SCAND J CLIN LAB INV, V42, P633; Chanard J, 1980, Adv Exp Med Biol, V128, P495; DECHAVANNE M, 1974, NOUV PRESSE MED, V3, P2549; DIAMOND T, 1989, AM J MED, V86, P282, DOI 10.1016/0002-9343(89)90297-0; DICK M, 1969, J CLIN PATHOL, V22, P152, DOI 10.1136/jcp.22.2.152; DIXON WJ, 1988, BMDP STATISTICAL SOF; EARLL JM, 1976, AVIAT SPACE ENVIR MD, V47, P808; ERIKSSON CJP, 1977, ANAL BIOCHEM, V80, P116, DOI 10.1016/0003-2697(77)90631-5; FEITELBERG S, 1987, METABOLISM, V36, P322, DOI 10.1016/0026-0495(87)90201-0; FLINK EB, 1986, ALCOHOL CLIN EXP RES, V10, P590, DOI 10.1111/j.1530-0277.1986.tb05150.x; GRAHAM LA, 1960, METABOLISM, V9, P646; HEMMINGSEN R, 1980, PSYCHOPHARMACOLOGY, V67, P255, DOI 10.1007/BF00431266; JOHNELL O, 1982, BRIT J ADDICT, V77, P93; KALBFLEISCH JM, 1963, J CLIN INVEST, V42, P1471, DOI 10.1172/JCI104831; LALOR BC, 1986, Q J MED, V59, P497; LINDEMAN RD, 1967, J LAB CLIN MED, V70, P236; LINKOLA J, 1979, ACTA PHYSIOL SCAND, V107, P333, DOI 10.1111/j.1748-1716.1979.tb06484.x; LJUNGHALL S, 1985, EXP CLIN ENDOCRINOL, V85, P365, DOI 10.1055/s-0029-1210464; LUISIER M, 1977, SCHWEIZ MED WSCHR, V107, P1529; LUND B, 1977, ACTA MED SCAND, V202, P221; MARKKANEN T, 1966, EXPERIENTIA, V22, P753, DOI 10.1007/BF01901361; MARX SJ, 1987, CLIN DISORDERS FLUID, P207; MILSOM S, 1987, BRIT MED J, V295, P231, DOI 10.1136/bmj.295.6592.231; NIKKILA EA, 1975, DIABETES, V24, P933, DOI 10.2337/diabetes.24.10.933; PAK CYC, 1988, CALCIFIED TISSUE INT, V43, P55, DOI 10.1007/BF02555147; Pitts T O, 1986, Recent Dev Alcohol, V4, P357; Quamme GA, 1987, CLIN DISORDERS FLUID, P297; RATCLIFFE WA, 1989, CLIN CHEM, V35, P1957; RICO H, 1987, BONE MINER, V2, P221; RUDE RK, 1978, J CLIN ENDOCR METAB, V47, P800, DOI 10.1210/jcem-47-4-800; RUDE RK, 1976, CLIN ENDOCRINOL, V5, P209, DOI 10.1111/j.1365-2265.1976.tb01947.x; SAVILLE PD, 1965, J BONE JOINT SURG AM, VA 47, P492, DOI 10.2106/00004623-196547030-00005; SPENCER H, 1986, AM J MED, V80, P393, DOI 10.1016/0002-9343(86)90712-6; TORNQUIST K, 1987, ACTA ENDOCRINOL-COP, V115, P225, DOI 10.1530/acta.0.1150225; TORNQUIST K, 1987, ACTA ENDOCRINOL-COP, V116, P568, DOI 10.1530/acta.0.1160568; VODOZ JF, 1977, SCHWEIZ MED WSCHR, V107, P1525; WILLIAMS GA, 1978, P SOC EXP BIOL MED, V159, P187	42	79	82	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					721	727		10.1056/NEJM199103143241103	http://dx.doi.org/10.1056/NEJM199103143241103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997837				2022-12-28	WOS:A1991FB55600003
J	BLOOMFIELD, P; WHEATLEY, DJ; PRESCOTT, RJ; MILLER, HC				BLOOMFIELD, P; WHEATLEY, DJ; PRESCOTT, RJ; MILLER, HC			12-YEAR COMPARISON OF A BJORK-SHILEY MECHANICAL HEART-VALVE WITH PORCINE BIOPROSTHESES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAILURE; REPLACEMENT; HANCOCK; EDWARDS; PERSPECTIVE; PROSTHESES; POSITION	Background. Patients undergoing heart-valve replacement may receive a mechanical prosthesis, necessitating lifelong anticoagulant treatment, or a porcine bioprosthesis, which involves no absolute need for anticoagulants. Methods. We carried out a randomized, prospective trial to compare the durability of the Bjork-Shiley mechanical prosthesis (spherical tilting-disk model) and the incidence of valve-related complications with those variables in the Hancock and the Carpentier-Edwards porcine prostheses. The mitral valve was replaced in 261 patients, the aortic valve in 211, and both in 61; the survivors have been followed up for a mean of 12 years. Results. We found a trend toward improved actuarial survival after 12 years with the Bjork-Shiley prosthesis, but this trend was not statistically significant (group with Bjork-Shiley valve vs. group with porcine valve [mean +/- SE], 51.5 +/- 3.2 vs. 44.4 +/- 3.2 percent; P = 0.08). There was no significant difference in the actuarial incidence of reoperation after 5 years, but after 12 years significantly more patients with a porcine prosthesis had undergone reoperation (8.5 +/- 2.0 vs. 37.1 +/- 4.1 percent, P < 0.001). An analysis combining death and reoperation as end points for an actuarial assessment of survival with the original prosthesis intact confirmed that the patients with Bjork-Shiley prostheses had improved survival (48.6 +/- 3.2 vs. 30.0 +/- 3.0 percent after 12 years, P < 0.001). Bleeding requiring hospitalization of blood transfusion was significantly more frequent in the patients with Bjork-Shiley prostheses (18.6 +/- 3.2 vs. 7.1 +/- 2.3 percent after 12 years, P < 0.01). There was no significant difference after 12 years in the actuarial occurrence of embolism (Bjork-Shiley vs. porcine, 21.1 +/- 3.1 vs. 26.4 +/- 3.5 percent) or endocarditis (3.7 +/- 1.4 vs. 4.6 +/- 1.6 percent). Conclusions. Survival with an intact valve is better among patients with the Bjork-Shiley spherical tilting-disk prosthesis than among patients with porcine bioprostheses, but use of the Bjork-Shiley valve carries an attendant increased risk of bleeding associated with the need for anticoagulant treatment.	ROYAL INFIRM,DEPT CARDIOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT CARDIAC SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT CARDIOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh								BLOOMFIELD P, 1986, CIRCULATION, V73, P1213, DOI 10.1161/01.CIR.73.6.1213; BOLOOKI H, 1983, ANN THORAC SURG, V36, P246, DOI 10.1016/S0003-4975(10)60124-5; COX DR, 1972, J R STAT SOC B, V34, P187; FORFAR JC, 1979, BRIT HEART J, V42, P128; FOSTER AH, 1987, ANN THORAC SURG, V44, P568, DOI 10.1016/S0003-4975(10)62137-6; GALLO I, 1988, ANN THORAC SURG, V45, P66, DOI 10.1016/S0003-4975(10)62400-9; GALLUCCI V, 1984, ANN THORAC SURG, V38, P571, DOI 10.1016/S0003-4975(10)62313-2; HAMMERMEISTER KE, 1987, J AM COLL CARDIOL, V10, P719, DOI 10.1016/S0735-1097(87)80263-2; HIRSH J, 1987, ARCH INTERN MED, V147, P769, DOI 10.1001/archinte.147.4.769; JAMIESON WRE, 1988, ANN THORAC SURG, V46, P155, DOI 10.1016/S0003-4975(10)65888-2; MAGILLIGAN DJ, 1985, J THORAC CARDIOV SUR, V89, P499; MAGILLIGAN DJ, 1987, CIRCULATION, V76, P141; MURPHY DA, 1983, J THORAC CARDIOV SUR, V86, P746; POLLER L, 1985, BRIT MED J, V290, P1683, DOI 10.1136/bmj.290.6483.1683; RAHIMTOOLA SH, 1989, CIRCULATION, V79, P732; RAHIMTOOLA SH, 1989, J AM COLL CARDIOL, V14, P1, DOI 10.1016/0735-1097(89)90047-8; RAHIMTOOLA SH, 1975, AM J CARDIOL, V35, P711, DOI 10.1016/0002-9149(75)90063-6; RAHIMTOOLA SH, 1988, CIRCULATION, V78, P1503, DOI 10.1161/01.CIR.78.6.1503; TAYLOR K, 1988, BRIT MED J, V297, P996, DOI 10.1136/bmj.297.6655.996; TEPLY JF, 1981, ANN THORAC SURG, V32, P111, DOI 10.1016/S0003-4975(10)61017-X; WARNES CA, 1983, AM J CARDIOL, V51, P965, DOI 10.1016/S0002-9149(83)80174-X; WESSLER S, 1988, J AM COLL CARDIOL  S, V8, pB10	22	278	288	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 28	1991	324	9					573	579		10.1056/NEJM199102283240901	http://dx.doi.org/10.1056/NEJM199102283240901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY886	1992318				2022-12-28	WOS:A1991EY88600001
J	DAVIDSON, KM; RICHARDS, DS; SCHATZ, DA; FISHER, DA				DAVIDSON, KM; RICHARDS, DS; SCHATZ, DA; FISHER, DA			SUCCESSFUL INUTERO TREATMENT OF FETAL GOITER AND HYPOTHYROIDISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							THYROID-FUNCTION; AMNIOTIC-FLUID; GRAVES-DISEASE; LUNG MATURITY; THYROXINE; HORMONE; PROPYLTHIOURACIL; THYROTROPIN; METABOLISM; PITUITARY		UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV FLORIDA,J HILLIS MILLER HLTH CTR,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32610	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; State University System of Florida; University of Florida	DAVIDSON, KM (corresponding author), UNIV FLORIDA,J HILLIS MILLER HLTH CTR,COLL MED,DEPT OBSTET & GYNECOL,BOX J-294,GAINESVILLE,FL 32610, USA.							BECKER WF, 1959, ANN SURG, V149, P867, DOI 10.1097/00000658-195906000-00010; BONGIOVANNI AM, 1956, J CLIN ENDOCR METAB, V16, P146, DOI 10.1210/jcem-16-1-146; BURROW GN, 1988, MED COMPLICATIONS PR, P224; CHERON RG, 1981, NEW ENGL J MED, V304, P525, DOI 10.1056/NEJM198102263040907; DAFFOS F, 1989, ANNU REV MED, V40, P319; FISHER DA, 1981, NEW ENGL J MED, V304, P702, DOI 10.1056/NEJM198103193041205; FISHER DA, 1970, PEDIATRICS, V46, P208; FISHER DA, 1989, CLIN PEDIATRIC ENDOC, P87; FISHER DA, 1986, THYROID TODAY, V9, P1; HOLLINGSWORTH DR, 1983, J CLIN ENDOCR METAB, V57, P349, DOI 10.1210/jcem-57-2-349; KLEIN AH, 1980, AM J OBSTET GYNECOL, V136, P626, DOI 10.1016/0002-9378(80)91014-5; KLEIN AH, 1978, J CLIN ENDOCR METAB, V47, P1034, DOI 10.1210/jcem-47-5-1034; KLEIN AH, 1982, EARLY HUM DEV, V6, P321, DOI 10.1016/0378-3782(82)90070-6; KLEIN AH, 1980, ENDOCRINOLOGY, V106, P697, DOI 10.1210/endo-106-3-697; LAFRANCHI SH, 1979, PEDIATR CLIN N AM, V26; MARCHANT B, 1977, J CLIN ENDOCR METAB, V45, P1187, DOI 10.1210/jcem-45-6-1187; MASHIACH S, 1979, J PERINAT MED, V7, P161, DOI 10.1515/jpme.1979.7.3.161; MASHIACH S, 1978, AM J OBSTET GYNECOL, V130, P289; MCCOLGIN SW, 1989, OBSTET GYNECOL, V74, P464; MUNRO DS, 1978, BRIT J OBSTET GYNAEC, V85, P837, DOI 10.1111/j.1471-0528.1978.tb15839.x; PERELMAN AH, 1990, J CLIN ENDOCR METAB, V71, P618, DOI 10.1210/jcem-71-3-618; PORRECO RP, 1990, OBSTET GYNECOL, V76, P509; Romero R, 1988, PRENATAL DIAGNOSIS C, P119; ROTI E, 1983, ENDOCR REV, V4, P131, DOI 10.1210/edrv-4-2-131; ROVET J, 1987, J PEDIATR-US, V110, P700, DOI 10.1016/S0022-3476(87)80005-7; SACK J, 1975, J PEDIATR-US, V87, P364, DOI 10.1016/S0022-3476(75)80636-6; SACK J, 1975, PEDIATR RES, V9, P837, DOI 10.1203/00006450-197509110-00007; VESZELOVSZKY I, 1986, J PERINAT MED, V14, P227, DOI 10.1515/jpme.1986.14.4.227; VULSMA T, 1989, NEW ENGL J MED, V321, P13, DOI 10.1056/NEJM198907063210103; WEINER S, 1980, J REPROD MED, V24, P39; WENSTROM KD, 1990, OBSTET GYNECOL, V76, P513; ZAKARIJA M, 1983, J CLIN ENDOCR METAB, V57, P1036, DOI 10.1210/jcem-57-5-1036; 1990, J PEDIATR, V116, P27	33	103	104	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					543	546		10.1056/NEJM199102213240807	http://dx.doi.org/10.1056/NEJM199102213240807			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1992308	Bronze			2022-12-28	WOS:A1991EX91800007
J	KECHIJIAN, P				KECHIJIAN, P			TRAUMATIC SPLIT NAIL DYSTROPHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KECHIJIAN, P (corresponding author), NYU MED CTR,NEW YORK,NY 10016, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					912	912						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992192				2022-12-28	WOS:A1991EX58700047
J	SERRI, O; BEAUREGARD, H; BRAZEAU, P; ABRIBAT, T; LAMBERT, J; HARRIS, A; VACHON, L				SERRI, O; BEAUREGARD, H; BRAZEAU, P; ABRIBAT, T; LAMBERT, J; HARRIS, A; VACHON, L			SOMATOSTATIN ANALOG, OCTREOTIDE, REDUCES INCREASED GLOMERULAR-FILTRATION RATE AND KIDNEY SIZE IN INSULIN-DEPENDENT DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-DISEASE; SOMATOMEDIN-C; NEPHROPATHY; RADIOIMMUNOASSAY; HYPERGLYCEMIA; MELLITUS	To determine whether treatment with a somatostatin analogue can reduce kidney hyperfiltration and hypertrophy in insulin-dependent diabetes mellitus, we studied 11 patients with insulin-dependent diabetes mellitus and glomerular hyperfiltration. The patients were assigned randomly to receive continuous subcutaneous infusion of either octreotide, 300-mu-g/24 h (five patients) or placebo (six patients) for 12 weeks. At baseline, mean glomerular filtration rate and mean total kidney volume were not significantly different in the two groups. However, after 12 weeks of treatment, the mean glomerular filtration rate was significantly lower in the octreotide group (136 mL/min per 1.73 m2; range, 91 to 158 mL/min per 1.73 m2) than in the placebo group (157 mL/min per 1.73 m2; range, 138 to 184 mL/min per 1.73 m2). Furthermore, the mean total kidney volume was significantly lower after treatment in the octreotide group (379 mL/1.73 m2; range, 307 to 454 mL/1.73 m2) than in the placebo group (389 mL/1.73 m2; range, 347 to 465 mL/1.73 m2). Glycemic control did not change significantly in either group. We conclude that subcutaneous infusion of octreotide for 12 weeks reduces increased glomerular filtration rate and kidney size in patients with insulin-dependent diabetes mellitus despite the fact that glycemic control remains unchanged.	UNIV MONTREAL,HOP NOTRE DAME,FAC MED,CTR RECH,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,HOP NOTRE DAME,FAC MED,CTR RECH,DEPT SOCIAL & PREVENT MED,MONTREAL H3C 3J7,QUEBEC,CANADA; SANDOZ CANADA INC,SANDOZ CLIN RES,DORVAL,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal; Novartis; Sandoz	SERRI, O (corresponding author), UNIV MONTREAL,HOP NOTRE DAME,FAC MED,CTR RECH,DEPT NUTR,METAB UNIT,1560 SHERBROOKE E,MONTREAL H2L 4M1,QUEBEC,CANADA.			Harris, Alan/0000-0002-6618-2092				ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ANDERSON S, 1986, KIDNEY INT, V29, P314; BALA RM, 1979, J CLIN ENDOCR METAB, V49, P770, DOI 10.1210/jcem-49-5-770; CARLSEN JE, 1980, J NUCL MED, V21, P126; CHRISTENSEN S E, 1988, Diabetes Research and Clinical Practice, V5, pS87; CHRISTIANSEN JS, 1982, KIDNEY INT, V21, P683, DOI 10.1038/ki.1982.81; CONOVER WJ, 1982, BIOMETRICS, V38, P715, DOI 10.2307/2530051; FELDTRASMUSSEN B, 1986, NEW ENGL J MED, V314, P665, DOI 10.1056/NEJM198603133141101; FLYVBJERG A, 1989, DIABETOLOGIA, V32, P261, DOI 10.1007/BF00285295; FURLANETTO RW, 1977, J CLIN INVEST, V60, P648, DOI 10.1172/JCI108816; GARCIAPUIG J, 1981, DIABETOLOGIA, V21, P363; GULER HP, 1989, P NATL ACAD SCI USA, V86, P2668; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; KLEINMAN KS, 1988, DIABETES METAB REV, V4, P179, DOI 10.1002/dmr.5610040207; LERVANG HH, 1988, DIABETOLOGIA, V31, P723, DOI 10.1007/BF00274773; MOGENSEN C E, 1976, Acta Medica Scandinavica Supplement, V602, P29; MOGENSEN CE, 1975, DIABETOLOGIA, V11, P221, DOI 10.1007/BF00422325; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1983, DIABETES, V32, P64, DOI 10.2337/diab.32.2.S64; MOGENSEN CE, 1971, SCAND J CLIN LAB INV, V28, P79, DOI 10.3109/00365517109090666; MOGENSEN CE, 1978, DIABETES, V27, P35; MOGNSEN CE, 1982, BMJ, V285, P686; MOSS AA, 1981, J COMPUT ASSIST TOMO, V5, P12, DOI 10.1097/00004728-198102000-00002; PARVING HH, 1983, LANCET, V1, P1175; POIRIER JY, 1988, DIABETOLOGIA, V31, pA532; STEER KA, 1988, BIOCHEM MED METAB B, V39, P226, DOI 10.1016/0885-4505(88)90080-1; VASQUEZ B, 1984, DIABETOLOGIA, V26, P127, DOI 10.1007/BF00281119; VIBERTI GC, 1983, BRIT MED J, V286, P598, DOI 10.1136/bmj.286.6365.598; VORA J, 1987, J CLIN ENDOCR METAB, V64, P975, DOI 10.1210/jcem-64-5-975; WISEMAN M, 1983, DIABETOLOGIA, V25, P530; WISEMAN MJ, 1985, NEW ENGL J MED, V312, P617, DOI 10.1056/NEJM198503073121004	31	97	100	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					888	892		10.1001/jama.265.7.888	http://dx.doi.org/10.1001/jama.265.7.888			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992187				2022-12-28	WOS:A1991EX58700041
J	CARRHILL, RA; SHELDON, T				CARRHILL, RA; SHELDON, T			DESIGNING A DEPRIVATION PAYMENT FOR GENERAL-PRACTITIONERS - THE UPA(8) WONDERLAND	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS	Objective-To analyse critically the deprived area payment introduced in the new general practitioner contract. The payment formula is based on the Jarman underprivileged area index (UPA(8)) and aims at compensating general practitioners for increases in workload. Design-Evaluation of the deprived area payment against the stated policy objective with a set of criteria for developing resource allocation formulas. Main outcome measures-The degree to which the components of the Jarman index predict the work-load of general practitioners; whether construction of the index is sensible and comprehensible; and how the formula incorporates the index and is likely to work in practice. Results-The fact that the index relies on census data and the way the weighting was derived means that the formula will not accurately reflect the workload. The use of statistical transformations obscures the original policy intent. There has been no validation to support the application of the index as part of a national policy. The payments are not linked to the quality of service provided and may have the perverse effect of increasing list size. Conclusion-The formula used as the basis of the deprived area payments is poorly suited to the policy objective of compensating general practitioners for increases in workload. More research is urgently needed to enable the effect of the payment to be monitored and a more empirically sound set of incentives to be developed.	UNIV LEEDS,DEPT PUBL HLTH MED,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds	CARRHILL, RA (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913				Carr-Hill RA, 1987, HLTH STATUS RESOURCE; CHARLTON JRH, 1985, BRIT MED J, V290, P1714, DOI 10.1136/bmj.290.6483.1714; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; DELAMOTHE T, 1990, BRIT MED J, V300, P1609; DONALDSON C, 1989, J ROY COLL GEN PRACT, V39, P114; GRAY DP, 1986, BRIT MED J, V292, P1313, DOI 10.1136/bmj.292.6531.1313; HOBBS R, 1990, MED MONITOR     0323, P23; INNES J, 1988, PLANNING OUTLOOK, V31, P95; IRVING D, 1984, KFC8411 KINGS FUND T; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JARMAN B, 1988, BRIT MED J, V296, P1775, DOI 10.1136/bmj.296.6639.1775; JARMAN B, 1985, MED ANN, P224; KLEIN R, 1983, POLITICS NATIONAL HL; KRASNIK A, 1990, BRIT MED J, V300, P1698, DOI 10.1136/bmj.300.6741.1698; LEAVEY R, 1985, BRIT MED J, V291, P709, DOI 10.1136/bmj.291.6497.709; THURNHURST C, 1985, STATISTICIAN, V34, P93; WILKIN D, 1986, MED ANN, P185; 1987, CMND249; 1983, CENSUS POPULATION 19; 1990, NATIONAL HLTH SERVIC; 1987, WELSH INTERCENSAL SU	22	73	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					393	396		10.1136/bmj.302.6773.393	http://dx.doi.org/10.1136/bmj.302.6773.393			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	2004146	Bronze, Green Published			2022-12-28	WOS:A1991EX85800030
J	WORKMAN, JL; TAYLOR, ICA; KINGSTON, RE				WORKMAN, JL; TAYLOR, ICA; KINGSTON, RE			ACTIVATION DOMAINS OF STABLY BOUND GAL4 DERIVATIVES ALLEVIATE REPRESSION OF PROMOTERS BY NUCLEOSOMES	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONALLY ACTIVE CHROMATIN; IMMEDIATE EARLY PROTEIN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; HYPERSENSITIVE SITES; REGULATORY PROTEIN; MAJOR LATE; TATA-BOX; YEAST	GAL4 derivatives containing an activation domain alleviated repression of a promoter during nucleosome assembly. A GAL4 derivative lacking an activation domain stably bound the promoter during nucleosome assembly but was not sufficient to preserve promoter function. The activation domain of GAL4 derivatives was essential for preserving promoter function, and thus the transcriptional stimulatory activity attributable to these activation domains increased dramatically during nucleosome assembly. Furthermore, promoter-bound activation domains allowed the formation of preinitiation complexes after nucleosome assembly. Finally, GAL4 derivatives containing activation domains significantly stimulated transcription through bacterially produced yeast TFIID only from nucleosome-assembled templates. These data indicate that acidic activation domains stimulate transcription by enhancing the ability of basal transcription factors to compete with nucleosomes for occupancy of the promoter.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	WORKMAN, JL (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAZVI F, 1983, GENE, V23, P175, DOI 10.1016/0378-1119(83)90049-5; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4349; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SHURE M, 1976, CELL, V8, P215, DOI 10.1016/0092-8674(76)90005-2; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YANIV M, 1986, CRIT REV BIOCHEM MOL, V21, P1, DOI 10.3109/10409238609113607	66	213	213	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					533	544		10.1016/0092-8674(91)90237-S	http://dx.doi.org/10.1016/0092-8674(91)90237-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991320				2022-12-28	WOS:A1991EX36100009
J	KAGAN, ML; KEPLER, TB; EPSTEIN, IR				KAGAN, ML; KEPLER, TB; EPSTEIN, IR			GEOMETRIC PHASE-SHIFTS IN CHEMICAL OSCILLATORS	NATURE			English	Article							QUANTUM PHASE; SYSTEMS	ONE of the most remarkable developments in quantum mechanics in recent years has been the discovery that when a system is moved adiabatically around a closed loop in parameter space there occurs, besides the familiar dynamical phase shift, an additional phase shift (sometimes referred to as 'Berry's phase') that is purely geometric in nature 1-3. The dynamical phase shift, which results from the variation of the period of the oscillatory system with the change in parameters, is relatively easily understood and is proportional to the time over which the parameter change occurs. The geometric phase shift, on the other hand, is less intuitive and depends on the curvature of the surface in parameters space bounded by the closed path, but is independent of the time taken to traverse the circuit. Here we present evidence for time-independent geometric phase shifts in numerical solutions for a model of an oscillating chemical reaction. The conditions for the occurrence of such shifts seem to be sufficiently general that geometric phase effects should be experimentally observable in essentially all chemical oscillators as well as in biological networks such as the brain and the central nervous system, where phase control is of vital importance4.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University	KAGAN, ML (corresponding author), BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254, USA.			Kepler, Thomas/0000-0002-1383-6865				BASAR E, IN PRESS INDUCED RHY; BERRY M, 1988, SCI AM, V259, P46, DOI 10.1038/scientificamerican1288-46; BERRY MV, 1984, PROC R SOC LON SER-A, V392, P45, DOI 10.1098/rspa.1984.0023; BERRY MV, 1985, J PHYS A-MATH GEN, V18, P15, DOI 10.1088/0305-4470/18/1/012; BERRY MV, 1987, P ROY SOC LOND A MAT, V414, P31, DOI 10.1098/rspa.1987.0131; DEKEPPER P, 1982, J PHYS CHEM-US, V86, P170, DOI 10.1021/j100391a007; EPSTEIN IR, 1989, J CHEM EDUC, V66, P191, DOI 10.1021/ed066p191; Field R. J., 1985, OSCILLATIONS TRAVELI; HANNAY JH, 1985, J PHYS A-MATH GEN, V18, P221, DOI 10.1088/0305-4470/18/2/011; KEPLER TB, IN PRESS PHYS REV LE; LENGYEL I, 1990, J AM CHEM SOC, V112, P9104, DOI 10.1021/ja00181a011; MADDOX J, 1988, NATURE, V334, P99; PRIGOGIN.I, 1968, J CHEM PHYS, V48, P1695, DOI 10.1063/1.1668896; SHAPERE A, 1989, J FLUID MECH, V198, P557, DOI 10.1017/S002211208900025X; Shapere A., 1989, GEOMETRIC PHASES PHY; SIMON R, 1988, PHYS REV LETT, V61, P19, DOI 10.1103/PhysRevLett.61.19; SUTER D, 1988, PHYS REV LETT, V60, P1218, DOI 10.1103/PhysRevLett.60.1218; ZEE A, 1988, PHYS REV A, V38, P1, DOI 10.1103/PhysRevA.38.1	18	18	18	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					506	508		10.1038/349506a0	http://dx.doi.org/10.1038/349506a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992353				2022-12-28	WOS:A1991EW57100059
J	STECKELBERG, JM; MURPHY, JG; BALLARD, D; BAILEY, K; TAJIK, AJ; TALIERCIO, CP; GIULIANI, ER; WILSON, WR				STECKELBERG, JM; MURPHY, JG; BALLARD, D; BAILEY, K; TAJIK, AJ; TALIERCIO, CP; GIULIANI, ER; WILSON, WR			EMBOLI IN INFECTIVE ENDOCARDITIS - THE PROGNOSTIC VALUE OF ECHOCARDIOGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Article							DIMENSIONAL ECHOCARDIOGRAPHY; BACTERIAL-ENDOCARDITIS; VALVE-REPLACEMENT; VEGETATION SIZE	Objective: To determine whether vegetations visualized on two-dimensional echocardiography are an independent risk factor for the development of subsequent emboli in patients with infective endocarditis and to assess the timing of emboli relative to the initiation of antimicrobial therapy. Design: Investigator-blinded, retrospective incidence cohort study. Setting: Tertiary referral center. Patients: Patients with left-sided native valve infective endocarditis who had two-dimensional echocardiography within 72 hours of beginning antimicrobial therapy. Measurements and Main Results: The crude incidence rate of first embolic events in patients receiving antimicrobial therapy was 6.2 per 1000 patient-days (95% CI, 4.2 to 9.2). The rates in patients with and without vegetations were 7.1 and 4.9 per 1000 patient-days, respectively (incidence rate ratio, 1.4; 95% CI, 0.6 to 3.3). The relation between vegetations and risk for emboli was microorganism-dependent: Stratified incidence rate ratios were 6.9 (95% CI, 1.1 to 42.5; P < 0.05) and 1.0 (95% CI, 0.2 to 3.9) for viridans streptococcal and Staphylococcus aureus endocarditis, respectively. The rate of first embolic events diminished over time (P < 0.001), falling from 13 per 1000 patient-days during the first week of therapy to less than 1.2 per 1000 patient-days after completion of the second week of therapy. Conclusions: Overall, the presence of vegetations on echocardiography was not associated with a significantly higher risk for embolus in patients with left-sided native valve infective endocarditis. The relative risk for embolic events associated with echocardiographically visualized vegetations may be microorganism-dependent, with a significantly increased risk seen only in patients with viridans streptococcal infection. The rate of embolic events declines with time after initiation of antimicrobial treatment.			STECKELBERG, JM (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							BAIN RJI, 1987, J ANTIMICROB CHEMOTH, V20, P17, DOI 10.1093/jac/20.suppl_A.17; BRANDENBURG RO, 1983, J AM COLL CARDIOL, V1, P280, DOI 10.1016/S0735-1097(83)80029-1; BUDA AJ, 1986, AM HEART J, V112, P1291, DOI 10.1016/0002-8703(86)90362-5; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS RS, 1980, AM J MED, V69, P57, DOI 10.1016/0002-9343(80)90500-8; EGEBLAD H, 1979, EUR J CARDIOL, V10, P369; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LUTAS EM, 1986, AM HEART J, V112, P107, DOI 10.1016/0002-8703(86)90687-3; MANOLIS AS, 1988, ARCH INTERN MED, V148, P2461, DOI 10.1001/archinte.148.11.2461; MARTIN RP, 1980, AM J CARDIOL, V46, P379, DOI 10.1016/0002-9149(80)90004-1; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; OBRIEN JT, 1984, AM HEART J, V108, P386, DOI 10.1016/0002-8703(84)90630-6; Rothman K, 1986, MODERN EPIDEMIOLOGY; ROY P, 1976, CIRCULATION, V53, P474, DOI 10.1161/01.CIR.53.3.474; SCHOENBERG B S, 1983, Neuroepidemiology, V2, P257, DOI 10.1159/000110529; STEWART JA, 1980, CIRCULATION, V61, P374, DOI 10.1161/01.CIR.61.2.374; STULZ P, 1989, J CARDIOVASC SURG, V30, P20; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; WANN LS, 1979, CIRCULATION, V60, P728, DOI 10.1161/01.CIR.60.4.728	19	274	283	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					635	640		10.7326/0003-4819-114-8-635	http://dx.doi.org/10.7326/0003-4819-114-8-635			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003709				2022-12-28	WOS:A1991FG03100004
J	WILLIS, WD; KOPPE, JA				WILLIS, WD; KOPPE, JA			BRAIN BROWSER - HYPERCARD APPLICATION FOR THE MACINTOSH	SCIENCE			English	Software Review									UNIV TEXAS,MED BRANCH,INST MARINE BIOMED,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	WILLIS, WD (corresponding author), UNIV TEXAS,MED BRANCH,DEPT ANAT & NEUROSCI,GALVESTON,TX 77550, USA.							MACINTOSH HYPERCARD; BRAIN BROWSER	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1500	1502		10.1126/science.2006425	http://dx.doi.org/10.1126/science.2006425			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006425				2022-12-28	WOS:A1991FC85300052
J	POUW, EM; PRUMMEL, MF; OOSTING, H; ROOS, CM; ENDERT, E				POUW, EM; PRUMMEL, MF; OOSTING, H; ROOS, CM; ENDERT, E			BECLOMETHASONE INHALATION DECREASES SERUM OSTEOCALCIN CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article									UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam								BARNES PJ, 1989, NEW ENGL J MED, V321, P571; BROWN JP, 1984, LANCET, V1, P1091; CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem-60-4-736; PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem-72-2-382	5	130	130	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					627	628		10.1136/bmj.302.6777.627	http://dx.doi.org/10.1136/bmj.302.6777.627			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012877	Bronze, Green Published			2022-12-28	WOS:A1991FC07100023
J	WONG, ES; STOTKA, JL; CHINCHILLI, VM; WILLIAMS, DS; STUART, CG; MARKOWITZ, SM				WONG, ES; STOTKA, JL; CHINCHILLI, VM; WILLIAMS, DS; STUART, CG; MARKOWITZ, SM			ARE UNIVERSAL PRECAUTIONS EFFECTIVE IN REDUCING THE NUMBER OF OCCUPATIONAL EXPOSURES AMONG HEALTH-CARE WORKERS - A PROSPECTIVE-STUDY OF PHYSICIANS ON A MEDICAL-SERVICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NOSOCOMIAL INFECTIONS; RISK; HEPATITIS; HIV; PREVENTION; GUIDELINE; BLOOD; AIDS	Using a daily questionnaire, we prospectively studied 277 physicians from two hospital medical services for incidents of exposure to blood and body fluids and barrier use before and after the implementation of universal precautions. We found that implementation significantly increased the frequency of barrier use during exposure incidents from 54% before implementation to 73% after implementation of universal precautions. Implementation led to a decrease in the number of exposure incidents that resulted in direct contact with blood and body fluids (actual exposures), from 5.07 to 2.66 exposures per physician per patient care month, and to an increase in averted exposures in which direct contact was prevented by the use of barrier devices, from 3.41 exposures per patient care month before implementation to 5.90 exposures per patient care month after implementation. Implementation affected neither the types of body fluid or procedures involved nor the overall rate of exposure incidents (8.5 per patient care month) but, through an increase in barrier use, it did prevent direct contact with blood and body fluids and thus converted what would have been an actual exposure into an averted one. We conclude that universal precautions were effective in reducing the risk of occupational exposures among physicians on a medical service.	HUNTER HOLMES MCGUIRE DEPT VET AFFAIRS MED CTR,MED SERV,HOSP EPIDEMIOL UNIT,RICHMOND,VA 23249; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	WONG, ES (corresponding author), HUNTER HOLMES MCGUIRE DEPT VET AFFAIRS MED CTR,MED SERV,INFECT DIS SECT 111C,RICHMOND,VA 23249, USA.							BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; DOEBBELING BN, 1990, JAMA-J AM MED ASSOC, V264, P2083, DOI 10.1001/jama.264.16.2083; Francis D P, 1981, Semin Liver Dis, V1, P27, DOI 10.1055/s-2008-1063927; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HAGAN MD, 1989, ARCH INTERN MED, V149, P1541; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; HOOFNAGLE JH, 1979, ANN INTERN MED, V91, P813, DOI 10.7326/0003-4819-91-6-813; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; KUHLS TL, 1987, AM J PUBLIC HEALTH, V77, P1306, DOI 10.2105/AJPH.77.10.1306; LYNCH P, 1987, ANN INTERN MED, V107, P243, DOI 10.7326/0003-4819-107-2-243; LYNCH P, 1990, AM J INFECT CONTROL, V18, P1, DOI 10.1016/0196-6553(90)90204-6; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCEVOY M, 1987, BRIT MED J, V294, P1595, DOI 10.1136/bmj.294.6587.1595; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; PRENTICE RL, 1988, BIOMETRICS, V44, P1033, DOI 10.2307/2531733; SIMMONS BP, 1983, AM J INFECT CONTROL, V11, P183, DOI 10.1016/0196-6553(83)90079-2; WEISS SH, 1985, JAMA-J AM MED ASSOC, V254, P2089, DOI 10.1001/jama.254.15.2089; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; 1970, US DHEW PHS702054 PU; 1989, MMWR SS4, V38, P1; 1985, SAS USERS GUIDE BASI; 1987, MMWR S2S, V36, pS3; 1985, PROC IML VERSION 5	28	115	121	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1123	1128		10.1001/jama.265.9.1123	http://dx.doi.org/10.1001/jama.265.9.1123			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995997				2022-12-28	WOS:A1991EZ47400028
J	BOZZETTE, SA; LARSEN, RA; CHIU, J; LEAL, MAE; JACOBSEN, J; ROTHMAN, P; ROBINSON, P; GILBERT, G; MCCUTCHAN, JA; TILLES, J; LEEDOM, JM; RICHMAN, DD				BOZZETTE, SA; LARSEN, RA; CHIU, J; LEAL, MAE; JACOBSEN, J; ROTHMAN, P; ROBINSON, P; GILBERT, G; MCCUTCHAN, JA; TILLES, J; LEEDOM, JM; RICHMAN, DD			A PLACEBO-CONTROLLED TRIAL OF MAINTENANCE THERAPY WITH FLUCONAZOLE AFTER TREATMENT OF CRYPTOCOCCAL MENINGITIS IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY SYNDROME; CEREBROSPINAL-FLUID; ORAL FLUCONAZOLE; AMPHOTERICIN-B; INFECTIONS; PENETRATION; NEOFORMANS; TRIAZOLES; AIDS	Background and Methods. In patients with the acquired immunodeficiency syndrome (AIDS), the rate of relapse after primary treatment for cryptococcal meningitis remains high. We conducted a controlled, double-blind trial to evaluate the efficacy of maintenance therapy with fluconazole. At entry into the study, all participants had sterile cultures of cerebrospinal fluid, blood, and urine after following a standardized course of therapy for culture-proved cryptococcal meningitis. The patients were randomly assigned to take either fluconazole or placebo as maintenance therapy. The dose of fluconazole was 100 mg daily in the first phase of the study and 200 mg daily in the second phase. Results. Of 84 patients initially enrolled, 16 (19 percent) were found to have silent, persistent infection on the basis of cultures that became positive after entry into the study; 7 other patients were lost to follow-up shortly after entry. Of the remaining 61 patients, 10 of 27 assigned to placebo (37 percent) and 1 of 34 assigned to fluconazole (3 percent) had a recurrence of cryptococcal infection at any site (difference in risk, 34 percent; 95 percent confidence interval, 15 to 53). Of the 11 recurrent infections, 7 were detected in urine obtained after prostatic massage. There were four recurrent meningeal infections in the patients taking placebo, but none in those taking fluconazole (mean duration of follow-up, 164 days) (P = 0.03). In multivariate analyses, the best predictors of recurrence-free survival were fluconazole treatment (P = 0.02; relative hazard, 13.2), a lower serum cryptococcal-antigen titer (P = 0.05; relative hazard, 1.2), and more prolonged primary therapy with flucytosine (P = 0.09; relative hazard, 1.1). Survival and toxicity were similar in the two maintenance-treatment groups. Conclusions. In patients with AIDS, silent persistent infection is common after clinically successful treatment for cryptococcal meningitis. Maintenance therapy with fluconazole is highly effective in preventing recurrent cryptococcal infection.	LOS ANGELES CTY HOSP,DEPT MED,LOS ANGELES,CA; SHERMAN OAKS MED GRP,SHERMAN OAKS,CA; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103; PFIZER INC,CENT RES,GROTON,CT 06340; UNIV SO CALIF,DIV INFECT DIS,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90089; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717; LOS ANGELES CTY HOSP,DIV INFECT DIS,LOS ANGELES,CA	University of California System; University of California San Diego; University of California System; University of California San Diego; Pfizer; University of Southern California; University of Southern California; University of California System; University of California Irvine	BOZZETTE, SA (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,DIV INFECT DIS,BOX H208,225 DICKINSON ST,SAN DIEGO,CA 92103, USA.							ARNDT CAS, 1988, J INFECT DIS, V157, P178, DOI 10.1093/infdis/157.1.178; BOZZETTE SA, 1989, 5TH INT C AIDS MONTR, P356; BURR IW, 1974, APPLIED STATISTICAL, P226; BUTLER WT, 1964, NEW ENGL J MED, V270, P59, DOI 10.1056/NEJM196401092700201; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DEGANS J, 1988, BMJ-BRIT MED J, V296, P339, DOI 10.1136/bmj.296.6618.339; DIAMOND RD, 1974, ANN INTERN MED, V80, P176, DOI 10.7326/0003-4819-80-2-176; DISMUKES WE, 1987, NEW ENGL J MED, V317, P334, DOI 10.1056/NEJM198708063170602; DISMUKES WE, 1988, ANN INTERN MED, V109, P177, DOI 10.7326/0003-4819-109-3-177; DISMUKES WE, 1988, J INFECT DIS, V157, P624, DOI 10.1093/infdis/157.4.624; ENG RHK, 1986, AM J MED, V81, P19, DOI 10.1016/0002-9343(86)90176-2; KERKERING TM, 1981, ANN INTERN MED, V94, P611, DOI 10.7326/0003-4819-94-5-611; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LARSEN RA, 1989, ANN INTERN MED, V111, P125, DOI 10.7326/0003-4819-111-2-125; PERFECT JR, 1985, J ANTIMICROB CHEMOTH, V16, P81, DOI 10.1093/jac/16.1.81; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; STERN JJ, 1988, AM J MED, V85, P477, DOI 10.1016/S0002-9343(88)80081-0; SUGAR AM, 1988, AM J MED, V85, P481, DOI 10.1016/S0002-9343(88)80082-2; ZUGER A, 1988, ANN INTERN MED, V109, P592, DOI 10.7326/0003-4819-109-7-592; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	20	231	237	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 28	1991	324	9					580	584		10.1056/NEJM199102283240902	http://dx.doi.org/10.1056/NEJM199102283240902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY886	1992319				2022-12-28	WOS:A1991EY88600002
J	DINSMORE, JH; SOLOMON, F				DINSMORE, JH; SOLOMON, F			INHIBITION OF MAP2 EXPRESSION AFFECTS BOTH MORPHOLOGICAL AND CELL-DIVISION PHENOTYPES OF NEURONAL DIFFERENTIATION	CELL			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; EMBRYONAL CARCINOMA-CELLS; DEPENDENT PHOSPHORYLATION; MAMMALIAN NEURONS; TAU; RNA; INVITRO; LINE; DNA; IDENTIFICATION	Expression of the differentiated neuronal phenotype is typically manifest in several properties: distinct morphologies and organizations of the underlying cytoskeleton; appearance of specific macromolecules; and cessation of cell division. All of these properties are induced in undifferentiated embryonal carcinoma cells exposed to retinoic acid. We show here that the mRNA and protein for the microtubule component MAP2 is also induced by retinoic acid. Stable transfectants of undifferentiated cells, constitutively expressing MAP2 antisense RNA, show significantly reduced levels of MAP2 protein upon induction compared with controls. These cells do express other neuronal markers, but they do not undergo normal morphological differentiation nor do they withdraw from the cell cycle. The results suggest that MAP2 expression may be necessary for both neurite extension and cessation of cell division.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	DINSMORE, JH (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; DOTTI CG, 1987, NEUROSCIENCE, V23, P121, DOI 10.1016/0306-4522(87)90276-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HARRIS PJ, 1986, METHOD CELL BIOL, V27, P243, DOI 10.1016/S0091-679X(08)60352-0; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KIM S, 1987, J CELL BIOL, V104, P51, DOI 10.1083/jcb.104.1.51; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MONARD D, 1973, P NATL ACAD SCI USA, V70, P1894, DOI 10.1073/pnas.70.6.1894; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; Rudnicki M.A., 1987, TERATOCARCINOMAS EMB; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; SAMBROOK S, 1989, MOL CLONING; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; SLOBODA RD, 1979, BIOCHEMISTRY-US, V18, P48, DOI 10.1021/bi00568a008; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; TUCKER RP, 1988, J NEUROSCI, V8, P4503; WALLACE DM, 1987, METHOD ENZYMOL, V152, P33	54	197	202	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					817	826		10.1016/0092-8674(91)90510-6	http://dx.doi.org/10.1016/0092-8674(91)90510-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997209				2022-12-28	WOS:A1991EZ47800016
J	BUDRENE, EO; BERG, HC				BUDRENE, EO; BERG, HC			COMPLEX PATTERNS FORMED BY MOTILE CELLS OF ESCHERICHIA-COLI	NATURE			English	Article							CHEMOTAXIS; MIGRATION; MOVEMENT	WHEN chemotactic strains of the bacterium Escherichia coli are inoculated on semi-solid agar containing mixtures of amino acids or sugars, the cells swarm outwards in a series of concentric rings: they respond to spatial gradients of attractants generated by uptake and catabolism 1-3. Cells also drift up gradients generated artificially, for example by diffusion from the tip of a capillary tube 4 or by mixing 5. Here we describe conditions under which cells aggregate in response to gradients of attractant which they excrete themselves. When cells are grown in semi-solid agar on intermediates of the tricarboxylic acid cycle, they form symmetrical arrays of spots or stripes that arise sequentially. When cells in a thin layer of liquid culture are exposed to these compounds, spots appear synchronously, more randomly arrayed. In either case, the patterns are stationary. The attractant is a chemical sensed by the aspartate receptor. Its excretion can be triggered by oxidative stress. As oxygen is limiting at high cell densities, aggregation might serve as a mechanism for collective defence.	ROWLAND INST SCI INC,CAMBRIDGE,MA 02142		BUDRENE, EO (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; BERG HC, 1979, NATURE, V278, P349, DOI 10.1038/278349a0; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; BERG HC, 1990, COLD SPRING HARB SYM, V55, P539; DAHLQUIS.FW, 1972, NATURE-NEW BIOL, V236, P120, DOI 10.1038/newbio236120a0; GERHART J, 1989, TRENDS GENET, V5, P233, DOI 10.1016/0168-9525(89)90093-0; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; LOSICK R, 1984, MICROBIAL DEV; MACNAB RM, 1987, ESCHERICHIA COLI SAL, V1, P732; MESIBOV R, 1972, J BACTERIOL, V112, P315, DOI 10.1128/JB.112.1.315-326.1972; Miller J. H., 1972, EXPT MOL GENETICS, P431; NEIDHARDT FC, 1990, PHYSL BACTERIAL CELL, pCH7; NOSSAL R, 1972, EXP CELL RES, V75, P138, DOI 10.1016/0014-4827(72)90529-0; OSTER GF, 1989, J EXP ZOOL, V251, P186, DOI 10.1002/jez.1402510207; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; QU Y, 1989, P NATL ACAD SCI USA, V86, P8358; SHIMKETS LJ, 1982, J BACTERIOL, V152, P451; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973	22	426	430	3	60	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					630	633		10.1038/349630a0	http://dx.doi.org/10.1038/349630a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000137				2022-12-28	WOS:A1991EX57000066
J	NASMYTH, DG; PICKERSGILL, A; HOGARTH, M				NASMYTH, DG; PICKERSGILL, A; HOGARTH, M			REDUCING HOURS OF WORK OF PREREGISTRATION HOUSE OFFICERS - REPORT ON A SHIFT SYSTEM	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the advantages and disadvantages of a shift system of working compared with the conventional on call system for preregistration house officers. Design - A shift system of working was employed in the unit from 1 August 1989 to 31 July 1990. During attachments of three or six months four house officers rotated at intervals of one month among three daytime shifts and one night shift (Mondays to Fridays only). Weekends (48 hours) were worked on a one in three rota by the doctors working a day shift. The views of the house officers working this shift system were sought in writing and by direct interview. Setting - Professorial surgical unit, Royal Liverpool Hospital. Subjects - The 14 house officers who were attached to the unit for three or six months during their preregistration year. Results - The shift system was preferred to conventional on call without exception. The incidence of chronic tiredness was reduced and formal handover between shifts resulted in more informed decision making by doctors while on call. During annual leave it was sometimes necessary to revert to the conventional one in three on call system to ensure that daytime work was completed. Other disadvantages were the long weekend shift and an inequitable distribution of the night shift. The house officers recommended extending the shifts to weekends and working the night shift one week in four. Conclusion - A shift system of working was effective in reducing chronic tiredness among house officers, who found it preferable to conventional on call arrangements. Shift working is feasible only if the daytime duties of the doctor working at night can be completed by the other doctors on the rota.	ROYAL LIVERPOOL HOSP,PROFESSORIAL SURG UNIT,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital								LESLIE PJ, 1990, BRIT MED J, V300, P1038, DOI 10.1136/bmj.300.6731.1038	1	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					93	94		10.1136/bmj.302.6768.93	http://dx.doi.org/10.1136/bmj.302.6768.93			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995124	Bronze, Green Published			2022-12-28	WOS:A1991ER95100023
J	TAYLOR, DN; SANCHEZ, JL; CANDLER, W; THORNTON, S; MCQUEEN, C; ECHEVERRIA, P				TAYLOR, DN; SANCHEZ, JL; CANDLER, W; THORNTON, S; MCQUEEN, C; ECHEVERRIA, P			TREATMENT OF TRAVELERS DIARRHEA - CIPROFLOXACIN PLUS LOPERAMIDE COMPARED WITH CIPROFLOXACIN ALONE - A PLACEBO-CONTROLLED, RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; ADHERENCE; THERAPY	Objective: To compare the safety and efficacy of loperamide used in combination with ciprofloxacin or ciprofloxacin alone for the treatment of travelers' diarrhea. Design: Double-blind, placebo-controlled, randomized clinical trial. Setting: United States Army hospital in Egypt. Participants: United States military personnel with travelers' diarrhea (n = 104) during a military exercise in November 1989. Persons who were noncompliant, had bloody diarrhea, or had received antidiarrheal medications before entry into the study were excluded. Interventions: All participants with travelers' diarrhea were treated with ciprofloxacin, 500 mg twice daily for 3 days. Fifty of these patients were randomly assigned to receive loperamide, a 4-mg first dose and 2 mg for every loose stool (as much as 16 mg/d), and 54 were randomly assigned to receive placebo. Measurements: Enterotoxigenic Escherichia coli was isolated from 57% of patients; Shigella and Salmonella, seen in 4% and 2% of patients, respectively, were not common. Main Results: After 24 hours, the symptoms of 82% of patients in the ciprofloxacin and loperamide group compared with 67% in the ciprofloxacin and placebo group had improved or fully recovered (odds ratio, 2.3; 95% CI, 0.8 to 6.3; P = 0.08). After 48 hours, the symptoms of 90% of both groups had improved or fully recovered. The mean number of stools for those receiving loperamide was not much lower than those who did not receive loperamide after 24 hours (1.9 +/- 0.2 [SE] compared with 2.6 +/- 0.2) or 48 hours (3.1 +/- 0.3 compared with 4.0 +/- 0.3) of treatment (P = 0.19). Conclusions: In a region where enterotoxigenic E. coli was the predominant cause of travelers' diarrhea, loperamide combined with ciprofloxacin was not better than treatment with ciprofloxacin alone. Loperamide appeared to have some benefit in the first 24 hours of treatment in patients infected with enterotoxigenic E. coli. Both regimens were safe.	USN, RES UNIT 3, CAIRO, EGYPT; WALTER REED ARMY MED CTR, DIV PREVENT MED, DEPT FIELD STUDIES, WASHINGTON, DC 20307 USA; ARMED FORCES RES INST MED SCI, BANGKOK, THAILAND	Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	TAYLOR, DN (corresponding author), WALTER REED ARMY MED CTR, DIV COMMUN DIS & IMMUNOL, ENTER INFECT BRANCH, WASHINGTON, DC 20307 USA.							BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BLACK RE, 1990, REV INFECT DIS, V12, pS73; DUPONT HL, 1973, JAMA-J AM MED ASSOC, V226, P1525, DOI 10.1001/jama.226.13.1525; ERICSSON CD, 1990, JAMA-J AM MED ASSOC, V263, P257, DOI 10.1001/jama.263.2.257; ERICSSON CD, 1987, ANN INTERN MED, V106, P216, DOI 10.7326/0003-4819-106-2-216; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; GUANDALINI S, 1984, J PEDIATR GASTR NUTR, V3, P593, DOI 10.1097/00005176-198409000-00020; JOHNSON PC, 1986, JAMA-J AM MED ASSOC, V255, P757, DOI 10.1001/jama.255.6.757; NATARO JP, 1985, J INFECT DIS, V152, P560, DOI 10.1093/infdis/152.3.560; PICHLER HET, 1987, AM J MED, V82, P329; SCALETSKY ICA, 1984, INFECT IMMUN, V45, P534, DOI 10.1128/IAI.45.2.534-536.1984; STEELE TW, 1984, PATHOLOGY, V16, P263, DOI 10.3109/00313028409068535; STEFFEN R, 1988, TRAVEL MED INT, V6, P153; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; TAYLOR DN, 1986, J INFECT DIS, V153, P1132, DOI 10.1093/infdis/153.6.1132; SAS USERS GUIDE STAT, P529	16	101	102	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					731	734		10.7326/0003-4819-114-9-731	http://dx.doi.org/10.7326/0003-4819-114-9-731			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012354				2022-12-28	WOS:A1991FJ11700004
J	SCHWARTZ, WB; MENDELSON, DN				SCHWARTZ, WB; MENDELSON, DN			HOSPITAL COST CONTAINMENT IN THE 1980S - HARD LESSONS LEARNED AND PROSPECTS FOR THE 1990S	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. A key strategy used to contain hospital costs during the 1980s was to reduce the total number of admissions and average lengths of stay. We assessed the magnitude of the savings achieved, the effect of the reductions on the rate of increase in costs, and the prospects for future savings through reductions in the number of days patients spend in the hospital (inpatient days). Methods. Using data from the American Hospital Association and the Health Care Financing Administration, we calculated the savings in the total number of inpatient days as the deviation from the historical increase in the number of inpatient days per year. We then estimated the real increase in costs that would have been observed if the reduction in the number of inpatient days had not occurred; we defined this value as the "underlying" rate of increase in costs. Finally, we compared the rates of increase in hospital reimbursement for Medicare beneficiaries and patients not covered by Medicare (non-Medicare patients). Results. The total number of inpatient days per year decreased by 28 percent, in aggregate, between 1981 and 1988. The annual reduction was greatest in 1984 and 1985 and became progressively smaller in each subsequent year; by 1988 there was virtually no further reduction in the total number of inpatient days. The brief slowing of the increase in costs in the mid-1980s can be attributed entirely to the reduction in the number of inpatient days per year. The underlying rate of increase in costs was thus unaffected by efforts to contain spending. An increased number of outpatient visits partially offset the savings that resulted from the reduction in the number of inpatient days. This increase persisted even when the savings due to the lower number of inpatient days dwindled, and it virtually eliminated any dollar savings during the latter part of the 1980s. Between 1976 and 1982, Medicare spending on services provided by acute care hospitals rose by 9.2 percent per year in real terms, whereas non-Medicare expenditures rose by only 4.6 percent. This pattern has been reversed in recent years; in 1987-1988, Medicare spending rose by only 0.6 percent per year, whereas non-Medicare spending rose by 9 percent. Conclusions. Our findings suggest that the era of easy reductions in the number of inpatient days, with the associated attenuation of rising costs, is largely over. If further reductions in inpatient days are accompanied by an increase in the amount of ambulatory care similar to that during the past few years, the net savings will probably be negligible. Once the potential savings due to reductions in the number of inappropriate inpatient days has been exhausted, real hospital costs can be expected to rise, unless other effective measures to contain costs are implemented.			SCHWARTZ, WB (corresponding author), TUFTS UNIV,SCH MED,DEPT MED,136 HARRISON AVE,BOSTON,MA 02111, USA.							PAULY MV, 1986, HEALTH SERV RES, V21, P403; 1990, EC REPORT PRESIDENT, P298; 1990, HLTH CARE FINANC REV, V11, P20; 1986, ANN MEDICARE PROGRAM; 1976, HOSPITAL STATISTICS; 1990, HLTH CARE FINANC REV, V11, P33	6	113	113	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1037	1042		10.1056/NEJM199104113241506	http://dx.doi.org/10.1056/NEJM199104113241506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	2005941	Bronze			2022-12-28	WOS:A1991FF77100006
J	VAN, R; WUN, CC; MORROW, AL; PICKERING, LK				VAN, R; WUN, CC; MORROW, AL; PICKERING, LK			THE EFFECT OF DIAPER TYPE AND OVERCLOTHING ON FECAL CONTAMINATION IN DAY-CARE-CENTERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIARRHEAL ILLNESS; ROTAVIRUS; TODDLERS; INFANTS; GIARDIA; STOOL	Fecal coliform contamination of environmental surfaces and hands in the daycare center is common. This study evaluated the effect of two diaper types on fecal contamination. Ten rooms in four day-care centers containing 141 children were studied in a prospective, randomized, crossover study. A total of 2946 samples were cultured during the 9-week study. Fecal coliforms were isolated from 307 inanimate objects (15%), 73 toy balls (46%), and 131 hands (17%). The number of contaminated inanimate objects was significantly less in rooms where paper diapers were worn when compared with that in rooms where double cloth diapers with plastic overpants were worn and in rooms where clothes were worn over diapers. Inanimate object cultures had more contamination in rooms in which diarrhea had occurred. Containment of feces by overclothes and diaper type may be important in decreasing transmission of enteric pathogens in day-care environments.	UNIV TEXAS,SCH MED,DEPT PEDIAT,DIV INFECT DIS,6431 FANNIN ST,ROOM 1739,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,SCH PUBL HLTH,HOUSTON,TX 77225	Baylor College of Medicine; University of Texas System; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health								BARTLETT AV, 1985, J PEDIATR-US, V107, P495, DOI 10.1016/S0022-3476(85)80004-4; BARTLETT AV, 1988, AM J EPIDEMIOL, V127, P808, DOI 10.1093/oxfordjournals.aje.a114863; BLACK RE, 1981, AM J EPIDEMIOL, V113, P445, DOI 10.1093/oxfordjournals.aje.a113112; EKANEM EE, 1983, AM J EPIDEMIOL, V118, P562, DOI 10.1093/oxfordjournals.aje.a113661; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P220; KADO CI, 1981, J BACTERIOL, V145, P1365, DOI 10.1128/JB.145.3.1365-1373.1981; KNISLEY CV, 1989, AM J CLIN PATHOL, V91, P704, DOI 10.1093/ajcp/91.6.704; KNISLEY CV, 1986, J CLIN MICROBIOL, V23, P897, DOI 10.1128/JCM.23.5.897-900.1986; KOSHLAND DE, 1990, SCIENCE, V249, P1481, DOI 10.1126/science.2218484; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; ORYAN M, 1990, SEMIN PEDIATR INFECT, V1, P252; PICKERING LK, 1981, J PEDIATR-US, V99, P51, DOI 10.1016/S0022-3476(81)80956-0; PICKERING LK, 1990, SEMIN PEDIATR INFECT, V1, P263; PRIMOMO J, 1990, AM J PUBLIC HEALTH, V80, P743; REVES RR, 1987, J INFECT DIS, V156, P758, DOI 10.1093/infdis/156.5.758; REVES RR, 1990, ANTIMICROB AGENTS CH, V34, P1429, DOI 10.1128/AAC.34.7.1429; VAN R, 1991, AM J EPIDEMIOL, V133, P460, DOI 10.1093/oxfordjournals.aje.a115913; WENIGER BG, 1983, APPL ENVIRON MICROB, V45, P733, DOI 10.1128/AEM.45.2.733-735.1983; 1984, GUIDELINES DRINKING, V2	19	38	38	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1840	1844		10.1001/jama.265.14.1840	http://dx.doi.org/10.1001/jama.265.14.1840			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005734				2022-12-28	WOS:A1991FE86200024
J	PRITCHETT, ELC; MCCARTHY, EA; WILKINSON, WE				PRITCHETT, ELC; MCCARTHY, EA; WILKINSON, WE			PROPAFENONE TREATMENT OF SYMPTOMATIC PAROXYSMAL SUPRAVENTRICULAR ARRHYTHMIAS - A RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL IN PATIENTS TOLERATING ORAL-THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article							PARKINSON-WHITE SYNDROME; TERM FOLLOW-UP; ATRIAL-FIBRILLATION; LONG-TERM; ELECTROPHYSIOLOGIC FINDINGS; DOUBLE-BLIND; TACHYCARDIA; PREVENTION; EFFICACY	Objective: To test the hypothesis that propafenone, administered orally, prevents symptomatic paroxysmal supraventricular arrhythmias. Design: A 6-month, open-label, dose-finding phase followed by a randomized, double-blind, placebo-controlled, crossover phase, with each treatment period lasting up to 60 days. Setting: An outpatient clinic. Patients: Thirty-three patients with either paroxysmal supraventricular tachycardia (n = 16) or paroxysmal atrial fibrillation (n = 17) were enrolled. Their arrhythmias were documented by electrocardiogram before enrollment. Twenty-three patients (14 with paroxysmal supraventricular tachycardia and 9 with paroxysmal atrial fibrillation) were randomized and the data obtained from these patients were used in the efficacy analysis. Intervention: Propafenone (300 mg three times daily in 19 patients, 300 mg twice daily in 3 patients, and 150 mg twice daily in 1 patient) and matching placebo tablets were administered in a randomized sequence. Measurements: Symptomatic arrhythmia was documented by telephone transmission of the electrocardiogram. Main Results: The time to first recurrence was prolonged for the overall group of 23 patients while they received propafenone (P = 0.004). The recurrence rate of arrhythmia during treatment with propafenone was estimated to be approximately one fifth of the recurrence rate during treatment with placebo. Conclusions: Propafenone is effective in reducing symptomatic paroxysmal supraventricular arrhythmias.			PRITCHETT, ELC (corresponding author), DUKE UNIV, MED CTR, DURHAM, NC 27710 USA.				NCRR NIH HHS [M01 RR30] Funding Source: Medline; NHLBI NIH HHS [R01 HL40392] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040392] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN BJ, 1988, CHEST, V94, P853, DOI 10.1378/chest.94.4.853; ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; ANTMAN EM, 1988, J AM COLL CARDIOL, V12, P1005, DOI 10.1016/0735-1097(88)90468-8; BREITHARDT G, 1984, AM J CARDIOL, V54, pD29, DOI 10.1016/S0002-9149(84)80283-0; CONNOLLY SJ, 1989, AM J CARDIOL, V63, P817, DOI 10.1016/0002-9149(89)90049-0; CONOVER W. J, 1980, PRACTICAL NONPARAMET; FUNCKBRENTANO C, 1990, NEW ENGL J MED, V322, P518; HAMMILL SC, 1988, AM J CARDIOL, V61, P473, DOI 10.1016/0002-9149(88)90312-8; HARAPAT SR, 1982, J CHROMATOGR, V230, P448, DOI 10.1016/S0378-4347(00)80498-3; HENTHORN RW, 1991, CIRCULATION, V83, P119, DOI 10.1161/01.CIR.83.1.119; HOLT JD, 1974, BIOMETRIKA, V61, P17, DOI 10.1093/biomet/61.1.17; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERR CR, 1988, AM J CARDIOL, V61, P914, DOI 10.1016/0002-9149(88)90373-6; LUDMER PL, 1987, J AM COLL CARDIOL, V9, P1357, DOI 10.1016/S0735-1097(87)80478-3; MAURITSON DR, 1982, ANN INTERN MED, V96, P409, DOI 10.7326/0003-4819-96-4-409; MIDTBO K, 1981, CURR THER RES CLIN E, V30, P372; OBRIEN PC, 1987, BIOMETRICS, V43, P169, DOI 10.2307/2531957; PRITCHETT ELC, 1988, J CLIN EPIDEMIOL, V41, P851, DOI 10.1016/0895-4356(88)90101-1; PRITCHETT ELC, 1984, CIRCULATION, V70, P1, DOI 10.1161/01.CIR.70.1.1; PRITCHETT ELC, 1983, AM J CARDIOL, V52, P1007, DOI 10.1016/0002-9149(83)90521-0; WEINER HL, 1990, J AM COLL CARDIOL A, V193	21	111	111	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					539	544		10.7326/0003-4819-114-7-539	http://dx.doi.org/10.7326/0003-4819-114-7-539			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001087				2022-12-28	WOS:A1991FD66100003
J	ANDERSON, RM; GUPTA, S; MAY, RM				ANDERSON, RM; GUPTA, S; MAY, RM			POTENTIAL OF COMMUNITY-WIDE CHEMOTHERAPY OR IMMUNOTHERAPY TO CONTROL THE SPREAD OF HIV-1	NATURE			English	Article							PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; AZIDOTHYMIDINE AZT; ZIDOVUDINE AZT; DOUBLE-BLIND; INFECTION	WHETHER zidovudine (3'-azido-3'-deoxythymidine, AZT) should be offered to symptomless individuals infected with human immunodeficiency virus type-1 (HIV-1), in the hope of delaying or even preventing progression to AIDS, has been much debated 1. The discussion has focused on the efficacy of the drug in delaying progression to disease 2, the severity of its side-effects 3, and the likelihood of its prolonged and widespread use resulting in zidovudine-resistant strains of the virus 4. Little attention has been given to the degree to which treatment reduces the infectiousness of symptomless patients, and to the concomitant implications for the overall transmission rate of HIV-1 in the community. Here we use simple mathematical models to show that community treatment with antiviral drugs or immunotherapies that lengthen the incubation period of AIDS without significantly reducing the infectiousness of treated individuals, can increase the rate at which HIV-1 infection spreads (which is fairly obvious) and can even, under certain circumstances, increase the AIDS-related death rate in the community (which is less obvious).			ANDERSON, RM (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOL,LONDON SW7 2BB,ENGLAND.			Anderson, Roy/0000-0002-9528-3175				ANDERSON R M, 1986, IMA Journal of Mathematics Applied in Medicine and Biology, V3, P229; ANDERSON RM, 1988, J ROY STAT SOC A STA, V151, P66, DOI 10.2307/2982185; ANDERSON RM, 1990, J ACQ IMMUN DEF SYND, V3, P417; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; CAPON DJ, 1989, NATURE, V337, P325; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LAURIAN Y, 1989, NEW ENGL J MED, V320, P183; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; MCLEAN AR, IN PRESS J MATH BIOL; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; RATNER L, 1989, AIDS RES HUM RETROV, V5, P115, DOI 10.1089/aid.1989.5.115; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1989, LANCET, V1, P415	18	95	95	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					356	359		10.1038/350356a0	http://dx.doi.org/10.1038/350356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008214				2022-12-28	WOS:A1991FD83800098
J	DANIS, M; SOUTHERLAND, LI; GARRETT, JM; SMITH, JL; HIELEMA, F; PICKARD, CG; EGNER, DM; PATRICK, DL				DANIS, M; SOUTHERLAND, LI; GARRETT, JM; SMITH, JL; HIELEMA, F; PICKARD, CG; EGNER, DM; PATRICK, DL			A PROSPECTIVE-STUDY OF ADVANCE DIRECTIVES FOR LIFE-SUSTAINING CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The use of advance directives is recommended so that people can determine the medical care they will receive when they are no longer competent, but the effectiveness of such directives is not clear. Methods. In a prospective study conducted over a two-year period, 126 competent residents of a nursing home and 49 family members of incompetent patients were interviewed to determine their preferences with respect to hospitalization, intensive care, cardiopulmonary resuscitation, artificial ventilation, surgery, and tube feeding in the event of critical illness, terminal illness, or permanent unconsciousness. Advance directives, consisting of signed statements of treatment preferences, were placed in the medical record to assist in care in the nursing home and to be forwarded to the hospital if necessary. Results. In an analysis of 96 outcome events (hospitalization or death in the nursing home), care was consistent with previously expressed wishes 75 percent of the time; however, the presence of the written advance directive in the medical record did not facilitate consistency. Among the 24 events in which inconsistencies occurred, care was provided more aggressively than had been requested in 6 cases, largely because of unanticipated surgery or artificial ventilation, and less aggressively than requested in 18, largely because hospitalization or cardiopulmonary resuscitation was withheld. Inconsistencies were more likely in the nursing home than in the hospital. Conclusions. The effectiveness of written advance directives is limited by inattention to them and by decisions to place priority on considerations other than the patient's autonomy. Since our study was performed in only one nursing home and one hospital, other studies are necessary to determine the generalizability of our findings.	UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	DANIS, M (corresponding author), UNIV N CAROLINA,DEPT MED,DIV GEN MED & CLIN EPIDEMIOL,CAMPUS BOX 7110,5025A OLD CLIN BLDG,CHAPEL HILL,NC 27599, USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492				BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; EISENDRATH SJ, 1983, JAMA-J AM MED ASSOC, V249, P2054, DOI 10.1001/jama.249.15.2054; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; HACKLER C, 1989, ADV DIRECTIVES MED S; JONSEN AR, 1982, CLIN ETHICS; KUTNER L, 1969, INDIANA LAW J, V44, P537; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; REDLEAF DL, 1979, STANFORD LAW REV, V31, P913, DOI 10.2307/1228530; 1982, SUDOC198203835158763; 1987, GUIDELINES TERMINATI; 1983, AM J PUBLIC HEALTH, V73, P918	12	387	389	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					882	888		10.1056/NEJM199103283241304	http://dx.doi.org/10.1056/NEJM199103283241304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000110				2022-12-28	WOS:A1991FD11100004
J	SCHMIEDER, RE; ROCKSTROH, JK; MESSERLI, FH				SCHMIEDER, RE; ROCKSTROH, JK; MESSERLI, FH			ANTIHYPERTENSIVE THERAPY - TO STOP OR NOT TO STOP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LEFT-VENTRICULAR HYPERTROPHY; BLOOD-PRESSURE; SYSTEMIC HYPERTENSION; BORDERLINE HYPERTENSION; MILD HYPERTENSION; LONG-TERM; CONTROLLED TRIAL; TIME COURSE; WITHDRAWAL; REGRESSION	The benefits of continuous antihypertensive therapy have been extensively documented. However, lack of compliance with the prescribed regimen, excessive cost, and troublesome adverse effects of some antihypertensive agents led to the consideration of intermittent therapy or even complete discontinuation of therapy as an effective alternative to lifelong medication. Prospective studies dealing with this subject reported inconsistent results. Nevertheless, they allowed us to identify selection criteria of candidates for step-down or discontinuation of antihypertensive therapy. Such candidates include patients with mild essential hypertension who have one or more of the following characteristics: young age, normal body weight, low salt intake, no alcohol consumption, low pretreatment blood pressure, successful therapy with one drug only, and no or only minimal signs of target organ damage. Stopping antihypertensive therapy without subsequent rise in arterial pressure was shown to be possible in a subset of patients with mild essential hypertension for a period of months to years. This approach appears to be safe, provided that blood pressure is monitored frequently, and may improve compliance, save treatment costs, and reduce adverse effects of certain drugs, although its long-term consequences for morbidity and mortality remain to be determined.	ALTON OCHSNER MED FDN & OCHSNER CLIN, NEW ORLEANS, LA 70121 USA; ALTON OCHSNER MED FDN & OCHSNER CLIN, DEPT INTERNAL MED, HYPERTEN DIS SECT, NEW ORLEANS, LA 70121 USA	Ochsner Health System; Ochsner Health System	SCHMIEDER, RE (corresponding author), UNIV ERLANGEN NURNBERG, DEPT MED, KONTUMAZGARTEN 14-18, W-8500 NURNBERG, GERMANY.		Messerli, Franz/AAR-4783-2021					ADAMS MA, 1989, J HYPERTENS, V7, pS351; ALDERMAN MH, 1986, ARCH INTERN MED, V146, P1309, DOI 10.1001/archinte.146.7.1309; ALDERMAN MH, 1984, INT SOC HYPERTENSION, P87; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1982, Lancet, V1, P185; ASMAR RG, 1988, CIRCULATION, V78, P941, DOI 10.1161/01.CIR.78.4.941; BAHR M, 1989, MED WELT, V40, P1336; BECKENRIDGE A, 1983, HYPERTENSION S3, V5, P85; BLAUFOX MD, 1984, J HYPERTENS       S3, V2, P179; BOYLE RM, 1979, J ROY COLL PHYS LOND, V13, P172; CHRISTENSEN KL, 1989, J HYPERTENS, V7, P83; CRUICKSHANK JM, 1987, J HUM HYPERTENS, V1, P73; DUNN FG, 1987, CIRCULATION, V76, P254, DOI 10.1161/01.CIR.76.2.254; DUSTAN HP, 1968, CIRCULATION, V37, P370, DOI 10.1161/01.CIR.37.3.370; FERNANDEZ PG, 1983, CURR MED RES OPIN, V8, P509, DOI 10.1185/03007998309109790; FINNERTY FA, 1984, AM J CARDIOL, V53, P1304, DOI 10.1016/0002-9149(84)90084-5; FLETCHER AE, 1988, J HYPERTENS, V6, P431, DOI 10.1097/00004872-198806000-00001; FOLKOW B, 1978, CLIN SCI MOL MED, V55, pS3, DOI 10.1042/cs055003s; FOLKOW B, 1958, ACTA PHYSIOL SCAND, V44, P255, DOI 10.1111/j.1748-1716.1958.tb01626.x; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; FREIS ED, 1960, PHYSIOL REV, V40, P27, DOI 10.1152/physrev.1960.40.1.27; FREIS ED, 1989, AM J CARDIOL, V63, P702, DOI 10.1016/0002-9149(89)90255-5; FREWIN DB, 1977, MED J AUSTRALIA, V1, P659, DOI 10.5694/j.1326-5377.1977.tb130994.x; FROHLICH ED, 1982, FED PROC, V41, P2400; FROHLICH ED, 1970, CIRC RES, V27, pI55; GARAVAGLIA GE, 1988, AM J HYPERTENS, V1, pS214, DOI 10.1093/ajh/1.3.214S; GARBUS SB, 1979, J CLIN PHARMACOL, V19, P476, DOI 10.1002/j.1552-4604.1979.tb02510.x; GREENBERG G, 1986, BRIT MED J, V293, P988; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GRIMM RH, 1981, ANN INTERN MED, V94, P7, DOI 10.7326/0003-4819-94-1-7; HANSEN AG, 1983, ACTA MED SCAND, P178; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; HOLLIFIELD JW, 1984, AM J MED, V77, P28, DOI 10.1016/S0002-9343(84)80005-4; HORWITZ D, 1967, CLIN PHARMACOL THER, V8, P224; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; INOUYE I, 1984, AM J CARDIOL, V53, P120, DOI 10.1016/0002-9149(84)90695-7; Jennings G, 1984, J HYPERTENS       S3, V2, P217; JULIUS S, 1974, ACTA PHYSIOL LAT AM, V24, P425; JULIUS S, 1971, CIRCULATION, V43, P382, DOI 10.1161/01.CIR.43.3.382; KANNEL WB, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90111-0; KANNEL WB, 1988, CIRCULATION S2, V78, P89; KEYS A, 1971, ARCH INTERN MED, V128, P201, DOI [10.1001/archinte.128.2.201, 10.1001/archinte.1971.00310200037002]; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KORNER PI, 1989, J HYPERTENS, V7, pS125; LANGFORD HG, 1982, HYPERTENSION, V4, P166; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; LANGFORD HG, 1984, T AM CLIN CLIMAT ASS, V96, P111; LEVINSON PD, 1982, ARCH INTERN MED, V142, P2265, DOI 10.1001/archinte.142.13.2265; MACMAHON SW, 1986, J HYPERTENS, V4, pS14; MALAND LJ, 1983, HYPERTENSION, V5, P539, DOI 10.1161/01.HYP.5.4.539; MANCIA G, 1983, HYPERTENSION, V5, P5; MESSERLI FH, 1981, CIRCULATION, V64, P760, DOI 10.1161/01.CIR.64.4.760; MESSERLI FH, 1978, CIRCULATION, V58, P441, DOI 10.1161/01.CIR.58.3.441; PAGE IH, 1962, CIRCULATION, V25, P433, DOI 10.1161/01.CIR.25.3.433; PERERA LGA, 1955, J CHRON DIS, V1, P33; PERRY HM, 1966, CIRCULATION, V33, P958, DOI 10.1161/01.CIR.33.6.958; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; SCHMIEDER RE, 1989, AM J MED, V87, P22; SCHMIEDER RE, 1987, CIRCULATION, V75, P1030, DOI 10.1161/01.CIR.75.5.1030; SCHMIEDER RE, 1987, AM J MED, V82, P11, DOI 10.1016/0002-9343(87)90370-6; SCHMIEDER RE, 1985, J HYPERTENS, V3, pS457; SCOTT JN, 1976, BRIT MED J, V2, P367, DOI 10.1136/bmj.2.6031.367-b; SEN S, 1983, AM J PHYSIOL, V244, pH97, DOI 10.1152/ajpheart.1983.244.1.H97; SHAPER AG, 1988, J HUM HYPERTENS, V2, P71; SMITH VE, 1987, HEART HYPERTENSION, P143; SPECH MM, 1980, HYPERTENSION, V2, P75, DOI 10.1161/01.HYP.2.1.75; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STAMLER R, 1984, J HYPERTENSION S3, V2, P167; TANAKA S, 1978, JPN HEART J, V19, P66; TARAZI RC, 1983, AM J MED, V75, P80, DOI 10.1016/0002-9343(83)90123-7; THURM RH, 1967, J AMER MED ASSOC, V201, P301, DOI 10.1001/jama.1967.03130050035010; TRIMARCO B, 1988, AM J CARDIOL, V62, P745, DOI 10.1016/0002-9149(88)91215-5; TRIMARCO B, 1984, HYPERTENSION, V6, P150; TRIMARCO B, 1988, CIRCULATION S2, V78, P64; TUBAU JF, 1986, J AM COLL CARDIOL, V7, pA112; ZANCHETTI A, 1984, AM J MED, V76, P1, DOI 10.1016/0002-9343(84)90951-3; 1975, CIRCULATION, V51, P1107	80	22	23	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1566	1571		10.1001/jama.265.12.1566	http://dx.doi.org/10.1001/jama.265.12.1566			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999906				2022-12-28	WOS:A1991FC60400033
J	BEAL, PA; DERVAN, PB				BEAL, PA; DERVAN, PB			2ND STRUCTURAL MOTIF FOR RECOGNITION OF DNA BY OLIGONUCLEOTIDE-DIRECTED TRIPLE-HELIX FORMATION	SCIENCE			English	Article							SEQUENCE-SPECIFIC CLEAVAGE; STRANDED-DNA; DUPLEX DNA; BINDING; SITE; INHIBITION; GUANINE	Relative orientations of the DNA strands within a purine.purine.pyrimidine triple helix have been determined by affinity cleaving. A purine-rich oligonucleotide bound in the major groove of double-helical DNA antiparallel to the Watson-Crick purine strand. Binding depended upon the concentration of multivalent cations such as spermine or Mg2+, and appeared to be relatively independent of pH. Two models with specific hydrogen-bonding patterns for base triplets (G.GC, A.AT, and T.AT) are proposed to explain the sequence specificity of binding. The two models differ in the conformation about the glycosyl bond (syn or anti) and the location of the phosphate-deoxyribose backbone in the major groove of DNA. This motif broadens the structural frameworks available as a basis for the design of sequence-specific DNA binding molecules.	CALTECH,DIV CHEM & CHEM ENGN,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125	California Institute of Technology								BROITMAN SL, 1987, P NATL ACAD SCI USA, V85, P3781; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P192; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DERVAN PB, UNPUB; DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1989, J BIOL CHEM, V264, P5891; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; IVERSON BL, 1987, NUCLEIC ACIDS RES, V15, P7823, DOI 10.1093/nar/15.19.7823; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P7749; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MARK C, 1978, NUCLEIC ACIDS RES, V5, P1017; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJOGOPAL P, 1989, NATURE, V339, P637; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P119; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1989, J AM CHEM SOC, V111, P7286, DOI 10.1021/ja00200a073; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUN JS, 1989, P NATL ACAD SCI USA, V86, P8198; WILLIAMS NG, 1989, J AM CHEM SOC, V111, P7205, DOI 10.1021/ja00200a046	28	586	732	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1360	1363		10.1126/science.2003222	http://dx.doi.org/10.1126/science.2003222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003222				2022-12-28	WOS:A1991FB73300045
J	RUOSLAHTI, E; YAMAGUCHI, Y				RUOSLAHTI, E; YAMAGUCHI, Y			PROTEOGLYCANS AS MODULATORS OF GROWTH-FACTOR ACTIVITIES	CELL			English	Review							SEQUENCE; SYNDECAN; HEPARIN				RUOSLAHTI, E (corresponding author), LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; PERIN JP, 1988, BIOCHEM J, V255, P1007, DOI 10.1042/bj2551007; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	19	1291	1329	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					867	869		10.1016/0092-8674(91)90308-L	http://dx.doi.org/10.1016/0092-8674(91)90308-L			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001586				2022-12-28	WOS:A1991FA94000001
J	VLAHOV, D; BREWER, TF; CASTRO, KG; NARKUNAS, JP; SALIVE, ME; ULLRICH, J; MUNOZ, A				VLAHOV, D; BREWER, TF; CASTRO, KG; NARKUNAS, JP; SALIVE, ME; ULLRICH, J; MUNOZ, A			PREVALENCE OF ANTIBODY TO HIV-1 AMONG ENTRANTS TO UNITED-STATES CORRECTIONAL FACILITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRISON; INFECTION; INMATES; AIDS	Prevalence of antibody to the human immunodeficiency virus type 1 (HIV-1) was assessed among 10 994 consecutive male and female entrants to 10 correctional systems in the United States. The HIV-1 seroprevalence for the 10 systems ranged from 2.1% to 7.6% for men and 2.5% to 14.7% for women; seroprevalence among women was higher than among men across nine of 10 systems. Using age 25 years to divide the population, HIV-1 prevalence among young women (5.2%) was significantly higher than among young men (2.3%), but similar to that in both older women (5.3%) and older men (5.6%). Overall, HIV-1 rates for nonwhites (4.8%) were higher than those for whites (2.5%). Although categories were identified across correctional systems, which may serve to focus prevention programs, variability in rates among correctional systems indicates that program planning must take local conditions into consideration.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Johns Hopkins University; Centers for Disease Control & Prevention - USA	VLAHOV, D (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,ROOM 763,624 N BROADWAY,BALTIMORE,MD 21205, USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				BARTON WI, 1980, INT J ADDICT, V15, P233, DOI 10.3109/10826088009040011; Breslow N, 1980, STATISTICAL METHODS, V32; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; FRIEDMAN SR, 1987, MILBANK Q, V65, P455, DOI 10.2307/3349999; HAMMETT TM, 1990, UPDATE 1989 AIDS COR; HARDING TW, 1987, LANCET, V2, P1260; HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209; JARLAIS DCD, 1988, PSYCHOL NEUROPSYCHIA, P159; KELLEY PW, 1986, JAMA-J AM MED ASSOC, V256, P2198, DOI 10.1001/jama.1986.03380160056015; NOONE S, 1988, 4 INT C AIDS STOCKH; SALIVE ME, 1990, AM J PUBLIC HEALTH, V80, P1479, DOI 10.2105/AJPH.80.12.1479; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; TRUMAN BI, 1988, 4 INT C AIDS STOCKH; Vlahov D., 1988, AIDS and Public Policy Journal, V3, P42; VLAHOV D, 1989, J ACQ IMMUN DEF SYND, V2, P283; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, FED REG         0810, V52, P29569; 1988, NCJ103957 US DEP JUS; 1987, MMWR, V36, pS6; 1989, MMWR, V38, pS4; 1989, CDC WEEKLY, V2, P7; 1989, AIDS SURVEILLANCE MO; 1989, MMWR, V38, P1; 1986, ACQUIRED IMMUNODEFIC; 1987, MMWR, V36, P157	25	108	110	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1129	1132		10.1001/jama.265.9.1129	http://dx.doi.org/10.1001/jama.265.9.1129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EZ474	1995998				2022-12-28	WOS:A1991EZ47400029
J	HANKEY, GJ; SLATTERY, JM; WARLOW, CP				HANKEY, GJ; SLATTERY, JM; WARLOW, CP			PROGNOSIS AND PROGNOSTIC FACTORS OF RETINAL INFARCTION - A PROSPECTIVE COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY-STROKE-PROJECT; CAROTID-ARTERY DISEASE; AMAUROSIS FUGAX; YOUNG-ADULTS; OCCLUSION; OBSTRUCTION; PATIENT; RISK	Objective - To determine the prognosis and adverse prognostic factors in patients with retinal infarction due to presumed atheromatous thromboembolism or cardiogenic embolism. Design - Prospective cohort study. Setting - University hospital departments of clinical neurology. Patients - 99 patients with retinal infarction, without prior stroke, referred to a single neurologist between 1976 and 1986 and evaluated and followed up prospectively until death or the end of 1986 (mean follow up 4.2 years). Interventions - Cerebral angiography (55 patients), aspirin treatment (37), oral anticoagulant treatment (eight), carotid endarterectomy (13), cardiac surgery (six), and peripheral vascular surgery (two). Main outcome measures - Death, stroke, coronary events, contralateral retinal infarction; survival analysis confined to 98 patients with retinal infarction due to presumed atheromatous thromboembolism or cardiogenic embolism (one patient with giant cell arteritis excluded), and Cox's proportional hazards regression analysis, including age as a prognostic factor. Results - During follow up 29 patients died (21 of vascular causes and eight of non-vascular or unknown causes), 10 had a first ever stroke, 19 had a coronary event, and only one developed contralateral retinal infarction. A coronary event accounted for more than half (59%) of the deaths whereas stroke was the cause of only one death (3%). Over the first five years after retinal infarction the actuarial average absolute risk of death was 8% per year; of stroke 2.5% per year (7.4% in the first year); of coronary events 5.3% per year, exceeding that of stroke; and of stroke, myocardial infarction, or vascular death 7.4% per year. Prognostic factors associated with an increased risk of death were increasing age, peripheral vascular disease, cardiomegaly, and carotid bruit. Adverse prognostic factors for serious vascular events were increasing age and carotid bruit for stroke, and increasing age, cardiomegaly, and carotid bruit both for coronary events and for stroke, myocardial infarction, or vascular death. Conclusions - Patients who present with retinal infarction due to presumed atherothromboembolism or cardiogenic embolism are at considerable risk of a coronary event. The risk of stroke, although high, is not so great. Not all strokes occurring after retinal infarction relate directly to disease of the ipsilateral carotid system, although this is probably the most common cause. Few patients experience contralateral retinal infarction. Non-arteritic retinal infarction should be diagnosed or confirmed by an ophthalmologist, and the long term care of patients with the condition should involve a physician who has an active interest in managing vascular disease.			HANKEY, GJ (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				[Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; APPEN RE, 1975, AM J OPHTHALMOL, V79, P374, DOI 10.1016/0002-9394(75)90609-1; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BROWN GC, 1981, OPHTHALMOLOGY, V88, P18; CHAWLUK JB, 1988, NEUROLOGY, V38, P858, DOI 10.1212/WNL.38.6.858; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DOUGLAS DJ, 1988, ANN SURG, V208, P85, DOI 10.1097/00000658-198807000-00012; GOODMAN GK, 1982, CAN J OPHTHALMOL, V17, P124; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HANKEY GJ, IN PRESS J NEUROL NE; HARBISON JW, 1982, ANN NEUROL, V12, P74; HOLLENHORST RW, 1987, OCCLUSIVE CEREBROVAS, P82; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; HOWARD RS, 1987, J NEUROL NEUROSUR PS, V50, P1142, DOI 10.1136/jnnp.50.9.1142; JORGENSEN R, 1988, SURGERY, V104, P507; KOLLARITS CR, 1972, J AMER MED ASSOC, V222, P1273, DOI 10.1001/jama.222.10.1273; LIVERSEDGE L A, 1962, Trans Ophthalmol Soc U K, V82, P571; LORENTZEN SE, 1969, ACTA OPHTHALMOL, V47, P690; MACHIN D, 1989, STATISTICS CONFIDENC, P64; MARSHALL J, 1968, BRAIN, V91, P419, DOI 10.1093/brain/91.3.419; MERCHUT MP, 1988, STROKE, V19, P1239, DOI 10.1161/01.STR.19.10.1239; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; POOLE CJM, 1985, J NEUROL NEUROSUR PS, V48, P902, DOI 10.1136/jnnp.48.9.902; ROS MA, 1989, ANN OPHTHALMOL, V21, P103; RUSSELL RW, 1961, LANCET, V2, P1422; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; SAVINO PJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P1185, DOI 10.1001/archopht.1977.04450070083005; TIPPIN J, 1989, ANN NEUROL, V26, P69, DOI 10.1002/ana.410260111; TOMSAK RL, 1979, CLEVELAND CLIN Q, V46, P7, DOI 10.3949/ccjm.46.1.7; WILSON LA, 1979, LANCET, V1, P292; WRAY SH, 1988, AMAUROSIS FUGAX, P81	37	56	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1991	302	6775					499	504		10.1136/bmj.302.6775.499	http://dx.doi.org/10.1136/bmj.302.6775.499			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012845	Green Published, Bronze			2022-12-28	WOS:A1991FB05500018
J	DONALDSON, LJ; HILL, PM				DONALDSON, LJ; HILL, PM			THE DOMICILIARY CONSULTATION SERVICE - TIME TO TAKE STOCK	BRITISH MEDICAL JOURNAL			English	Article								Objective-To review the use of the domiciliary consultation service in modern clinical practice in the Northern region. Design-Retrospective study of data on domiciliary consultations from claim forms for payment submitted to the regional health authority by consultants during 1984-5 and prospective study during 1985-9. Peer review of patterns of practice by consultants. Setting-15 Of the 16 health districts in the Northern region, comprising a mixed urban and rural population of about 2.8 million. Participants-760 Consultants in 28 specialties and 1666 general practitioners who were eligible to perform or request domiciliary consultations. Main outcome measures-Numbers of domiciliary consultations, general practitioners' requests for consultations, and consultants performing consultations and expenditure on the service by the region. Results-Use of the domiciliary consultation service in the Northern region declined by 53% between 1984-5 and 1988-9, considerably in excess of the national rate of decline of 27%, and expenditure on the service was reduced, after allowing for inflation, by L604 000, or 38%, in real terms. Most consultants and general practitioners used the service sparingly whereas a small proportion used it heavily; a few specific consultants and general practitioners were responsible for a relatively high rate of domiciliary consultations. Contrary to the original definition of domiciliary consultation, the general practitioner accompanied the consultant on only one occasion in 17 and, in one specialty examined (paediatrics) patients who received domiciliary consultations seemed to have minor medical problems. Conclusions-Peer review examination of the pattern of practice in the domiciliary consultation service proved effective in rationalising use of the service, although a substantial minority of consultants and general practitioners continued to use the service heavily. The place of the service in modern clinical practice would benefit from a national review.			DONALDSON, LJ (corresponding author), NO REG HLTH AUTHOR,NEWCASTLE TYNE NE6 4PY,ENGLAND.							COUPLAND AI, 1985, BRIT MED J, V290, P1399, DOI 10.1136/bmj.290.6479.1399; DOWIE R, 1983, BRIT MED J, V286, P819, DOI 10.1136/bmj.286.6367.819; HILL C, 1949, NATIONAL HLTH SERVIC; JACKSON PE, 1980, BRIT MED J, V280, P256, DOI 10.1136/bmj.280.6209.256; LITTLEJOHNS PC, 1986, J ROY COLL GEN PRACT, V36, P313; MAYO E, 1949, HAWTHORNE W ELECTRIC, P60; MULLEY GP, 1988, BMJ-BRIT MED J, V296, P515, DOI 10.1136/bmj.296.6621.515; Porritt A., 1962, REV MED SERVICES GRE; SANDERS GL, 1987, COMMUNITY MED, V9, P121; 1948, CM7420; 1986, HOSPITAL MED DENTAL; 1982, 12TH REV BOD DOCT DE	12	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					449	451		10.1136/bmj.302.6774.449	http://dx.doi.org/10.1136/bmj.302.6774.449			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004173	Green Published, Bronze			2022-12-28	WOS:A1991EZ03300023
J	CLEVES, AE; MCGEE, TP; WHITTERS, EA; CHAMPION, KM; AITKEN, JR; DOWHAN, W; GOEBL, M; BANKAITIS, VA				CLEVES, AE; MCGEE, TP; WHITTERS, EA; CHAMPION, KM; AITKEN, JR; DOWHAN, W; GOEBL, M; BANKAITIS, VA			MUTATIONS IN THE CDP CHOLINE PATHWAY FOR PHOSPHOLIPID BIOSYNTHESIS BYPASS THE REQUIREMENT FOR AN ESSENTIAL PHOSPHOLIPID TRANSFER PROTEIN	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST GOLGI; GENE; CLONING; ACTIN; CELLS; TRANSFORMATION; MUTANTS	SEC14p is the yeast phosphatidylinositol (PI)/phosphatidylcholine (PC) transfer protein, and it effects an essential stimulation of yeast Golgi secretory function. We now report that the SEC14p localizes to the yeast Golgi and that the SEC14p requirement can be specifically and efficiently bypassed by mutations in any one of at least six genes. One of these suppressor genes was the structural gene for yeast choline kinase (CKI), disruption of which rendered the cell independent of the normally essential SEC14p requirement. The antagonistic action of the CKI gene product on SEC14p function revealed a previously unsuspected influence of biosynthetic activities of the CDP-choline pathway for PC biosynthesis on yeast Golgi function and indicated that SEC14p controls the phospholipid content of yeast Golgi membranes in vivo.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225; INDIANA UNIV,WALTHER ONCOL CTR,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	University of Texas System; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	CLEVES, AE (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801, USA.			McGee, Todd/0000-0002-3901-1001; Cleves, Ann/0000-0002-1622-2770	NIGMS NIH HHS [R01 GM044530, GM35143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; Goldstein A, 1975, Methods Enzymol, V42, P504; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MASON TL, 1973, J BIOL CHEM, V248, P1346; MIMMS LT, 1990, VIROLOGY, V176, P604, DOI 10.1016/0042-6822(90)90031-L; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHMAN JE, 1990, NATURE, V347, P519, DOI 10.1038/347519a0; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; Sherman F., 1983, METHODS YEAST GENETI; Silhavy T. J., 1984, EXPT GENE FUSIONS; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	36	304	306	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					789	800		10.1016/0092-8674(91)90508-V	http://dx.doi.org/10.1016/0092-8674(91)90508-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997207	Green Accepted, Green Submitted			2022-12-28	WOS:A1991EZ47800014
J	SILVER, PA				SILVER, PA			HOW PROTEINS ENTER THE NUCLEUS	CELL			English	Review							SIGNAL-BINDING PROTEINS; WHEAT-GERM AGGLUTININ; HEAT-SHOCK PROTEIN; PORE COMPLEX; GLUCOCORTICOID RECEPTOR; NUCLEOCYTOPLASMIC TRANSPORT; KARYOPHILIC PROTEINS; LOCALIZATION SIGNALS; LOCATION SIGNAL; XENOPUS-LAEVIS				SILVER, PA (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.							ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DABAUVALLE MC, 1982, P NATL ACAD SCI-BIOL, V79, P5302, DOI 10.1073/pnas.79.17.5302; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DABAUVALLE MC, 1984, EXP CELL RES, V153, P308, DOI 10.1016/0014-4827(84)90603-7; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DEROBERTIS EM, 1978, NATURE, V272, P254, DOI 10.1038/272254a0; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GARCIABUSTOS JF, 1991, IN PRESS BIOCH BIOPH; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOVIND S, 1991, IN PRESS TRENDS GENE; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALINICH JF, 1989, J BIOL CHEM, V264, P17979; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1988, MOL CELL BIOL, V8, P2722, DOI 10.1128/MCB.8.7.2722; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROBBINS J, 1991, CELL, V64; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	77	536	568	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					489	497		10.1016/0092-8674(91)90233-O	http://dx.doi.org/10.1016/0092-8674(91)90233-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991319				2022-12-28	WOS:A1991EX36100005
J	SMITH, LFP; JEWELL, D				SMITH, LFP; JEWELL, D			CONTRIBUTION OF GENERAL-PRACTITIONERS TO HOSPITAL INTRAPARTUM CARE IN MATERNITY UNITS IN ENGLAND AND WALES IN 1988	BRITISH MEDICAL JOURNAL			English	Article								Objective - To ascertain the contribution of general practitioners to hospital intrapartum care in 1988. Design - Confidential postal questionnaire. Setting - All maternity units in England and Wales. Main outcome measures - Type of general practitioner unit (it any); number of bookings, transfers, and deliveries by general practitioners; participation of general practitioners in the policy and audit of the unit. Results - 277 (93%) of 297 units replied. Of 611 644 deliveries, 36 043 (5.9%) were under general practitioner care. In all 228 units permitted general practitioners to book women under their sole care: 65 were isolated, 29 alongside, and 134 integrated general practitioner units. Alongside units had significantly more bookings (568), antenatal transfers (69), intrapartum transfers (86), and deliveries (387) compared with isolated units (185, 18, 16, and 125, respectively) and integrated units (106, 18, 18, and 52) (p < 0.001) for all differences. The percentage of women booked by general practitioners transferred either before of during labour was independent of both the type of unit and the number of general practitioner bookings. General practitioners in consultant units were significantly less likely to attend meetings reviewing perinatal mortality (p < 0.01), and these units were less likely to have form of general practitioner-consultant liaison committee (p < 0.001) compared with general practitioner units as a whole. Compared with those in isolated and alongside units, general practitioners in integrated units were less likely to have taken part in deciding the unit's booking policy (p < 0.01) and consultants more likely to be the final determinant of whether a general practitioner should be permitted to practice within the unit (p < 0.001). Conclusions - Both the number of deliveries booked by general practitioners and the number of isolated general practitioner units have fallen. Transfer from general practitioner to consultant care was independent of the general practitioner unit's caseload or the type of unit. General practitioner units differ from consultant units in important ways and differ among themselves as well. Except in remote areas, alongside units may be the ideal type of unit to encourage general practitioners to continue to provide intrapartum care.			SMITH, LFP (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,GEN PRACTICE UNIT,BRISTOL BS8 2PR,ENGLAND.							BRYCE FC, 1990, BRIT MED J, V300, P725, DOI 10.1136/bmj.300.6726.725; CAMPBELL R, 1987, BE BORN DEBATE EVIDE; CAVENAGH AJM, 1984, BRIT MED J, V288, P1438, DOI 10.1136/bmj.288.6428.1438; LOWE SW, 1987, J ROY COLL GEN PRACT, V37, P484; MARSH GN, 1985, BRIT MED J, V290, P971, DOI 10.1136/bmj.290.6473.971; PRENTICE A, 1989, BRIT MED J, V299, P1090, DOI 10.1136/bmj.299.6707.1090; ROSENBLATT RA, 1985, LANCET, V2, P429; SANGALA V, 1990, BRIT MED J, V301, P418, DOI 10.1136/bmj.301.6749.418; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744; 1929, STATISTICAL REV 1927; 1981, REPORT TRAINING OBST; 1948, MATERNITY GREAT BRIT; 1982, REPORT RCOG WORKING; 1988, BIRTH STATISTICS	14	17	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					13	16		10.1136/bmj.302.6767.13	http://dx.doi.org/10.1136/bmj.302.6767.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991179	Green Published, Bronze			2022-12-28	WOS:A1991ER37200017
J	CLARKE, R; DALY, L; ROBINSON, K; NAUGHTEN, E; CAHALANE, S; FOWLER, B; GRAHAM, I				CLARKE, R; DALY, L; ROBINSON, K; NAUGHTEN, E; CAHALANE, S; FOWLER, B; GRAHAM, I			HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYSTATHIONINE BETA-SYNTHASE; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; ENDOTHELIAL-CELL INJURY; LOW-DENSITY LIPOPROTEIN; CONTAINING AMINO-ACIDS; MYOCARDIAL-INFARCTION; PLASMA HOMOCYSTEINE; FAMILY HISTORY; FOLIC-ACID	Background. Hyperhomocysteinemia arising from impaired methionine metabolism, probably usually due to a deficiency of cystathionine beta-synthase, is associated with premature cerebral, peripheral, and possibly coronary vascular disease. Both the strength of this association and its independence of other risk factors for cardiovascular disease are uncertain. We studied the extent to which the association could be explained by heterozygous cystathionine beta-synthase deficiency. Methods. We first established a diagnostic criterion for hyperhomocysteinemia by comparing peak serum levels of homocysteine after a standard methionine-loading test in 25 obligate heterozygotes with respect to cystathionine beta-synthase deficiency (whose children were known to be homozygous for homocystinuria due to this enzyme defect) with the levels in 27 unrelated age- and sex-matched normal subjects. A level of 24.0-mu-mol per liter or more was 92 percent sensitive and 100 percent specific in distinguishing the two groups. The peak serum homocysteine levels in these normal subjects were then compared with those in 123 patients whose vascular disease had been diagnosed before they were 55 years of age. Results. Hyperhomocysteinemia was detected in 16 of 38 patients with cerebrovascular disease (42 percent), 7 of 25 with peripheral vascular disease (28 percent), and 18 of 60 with coronary vascular disease (30 percent), but in none of the 27 normal subjects. After adjustment for the effects of conventional risk factors, the lower 95 percent confidence limit for the odds ratio for vascular disease among the patients with hyperhomocysteinemia, as compared with the normal subjects, was 3.2. The geometric-mean peak serum homocysteine level was 1.33 times higher in the patients with vascular disease than in the normal subjects (P = 0.002). The presence of cystathionine beta-synthase deficiency was confirmed in 18 of 23 patients with vascular disease who had hyperhomocysteinemia. Conclusions. Hyperhomocysteinemia is an independent risk factor for vascular disease, including coronary disease, and in most instances is probably due to cystathionine beta-synthase deficiency.	ADELAIDE HOSP,DEPT CARDIOL,PETER ST,DUBLIN 8,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT MED,DUBLIN 2,IRELAND; CHILDRENS HOSP,NATL SCREENING CTR METAB DIS,DUBLIN,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT COMMUNITY MED & EPIDEMIOL,DUBLIN 4,IRELAND; ROYAL MANCHESTER CHILDRENS HOSP,WILLINK BIOCHEM GENET UNIT,MANCHESTER M27 1HA,LANCS,ENGLAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; University College Dublin; Royal Manchester Children's Hospital								USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4; BARRETTCONNOR E, 1984, CIRCULATION, V69, P1065, DOI 10.1161/01.CIR.69.6.1065; BERG K, 1989, ARTERIOSCLEROSIS S, V9, P50; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; BRATTSTROM LE, 1985, METABOLISM, V34, P1073, DOI 10.1016/0026-0495(85)90082-4; BRESLOW NE, 1980, IARC SCI PUBL, V32, P124; CAREY MC, 1968, AM J MED, V45, P26, DOI 10.1016/0002-9343(68)90004-1; FOWLER B, 1978, J CLIN INVEST, V61, P645, DOI 10.1172/JCI108976; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; FRIMPTER GW, 1961, J BIOL CHEM, V236, pPC51; GOLDBOURT U, 1986, ARTERIOSCLEROSIS, V6, P357, DOI 10.1161/01.ATV.6.4.357; GRAEBER JE, 1982, PEDIATR RES, V16, P490, DOI 10.1203/00006450-198206000-00018; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; KANNEL WB, 1977, HYPERTENSION PHYSIOP, P880; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P2047, DOI 10.1073/pnas.83.7.2047; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MCCULLY KS, 1987, RES COMMUN CHEM PATH, V56, P349; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1989, METABOLIC BASIS INHE, V1, P693; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; MYERS RH, 1989, 2ND P INT C PREV CAR, pA376; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; OLSZEWSKI AJ, 1988, ATHEROSCLEROSIS, V69, P109, DOI 10.1016/0021-9150(88)90003-2; PANGANAMALA RV, 1986, PROSTAG LEUKOTR ESS, V22, P349, DOI 10.1016/0262-1746(86)90145-9; PARTHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337, DOI 10.1016/0005-2760(87)90139-1; ROBINSON K, 1990, CDNA12834ENC OFF OFF; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; SKOVBY F, 1984, HUM GENET, V65, P291, DOI 10.1007/BF00286520; SOLBERG LA, 1983, ARTERIOSCLEROSIS, V3, P187, DOI 10.1161/01.ATV.3.3.187; STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; WILCKEN DEL, 1983, METABOLISM, V32, P363, DOI 10.1016/0026-0495(83)90045-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950; 1981, NIH822035 DEP HLTH H	49	1867	1956	3	54	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1149	1155		10.1056/NEJM199104253241701	http://dx.doi.org/10.1056/NEJM199104253241701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011158				2022-12-28	WOS:A1991FH57200001
J	JOHNSTON, CC; SLEMENDA, CW; MELTON, LJ				JOHNSTON, CC; SLEMENDA, CW; MELTON, LJ			CLINICAL USE OF BONE DENSITOMETRY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSTMENOPAUSAL OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; FRACTURE; PREVENTION; HIP; ESTROGEN; WOMEN; MASS		MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic	JOHNSTON, CC (corresponding author), INDIANA UNIV, SCH MED,DEPT MED,DIV ENDOCRINOL,545 BARNHILL DR, EMERSON 421, INDIANAPOLIS, IN 46202 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG005793] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 27065] Funding Source: Medline; NIA NIH HHS [P01AG 5793] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; BARRETTCONNER E, IN PRESS JAMA; BROWNER WS, 1989, J BONE MINER RES  S1, V4, pS171; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; CHRISTIANSEN C, 1987, LANCET, V1, P1106; CIVITELLI R, 1988, J CLIN INVEST, V82, P1268, DOI 10.1172/JCI113725; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DALEN N, 1974, ACTA ENDOCRINOL-COP, V75, P297, DOI 10.1530/acta.0.0750297; DOYLE FH, 1967, BRIT J RADIOL, V40, P241, DOI 10.1259/0007-1285-40-472-241; EASTELL R, 1988, ENDOCRIN METAB CLIN, V17, P547, DOI 10.1016/S0889-8529(18)30416-X; GARDSELL P, IN PRESS CALCIF TISS; GENNARI C, 1985, BONE MINERAL RES ANN, V3, P213; GLUER CC, 1990, RADIOLOGY, V174, P223, DOI 10.1148/radiology.174.1.2294552; GRISSO JA, 1990, J BONE MINER RES, V5, P213, DOI 10.1002/jbmr.5650050303; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; HULKA BS, 1990, CA-CANCER J CLIN, V40, P289, DOI 10.3322/canjclin.40.5.289; HUTCHINSON TA, 1979, LANCET, V2, P705; JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1; JOHNSTON CC, 1983, OSTEOPOROSIS MULTIDI, P223; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KLEEREKOPER M, 1983, CLIN DISORDERS BONE, P328; LEPPLA DC, 1982, INVEST RADIOL, V17, P604, DOI 10.1097/00004424-198211000-00013; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1976, LANCET, V1, P1038; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PARFITT AM, 1987, AM J MED, V82, P68, DOI 10.1016/0002-9343(87)90274-9; PARFITT AM, 1976, AM J ROENTGENOL, V126, P1292, DOI 10.2214/ajr.126.6.1292; PECK W, 1984, CALCIFIED TISSUE INT, V36, P4, DOI 10.1007/BF02405286; SARTORIS DJ, 1990, RADIOL CLIN N AM, V28, P257; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SSELEY DG, 1990, 3RD P INT S OST COP, V2, P463; STEIGER P, 1990, RADIOLOGY, V175, P537, DOI 10.1148/radiology.175.2.2326479; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; WAHNER HW, 1989, ENDOCRIN METAB CLIN, V18, P995, DOI 10.1016/S0889-8529(18)30352-9; WASNICH RD, 1989, J NUCL MED, V30, P1166; Wasnich RD., 1987, OSTEOPOROSIS UPDATE, P95; WASNICH RD, 1987, J BONE MINER RES  S1, V2, P343; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	46	305	312	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1105	1109						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008183				2022-12-28	WOS:A1991FG91200006
J	STREISSGUTH, AP; AASE, JM; CLARREN, SK; RANDELS, SP; LADUE, RA; SMITH, DF				STREISSGUTH, AP; AASE, JM; CLARREN, SK; RANDELS, SP; LADUE, RA; SMITH, DF			FETAL ALCOHOL SYNDROME IN ADOLESCENTS AND ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL ALCOHOL; FOLLOW-UP; EXPOSURE; INFANCY	Fetal alcohol syndrome is a specific recognizable pattern of malformation. Manifestations in 61 adolescents and adults suffering from alcohol teratogenesis are presented. After puberty, the faces of patients with fetal alcohol syndrome or fetal alcohol effects were not as distinctive. Patients tended to remain short and microcephalic, although their weight was somewhat closer to the mean. The average IQ was 68, but the range of IQ scores widely varied. Average academic functioning was at the second- to fourth-grade levels, with arithmetic deficits most characteristic. Maladaptive behaviors such as poor judgment, distractibility, and difficulty perceiving social cues were common. Family environments were remarkably unstable. Fetal alcohol syndrome is not just a childhood disorder; there is a predictable long-term progression of the disorder into adulthood, in which maladaptive behaviors present the greatest challenge to management.	UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, CTR CHILD DEV MENTAL RETARDAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, INST ALCOHOLISM & DRUG ABUSE, SEATTLE, WA 98195 USA; UNIV VANCOUVER, DEPT PEDIAT, VANCOUVER, BC, CANADA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	STREISSGUTH, AP (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PSYCHIAT & BEHAV SCI, GG-20, 2707 NE BLAKELEY, SEATTLE, WA 98195 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA001455, R01AA001455] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA01455] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aase JM, 1990, DIAGNOSTIC DYSMORPHO; ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; CLARREN SK, 1990, ALCOHOL CLIN EXP RES, V14, P674, DOI 10.1111/j.1530-0277.1990.tb01226.x; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; DEHAENE P, 1977, REV ALCOOL, V23, P145; Dorris Michael, 1989, BROKEN CORD; DRISCOLL CD, 1990, NEUROTOXICOL TERATOL, V12, P231, DOI 10.1016/0892-0362(90)90094-S; GRAY J K, 1990, Alcoholism Clinical and Experimental Research, V14, P294; Grossman H. J., 1983, CLASSIFICATION MENTA; HALL JG, 1989, HDB NORMAL PHYSICAL; HANSON JW, 1978, J PEDIATR-US, V92, P457, DOI 10.1016/S0022-3476(78)80449-1; HARRIS JC, 1988, YOUNG PERSON DOWN SY, P35; IOSUB S, 1981, ALCOHOL CLIN EXP RES, V5, P523; JASTAK S, 1984, MANUAL WIDE RANGE AC; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; LANDESMANDWYER S, 1981, NEUROBEH TOXICOL TER, V3, P187; Lemoine P., 1968, OUEST MED THER DRUG, P476; LITTLE BB, 1990, AM J DIS CHILD, V144, P1142, DOI 10.1001/archpedi.1990.02150340088030; MAJEWSKI F, 1988, INT CONGR SER, V805, P837; MAY PA, 1983, SOC BIOL, V30, P374; RILEY EP, 1990, ALCOHOL CLIN EXP RES, V14, P670, DOI 10.1111/j.1530-0277.1990.tb01225.x; ROBINSON GC, 1987, CAN MED ASSOC J, V137, P203; SAMPSON PD, 1989, NEUROTOXICOL TERATOL, V11, P477, DOI 10.1016/0892-0362(89)90025-1; SAVAGE DD, 1989, ALCOHOL CLIN EXP RES, V13, P588, DOI 10.1111/j.1530-0277.1989.tb00382.x; Smith, 1982, RECOGNIZABLE PATTERN; SPARROW SS, 1984, MANUAL VINELAND; SPOHR HL, 1987, NEUROPEDIATRICS, V18, P13, DOI 10.1055/s-2008-1052428; STEINHAUSEN HC, 1984, J AM ACAD CHILD PSY, V23, P465, DOI 10.1016/S0002-7138(09)60326-5; STREISSGUTH AP, 1989, NEUROTOXICOL TERATOL, V11, P493, DOI 10.1016/0892-0362(89)90026-3; STREISSGUTH AP, 1985, LANCET, V2, P85; STREISSGUTH AP, 1978, ALCOHOL CLIN EXP RES, V2, P165, DOI 10.1111/j.1530-0277.1978.tb04717.x; STREISSGUTH AP, 1990, ALCOHOL CLIN EXP RES, V14, P662, DOI 10.1111/j.1530-0277.1990.tb01224.x; STREISSGUTH AP, 1989, ANN NY ACAD SCI, V562, P145, DOI 10.1111/j.1749-6632.1989.tb21013.x; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler D, 1974, WECHSLER ADULT INTEL; WEST JR, 1986, ALCOHOL BRAIN DEV; 1976, MONTHLY VITAL STATIS, V25; 1981, FDA DRUG B, V2, P10	39	574	577	2	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1961	1967		10.1001/jama.265.15.1961	http://dx.doi.org/10.1001/jama.265.15.1961			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008025				2022-12-28	WOS:A1991FF76800021
J	PETERSON, WL				PETERSON, WL			CURRENT CONCEPTS - HELICOBACTER-PYLORI AND PEPTIC-ULCER DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; UREA BREATH TEST; CAMPYLOBACTER-LIKE ORGANISMS; GASTRIC-MUCOSA; DUODENAL-ULCERS; DE-NOL; INFECTION; COLONIZATION; EPITHELIUM; ULTRASTRUCTURE		UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	PETERSON, WL (corresponding author), VET AFFAIRS MED CTR, MED SERV, 4500 S LANCASTER RD, DALLAS, TX 75216 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADER JP, 1987, DIGESTION, V37, P53, DOI 10.1159/000199559; BASKERVILLE A, 1988, GUT, V29, P465, DOI 10.1136/gut.29.4.465; BAYERDORFFER E, 1989, J CLIN PATHOL, V42, P834, DOI 10.1136/jcp.42.8.834; BECKINGHAM IJ, 1989, GUT, V30, P1016, DOI 10.1136/gut.30.7.1016; CAVE DR, 1989, LANCET, V2, P187; CLAYTON CL, 1990, NUCLEIC ACIDS RES, V18, P362, DOI 10.1093/nar/18.2.362; COGHLAN JG, 1987, LANCET, V2, P1109; DECOTHI GA, 1989, J CLIN PATHOL, V42, P132, DOI 10.1136/jcp.42.2.132; DEHESA M, 1989, Gastroenterology, V96, pA115; DOBRILLA G, 1988, GUT, V29, P181, DOI 10.1136/gut.29.2.181; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DRUMM B, 1987, NEW ENGL J MED, V316, P1557, DOI 10.1056/NEJM198706183162501; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; DUNK AA, 1990, ALIMENT PHARM THERAP, V4, P157; DUNN BE, 1990, J BIOL CHEM, V265, P9464; DYE KR, 1990, AM J CLIN PATHOL, V93, P144, DOI 10.1093/ajcp/93.1.144; DYE KR, 1989, DIGEST DIS SCI, V34, P1787, DOI 10.1007/BF01540059; EATON K A, 1990, Gastroenterology, V98, pA654; EATON KA, 1989, INFECT IMMUN, V57, P1119, DOI 10.1128/IAI.57.4.1119-1125.1989; ENGSTRAND L, 1990, INFECT IMMUN, V58, P1763, DOI 10.1128/IAI.58.6.1763-1768.1990; EVANS DG, 1988, INFECT IMMUN, V56, P2896, DOI 10.1128/IAI.56.11.2896-2906.1988; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FICH A, 1990, MAYO CLIN PROC, V65, P187, DOI 10.1016/S0025-6196(12)65013-7; FLEJOU JF, 1989, GUT, V30, P60, DOI 10.1136/gut.30.1.60; FOX JG, 1990, GASTROENTEROLOGY, V99, P352, DOI 10.1016/0016-5085(90)91016-Y; FRANCIS ND, 1990, J CLIN PATHOL, V43, P60, DOI 10.1136/jcp.43.1.60; Freedberg A. S., 1940, AM J DIG DIS, V7, P443, DOI DOI 10.1007/BF02997393; GAVEY CJ, 1989, ALIMENT PHARM THERAP, V3, P21; GLUPCZYNSKI Y, 1988, AM J GASTROENTEROL, V83, P365; GLUPCZYNSKI Y, 1990, HELICOBACTER PYLORI, P49; GOODWIN CS, 1989, INT J SYST BACTERIOL, V39, P397, DOI 10.1099/00207713-39-4-397; GOODWIN CS, 1985, J CLIN PATHOL, V38, P1127, DOI 10.1136/jcp.38.10.1127; Goodwin CS, 1990, HELICOBACTER PYLORI, P3; GRAHAM D Y, 1989, Gastroenterology, V96, pA180; GRAHAM DY, 1988, J INFECT DIS, V157, P777, DOI 10.1093/infdis/157.4.777; GRAHAM DY, 1988, AM J GASTROENTEROL, V83, P974; GRAHAM DY, 1990, AM J GASTROENTEROL, V85, P394; GRAHAM DY, 1987, LANCET, V1, P1174; HAOT J, 1990, GUT, V31, P282, DOI 10.1136/gut.31.3.282; HESSEY SJ, 1990, GUT, V31, P134, DOI 10.1136/gut.31.2.134; JOHNSTON BJ, 1988, SCAND J GASTROENTERO, V23, P69, DOI 10.3109/00365528809091717; KANG JY, 1990, GUT, V31, P476, DOI 10.1136/gut.31.4.476; KIM F, 1989, Gastroenterology, V96, pA256; KONTUREK SJ, 1988, GUT, V29, P894, DOI 10.1136/gut.29.7.894; KRAKOWKA S, 1987, INFECT IMMUN, V55, P2789, DOI 10.1128/IAI.55.11.2789-2796.1987; LAMBERT J R, 1990, Gastroenterology, V98, pA74; LAMBERT JR, 1989, SCAND J GASTROENTERO, V24, P7, DOI 10.3109/00365528909091728; LANGENBERG W, 1990, J INFECT DIS, V161, P507, DOI 10.1093/infdis/161.3.507; LEE A, 1988, INFECT IMMUN, V56, P2843, DOI 10.1128/IAI.56.11.2843-2850.1988; LEE A, 1990, GASTROENTEROLOGY, V99, P1315, DOI 10.1016/0016-5085(90)91156-Z; LEUNK RD, 1990, J CLIN MICROBIOL, V28, P1181, DOI 10.1128/JCM.28.6.1181-1184.1990; LEVI S, 1989, BRIT MED J, V299, P1504, DOI 10.1136/bmj.299.6714.1504; LINGWOOD CA, 1989, LANCET, V2, P238; LOFFELD RJLF, 1989, GUT, V30, P1206, DOI 10.1136/gut.30.9.1206; MAI EUH, 1990, GASTROENTEROLOGY S, V98, pA662; MARSHALL B J, 1990, Gastroenterology, V98, pA83; MARSHALL BJ, 1988, J NUCL MED, V29, P11; MARSHALL BJ, 1990, GASTROENTEROLOGY, V99, P697, DOI 10.1016/0016-5085(90)90957-3; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MCNULTY CAM, 1989, GUT, V30, P1058, DOI 10.1136/gut.30.8.1058; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MITCHELL HM, 1989, SCAND J GASTROENTERO, V24, P396, DOI 10.3109/00365528909093065; MORGAN D, 1988, GASTROENTEROLOGY, V95, P1178, DOI 10.1016/0016-5085(88)90348-4; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; OCONNOR HJ, 1989, GASTROENTEROLOGY, V97, P958, DOI 10.1016/0016-5085(89)91504-7; ORIORDAN T, 1990, GUT, V31, P999, DOI 10.1136/gut.31.9.999; ORMAND J E, 1989, Gastroenterology, V96, pA378; PARSONS CL, 1984, J UROLOGY, V132, P365, DOI 10.1016/S0022-5347(17)49628-5; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; PODOLSKY I, 1989, Gastroenterology, V96, pA394; RADIN MJ, 1990, INFECT IMMUN, V58, P2606, DOI 10.1128/IAI.58.8.2606-2612.1990; RAIG PM, 1990, GASTROENTEROLOGY S, V98, pA33; RAMSEY EJ, 1979, GASTROENTEROLOGY, V76, P1449; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; ROKKAS T, 1988, GUT, V29, P1386, DOI 10.1136/gut.29.10.1386; SAROSIEK J, 1988, SCAND J GASTROENTERO, V23, P585, DOI 10.3109/00365528809093916; SATOH H, 1983, GASTROENTEROLOGY, V84, P483; SHAMES B, 1989, J CLIN MICROBIOL, V27, P2849, DOI 10.1128/JCM.27.12.2849-2850.1989; SIURALA M, 1990, LANCET, V335, P1233; SMITH JTL, 1990, GUT, V31, P522, DOI 10.1136/gut.31.5.522; SMOOT DT, 1990, INFECT IMMUN, V58, P1992, DOI 10.1128/IAI.58.6.1992-1994.1990; SPYCHAL RT, 1990, GASTROENTEROLOGY, V98, P1250, DOI 10.1016/0016-5085(90)90341-W; STEER HW, 1975, J CLIN PATHOL, V28, P639, DOI 10.1136/jcp.28.8.639; STEER HW, 1984, GUT, V25, P1203, DOI 10.1136/gut.25.11.1203; TALLEY NJ, 1988, MAYO CLIN PROC, V63, P1176, DOI 10.1016/S0025-6196(12)65402-0; TALLEY NJ, 1990, HELICOBACTER PYLORI, P361; TALLEY NJ, 1990, CAMPYLOBACTER PYLORI, P361; VAIRA D, 1988, LANCET, V2, P725; WARREN JR, 1983, LANCET, V1, P1273; WEGENER M, 1988, AM J GASTROENTEROL, V83, P737; WEIL J, 1990, ALIMENT PHARM THERAP, V4, P651; WELLER MPI, 1988, POSTGRAD MED J, V64, P308, DOI 10.1136/pgmj.64.750.308; WOLBER R, 1990, GASTROENTEROLOGY, V98, P310, DOI 10.1016/0016-5085(90)90819-M; WYATT JI, 1989, CAMPYLOBACTER PYLORI, P117; XIAO GC, 1986, AM J CLIN PATHOL, V86, P575, DOI 10.1093/ajcp/86.5.575	97	633	672	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1043	1048						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	2005942				2022-12-28	WOS:A1991FF77100007
J	BURKE, GL; SPRAFKA, JM; FOLSOM, AR; HAHN, LP; LUEPKER, RV; BLACKBURN, H				BURKE, GL; SPRAFKA, JM; FOLSOM, AR; HAHN, LP; LUEPKER, RV; BLACKBURN, H			TRENDS IN SERUM-CHOLESTEROL LEVELS FROM 1980 TO 1987 - THE MINNESOTA HEART SURVEY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE RISK-FACTORS; 2 NATIONAL SURVEYS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; DEATH; PERSPECTIVE; PREVALENCE; MORTALITY	Background and Methods. We assessed community trends in the awareness, treatment, and control of hypercholesterolemia (defined as a serum cholesterol level greater-than-or-equal-to 6.21 mmol per liter [240 mg per deciliter]) during the 1980s in the Minneapolis-St. Paul (Twin Cities) metropolitan area. Twin Cities residents 25 to 74 years old participated in independent, cross-sectional, population-based surveys of risk factors for cardiovascular disease in 1980-1982 (n = 3365) and 1985-1987 (n = 4545). Results. Mean serum total cholesterol levels, as adjusted for age, decreased significantly (P < 0.01) from 1980-1982 to 1985-1987 in men (from 5.30 mmol per liter [205 mg per deciliter] to 5.16 mmol per liter [200 mg per deciliter]) and women (from 5.19 mmol per liter [201 mg per deciliter] to 5.04 mmol per liter [195 mg per deciliter]). The prevalence of hypercholesterolemia as adjusted for age decreased significantly (P < 0.05) in men (17.8 to 15.1 percent) and women (17.1 to 13.6 percent). The ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was unchanged during this period, because of a concurrent decline in the level of HDL cholesterol. Participants with hypercholesterolemia in the 1985-1987 survey were more likely than those in the 1980-1982 survey to be aware of their condition (32.6 vs. 25.4 percent), to be treated with lipid-lowering agents (4.3 vs. 1.9 percent), and to have their condition controlled (1.9 vs. 0.3 percent). Among those who reported treatment by a physician for hyperlipidemia, changes were observed in the type of treatment recommended. A significant increase (P < 0.05) was noted from 1980-1982 to 1985-1987 in the percentage of men being treated for hyperlipidemia with lipid-lowering medication (5.2 vs. 11.6 percent) and with exercise programs (10.3 vs. 20.1 percent). In women being treated for hyperlipidemia, a nonsignificant increase was noted in the use of lipid-lowering medication (8.2 vs. 13.9 percent), and a significant increase (P < 0.05) was observed in the number of exercise prescriptions (4.1 vs. 12.0 percent). Conclusions. We found a substantial decline in the prevalence of hypercholesterolemia in the Twin Cities between 1980-1982 and 1985-1987 that may be attributed to changes in lifestyle, such as diet and exercise, and to a lesser extent to more aggressive intervention with lipid-lowering drugs by physicians.	UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	BURKE, GL (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103, USA.				PHS HHS [R01-23727] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; GILLUM RF, 1984, AM J MED, V76, P1055, DOI 10.1016/0002-9343(84)90857-X; GRAVES KL, 1990, CIRCULATION, V82, P347; GRUNDY SM, 1985, ARTERIOSCLEROSIS, V72, pA1135; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P2087, DOI 10.1001/jama.253.14.2087; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; KEYS A, 1970, CIRCULATION S1, V41, P162; LUEPKER RV, 1988, J CLIN EPIDEMIOL, V41, P825, DOI 10.1016/0895-4356(88)90098-4; LUEPKER RV, 1985, J CHRON DIS, V38, P671, DOI 10.1016/0021-9681(85)90021-9; MARTIN MJ, 1986, LANCET, V2, P933; REED D, 1986, AM J MED, V80, P871, DOI 10.1016/0002-9343(86)90631-5; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SPRAFKA JM, 1988, AM J PUBLIC HEALTH, V78, P1546, DOI 10.2105/AJPH.78.12.1546; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TIKKANEN MJ, 1987, CIRCULATION, V76, P529, DOI 10.1161/01.CIR.76.3.529; TYROLER HA, 1971, ARCH INTERN MED, V128, P907, DOI 10.1001/archinte.128.6.907; 1979, J CHRON DIS, V32, P609; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1988, ARCH INTERN MED, V148, P36; 1985, SAS USERS GUIDE BASI; 1984, JAMA-J AM MED ASSOC, V251, P365; 1987, JAMA-J AM MED ASSOC, V257, P937; 1974, DHEW NIH75628 NAT HE; 1979, PREV MED, V8, P612	29	66	66	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					941	946		10.1056/NEJM199104043241402	http://dx.doi.org/10.1056/NEJM199104043241402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	2002818				2022-12-28	WOS:A1991FE37600002
J	OPPENHEIM, RW; PREVETTE, D; YIN, QW; COLLINS, F; MACDONALD, J				OPPENHEIM, RW; PREVETTE, D; YIN, QW; COLLINS, F; MACDONALD, J			CONTROL OF EMBRYONIC MOTONEURON SURVIVAL INVIVO BY CILIARY NEUROTROPHIC FACTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; NORMAL-CELL-DEATH; CHICK-EMBRYO; SPINAL-CORD; NEURONAL DEATH; NEURONOTROPHIC FACTOR; PURIFICATION; REDUCTION; GANGLION; BRAIN	During development of the nervous system, neurons in many regions are overproduced by proliferation, after which the excess cells are eliminated by cell death. The survival of only a proportion of neurons during normal development is thought to be regulated by the limited availability of neurotrophic agents. One such putative trophic agent is ciliary neurotrophic factor (CNTF), a polypeptide that promotes the survival of ciliary, sensory, and sympathetic neurons in vitro. In contrast to the results of in vitro studies, however, the daily treatment of chick embryos in vivo with purified human recombinant CNTF failed to rescue any of these cell populations from cell death, whereas CNTF did promote the in vivo survival of spinal motoneurons. Thus, CNTF may not act as a neurotrophic agent in vivo for those embryonic neurons (especially ciliary neurons) on which it acts in vitro. Rather, CNTF may be required for in vivo survival of motoneurons.	SYNERGEN INC,BOULDER,CO 80301; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27103, USA.				NINDS NIH HHS [NS 20402] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020402] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], [No title captured]; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1988, TRENDS NEUROSCI, V11, P343, DOI 10.1016/0166-2236(88)90055-0; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Bhattacharyya A., UNPUB; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; CHUWANG IW, 1978, J COMP NEUROL, V177, P33, DOI 10.1002/cne.901770105; CLARKE PGH, 1985, TRENDS NEUROSCI, V8, P345, DOI 10.1016/0166-2236(85)90120-1; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVIES AM, 1988, TRENDS NEUROSCI, V11, P243, DOI 10.1016/0166-2236(88)90099-9; ECKENSTEIN FP, 1990, NEURON, V4, P623, DOI 10.1016/0896-6273(90)90120-5; ERNBERGER U, 1989, NEURON, V2, P1275; FURBER S, 1987, J NEUROSCI, V7, P1816; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOFFMANN HD, 1988, J NEUROCHEM, V51, P109; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HUGHES S, 1988, NATURE, V355, P70; LANDMESSER L, 1974, J PHYSIOL-LONDON, V241, P715, DOI 10.1113/jphysiol.1974.sp010680; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LIN LFH, 1990, J BIOL CHEM, V265, P8942; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1986, BRAIN RES, V367, P282, DOI 10.1016/0006-8993(86)91603-3; MCMANAMAN JL, 1990, NEURON, V4, P891, DOI 10.1016/0896-6273(90)90142-3; MERINEY SD, 1985, SCIENCE, V228, P1451, DOI 10.1126/science.2990029; OPPENHEIM RC, UNPUB; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; PITTMAN RH, 1978, NATURE, V271, P364, DOI 10.1038/271364a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P7537; WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.neuro.12.1.103; WATTERS D, 1985, BIOCHEM INT, V11, P245; WATTERS DJ, 1987, J NEUROCHEM, V49, P705	50	418	439	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1616	1618		10.1126/science.2011743	http://dx.doi.org/10.1126/science.2011743			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011743				2022-12-28	WOS:A1991FD89000040
J	PACHOLCZYK, T; BLAKELY, RD; AMARA, SG				PACHOLCZYK, T; BLAKELY, RD; AMARA, SG			EXPRESSION CLONING OF A COCAINE-SENSITIVE AND ANTIDEPRESSANT-SENSITIVE HUMAN NORADRENALINE TRANSPORTER	NATURE			English	Article							SK-N-SH; NOREPINEPHRINE UPTAKE; TRANSIENT-EXPRESSION; DNA TRANSFECTION; ACTIVE UPTAKE; CELL-LINE; DOPAMINE; RECEPTOR; STORAGE; INHIBITION	AT most synapses, chemical signalling is terminated by a rapid reaccumulation of neurotransmitter into presynaptic terminals 1-5. Uptake systems for the biogenic amines are the initial site of action for therapeutic antidepressants and drugs such as cocaine and the amphetamines. We have isolated a complementary DNA clone encoding a human noradrenaline transporter. The cDNA sequence predicts a protein of 617 amino acids, with 12-13 highly hydrophobic regions compatible with membrane-spanning domains. Expression of the cDNA clone in transfected HeLa cells indicates that noradrenaline transport activity is sodium-dependent and sensitive to selective noradrenaline transport inhibitors. Transporter RNA is localized to the brainstem and the adrenal gland. The predicted protein sequence demonstrates significant amino-acid identity with the Na+/gamma-aminobutyric acid transporter, thus identifying a new gene family for neurotransmitter transporter proteins. Analysis of its structure and function may lead to structure-based drug design for the treatment of human depression and could help determine whether transporter abnormalities underlie affective disorders.	YALE UNIV,PROGRAM NEUROSCI,NEW HAVEN,CT 06510	Yale University	PACHOLCZYK, T (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,MOLEC NEUROBIOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Amara, Susan/0000-0001-8914-1106				ANDERSEN PH, 1989, EUR J PHARMACOL, V166, P493, DOI 10.1016/0014-2999(89)90363-4; BIEDLER JL, 1973, CANCER RES, V33, P2643; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BUCK J, 1985, CANCER RES, V45, P6366; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO AK, 1990, SCIENCE, V249, P631, DOI 10.1126/science.249.4969.631; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; Iversen L., 1967, UPTAKE STORAGE NORAD; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KIMELBERG HK, 1983, J NEUROCHEM, V40, P1265, DOI 10.1111/j.1471-4159.1983.tb13565.x; KOSTRZEWA RM, 1974, PHARMACOL REV, V26, P199; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHAR MJ, 1990, EUR NEUROL, V30, P15; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; RICHARDS ML, 1986, BRAIN RES, V384, P132, DOI 10.1016/0006-8993(86)91228-X; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROSS SB, 1976, J PHARM PHARMACOL, V28, P458, DOI 10.1111/j.2042-7158.1976.tb04659.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMETS LA, 1989, CANCER RES, V49, P2941; SNYDER S H, 1970, Biological Psychiatry, V2, P367; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0	37	804	850	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					350	354		10.1038/350350a0	http://dx.doi.org/10.1038/350350a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD838	2008212				2022-12-28	WOS:A1991FD83800096
J	PETERSON, CL; KRUGER, W; HERSKOWITZ, I				PETERSON, CL; KRUGER, W; HERSKOWITZ, I			A FUNCTIONAL INTERACTION BETWEEN THE C-TERMINAL DOMAIN OF RNA POLYMERASE-II AND THE NEGATIVE REGULATOR SIN1	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; LARGEST SUBUNIT; TRANSCRIPTION INITIATION; HO GENE; ESCHERICHIA-COLI; REPEAT DOMAIN; YEAST; EXPRESSION; PROTEIN; BINDING	The C-terminal domain (CTD) of the largest subunit of yeast RNA polymerase II contains 26-27 tandem copies of a conserved heptapeptide of unknown function. Yeast strains whose CTD contains ten heptamers are viable but defective for transcription of the INO1 gene and cold sensitive for growth. Deletion of the SIN1 gene, which codes for a DNA-binding protein that negatively regulates HO transcription, restores INO1 transcription and reduces the cold sensitivity of such strains. A SIN1 deletion suppresses the lethality of a CTD with nine heptamer repeats but not with seven repeats. These observations indicate a functional relationship between SIN1 and the CTD: the CTD might remove SIN1 from DNA, or removal of SIN1 may be a prerequisite for function of the CTD. The SWI1, SWI2, and SWI3 genes, whose products activate HO transcription by antagonizing SIN1, are also required for INO1 transcription and may assist the CTD. In addition, an intact CTD binds nonspecifically to DNA in vitro.			PETERSON, CL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.		kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM WY, 1988, J BIOL CHEM, V263, P18880; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROEDER GS, 1985, MOL CELL BIOL, V5, P1543, DOI 10.1128/MCB.5.7.1543; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCAFE C, 1990, MOL CELL BIOL, V10, P1270, DOI 10.1128/MCB.10.3.1270; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SCHROTER H, 1982, EUR J BIOCHEM, V127, P429, DOI 10.1111/j.1432-1033.1982.tb06890.x; SILVERMAN SJ, 1984, MOL CELL BIOL, V4, P1246, DOI 10.1128/MCB.4.7.1246; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	39	163	163	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1135	1143		10.1016/0092-8674(91)90268-4	http://dx.doi.org/10.1016/0092-8674(91)90268-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004420				2022-12-28	WOS:A1991FD55800011
J	ROSNER, MH; DESANTO, RJ; ARNHEITER, H; STAUDT, LM				ROSNER, MH; DESANTO, RJ; ARNHEITER, H; STAUDT, LM			OCT-3 IS A MATERNAL FACTOR REQUIRED FOR THE 1ST MOUSE EMBRYONIC DIVISION	CELL			English	Article							DNA-REPLICATION; BINDING-PROTEINS; EMBRYOGENESIS; SEQUENCE; CELLS; TRANSCRIPTION	Oct-3 is a POU domain transcription factor that binds the octamer DNA motif and is present in mouse oocytes before and after fertilization. When fertilized oocytes were injected with antisense Oct-3 oligonucleotides or double-stranded DNA containing the octamer motif, embryonic DNA synthesis was inhibited and the embryos were arrested at the one-cell stage. In vitro synthesized Oct-3 mRNA rescued the developmental block induced by antisense Oct-3 oligonucleotide. We conclude that maternally inherited Oct-3 is required for DNA replication and division of the one-cell embryo.	GEORGETOWN UNIV,SCH MED,DEPT PATHOL,WASHINGTON,DC 20057	Georgetown University	ROSNER, MH (corresponding author), NCI,METAB BRANCH,BETHESDA,MD 20892, USA.		Staudt, Louis/AAC-5324-2019					Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRAUDE P, 1979, NATURE, V282, P102, DOI 10.1038/282102a0; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DWORKIN MB, 1990, MOL REPROD DEV, V26, P261, DOI 10.1002/mrd.1080260310; HOGAN B, 1986, MANIPULATING MOUSE E; HOWLETT SK, 1985, J EMBRYOL EXP MORPH, V87, P175; JOHNSON MH, 1981, BIOL REV, V56, P463, DOI 10.1111/j.1469-185X.1981.tb00356.x; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LEVEY IL, 1977, J REPROD FERTIL, V50, P147; MAGNUSON T, 1981, BIOL REV, V56, P369, DOI 10.1111/j.1469-185X.1981.tb00354.x; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787	26	49	63	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1103	1110		10.1016/0092-8674(91)90265-Z	http://dx.doi.org/10.1016/0092-8674(91)90265-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004418	hybrid			2022-12-28	WOS:A1991FD55800008
J	SUN, H; TRECO, D; SZOSTAK, JW				SUN, H; TRECO, D; SZOSTAK, JW			EXTENSIVE 3'-OVERHANGING, SINGLE-STRANDED-DNA ASSOCIATED WITH THE MEIOSIS-SPECIFIC DOUBLE-STRAND BREAKS AT THE ARG4 RECOMBINATION INITIATION SITE	CELL			English	Article							MEIOTIC GENE CONVERSION; SACCHAROMYCES-CEREVISIAE; YEAST; CHROMOSOME; SYNAPSIS; EXCHANGE	Meiosis-specific double-strand breaks occur at the initiation site for meiotic gene conversion in the yeast ARG4 gene. Here we show that the break fragments end in extensive 3'-overhanging, single-stranded tails. The single-stranded tails vary in length, generating a gradient of single-strandedness that parallels the gradient of gene conversion frequencies in ARG4. In strains carrying a rad50S mutation, which blocks meiotic recombination, the extensive single-stranded tails do not form, suggesting that their generation is an obligatory step in meiotic recombination. Using the rad50S mutant, we have mapped the site of the ARG4 break to a small region within the genetically defined recombination initiation site. These results strongly support the double-strand break model of meiotic recombination.			SUN, H (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORTS RH, 1986, GENETICS, V113, P551; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; FOGEL S, 1981, MOL BIOL YEAST SACCH, V1, P289; GAME JC, 1980, GENETICS, V94, P51; GAME JC, 1989, GENETICS, V123, P695; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KLAPHOLZ S, 1985, GENETICS, V110, P187; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LICHTEN MJ, 1983, NUCLEIC ACIDS RES, V11, P3959, DOI 10.1093/nar/11.12.3959; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; Maniatis T., 1982, MOL CLONING; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; SCHULTES NP, 1990, GENETICS, V126, P813; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; Whitehouse H. L. K., 1982, GENETIC RECOMBINATIO; WILLIAMSON MS, 1985, GENETICS, V110, P609	32	461	467	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1155	1161		10.1016/0092-8674(91)90270-9	http://dx.doi.org/10.1016/0092-8674(91)90270-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004421				2022-12-28	WOS:A1991FD55800013
J	MEADOR, CK				MEADOR, CK			A LAMENT FOR INVALIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Pickering GW., 1974, CREATIVE MALADY ILLN; WHEELER EO, 1950, JAMA-J AM MED ASSOC, V142, P878, DOI 10.1001/jama.1950.02910300016005	2	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1374	1375		10.1001/jama.265.11.1374	http://dx.doi.org/10.1001/jama.265.11.1374			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999875				2022-12-28	WOS:A1991FB55000008
J	VANDONSELAAR, CA; GEERTS, AT; SCHIMSHEIMER, RJ				VANDONSELAAR, CA; GEERTS, AT; SCHIMSHEIMER, RJ			IDIOPATHIC 1ST SEIZURE IN ADULT LIFE - WHO SHOULD BE TREATED	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNPROVOKED SEIZURE; EPILEPSY; PROGNOSIS; CARBAMAZEPINE; RECURRENCE; PHENYTOIN; CHILDHOOD; VALPROATE; PATIENT	Objective-To assess the accuracy of the diagnosis, recurrence rate, and fate after the first recurrence in adult patients with an untreated idiopathic first seizure. Design-Hospital based follow up study. Setting-One university hospital and three general hospitals in The Netherlands. Patients-165 patients aged 15 years or more with a clinically presumed idiopathic seizure; diagnosis was based on a description of the episode according to prespecified diagnostic criteria. Main outcome measures-Results of additional investigations and follow up regarding the accuracy of the diagnosis; first recurrence; and response to treatment after the first recurrence. Results-Computed tomography showed major abnormalities in 5.5% of the patients and follow up led to doubts about the initial clinical diagnosis in another 6%. Cumulative risk of recurrence was 40% at two years. The cumulative risk of recurrence at two years was 81% (95% confidence interval 66% to 97%) in patients with epileptic discharges on a standard or partial sleep deprivation electroencephalogram, 39% (27% to 51%) in patients with other electroencephalographic abnormalities, and 12% (3% to 21%) in patients with normal electroencephalograms. Treatment was initiated in most patients who had one or more recurrences; 40 (70%) patients were completely controlled, eight (14%) had sporadic seizures, and nine (16%) did not become free of seizures within one year despite treatment. Conclusions-The decision to initiate or delay treatment should be based on electroencephalographic findings.	ERASMUS UNIV, DEPT PUBL HLTH & SOCIAL MED, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam	VANDONSELAAR, CA (corresponding author), ERASMUS UNIV, HOSP DIJKZIGT, DEPT NEUROL, 3015 GD ROTTERDAM, NETHERLANDS.							ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1981, Epilepsia, V22, P489; BODENSTEINER JB, 1988, EPILEPSIA, V29, P123, DOI 10.1111/j.1528-1157.1988.tb04407.x; CALLAGHAN N, 1985, J NEUROL NEUROSUR PS, V48, P639, DOI 10.1136/jnnp.48.7.639; CAMFIELD P, 1989, NEUROLOGY, V39, P851, DOI 10.1212/WNL.39.6.851; CLELAND PG, 1981, BRIT MED J, V283, P1364, DOI 10.1136/bmj.283.6303.1364; ELWES RDC, 1988, LANCET, V2, P36; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; ELWES RDC, 1985, LANCET, V2, P752; ELWES RDC, 1988, BMJ-BRIT MED J, V47, P620; HACHINSKI V, 1986, ARCH NEUROL-CHICAGO, V43, P1290, DOI 10.1001/archneur.1986.00520120066019; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P1289, DOI 10.1001/archneur.1986.00520120065018; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HAUSER WA, 1986, ARCH NEUROL-CHICAGO, V43, P1287, DOI 10.1001/archneur.1986.00520120063017; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HOLMES GL, 1988, POSTGRAD MED, V83, P199, DOI 10.1080/00325481.1988.11700149; HOPKINS A, 1988, LANCET, V1, P721; JOHNSON LC, 1972, ARCH NEUROL-CHICAGO, V27, P193, DOI 10.1001/archneur.1972.00490150001001; LUHDORF K, 1986, ACTA NEUROL SCAND, V74, P409; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; RAMSAY RE, 1983, NEUROLOGY, V33, P904, DOI 10.1212/WNL.33.7.904; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; REYNOLDS EH, 1983, LANCET, V2, P952; SAUNDERS M, 1975, EPILEPSIA, V16, P731, DOI 10.1111/j.1528-1157.1975.tb04757.x; SCHOTT GD, 1977, BRIT MED J, V1, P1454, DOI 10.1136/bmj.1.6074.1454; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; SHORVON SD, 1982, BMJ-BRIT MED J, V285, P1699, DOI 10.1136/bmj.285.6356.1699; THOMAS MH, 1959, JAMA-J AM MED ASSOC, V169, P457, DOI 10.1001/jama.1959.03000220037008; TURNBULL DM, 1985, BRIT MED J, V290, P815, DOI 10.1136/bmj.290.6471.815; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267; VANDONSELAAR CA, 1990, EPILEPSIA, V31, P529; 1981, STATISTICAL SOFTWARE	33	50	51	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	1991	302	6777					620	623		10.1136/bmj.302.6777.620	http://dx.doi.org/10.1136/bmj.302.6777.620			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012874	Green Published, Bronze			2022-12-28	WOS:A1991FC07100019
J	BELL, MV; HIRST, MC; NAKAHORI, Y; MACKINNON, RN; ROCHE, A; FLINT, TJ; JACOBS, PA; TOMMERUP, N; TRANEBJAERG, L; FROSTERISKENIUS, U; KERR, B; TURNER, G; LINDENBAUM, RH; WINTER, R; PEMBREY, M; THIBODEAU, S; DAVIES, KE				BELL, MV; HIRST, MC; NAKAHORI, Y; MACKINNON, RN; ROCHE, A; FLINT, TJ; JACOBS, PA; TOMMERUP, N; TRANEBJAERG, L; FROSTERISKENIUS, U; KERR, B; TURNER, G; LINDENBAUM, RH; WINTER, R; PEMBREY, M; THIBODEAU, S; DAVIES, KE			PHYSICAL MAPPING ACROSS THE FRAGILE-X - HYPERMETHYLATION AND CLINICAL EXPRESSION OF THE FRAGILE-X SYNDROME	CELL			English	Article							LINKED MENTAL-RETARDATION; CHROMOSOME; DNA; SITE; METHYLATION; LINKAGE; LOCUS; FREQUENCY; REGION; FAMILY	The most common genetic cause of mental retardation after Down's syndrome, the fragile X syndrome, is associated with the occurrence of a fragile site at Xq27.3. This X-linked disease is intriguing because transmission can occur through phenotypically normal males. Theories to explain this unusual phenomenon include genomic rearrangements and methylation changes associated with a local block of reactivation of the X chromosome. Using microdissected markers close to the fragile site, we have been able to test these hypotheses. We present evidence for the association of methylation with the expression of the disease. However, there is no simple relationship between the degree of methylation and either the level of expression of the fragile site or the severity of the clinical phenotype.	GEN HOSP, WESSEX REG GENET LAB, SALISBURY SP2 7SX, WILTS, ENGLAND; ULLEVAL HOSP, DEPT MED GENET, N-0315 OSLO 3, NORWAY; UNIV TROMSO, N-9001 TROMSO, NORWAY; REG HOSP CORK, POLAR INST MED GENET, N-9012 TROMSO, NORWAY; LUBECK MED UNIV, DEPT GYNAECOL & OBSTET, W-2400 LUBECK, GERMANY; PRINCE WALES HOSP, DEPT MED GENET, RANDWICK, NSW 2031, AUSTRALIA; CHURCHILL HOSP, DEPT MED GENET, OXFORD OX3 7LJ, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, CLIN RES INST, NW THAMES REG GENET SERV, HARROW HA1 3UJ, MIDDX, ENGLAND; UNIV LONDON, INST CHILD HLTH, MOTHERCARE UNIT, LONDON WC1, ENGLAND; MAYO CLIN & MAYO FDN, DEPT LAB MED, ROCHESTER, MN 55905 USA	Salisbury District Hospital; University of Oslo; UiT The Arctic University of Tromso; University of Oxford; Imperial College London; University of London; Mayo Clinic	BELL, MV (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC GENET GRP, OXFORD OX3 9DU, ENGLAND.		Tommerup, Niels/T-8776-2017; MacKinnon, Ruth/E-6202-2011	Tommerup, Niels/0000-0003-2304-0112; MacKinnon, Ruth/0000-0003-0294-5051				BARLOW D P, 1990, Technique (Philadelphia), V2, P79; DAHL N, 1989, AM J HUM GENET, V45, P304; DAVIES KE, 1985, HUM GENET, V70, P249; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRYNS JP, 1989, FRAGILE X SYNDROME, P1; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HARRISON CJ, 1983, J MED GENET, V20, P280, DOI 10.1136/jmg.20.4.280; HIRST MC, 1991, IN PRESS GENOMICS; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KENWRICK S, 1987, CELL, V48, P351, DOI 10.1016/0092-8674(87)90438-7; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LUBS HA, 1969, AM J HUM GENET, V21, P231; MACKINNON RN, 1990, AM J HUM GENET, V47, P181; Martin JP, 1943, J NEUROL PSYCHIATRY, V6, P154, DOI 10.1136/jnnp.6.3-4.154; NUSSBAUM RL, 1986, AM J MED GENET, V23, P715, DOI 10.1002/ajmg.1320230162; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; PATTERSON M, 1988, AM J HUM GENET, V43, P684; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; SUTHERS GK, 1989, SCIENCE, V246, P1298, DOI 10.1126/science.2573953; TOMMERUP N, 1987, 3RD INT WORKSH FRAG; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; TURKER MS, 1989, J BIOL CHEM, V264, P11632; TURNER G, 1980, J PEDIATR-US, V96, P837, DOI 10.1016/S0022-3476(80)80552-X; VINCENT A, 1991, IN PRESS NATURE; VOELCKEL MA, 1989, HUM GENET, V81, P353, DOI 10.1007/BF00283690; WEBB TP, 1986, J MED GENET, V23, P396, DOI 10.1136/jmg.23.5.396; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YEN PH, 1984, P NATL ACAD SCI-BIOL, V81, P1759, DOI 10.1073/pnas.81.6.1759	34	307	313	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					861	866		10.1016/0092-8674(91)90514-Y	http://dx.doi.org/10.1016/0092-8674(91)90514-Y			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997211				2022-12-28	WOS:A1991EZ47800020
J	ROBBINS, J; DILWORTH, SM; LASKEY, RA; DINGWALL, C				ROBBINS, J; DILWORTH, SM; LASKEY, RA; DINGWALL, C			2 INTERDEPENDENT BASIC DOMAINS IN NUCLEOPLASMIN NUCLEAR TARGETING SEQUENCE - IDENTIFICATION OF A CLASS OF BIPARTITE NUCLEAR TARGETING SEQUENCE	CELL			English	Article							PHOSPHOROTHIOATE-MODIFIED DNA; XENOPUS-LAEVIS OOCYTES; AMINO-ACID SEQUENCE; LARGE-T-ANTIGEN; LOCATION SIGNALS; TRANSPORT SIGNAL; HISTONE-BINDING; PROTEIN; LOCALIZATION; COMPLEXES	Point mutagenesis of the nuclear targeting sequence of nucleoplasmin has identified two interdependent basic domains. These are separated by 10 intervening "spacer" amino acids that tolerate point mutations and some insertions. Amino acids in both basic domains are required for nuclear targeting, and the transport defect of a mutation in one domain is amplified by a simultaneous mutation in the other. Therefore, these basic domains are interdependent. A strikingly similar motif of two clusters of basic residues is seen in the nuclear targeting sequence of Xenopus N1. It is also conserved in the related nucleolar protein NO38. Several other short sequences known to be necessary for nuclear targeting fall within a similar motif.	HAMMERSMITH HOSP,ROYAL POST GRAD MED SCH,DEPT CHEM PATHOL,LONDON W12 0NN,ENGLAND; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Imperial College London; MRC Laboratory Molecular Biology	ROBBINS, J (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,CANC RES CTR,MOLEC EMBRYOL RES GRP,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADDISON C, 1990, ONCOGENE, V5, P423; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; Dingwall C, 1989, J Cell Sci Suppl, V11, P243; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; Goldfarb DS, 1989, CURR OPIN CELL BIOL, V1, P441, DOI 10.1016/0955-0674(89)90003-3; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Graessmann A, 1980, Methods Enzymol, V65, P816; GREENSPAN D, 1988, J VIROL, V62, P3020, DOI 10.1128/JVI.62.8.3020-3026.1988; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1990, EXP CELL RES, V186, P32, DOI 10.1016/0014-4827(90)90206-P; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Maniatis T., 1982, MOL CLONING; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORIN N, 1989, MOL CELL BIOL, V9, P4372, DOI 10.1128/MCB.9.10.4372; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RICHARDSON WD, 1983, CURR TOP MICROBIOL, V109, P147; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; STURZBECHER HW, 1990, ONCOGENE, V5, P759; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WYCHOWSKI C, 1985, GENE, V37, P63, DOI 10.1016/0378-1119(85)90258-6; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028	48	1336	1374	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					615	623		10.1016/0092-8674(91)90245-T	http://dx.doi.org/10.1016/0092-8674(91)90245-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991323				2022-12-28	WOS:A1991EX36100017
J	ROBERTS, J				ROBERTS, J			THE NHS OBSERVED - NAVIGATING THE SEAS OF CHANGE	BRITISH MEDICAL JOURNAL			English	Editorial Material								British and American medicine are like two ships crossings the Atlantic towards the other's shores. Both are curious what the other holds. The questions are: Will they meet and inspect one another? Will they quietly pass by each other? or Will they collide and both sink? At the same time, Europe's biggest employer, the NHS, prepares to join the European Community. And at home the government has set about restructuring how Britons will give and receive medical care. Doctors seem adrift in change. John Roberts, an American internist, toured England and Scotland for six weeks, interviewing general practitioners, nurses, consultants, students, house officers, patients, politicians, and people on the street. Here, and for the next few weeks, he reports how doctors in Britain have adapted to the constant political, economic, and technological changes placed before them.			ROBERTS, J (corresponding author), MUHIMBILI MED CTR,POB 8098,DAR ES SALAAM,TANZANIA.							AARON HJ, 1984, PAINFUL PRESCRIPTION; Cartwright F.F., 1977, SOCIAL HIST MED; DAVIES P, 1989, HLTH SERVICE J, V22, P750; DURHAM M, 1990, SUNDAY TIMES    1021, P1; Illich I., 1976, MED NEMESIS; PEYER L, 1988, MED CULTURE; SCHWARTZ R, 1985, HASTINGS CTR REP AUG, P19; WIDGERY D, 1988, NATIONAL HLTH RADICA; 1989, 6 SECR STAT HLTH WOR; 1989, WORKING PATIENTS	10	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					34	37		10.1136/bmj.302.6767.34	http://dx.doi.org/10.1136/bmj.302.6767.34			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER372	1991186	Green Published, Bronze			2022-12-28	WOS:A1991ER37200025
J	LECHLEITER, J; GIRARD, S; PERALTA, E; CLAPHAM, D				LECHLEITER, J; GIRARD, S; PERALTA, E; CLAPHAM, D			SPIRAL CALCIUM WAVE-PROPAGATION AND ANNIHILATION IN XENOPUS-LAEVIS OOCYTES	SCIENCE			English	Article							SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; RELEASE; ACTIVATION; CURVATURE; MODEL	Intracellular calcium (Ca2+) is a ubiquitous second messenger. Information is encoded in the magnitude, frequency, and spatial organization of changes in the concentration of cytosolic free Ca2+. Regenerative spiral waves of release of free Ca2+ were observed by confocal microscopy in Xenopus laevis oocytes expressing muscarinic acetylcholine receptor subtypes. This pattern of Ca2+ activity is characteristic of an intracellular milieu that behaves as a regenerative excitable medium. The minimal critical radius for propagation of focal Ca2+ waves (10.4 micrometers) and the effective diffusion constant for the excitation signal (2.3 x 10(-6) square centimeters per second) were estimated from measurements of velocity and curvature of circular wavefronts expanding from foci. By modeling Ca2+ release with cellular automata, the absolute refractory period for Ca2+ stores (4.7 seconds) was determined. Other phenomena expected of an excitable medium, such as wave propagation of undiminished amplitude and annihilation of colliding wavefronts, were observed.	MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Mayo Clinic; Harvard University			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				BACKX PH, 1989, J GEN PHYSIOL, V93, P963, DOI 10.1085/jgp.93.5.963; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1989, PROC R SOC SER B-BIO, V238, P235, DOI 10.1098/rspb.1989.0079; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CHEEK TR, 1989, J CELL SCI, V93, P211; DASCAL N, 1990, FEBS LETT, V267, P22, DOI 10.1016/0014-5793(90)80278-Q; DELISLE S, 1990, J BIOL CHEM, V265, P11726; FOERSTER P, 1989, P NATL ACAD SCI USA, V86, P6831, DOI 10.1073/pnas.86.18.6831; FOERSTER P, 1988, SCIENCE, V241, P685, DOI 10.1126/science.241.4866.685; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HARKINS A B, 1991, Biophysical Journal, V59, p240A; KEENER JP, 1986, PHYSICA D, V21, P307, DOI 10.1016/0167-2789(86)90007-2; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, IN PRESS NATURE; MARKUS M, 1990, NATURE, V347, P56, DOI 10.1038/347056a0; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAYLOR CW, 1989, BIOCHEM J, V259, P645, DOI 10.1042/bj2590645; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; Winfree AT, 1987, TIME BREAKS; WINFREE AT, 1990, ANN NY ACAD SCI, V591, P190; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	32	610	624	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1991	252	5002					123	126		10.1126/science.2011747	http://dx.doi.org/10.1126/science.2011747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011747				2022-12-28	WOS:A1991FE95200049
J	LEVINE, BD; GRAYBURN, PA; VOYLES, WF; GREENE, ER; ROACH, RC; HACKETT, PH				LEVINE, BD; GRAYBURN, PA; VOYLES, WF; GREENE, ER; ROACH, RC; HACKETT, PH			INTRACARDIAC SHUNTING ACROSS A PATENT FORAMEN OVALE MAY EXACERBATE HYPOXEMIA IN HIGH-ALTITUDE PULMONARY-EDEMA	ANNALS OF INTERNAL MEDICINE			English	Note							PREVALENCE		VET ADM MED CTR, DALLAS, TX 75216 USA; LOVELACE FDN MED EDUC & RES, ALBUQUERQUE, NM USA; UNIV ALASKA, ANCHORAGE, AK USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Lovelace Respiratory Research Institute; University of Alaska System; University of Alaska Anchorage	LEVINE, BD (corresponding author), UNIV TEXAS, SW MED CTR, DIV CARDIOL, H8116, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Roach, Robert/F-4729-2011	Roach, Robert/0000-0002-7998-8976	NHLBI NIH HHS [R15HL4047601, HL 07360] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007360, R15HL040476] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENUMOF JL, 1981, J APPL PHYSIOL, V51, P871, DOI 10.1152/jappl.1981.51.4.871; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; HACKETT PH, 1988, J APPL PHYSIOL, V64, P1268, DOI 10.1152/jappl.1988.64.3.1268; HACKETT PH, 1990, J WILDERNESS MED, V1, P3, DOI 10.1580/0953-9859-1.1.3; Hackett PH, 1986, AM ALPINE J, V28, P129; HULTGREN HN, 1971, CIRCULATION, V44, P759, DOI 10.1161/01.CIR.44.5.759; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MISSRI J, 1986, CLIN DOPPLER ECHOCAR, P145; WAGNER PD, 1987, J APPL PHYSIOL, V63, P2348, DOI 10.1152/jappl.1987.63.6.2348	10	32	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					569	570		10.7326/0003-4819-114-7-569	http://dx.doi.org/10.7326/0003-4819-114-7-569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001089				2022-12-28	WOS:A1991FD66100008
J	BARRY, M				BARRY, M			THE INFLUENCE OF THE UNITED-STATES TOBACCO INDUSTRY ON THE HEALTH, ECONOMY, AND ENVIRONMENT OF DEVELOPING-COUNTRIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SMOKING				BARRY, M (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06504, USA.							CHANDLER WU, 1986, 68 WORLDW I WORLDW P, P20; COCKBURN A, 1989, NATION          1030, P482; CONNOLLY G, 1989, 1989 TOB US AM C HOU, P49; CORTI EC, 1931, HIST SMOKING, P1; COYLE P, 1990, NEW HAVEN REGIS 0625, P5; COYLE P, 1990, NEW HAVEN REGIS 0625, P1; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P993; FORBES WF, 1985, STRATEGIES SMOKE FRE, P21; JACOBSON B, 1983, BRIT MED J, V287, P483, DOI 10.1136/bmj.287.6390.483; JONES D, 1989, TOBACCO REPORTER JAN, P32; LEWIN T, 1990, NY TIMES        0524, pB10; Lewin Tamar, 1990, N Y Times Web, pA15; MAKHYOUN NA, 1974, BRIT J CANCER, V30, P577, DOI 10.1038/bjc.1974.238; NATH UR, 1986, WORLD HLTH       JUN, P6; NATH UR, 1986, SMOKING 3RD WORLD AL, P192; PETO R, 1987, LANCET, V2, P211; SAYCEL K, 1987, ENCY ZIMBABWE, P380; STEBBINS KR, 1990, SOC SCI MED, V30, P227, DOI 10.1016/0277-9536(90)90084-6; Taylor SA, 1989, BUSINESS CONT WO WIN, V55, P55; WARNER KE, 1990, AM J PUBLIC HEALTH, V80, P529, DOI 10.2105/AJPH.80.5.529; WHELAN E, 1984, SMOKING GUN TOBACCO, P167; WILLCOX PA, 1982, THORAX, V37, P598, DOI 10.1136/thx.37.8.598; YACH D, 1986, INT J HEALTH SERV, V16, P279, DOI 10.2190/Q27T-A7ER-0PYK-9LED; 1983, WHO TECH REP SER, V695; 1989, FT889 DEP AGR REP; 1990, JAMA-J AM MED ASSOC, V263, P3312; 1988, ADVERTISING AGE 1121, P37; 1990, MMWR, V39, P1; 1988, ACTIVITIES P MORRIS; 1990, MMWR, V39, P261	31	36	37	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					917	920		10.1056/NEJM199103283241311	http://dx.doi.org/10.1056/NEJM199103283241311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000116				2022-12-28	WOS:A1991FD11100011
J	KATO, H; HORIKOSHI, M; ROEDER, RG				KATO, H; HORIKOSHI, M; ROEDER, RG			REPRESSION OF HIV-1 TRANSCRIPTION BY A CELLULAR PROTEIN	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; PREINITIATION COMPLEX; GENE-EXPRESSION; T-ANTIGEN; BINDING; PROMOTER; TATA; REGION	A cellular DNA binding protein, LBP-1, sequentially interacts in a concentration-dependent manner with two sites that surround the transcriptional initiation site of the human immunodeficiency virus type 1 (HIV-1) promoter. Although sequences in the downstream site (site I) were found to enhance transcription, purified LBP-1 specifically repressed transcription in vitro by binding to the upstream site (site II), which overlaps the TATA element. The binding of human TATA binding factor (TFIID) to the promoter before LBP-1 blocked repression, suggesting that repression resulted from an inhibition of TFIID binding to the TATA element. Furthermore, mutations that eliminated binding to site II both prevented repression in vitro and increased HIV-1 transcription in stably transformed cells. These findings suggest that a cellular factor regulates HIV-1 transcription in a manner that is characteristic of bacterial repressors and that this factor could be important in HIV-1 latency.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; Horikoshi M., UNPUB; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KATO H, UNPUB; KLIEWER S, 1989, J VIROL, V63, P4616, DOI 10.1128/JVI.63.11.4616-4625.1989; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; PAVLAKIS GN, 1990, BIOLOGIST, V2, P20; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	38	142	145	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1476	1479		10.1126/science.2006421	http://dx.doi.org/10.1126/science.2006421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006421				2022-12-28	WOS:A1991FC85300045
J	MALANE, MS; GRANTKELS, JM; FEDER, HM; LUGER, SW				MALANE, MS; GRANTKELS, JM; FEDER, HM; LUGER, SW			DIAGNOSIS OF LYME-DISEASE BASED ON DERMATOLOGICAL MANIFESTATIONS	ANNALS OF INTERNAL MEDICINE			English	Review							ERYTHEMA CHRONICUM MIGRANS; LYMPHADENOSIS BENIGNA CUTIS; BORRELIA-BURGDORFERI; CLINICAL MANIFESTATIONS; SPIROCHETAL ETIOLOGY; LICHEN SCLEROSUS; ATROPHICANS; AFZELIUS; MORPHEA; ARTHRITIS	Lyme disease, or Lyme borreliosis, is an infection caused by the spirochete Borrelia burgdorferi, which is most commonly transmitted to humans by a tick bite. Characterized by early and late phases, Lyme disease is a multisystem illness involving the skin, heart, joints, and nervous system. Diagnosis is based predominantly on clinical manifestations, the most specific being dermatologic. Thus, recognizing the dermatologic manifestations of Lyme disease is important for diagnosis and institution of appropriate, effective therapy. Approximately 75% of patients with Lyme disease present with the pathognomonic skin lesion erythema migrans, an expanding erythematous lesion. During early infection, secondary erythema migrans lesions or Borrelia lymphocytoma may occur. Borrelia lymphocytoma commonly presents as an erythematous nodule on the ear lobe or nipple. During late infection, acrodermatitis chronica atrophicans, an erythematous, atrophic plaque unique to Lyme disease may appear; it has been described in about 10% of patients with Lyme disease in Europe. Fibrotic nodules associated with acrodermatitis chronica atrophicans as well as other sclerotic and atrophic lesions, such as morphea, lichen sclerosus et atrophicus, anetoderma, and atrophoderma of Pasini and Pierini, have been seen late in the course of Lyme disease. In a few cases, other sclerodermatous lesions, such as eosinophilic fasciitis and progressive facial hemiatrophy, have been linked to B. burgdorferi infection. We review the cutaneous lesions associated with Lyme disease.	UNIV CONNECTICUT, CTR HLTH, DEPT FAMILY PRACTICE, FARMINGTON, CT 06032 USA	University of Connecticut								AABERG TM, 1989, AM J OPHTHALMOL, V107, P77, DOI 10.1016/0002-9394(89)90819-2; ABELE DC, 1989, J AM ACAD DERMATOL, V21, P795, DOI 10.1016/S0190-9622(89)80273-7; ABELE DC, 1990, J AM ACAD DERMATOL, V22, P531, DOI 10.1016/S0190-9622(08)80402-1; ABERER E, 1987, AM J DERMATOPATH, V9, P374, DOI 10.1097/00000372-198710000-00002; ABERER E, 1987, ACTA DERM-VENEREOL, V67, P225; ABERER E, 1988, J AM ACAD DERMATOL, V19, P820, DOI 10.1016/S0190-9622(88)70239-X; Afzelius A., 1910, ARCH DERM SYPH-BERL, P405; ASBRINK E, 1985, ACTA DERM-VENEREOL, V65, P43; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; ASBRINK E, 1986, AM J DERMATOPATH, V8, P209, DOI 10.1097/00000372-198606000-00005; ASBRINK E, 1985, ACTA PATH MICRO IM B, V93, P161; ASBRINK E, 1986, ZBL BAKT-INT J MED M, V263, P229; ATLAS E, 1988, ANN INTERN MED, V109, P245, DOI 10.7326/0003-4819-109-3-245; BARBOUR A G, 1988, Clinical Microbiology Reviews, V1, P399; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; BERGER BW, 1983, AM J DERMATOPATH, V5, P111, DOI 10.1097/00000372-198304000-00008; BURGDORF WHC, 1979, INT J DERMATOL, V18, P595, DOI 10.1111/j.1365-4362.1979.tb04672.x; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; CERIO R, 1985, J CUTAN PATHOL, V12, P442, DOI 10.1111/j.1600-0560.1985.tb00441.x; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; DATTWYLER RJ, 1987, LANCET, V1, P681; DURAY PH, 1988, ANN NY ACAD SCI, V539, P65, DOI 10.1111/j.1749-6632.1988.tb31839.x; DURAY PH, 1988, 1987 P LYM BORR; FINKEL MF, 1988, ARCH NEUROL-CHICAGO, V45, P99, DOI 10.1001/archneur.1988.00520250105031; FITZPATRICK TB, 1987, DERMATOLOGY GENERAL; FRITHZ A, 1983, ACTA DERM-VENEREOL, V63, P432; GROSS GP, 1979, ARCH DERMATOL, V115, P873, DOI 10.1001/archderm.115.7.873; HERZER P, 1988, ANN RHEUM DIS, V47, P789, DOI 10.1136/ard.47.9.789; HOESLY JM, 1987, J AM ACAD DERMATOL, V17, P455, DOI 10.1016/S0190-9622(87)70229-1; HOVINDHOUGEN K, 1986, ZBL BAKT-INT J MED M, V263, P103; HOVMARK A, 1986, ACTA DERM-VENEREOL, V66, P479; JACOB JC, 1988, JAMA-J AM MED ASSOC, V256, P1138; JESSNER M, 1953, ARCH DERMATOL, V68, P447; KAUFMAN LD, 1989, AM J MED, V86, P828, DOI 10.1016/0002-9343(89)90482-8; KIRSCH M, 1988, JAMA-J AM MED ASSOC, V259, P2737, DOI 10.1001/jama.259.18.2737; KRAMER N, 1986, AM J MED, V81, P149, DOI 10.1016/0002-9343(86)90200-7; LAVOIE PE, 1986, ZBL BAKT-INT J MED M, V263, P262; MAGNARELLI LA, 1988, J CLIN MICROBIOL, V26, P1482, DOI 10.1128/JCM.26.8.1482-1486.1988; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MAST WE, 1976, JAMA-J AM MED ASSOC, V236, P859, DOI 10.1001/jama.236.7.859; MAST WE, 1976, JAMA-J AM MED ASSOC, V236, P2392; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MOORE JA, 1987, CUTIS, V39, P397; OLSON JC, 1990, J AM ACAD DERMATOL, V22, P1114, DOI 10.1016/S0190-9622(08)81019-5; OLSSON I, 1988, ANN NY ACAD SCI, V539, P480, DOI 10.1111/j.1749-6632.1988.tb31913.x; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; ROSENSTEIN ED, 1987, ANN INTERN MED, V107, P782, DOI 10.7326/0003-4819-107-5-782_1; Schaumburg-Lever G., 1983, LIPPINCOTT, P422; Schoen R T, 1989, Hepatology, V9, P335, DOI 10.1002/hep.1840090229; SCRIMENTI RJ, 1970, ARCH DERMATOL, V102, P104, DOI 10.1001/archderm.102.1.104; SEPP N, 1988, J AM ACAD DERMATOL, V18, P1361, DOI 10.1016/S0190-9622(88)80117-8; Shulman L E, 1975, Trans Assoc Am Physicians, V88, P70; SIGAL LH, 1988, CLIN EXP RHEUMATOL, V6, P411; STANEK G, 1987, ZBL BAKT-INT J MED M, V263, P442; STANEK G, 1988, ANN NY ACAD SCI, V539, P274, DOI 10.1111/j.1749-6632.1988.tb31861.x; STANEK G, 1987, LANCET, V1, P1490, DOI 10.1016/S0140-6736(87)92235-5; STANEK G, 1990, NEW ENGL J MED, V322, P249, DOI 10.1056/NEJM199001253220407; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1979, ANN INTERN MED, V91, P730, DOI 10.7326/0003-4819-91-5-730; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; STEWART A, 1982, MED J AUSTRALIA, V1, P139, DOI 10.5694/j.1326-5377.1982.tb132207.x; STIERNSTEDT G, 1988, ANN NY ACAD SCI, V539, P46, DOI 10.1111/j.1749-6632.1988.tb31837.x; Tsai T F, 1989, Conn Med, V53, P324; WALDO ED, 1983, AM J DERMATOPATH, V5, P125, DOI 10.1097/00000372-198304000-00009; WEBER K, 1988, INFECTION, V16, P25, DOI 10.1007/BF01646925; WEBER K, 1984, YALE J BIOL MED, V57, P463; WEBER K, 1988, PEDIATR INFECT DIS J, V7, P286, DOI 10.1097/00006454-198804000-00010; 1989, MED LETT DRUGS THER, V31, P57; 1988, MMWR, V37, P1	74	105	106	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					490	498		10.7326/0003-4819-114-6-490	http://dx.doi.org/10.7326/0003-4819-114-6-490			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994797				2022-12-28	WOS:A1991FB64000010
J	SJOGREN, MH; HOKE, CH; BINN, LN; ECKELS, KH; DUBOIS, DR; TSUCHIDA, A; OAKS, S; MARCHWICKI, R; LEDNAR, W; CHLOUPEK, R; TICEHURST, J; BANCROFT, WH				SJOGREN, MH; HOKE, CH; BINN, LN; ECKELS, KH; DUBOIS, DR; TSUCHIDA, A; OAKS, S; MARCHWICKI, R; LEDNAR, W; CHLOUPEK, R; TICEHURST, J; BANCROFT, WH			IMMUNOGENICITY OF AN INACTIVATED HEPATITIS-A VACCINE	ANNALS OF INTERNAL MEDICINE			English	Note							NEUTRALIZING ANTIBODY; VIRUS		USA, MAT DEV ACT, FREDERICK, MD 21701 USA		SJOGREN, MH (corresponding author), WALTER REED ARMY MED CTR, DEPT VIRUS DIS, WASHINGTON, DC 20307 USA.		Ticehurst, John/I-7532-2012	Ticehurst, John/0000-0002-7137-8495				Binn LN, 1988, VIRAL HEPATITIS LIVE, P91; LEMON SM, 1983, J INFECT DIS, V148, P1033, DOI 10.1093/infdis/148.6.1033; SJOGREN MH, 1988, VIRAL HEPATITIS LIVE, P94; STAPLETON JT, 1985, GASTROENTEROLOGY, V89, P637, DOI 10.1016/0016-5085(85)90462-7; 1989, 52 CTR DIS CONTR HEP, P10	5	39	40	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					470	471		10.7326/0003-4819-114-6-470	http://dx.doi.org/10.7326/0003-4819-114-6-470			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994794				2022-12-28	WOS:A1991FB64000007
J	SALOMAA, VV; STRANDBERG, TE; VANHANEN, H; NAUKKARINEN, V; SARNA, S; MIETTINEN, TA				SALOMAA, VV; STRANDBERG, TE; VANHANEN, H; NAUKKARINEN, V; SARNA, S; MIETTINEN, TA			GLUCOSE-TOLERANCE AND BLOOD-PRESSURE - LONG-TERM FOLLOW-UP IN MIDDLE-AGED MEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESSENTIAL-HYPERTENSION; INSULIN RESISTANCE; HYPERINSULINEMIA	Objective - To investigate the role of glucose tolerance in the development of hypertension. Design - Retrospective analysis of the results of a health check up in a group of clinically healthy middle aged men in the late 1960s (median year 1968). The subjects were invited to enter into a primary prevention trial for cardiovascular disease in 1974, when they underwent clinical examination for risk factors. The trial was completed in 1979, when the men were re-examined. Follow up was in 1986. Setting - Institute of Occupational Health, Helsinki, Finland and second department of medicine, University of Helsinki. Subjects - In all, 3490 men born during 1919-34 participated in a health check up in the late 1960s. In 1974, 1815 of these men who were clinically healthy were entered into a primary prevention trial for cardiovascular disease. On clinical examination 1222 of the men were considered at high risk of cardiovascular disease. Of these, 612 received an intervention and were excluded from the study. A total of 593 men were without risk factors. The study comprised all of the men who did not have an intervention (n = 1203). In 1979, 1120 men were re-examined, and in 1986 945 men attended follow up. There were two groups for analysis: one comprising all subjects and the other comprising only men who were normotensive in 1968 and for whom complete information was available. Interventions - By 1979, 103 men were taking antihypertensive drugs, and by 1986, 131 were taking antihypertensive drugs and 12 were taking drugs for hyperglycaemia. Main outcome measures - Blood glucose concentration one hour after a glucose load, blood pressure, and body weight were measured in 1968, 1974, and 1979. In 1986 blood pressure and body weight were recorded. Results - Men who were hypertensive in 1986 had significantly higher blood pressures (p < 0.0001) and (after adjustment for body mass index and alcohol intake) significantly higher blood glucose concentrations one hour after a glucose load at all examinations than those who were normotensive in 1986. Regression analysis showed that the higher the blood glucose concentration after a glucose load in 1968 the higher the blood pressure during the following years. Those men between the second and third tertiles of blood glucose concentration in 1968 had a significantly higher risk of developing hypertension (odds ratio 1.71, 95% confidence interval 1.05 to 2.77) compared with those below the first tertile. Conclusion - In this study men who developed hypertension tended to have shown an increased intolerance to glucose up to 18 years before the clinical manifestation of their disorder. Blood glucose concentration one hour after a glucose load was an independent predictor of future hypertension.	UNIV HELSINKI, DEPT MED 2, SF-00100 HELSINKI 10, FINLAND; JORVI DIST HOSP, DEPT MED, ESPOO, FINLAND; UNIV HELSINKI, DEPT PUBL HLTH SCI, SF-00100 HELSINKI 10, FINLAND	University of Helsinki; University of Helsinki	SALOMAA, VV (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL, SF-00510 HELSINKI, FINLAND.			Sarna, Seppo/0000-0003-3458-1627; strandberg, timo/0000-0001-6299-925X				DIXON WJ, 1985, BMDP STATISTICAL SOF; DUVFLOREY C, 1976, BRIT MED J, V1, P1368, DOI 10.1136/bmj.1.6022.1368; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FOSTER DW, 1989, NEW ENGL J MED, V320, P733, DOI 10.1056/NEJM198903163201111; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; HULTMAN E, 1959, NATURE, V183, P108, DOI 10.1038/183108a0; JARRETT RJ, 1978, INT J EPIDEMIOL, V7, P15, DOI 10.1093/ije/7.1.15; Kessler G., 1966, AUTOMATION ANALYTICA, P341; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATTILA S, 1980, THESIS U HELSINKI FI; MBANYA JCN, 1988, LANCET, V1, P733; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NAUKKARINEN VA, 1989, ANN MED, V21, P441, DOI 10.3109/07853898909149236; PORTA M, 1988, NEW ENGL J MED, V318, P383; REAVEN PD, 1990, DIABETES CARE, V13, P119, DOI 10.2337/diacare.13.2.119; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105; 1985, WHO TECH REP SER, V727	20	65	69	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1991	302	6775					493	496		10.1136/bmj.302.6775.493	http://dx.doi.org/10.1136/bmj.302.6775.493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012844	Green Published, Bronze			2022-12-28	WOS:A1991FB05500016
J	GUO, XD; JOHNSON, JJ; KRAMER, JM				GUO, XD; JOHNSON, JJ; KRAMER, JM			EMBRYONIC LETHALITY CAUSED BY MUTATIONS IN BASEMENT-MEMBRANE COLLAGEN OF C-ELEGANS	NATURE			English	Article							CAENORHABDITIS-ELEGANS; IV COLLAGEN; DNA; SEQUENCE; REGION; DOMAIN; GENES; CHAIN	BASEMENT membranes are specialized forms of extracellular matrix with important functions in development 1-3. A major structural component of basement membranes is type IV collagen, a heterotrimer of two alpha-1(IV) and one alpha-2(IV) chains, which forms a complex, polygonal network associated with other basement membrane components 4,5. Here we report that the alpha-1(IV) collagen chain of Caenorhabditis elegans is encoded by the genetic locus emb-9. Mutations in emb-9 cause temperature-sensitive lethality during late embryogenesis. We have identified single nucleotide alterations that substitute glutamic acid for glycine in the triple-helical Gly-X-Y repeat region of the alpha-1(IV) collagen in three emb-9 mutant strains. These results are direct evidence that defects in basement membranes can disrupt embryonic development and form a basis for the genetic analysis of basement membrane function.	UNIV ILLINOIS,DEPT BIOL SCI,MOLEC BIOL LAB,POB 4348,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; CASADA R, 1981, DEV BIOL, V84, P193; CHEAH KSE, 1985, BIOCHEM J, V229, P287, DOI 10.1042/bj2290287; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GLANVILLE RW, 1985, EUR J BIOCHEM, V152, P213, DOI 10.1111/j.1432-1033.1985.tb09186.x; GREENWALD I, 1987, NUCLEIC ACIDS RES, V15, P2295, DOI 10.1093/nar/15.5.2295; GUO XD, 1989, J BIOL CHEM, V264, P17574; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; ISNENGHI E, 1983, DEV BIOL, V98, P465, DOI 10.1016/0012-1606(83)90376-7; KRAMER JM, 1988, CELL, V55, P555, DOI 10.1016/0092-8674(88)90214-0; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MIWA J, 1980, DEV BIOL, V76, P160, DOI 10.1016/0012-1606(80)90369-3; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SOININEN R, 1987, FEBS LETT, V225, P188; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	27	90	95	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					707	709		10.1038/349707a0	http://dx.doi.org/10.1038/349707a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996137				2022-12-28	WOS:A1991EY62700051
J	SALUSKY, IB; FOLEY, J; NELSON, P; GOODMAN, WG				SALUSKY, IB; FOLEY, J; NELSON, P; GOODMAN, WG			ALUMINUM ACCUMULATION DURING TREATMENT WITH ALUMINUM HYDROXIDE AND DIALYSIS IN CHILDREN AND YOUNG-ADULTS WITH CHRONIC RENAL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBULATORY PERITONEAL-DIALYSIS; CALCIUM-CARBONATE; PHOSPHATE BINDER; FAILURE; PHOSPHORUS; BONE; OSTEODYSTROPHY; ABSORPTION; METABOLISM; ACETATE	Background. The control of hyperphosphatemia is a major clinical problem in patients with chronic renal failure receiving regular dialysis treatment. Despite continuing concern about aluminum toxicity, aluminum-containing antacids are still used in many of these patients as phosphate-binding agents. Although maximal acceptable doses of aluminum hydroxide have been recommended, the safety and efficacy of these guidelines have not been evaluated. Methods. Seventeen children and young adults (mean [+/- SD] age, 14.1 +/- 3.7 years) undergoing regular peritoneal dialysis were randomly assigned to treatment with either aluminum hydroxide (n = 7; maximal dose, 30 mg per kilogram of body weight per day) or calcium carbonate (n = 10; dose range, 2.5 to 12 g per day, according to serum phosphorus levels). Aluminum retention was assessed by serial measurements of plasma aluminum, deferoxamine-infusion tests, and measurements of bone aluminum content during a mean (+/- SD) follow-up of 13 +/- 2 months. The evolution of bone disease was also evaluated. Results. Plasma aluminum levels and the increment in plasma aluminum after infusion of deferoxamine increased from base-line values in the patients treated with aluminum hydroxide, and aluminum-related bone disease developed in one patient. Serum phosphorus levels remained higher and serum calcium levels lower in the patients receiving aluminum hydroxide than in those receiving calcium carbonate. The skeletal lesions of secondary hyperparathyroidism improved in 7 of 10 patients receiving calcium carbonate but persisted or progressed in 6 of 7 patients given aluminum hydroxide (P < 0.025). Conclusions. Aluminum hydroxide is less effective than calcium carbonate as a phosphate-binding agent for the control of hyperphosphatemia and is associated with aluminum retention in children and young adults with chronic renal failure who are receiving dialysis therapy.	SEPULVEDA VET AFFAIRS MED CTR, MED SERV, SEPULVEDA, CA USA; SEPULVEDA VET AFFAIRS MED CTR, RES SERV, SEPULVEDA, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SALUSKY, IB (corresponding author), UNIV CALIF LOS ANGELES, CTR HLTH SCI, SCH MED, DEPT PEDIAT, A2-331 MDCC, LOS ANGELES, CA 90024 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035423] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00865] Funding Source: Medline; NIAMS NIH HHS [AR-35470] Funding Source: Medline; NIDDK NIH HHS [DK-35423] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREOLI SP, 1984, NEW ENGL J MED, V310, P1079, DOI 10.1056/NEJM198404263101704; COBURN JW, 1989, NEW ENGL J MED, V320, P1140, DOI 10.1056/NEJM198904273201709; FOURNIER A, 1986, KIDNEY INT       S18, V29, pS114; FROMENT DP, 1989, KIDNEY INT, V36, P978, DOI 10.1038/ki.1989.290; GOKAL R, 1983, KIDNEY INT, V23, P15, DOI 10.1038/ki.1983.4; HERCZ G, 1986, KIDNEY INT, V30, P944, DOI 10.1038/ki.1986.277; HRUSKA KA, 1975, J CLIN INVEST, V56, P39, DOI 10.1172/JCI108077; JENKINS DAS, 1989, NEPHROL DIAL TRANSPL, V4, P51; LEGENDRE GR, 1976, CLIN CHEM, V22, P53; MACTIER RA, 1987, CLIN NEPHROL, V28, P222; MAI ML, 1989, KIDNEY INT, V36, P690, DOI 10.1038/ki.1989.247; MALONEY NA, 1982, J LAB CLIN MED, V99, P206; MORINIERE P, 1982, P EUR DIAL TRANS, V19, P784; PREECE MA, 1989, PEDIATRIC ADOLESCENT, V20, P4; SALUSKY IB, 1983, AM J CLIN NUTR, V38, P599, DOI 10.1093/ajcn/38.4.599; SALUSKY IB, 1987, KIDNEY INT, V32, P89, DOI 10.1038/ki.1987.176; SALUSKY IB, 1986, J PEDIATR-US, V108, P767, DOI 10.1016/S0022-3476(86)81064-2; SALUSKY IB, 1988, KIDNEY INT, V33, P975, DOI 10.1038/ki.1988.96; SALUSKY IB, 1984, J PEDIATR-US, V105, P717, DOI 10.1016/S0022-3476(84)80289-9; SCHILLER LR, 1989, NEW ENGL J MED, V320, P1110, DOI 10.1056/NEJM198904273201703; SEDMAN AB, 1984, KIDNEY INT, V26, P201, DOI 10.1038/ki.1984.156; SLATOPOLSKY E, 1986, NEW ENGL J MED, V315, P157, DOI 10.1056/NEJM198607173150304; SLATOPOLSKY E, 1989, KIDNEY INT, V36, P897, DOI 10.1038/ki.1989.277; WINNEY RJ, 1986, KIDNEY INT, pS91; [No title captured]	25	125	127	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					527	531		10.1056/NEJM199102213240804	http://dx.doi.org/10.1056/NEJM199102213240804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1992306				2022-12-28	WOS:A1991EX91800004
J	COMPANY, M; ARENAS, J; ABELSON, J				COMPANY, M; ARENAS, J; ABELSON, J			REQUIREMENT OF THE RNA HELICASE-LIKE PROTEIN PRP22 FOR RELEASE OF MESSENGER-RNA FROM SPLICEOSOMES	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; NUCLEOTIDE-SEQUENCE; RIBOSOMAL PROTEIN-S1; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; PUTATIVE HELICASES; YEAST; GENE; CLONING; ATP	The product of the yeast PRP22 gene acts late in the splicing of yeast pre-messenger RNA, mediating the release of the spliced mRNA from the spliceosome. The predicted PRP22 protein sequence shares extensive homology with that of PRP2 and PRP16 proteins, which are also involved in nuclear pre-mRNA splicing. The homologous region contains sequence elements characteristic of several demonstrated or putative ATP-dependent RNA helicases. A putative RNA-binding motif originally identified in bacterial ribosomal protein S1 and Escherichia coli polynucleotide phosph orylase has also been found in PRP22.			COMPANY, M (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BJORN SP, 1989, MOL CELL BIOL, V9, P3698, DOI 10.1128/MCB.9.9.3698; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHANG TH, 1990, P NATL ACAD SCI USA, V87, P1571, DOI 10.1073/pnas.87.4.1571; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; ERNST H, 1987, J BIOL CHEM, V262, P1206; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAIN S, 1989, GENE, V82, P357, DOI 10.1016/0378-1119(89)90063-2; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LAIN S, 1989, VIRUS RES, V13, P157, DOI 10.1016/0168-1702(89)90013-0; LAIN S, 1991, J VIROL, V65, P1, DOI 10.1016/0042-6822(91)90641-N; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LANE D, 1988, NATURE, V334, P478, DOI 10.1038/334478a0; LIN RJ, 1987, GENE DEV, V1, P7, DOI 10.1101/gad.1.1.7; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; MACKOW E, 1987, VIROLOGY, V159, P217, DOI 10.1016/0042-6822(87)90458-2; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RAY BK, 1985, J BIOL CHEM, V260, P7651; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUBY SW, 1991, TRENDS GENET, V7, P79; SANDS JF, 1987, NUCLEIC ACIDS RES, V15, P5157, DOI 10.1093/nar/15.13.5157; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHNIER J, 1988, NUCLEIC ACIDS RES, V16, P3075, DOI 10.1093/nar/16.7.3075; SCHNIER J, 1982, P NATL ACAD SCI-BIOL, V79, P1008, DOI 10.1073/pnas.79.4.1008; SCHNIER J, 1985, MOL GEN GENET, V200, P476, DOI 10.1007/BF00425734; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SIJBENMULLER G, 1986, NUCLEIC ACIDS RES, V14, P1029, DOI 10.1093/nar/14.2.1029; SIKORSKI RS, 1989, GENETICS, V122, P19; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SUBRAMANIAN AR, 1985, ESSAYS BIOCHEM, V21, P45; UMESONO K, 1984, NUCLEIC ACIDS RES, V12, P9551, DOI 10.1093/nar/12.24.9551; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; VIJAYRAGHAVAN U, 1989, NUCLEIC ACIDS MOL BI, V3, P197; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	67	303	307	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 7	1991	349	6309					487	493		10.1038/349487a0	http://dx.doi.org/10.1038/349487a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992352				2022-12-28	WOS:A1991EW57100055
